[{"article": "\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\nThe authors suggest the score can be useful for standardizing diagnoses and improving safety.\nThe clinical chemistry score worked equally well in men and women.\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack.\nThe researchers validated the clinical chemistry score as a predictor of heart attack or death within 30 days using data on 4245 patients from emergency department studies in the four countries.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the score is based on commonly available tests.", "answer": 1}, {"article": "Dr. Sonia Friedman is an associate professor of medicine at Harvard Medical School.\nWhether Xeljanz should be used as a first treatment is still not clear, said Dr. Arun Swaminath, director of the inflammatory bowel disease program at Lenox Hill Hospital in New York City.\n\"Treatment with oral tofacitinib is potentially a new treatment option for patients with moderate to severe ulcerative colitis, pending review by the [U.S. Food and Drug Administration],\" Sandborn said.\nXeljanz targets certain proteins involved in the body's inflammatory and immune responses that other so-called biologic drugs don't, the researchers said.\nHowever, in all of the trials, more patients taking Xeljanz suffered from infections, such as shingles, than those receiving placebo, researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear both that Xeljanz is already on the market for treating arthritis and that it has not yet been approved by the FDA for use in treating ulcerative colitis.\u00a0It would have been helpful to note if some doctors currently prescribe Xeljanz as an off-label treatment for ulcerative colitis.", "answer": 1}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\nBut prior to the present study there was very limited evidence of any cognitive benefits in humans.\nEven though this increase is moderate, and all patients remained severely cognitively impaired, these results are important because they are the first to show that probiotics can improve human cognition.\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release provided a thorough description of the probiotic milk intervention, but did not mention the fact that it was manufactured (in Iran) specifically for this study and is not available for purchase. A brief discussion of what it would take to get such a product on the market \u2014 in addition to its cost \u2014 would be beneficial.", "answer": 0}, {"article": "After one year, both groups experienced minimal body weight, triglyceride, and HDL cholesterol changes, but the walnut-eaters had significant reductions in LDL cholesterol (\"bad\" cholesterol) compared to the nut-free control group.\nWalnuts have long been touted as a healthy, whole food, but new research just upped the homely nut's reputation another notch.\nThey're rich in fiber, folic acid, and potassium.\nWalnuts are especially heart healthy because they have more polyunsaturated fat than almonds, cashews, peanuts, pecans, pistachios, and macadamia nuts per serving.\nWalnut oil can be a good alternative too, in dressings and for light basting, Politi said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are widely available everywhere, so this is not applicable.", "answer": 2}, {"article": "\"It's only been relatively recently that energy surplus has become a problem,\" Wu said.\nNow, before anyone goes dumping tons of extra cinnamon in their egg nog in hopes of keeping holiday-season pounds at bay, Wu cautioned that further study is needed to determine how best to harness cinnamaldehyde's metabolic benefits without causing adverse side effects.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\nANN ARBOR--New research from the University of Michigan Life Sciences Institute has determined how a common holiday spice--cinnamon--might be enlisted in the fight against obesity.\nTheir findings, which appear in the December issue of the journal Metabolism, indicated that cinnamaldehyde improves metabolic health by acting directly on fat cells, or adipocytes, inducing them to start burning energy through a process called thermogenesis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release strongly suggests that cinnamon is not yet ready as a weight loss aid without saying the actual words. The news release warns that researchers have not yet determined \u201chow best to harness cinnamaldehyde\u2019s metabolic benefits without causing adverse side effects.\u201d It also cautions against using cinnamon as an obesity protectant or treatment at this time.", "answer": 1}, {"article": "\"We know that art therapy can work, music therapy can work.\nThe apps were freely available on iTunes and varied greatly in their cognitive complexity--from an app that displayed puppy photos to one that featured Sudoku puzzles.\nResearchers loaded a menu of 70 apps onto the tablets for the study.\nThe tablet, however, gives you the option of switching from one app to another easily, modifying the therapy seamlessly to suit the individual.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that computer tablets are widely available, and at ever-diminishing costs. The release explained that all of the 70 apps used were available for free on iTunes.", "answer": 1}, {"article": "Most are still of the opinion that sunscreens with an SPF of up to 50, and containing avobenzone and oxybenzone, efficiently protect the skin from both UVA and UVB ultraviolet rays.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\nAnd though dermatologists who have experience with Fernblock think it offers a measure of protection, even the manufacturer warns it won't suffice alone.\nOur two cents' worth:There's no reason not to take a flyer on Fernblock \u2014 actress Reese Witherspoon gives it a hearty endorsement - but keep slathering up, too.\nIf you're squeamish about vitamin A, there are a number of alternatives.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0It seems clear that the product is available and being actively promoted.", "answer": 1}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nThe diets had the same number of calories, but the fat, protein and carbohydrate content varied.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\n\u2022A low-glycemic index diet, similar to a Mediterranean diet, made up of vegetables, fruit, beans, healthy fats (olive oil, nuts) and mostly healthy grains (old-fashioned oats, brown rice).\nParticipants were fed food that was prepared for them by diet experts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the 3 diets is not question.", "answer": 2}, {"article": "Rick lost 20 pounds, and Nina said she feels 20 again.\nLike many on the various detox plans, she couldn't stomach the all-liquid diet and craved solid food.\n\"Since it's predominately water weight, you'll regain the weight very quickly.\"\n\"I definitely am planning on doing this on a regular basis.\"\nBecause of that promised quick fix, the detox diet business is booming.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \u2018treatments\u2019 mentioned ranged from concoctions you could prepare yourself with ingredients in your kitchen to products you could purchase on-line or at a local drug store.", "answer": 1}, {"article": "\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nKetamine could improve treatment of bipolar illness and depression in a variety of ways, Zarate said; for example, as a means to jump-start standard drug treatment, or as an anesthetic before ECT.\nBy developing more specifically targeted drugs, Zarate noted, it may be possible to treat patients effectively while avoiding these symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that ketamine is not currently widely prescribed for depression but that it is available for other purposes, thereby lending itself to off label use.\u00a0", "answer": 1}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear from the story that the drugs in question are commonly prescribed and available.\u00a0\u00a0 \n\u00a0", "answer": 1}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\nScientists say the drug, ebselen, may be a swift answer to long-sought after better medications for patients with the manic depressive disorder, since it is already known to be safe.\n\u201cEbselen is an experimental drug that has been tested in people for other conditions, and does not have problematic side effects like lithium does,\u201d said Grant Churchill of the department of pharmacology at Britain\u2019s Oxford University.\nIf the drug could be \u201crepurposed\u201d and licensed for the treatment of bipolar disorder, it could reduce the unpleasant side effects of weight gain, thirst and potential kidney damage that patients risk when taking lithium.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug is not available by noting, \u201cEbselen is an antioxidant originally developed up to late stage, or phase III, clinical trials by the Japanese firm Daiichi Sankyo for the treatment of stroke, but which never reached market and is now out of patent.\u201d", "answer": 1}, {"article": "\"I would say that hearing better kind of completes your personality, and I think Ethan became a complete personality once his hearing came online.\u201d\n\nAfter witnessing Priddy's miraculous results, Naberhaus was inspired to shrug off his image as the hard-of-hearing teacher and get a cochlear implant.\nHe warns people that there is a risk the implant will not work and that they may need to have it replaced if it stops working.\nBerryhill said the cost of the implant and surgery is in excess of $60,000, but it is covered by most insurance companies as well as Medicare and Medicaid.\nAccording to Cochlear.com, the implant works by picking up sound through tiny microphones on a sound processor and converting the sound into digital signals.\nBerryhill explained how the implants function and their possible risks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story fails to explain whether cochlear implants are an FDA-approved device or widely available, or if trained personnel are widely available who can identify appropriate patients for the devices and surgically implant them.", "answer": 0}, {"article": "The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more on rheumatoid arthritis.\nNor do the study authors advise drinking as a cure for arthritis.\n\"We would therefore recommend that a future prospective study should be performed to further assess the impact of alcohol consumption on rheumatoid arthritis, a study recording alcohol consumption at the time rather than asking about it later.\"\nThis finding is slightly different than what is reported in the current study (that the severity of the disease decreased with more alcohol).\n\"This actually isn't a new concept.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of alcohol is not in question.\u00a0 In fact, we need a drink after reading another story that conflates association with causation. ", "answer": 2}, {"article": "For those with neglect, doctors typically prescribe cognitive rehabilitation, in which therapists teach skills and help the patient become more aware of the affected side of the body.\nHe said that larger studies at multiple treatment sites are needed to determine how helpful magnetic stimulation can be in stroke recovery.\nThe treatment involved an electromagnetic coil placed over the left side of the brain that transmitted pulses of electrical currents.\nHe added that the treatment isn\u2019t painful, and only takes a few minutes for each session.\nThat post-stroke condition is known as neglect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201c\u2026brain stimulation is still an experimental technique, and not ready to be used as part of normal stroke rehabilitation.\u201d", "answer": 1}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\n[One day, doctors might prescribe viruses instead of antibiotics]\n\nUsing a virus as a drug isn't a new idea.\nThat means it's just waiting for a final okay from the FDA before the Amgen product can hit the market.\nBefore he signed onto the project, it was primarily being investigated as a breast cancer treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a bit too much crystal ball-gazing as to when this drug might become available. The start of the article refers to the drug as being months away from approval. Later in the story, the Amgen-affiliated researcher says he expects approval within the year. But his optimism might not be shared by those outside the company \u2014 the story should at least have asked for an independent take. While it\u2019s true that an FDA advisory panel has recommended approval of the drug, the researcher can\u2019t know if the FDA will in fact approve the drug or when. One analysis suggested that the FDA does not follow the advice of its advisory panels\u00a0about a quarter of the time.", "answer": 0}, {"article": "...\nMore than half the trial sites were led by doctors who practice chelation, says Paul Armstrong, a professor of cardiology at the University of Alberta, chosen to discuss the study on a panel at the heart meeting.\nEven more concerning, that benefit passed the bar for statistical significance \u2014 the standard for judging whether a result is real or a fluke \u2014 by only 0.001.\nUnder the best of circumstances, that's not a strong result, says anesthesiologist Kimball Atwood of Newton-Wellesley Hospital in Massachusetts, who has followed the study from its beginning.\nYet some doctors say the study was far from rigorously performed, and so badly run that its marginally positive results are meaningless.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Another mixed bag for which we\u2019ll give a satisfactory score.\nThe story is not clear about exactly what chelating agent was used in this study, or where one would go to find a practitioner who can prescribe it.\u00a0 (But, to its credit, it mentioned problems with off-label prescribing.) It was relatively easy to find out online that EDTA was the agent used in the study.\nWe give the story for credit for reporting that \u201cthe Food and Drug Administration had taken the study drug off of its list of approved medications.\u201d", "answer": 1}, {"article": "Early menopause is often a side effect for women treated with chemotherapy for breast cancer, but a new study reveals some guarded promise for preventing early menopause breast cancer patients.\nThe researchers followed the women for one year after they had finished chemotherapy.\nThey also stress that women resuming their menstrual cycles does not mean the same thing as women preserving their fertility.\nThey conclude that using assisted reproductive technology \u2013 such as storing eggs before chemo, is \u201cthe most effective option for fertility preservation.\u201d\nPatients were randomly selected to be treated with chemotherapy alone or with chemotherapy and triptorelin, a drug, called a GnRH analogue, that prevents the ovaries from releasing eggs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no statement in the article as to availability of the treatment, although the information is correctly identified as arising from a \u201cphase three study.\u201d But are readers really supposed to know what a Phase Three study means?\u00a0 Want to do a reader poll to test how many do?", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\nFurther research will hopefully also help answer those questions, she says.\nHe says that why this is happening is still unclear.\nThis could change in the future if larger clinical trials and longer patient outcomes confirm the results of this early research published Monday in the journal The Lancet.\nShe is hopeful further studies will confirm these early results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear not only that the treatment is experimental but that it has to clear many more hurdles before becoming a clinical option.\n\u00a0", "answer": 1}, {"article": "In contrast to photon radiotherapy, in which a dose of radiation is delivered all along the x-ray beam as it passes through a patient's body, in proton therapy the dose is precisely focused on the target area with little or no dose delivered to normal tissues in front of or behind the tumor.\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\n\"Our results indicate that proton therapy maintains excellent cure rates in pediatric medulloblastoma while reducing long-term side effects, particularly in hearing and neurocognitive function, and eliminating cardiac, pulmonary, gastrointestinal and reproductive effects,\" says Yock, who is an associate professor of Radiation Oncology at Harvard Medical School.\n\"While we are currently investigating quality of life differences between proton and photon treatment, I truly believe that - particularly for the youngest children - the ability to offer them proton therapy can make a big difference in their lives.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the therapy is not widely available and not often used. The first quote says, \u201cProton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population.\u201d", "answer": 1}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. Vegetarian foods are widely available.", "answer": 2}, {"article": "Adults with arm or leg pain caused by a sprain, strain or fracture.\nThe drug industry\u2019s triumph over the DEA, even as opioid-related deaths rise\n\nShingles can be intensely painful; it may also mean health problems ahead\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nMight non-opioid painkillers work just as well as these addictive drugs?\nResearch has shown that even short-term opioid use, such as that stemming from an initial prescription for pain from an injury or surgery, can make people predisposed to a dependence on the powerful drugs \u2014 partly from their effectiveness at relieving pain and partly from the euphoria they produce.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story doesn\u2019t explicitly state that the relevant drugs are clinically available, acetaminophen and ibuprofen are both sufficiently well-known over-the-counter painkillers that the writer can assume most readers are familiar with their availability. Opioid drugs, meanwhile, are generally much harder to access and tightly regulated in many states.", "answer": 1}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nFIT goes one step further than MI, as it makes use of multisensory imagery to explore these changes by teaching clients how to elicit and practice motivational imagery themselves.\nThe full study, entitled Functional Imagery Training versus Motivational Interviewing for Weight Loss: A randomised controlled trial of brief individual interventions for overweight and obesity is available to view in the International Journal of Obesity (doi: 10.1038/s41366-018-0122-1).\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release describes FIT as a \u201cnew motivational intervention.\u201d Is it in widespread use? How difficult would it be for someone to find a practice that can provide FIT for weight loss? The release doesn\u2019t address this.", "answer": 0}, {"article": "Nighttime and morning BP decreased more profoundly on average -8/3.5 mm Hg for SBP/DBP, respectively.\nLuckily, as we show in our research, melatonin helps to ameliorate both trends.\nThe improvement of circadian pacemaker functions may also provide a new strategy in the treatment of hypertension.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nFirst week control data were collected for 7 successive days.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Melatonin supplements are available almost everywhere.", "answer": 2}, {"article": "According to the FDA, \"Testosterone products are FDA-approved only for use in men who lack or have low testosterone levels in conjunction with an associated medical condition.\nTestosterone isn't prescribed with the goal of improving heart health, but that is a consideration in many cases.\nBarua and colleagues say they don't know the exact reasons for testosterone's apparent benefits for the heart and overall survival.\nThe new VA study is likely to draw attention because of its large size and relatively long follow-up period.\nThe findings may sway the ongoing debate over testosterone therapy's benefits and risks, especially for the heart.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that testosterone therapy is available to patients.\u00a0 The narrative does go to the trouble of noting that \u201coff-label\u201d use of testosterone is a no-no.", "answer": 1}, {"article": "But an electrolyte imbalance caused by dehydration, influenza or other health problems that deplete the system of potassium, magnesium and other minerals also can cause cardiac arrest.\nHe said a doctor at Mercy Hospital also is using the therapy on patients.\nDr. Ashis Tayal, an AGH stroke neurologist, said trials are under way to use the therapy to help stroke victims.\nThere are now calls for paramedics to use the cooling procedure in the field en route to the hospital.\nUPMC Presbyterian does about 50 hypothermic therapies a year, said Dr. Clifton Callaway, assistant professor of emergency medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that this treatment is not available at all hospitals.", "answer": 1}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nThere was no funding used for this study.\nThe goal is to help the concussion patient feel better as the brain heals.\nPhotophobia is so common that many neurosurgical intensive care units consider it standard operating procedure to keep lights dimmed in rooms containing TBI patients says Clark.\nCertain colors make seeing stop lights or emergency vehicle lights difficult.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These lenses are presumably available at optical shops, but it\u2019s unclear from the release.", "answer": 0}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nImportantly, one patient showed some improvement, though he and his colleagues noted that this outcome \"must be interpreted with caution\" since the study wasn't designed to measure effectiveness of the treatment.\nIn Pharr's opinion, this and other stem cell studies are certainly fair from a participant's perspective, since beforehand, \"patients are presented with all the risk factors involved so they can make an informed decision.\"\nThe results of one new study may be less than hoped for, but the science is sound: The study concluded that injecting stem cells into the spinal cords of patients with amyotrophic lateral sclerosis is safe in most, though not all, cases.\n\"People who do these studies should be considered medical heroes,\" Goldstein said, adding, \"The selflessness of these people when they're told they're gonna die.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes a lead researcher saying, \u201cwe are just now getting started with testing our hypotheses about using stem cells as therapeutics. \u2026 We do not know if these treatments\u00a0will work, and it will take time\u00a0to test these therapies in a systematic and safe way.\u201d", "answer": 1}, {"article": "And for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\nThen the researchers will need to show that the rate of false alarms remains very low, otherwise people will be sent on needless and expensive medical odysseys.\nAs for the cost of the test, Papadopoulos says the research team has tried hard to make it affordable.\nTheir experience will help answer the next big question, which is whether CancerSEEK will pick up cancer in people who don't have symptoms.\nThe scientists at Hopkins have already launched their next study, which could involve tens of thousands of apparently healthy volunteers who are enrolled in the Geisinger Health Plan in Pennsylvania.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned the authors of the study are \u201choping their idea would eventually lead to a $500 test \u2026 but they have a long way to go.\u201d Future studies of the screening test are also discussed, so it seems clear this test is not currently available.", "answer": 1}, {"article": "The researchers, Drs.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\nAlso, the men in this study were diagnosed only after they had symptoms, unlike the majority of men in the United States, Greenberg said.\nThere was also a benefit in men whose tumors had low-risk characteristics.\n\"The management of early stage prostate cancer continues to require further randomized controlled studies, which are underway, to determine the true benefit of treatment versus expectant management,\" said Dr. Marc Danziger, an attending urologist at Lenox Hill Hospital in New York City, who was not involved with the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "An important caveat about how the prostate cancer in the study differed from the way in which prostate cancer is most commonly detected today in the US was explained.", "answer": 1}, {"article": "\"I can do what everybody does.\"\n\"That's huge,\" said lead author Fran Weaver, a researcher with the Hines VA Hospital in Hines, Ill.\n\nShe said the best drugs provide only one to two hours of added improvement, or \"on time.\"\nA study released online Tuesday concluded that so-called deep brain stimulation was substantially more effective in treating Parkinson's than the best drug therapy, but it also carried a much greater risk of serious adverse side effects.\nNausieda said much of the benefit found in the study could be due to a placebo effect.\nThe hospital has done about 300 of the procedures since 2005, said Brad Hiner, an associate professor of neurology at the Medical College of Wisconsin and neurologic director of the hospital's deep brain stimulation program.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the article does not make a clear statement about availability, it does imply that deep brain stimulation is available in at least some hospitals, has been in use since at least 2005, and is applied to a variety of conditions. \nThe story says that only 2 percent of patients get the surgery, while 15 percent are eligible. It would have been useful to know if availability played any role in this discrepancy. ", "answer": 1}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story does not report that this trial tested a specific type of exercise program known as Jaques-Dalcroze eurhythmics, so readers have no way of finding out whether it is available to them.", "answer": 0}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nWe want them to know that mammography can detect cancer early \u2014 when it's most treatable and can be treated less invasively \u2014 which not only saves lives but helps preserve quality of life.\"\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\n\"The decision whether or not to get a mammogram remains with women.\nRisk-based screening is a poor approach.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability isn\u2019t mentioned. But because getting a mammogram is relatively routine, we\u2019ll mark this one \u201cnot applicable.\u201d", "answer": 2}, {"article": "Trigeminal neuralgia (TN) is a very painful nerve disorder that causes an electrical shock feeling in the face, usually in older people.\nThe authors, from Cleveland Clinic in the US, say considering radiosurgery earlier on could make a big difference to patients' lives.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\nBy considering it earlier as a treatment option, doctors could help improve the lives of patients with TN more quickly.\nHowever, it is often overlooked or delayed as a treatment because there is a lack of capability and experience with the method.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The authors suggest in the release that the radiation treatments should be used more, which implies it is not in wide use: \u201cit [radiosurgery] is often overlooked or delayed as a treatment because there is a lack of capability and experience with the method.\u201d This statement highlights that this may actually not be possible due to lack of trained clinicians.", "answer": 1}, {"article": "But only about 10 percent of smokers ever develop lung cancer, although they often die of other causes such as heart disease, stroke or emphysema.\nThe researchers have patented their findings through the universities but Bild said myo-inositol supplements are cheap and freely available.\n\u201cEven in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,\u201d said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\nAnd the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This genetic test is not yet available, but the story could have been clearer on that point. The story suggests there is no question regarding the availability of myo-inositol; however, more information on the specific formulation used in the study, as well as the dosage would have been useful. ", "answer": 1}, {"article": "Aside from hair transplants, which can cost about $10,000 each and do not always look natural, the only current hope for complete replacement is hair cloning, the act of producing entirely new hair from the DNA of an existing one, which researchers have been attempting, unsuccessfully, for years.\nThe result is an enhanced, refortified hairline rather than a brand new head of hair.\n\u201cIt was a noticeable difference.\u201d\n\nBut Latisse does not appear to be a silver bullet for hair loss.\nThe potential for Latisse is not lost on Allergan.\napproved a new hair-loss remedy (Propecia, in 1997), so it is understandable that anticipation for a new one might be running high.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Latisse is a prescription product sold for eyelashes but being used off label by some doctors for hair loss.", "answer": 1}, {"article": "Labor may be induced by breaking the amniotic sac or by using hormones called prostaglandins or medication such as oxytocin, which can set off contractions.\nAs with any change in standard medical care, extensive research is needed before it can be safely and widely adopted.\n\u201cSince we don\u2019t know exactly what triggers labor, why mess with it?\u201d\n\nHausman suggested learning from countries such as Denmark or Sweden, where midwifery is the first line of care and where fetal and maternal mortality rates are lower than in the United States.\nFor Dekker, the major benefit of spontaneous labor is avoiding the risks of a medical induction.\nWhen doctors who treat pregnant women recently met to debate the best time to induce labor, they came up with a surprising answer: 39 weeks \u2014 three weeks earlier than currently recommended.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the discussion centers on when to induce labor, it is clear that treatments to induce labor are widely available.", "answer": 1}, {"article": "The scientists, meanwhile, collected blood samples from the men several weeks before the race, as well as immediately before to the start, at the finish line and on select days afterward.\nAlcoholic beer happens to be drenched in polyphenols, too \u2014 \u201ceven more than nonalcoholic beer,\u201d Dr. Scherr said \u2014 but has the signal disadvantage of being alcoholic.\n\u201cFurthermore, it is not possible to drink one to one and a half liters of alcoholic beer per day, especially not during strenuous training.\u201d We all knew that, right?\nFor that, at least, the beer can be full-potency.\nJust how nonalcoholic beer eases the ravages of strenuous marathon training and racing is still being investigated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nNot applicable.\u00a0 The availability of nonalcoholic beer is not in question.\nHowever, it is not clear from the original abstract whether the type of beer matters, as the brand and/or the characteristics (such as calories) were not provided. This is not mentioned in the story. (note: the brand was provided in a press release)", "answer": 2}, {"article": "Some doctors say the increased rate of Caesareans is partially attributable to maternal demand: busy mothers may want to schedule their deliveries.\nAnd some women are scheduling them early.\nBut defining medical necessity is complicated.\n\"There are certainly women who want timed, elective delivery surgically.\"\nto her seconds-old son in her bathtub, will give them another view.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly Caesarean\u00a0birth is available.", "answer": 1}, {"article": "The women were followed for an average of about 3.5 years.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\nHowever, \"what our findings show is that women who choose to have these surgeries will reduce their risk of dying of breast or ovarian cancer by about 70 to 80 percent, which is pretty profound,\" said study senior author Dr. Timothy Rebbeck, a professor of epidemiology at the University of Pennsylvania School of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "Exercise, and in particular strength-training routines that develop muscles of the trunk and core, can help reduce pain and improve function, though many people avoid them for fear of doing further harm.\n\u201cMore participants in the yoga and stretching groups were very satisfied with their overall care for back pain.\u201d\n\nDr. Sherman said that like many other therapies for low back pain, yoga probably would not work for everyone.\nBut she cautioned that her study looked specifically at deep stretching that is far more involved than the brief, light stretches most people do before or after a workout.\n\u201cThe smaller studies which hinted that yoga might be helpful all had problems one way or another.\nFor those who want to try, a weekly class and a few 20-minute sessions at home might be a good starting point, she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\n \nThe writer probably assumed that yoga classes and stretching programs are widely available across the United States. So we\u2019ll award a \u201csatisfactory\u201d here.\nBut it is not actually all that clear that similar \u201cviniyoga\u201d classes and intensive stretching programs are available in most communities\u2014or that physicians and patients can easily find them. And it is not clear to what extent they are covered by health insurance plans.\n", "answer": 1}, {"article": "\u201cNot everything that is natural is safe,\u201d she said.\nHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract.\nResearchers would still need to conduct pre-clinical trials to test its medicinal benefits.\nFrom an ecological standpoint, Quave said, it makes sense that invasive weeds have a chemical advantage that may help protect them from diseases so they can spread more easily in a new environment.\nThe discovery may hold the potential for new ways to treat and prevent antimicrobial-resistant infections, an enormous global problem that was the focus of a rare high-level United Nations summit last fall.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the product isn\u2019t available yet:\n\u201cHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract. Researchers would still need to conduct pre-clinical trials to test its medicinal benefits.\u201d\nAs we noted above, the story also could have mentioned the need for expensive follow-up studies involving many patients, should those pre-clinical studies produce positive results.", "answer": 1}, {"article": "Politicians started giving scary speeches about rationing health care.\nSo perhaps it\u2019s not surprising that the company\u2019s PowerPoint presentation to the FDA included the unsubtle phrase \u201chuge breakthrough,\u201d or that the first American patient to undergo 3-D mammography \u2013 Laura Lang, a polished 55-year-old Boston marketing executive and breast cancer survivor \u2013 did so in front of a CBS camera crew last February.\n\u201cThe images sort of sell themselves.\u201d\n\nMuch of the criticism focused on the data the task force had used to make its decision, which consisted largely of the results from prospective, randomized clinical trials conducted in the United States.\n\u201cIt\u2019s a step, but it\u2019s a step by a person who has a stride of 7 feet.\u201d \u201cIt\u201d is a 3-D mammography machine, the Selenia Dimensions system, one of which sits in the breast imaging clinic at Massachusetts General Hospital that Rafferty, a radiologist, runs.\nOf course, Hologic has done some selling of its own.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Early in the piece, the story mentions the limited availability of 3-D mammography, which received FDA approval in February 2011.\u00a0 The technology is currently available in \u201c\u2026at least nine states, three of which have multiple sites.\u201d\u00a0 The technology is clearly available for the paper\u2019s readers because the piece focuses on Massachusetts General Hospital, which was both a development and\u00a0a test site for the equipment.", "answer": 1}, {"article": "Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\n\"While the information in this analysis is helpful to physicians, patients also can benefit from these findings and use it with their doctors to weigh all possible treatment options.\"\nMore information about the AAOS and JAAOS\n\nFollow the AAOS on Facebook, Twitter and Instagram \n\nFollow the conversation about JAAOS on Twitter\n\nFrom the Department of Orthopaedics, Dartmouth-Hitchcock Medical Center, Lebanon, NH (Dr. Jevsevar), American Academy of Orthopaedic Surgeons, Rosemont, IL (Mr. Shores, Mr. Mullen, Ms. Schulte, and Dr. Cummins), and Franciscan Orthopedic Associates, Tacoma, WA (Dr. Brown).\nThis new research analyzed data from multiple trials to determine the relative effectiveness of various nonsurgical treatments for knee OA.\n\u2022 HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that all the treatments noted in the release are generally available.", "answer": 1}, {"article": "More than half of the 35 million people living with HIV worldwide are women, and the vast majority live in sub-Saharan Africa.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\nLooking by age, the researchers saw that the ring did not seem to help women younger than 21.\nOne of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\nBut 1 in 3 infections were prevented overall \u2014 and that\u2019s huge.\u201d\n\nWarren noted that other rings with antiretrovirals are also being developed, as well as rings that could offer multipurpose protection, against not only HIV but pregnancy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that the dapivirine ring \u201chas been in development for more than a decade,\u201d suggesting that it is not yet available. Some comment on when the device might become available would have been useful.", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these different diets is not in question.", "answer": 2}, {"article": "\"The disc is made up of mostly water, and it get tears in it.\nHe says his intent was not to put some orthopedic surgeons out of business.\nWhether you have surgery often depends on where you live and what doctor you see.\nBut no matter where you live, surgery is not necessarily the best or only option.\nThe operation was a success and she's been pain-free for four years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear from the storyt that surgery for herniated disc is widely available. ", "answer": 1}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story fails to mention a projected date for or the next steps in obtaining FDA approval. While the FDA usually follows the advice of the advisory panel, which in this case recommended the drug\u2019s approval for treatment of dementia associated with Parkinson\u2019s Disease, the FDA does not have to follow the panel\u2019s recommendation. There is no discussion of when the FDA might approve the drug for this indication. ", "answer": 0}, {"article": "Compare that with a decrease of about 7 mg/dL for the low-fat diet, and about a 8 mg/dl drop from the moderate-fat diet.\nWe asked Kris-Etherton if she would have published the results had there been no positive findings for the avocado.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\n\"I was surprised to see the added benefit [of the avocado],\" Penny Kris-Etherton, a nutrition scientist at Penn State and the lead author of the study, tells us.\"\nShe says she'd like to do follow-up research to look at the bioactive compounds in avocados, which may explain the added reduction in LDL cholesterol in the study participants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Avocados are widely available, so we won\u2019t ding the story for not discussing availability. As with the competing stories, we would have liked to have seen some acknowledgment that there are areas where avocados may be more difficult to find.", "answer": 1}, {"article": "Bitter taste receptors as targets for tocolytics in preterm labor therapy.\nThe researchers first exposed the tissue to native hormones such as oxytocin and chemical compounds to make it contract, mimicking normal or premature labor.\nThey then exposed the tissue to bitter substances.\n\"The biological mechanism of labor initiation remains unknown, and a large percentage of preterm pregnancies do not respond well to current medications,\" said Ronghua Zhuge, Ph.D., associate professor within the University of Massachusetts Medical School's Department of Microbiology and Physiological Systems in Worcester, Massachusetts.\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not mention the name of the substances tested, so there is no way to know anything about availability. After looking at the research paper we found that the substance was chloroquine which is readily available.", "answer": 0}, {"article": "An epileptic seizure occurs when large groups of neurons in the brain begin firing uncontrollably, disrupting the balance of electrical activity and causing changes in mental function, motor function and behavior.\nReplacing anticonvulsants is not merely an end in itself.\nBut there are dangers to this approach.\n\u201cThe challenge for the next few years is to find out the limitations, the boundaries, the real mechanisms.\u201d\n\nStill, whatever the role of inflammation in epilepsy, Elisa Moller says that anti-inflammatories were a miracle intervention for her son.\nNow Dr. Vezzani and colleagues are testing a molecule called VX-765 that disrupts the inflammatory process she discovered.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "By leaning so heavily on the William Moller anecdote, the story may confuse some readers as to whether anti-inflammatory treatments are widely available for people with epilepsy. But the story also makes clear in several places how one particular treatment being prepared for market \u2013 VX-765 \u2013 is progressing through the various clinical trials necessary for it to become a clinical application.", "answer": 1}, {"article": "An 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.3\n\n\"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini\u00ae applicator for the CoolSculpting\u00ae system to treat the submental area,\" said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass.\nDUBLIN, Dec. 12, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the CoolSculpting\u00ae treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments.\nAllergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life.\nYou should not have the CoolSculpting procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.\nThe CoolSculpting procedure is not for everyone.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says the technology is available through a network of CoolSculpting centers worldwide. It also refers readers to its website, where you can search for a list of clinicians and specialists offering the procedure.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe FDA granted this application Priority Review, Fast Track (for the mastocytosis indication) and Breakthrough Therapy (for the AML indication) designations.\nThe drug is approved for use with a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay, which is used to detect the FLT3 mutation in patients with AML.\n\u201cRydapt is the first targeted therapy to treat patients with AML, in combination with chemotherapy,\u201d said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology Products in the FDA\u2019s Center for Drug Evaluation and Research and director of the FDA\u2019s Oncology Center of Excellence.\nThe FDA granted the approval of Rydapt to Novartis Pharmaceuticals Corporation.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While the release doesn\u2019t specifically state the availability of the drug, the FDA approval for its use suggests that it should start to become available in a matter of months and not years.", "answer": 1}, {"article": "In new research that could suggest a road to cure, scientists at Dana-Farber Cancer Institute and Boston Children's Hospital have found that CML stem cells die in response to inhibition of a protein called Ezh2.\nJoining senior author Orkin, the study's lead author is Huafeng Xie, PhD, of Dana/Farber/Boston Children's.\nDana-Farber/Boston Children's is a site in the multi-center Phase 1 trial.\nCo-authors are Cong Peng, Jialiang Huang, PhD, Bin E. Li, PhD, Woojin Kim, Elenoe C. Smith, Yuko Fujiwara, PhD, Partha P. Das, Minh Nguyen, of Dana-Farber/Boston Children's; Jun Qi, PhD, of Dana-Farber; James E. Bradner, MD, of Dana-Farber and the Novartis Institute for BioMedical Research; Shaoguang Li, MD, PhD, of University of Massachusetts Medical School; and Giulia Cheloni of UMass Medical School and the University of Florence, Florence, Italy.\nAlthough adding Ezh2-targeting agents to the standard drug regimen for CML has the potential to dramatically shorten the treatment period for many patients, ethical considerations may lead to the agents' first being tested in patients who don't respond to Gleevec and similar drugs, either initially or after drug resistance develops, Orkin remarks.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes imatinib-like drugs are\u00a0the standard of care for CML patients, implying a\u00a0diagnosis would grant access to the drugs by prescription.\u00a0Though it doesn\u2019t name the potential\u00a0Ezh2 inhibitor drug, the release does note it\u2019s part of a Phase 1 trial, as well as other clinical trials\u00a0\u2014 implying it\u2019s not readily available. A\u00a0lack of absolute clarity here isn\u2019t helpful to readers, but there\u2019s enough to mark\u00a0this satisfactory. A statement that clarified that it would likely be years before testing in humans would be complete would have been appropriate here.", "answer": 1}, {"article": "Levels of the biomarker were lower in mild cases, and were much more elevated in severe case,\" said Papa.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\nAs expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries.\nNeither scenario gives doctors an objective indication of the severity of the injury.\nThe biomarker this particular blood test looks for is known as glial fibrillary acidic protein (GFAP).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the GFAP test is not available for clinical use, and that the researchers hope to develop a test for clinical applications within the next five years.", "answer": 1}, {"article": "All of these study participants \u2014 largely people in their 70s, all with a diagnosis of either \"mild cognitive impairment\" or atypical dementia \u2014 are living with the unconfirmed suspicion that they have Alzheimer's. The study is underwritten by the Centers for Medicare & Medicaid Services and the Alzheimer's Assn. It set out to find out whether knowing \u2014 getting the costly test that would offer either confirmation or reprieve \u2014 would change the way that patients with cognitive troubles are treated, or the way that they plan their lives.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a close call. In general, PET scans are widely available, if costly. The story also made it clear that Medicare doesn\u2019t cover this scan. But, the story could have gone a step further and explained without Medicare coverage, it\u2019s unlikely to become widely available.", "answer": 1}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nOne study participant \u2014 Bob O'Keefe, 68, of suburban Boston \u2014 was glad to avoid surgery for his meniscus injury three years ago.\nSurgery costs about $5,000, compared with $1,000 to $2,000 for a typical course of physical therapy, Katz said.\nThe new federally funded study compared surgery with a less drastic option.\nBut those who stuck with therapy had improved as much six months and one year later as those who had arthroscopic surgery right away, researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the various treatment approaches is not in question. The story could have cited stats from the study:\n\u201cThis procedure, in which the surgeon trims the torn meniscus back to a stable rim, is performed for a range of indications in more than 465,000 persons annually in the United States.\u201d", "answer": 2}, {"article": "Those most at risk of developing such cancers are of Eastern European Jewish descent.\nThe prescription-free test is the first to report on three specific BRCA1 and BRCA2 breast cancer gene mutations, according to the FDA.\nThat accounts for a small percentage of people.\nMore: Breast cancer: Study finds tumor risk increased by use of oral contraceptives\n\nBut \u201cit has a lot of caveats,\u201d warned Donald St. Pierre, acting director of the FDA's Office of In Vitro Diagnostics and Radiological Health.\n\u201cThe test should not be used as a substitute for seeing your doctor for cancer screenings or counseling on genetic and lifestyle factors that can increase or decrease cancer risk,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make it clear when this test will be available.\u00a0\u00a0The company\u2019s website notes that said testing results will be available \u201cin the coming weeks.\u201d", "answer": 0}, {"article": ".\nRegister now for the 2018 AAN Annual Meeting Press Room in Los Angeles, April 21-27, 2018\n\nThe study was supported by the National Institute on Aging.\n\"Future studies are now needed to confirm these results and to determine the best nutritional components of the DASH diet to prevent depression later in life and to best help people keep their brains healthy,\" said Cherian.\nCherian noted that the study does not prove that the DASH diet leads to a reduced risk of depression; it only shows an association.\nThe odds of becoming depressed over time was 11 percent lower among the top group of DASH adherers versus the lowest group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release refers repeatedly to the DASH diet. However, while the DASH diet has been around for years, many readers will likely never have heard of it. The release appears to assume that the DASH diet is common knowledge. While the DASH diet isn\u2019t a secret, it\u2019s not something you can assume readers are familiar with either. This could have been addressed by simply noting that the DASH diet has, well, been around for years. It could even have referred readers to a description of the plan on an NIH website.", "answer": 0}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\nThe study was published on August 5th in the Journal of the American Academy of Dermatology.\nThe study was supported in part by a grant from the National Institutes of Health.\nDr. Lazova is currently the Director of Dermatopathology at California Skin Institute in San Jose, California.\nEarly diagnosis of melanoma is critical to cure and long term survival.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While IMS use is growing in different fields of medicine, the news release doesn\u2019t explain how accessible it is. Can a patient request one from their local dermatologist? Would most dermatologists know how to interpret the test results? The news release makes no attempt to inform us.", "answer": 0}, {"article": "Ilaris is manufactured and distributed by Novartis Pharmaceuticals Corporation, of East Hanover, New Jersey.\nThere are no previously approved therapies for TRAPS or HIDS/MKD.\nHealth care professionals should review the prescribing information in the labeling for detailed information about the approved uses.\nApprovals for the new indications were based on clinical studies, including safety, efficacy and pharmacokinetic data.\nThe most common adverse reactions for these indications are injection site reactions and being more susceptible to catching colds.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the drug has already been approved for two other conditions, it\u2019s safe to assume that the drug is already on the market and generally available.", "answer": 1}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\nFuture research will look at whether safety and tolerability might be improved and whether efficacy of CBD can be maintained at lower doses.\nThis new, randomized, controlled clinical study eliminated those concerns as participants and their physicians did not know if they were on CBD or placebo, say the study authors.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that Epidiolex \u201chas not been approved by the U.S. Food and Drug Administration\u201d yet, so readers can assume that it is not yet available to the public. The FDA does, however, consider cannabidiol an investigational product for treating children with epilepsy and has \u201cexpanded access provisions\u201d that allow its use. This would have been useful information to include in the release.", "answer": 1}, {"article": "\"Now they tell me, 'You never say 'What?'\nIn March, she plans to have one put in her right ear.\nFor patients with profound hearing loss, a cochlear implant is a better option, he said.\nEven with one implant, Merlo called the results \"surreal.\"\nNow, thanks to an implant called Esteem, Merlo can multitask.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story mentions that the Esteem implant is FDA approved, it is not clear why Dr. Marzo is the only surgeon in the entire Chicagoland area authorized to implant the device. Is this typical of other cities? Why is the procedure not more widespread?", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott said it does not disclose the price of its stents.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\nHe says a \"perfect storm of events,\" including safety concerns and the economic downturn led Abbott and competitors Medtronic Inc. and Boston Scientific Corp. to slash prices in recent years.\nDoctors who studied Absorb said it may take several years before its advantages become clear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news peg for this story was FDA approval of the device for patients with coronary artery disease.\u00a0 But although the Abbott Labs\u2019 press release suggests that the dissolvable stent is available worldwide (\u201cin more than 100 countries, including the United States\u201d), the story does not mention U.S. access to the device. The Reuters story covered this criterion better.", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story makes it clear that the device studied is in clinical trials for the targeted patient population and that a similar device is on the market. \u201cJust over a month ago, Boston Scientific won federal approval to treat mild-symptom heart-failure patients with such devices. Medtronic is seeking such approval, but already sells it for more severe heart failure patients.\u201d We would have liked to have seen some estimate of how many people have these devices implanted every year.", "answer": 1}, {"article": "Men who had the highest levels of lycopene in their blood were 55% less likely to have a stroke, compared with men who had the lowest levels of the antioxidant in their blood.\nTomatoes are not the only food that is rich in this antioxidant.\nDuring that time, 67 men had a stroke.\nThe new study included slightly more than 1,000 men from Finland aged 46 to 65.\nThe findings appear in the Oct. 9, 2012, issue of Neurology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes isn\u2019t in question.", "answer": 2}, {"article": "Heterosexuals who are HIV negative can significantly reduce their risk of infection by taking a daily dose of an antiviral drug, according to a new study by the Centers for Disease Control and Prevention.\nThe news comes at the same time a second study looking at PrEP in heterosexual couples in Kenya and Uganda also found significant reductions in infection rates.\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nAt the same time he says, there was no evidence of safety concerns.\n\u201ciPrEx provided the first proof of an important new method of HIV prevention that can help slow the global toll of 2.6 million new HIV infections each year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the competing AP story, this story didn\u2019t make it clear that there will be issues in getting this strategy implemented in Africa and in the US.", "answer": 0}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\n\"We're trying to provide an alternative material, an alternative therapy,\" he said, because the current method involves the dentist removing all of the infected pulp tissue, \"scraping it out, and it can be very painful.\"\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nIf successful, a treatment like this could someday offer significant benefits for millions of dental patients each year.\nThe stem cell procedure is in the earliest stages of development, said Celiz.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the research is \u201cstill in its early stages, and has not yet been tested in people.\u201d It also quotes a researcher saying, \u201cIt\u2019s hard to put timeline on it, but we\u2019re talking years before we test it in humans.\u201d\nStill, the story could have been more skeptical in its approach, pointing out that the therapy may never pan out.", "answer": 1}, {"article": "Mark Thomas, who researches addiction at the University of Minnesota Health Sciences, says that a vaccine like this could help a former heroin abuser, \u201cforge a path to abstinence.\u201d Thomas, who was not involved with the study, explains that he was initially wary of the vaccine approach.\nA vaccine that blocks the high from heroin has just moved one step closer to reality.\nThe compound, created by chemists at the Scripps Research Institute, works in a way that\u2019s similar to other vaccines.\nAs a result, those molecules never reach the brain, preventing the euphoria that may have otherwise resulted.\nBremer and Janda now hope to find a company interested in conducting a human study so that the vaccine can become commercially available.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that research has not yet taken place in humans, indirectly inferring that it\u2019s not available.", "answer": 1}, {"article": "About 35% of U.S. adults take calcium supplements, alone or in multivitamins, according to a recent report in the medical journal JAMA.\nTeen girls, who are in crucial bone-building years, often have diets that fall short of their needs, 1,300 mg a day, Wallace says.\n\u201cIf you look at the overall totality of the evidence, there\u2019s a lack of association between supplement use and heart attack and other cardiovascular events,\u201d says Manson, who co-wrote an editorial accompanying the review.\nSome people do need supplements.\nThe larger review did not include all potentially relevant studies, says Erin Michos, an associate professor of medicine and epidemiology who led the Johns Hopkins study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not address calcium supplement availability. However, given that these supplements are not new, and are widely available, we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "In a study of 240 adults, half younger than 50 and half over, one shot prompted the same kind of immune response indicating protection that is seen with regular flu vaccine.\nHealth officials say influenza is circulating unusually early this year with cases in every state \u2013 and nearly all the infections are swine flu.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nSupplies of swine flu vaccine are expected to be available in mid-October.\nDespite all the headlines about swine flu, which has become the main influenza strain circulating in the world, doctors do expect some garden-variety flu to hit this fall too \u2013 the kind that every year kills 36,000 Americans and hospitalizes 200,000.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that H1N1 vaccinations are expected to be available in mid-October and that seasonal flu shots are available now.", "answer": 1}, {"article": "To fight harmful bacteria, researchers isolate beneficial bacteria from our skin and grow it in a lab.\nExperts say there is more research to be done, but that the goal of the trial is to discover the best combination of bacteria to clear eczema from the skin and then make it available to patients as a prescription cream.\nResearchers hope that using the bacteria-infused cream will offer a long-term solution where other treatments fall short.\nA new clinical trial is testing a natural treatment that researchers hope will provide a long-term solution for those dealing with the dry, itchy and painful skin that comes with chronic eczema.\nThe next steps involve testing those different combinations, ensuring they're safe and conducting a longer trial to see if the benefits of bacterial cream can truly provide a permanent solution for eczema patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests the benefit of the cream was already proven and hints that the treatment would be available soon.\nIt would have been helpful to note for readers something like, \u201cbecause this lotion is in clinical trials, it is not currently available on the market; furthermore the preliminary results have not been published or peer-reviewed.\u201d", "answer": 0}, {"article": "The F.D.A.\nThe analysis is part of a controversial review by the Centers for Medicare and Medicaid Services to determine whether to pay for Provenge, which costs $93,000 per patient and extended lives by about four months in clinical trials.\nThere is only \u201cmoderate\u2019\u2019 evidence that the newly approved prostate cancer drug Provenge helps patients, according to an analysis done for Medicare that was made public on Wednesday.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nAfter Dendreon completed another trial, which reaffirmed a survival advantage for the drug, Provenge was approved this April.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that treatment with Provenge has been approved for certain patients with advanced prostate cancer but that availability is limited by manufacturing capacity.", "answer": 1}, {"article": "They found that the saliva of people with Alzheimer's had different levels of certain substances compared to the saliva of healthy people or those with mild cognitive impairment.\nExperts agreed that the findings held promise, but much more research will be needed.\nBut that convenience also brings its own problems, Wright added.\nThe study was to be presented Sunday at the Alzheimer's Association International Conference in Washington, D.C.\nExperts note that studies presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "At a number of different points in the story we are reminded of the preliminary nature of the research, suggesting that it is years away from prime time.", "answer": 1}, {"article": "The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.\nBut after 11 months, more than half of the combination group had yet to see their disease worsen.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\nThere were no complete responses with Yervoy alone.\nThe complete response rate was 22 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that both drugs are currently on the market. However, the story doesn\u2019t make clear to readers that both drugs have been approved by the FDA for use in treating advanced melanoma. That said, it\u2019s not a major oversight for most readers.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A reader might reasonably conclude that the treatments the story describes are generally available. Whether the same outcomes are equally obtainable at all hospitals is unclear. The studies were performed at some of the leading spine centers in the world.", "answer": 1}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the highlighted device, the RapidArc, was currently in use in only 30 locations in the US. \u00a0\n\u00a0", "answer": 1}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that these genetic tests are currently available.", "answer": 1}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nNonetheless, several experts said they would continue to support taking DHA in pregnancy, especially since it is safe and apparently has few downsides.\nDr. Jatinder Bhatia, a neonatologist heading the nutrition committee of the American Academy of Pediatrics, said that unless further studies showed no benefit as children got older, he would continue recommending DHA, now in many prenatal vitamins, because \u201cI\u2019m not convinced at this time that we should reverse course.\u201d\n\nMuch about DHA is unknown.\nShe said babies in her study might have received more DHA than those in this study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread availability and use of fish oil is clear from the story.\u00a0 Although the story would have helped readers more by reporting on issues of purity, quality control, and difficulties for consumers in assessing the quality of a source or brand.\u00a0 This would have made it clear that this not a straightforward choice to just \"take fish oil.\"\u00a0 ", "answer": 1}, {"article": "And is the outcome the same for everyone?\u201d\n\nPuigserver, who runs a cancer biology lab at Dana-Farber Cancer Institute, noted that addressing health and aging through metabolism involves a complex web of pathways and mechanisms.\nGuarente pledged that Elysium Health would be unlike most other companies in the business: It is conducting studies of its pill in humans and will release the results.\nOne of the venture capitalists backing Elysium Health acknowledged that skepticism is among the company\u2019s greater challenges.\nAt a recommended dose of two gel caps daily, a month\u2019s supply of Basis will cost $60 ($50 with a membership) and will be available online only.\nSzostak said his role at Elysium Health is to scour scientific literature for new natural compounds that are shown to improve health and bring them to the company\u2019s attention as potential ingredients in new products.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions the pill will be available online and debuted on Tuesday.", "answer": 1}, {"article": "\"And in that case, I see this as just a waste of money.\"\nFor her part, Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group \"Safe Minds,\" expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\nThe study was limited to high-functioning males and so did not allow researchers to generalize the findings to females, younger children, or \"lower functioning\" individuals with autism, the researchers wrote.\nInformation from this investigation will be pooled with those of another ongoing long-term study, which is tracking brain activity among an additional 100 autism patients.\nTHURSDAY, Oct. 14, 2010 (HealthDay News) -- With the aim of catching autism in children at an earlier age than currently possible, scientists are exploring the potential of using MRI scans as a screening tool.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "MRI is FDA approved and has been around for a good while and is available to most of the US population.\u00a0Still, there is no explicit mention in the story of MRI\u2019s availability in general, nor any specific mention some mention of how much difficulty patients might have seeking an MRI for this use. ", "answer": 0}, {"article": "\"If you are an Asian kid, you've had these placed on you since time immemorial,\" he said.\nBefore the FDA action, pain-relieving patches were available in the United States only by prescription, said Dr. John Dombrowski, director of the Washington Pain Center in Washington, D.C. Their active ingredients include such medications as lidocaine, capsaicin and non-steroidal anti-inflammatory drugs, or NSAIDs.\nThey've been sold in various countries in Asia since the 1930s, according to their manufacturer, the Japanese firm Hisamitsu Pharmaceutical.\nThe patches also deliver their medicine directly to the site of a person's pain.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that pain-relief patches have been used in some form for decades while only recently becoming popular in the US. \u201cThe U.S. Food and Drug Administration approved the country\u2019s first over-the-counter, pain-relieving transdermal patches in 2008. But the patches, marketed under the brand name Salonpas, are nothing new. They\u2019ve been sold in various countries in Asia since the 1930s, according to their manufacturer, the Japanese firm Hisamitsu Pharmaceutical.\u201d", "answer": 1}, {"article": "However, he said, \"I think it is becoming more popular, both from a physician perspective but also from a patient perspective.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nCancer Treatment Centers was among the first to adopt brachytherapy for breast cancer patients a decade ago, Kelly said.\nNot all communities offer radiation treatment, so women often must travel to receive it.\nBrachytherapy remains a mainstay of prostate cancer treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not indicate whether brachytherapy is available at any hospital that provides cancer treatment or only at specialized facilities. ", "answer": 0}, {"article": "The researchers found that 10.2 percent of the patients who received zotarolimus-coated stents suffered a major adverse cardiac event, compared with 8.3 percent of the patients who received sirolimus-coated stents and 14.1 percent of those with paclitaxel-coated stents.\nA newer version, one coated with zotarolimus, fell short, the study found.\nThe trial was partially funded by Medtronic, maker of the zotarolimus-eluting stent.\nThe study was released online Sept. 27 ahead of print publication in the Oct. 5 issue of the Journal of the American College of Cardiology.\nMONDAY, Sept. 27, 2010 (HealthDay News) -- In a head-to-head comparison of drug-coated stents -- the metal mesh tubes used to keep clogged arteries open -- the well-established model using the drug sirolimus came out on top, South Korean researchers report.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article could\u2019ve been more explicit about the availability of these 3 stents, but the last sentence describing the study\u2019s\u00a0real-world implications,\u00a0suggests that all 3 are currently available in cath labs.", "answer": 1}, {"article": "\u201cI tell my patients, \u2018buyer beware,\u2019\u201d Shepard said in an email.\n\u201cHowever, it should not replace other therapy such as quad strengthening exercises, and weight loss, which we know will provide benefit.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\nA daily supplement of pharmaceutical grade chondroitin is as good as celecoxib (Celebrex) at relieving arthritic knee pain and doesn\u2019t have dangerous side effects, researchers say.\nIn addition, U.S.-based studies of chondroitin have had mixed results, said Shepard, who wasn\u2019t involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that pharmaceutical-grade chondroitin is not the same as the labeled supplement one might buy over-the-counter, but makes no mention of how else to obtain it. Can doctors prescribe it? And do patients need a prescription to obtain it? Is there a brand name associated with the high-grade\u00a0formulation?", "answer": 0}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cAlthough gastric banding has been controversial and is currently less used in adults with severe obesity, lap band surgery is one of the most studied surgeries for obesity management, has a high safety record and can be a temporary option to manage severe obesity during adolescence,\u201d says Mr Khurana, who is also a Senior Lecturer in the University of Adelaide\u2019s Discipline of Paediatrics.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n\u201cWe are talking about a group of adolescents with severe obesity and significant health and psychological problems related to their increased weight \u2013 this is not for everyone,\u201d says corresponding author and Paediatric Endocrinologist Dr Alexia Pe\u00f1a, who is a Senior Lecturer with the University of Adelaide\u2019s Robinson Research Institute.\n\u201cIt is also important that teenagers undergoing this surgery have access to an experienced surgeon as part of a multidisciplinary paediatric team of doctors and Health professionals to ensure there is long-term regular follow-up.\u201d\n\nPaediatric surgeon Mr Sanjeev Khurana, who did all the lap band surgeries between 2009 and 2013, says lap band surgery is a reversible surgical procedure that can be safely used in teens with severe obesity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that lap bands are now in use. The question posed here is whether they would be appropriate for seriously obese teenagers.", "answer": 1}, {"article": "Functional MRI scans generate a dynamic map of the outer surface of the brain, showing changing hot spots of activity over time.\nWe show here that it's not measuring what you're thinking, but how your brain is organized.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nThe consistency of the fcMRI scans makes them a promising diagnostic tool.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are not told how available fcMRIs are to the general public.", "answer": 0}, {"article": "Airways became less likely to close off after exposure to an allergen.\nIt likely will be three to four years before Gleevec could be approved for asthma treatment, Israel estimated.\nThe drug also improved overall airway function, an effect researchers hadn't expected, Israel said.\nPhysical examinations showed that people taking Gleevec actually experienced a slight overall widening of their airways, Israel added.\nTwo generic versions of the drug were launched last year, which could make it less pricey than new-wave asthma drugs headed for the market, Israel added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tempers expectations when it quotes a researcher saying it will \u201clikely will be three to four years before Gleevec could be approved for asthma treatment.\u201d Further, it quotes an independent expert: \u201cIt will take years of study to determine the usefulness of this drug in treatment.\u201d", "answer": 1}, {"article": "Researchers found that the hormones, known as cardiac natriuretic peptides, caused regular energy-storing white fat cells to turn into energy-burning brown fat in mice.\nThe study appears online in the Journal of Clinical Investigation.\nFeb. 6, 2012 -- You may have heard about brown fat -- a unique type of fat that acts like a furnace in the body to burn calories instead of storing them as excess weight.\nIf studies show the same thing in humans, the heart hormone may hold the key to an effective weight loss treatment, says researcher Sheila Collins, PhD, of Sanford-Burnham Medical Research Institute in Orlando, Fla.\n\u201cThese hormones are involved in fluid regulation, but we showed in this study that they also play a role in breaking down fat,\u201d she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable; there\u2019s no product or treatment that can increase brown fat.", "answer": 2}, {"article": "\"The concept is very simple,\" Lee said.\nResearchers plan to start clinical trials next year to test this technology in humans, Sen said.\n\"This is difficult to imagine, but it is achievable, successfully working about 98 percent of the time.\nIn my lab, we have ongoing research trying to understand the mechanism and do even better.\nWith this technology, we can convert skin cells into elements of any organ with just one touch.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "From the final sentence we get a hint that applicability in humans is a long way off: \u201cResearchers\u00a0plan to start clinical trials next year to test this technology in humans.\u201d\nIt\u2019s important to note that\u00a0potential treatments in mice fail to materialize as a treatment in humans about 95 percent of the time. The release should have been a lot more cautious and pointed out that this concept will require many years of study.", "answer": 1}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\nWe\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nAccording to Andrew Lee, co-founder of Medherant, \u201cwe\u2019ve only been in the lab about 12 months, but in the 12 months we\u2019ve essentially assessed about 90 percent of the drugs that are currently available as either creams or patches.\n\u201cWhat\u2019s important is to be able to extend the range of drugs that are available by patches because at the moment we\u2019re limited to about 20 different drugs, and there are thousands of drugs out there, and only about 20 are used in patches at the moment, which is limited by the technology of the adhesive, essentially,\u201d he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tells us the the patches are expected to hit the market in three years, but the information comes direct from the company and isn\u2019t independently verified. Given the stage of development for this technology, three years sounds like a very aggressive timeline given the need for clinical validation of the assumptions made and the need for regulatory approval.", "answer": 0}, {"article": "Lung cancer is the No.\nBut Dr. David Gutterman, president of the American College of Chest Physicians, said more research would be needed before this could be proposed.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\nMetformin is one of the most widely used drugs for type 2 diabetes, with 41 million prescriptions written in the United States in 2008, the American College of Chest Physicians said in a statement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drugs are commonly used for diabetes and some are available generically. Ideally the article could\u2019ve stated explicitly that they\u2019re not approved to prevent or control cancer.", "answer": 1}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nGille is head of clinical and translational science strategy at CSL Limited (which funded the study) in Parkville, Australia.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Significant omission.\u00a0 How does one get IV infusions of \u201cgood\u201d HDL cholesterol?\u00a0 Where does one go for this?\u00a0 Is it only the experimental setting?\u00a0 You can\u2019t assume that readers know and understand this.", "answer": 0}, {"article": "\"Even though children in the Head Start group began the observation period more obese, equally overweight, and moreunderweight than children in the comparison groups, at the end of the observation period the initially obese and overweight Head Start children were substantially less obese andoverweight than the children in the comparison groups,\" the authors wrote.\nMONDAY, Jan. 12, 2015 (HealthDay News) -- School readiness isn't the only benefit young children can gain from Head Start.\nThe daily routine might translate into less TV time and more regular sleep schedules, she said.\nWhether those children were in another preschool program wasn't stated.\nHead Start might provide a structured, supervised routine that's lacking in the home, Katz suggested.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that Head Start is available to children ages 3-5 who live in poverty. We\u2019ll rate this good enough for a satisfactory grade. \u00a0Detail about how to enroll in the program would have helpful.", "answer": 1}, {"article": "While some cases of anosmia may be treated by caring for an underlying cause (often nasal obstruction, in which odors can\u2019t reach the nerves of the olfactory system due to swelling, polyps or sinus disease), other cases involving damage to the sensory nerves of the nose (i.e.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\nThere are currently no proven therapies for these cases.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that a tremendous amount of work needs to be done before any relevant treatment technology might become available.", "answer": 1}, {"article": "Drs.\nAsher and Burri are now working on a new method of focused therapy for tumors that have spread to the brain that combines radiation and surgery.\nThe technique was pioneered at Levine Cancer Institute and they are looking to expand and further validate the approach with the National Cancer Institute.\nFurthermore, whole brain therapy was associated with considerably worse quality of life.\n\"Having the research published in JAMA is validation of more than a decade of work,\" says Dr. Burri. \"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the treatments are currently in general use.", "answer": 1}, {"article": "Coleman RE, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, and Gomis RR.\nThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\n\u201cThe difficulty is identifying which patients will benefit from these drugs,\u201d said Professor Robert Coleman, emeritus professor of medical oncology who led the new study.\nThe new study, which is published in the journal Lancet Oncology, was part of an international phase 3 clinical trial involving 3,360 women with stage II or III breast cancer.\nWomen who do not carry the gene - approximately 80 per cent of women with breast cancer - were found to benefit from the bone strengthening treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that \u201cThe results need to be confirmed in a second trial, currently underway in the United States, before the test is likely to receive approval for wider use in patients.\u201d \u00a0A direct statement that the test is not yet available anywhere would have been more helpful to readers but the quote does let readers know that the test is part of another trial and has not yet been approved.", "answer": 1}, {"article": "It makes the virus particle fall apart,\" he said.\nIf there is a similarity, it may explain why H1 viruses are vulnerable to urumin's wrath.\nIf those studies prove to be successful, human testing could be next.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\nIt doesn't touch H3.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it very clear\u00a0that research has been conducted only in mice and that much more work needs to be done before it can even be assessed in humans.", "answer": 1}, {"article": "Characterized by the World Health Organization as a \"neglected tropical disease,\" leprosy (also known as Hansen's disease) is one of the most ancient diseases known to humankind and is caused by the bacteria Mycobacterium leprae.\nEarly results from the Phase I study should be available in 2018, and the partners are currently exploring mechanisms to advance the vaccine through later-phase clinical trials should results from the Phase I study (clinical trial NCT03302897) support further evaluation.\nThe vaccine candidate will serve as part of an overall strategy to end leprosy, which will require detection, prevention and treatment.\nThe clinical trial is focused on safety, as well as evaluating the immune response to the vaccine.\nBased on data generated in preclinical studies, the vaccine candidate, called LepVax, has progressed to Phase I clinical testing in the United States, the first stage of safety testing in human volunteers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does a good job here, noting: \u201cEarly results from the Phase I study should be available in 2018, and the partners are currently exploring mechanisms to advance the vaccine through later-phase clinical trials should results from the Phase I study (clinical trial NCT03302897) support further evaluation.\u201d", "answer": 1}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThe reduction in risk was even greater for early deliveries.\nIt can affect all of the organs in a woman's body, according to the American College of Obstetricians and Gynecologists (ACOG).\nWEDNESDAY, June 28, 2017 (HealthDay News) -- Something as simple as taking a low-dose aspirin every day may protect pregnant women from the life-threatening condition known as preeclampsia, new research suggests.\nThis is important because it will reduce the need for preterm delivery, which is risky for the baby.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As mentioned above, aspirin is ubiquitous in the modern world so there is hardly a problem with its availability.", "answer": 1}, {"article": "Compared with the 16% of people who didn't drink coffee at all, those who downed two or more cups each day were about 18% less likely to have died during the study period. In addition, those who drank just one to six cups of coffee per week were 12% less likely to die. Both of these figures were calculated after taking into account known risk factors for early death, such as smoking (which is often paired with coffee drinking), diet and body mass index.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is so widely available that there\u2019s no need to make the point.", "answer": 2}, {"article": "After six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\nThe treatments lasted for six months.\nPart of the group was given gemcitabine, the most favored treatment according to oncologists.\nIt was funded by the government of France.\nThe purpose of the study was to record the overall survival rates of each group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the drugs was not discussed.\u00a0 This was a story about a French study.\u00a0 Are the drugs widely available in the US?\u00a0 The story never explained.", "answer": 0}, {"article": "For more on stroke, visit the National Stroke Association.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nThe investigators found that 22 percent of the patients treated with tenecteplase had more than 50 percent of blood flow return to the brain, compared with 10 percent of those treated with alteplase.\nArora explained that tenecteplase is not widely used in the United States for heart attack patients because these patients are typically treated with angioplasty or heart bypass surgery.\nThe researchers specifically looked to see which drug was better at restoring blood flow to clot-blocked blood vessels in the brain, and which drug resulted in patients having better outcomes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story said tenecteplase is not approved for stroke in the United States, though it used for other purposes like heart attacks and blood clots in the lungs.\nIt also notes that \u201cfor either drug to be most effective, it needs to be given as soon as possible after a stroke occurs,\u201d and in this study patients were given the drug within 4.5 hours of the onset of a stroke.", "answer": 1}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes pretty darn\u00a0clear that there will be a) no final answers to the amyloid hypothesis debate any time soon; and b) the advent of a successful anti-amyloid drug that helps those with\u00a0Alzheimer\u2019s is not close at hand.", "answer": 1}, {"article": "They were divided in groups of 10.\n\u201cHowever, much more work needs to be done until we can say with certainty that it will tackle the disease in humans as mouse models don't always faithfully replicate the human disease.\nOur research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nBut, they also warned that these \u201cdrugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage - studies in people are needed first.\u201d\n\nThe research was published in the journal Nature Communications on Thursday.\nBrough, however, cautioned that further research is required to identify its impact on humans and the long-term implications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It says that the drug being studied is\u00a0\u201ca common Non-Steroidal Anti Inflammatory Drug (NSAID).\u201d This\u00a0is\u00a0true for readers in the UK (where the study originates), so we\u2019ll rate this Satisfactory. However, for readers in the U.S. (Medical Daily is an American-owned news site), this is not the case, and it would have been helpful to explain the drug is available by prescription in the U.S., though it is not commonly used.", "answer": 1}, {"article": "\"We're looking right now through a small keyhole at a very very large room, and we really don't know yet how big it will be.\"\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\nThere have been no other recent treatment breakthroughs in squamous cancer, which most commonly occurs in smokers or former smokers, so this advance is particularly welcome, said Janne.\n\"It is early days for the successes of immune therapy,\" said Mark Fishman, president of the Novartis Institutes for BioMedical Research, a research arm of drug company Novartis, which is taking a different approach to turning the immune system against cancer.\nMerck is also studying Keytruda in people with advanced lung cancer to better understand how they are responding to treatment, what determines how well a patient will respond, and how to get good results for more patients, Perlmutter said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Opdivo is approved to treat advanced melanoma. And Pasi Janne, a professor at Harvard Medical School and director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, says more research is needed before \u201cpatients should be routinely treated with Opdivo\u201d and that \u201cit\u2019s a little premature to start treating people today\u2026but I don\u2019t think we\u2019re far away from that.\u201d That\u2019s all very useful context. However, it\u2019s not clear at the end of the day what any of this means for patients. Could Opdivo, given it\u2019s melanoma approval, now be used off-label to treat lung cancer? Should patients expect this treatment to become available in six months? Six years? Ten years? The story also doesn\u2019t note that the study being halted by Bristol-Myers Squibb is a Phase III trial.", "answer": 0}, {"article": "\"When adolescent depression persists without successful treatment, it can interfere with achieving important developmental milestones.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\n\"Although ketamine is potentially a huge breakthrough in the treatment of depression, we still don\u2019t know about the long-term safety, or about how to keep people well from depression without requiring regular ketamine dosing,\" Stone added.\nThe latest study involved 13 young people ages 12 to 18 who had failed two previous trials of antidepressants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story called ketamine \u201ca popular recreational drug and a useful medical anesthetic.\u201d It could have added that while ketamine is an FDA-approved drug for years and is widely available at medical facilities, it hasn\u2019t been approved by regulators for use as an antidepressant.\nIn addition, Johnson & Johnson has said it is close to seeking FDA approval of a ketamine derivative called esketamine, which would be taken as a nasal spray.", "answer": 1}, {"article": "Premature birth can lead to a long list of medical problems and puts babies at risk of dying.\n\"If you are going to be alarming a patient by saying that she may have premature delivery, you want to make sure that's truly the case.\"\nIt would require several years to go through the U.S. Food and Drug Administration approval process.\nThe closer to the preterm birth, the more likely you are to have significant changes in the physiology of the woman that is observed in the blood.\"\nThe test may cost $150 to $250, Graves said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that \u201cIt would require several years to go through the U.S. Food and Drug Administration approval process.\u201d", "answer": 1}, {"article": "In the UK, at least 40,000 people a year die prematurely from air pollution, with a cross-party committee of MPs calling it a \u201cpublic health emergency\u201d.\nThe best thing is that we have clean air because then we don\u2019t need any prophylactic treatment.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nIt is expected to be available as an inexpensive, over-the-counter product.\n\u201cThe point that it can prevent the lung inflammation induced by ultrafine particles is established \u2013 there is no more doubt,\u201d Krutmann said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it relatively clear that the inhaler isn\u2019t available but should be soon.\u00a0More specifics would have been helpful, though.", "answer": 1}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text mentioned that vitamin B12 supplements were available in pill and injectable form; \u00a0a table listing food sources of B12 was included.", "answer": 1}, {"article": "But in some people HPV leads to genital warts and cancers \u2013 notably, cervical cancer.\nThe researchers did not observe any side effects.\nThe study was not done as a randomized controlled trial, the gold standard for determining whether a drug works better than chance.\n\u201cSeveral therapeutic vaccines have shown great promise in phase 1 and then not panned out in phase 2,\u201d she noted in an e-mail.\nKim said the next phase results should be out at the end of 2013; then comes a larger phase 3 trial with about 500 patients, to be concluded around 2016 or 2017.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "They did briefly discuss future clinical trials and did not try to estimate when a vaccine would be available.", "answer": 1}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\nTherefore, they expect it will be safe if ultimately developed for clinical use.\nIt could also become useful as a non-invasive way to assess breast cancer treatment progress.\u201d\n\nThe team plans to complete safety testing of the imaging agent during the next three years.\n\u201cWe think this targeted approach holds great promise for earlier imaging of high-risk cancers in the clinic.\nPrior to their study with this contrast agent, Lu\u2019s team had conducted studies to determine its clearance from the body after the imaging, which is essential for safe clinical use.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although it takes time to get there, the release does explain that this is not available for clinical use now and will not be until further work is done.", "answer": 1}, {"article": "Attention, memory, and language improved.\nThe main foods in the Mediterranean diet (MedDiet) include plant foods, such as leafy greens, fresh fruit and vegetables, cereals, beans, seeds, nuts, and legumes.\nThe Mediterranean diet can improve your mind, as well your heart, shows a study published in the open-access journal Frontiers in Nutrition.\nIn total, 18 out of the 135 articles met their strict inclusion criteria.\nThe MedDiet is also low in dairy, has minimal red meat, and uses olive oil as its major source of fat.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The ingredients of the Mediterranean Diet are available worldwide.", "answer": 2}, {"article": "For example, children with Down syndrome often have flat nasal bridges \u2014 as do typically developing African or African-American children.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\nThe ultimate goal would be a simple tool that any doctor could use anywhere to get fast results and better diagnose their patients.\nFDNA is working on establishing partnerships with pharmaceutical companies to start their commercial outreach.\nAs both groups work on recruiting more researchers, they are also working to push their tech forward.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear if this technology is available to anyone or if it is entirely in the research phase. This sounds developmental, but it was not clear. On visiting their website, it appears that it is already available for use.", "answer": 0}, {"article": "\"We adjusted for as many of those differences as we could,\" Wong said.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\n\"For many years, the thinking has been that observation or 'watchful waiting' was the safest option for elderly patients with early prostate cancer,\" said Yu-Ning Wong of the Fox Chase Cancer Center in Philadelphia, who led the study.\nThe findings prompted debate among specialists, who said the results could have potentially far-reaching implications because they address one of the central quandaries about prostate cancer and because the disease is so common.\nThe study of more than 44,000 American men ages 65 to 80 found that those who chose to aggressively treat their prostate cancer with surgery or radiation were about 30 percent less likely to die than those who waited, indicating that treatment offered a clear advantage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that\u00a0the study followed men who chose aggressive treatment (either surgery or radiation) or observation (also known as watchful waiting)\u00a0for early prostate cancer, indicating these options are currently available to manage early prostate cancer.\u00a0 ", "answer": 1}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nResearch findings from Stanford University released Monday could point the way to a long-sought diagnostic laboratory test for the condition, and possibly a first-ever treatment.\nWhat's more, the findings also point to possible treatment with immune-modifying or anti-inflammatory therapy.\n\"There is much to learn,\" Komaroff writes, in the journal.\nIn fact, they're experiencing profound exhaustion that isn't relieved with sleep, flu-like symptoms, muscle pain, \"brain fog\" and various other physical symptoms, all of which characteristically worsen with even minor exertion.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that both this type of test and proposed treatments are still experimental.", "answer": 1}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\nUse of this approach is likely to have major benefits for both patients and healthcare providers.\nThis study was funded by the British Heart Foundation and Chief Scientists Office (Scotland).\nUsing this test, troponin levels were measured in over 6000 patients with chest pain admitted to four hospitals in Scotland and the USA.\nUsing this threshold in routine practice could potentially double the number of patients suitable for immediate discharge directly from the emergency department, say the authors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release never explicitly states whether this is now being used, either at the study sites involved or elsewhere.", "answer": 0}, {"article": "The researchers found that the risk for heart disease during the follow-up period was similar to that seen while the women were taking the hormone.\nIn fact, the women who took the hormone ended up being at somewhat higher risk for fractures.\nThere\u2019s some good news and some bad news for women who took estrogen to help them get through menopause until the health risks of taking the hormone were discovered.\nBut the Women\u2019s Health Initiative stunned doctors and women when researchers reported that the risks of the hormones outweighed any benefits.\nThat\u2019s the good news.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nEstrogen is widely available, so the story does not need to dwell on this.", "answer": 2}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\n\"Based on currently available evidence, it appears reasonable to substitute core needle biopsy procedures for open surgical biopsy given the comparable sensitivity and lower complication rates,\" write researcher Wendy Bruening, PhD, of the ECRI Institute Evidence-Based Practices Center in Plymouth Meeting, Pa., and colleagues.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if all hospitals offer women core needle biopsy as an option prior to, or instead of open surgical biopsy. We are not told if recent evidence has affected clinical guidelines for suggested biopsies following an abnormal mammogram.\u00a0 We are not told that some women may not be appropriate candidates for core needle biopsies.\u00a0 The article notes:\u00a0The location and type of lesion, as well as other medical considerations, sometimes dictate the type of biopsy, but in many cases patient preference is the most important factor in the decision.", "answer": 0}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nBut it takes no position on MRI imaging for women who have had breast cancer, saying there is not enough evidence to recommend one way or the other.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\nMONDAY, Nov. 29, 2010 (HealthDay News) -- Women who have had breast cancer should consider annual screening with breast MRI in addition to an annual mammogram, new research indicates.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story does not address the availability of appropriate equipment and skilled operators and radiologists. The story should have pointed out that MRI imaging available to women in general may not match the quality of the work done in this research study.", "answer": 0}, {"article": "The Health System consists of Temple University Hospital (TUH), ranked among the \"Best Hospitals\" in the region by U.S. News & World Report; TUH-Episcopal Campus; TUH-Northeastern Campus; Fox Chase Cancer Center, an NCI-designated comprehensive cancer center; Jeanes Hospital, a community-based hospital offering medical, surgical and emergency services; Temple Transport Team, a ground and air-ambulance company; and Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices.\nThe study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma.\nThe study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.\nBut now, researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) are breaking through that barrier.\nOther researchers contributing to the study include Phillip F. Giannopoulos and Jian Chiu at the Alzheimer's Center at Temple, LKSOM.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes the statement, albeit at the very end, that the research could \u201csoon translate\u201d into clinical use. That is at best misleading and provides a false hope for patients and their families, given that no timetable or process is given for what would be required to take the step to human use. \u00a0A plus is that the drug already is approved for use in asthma, but it is likely that even if further animal studies confirm the current work, clinical use is still months or even years away.", "answer": 0}, {"article": "For example, a normal-weight woman should gain between 25 and 35 pounds, while an overweight woman should gain between 15 and 25 pounds.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nShe cautioned, however, that women should check with their doctors before starting a diet and exercise program during pregnancy.\nObese women should gain even less.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It might have been useful to give readers a sense of\u00a0whether diet and/or exercise programs are routinely available to pregnant women (either through their obstetricians or in the community). However, we won\u2019t penalize the story for not addressing this, since it\u2019s also possible to exercise without any supervision.", "answer": 2}, {"article": "The U.S. National Institute of Allergy and Infectious Diseases has more about vaccines.\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\n\"This research illustrates the remarkable capacity of the most superficial layer of skin to generate powerful protective immune responses after vaccination,\" study senior researcher Dr. Thomas Kupper, chairman of the dermatology department at the hospital, said in a news release from the hospital.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was not at all clear from the story whether anyone still uses the skin scratch \u2013 or scarification \u2013 method of vaccine delivery. ", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nOrlistat is marketed as Xenical, a prescription medication, and Alli, available over the counter.\nTwo other studies in the same issue of the journal look at the effectiveness of the anti-hypertension DASH diet and a physician-supervised plan.\nWhat often makes the difference in whether or not a diet is successful, she said, is whether or not there's a counseling and support component to the plan.\nAnd, she said, these studies show that you don't necessarily need to get to your \"ideal body weight\" to make substantial improvements to your health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that orlistat is available via prescription as Xenical and over the counter as Alli. The availability of the low-carb and low-fat diet options is not in question.", "answer": 1}, {"article": "\"To address inconsistencies in prior studies on vitamin D and to investigate associations in population subgroups, we analyzed participant-level data, collected before colorectal cancer diagnosis, from 17 prospective cohorts and used standardized criteria across the studies,\" said Stephanie Smith-Warner, PhD, an epidemiologist at the Harvard T.H.\nA single, widely accepted assay and laboratory was used for new vitamin D measurements and calibration of existing vitamin D measurements.\nExperts recommend vitamin D be obtained through diet whenever possible because excessive ultraviolet radiation is a major risk factor for skin cancer.\nHowever, risk did not continue to decline at the highest concentrations.\nOptimal vitamin D concentrations for colorectal cancer prevention may be higher than the current National Academy of Medicine recommendations, which are based only on bone health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Supplements, vitamin D-containing foods, and sunlight are pretty much available everywhere.", "answer": 2}, {"article": "Patients lie in a CT scanner, which takes a series of pictures from a variety of different angles, and a computer compiles the snapshots in two different ways.\nAdd to that the aggressive public awareness campaign for colonoscopy screening led by celebrities like Katie Couric, who allowed TV cameras in as she got her first test, and it\u2019s clear why more people are familiar with the scope than with its virtual cousin.\nThat\u2019s a bit of a surprise, given that not all medical experts agree on whether the virtual screen is as reliable as a traditional colonoscopy, in which doctors insert a scope with a small camera into the colon.\nBut in spite of those challenges, Megan McHugh at the Health Research and Educational Trust in Chicago and her team report that about 17% of hospitals in the U.S. now offer the screening test, up from 13% in 2005.\nAnd given the relatively low cost of investing in the software and other equipment required to run a virtual scan, more hospitals may be adding the option to their patient services.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is based on estimates of the rising use of virtual colonoscopy and cites one estimate that 17% of US hospials now offer it. The story suggests that the availability of CT colonoscopy is \u201con the rise.\u201d In reality the study in question actually demonstrated only a 3% increase over a 3 year period.\u00a0 Is that high or low?", "answer": 1}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\nThe cost of vitamin D supplements would be roughly comparable with both of these remedies.\nGraham and Rabin agreed that much larger trials should be done before they would recommend vitamin D3 use to any of their patients for cramp relief.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have done a better job on this point. Although Vitamin D is available over the counter, it is available in the high dose used in the study only by prescription. Just to put this dose issue in context, when people are Vitamin D deficient, a typical replacement dose is 50,000 units weekly for 8 weeks (a total of 400,000 units).\u00a0 So the 300,000 one-time doses are not as outlandish as they seem when compared with a typical maintenance dose of 600-800 IU/day.", "answer": 0}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\nAnd for this, patients should do their part.\nBoth groups could do things to improve the detection rate, they said.\n\u201cIt may be a nuisance but it will help maximize the view during (colonoscopy).\u201d\nBut he added that the risk factors identified match those in the earlier studies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the screening is widely available and is the standard.", "answer": 1}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\n(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the story the benefit of the doubt on this one because it explained that the drug is Merck\u2019s top selling drug and has already been FDA-approved for use in other cancers.\nHowever, the story didn\u2019t explain that because Keytruda is not approved for use in gastric cancers, some providers including Medicare supplement providers, may not provide coverage.", "answer": 1}, {"article": "In devising their models, the researchers updated assumptions that have cast doubt on the relevance of existing breast-cancer risk calculators, which relied on the experiences of women who got an earlier generation of screening mammograms and were more likely to die of breast cancer than is currently the case. Here, teams of modelers from Erasmus University in the Netherlands, Albert Einstein College of Medicine in New York and Harvard Pilgrim Healthcare assumed that women were getting digital mammograms, which offer improved cancer detection rates at lower radiation dosages than earlier mammographic methods. They took into account improved rates of breast cancer treatment effectiveness, and changing causes of mortality for women older than 50. They also took account of the fact that breast density decreases in older women.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Digital mammography is available across the United States, so we\u2019ll rate this N/A.\nHowever, the news story would have been stronger had it more clearly explained that these findings were based on an assumption of all-digital mammography. Not all women have access to digital mammography and\u00a0may have to travel farther for digital screening. Travel is often a barrier to screening in the first place, especially for those who rely on public transportation.", "answer": 2}, {"article": "In the past, babies acquired Bifidobacterium from their mother during childbirth, but due to the increased use of modern medical practices such as antibiotics, C-sections and formula feeding, nine out of 10 babies born in the U.S. today no longer acquire it.\nEvivo has commenced rigorous clinical trials with the prototype to demonstrate the results from infant stool samples.\nIn a landmark clinical trial, Evivo produced rapid, substantial and persistent stabilization of the infant gut microbiome, to help set a foundation for life-long health.\nEvolve BioSystems' Evivo is the only baby probiotic clinically proven to restore Bifidobacterium to a baby's gut and reduce potentially harmful bacteria by 80 percent.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The Evivo stool test is described as a prototype, implying it\u2019s not available on the market.", "answer": 1}, {"article": "LONDON -- AstraZeneca PLC said Monday its experimental heart pill Brilinta was more effective at preventing heart attacks and strokes in a large clinical trial than the blockbuster pill Plavix, boosting commercial prospects for the U.K. drug maker's still unmarketed treatment.\n\nPlavix, which is marketed by Sanofi-Aventis SA and Bristol-Myers Squibb Co., was the second-biggest-selling drug in the world last year, with global revenue of $8.6 billion, according to IMS Health. Any competitor to it could have a shot at big sales.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Brilinta is not yet available. It says the company plans to submit the drug for approval in the fourth quarter of this year. \nWisely, the reporter resists predicting when the drug might be on the market, since this is not guaranteed. ", "answer": 1}, {"article": "Feb. 2, 2011 -- The human papillomavirus (HPV) vaccine can help stave off genital warts in boys and men, according to a new study in the Feb. 3 issue of the New England Journal of Medicine.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nThe vaccine is recommended for optional use in boys and men.\nThese vaccines are now on the CDC\u2019s routine childhood vaccine schedule for girls starting at age 9.\nBoth of these vaccines are recommended to prevent cervical cancers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Gardasil is avaialble and has been approved for use in girls and young women as well as in their male counterparts.", "answer": 1}, {"article": "It measures the damage to the DNA of white blood cells when subjected to different intensities of ultraviolet (UV) light, revealing measurable differences in the cells' susceptibility to further damage in patients with cancer.\nIMSTAR's vice-president for medical applications, Dr Michel Soussaline, confirmed that the company will be working to automate the full test workflow further to take it to market.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nThe Bradford team had scored 100 cells per slide, but the Pathfinder\u2122 system is able to analyse up to 10,000 cells per slide, and uses Artificial Intelligence concepts in its proprietary software.\nIn addition, test results must be available in 24hrs and at affordable cost.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers only a general statement at its end indicating that work to develop the test will continue. Ideally the release would have explained that a prospective trial is still needed.", "answer": 0}, {"article": "\"I don't think pregnancy should be the thing that tips the scale,\" said Caughey.\nNearly 179,000 obese people underwent weight-loss surgery in the United States in 2013, according to the American Society for Metabolic and Bariatric Surgery.\nThe American Society for Metabolic and Bariatric Surgery offers more about weight-loss surgery.\nSwedish scientists found that weight-loss (or \"bariatric\") surgery before pregnancy lowers the chances of certain complications for mothers and babies but raises the odds for others.\nWhile various techniques may be used, the surgery restricts the amount of food the stomach can hold and/or reduces the intestines' absorption of calories and nutrients from food.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article provides nice context for the scope and nature of bariatric surgery in the U.S.: \u201cNearly 179,000 obese people underwent weight-loss surgery in the United States in 2013, according to the American Society for Metabolic and Bariatric Surgery. While various techniques may be used, the surgery restricts the amount of food the stomach can hold and/or reduces the intestines\u2019 absorption of calories and nutrients from food.\u201d", "answer": 1}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nPeople can include berries in their regular diet.\nBut, he added, it's important for people to realize that this research isn't applicable to people who already have the disease.\n\"Berries could be a neuroprotective agent.\nThe study findings should be interpreted cautiously because the participants were mostly white professionals, and the results might not apply to other ethnic groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these foods is not in question.", "answer": 2}, {"article": "An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\nGriffith said a German study recently found that donated corneas cost about $2,500.\nFor more than a century, doctors have considered transplantation of corneal tissue from deceased donors to be the best treatment, the study authors wrote.\nArtificial corneas are another option, but they're difficult to implant into the eye and can cause side effects, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The only hint that this research is preliminary is toward the end when the story says, The next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients. This actually sounds actually more optimistic than the comments from Griffith in the press release, leading one to believe that she was more cautious than this sentence implies.", "answer": 0}, {"article": "Neurostimulation works by sending low-intensity electrical impulses to targeted portions of the spinal cord.\nThere is considerable data showing connections between the brain, nervous system and heart, said Torre, but until now, no one has attempted to take advantage of the relationship therapeutically.\nA typical heart failure patient is on seven such drugs, which Torre characterized as \"the limit.\"\nIf the experiment proves successful, it would provide an entirely different approach to heart failure, a chronic, progressive disease that affects nearly 6 million Americans.\nTorre said though patients may feel some euphoria in the early days, it likely will take about a month before doctors have a good idea whether the therapy is working.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story is clear that this treatment is in the early stages of development, It doesn\u2019t give readers a very good sense as to when\u00a0it might be available to the general public. Paraphrasing one of the\u00a0researchers, the story states that it \"likely will take about a month before doctors have a good idea whether the therapy is working,\" which might suggest to some readers that it might soon be available after that. Yet this is a phase I study which is primarily geared to assess\u00a0safety. It is not until Phase II and III studies are completed and successful that companies will go for FDA device approval. This could take many years and the research may never come to fruition.\u00a0The story never explained this.", "answer": 0}, {"article": "Male infertility has a range of root causes, from low or abnormal sperm production to blockages to illness.\n\u201cThe accuracy of this approach was very similar to that of computer-assisted laboratory analysis, even when it was performed by untrained users with no clinical background,\u201d they wrote in the study.\nCurrently, they\u2019re required to make office visits to a urologist for several months to ensure that the operation was successful.\nThe researchers say the optical attachment could be created by 3D-printing, and the device would only cost about $5.\nThe researchers tested the device on 350 clinical semen specimens in Massachusetts, including both trained and untrained users in their trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are told the device is only in a prototype stage, implying it\u2019s not yet for sale. More details could have been provided, but this is sufficient for a satisfactory rating.", "answer": 1}, {"article": "The research team, led by Cleveland Clinic's Eric Klein, M.D., conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the U.S. enrolled between August 2015 and December 2016.\nVisit us at clevelandclinic.org.\nFollow us at twitter.com/ClevelandClinic.\nDr. Klein has no personal financial interest in the company.\nNews and resources available at newsroom.clevelandclinic.org.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that IsoPSA is not available at your local doctor\u2019s office, since this blood test needs to undergo further study and then be adopted clinically.", "answer": 1}, {"article": "Iron and folic acid deficiency are very common,\u201d she said.\nThey said ensuring that pregnant women get this basic prenatal care could have a big effect on the educational futures of children who live in poor communities where iron deficiency is common.\nShe said many children in poor communities would benefit from better prenatal programs that include the low-cost nutritional supplements.\nThe World Health Organization estimates that in developing countries, every other pregnant woman is anemic and about 40 percent of preschool children are anemic.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One assumes that iron and folic acid supplements are widely available, but this may not be the case in some countries. There wouldn\u2019t be a need for this sort of intervention if these nutrients were part of the regular diet in Nepal and other countries. At least some nod to how hard it might be to get access to these supplements was warranted.\u00a0It also would have been helpful to include information about whether any existing public health programs routinely supplement with iron and folic acid in developing countries.", "answer": 0}, {"article": "In the longest study of Orlistat, participants who took the drug in addition to eating fewer calories and increasing exercise shed up to 12 percent of their body weight the first year.\nIf it does, Orlistat (xenical) -- currently sold only by prescription -- could be available over-the-counter (OTC) later this year.\nBut it's important to know that the weight loss that's typical for users of the drug -- 5 to 10 percent of total weight -- will be less than many dieters expect.\nAt the current recommended prescription dose -- 120 milligrams taken up to three times per day, for example up to 360 milligrams daily -- about 70 percent of users experience gastrointestinal complications, Klein says.\nWhile Americans spend an estimated $1 billion on nonprescription weight loss products, few if any of those products have undergone the rigorous testing that is required by the FDA for prescription medications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Article \nincludes the fact that the switch in status from prescription only to OTC is under FDA consideration.", "answer": 1}, {"article": "Breakfast on the diet might consist of bacon, eggs with cheese, and a cup of heavy cream diluted with water; some children drink oil to obtain the fats that they need.\nAs the first randomized trial of the diet, the new study lends legitimacy to a treatment that has been used since the 1920s but has until recently been dismissed by many doctors as a marginal alternative therapy.\n\u201cThis is the first time that we\u2019ve really got Class 1 evidence that this diet works for treatment of epilepsy,\u201d said Dr. J. Helen Cross, professor of pediatric neurology at University College London and Great Ormond Street Hospital.\nShe is a principal investigator on the study, which will appear in the June issue of The Lancet Neurology.\nFor the British trial, the researchers enrolled 145 children ages 2 to 16 who had never tried the diet, who were having at least seven seizures a week and who had failed to respond to at least two anticonvulsant drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that this dietary approach to managing epilepsy is a standard treatment at hospitals and epilepsy centers in the United States and abroad.\u00a0 So we get somewhat of a sense of its availability.\u00a0 But the story doesn\u2019t make clear just how many hospitals and epilepsy centers use this approach, or how many have the necessary cross-discipline resources to manage the approach.\u00a0 ", "answer": 1}, {"article": "Those patches of dry, red, itchy skin are at increased risk of infections, particularly from a worrisome germ known as Staphylococcus aureus.\n\u201cPeople with this type of eczema, for some reason that\u2019s not quite known yet, have a lot of bacteria on the skin but it\u2019s the wrong type of bacteria.\nA day later, much of the staph on the treated arms was killed \u2014 and in two cases, it was wiped out \u2014 compared to the untreated arms, Gallo said.\nLearning what makes a healthy microbiome is a huge field of research, and already scientists are altering gut bacteria to fight diarrhea-causing infections.\nGallo\u2019s team took a closer look at how microbes in healthy skin might be keeping that bad staph in check.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that this idea is still in the experimental stage and hence not available at your local pharmacy. Ideally the story would have explained a bit more about the many steps left in bringing this product to the marketplace (if it ever makes it there; many experimental products never do).", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\nEven after considering other factors tied to the disease \u2014 like aspirin or statin use and eating lots of vegetables \u2014 their risk was 59 percent lower than that of women who hadn\u2019t taken the drugs.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\n\u201cFortunately, there are proven ways to help prevent colorectal cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story is clear on the drugs\u2019 availability. It says that the drug studied was \u201cmainly the drug alendronate (Fosamax)\u201d.", "answer": 1}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of sugar pills is not in question. However, many physicians would not consider it ethical to prescribe a placebo. The story does not convey this nuance.", "answer": 0}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\nAs part of this agreement, Merck committed to ensure that 300,000 doses of the vaccine are available for emergency use in the interim, and to submit the vaccine for licensure by the end of 2017.\nMerck has also submitted the vaccine to WHO's Emergency Use and Assessment Listing procedure, a mechanism through which experimental vaccines, medicines and diagnostics can be made available for use prior to formal licensure.\nIn January, GAVI, the Vaccine Alliance provided US$5 million to Merck towards the future procurement of the vaccine once it is approved, prequalified and recommended by WHO.\nThe vaccine's manufacturer, Merck, Sharpe & Dohme, this year received Breakthrough Therapy Designation from the United States Food and Drug Administration and PRIME status from the European Medicines Agency, enabling faster regulatory review of the vaccine once it is submitted.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release provides fairly detailed information about the next steps in the vaccine approval process, noting that Merck has committed to submitting the vaccine for regulatory approval by the end of 2017 and that the company has committed to making 300,000 doses available should an outbreak occur before approval is gained. It also notes that if an outbreak occurred before the vaccine is approved, it could be used, with informed consent of those vaccinated, through a \u201ccompassionate use\u201d program.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThe trial results are preliminary, as talazoparib has not yet been approved by the U.S. Food and Drug Administration.\nSimilar drugs have already been used to treat advanced, BRCA-mutated ovarian cancer, according to the agency.\nThe drug does have side effects.\nThe trial was funded by drug maker Pfizer, and the results were published Aug. 15 in the New England Journal of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that\u00a0talazoparib is not yet approved by the FDA.", "answer": 1}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\nCURATE.AI is applicable to all diseases and all patients, and a first generation of the platform was previously validated in the clinic for single drug optimisation in post-transplant immunosuppression.\nThis new study demonstrates that CURATE.AI can optimise multi-drug regimens.\nThis calibration is then used to create an individualised CURATE.AI profile, or map, that identifies the drug doses which enable the best possible treatment outcome at any given point in time.\nThe CURATE.AI team expects to broadly deploy the platform for the prevention of transplant rejection, adult and paediatric cancers, cardiovascular medicine, diabetes management, infectious diseases, and many other applications.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does make clear that clinical trials are under way. That\u2019s good. However, the release is written as if the clinical trials have already been completed successfully. For example, the release states that \u201cCURATE.AI is applicable to all diseases and all patients.\u201d There is, as far as can be discerned from everything else in the release, nothing that supports that statement. And despite the sweeping language used in the release, it is not at all clear when CURATE.AI may be available for clinical use.", "answer": 0}, {"article": "Spinal cord stimulation works by implanting an electrode near the spinal cord, inserted through the same place where epidural pain relief is injected for women in labor.\nDoctors say simple adjustments to the device may solve that problem.\n\u201cIt quickly becomes clear that \u2018weird\u2019 is going to be just fine if it replaces the pain.\u201d\n\nChronic pain is a particularly difficult problem to understand and solve.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that spinal stimulation devices \u201care not widely used,\u201d though it does not mention that they are approved by the FDA for the treatment of chronic pain.", "answer": 1}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nThat\u2019s not to mention cost: The drug\u2019s price is listed at $850 per month.\nAn endometriosis pain treatment was just approved by the Food and Drug Administration, and it\u2019s expected to arrive at pharmacies as soon as August.\nThe pill, called elagolix (brand name Orilissa), from the drugmaker AbbVie, is the first FDA-approved oral treatment in more than a decade for the moderate to severe pain that comes with endometriosis.\nSoon, it seems, women like Dunham with endometriosis pain will have a new option for relief.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers a likely date when this just-approved drug would become available at pharmacies.", "answer": 1}, {"article": "\"Some will benefit in a very large way.\n...\nHow many lives?\nThis means some women will undergo needless surgery, radiation, or chemotherapy.\nSo should U.S. women continue to get routine mammograms?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Researchers told the American Diabetes Association\u2019s (ADA) annual meeting that 13.0 percent of patients on Victoza died from cardiovascular causes or suffered non-fatal heart attacks or strokes, against 14.9 percent of those on placebo.\nVictoza\u2019s effect was evident across risks.\nBut investors had been anticipating a bigger effect.\n\u201cThe significance of this is that now we can start to change the conversation around diabetes management from one of \u2018let\u2019s manage your blood sugar\u2019 to one of \u2018let\u2019s manage your risk of complications\u2019,\u201d Buse said.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is already established on the market, calling it \u201ctop-selling\u201d in the first line and mentioning that it is typically prescribed as a third or fourth option.", "answer": 1}, {"article": "Research presented at meetings is considered preliminary until published in a peer-reviewed medical journal.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\n\"We cannot, however, recommend statins for cancer prevention without a positive clinical trial.\"\n\"There is little evidence that statins affect cancer risk or survival, but clear evidence that they can help some people lower risk of heart attacks and strokes,\" he said.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s obvious from the story that statins are widely available. If research shows they can lower risk, they are available already for that purpose.", "answer": 1}, {"article": "All rights reserved.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\nThe U.S. Food and Drug Administration in 2015 gave the food industry until next year to eliminate artificial trans fats from American products.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lets readers know that soon a trans fat ban will apply to the entire country:\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say. The U.S. Food and Drug Administration in 2015 gave the food industry until next year to eliminate artificial trans fats from American products", "answer": 1}, {"article": "\u201cWe are looking for corporate partners as we head into Phase II trials,\u201d Kalos said.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\nThe research group plans to treat four more patients with CLL before moving into a larger Phase II trial.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nAll of the funding for the University of Pennsylvania\u2019s gene therapy work has come from the academic community, but the work is expensive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does note the study is a Phase 1 trial iin the 4th sentence and also notes that\u00a0researchers intend to enroll\u00a0four more\u00a0subjects. WebMD did a better job showing that, even for people hoping to enroll in a trial for this therapy, the odds will be long.\nWe wish stories would take for granted that readers know what Phase I and Phase II means.", "answer": 1}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nIf the old device is left in place, it is not known what the long-term effects of this will be.\"\nIt's also not clear when the pacemaker may be publicly available, and its cost is unknown.\nStill, he said, the new device will probably be more expensive than other pacemakers, and may pose special risks of its own.\nAnd the existing version of the device won't work for most pacemaker patients because it lacks some key features.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the second paragraph the story explains that \u201cit\u2019s not clear when the pacemaker may be publicly available.\u201d", "answer": 1}, {"article": "\u201cC.\nThough physicians think they know how FMTs work, it remains somewhat mysterious.\nThe 116 patients used in this study may have been selected in part because they were ideal candidates for FMTs, Dr. Elizabeth Hohmann noted, but she said the paper is solid overall.\nDespite the FDA\u2019s advice, some people have set up shop as FMT providers anyway.\nPrevious research found that while every part of this treatment was unappealing to most people, being offered the treatment in a pill form made patients significantly more open to the idea.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unfortunately, the story doesn\u2019t spell out whether the pill form FMT is now, or soon will be, available to the public. The story does mention that numerous other clinical trials are using FMT as a possible treatment for various diseases but it is unclear whether the pill form is an option for physicians at this point.", "answer": 0}, {"article": "\u201cHowever, we still don\u2019t know whether it will provide protection against Ebola infection in a real-world situation,\u201d he said.\nThe vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola \u2014 the one circulating in West Africa \u2014 and the first doses for a larger trial arrived in Liberia last week.\nJeremy Farrar, director of the Wellcome Trust charity which helped fund the trial, said it provided \u201cgood initial evidence that the GSK vaccine will be safe to use in people\u201d.\nThat trial is the first of several mid-stage studies planned for West Africa and aims to test GSK\u2019s vaccine and one from Merck and NewLink.\nHill said the lower antibody levels, together with a lower response detected in the immune system\u2019s T-cells, suggested to him that a booster may well be needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the vaccine is under development and that clinical trials in West Africa are under consideration. The story could have mentioned the long testing process required before such a vaccine might be available on the ground in Africa.", "answer": 1}, {"article": "Scientists working for Google\u2019s parent company Alphabet have used artificial intelligence to determine a person\u2019s risk of having a heart attack from their retinal scan.\nFurther tests are required before this latest method can be used within a clinical setting.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\nThe method\u2014detailed in a paper published on Monday in the Nature journal Biomedical Engineering\u2014involves analyzing blood vessels in an area of the eye called the retinal fundus.\nThe risk factors include the person\u2019s gender, smoking status, blood pressure and age\u2014estimated to within four years of the patient\u2019s actual age.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that \u201cfurther tests\u201d are needed, but readers are left with no idea as to when, if ever, this new approach to determining risk might be available.\u00a0 There\u2019s no mention of when, if ever, clinical trials might be done to gauge its efficacy.", "answer": 0}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes plain that the female testosterone patch is not available in the United States but is on the market in Europe. ", "answer": 1}, {"article": ".\nNotably, carbon dioxide levels were lower when windows or doors were open.\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\nThey each slept alone, and the bedroom layout with furniture arrangement was kept consistent.\nThey also wore a sensor that tracked their movements at night, including indications of restlessness.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Windows and doors are widely available, and the story mentions that opening them might not work if there are noise or security concerns.", "answer": 2}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\nNow new technology is making this possible, and new research shows that an experimental system can improve nighttime blood sugar control.\nUsing sophisticated computer software, researchers were able to coordinate the actions of a commercially available continuous glucose monitoring device and insulin pump to allow automatic insulin delivery in response to real-time glucose readings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did a better job than the competing Reuters piece in explaining that the system tested in this study actually consisted of a commercially available glucose monitor and insulin pump\u2013not a \"new device\"\u00a0per se.\u00a0However, it still left the reader with the impression that system was automatically managing patients\u2019 glucose without any outside human intervention, which was not the case. We also wish the story had resisted the temptation to\u00a0predict that a new \"artificial pancreas\" system might be\u00a0be available clinicially in 3 to 5 years. The FDA approval process is notoriously uNPRedictable, and this technology has a lot of hurdles to clear before it will be available for patients.", "answer": 0}, {"article": "In 2012, a federally funded panel of experts on preventive care concluded there are more risks than benefits to screening American men for prostate cancer with the PSA test. And in April 2017, the U.S. Preventive Services Task Force dumped the decision squarely into the laps of patients and their doctors. Some men between 55 and 69 years of age might well decide to get their PSA checked, the task force said. After hearing the ledger of pros and cons, however, others in that age bracket might just as reasonably skip the screening test, the panel concluded.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that PSA screening is widely available.", "answer": 1}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this drug is still in the experimental phase and the FDA has not yet approved it.\u00a0 ", "answer": 1}, {"article": "Critically ill children in intensive care are unable to eat independently.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\nThe current standard of care for such children is based mostly on the assumption that they need to eat to regain their strength.\nThe results are remarkable.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Parenteral feedings are a part of standard care and that is understood.", "answer": 2}, {"article": "GAITHERSBURG, Md.\nIf approved by the Food and Drug Administration, bevirimat, developed by Panacos Pharmaceuticals Inc., would represent the first in a new class of drugs that uses an unusual approach to block maturation of the virus that causes AIDS.\nNow its derivative is being tapped to fight HIV by a small Watertown-based biotechnology company.\nPanacos estimates its drug could garner $500,000 to $1 billion in peak annual sales from a drug candidate initially spotted by a professor at the University of North Carolina at Chapel Hill who was screening natural products in search of potential HIV therapies.\nBevirimat is being developed as physicians begin to use drugs from different classes in combination to fight the virus at different steps in its life cycle.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug, bevirimat, is derived in part from the herb syzigium claviforum. This herb is currently used in traditional Chinese medicine to treat diarrhea and stop bleeding. Bevirimat is a manufactured drug, using certain components of this herb to potentially inhibit HIV replication. The story does mention that the drug is at least 3 years from market and still in early clinical trials.", "answer": 1}, {"article": "Researchers from Leeds Metropolitan University in the U.K. steeped thyme, marigold, and myrrh in alcohol to make what's called a tincture, and then tested them on the bacteria that cause acne.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nLargely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\nApril 12, 2012 -- The next new acne treatment may be found in the produce section of your food store.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The bold headline promising that thyme as an \u201cacne remedy may be coming soon\u201d promises an imminent availability that is beyond the evidence.", "answer": 0}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While acupuncture is widely available, the story doesn\u2019t clearly point out that the regimen used in the study was specially developed for this study. Where could a woman seeking this treatment find it? How many practitioners are trained on this regimen?", "answer": 0}, {"article": "\"I no longer work for a living,\" notes Dr. Ross, who now resides in Westfir, Ore. \"I wake up every day eager to hear about how a plant-based diet and a healthful lifestyle is changing and saving lives in our community.\nThe 2015 Dietary Guidelines for Americans highlights a healthy vegetarian diet as one of three healthful eating plans to follow.\nThe meta-analysis appears as an online advance in Nutrition Reviews.\nTaking small steps, like those proposed by the National Cholesterol Education Program Adult Treatment Panel 3, which include assessing heart disease risk, making lifestyle and dietary recommendations, and assessing the need for future follow-up appointments and pharmaceutical interventions, could prevent approximately 20,000 heart attacks, 10,000 cases of coronary heart disease, and save almost $3 billion in medical costs each year.\nFor clinicians concerned about spending extra time in and outside of the exam room, the study authors encourage time-strapped health care providers to refer patients to registered dietitians who can help with the transition to a plant-based vegetarian diet.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that registered dietitians can help people transition to a plant-based vegetarian diet. It also recommends the vegetarian diet plans contained in the 2015 Dietary Guidelines for Americans.", "answer": 1}, {"article": "The condition, in which a person\u2019s body clock does not automatically set to the 24-hour day, affects a majority of blind people.\n\u201cThese results also highlight the importance of chronic therapy in treating Non-24,\u201d CEO Mihael Polymeropoulos said in a statement on Wednesday.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nVanda on December 18 said the drug performed better than a placebo in the first of the four planned late-stage trials on the drug.\nThe company\u2019s shares rose as much as 37 percent on that day.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story referred to the drug tasimelteon as an \u201cexperimental drug.\u201d\u00a0 And it reported that the drug company plans to apply for FDA approval in mid-2013.", "answer": 1}, {"article": ".\nThe biggest drawback, Whitaker says, is the need for X-rays three months after the procedure to confirm the fallopian tubes are blocked.\nEven the IUD can't stay in place for more than 10 years.\nOne for the Guys Men, too, have an option for a faster, less painful procedure than vasectomy to tie the vas deferens -- the tubes that carry sperm from the testicles to the penis.\nNow a procedure called Essure, recently approved by the Food and Drug Administration, gives women an alternative.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story mentions that the Essure approach was relatively recently approved (in 2002), it does not comment on how widely it is available, how many providers have the special training required\u00a0and whether access may be limited as a result. ", "answer": 0}, {"article": "Novel standard for research in malnutrition may save lives\n\nProfessor Henrik Friis, the senior author on the paper, points to the importance of the collaboration between university researchers and humanitarian organizations:\n\n\"It has been a new way to conduct research, that we tested the effect of nutritional supplements used mainly by aid agencies, employing very advanced research methods in remote rural areas where humanitarian organization are working, and not at the university hospitals.\nDuring the trial, 1609 small children with moderate acute malnutrition were given either LNS or corn-soy porridge for 12 weeks.\nThe study, published Monday 11 September in the open access medical journal PLOS Medicine, showed that corn-soy porridge should be replaced with a lipid-based nutrient supplement (LNS), a fortified peanut butter.\nThe results of the study can be used directly both in the treatment and prevention of acute malnutrition.\nThe research was conducted in a malnutrition project run by the medical humanitarian organisation The Alliance for International Medical Action (ALIMA) and its Burkinabe partners Keoogo and SOS M\u00e9decins.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release assumes availability of both types of supplements, though no specific information is provided about how much each is currently used for treatment of moderate acute malnutrition in infants.", "answer": 1}, {"article": "The test, called a liquid biopsy, screens for cancer by detecting tiny bits of DNA released by cancer cells into blood.\nResearchers hope the test will become part of a \u201cuniversal screening\u201d tool that doctors can use to detect cancer in patients.\nResearchers said their results showed promise in the approach of blood screenings for cancer, but noted further \u201cclinical development\u201d was needed.\nA blood test for 10 different types of cancers could one day help doctors screen for the disease before patients show symptoms, researchers at the world\u2019s largest gathering of oncologists have said.\n\u201cWe hope this test could save many lives.\u201d\n\nThe study, by a research team that also included scientists from Stanford University, was presented at the annual conference of the American Society of Clinical Oncologists in Chicago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of liquid biopsies are not directly addressed, though it is implied they are not yet available. We\u2019ll give this one a just-barely satisfactory.", "answer": 1}, {"article": "LONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\nUsing the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nKuten and his colleagues studied the breath of 177 people \u2014 some healthy and some with various types of cancer \u2014 to detect the different chemicals emitted from the surface of cancer cells as they grow.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Reuters posted just one reader comment before closing the comment section.\u00a0 It read as follows \u2013 typos and all: \"This is a terrific Leap in Teachnology and should be made available Worldwide at hospitals, clinics and Good Dr. Offices.\" Readers should not have been led to believe the simple, proven breath test is at hand, ready to deploy to doctors. It\u2019s years away if we\u2019re lucky.\n ", "answer": 0}, {"article": "But in either case, \"Something is better than nothing,\" Sayre said.\nHands-only will be added to CPR training.\nThe CPR guidelines had been inching toward compression-only.\nNow the heart association has given equal standing to hands-only CPR.\nBut less than a third of victims get this essential help.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Hands-only CPR is implictly available anywhere. ", "answer": 1}, {"article": "Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in adults.\nIn addition, the agency is requiring hospitals and clinics that dispense Yescarta to be certified after undergoing special training.\n\u201cIt raises the potential that a cure can be possible.\u201d Some of the first patients who underwent treatment now have been in remission for three to five years, he said, although he cautioned that it's still too early to know whether those patients are cured.\nArmin Ghobadi, an oncologist at Siteman who was an investigator in the Kite trial, said the new treatment is \u201cjust the first step\u201d and that researchers are working to make it safer and more effective.\nEven so, Yescarta's cost is likely to stoke the ongoing debate about high drug prices.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The piece isn\u2019t clear on this point. It says \u201c[T]he agency [FDA] is requiring hospitals and clinics that dispense Yescarta to be certified after undergoing special training.\u201d This implies that not all places will be able to prescribe this.\u00a0", "answer": 0}, {"article": "They had stayed in school longer and earned more as adults.\nRelated: Too Many Babies Die on Their First Day\n\nCharpak\u2019s team found the babies randomly assigned to get this treatment were 39 percent more likely to live into adulthood.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\n\u201cKangaroo mother care may change the behavior of less well-educated mothers by increasing their sensitivity to the needs of their children, thus making them equivalent to mothers in more favorable environments.\u201d\n\nTwenty million babies are born at a low birth weight every year around the globe, the World Health Organization reports.\nMost of these small babies are premature and they are at high risk of dying, of developing cerebral palsy, or having learning disabilities, and they can grow up more prone to a range of diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that KMC requires parents to receive adequate support and follow-up. But we would have liked to see more information, such as how widely this approach is used to treat premature infants and what some of the barriers might be in high-income countries where incubator care has been the norm. For example, how many U.S. neonatal intensive care units incorporate skin-to-skin contact in their care? Which babies in intensive care don\u2019t or can\u2019t get this kind of care?", "answer": 0}, {"article": "The results were striking.\n\u201cThere is a body of literature that argues that the whole approach to studying acupuncture doesn\u2019t lend itself to the Western reductionist scientific method.\u201d\n\nBut the study\u2019s lead author, Dr. Maria E. Suarez-Almazor, notes that the sham treatment was developed with the help of trained acupuncturists.\nRather than proving that acupuncture does not work, in other words, the study may suggest that it works even when administered poorly.\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\nBut the real lesson, acupuncture supporters say, is how difficult it can be to apply Western research standards to an ancient healing art.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "      \n\n\n \n\n \nThe article does not discuss the availability of acupuncture in the United States. This is an important question. There appear to be significant obstacles\u00ad\u2014relating to geography, licensing, and reimbursement\u2014 to the widespread availability and utilization of acupuncture.\n\u00a0\n ", "answer": 0}, {"article": "In the United States, the Affordable Care Act designates HIV testing as a preventive service, meaning that all insurers must cover it without charging a co-pay.\nA sizable fraction of the undiagnosed may be people who have been tested, just not recently enough.\nBut if the goal is to let patients test as accurately as possible at home, the United States is falling behind.\nAnd because the incidence of other sexually transmitted infections declined for these men, after the diagnosis, the scientists had reason to believe the self-reports of condom usage were accurate.\nAdopting some version of the British at-home test could help Americans who have already been tested keep up their screening schedule.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly reports that this HIV test is now available in the UK, but not in the US. However, the murky quote from an FDA spokesperson leaves readers in the dark about whether the company selling this test in Britain has, or is planning to, apply for approval in the US.", "answer": 1}, {"article": "And Owens says that people with medical conditions like ulcers, kidney problems, liver problems or bleeding disorders are more vulnerable, as are people who take blood-thinning drugs and NSAIDs.\nBut for pretty much everyone else, assessing actual heart disease risk in consultation with your doctor is crucial to deciding whether to take aspirin every day.\nHowever, there is a caveat.\nPeople who don't really need to should not be taking aspirin every day, says Nissen.\n\"It's just not prudent or safe,\" he says, noting that bleeding in the abdomen or brain is extremely dangerous and can be fatal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Low-dose aspirin is readily available, of course, and the story makes this clear. \u00a0The story suggests that the typical healthy American NOT avail him/herself of this resource.", "answer": 1}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\nFor Terri Bradford, the years of searching for effective treatment proved futile.\nBut even a little can help, and according to Bernstein it doesn't have to be jogging for miles and miles.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "If the concept is that lifestyle changes are effective at treating migraines, then it is assumed that people can change their diets or exercise more no matter where they live. The story supports that impression, and we\u2019ll award a satisfactory on that basis. For extra credit, the story could have elaborated on why it was so hard for the woman in this story to find a doctor to prescribe this kind of therapy. Are doctors who embrace this approach difficult to locate? If these approaches are effective, why aren\u2019t they more widely used?", "answer": 1}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nDoctors, however, are unlikely to rush to change clinical practice.\nDaan Kromhout of Wageningen University, who led the study, told the European Society of Cardiology the lack of efficacy might reflect the good background drug treatment patients were receiving, with 85 percent on cholesterol-lowering statins, as well as blood pressure and blood-thinning tablets.\nThe margarines used in the study were developed for the researchers by food and consumer goods giant Unilever.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story indicated that the margarine used in the study was created for the researchers by Unilever, suggesting that they aren\u2019t commercially available. But why not make that point explicitly?", "answer": 1}, {"article": "The second study, published in 2013, had a similar set up \u2014 37 people complaining of gastrointestinal problems, randomized into high-gluten, low-gluten and no-gluten groups.\nSomewhere in that gap, a diet fad is thriving.\nRegardless of the reason, we are left with little convincing evidence that gluten avoidance matters.\nThe satisfying, slightly chewy texture of bread requires gluten.\nIt\u2019s hard to test for gluten sensitivities.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes the now-widespread availability of gluten-free foods.", "answer": 1}, {"article": "It\u2019s common for people who suffer from irritable bowel syndrome (IBS) to also struggle with depression.\n(Study co-author Premysl Bercik, associate professor of medicine at McMaster University, says the formula used in the new research isn\u2019t commercially available, anyway.)\nThat\u2019s why Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, thinks the fMRI findings are the most interesting and important aspect of the new study: they signal that the probiotics may really be working on the brain itself.\n(Nestle was not involved in collection, analysis or interpretation of study data.)\nThe probiotics were manufactured and provided by Nestle, which also funded the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although it appears close to\u00a0the end, the story does state that the probiotic used in the study is not commercially\u00a0available.", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThe full potential of food-based supplements to do the work of some drugs without their negative side effects is just beginning to be seriously investigated.\nThere is no magic bullet ingredient in nutrition - \"oiling\" one joint is not going to allow the rusted out machine to run.\nThe CHORI-bar is not just another nutrition bar.\nUnhealthy metabolism is like an old machine with many rusted out joints.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "One can only assume that something at the clinical trial stage is not yet available to consumers. But the press release does not make that clear. Some enthusiastic commenters out there can\u2019t wait to get their hands on the product!", "answer": 0}, {"article": "\u201cYou can\u2019t sit in your house and just vegetate,\u201d she said.\nIf the patient answers yes to one or both, a questionnaire is recommended to determine if the patient is depressed and the severity.\nDepression is about three times more common in heart attack survivors and those hospitalized with heart problems than the general population, according to the recommendations published in the journal Circulation.\nThe authors said only about half of heart doctors say they treat depression in their patients \u2014 and not all those diagnosed with depression are treated.\nIf depression is indicated, the patient may need to see a professional qualified in treating depression, the panel said, adding that treatment options include antidepressants, seeing a psychotherapist and exercise.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly depression screening is available but not as widely used as it should be in the context of heart disease patients.", "answer": 1}, {"article": "But the evidence that pot smoking actually helps with spasticity has been anecdotal.\nHowever, LaRocca said, researchers are developing cannabinoid-based medications for MS. That includes a cannabinoid mouth spray called Sativex that has been approved in the UK, Canada, Spain and New Zealand to treat MS-related spasticity.\n\u201cSpasticity is a big problem for many people with MS, and the current medications don\u2019t necessarily work for everyone,\u201d said LaRocca, who was not involved in the new study.\n\u201cBut smoking marijuana does not appear to be a long-term solution, because of the cognitive effects,\u201d he told Reuters Health.\n\u201cWe can\u2019t say anything about long-term effects,\u201d Corey-Bloom told Reuters Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that some people with MS are already using medical marijuana to treat certain symptoms.", "answer": 1}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nResearchers at Albert Einstein College of Medicine in New York hope to launch clinical trials of the procedure soon, but must first produce supplies of human neural stem cells in the lab which can be implanted into volunteers.\nThe next step is to create human neural stem cells in the lab for testing.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this research is preliminary. The story clearly says, \u201cThe next step is to create human neural stem cells in the lab for testing.\u201d\u00a0 It also states that, \u201cResearchers at Albert Einstein College of Medicine in New York hope to launch clinical trials of the procedure soon, but must first produce supplies of human neural stem cells in the lab which can be implanted into volunteers.\u201d", "answer": 1}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nLomaira is anticipated to be available by the end of September 2016.\n\"We developed Lomaira with this dosing flexibility and affordability in mind.\"\nSee Full Prescribing Information.\nThrough KVK Tech's , eligible patients will pay no more than 50\u00a2 per tablet for the duration of treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that, \u201cLomaira is anticipated to be available by the end of September 2016.\u201d", "answer": 1}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that, \u201cBased on the promising phase III clinical trials, the drug could be available later next year.\u201d", "answer": 1}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\nIt\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\n\u201cThey wanted to know where they could get (the hormone) after the study was over.\u201d\n\nBut that\u2019s jumping the gun, she warned, because the treatment is still experimental and GHRH is not approved to treat mental decline.\nAn expert who wasn\u2019t involved in the research echoed the cautions.\n\u201cIs it going to work in the long run and is it going to be safe?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the story had included even a line about how GHRH is used in medicine right now and whether there\u2019s any knowledge of off-label use for mild cognitive impairment.", "answer": 0}, {"article": "In his study published in the International Journal of Radiation Oncology, Biology, Physics, he and his colleagues found, \"in circumstances where surgery may result in significant neurologic or organ dysfunction, patients can be treated definitively with radiation therapy alone.\nThe San Francisco radiation oncologist not only shared Dr. Kabolizadeh's research paper, but also his contact information.\nIt is the only operational proton therapy center in Michigan.\nBeaumont's center is one of just 28 proton therapy centers in the U.S.\nThe lead author and researcher was Dr. Peyman Kabolizadeh, clinical director, Beaumont Proton Therapy Center in Royal Oak.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that there are 28 proton therapy centers in the U.S. and that the center at issue here is the only one located in Michigan.", "answer": 1}, {"article": "Smith also embarked on a new diet, cutting out dairy and red meat.\nBeim, the Celmatix CEO, said the test is already bringing \u201ctremendous\u201d value, in part by providing guidance that can act as a \u201ctiebreaker\u201d to help patients and their doctor decide which treatment to prioritize.\nMany of the other conditions that the test screens for are also quite rare.\nThat patient is now considering an egg donor.\nBut the report doesn\u2019t note that just 1 percent of women have that condition in the first place, making the odds still overwhelmingly in her favor.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text is clear that the test has been available since January 2017 and has been utilized by some doctors.", "answer": 1}, {"article": "Newswise \u2014 RESEARCH TRIANGLE PARK, NC\u2014 Major depressive disorder affects more than 32 million Americans, and their first stop for treatment is often their primary care provider.\nSuch shared and informed decision making might enhance treatment adherence which is one of the main challenges of treating major depressive disorder,\" said Gerald Gartlehner, M.D., associate director of the RTI-UNC Evidence-based Practice Center, who was the principal investigator of the evidence review, which was also published today by AHRQ.\n\"Primary care clinicians and their patients may not automatically consider alternatives when discussing treatment,\" said Halle Amick, research associate at the RTI International-University of Chapel Hill Evidence-based Practice Center and lead author.\nHowever, psychotherapy can be time-consuming and may be substantially more expensive, depending on the patient's insurance benefits.\n\"Bringing psychotherapy into discussions of treatment may also enhance coordination of care between primary care and mental health care providers in addition to addressing the issue of patient-centered care,\" Amick said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While CBT is in wide use, the release glides over the long wait times even people with health insurance must wait to be matched with a CBT therapist. In some states, the wait can take months. In addition, the release notes that most patients see their primary care physician first. We are unclear on what percentage of primary care physicians are trained in CBT and are willing to offer it.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that the procedure is at least 20 years old and is practiced in a significant percentage of hip-replacement operations, implying that it would not be too tough to find a surgeon who does the anterior procedure. Of course, learning a bit about what the learning curve is for this procedure and how many procedures any given surgeon has done are key questions", "answer": 1}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story tells us that the PET scan/radioactive tracer approach was approved by the FDA months ago.\u00a0 It also explains some of the limitations on availability:\n\u201cRajan Agarwal, an Abington Memorial Hospital radiologist, did the country\u2019s first three commercial Amyvid scans in June and has had no referrals since. Adler also has done three. Though doctors think the test can be a blockbuster, PETNET, a Siemens subsidiary that distributes the tracer, said it had made 100 commercial doses for this region since June.\nThe tracer is made individually for each patient on test day at 15 sites around the country, then delivered within a 2\u00bd-hour radius. \u2026\nLack of coverage for the $3,000 test is the biggest barrier to it here. Medicare\u2019s decision on coverage, which often sets the standard for private insurers, is due by July.\u201d", "answer": 1}, {"article": "Infants exposed to partial treatment in the womb healthier than those not exposed.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nTo arrange an interview with Dr. Higgins, please call Linda Huynh at 301-496-5133 or e-mail nichdpress@mail.nih.gov.\nThe study followed the infants from birth to 18 to 22 months of age and measured survival and brain and nervous system outcomes.\nResearchers evaluated 6,121 extremely premature infants who had been born between 22 and 27 weeks of pregnancy at sites in NICHD\u2019s Neonatal Research Network.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release reveals high up in the article that steroids are a standard treatment for pregnant women expecting preterm delivery, or before 34 weeks. \u201cThese drugs are known to reduce the chance of complications and heath among premature infants,\u201d it states.\nSince the release makes it clear that steroids are nothing new, we give it a Satisfactory rating here.", "answer": 1}, {"article": "For the control group, 56 percent displayed a significant increase in cognitive capacity, while 44 percent had no change.\nFull text of the article is available from the APA Public Affairs Office and at\n\nThe American Psychological Association, in Washington, D.C., is the largest scientific and professional organization representing psychology in the United States.\nThis study is the first to examine similar positive effects from college courses taken by older adults, said Lenehan, of the University of Tasmania.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\nThe research was published online in the journal Neuropsychology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Not noted explicitly but university courses are widely available especially at community colleges. This is suggested by the release so we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Mild traumatic brain injury is a public health issue.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\nWith these findings, it appears the I-Portal goggle may be a solution.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\n\"With accurate and timely diagnosis, which is possible through this technology, patients could receive better treatment faster.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release hints the goggle is not in widespread use \u2014 at least not yet. One of the study authors says, \u201cIt is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America.\u201d\nIt is our understanding that this PloS One article was the first peer-reviewed paper on the only clinical study of this product. We feel it is misleading and too early to claim that this goggle could be on \u201cevery sideline\u201d in the \u201cnear future.\u201d Not only that, the wording is also vague. What does the \u201cnear future\u201d mean anyway? Until that happens, researchers need to collect more data and gain FDA approval for the device, which all take time.\nAs a result, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "If the child said a word, the parent repeated it and added something.\nNevertheless, for parents of children with autism, even a modest reduction would be worthwhile.\u201d\n\nDr Max Davie, of the Royal College of Paediatrics and Child Health, said it offered \u201ca hugely cheering message for families\u201d, while Uta Frith, emeritus professor of cognitive development at University College London, called it \u201ca remarkably positive story, because the intervention itself was neither intensive nor invasive\u201d.\n\u201cThese results at follow-up are pretty consistent in showing the benefit of this early intervention for autism across a range of measures.\nMy impression is that this is an intervention that reduces the severity of autistic symptoms, rather than curing autism.\nThe success of the preschool autism communication trial (Pact) has surprised even the researchers who designed it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article leads the reader to conclude that the training program is a \u201cpotential breakthrough\u201d but says nothing about a) how many children would qualify for this training program in the UK; b) whether there are enough trainers; or c) how or when people inside or outside the National Health Service can find the program and sign up.", "answer": 0}, {"article": "Dr. Adolfo Llanos, a neonatologist at Nicklaus Children's Hospital in Miami, who was not involved with the new study, said the \"quality of this analysis is very good.\nThe takeaway from this study, Llanos said, is to breast-feed as long as possible, if possible.\nHow might human milk offer protection from the eye disorder?\nAnd it appeared that the more breast milk, the better.\nThe antioxidants in human milk may help, Chen said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We won\u2019t dock points from the story for not discussing the availability of formula and breast milk. Although those topics could certainly sustain such a discussion had the story chosen to address them.", "answer": 2}, {"article": "In type 1 diabetes, the immune system attacks and destroys insulin-producing cells within the pancreas.\nThe study was very small, and the procedure is not ready for widespread use.\nThe \"cocktail treatment\" combines stem cell therapy with drugs that suppress the body's immune system.\n\"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects,\" study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the procedure was not ready for widespread use.", "answer": 1}, {"article": "Co-authors include: Drs.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\n\"The low rate of serious adverse events and significant interventions supports the safety of procedural sedation in the hands of emergency department physicians,\" said Dr. Bhatt.\n\"We've been able to identify sedation medications and practices associated with the best clinical outcomes, which is practice-changing.\"\nThis study was funded by a Canadian Institutes of Health Research (CIHR) team grant in Pediatric Emergency Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of the different sedation methods isn\u2019t addressed. Readers must assume that the study looked at the common types of sedation used.", "answer": 2}, {"article": "\"The big difference is that with the knee, most of the things we're doing arthroscopically evolved from things we were doing in open surgery,\" Byrd said.\nThis is a marked uptick from a decade ago, when Ochiai said the single course in hip arthroscopy was nearly canceled due to lack of interest.\nNew York Yankees star Alex Rodriguez recently made headlines when he opted to have arthroscopy on such a tear in his right hip, a decision that has him sidelined from baseball for weeks.\nAnd they've found that it can be fixed using arthroscopic surgery, which uses narrow instruments inserted through smaller incisions than traditional surgery.\nDerek Ochiai, a surgeon with the Nirschl Orthopaedic Center in Arlington, who began performing hip arthroscopy six years ago, estimates that he did only about a dozen of the procedures that year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\n \nThe news story explains that orthopaedic surgeons are performing increasingly more hip arthroscopy procedures, and are taking increasingly more courses to learn how to do them. Readers are likely to correctly infer that the procedures are commonplace in some centers around the U.S. and less common in others.", "answer": 1}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nThe precision of the process is crucial to limiting side effects, the researchers said.\nAnd unlike conventional gene therapy -- where the offending gene is replaced by a new one or overridden -- this therapy is reversible, said Adams.\nThe experiment proceeded just as planned, as biopsies later showed.\n\"This directly interferes with the genetic mechanisms that promote cancer to stop the production of a particular protein,\" added Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the Reuters story, this story was very clear with this statement:\u00a0 \"Obviously the process will have to be refined and optimized before it\u2019s actually used for treatment.\" ", "answer": 1}, {"article": "ADVERSE EVENTS \n\nNasal pain, discomfort or burning (10.3%); transient electrical discomfort (5.2%); nosebleed (5.2%); nasal congestion (3.1%); headaches (2.1%); trace blood, dot heme in nostril (2.1%); facial pain (2.1%); sore eye (1.0%); sinus pain (1.0%); periorbital pain (1.0%); runny nose (1.0%); nasal ulcers (1.0%); and light-headedness (1.0%).\nThe new advancement is an addition to Allergan's current eye care portfolio.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nAll device-related adverse events were mild in nature.\nCaution: Federal law restricts this device to sale by or on the order of a licensed physician.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says that the device has been granted marketing authorization by the FDA. One can safely assume the product will be on the market by the end of the year.", "answer": 1}, {"article": "Prostate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nStill, he said the new test could help patients if it was used with caution.\nIt was released online on Wednesday, a journal spokeswoman said, because \u201cit is a very active area of research with a lot of competition.\u201d\n\nResearchers long knew that the disease often runs in families.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\n\u201cIt\u2019s the boutique medicine of the future,\u201d said Dr. Peter C. Albertsen, a surgery professor and prostate cancer specialist at the University of Connecticut.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported that the company that would be offering the test estimated that it would be available in a matter of months.", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nIn addition, the product's proprietary formulation contains unique combinations and concentrations of cleaning agents that weaken the core of the plaque structure to help the subject visualize and more effectively remove the plaque.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implies that Plaque HD toothpaste and testing for hs-CRP are both currently available.", "answer": 1}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nThe sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\nBut by the end, those who had been in the combined program had more symptom relief, and were functioning better as well.The researchers expect to have lowered average doses in the combined program but had not yet finished analyzing that data.\nDr. Mary E. Olson, an assistant professor of psychiatry at the University of Massachusetts Medical School, who has worked to promote approaches to psychosis that are less reliant on drugs, said the combined treatment had a lot in common with Open Dialogue, a Finnish program developed in the 1980s.\n\u201cI\u2019m very favorably impressed they were able to pull this study off so successfully, and it clearly shows the importance of early intervention,\u201d said Dr. William T. Carpenter, a professor of psychiatry at the University of Maryland School of Medicine, who was not involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story touches on availability when it says, \u201cIn 2014, Congress awarded $25 million in block grants to the states to be set aside for early-intervention mental health programs. So far, 32 states have begun using those grants to fund combined-treatment services, Dr. Heinssen said.\u201d That doesn\u2019t provide as much detail as readers might like as to when and where they might find these services, but it gives a general idea of where things stand.", "answer": 1}, {"article": "Followers of the popular regime eat during an eight-hour window, in this case between 10 a.m. and 6 p.m. And for the 16 hours in between, they consume only calorie-free drinks, such as water.\n\"There are also many studies that either report no overall effect or sometimes the opposite.\n\"But one of the benefits of the 16:8 diet may be that it is easier for people to maintain.\nNow, researchers have shed light on what one type of time-restricted eating does to the body.\nHe concluded, \"So far, the consensus seems to be \u2018let\u2019s wait until more rigorous studies, with larger sample sizes that adjust for confounding lifestyle behaviors, have been performed before we conclude anything prematurely.'\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is an intervention tied to eating schedules, not a product. There\u2019s no question of availability.", "answer": 2}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\n\u201cIn my belief, that\u2019s what\u2019s protected them against some of the ravages of the more modern-day high carbohydrate diet.\u201d\n\nLuckily, resistant starch is found in a range of delicious foods.\nEven if you heat them up again, they retain their new resistant starches.\nBut out of the pile of cast-off carbs, there are some you should keep.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of these foods are widely available.", "answer": 2}, {"article": "\"This is the first time gene therapy has been tested and shown to improve outcomes for patients with advanced heart failure,\" study lead author Dr. Donna Mancini, professor of medicine and the Sudhir Choudhrie professor of cardiology at Columbia University College of Physicians and Surgeons in New York City, said in a university news release.\nAfter that, the only option is a transplant.\nAt both six months and a year later, the patients who had received the new gene saw their risk for death, cardiac transplantation, worsening heart failure and hospitalization decline by half.\nThe study was funded by the Celladon Corp. of La Jolla, Calif.\nThe gene for SERCA2a raises levels of the enzyme back to where the heart can pump more efficiently.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that this gene therapy is experimental and not available to patients.", "answer": 1}, {"article": "The Journal of Medical Entomology is published by the Entomological Society of America, the largest organization in the world serving the professional and scientific needs of entomologists and people in related disciplines.\nThe effectiveness of the device came as a pleasant surprise to the researchers.\nSkepticism is inherent to the trade.\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nClip-on Repellent Device With Metofluthrin Tested on Aedes aegypti (Diptera: Culicidae) for Mortality at Different Time Intervals and Distances,\" is available at http://dx.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the device is widely available.", "answer": 1}, {"article": "Dr Gorlanova said: \"As research in this field progresses, we are understanding more and more about the gene-environment interaction for the development of asthma.\nThis is the first time that we were able to show the effect of the 17q21 variants on respiratory symptoms during the 1st year of life, depending on breastfeeding status.\nThe study is presented today (4 September, 2016) at the European Respiratory Society's International Congress.\nResearchers collected data on occurrence and severity of respiratory symptoms, breastfeeding status and genotyping was performed.\n368 infants from the Basel-Bern Infant Lung Development birth cohort in Switzerland were included in the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Breastfeeding is indeed routinely available but the availability of genetic testing for the\u00a0chromosome 17q21 variant is not described. Is this test generally available and if so, is it covered by insurance? The release doesn\u2019t say.", "answer": 0}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nHe said it will take at least two years and additional studies before such a test might reach clinics around the country.\nUsing existing laboratory technology, they developed a test that will light up when the 18 molecules are present in a blood sample.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\nBut he said that a test showing the likelihood that the disease will develop will help patients and family members prepare for what lies ahead.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story used words like \"proves\" and \"promising\", it also included estimates for the time needed for further testing\u00a0that made it clear that this was not something that was currently available.", "answer": 1}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nNew research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\nProton therapy is just one of several new methods for treating cancer.\nThis technique can precisely direct radiation to the most difficult-to-reach tumors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There are at least a dozen centers in the United States that currently offer proton therapy for cancer treatment, but that\u2019s not clear from the information in the release. The only treatment center mentioned in the release is the one that UMD plans to open this fall. What\u2019s more, proton therapy is repeatedly characterized as \u201cnew\u201d \u2014 when it has been a subject of widespread discussion (and reporting) for years.\u00a0 Additionally, most insurers still consider proton beam therapy to be \u201cnot medically necessary\u201d under usual circumstances except for a small number of conditions noted earlier.", "answer": 0}, {"article": "Inflammation occurs when the body is exposed to pathogens, such as bacteria or viruses, which puts the immune system in overdrive until the \"attack\" ceases and the inflammatory response abates.\n\"We know from our previous studies that by losing weight, people can reduce their overall levels of inflammation, and there is some evidence suggesting that taking vitamin D supplements can have a similar effect if one has insufficient levels of the nutrient,\" said lead and corresponding author Catherine Duggan, Ph.D., a principal staff scientist in the Public Health Sciences Division at Fred Hutch.\nDuggan encourages women to speak to their health care providers about measuring their levels of vitamin D to determine the most appropriate dosage.\nPrivate contributions are essential for enabling Fred Hutch scientists to explore novel research opportunities that lead to important medical breakthroughs.\n\"We were quite surprised to see that vitamin D had an effect on an inflammation biomarker only among women who lost at least 5 percent of their baseline weight,\" Duggan said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Primary care physicians and other health providers are well positioned to monitor blood levels of vitamin D, along with dietary and exercise regimens. The news release makes that clear, albeit indirectly. As noted above, we think the release goes too far in suggesting that people ask their doctors about having their vitamin D levels checked. But we\u2019ve already docked points for that, so we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "Over 3 percent of patients treated by cryoablation experienced a serious condition \u2014 a narrowing of the pulmonary vein in 7 out of 228 patients, one of whom required another procedure to widen the vein.\nHe said the larger study, which will include 180 centers, is currently enrolling patients.\nOnly Johnson & Johnson (JNJ.N) has an ablation device approved by U.S. health regulators specifically to treat atrial fibrillation.\nOver the past decade, more patients have been referred for ablation procedures when drugs proved ineffective.\nThe Medtronic device, which the company added to its portfolio with the 2008 acquisition of CryoCath, has been approved in Europe and Australia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Towards the end, the story mentions that the treatment device discussed is not yet approved for use, though a device made by a different company (Johnson and Johnson) has been used to treat AF for years.", "answer": 1}, {"article": "Researchers believe electrical pulses can act like a sort of pacemaker in the brain, heading off the chaotic \"electrical storms\" that cause epileptic seizures.\nAnd she hasn't had any seizures since she added low doses of a medication more than 18 months ago.\nThe device alone reduced that to about one seizure a year.\nThe device is appealing because it doesn't require surgery, doesn't have side effects and is very easy to use, Rees says.\nThe device causes \"a slight tingling sensation\" on her skin, she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story that aired\u00a0said at the very end, \u201cThe device isn\u2019t approved by the FDA yet. That\u2019s probably several years off.\u201d The accompanying online version of the story said roughly the same thing. Readers should have been told that they are very unlikely to be able to have this device prescribed for them unless they can find their way into a clinical trial. Nonetheless, we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Good job on this. It\u2019s clear\u00a0that businesses that assist with combing are easy to find, and over-the-counter\u00a0shampoos are even easier.", "answer": 1}, {"article": "They find that there are real deleterious side effects but that they are manageable, and conclude the drug is worth using under the proper circumstances,\" he said.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\nOverall, Avastin, like several other targeted agents have led to therapeutic advances in lung cancer, he added.\nHowever, several issues remain to be determined, including the optimal dose and the role of maintenance therapy with Avastin, he said.\nAnother expert, Dr. Norman H. Edelman, chief medical officer at the American Lung Association, and professor of preventive medicine, internal medicine, physiology & biophysics at Stony Brook University in New York, called the study \"very good bread-and-butter clinical research.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This piece correctly indicated that this drug is currently available for use. \u00a0 The story used the trade-name Avastin (as opposed to its generic name bevacizumab)\u00a0nearly exclusively throughout and, at the end, mentioned that this drug has already received FDA approval for use in the treatment of other types of cancer.\nThe story could have clarified that the use of Avastin in the treatment of metastic non-squamous cell lung cancer is still an off-label indication for this drug, which is more common in cancer treatment than in other diseases.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe news story explains that the therapy it describes is not widely available, and probably won\u2019t be mainstream for another 5-10 years. However, the story does not say whether the therapy is FDA-approved. Numerous immunotherapies have been approved for various cancers, but this treatment for melanoma does not appear to be among them.\n", "answer": 1}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nHe explained that the key to the device is TENS (transcutaneous electrical nerve stimulation), those electronic nerve stimulators you've probably seen in strip malls that hook up to the body to treat neck or back pain.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nBut there's some reason for optimism: The device is basically a repackaging of another (cheaper) technology that has already been proven to help women who suffer with their monthly cycles.\nFor now, it's only possible to preorder the device (at a cost of $85) and wait six months for it to ship.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the device is not available at the present time, and it makes it clear that there are available TENS units now that are not as expensive.", "answer": 1}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nThese supplements are not regulated by the Food and Drug Administration, said Vazquez Roque.\nAccording to the researchers, the higher sodium content of the alginate drink \u2014 a little over one gram per dose, or about half a teaspoon of salt \u2014 could have offset any potential blood-pressure reducing effect of the supplement.\nStill, the new results should be treated with caution, according to Dr. Maria Vazquez Roque, who has worked on alginate-based gels at the Mayo Clinic in Jacksonville, Florida, but was not involved in the study.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that alginate is already available in pill form \u2013 and that the FDA does not regulate such supplements \u2013 was mentioned.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article reported on what it terms \u2018the first human testing\u2019 of vaccine against the bird flu. While mentioning other studies underway, and not explicitly stating that this vaccine is not currently available to the public, a thread throughout the piece made it clear that vaccine against this strain of flu was still a work in progress.", "answer": 1}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nScientists are also investigating its use in depression and epilepsy, but this was the first time it had been used in patients with anorexia.\nUnder previous therapies, none had shown progress.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story gave some hint of availability by reporting:\n\u201cDBS is used to treat several neurological illnesses including Parkinson\u2019s disease and chronic pain. Scientists are also investigating its use in depression and epilepsy, but this was the first time it had been used in patients with anorexia.\u201d", "answer": 1}, {"article": "SAMe may influence the expression of genes involved in depression or alter the function of different receptors and structures that transport neurotransmitters in the brain.\nThat\u2019s probably the best hypothesis.\u201d\n\nOther studies have suggested that SAMe can relieve symptoms of depression.\n\u201cIt may be that SAMe is facilitating the synthesis of the neurotransmitters that the drugs then act on.\n\u201cThere are many directions in research that this opens up,\u201d said Dr. George I. Papakostas, director of treatment resistant depression studies at Mass General and the study\u2019s lead author.\nA monthly supply of the same brand of supplement studied would be about $143, the editorial notes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that this supplement is available and popular, and we get its costs.\u00a0 Because the story meets the lowest standard for this criterion, we rule it satisfactory.\u00a0 However\u2026..\nWe don\u2019t learn why it\u2019s been widely used for depression in Europe but not in the U.S. That claim of widespread European use is dubious and could lead readers to falsely conclude that Europeans have concluded it is an effective treatment. Following lemmings off the cliff may be programmed into our nature, but the outcome is often undesirable. \n And what\u2019s it used for with such great popularity in the U.S.?", "answer": 1}, {"article": "\u201cFor young people they don\u2019t want to commit themselves to a treatment which they might need to take for the next five to ten years,\u201d he said.\n\u201cAt the moment there\u2019s no state-of-the-art guideline (on) how to treat those people.\u201d\n\nPrescribing antipsychotic medications may be helpful, Amminger added, but these medications have serious side effects, and can also be stigmatizing.\nBut while psychiatrists now know how to identify these individuals, he added, they don\u2019t know what to do with them.\nThere are a number of mechanisms through which omega-3s could protect the brain, Amminger said; they are a major component of brain cells.\nSeventy-six of the 81 study participants, or 94 percent, completed the trial, Amminger noted, which underscores the safety and tolerability of fish oil.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not state that\u00a0fish oil/omega-3\u00a0PUFA\u00a0supplements are widely available. But we\u2019re not sure that\u2019s necessary, since most people are probably already aware of this. ", "answer": 2}, {"article": "At the end of the period, those students who received the snack more regularly experienced a decrease in their overall BMI (-.7kg/m2) compared to those who did not receive the regular peanut snack (-.3kg/m2).\nThe snack was administered after school as students were boarding the school bus to go home.\nThere's less supervision by parents and less structure.\nKids are sitting down at the TV and eating, eating, eating because they really didn't eat at school.\"\nPeanuts were chosen because nuts are nutrient-dense snacks that promote a feeling of being full.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that peanuts and peanut butter are available in every grocery and convenience store in the United States.", "answer": 2}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nHe was not involved with the research.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nAnd it has sulfur, which fights bacteria and infection, and a moisturizing cream to help rehydrate the skin, Draelos says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the product is available in drug stores.", "answer": 1}, {"article": "For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.\nPhysicians in this study rated the DCIS Score as the most important factor in planning treatment compared with pathologic features, patient preference, patient age, comorbidities or consultation with other physicians.\nThe Oncotype DX DCIS Score result provides patients with an individualized estimate of local (in the same breast) recurrence, which could be either invasive breast cancer or DCIS.\n\"The Oncotype DX DCIS Score result was validated in two studies including nearly 900 patients and is the only genomic test for patients with pre-invasive breast cancer,\" said Phil Febbo, M.D., chief medical officer, Genomic Health.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There was no mention on how available the Oncotype DX DCIS Score test is in clinical offices and no mention on whether it is covered by insurance. The test is, in fact,\u00a0widely available \u2014 the physician sends a\u00a0requisition form either to the pathology department, which will send the tissue to Genomic Health, or to Genomic Health, who will then request the tissue samples from pathology.", "answer": 0}, {"article": "\"Pecans are naturally high in monounsaturated and polyunsaturated fats, so replacing a portion of the saturated fat in the diet with these healthier fats can explain some of the cardio-protective effects we observed,\" said lead researcher, Diane McKay, Ph.D. \"But pecans also contain a number of bioactive plant compounds as well as vitamins and essential minerals that all likely contributed to this benefit.\nThe study was funded by the National Pecan Shellers Association.\nBoth the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\nIn this placebo-controlled crossover study of 26 men and women (average age 59 years), all meals were provided to carefully control their food intake.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Pecans are known to be widely available.", "answer": 2}, {"article": "Also some fancier CT studies, involving multiple \"slices\" through the body in a single examination, can be replaced by simpler CT tests, conventional X-rays or tests such as ultrasound or MRI that don't involve radiation.\nPatients often expect a scan.\nChildren, younger adults and women are especially susceptible.\nA low score indicates the test is unlikely to be necessary.\nDoctors love the detailed pictures created by CT scans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available.", "answer": 1}, {"article": "Try to eat a pound of vegetables each day, half of which are cooked and the other half eaten raw, as well as half a pound of raw fruit.\nA food does not have to be obviously acidic to be troublesome.\nshould be used in the lowest effective dose at the correct time and for the shortest possible period, experts say.\n\u201cStudies have revealed that 80 percent of Americans may be taking these powerful meds incorrectly,\u201d Dr. Aviv wrote.\nLosing weight is one of the best ways to find relief without having to rely on medication.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address availability\u2013but it doesn\u2019t need to: lifestyle changes are not products or services. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "\"Why does it work for some people and not others?\"\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\nDeng pointed out that clinicians have come to realize that the placebo effect is very important in treatment.\n\"There is a component of behavior of doing a sham procedure, so it psychologically may trigger a different kind of reaction from patients versus taking the placebo pill.\"\nFurthermore, the effects of acupuncture were \"significant and enduring for hot flashes while gabapentin's effect only happened when a patient was taking the medication,\" said study first author Dr. Jun Mao, an associate professor of family medicine and community health at the University of Pennsylvania in Philadelphia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Acupuncture is widely available and while the report did not establish the availability of the treatment, consumers certainly know about it. The story could have noted that insurance may not pay for acupuncture treatment, however. Gabaptentin is described as a drug that\u2019s typically used to treat nerve pain, and readers can work out from that that the drug is available.", "answer": 1}, {"article": ".\nThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors.\nDiagnostic Photonics, a start-up company Boppart co-founded that also collaborated on the study, is commercializing the OCT probe technology for broader use.\n\"It is likely better to check to see if any residual tumor cells might be left behind, rather than checking the tissue mass that was taken out.\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says the device \u201ccould soon enable reliable, real-time guidance for surgeons,\u201d which may be a bit optimistic, but at least suggests that the device is not available yet. Toward the end of the release it is stated that \u201cThe researchers will continue clinical studies with the OCT device, looking at other types of solid-state tumors,\u201d which arguably suggests the same.\nIdeally the text would have been more explicit about whether and/or when the device would be commercialized, but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": ".\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids\n\nDry needling may be a viable treatment alternative to cortisone injection for patients with chronic, intermittent pain and tenderness on the outside of the hip, thus avoiding the potentially harmful effects of steroids, according to a new study published in the April 2017 issue of the Journal of Orthopaedic & Sports Physical Therapy\u00ae (JOSPT\u00ae).\nResearchers at Baylor Scott & White Health in Temple, Texas, found that dry needling, which uses filament needles to stimulate sensitive loci, or trigger points, in the muscles, is as effective as cortisone injection in reducing pain and improving movement problems caused by greater trochanteric pain syndrome (GPTS).\nHowever, \"this study suggests dry needling as an effective alternative to cortisone injection.\"\nThis kind of hip pain has been reported to be more common in women and in patients with coexisting low back pain, osteoarthritis, Iliotibial band tenderness, and obesity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no discussion of what\u2019s involved with dry needling. While steroid injections take about five minutes and are usually done in a physician\u2019s office once every six weeks or more, dry needling is usually performed by a physical therapist and requires more frequent treatments of about 20 minutes apiece.\nDuring this six-week study, the dry needling group received an average of 5.4 treatments while those who received cortisone injections had one shot.\nDry needling might be more convenient than steroid injections if it\u2019s part of treatment strategy that also involves physical therapy.", "answer": 0}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\nBut that\u2019s changing.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nAll of which adds up to a compelling argument that psychedelics \u201cshould be the focus of intensive study for treating mental illness,\u201d Wood says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Magic mushrooms and MDMA may be \u2018available\u2019 in our society, but hardly through channels that one would consider reliable or trustworthy. While we might want more details on how to obtain these substances, in the interests of public service, it may be just as well that the story didn\u2019t delve into this issue too far.", "answer": 1}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nThe safety and effectiveness of Trulance have not been established in patients less than 18 years of age.\nTrulance should be avoided in patients six years of age to 18 years of age.\n\u201cWith the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition.\u201d\n\nAccording to the National Institutes of Health, an estimated 42 million people are affected by constipation.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA release announces approval and most readers will understand that this is essentially the last big step in market availability. The release would have been stronger had it noted that the drug may not be available widely for a short time.", "answer": 1}, {"article": "Patients with a record of pneumonia were followed for six months to see if they died, and the researchers found that 13 percent (109 out of 847) of statin users died compared with 20 percent (578 out of 2,927) of non-statin users.\n\u201cGiven the potential low number needed to treat to prevent a death suggested by this study, we believe that a strong case exists for randomized trials of statins in people with serious infection to determine if a simple and practical intervention at the point of diagnosis of pneumonia has a beneficial effect.\u201d\n\nDouglas\u2019s team, whose research was published in the British Medical Journal, used data from computerized medical records of doctors\u2019 practices in Britain to identify statin users.\n\u201cStatins are safe, cheap, and an easy intervention in terms of delivery,\u201d said Ian Douglas, a lecturer in epidemiology at the LSHTM who led the research.\nDouglas noted that since this study looked at patients who were already taking statins when they developed pneumonia, a full randomized clinical trial was needed to find out whether starting a statin at the time of diagnosis has a similar effect.\nStatins such as Lipitor, Crestor, and a generic called simvastatin are widely prescribed to lower so-called \u201cbad\u201d or LDL cholesterol \u2014 a risk factor for heart disease \u2014 and are credited with being among the most successful drugs in helping to prevent heart attacks and strokes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statin drugs are commercially available in\u00a0brand name and generic formulations as indicated.\nWe do think it\u2019s a bit odd \u2013 and unnecessary \u2013 to mention the manufacturer and the brand name.\u00a0 Early in our journalism training, we were discouraged from doing so unless absolutely necessary in the story \u2013 which is not the case herein.", "answer": 1}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThat doesn't tell the whole story.\nThe study makes that last point very clear.\nThe pill, called Truvada, is already on the market for treating HIV infections.\nNow health officials are warning doctors that preventing the disease will take more than just writing a prescription.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that Truvada is already on the market.", "answer": 1}, {"article": "Although surgeons can also take X-rays during the posterior procedure, it is much more difficult, and they wait until patients are in the recovery room, where, Bollinger says, \u201cthere\u2019s not much that can be done.\u201d He explains that while the body \u201ctolerates an imperfect alignment pretty well, if a new hip gets dislocated, it\u2019s often because it\u2019s not in perfectly.\u201d\n\nRobert Saunders, a nurse at Alta Bates Summit Medical Center in Berkeley, Calif., sees about 200 hip replacement patients a year.\nMany patients aren\u2019t aware of the option.\nThey must get training in classes and cadaver labs, and the learning curve can be steep.\nAccording to those who use this anterior technique, the benefits are substantial.\nSo when students leave and begin their practices, it\u2019s no longer foreign to them.\u201d\n\nHamilton, who has performed 1,100 anterior procedures and strongly supports the method, says that despite growing interest, \u201cit will take a generation of new surgeons\u201d before use of the anterior approach is widespread.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story spends a lot of time discussing why this technique is still only practiced by a minority of physicians, but it is clear that it is a widely available option.", "answer": 1}, {"article": "But when the virus does get into cells your T cells try to kill those infected cells.\nThis is 12 times higher than other less effective shingles vaccines.\nThe full paper is published online by the Journal of Infectious Diseases as Editor's choice: https:/\n\nThe Shingrix vaccine is developed by GlaxoSmithKline.\nThe trial included more than 15,000 participants across 18 countries in Europe, North America, Latin America, Asia and Australia.\nIt is the first shingles vaccine to combine a non-live antigen with a specifically designed adjuvant.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of whether Shingrix is widely available. It is, including in the US where it received FDA approval in October 2017.", "answer": 0}, {"article": "In their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nHe reviewed the study but was not involved in it.\nAnd though mammography did not catch all cancers in the women with a breast cancer history, the study still points out the value of the test, he said.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\nDr. William Audeh, medical director of the Samuel Oschin Cancer Center and the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center in Los Angeles, described the findings as \"not at all surprising.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Mammography is widely available and recommendations for annual mammography screening after a breast cancer diagnosis are standard. So the story didn\u2019t need to specifically discuss the availability.", "answer": 2}, {"article": "When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\nThe drug is currently being evaluated in late stage clinical trials for efficacy in patients with severe asthma, according to ClinTrials.gov.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\nThis is the technical name for the five year Europe-wide, EU funded project, which aimed to produce computer and physical models of the whole human airway system for people with asthma and chronic obstructive pulmonary disease (COPD).\nShe took part in the trial and was part of the Fevipiprant group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is fairly clear in pointing out that this was a clinical trial and that the drug, fevipiprant, isn\u2019t available to the public as of yet.", "answer": 1}, {"article": "According to the Centers for Disease Control and Prevention (CDC), birth defects caused by genetic disorders affect one in every 33 births in the United States.\nExperts say the couples are not the only people who benefit from these tests.\nA diagnosis before pregnancy may sound like a designer baby, but doctors say that\u2019s not the case.\nSpecialists now have a way to test the parents-to-be that may not only increase their chances of getting pregnant but also reduce the risk of them passing on certain genetic diseases.\nThese results have helped eliminate pre-term birth and hospitalizations for pre-term labor, and patients and families have better outcomes, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that preimplantation genetic screening is available, but it doesn\u2019t make clear that it is available only for pregnancies resulting from IVF.", "answer": 0}, {"article": "An enzyme is a protein that performs a chemical reaction.\nA new study, however, offers some potential for hope.\nFRIDAY, Feb. 8, 2013 (HealthDay News) -- For people with celiac disease, everyday foods such as bread, pizza crust and muffins are potential enemies.\nBut scientists anticipate that some day a simple pill could help prevent the digestive upsets caused by ingesting the gluten in wheat, rye or barley products.\nSome experts identified limitations to the research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental treatment and not available to the public, although we\u2019re a little uncomfortable with the prediction that a pill could\u00a0be available \u201cin a few years.\u201d That\u2019s true, but it\u2019s also possible that such a pill might\u00a0never be available. Why not mention that possibility as well?", "answer": 1}, {"article": "It involves taking a small amount of blood from the mother when she is between the 11th and 13th week of her pregnancy and detecting extra copies chromosome 21 in the fetus by analyzing the maternal blood.\nSince amniocentesis carries a small risk of spontaneous miscarriage \u2014 Patsalis put it at around one or two percent \u2014 scientists have been looking for new less invasive ways to test for Down\u2019s and other potential genetic problems.\nThe risk for a 40-year-old mother is 16 times that for one who is 25.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Allowing researchers to claim that a test \u201cmay soon be\u201d available after a study in just 40 pregnancies is not wise journalism.\u00a0 If the story had turned to an independent expert, perhaps this enthusiasm may have been put into a better perspective. The path to commercialization is likely years in the making.", "answer": 0}, {"article": "Other potential side effects include diarrhea, headache, rashes and changes in taste.\nLast year, the Food and Drug Administration cleared the first laser, PinPointe, for \u201ctemporary increase of clear nail\u201d in patients with onychomycosis, the medical term for a fungal infection of the nail.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nPractitioners have been using other lasers on toenail fungus since about 2009.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says, \u201cLast year, the Food and Drug Administration cleared the first laser, PinPointe, for \u201ctemporary increase of clear nail\u201d in patients with onychomycosis, the medical term for a fungal infection of the nail. The FDA cleared a second one, GenesisPlus, in April. Practitioners have been using other lasers on toenail fungus since about 2009.\u201d This covers the necessary bases.", "answer": 1}, {"article": "They might be more health conscious or conscientious, or have other traits associated with longevity.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\n\u201cNo matter how sophisticated, they shouldn\u2019t trump data from real people who participated in the randomized trials\u201d \u2014 which in PLCO found zero lives saved from PSA screening.\nBut 46 percent of the men in the no-PSA group had yearly PSAs anyway.\nThe analysis, published Monday in Annals of Internal Medicine, drew wildly different reactions, as is often the case with research on PSA screenings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the article that PSA testing is ubiquitous in America. Mentioning that it is covered by most insurers, and for those on Medicaid/Medicare, still would have been helpful, however.\n\u00a0", "answer": 1}, {"article": "\"This definitely has potential.\"\n\"We're now in the midst of a large study to look at whether or not activity of this pathway can be used to pick those who could benefit from this as a treatment as opposed to just prevention,\" said Spira, who is a co-founder of Allegro Diagnostics Inc., a company that plans to market this biomarker.\nWorking on the theory that cigarettes harm not only the lungs but a \"field of injury\" extending to other areas of the respiratory tract, the study authors surmised that evidence of existing or soon-to-develop lung cancer might be available further up in the airway.\nThe minimally invasive procedure involves using a small brush to collect a smattering of cells from the windpipe (a bronchoscopy), explained study co-author Andrea Bild, an assistant professor of pharmacology and toxicology at the University of Utah in Salt Lake City.\nIt turned out that gene activity in the PI3K pathway was \"off the chart\" in smokers with lung cancer versus those without the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The opening line of the article \u2014 \"Researchers may have found an easy way to detect lung cancer in its early or even pre-cancerousstages, as well as a way to reverse the start of the deadly disease with a readily available, over-the-counter drug\" \u2013 overstates the evidence for inositol\u2019s effectiveness, and implies that it is available in a form that could reverse the development of lung cancer.\u00a0 ", "answer": 0}, {"article": "\u201cWe believe the benefits increase with age.\nFor every 10,000 women screened repeatedly over 10 years, four lives are saved in women 40 to 49; eight in women 50 to 59; 21 in women 60 to 69; and 13 in women 70 to 74, the task force found.\nDr. Constance Lehman, a professor of radiology at Harvard Medical School and director of breast imaging at Massachusetts General Hospital, who is not on the task force, said she was pleased to see that although its advice had not changed, the group had placed more of an emphasis than before on the importance of women\u2019s having the freedom to decide how often to be screened and when to start.\n\u201cThe science supports mammography as an important tool in the fight against breast cancer,\u201d said Dr. Michael LeFevre, a former chairman of the task force and a professor of medicine at the University of Missouri.\nThe guidelines relied in part on a study of records from 405,191 women who had digital mammograms from 2003 to 2011, which found that false positives were common, especially in younger women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of mammograms as breast cancer screening tools is longstanding and well established. The story also discusses insurance coverage issues that would affect availability for many women. The story states, \u201cThe recommendations are not immediately expected to affect insurance coverage. In December, Congress passed a bill requiring private insurers to pay for screening mammograms for women 40 and over every one to two years without copays, coinsurance or deductibles, through 2017.\u201d", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\n\"We hope the findings will help surgeons choose the best implants and approaches for their patients,\" said Dr. Wanna.\n\"This is an exciting time in this field, and the advancement in hearing technology and continued improvements in techniques and outcomes will benefit patients and their families.\"\n\"Our results also revealed that using oral steroids also helped in the long term to preserve hearing by preventing inflammation.\"\nThe results, published in the June 23, 2017, online edition of The Laryngoscope, may transform how doctors approach cochlear implant procedures to give patients the best possible outcomes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Are these types of surgeries or cochlear implants available anywhere in the US? \u00a0We have no idea from reading this news release.", "answer": 0}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe drug is called Gammagard.\nIt's a form of intravenous immunoglobulin, or IVIG, drugs that are usually used to treat immune system disorders.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe findings were presented at the American Academy of Neurology meeting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told that IVIG is a decades-old drug. ", "answer": 1}, {"article": "Men with low-risk prostate cancer are currently put under active surveillance, where the disease is monitored and only treated when it becomes more severe.\nThe VTP treatment is now being reviewed by the European Medicines Agency (EMA) for possible license, but it likely to be several years before it can be offered to patients more widely.\n\u201cThe fact that the treatment was performed so successfully by non-specialist centers in various health systems is really remarkable,\u201d Emberton said.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\nNo significant side-effects remained after two years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the treatment is \u201cbeing reviewed by the European Medicines Agency (EMA) for possible license, but it is likely to be several years before it can be offered to patients more widely.\u201d\nStill, we\u2019re left wondering what \u201cmore widely\u201d means here. Is it already available to some patients? The story doesn\u2019t say.", "answer": 1}, {"article": "Unlike the 2012 campaign, which aired for 12 consecutive weeks, the 2014 campaign aired in two phases, from February 3 to April 6 and from July 7 to September 7.\nThe website includes detailed assistance developed by the National Cancer Institute to support smokers trying to quit.\nTips ads encourage smokers to call 1-800-QUIT-NOW or to visit www.cdc.gov/tips to view the personal stories from the campaign.\nThose new ads featured people and their struggles with smoking-related health issues, including cancer, gum disease, premature birth, and stroke caused by smoking combined with HIV.\n\u201cTips is also extremely cost-effective and a best buy, saving both lives and money.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release refers readers to the quit line and a web site containing the Tips ads.", "answer": 1}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\nThat plan marked a major shift designed to give adult smokers a wider range of alternatives, including potentially less harmful e-cigarettes.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\nThe move was part of a comprehensive plan the agency announced last summer to regulate tobacco and nicotine, FDA Commissioner Scott Gottlieb said on a call with reporters.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that lowering nicotine in cigarettes is in the proposal stage.", "answer": 1}, {"article": "Only 30-50 people with type 1 diabetes in the UK currently receive an islet transplant each year, owing to a lack of donors and the difficulty of extracting islets from pancreatic tissue.\nThe pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nThey are looking for investors to take Islexa all the way as a fully fledged external company.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nIslexa will use CGT\u2019s labs at Guy\u2019s and facilities at Aberdeen University.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are vague mentions of the need for clinical trials and reference to a \u201cfew years\u201d before treatment with the lab grown islets are available, but readers will not come away with a reasonable sense of what needs to happen before a treatment based on this approach would become available.", "answer": 0}, {"article": "A number of new multiple-sclerosis medications are beginning to hit the market that promise to make it easier for patients to control flare-ups of the disease and slow its progression.\n\nThe drugs, designed to be taken orally, represent a new generation of treatment for MS. Currently, people with the disease can choose from a range of drugs that are administered by injection.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Good job explaining which oral drugs are pending approval, and which is approved. The story says 6,000 patients are already taking Gilenya, the oral drug that is first in this family to win FDA approval.", "answer": 1}, {"article": "The Northwest's other participating centers are the Seattle Cancer Care Alliance and Swedish Cancer Institute in Seattle, Providence Cancer Center in Spokane, and Multicare Health System in Tacoma.\nFor now, federal regulators have authorized\n\nto people who have serious or immediately life-threatening, inoperable melanoma that has spread, who have no alternative treatment options, and whose physicians believe the drug is appropriate.\nResearchers linked 14 deaths to the study drugs, half caused by immune-system reactions.\nStill, the study stands as \"a major landmark in cancer immunotherapy,\" says Dr. Bernard Fox, president of the International Society for Biological Therapy of Cancer.\nSerious side effects also became clear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the approach is experimental.\u00a0 The story also states:\nMinor quibble:\u00a0 perhaps the story should have reminded readers that a drug company\u2019s timetable predictions may not be the most reliable. \nFor local readers it explained: ", "answer": 1}, {"article": "The procedure didn't help everyone, though.\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\nEarly findings suggest that a single outpatient treatment can reduce migraine pain levels by about 35 percent for up to a month after the procedure, according to this small, ongoing study.\nSUNDAY, March 1, 2015 (HealthDay News) -- A procedure that delivers the anesthetic lidocaine (Xylocaine) directly to nerves in the back of the nasal cavity appears to offer significant relief to migraine sufferers, preliminary research indicates.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of lidocaine (Xylocaine) was not in question, as the drug has been synthesized since the 1940s. It is now widely available in pharmacies. The bigger issue would be finding a specialist every month to deliver these infusions. Is it a procedure that any interventional radiologist could perform? Would they need any special training? The story doesn\u2019t establish whether one can request this procedure right now or if it\u2019s something headache sufferers will need to wait for.", "answer": 0}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\n\u201cWhen the hunger comes back, the topiramate kicks in,\u201d says study author Suzanne Oparil, MD, a professor of medicine, physiology, and biophysics and director of the vascular biology and hypertension program at the University of Alabama at Birmingham.\nThe new analysis of three separate studies included more than 4,500 people.\nData on this drug are slated to be reviewed this summer by an FDA advisory panel.\nOparil is a consultant for Qnexa manufacturer Vivus.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear from the story that the combination of the two drugs is not yet available. ", "answer": 1}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nWith a pill, you take it, it\u2019s eliminated from your body and you have to take it again.\u201d But T-cells, he said, \u201ccould potentially be given only once, maybe only once or twice or three times.\u201d\n\nThe Pennsylvania researchers said they were surprised to find any big drug company interested in their work, because a new batch of T-cells must be created for each patient \u2014 a far cry from the familiar commercial strategy of developing products like or medicines, in which millions of people take the same drug.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nBut Mr. Hoppenot said Novartis was taking a different path with cancer drugs, looking for treatments that would have a big, unmistakable impact on a small number of patients.\nThe researchers are not entirely sure why the treatment works, or why it sometimes fails.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this treatment is not widely available and won\u2019t be any time soon. As a service to patients and parents who might be in desperate straits, the story could have provided some information about research plans for the experimental treatment and the possibility (or lack thereof) of enrolling in a study.", "answer": 1}, {"article": "Kalluri and his colleagues examined serum samples from 190 patients with pancreatic cancer, 32 patients with breast cancer and 100 healthy volunteers.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\nAnd even if it passes muster, it will take some time before a test could be developed to screen for the disease.\nIt is a good example of how this disease sneaks up on people and gives no warning.\u201d\n\nA test for pancreatic cancer could save lives, perhaps even Flippo-Morton\u2019s, Raghavan said.\nWhile quite promising, the new findings will need to be verified and validated by other studies, experts told NBC News.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We were surprised to see mention in the story that a clinical test could be available within a year. Given that the test will need to be further validated in a much larger group of study subjects, we think that\u2019s very unlikely. The story does frame the comment as \u201cjust speculation\u201d and notes that additional research will be needed. We\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Massage therapy increases the activity level of the body's white blood cells that work to combat viruses.\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nTo find a massage therapist near you, the American Massage Therapy Association (AMTA), the most trusted name in massage therapy, offers a free professional massage therapist locator service at www.findamassagetherapist.org.\nEVANSTON, Ill., Nov. 4, 2015 /PRNewswire/ -- People looking to fend off cold and flu as the winter months arrive should speak to a massage therapist about prevention strategies.\nBy meeting or exceeding state training requirements, ascribing to a code of ethics and participating in continuing education, American Massage Therapy Association massage therapists are appropriate additions to any wellness regimen and create specialized approaches based on individual conditions, fitness and goals.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most people are aware that massage therapy is widely available nationwide. However, the news release provides a link to the American Massage Therapy Association\u2019s locator service, presumably\u00a0 dues-paying AMTA members.", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nThe label warns that evidence is limited.\n\u201cThis is a very important claim for us to allow to be incorporated into food labels,\u201d said Dr. Scott Gottlieb, the commissioner of the F.D.A.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n\u201cThe guidelines for how to approach allergens in children are changing, the science is changing, and it\u2019s important for parents to know.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the product is available for purchase and goes so far as to hyperlink to its website, where people can place an order. We\u2019d call this establishing availability \u2013 sure. But it also might go a step beyond and risk actually advertising the product under scrutiny in the story.", "answer": 1}, {"article": "At 12 months in patients receiving torcetrapib, there was a 72 percent increased in good cholesterol and a 24.9 percent decrease in bad cholesterol.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nA long-awaited postmortem released this morning of Pfizer's (NYSE: PFE) failed heart drug held out hope for the discovery of a safe version of the revolutionary heart pill.\nOf the 15,067 patients in seven countries taking part in the randomized clinical trial, called Illuminate, 82 patients taking a combination of torcetrapib and Lipitor died, compared with 51 taking Lipitor alone, which was the control group, according to the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that the HDL-targeting drugs are still in the early stages of development. The story does not make any claims about when a new drug would be available, however whether it will ever happen is still highly theoretical. However, atorvastatin was studied along with torcetrapib and a note that it is available commercialy and is the largest selling cholesterol lowering drug would have been useful to the readers.", "answer": 1}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nThe group will next focus on confirming their results and investigate the biological role of irisin in PCOS.\nThe cause of PCOS is unknown and there is currently no cure for the condition.\nLifestyle changes and different exercise-related signals that regulate the secretion of irisin could provide a potential option for the management of PCOS.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that it is too early to say whether irisin will serve as a good indicator for PCOS diagnosis.", "answer": 1}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\n\"Don't count on this to be the complete answer to high blood pressure,\" he said.\n\"They are not easy to find or one of those fruits that people readily grab.\"\nThe new study may just \"put kiwis on the map,\" he said.\nSo, is kiwi the new \"wonder\" fruit?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story noted that kiwis \u201care not easy to find\u201d", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nToday\u2019s action supports the FDA\u2019s Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging\u2014an effort to ensure that each patient is getting the right imaging exam, at the right time, with the right radiation dose,\u201d said FDA Commissioner Scott Gottlieb, M.D.\n\u201cA blood test to aid in concussion evaluation is an important tool for the American public and for our Service Members abroad who need access to quick and accurate tests,\u201d said Jeffrey Shuren, M.D., director of the FDA\u2019s Center for Devices and Radiological Health.\nTest results can be available within 3 to 4 hours.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release announces that the test is \u201capproved\u201d for use, so we assume it will be widely available. It also quotes an official who says the test \u201ccan be used both in the continental U.S. as well as foreign U.S. laboratories that service the American military.\u201d", "answer": 1}, {"article": "Anthony Cunningham, Executive Director of the Westmead Institute for Medical Research in Australia and Principal Investigator of the ZOE-70 study said: \"These data show that this investigational vaccine maintains high efficacy against herpes zoster in people over 70 and 80 years of age, the age groups who are most affected by the disease.\nThe candidate vaccine combines glycoprotein E, a protein found on the varicella zoster virus (VZV) that causes shingles, with an adjuvant system, AS01 , which is intended to enhance the immunological response to the antigen5.\nNotes to editors\n\nThe name Shingrix is not yet approved for use by regulatory authorities in most countries, including the US Food and Drug Administration (FDA).\nIn addition to older adults, the candidate vaccine is being evaluated in immunocompromised patient populations, including solid and haematological cancer patients, haematopoietic stem cell and renal transplant recipients and HIV-infected people.\nThese studies will provide additional information with respect to the efficacy and safety profile of the candidate vaccine as well as its ability to stimulate immune responses in other populations and in specific circumstances.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the press release that GSK has not yet applied for regulatory approval of the vaccine in any country. Thus, it should be obvious that the vaccine is not yet available for use.", "answer": 1}, {"article": "For example, robots that provide sensory feedback could eventually help a disabled person cook a meal or clean up things at home.\nThat makes it very challenging to perform simple tasks like grasping a foam coffee cup without crushing it, McLoughlin says.\nAnd there's no good way to control them without implanting electrodes in the brain.\nIt's a mind-controlled robotic arm that has pressure sensors in each fingertip that send signals directly to Copeland's brain.\nOf course, mind-controlled robots are still years away from consumer applications, McLoughlin says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear this patient is the first to receive this treatment in an experimental setting, so it is clear that this is not available except in a laboratory.", "answer": 1}, {"article": "Testing cholesterol in toddlers and babies?\nBut many parents balk at the idea of testing children for a disorder associated with middle age, experts say.\nThat\u2019s nearly twice as many as most studies in the past have suggested.\nNinety percent of them started taking preventive medicines after finding out.\nexpert panel.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Are these sorts of genetic tests available for parents to buy off the shelf, or ask for a referral from a doctor to get? The story doesn\u2019t clarify.", "answer": 0}, {"article": "Dr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nThe team needed to eliminate the 'noise' of the genetic patterns that make individuals unique, to leave them with the patterns that indicate cancer.\nTo take this method out of the laboratory, the team are now investigating a further trial with new cancer samples, and hope to involve a commercial partner to allow this to be used for patients being treated in the NHS.\nThey were able to do this using a computer algorithm, which left the team with 17 possible genetic markers for prostate cancer.\n\"The challenge in prostate cancer is how to look at all of these patterns within a cell, but hone in on the gene activity that suggests cancer, and not only this, what type of cancer - dangerous or manageable?\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "At the very end of the news release, the authors write that the next step is, \u201cto take this method out of the laboratory,\u201d and that the researchers hope that they will find a commercial partner to develop the test for general use. But this should have come much sooner, ideally in the first paragraph. The entire release (including the headline) made it sound like this test is already available, likely frustrating patients who felt duped at the end of the release.", "answer": 0}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses the relatively new Center for Surgical Innovation in New Hampshire and the program at\u00a0Brigham and Women\u2019s Hospital in Boston. But it\u2019s not clear from the story whether these real-time imaging surgical techniques are being implemented elsewhere. Is it widespread? Do we expect it to become widespread? If so, when? And at what cost?", "answer": 0}, {"article": "A former gang member recently recalled when he decided to join the gang.\nNewsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nHere\u2019s how he got out.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "\"We wanted something elastic that was form fitting, which led to the idea of a swim cap.\"\nOn the strength of these results, Vanderbilt University has applied for a patent on the design and the technology is available for licensing.\nIn essence, that is what a team of Vanderbilt University engineers are proposing in an effort to improve the reliability of the sophisticated \"GPS\" system that surgeons use for these delicate operations.\nThe new design allowed them to attach several dozen markers directly to the surface of the cap, which the researchers believe will also contribute to improving the guidance system's accuracy.\n\"Actually, we do have a solution to this problem but it involves drilling and attaching the markers directly to the skull...which we don't like to do because it is painful and it's a step backwards from the majority of what we are doing,\" said Assistant Professor of Otolaryngology Paul Russell, who is collaborating with the engineers on the project.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does the minimum, saying \u201cVanderbilt University has applied for a patent on the design and the technology is available for licensing. (Interested parties should contact the Vanderbilt Center for Technology Transfer and Commercialization.)\u201d A companion video states that \u201cthe next step is to work with a commercial partner to make it an FDA-approved product.\u201d\nInformation on how long FDA approval could take, as well as a nod to the fact that this might never make it to market, would have made this better.", "answer": 1}, {"article": "Most of the time, concussion testing in youth sports falls to volunteer coaches or parents with little if any medical experience.\nFor the greatest precision, you might want to have athletes perform the test twice and use their best reading.\nThe pace-along-the-tape test was also relatively accurate.\nresearchers decided to test it.\nFor more fitness, food and wellness news, \u201clike\u201d our Facebook page.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly state that one can purchase this test, but the implication is that it is available. We\u2019ll give the benefit of the doubt, but we\u2019d prefer it if the story linked to the sole supplier of the product offering yearly packages from its website. It\u2019s also available on the iTunes App Store.", "answer": 1}, {"article": "Instead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nThis place conducts some serious research on diet and weight.\nAfter a two-week gap, the groups were switched.\nThis message was brought to you by the American Egg Board.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of eggs and cereal is not in question.", "answer": 2}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains where the drug is in the regulatory process\u2013still far from being on the market.\nAnd it indicates how likely it is for the drug to get approval, saying, \u201cA\u00a02.6-point edge over placebo may\u00a0fall slightly short of what the\u00a0Food and Drug Administration would require for approval of a new Alzheimer\u2019s drug\u2026\u00a0the FDA typically wants to see a net benefit of at least\u00a03 or 4 points.\u201d", "answer": 1}, {"article": "The Centers for Disease Control and Prevention estimates there are 300,000 sports concussions among children each year.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nAnd new research indicates children and teens are more vulnerable than adults, because their brains are less developed and take longer to heal.\nSome 1,500 schools and sports teams across the country are using Impact.\n\"The brain, in its development, while it is actively developing, seems to be less able to take these forces and to really rebound from these forces,\" Dr. Gioia observed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe report describes the widespread availability of the Impact system in the U.S., but fails to describe how an athlete would gain access to such neurocognitive testing systems.\n", "answer": 0}, {"article": "All the women had been successfully treated for early-stage breast cancer.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not specifically mention the availability of a fresh fruits and vegetables for all populations, but the focus of the story is on the lack of evidence that a diet concentrated on these foods has any benefit for breast cancer recurrence.\u00a0 No preventative behavioral modification related to diet is advocated.\u00a0 The story was also suffienciently clear about what the \"treatment\" was (number of servings of vegetables and fruits, etc) such that if a person wanted to \"treat\" themselves in this manner they could replicate the intervention.\n\u00a0\n", "answer": 1}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\n\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\nResearchers agree there is a strong genetic component.\nBritish scientists said on Tuesday their rapid test had proved more than 90 percent accurate in adults and there was no reason why it should not work equally well in children.\nExperts not involved in the research applauded the research but cautioned further study was still needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although it is clear that this technology is not yet available to the public, the story\u00a0predicts the new scan \"could be ready for general use in a couple of years.\" Really?\u00a0Who says? It seems unlikely that any knowledgeable researcher would make such a wildly optimistic prediction on the basis of a 40-person study.\u00a0But the story\u00a0treats\u00a0this forecast\u00a0as an established fact\u00a0requiring no attribution, so\u00a0we can\u2019t tell where it came from.\u00a0\u00a0In any case, we think such\u00a0pie-in-the-sky guesstimates are usually wrong and should be avoided in health journalism. \u00a0", "answer": 0}, {"article": "Observational studies in people living with HIV have shown positive emotion is related to a higher CD4 count (an indicator of less HIV-related damage to the immune system).\nBased on the study results, the intervention is promising for people in the initial stages of adjustment to any serious chronic illness.\nThis is believed to be the first test of a positive emotion intervention in people newly diagnosed with HIV.\nThe HIV study is part of a larger body of positive affect research being conducted by Moskowitz.\nThe paper was published recently in the Journal of Consulting and Clinical Psychology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability of the training. In claiming this research has not been done before it suggests that the intervention would only be available via clinical trials. \u00a0The release could have been more specific about whether the skills training has been standardized or whether it is in widespread use in any context. Because we can\u2019t give the release a satisfactory score \u2013 because availability wasn\u2019t addressed \u2013 we also didn\u2019t think we could ding it with an unsatisfactory score. \u00a0Thus, the N/A score.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that rimonabant has been approved for use in Europe.\u00a0 When mentioning that the manufacturer hopes for approval by the end of the year, it did not emphasize that the drug is not approved in the U.S., is not available in the U.S. and that it is not possible to predict the timing of FDA approval or whether the FDA will, indeed, approve it.\u00a0 ", "answer": 0}, {"article": "In the 1960s sitcom Leave It to Beaver, Beaver Cleaver was so impressed by his dad's tales of ice cream and pretty nurses that he schemed to have his tonsils out, even though he didn't need it.\nThat's a far cry from the 1950s and '60s, when tonsillectomy was used to fight frequent sore throats.\nObviously, parents could use some help in deciding whether surgery is needed.\nBack then, it was the most popular surgery in the United States.\nThat's never without some risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a great job explaining how tonsil surgery as a first resort has evolved over the years.", "answer": 1}, {"article": "However, nearly 46 percent of low-risk women aged 50 to 59 were screened, as were 59 percent of low-risk women aged 60 to 64.\nMONDAY, May 25, 2015 (HealthDay News) -- Too few women at high risk for osteoporosis are being tested for the bone-depleting condition, while too many women at low-risk are being screened, a new study suggests.\nReminder notes to doctors and patients might help, one expert said.\nThe study was published online May 19 in the Journal of General Internal Medicine.\n\"DXA screening was underused in women at increased fracture risk, including women aged 65 years and older.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not say how commonly available the screening test is, but provides the impression that it\u2019s widely used. Since the test has been widely available for many years, we\u2019ll give the story a pass here.", "answer": 1}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\nDec. 5, 2012 -- A breath test similar to the one used to determine when a driver has had too much to drink shows promise as a screening tool for cancer .\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It always makes us nervous when a source is allowed to speculate, without reasonable justification,\u00a0about when an experimental device will be available clinically. And that\u2019s exactly what happened here\u00a0when an expert said that\u00a0a breath test for cancer \u201cmay be a reality in as little as five years if all goes well.\u201d On the other hand, the story did qualify things quickly when the expert added,\u00a0\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful.\u201d Borderline, but we\u2019ll call it satisfactory.", "answer": 1}, {"article": "\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nTrial leader and specialist emergency medicine physician at The Townsville Hospital, Dr Jeremy Furyk, said Tamsulosin was normally used to treat an enlarged prostate, but the research team found the treatment could also assist the passage of large kidney stones in the urine.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\nMillions of Australians suffering from kidney stones could soon get relief, with researchers discovering a prostrate treatment can also help ease the painful condition.\n\"It may also have implications for patients living in rural and regional areas, where access to urologists - the specialist doctors who treat this condition - can be limited.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Tamsulosin is currently prescribed for patients with benign prostatic hyperplasia (BPH), or enlarged prostate and other conditions and is readily available.", "answer": 2}, {"article": "Phentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\nThe Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.\nAccording to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.\nThe study was funded by the pharmaceutical company Vivus, which combined the two drugs into one pill called Qnexa, and petitioned the U.S. Food and Drug Administration for approval in October 2010.\nAmong the 2,487 study participants, nine became pregnant, and none of their children were born with cleft palates, the report said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that Qnexa was not approved: \u201cThe Food and Drug Administration denied the request, asking for more safety data from the company before moving forward.\u201d", "answer": 1}, {"article": "High cholesterol levels can increase the risk of heart attack.\nBut an association is only that; it doesn't mean one thing causes another.\nDr. Gregg C. Fonarow, a professor of cardiology at the University of California, Los Angeles, said that efforts to gauge the potential health impact of selenium have not yet demonstrated any clear benefit attributable to the trace mineral.\nThey also noted that the results can't necessarily be applied to Americans, because of differences in the food supply and diets of each country.\n\"Overall, the evidence is inadequate to establish a protective role of selenium in cardiovascular disease or to recommend selenium supplementation to improve cardiovascular health,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t really explain what selenium is,\u00a0why someone would want to take a selenium supplement, or where one can find them. While many readers will\u00a0know the answers to these questions, selenium is obscure enough, in our view, to warrant at least some background context on these issues.", "answer": 0}, {"article": "Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections.\nSo far, the treatments appear safe.\nIf the experimental drugs are ultimately approved, there will be the real-world issue of price.\nBut experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.\nOne is, how well do they work for younger patients?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drugs are not on the market.", "answer": 1}, {"article": ".\nThe results of the pre-specified subgroup analysis within the ACTIVE clinical trial will be presented Friday, April 1, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston.\nThe researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE trial to evaluate the efficacy and safety of 80 micrograms of abaloparatide-SC in preventing fractures in otherwise healthy, ambulatory, postmenopausal women with osteoporosis.\nOsteoporosis was defined broadly, using both BMD criteria as well as recent history of nonvertebral fracture and confirmed prevalent vertebral fracture on x-ray.\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is investigational which signifies it is not yet FDA approved and that the study was a phase 3 study.", "answer": 1}, {"article": "Dominic Gessler lifts two squirming mice from their cages.\nGao did not always believe the drug would ever make it out of the laboratory, because the field of gene therapy has been plagued with seemingly insurmountable obstacles, including the deaths of test subjects.\nFor the next 13 years, Gao would work for Wilson, engineering new and better viruses for the therapies, called \u201cviral vectors.\u201d These molecular FedEx trucks can be loaded with healthy versions of genes and deliver them to the correct location in the body.\n\u201cAnd other than gene therapy, there was no other way.\u201d\n\nGene therapy is well-suited for treating inherited brain diseases.\nScientists now argue it is our best, and perhaps only, chance at curing many diseases of the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told early on \u201cthere is no treatment and no cure for Canavan disease,\u201d but then later a researcher is quoted as saying: \u201cWe have the therapy. We are ready.\u201d\nThe word \u201ctherapy\u201d implies effective treatment of people.\u00a0Therapeutic misconception like this is confusing\u00a0to readers, and the story needed to counter this confusion by more strongly indicating this specific intervention\u00a0is and will be experimental for years to come.\nThis was made more confusing by the discussions of available gene therapies for other illnesses, including two that are in use in China and Europe, and one that might be approved in the U.S. How far behind are all the gene therapy approaches discussed in the piece? This is important to counter false hope among patients who may read this story and think that these are signals that availability of these other therapies can\u2019t be far away.", "answer": 0}, {"article": "It did reduce the severity and duration of colds slightly, but the researchers say the difference was so slight it ended up being pretty meaningless, and not worth the effort or expense of taking all that vitamin C.\n\nPeople apparently protected from colds by vitamin C, Senay said, are those who subject their immune systems to extraordinary amounts of physical stress, such as people who run marathons, or do serious trekking in the winter.\nPreventing colds just isn't one of them.\nVitamin C is also an antioxidant, which means it's believed to help prevent or minimize conditions that include cancer, heart disease, and inflammatory conditions such as arthritis.\nIf you suffer an injury, vitamin C is a vital part of the healing process.\nBut they were the exceptions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin C supplements are widely available.", "answer": 1}, {"article": "The shortage has eased, but some supply issues remain.\nOther IV solutions called balanced fluids include saline but also contain potassium and other things that make them more like plasma, the clear part of blood.\nSaline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for more than a century even as evidence has emerged that it can harm kidneys, especially when used a lot.\nIVs are one of the most common things in health care.\nChemotherapy is administered to a cancer patient via intravenous drip in Durham, N.C. IVs are one of the most common things in health care.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does well in including this important context:\nIVs are one of the most common things in health care \u2026 saline \u2014 salt dissolved in water \u2014 has been the most widely used fluid in the U.S. for centuries \u2026 other IV solutions called balanced fluids include saline but also potassium and other things that make them more like plasma, the clear part of blood. They\u2019re widely used in Europe and Australia.", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Like the WebMD story, the LA Times story wasn\u2019t clear whether a clinician could conduct the self-hypnosis trainings, or whether the patient needed to find another certified professional. And how were the hypnotic recordings obtained? Readers need to know if their \u201clocal\u201d hypnotherapist can do this.", "answer": 0}, {"article": "In nonsurgical spinal decompression, a patient is placed on a special type of table with harnesses on the pelvis and rib cage.\nI would say a quarter of my patients fall asleep.\u201d\n\nThe decompression therapy is used to treat herniated discs, ruptured discs, sciatica, bulging discs, degenerative discs, posterior facet syndrome and spinal stenosis/arthritis.\nThe new beds, Fuh said, are much different than similar beds made 20 years ago where patients would lie on their stomachs, put a strap around their pelvis and \u201chold onto handle bars for dear life.\u201d\n\n\u201cThe table now, you just lay on your back, and the machine does all of the work.\nUntil now, the main options for treatment were surgeries that could involve cutting away bone and placing rods, and rising doses of painkilling medicines that often lead to addiction.\nThe treatment, which includes several 20-minute procedures and rehabilitation, costs between $3,500 and $4,000.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does explain that this treatment is available and claims that the treatment is common on the West Coast but not in the Midwest, this is not sufficient information on availability. The story doesn\u2019t give the reader any information on where to look for the treatment other than the owner of one facility. ", "answer": 0}, {"article": "Among other changes, they found that levels of human growth hormone, or HGH, surged after fasting \u2014 increasing 20 times in men and 13 times in women.\nRegular fasting may be good for your heart.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\nHe said the group was planning additional research into the potential health effects of regular fasting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Anyone can fast.", "answer": 2}, {"article": "Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment.\nEmerging evidence indicates that overall eating patterns may have greater effects on patients\u2019 health and longevity.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nNewswise \u2014 Washington, DC (December 8, 2016) \u2014 A diet that emphasizes healthy foods rather than individual nutrients may help patients with chronic kidney disease live longer.\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of healthy dietary options is one of the main points of the release.", "answer": 1}, {"article": "\u201cFor antidepressants in adolescents, this equation will rarely favor prescribing; in younger children, almost never.\u201d\n\nTo be clear, Jureidini believes there is almost never a justification for prescribing antidepressants to children or adolescents.\nA comment attached to the Oxford paper, written by Dr. Jon Jureidini, a child psychiatrist at the Women\u2019s and Children\u2019s Hospital in Adelaide, Australia, goes even further in decrying the use of antidepressants in kids.\nThere\u2019s good reason for this.\nI called him to be sure.\nOf course, having an effective intervention once it is recognized would help.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says all the 14 antidepressants studied were \u201ccommercially available.\u201d", "answer": 1}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\nThe results are often inaccurate.\nThere are several scientists who say this field is so new that it's lacking in good evidence that brain changes actually occur.\nSo some scientists believe that by playing this game \u2014 Project Evo \u2014 you can improve a range of cognitive skills and, by extension, relieve a range of symptoms associated with cognitive disorders.\nBut this kind of goal requires a totally different business model; before they can deliver their game to players, they first have to go through the Food and Drug Administration \u2014 the FDA.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that these video games are experimental and not currently available.", "answer": 1}, {"article": "But 'fish oil supplements just don't cut it.'\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\nAs a result of the congressional action, women in their 40s will continue to be able to get annual mammograms at no cost.\nFor women in their 40s, the likelihood of benefit is less and the potential harms are proportionally greater, it said.\nDespite the decades of marketing of mammography to women, \"women are capable of understanding the complexities of the issue, evaluating the evidence and making their own health decisions,\" she said in a statement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of mammograms as breast cancer screening tools is longstanding and well established. The story also discusses insurance coverage issues that would affect availability for many women.", "answer": 1}, {"article": "He says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\n\"New procedures are generally associated with a learning curve, but the lack of complications in the trial suggests that the treatment protocol is safe, efficient and relatively easy to scale up.\nWe would also expect the treatment to be far more precise if we repeated it today, as technology has come a long way since the study began in 2011.\n\"The fact that the treatment was performed so successfully by non-specialist centres in various health systems is really remarkable,\" says Professor Emberton, who is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release passes the bar with this statement at the very end:\nThe VTP treatment is currently being reviewed by the European Medicines Agency (EMA), so it is likely to be a number of years before it can be offered to patients more widely.\nThe news release also quotes a researcher stating that the treatment\u2019s implementation at 47 sites \u201cwithout complication\u201d indicates it\u2019s \u201csafe, efficient and relatively easy to scale up.\u201d That\u2019s an optimistic take but we\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "Some prostate cancers evolve to use energy from lipids (fat).\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\n\u201cSince the drugs are clinically safe, a clinical trial can be designed in patients for whom enzalutamide is prescribed.\u201d\n\u201cThis is a huge development for men with CRPC that previously did not have many options,\u201d says Isabel Schlaepfer, PhD, CU Cancer Center member, assistant professor in the Division of Medical Oncology and senior author of the study.\nIn fact, we are already able to block the action of the CPT1A enzyme.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The key drug in question, enzalutamide, (trade name Xtandi) is already widely marketed as a treatment for prostate cancer. This fact was not included in the news release.", "answer": 0}, {"article": "HEART DISEASE\n\nMen with high blood pressure who have one or two drinks per day are less likely to have a heart attack, says a study in the current Annals of Internal Medicine.\nCould negative stereotypes be self-fulfilling prophecies?\nCAUTIONS: The study looks only at spatial reasoning.\n\"It's the difference between a B and an A\" on a test, says Wraga.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly alcoholic drinks are available.", "answer": 2}, {"article": "He noted that the technology's cost \"is not prohibitive, and it is safe.\nBut this type of light can cause skin cancer and cataracts, so it's not used in public spaces.\nHowever, Brenner and his colleagues wondered if a much narrower spectrum of ultraviolet light, far-UVC, might be a safer option.\nAs the researchers explained, broad-spectrum UVC light kills viruses and bacteria, and it is currently used to decontaminate surgical equipment.\nLamps with this type of UV light currently cost less than $1,000, Brenner said, but that price would likely fall if the lamps were mass-produced.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We get the idea that UVC lamps are available and already used to disinfect surgical equipment. What\u2019s not clear is if \u201cfar-UVC only\u201d lamps are commercially available at this time.", "answer": 0}, {"article": "Cervical cancer is still the fourth most common cancer in women, with over 500,000 cases and 250,000 deaths per year worldwide.\nThe new vaccine offers significantly greater protection than the current vaccine, which protects against only two cancer causing types of HPV.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nA pivotal international clinical trial compared the safety and efficacy of the new vaccine, Gardasil 9, with the current vaccine, Gardasil, in more than 14,200 women aged between 16 and 26 years old.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the new vaccine is available in the US but not yet in the UK.", "answer": 1}, {"article": "What if doctors had a pill that prevents breast cancer and nobody wanted to take it? That has pretty much been the situation with tamoxifen, an estrogen-like drug that was proved in 1998 to cut in half the chance of developing breast cancer if taken for five years by women with increased risk of the malignancy. The trouble is, tamoxifen also triggers menopausal symptoms like hot flashes and slightly increases the chances that a woman will develop blood clots and uterine cancer. As a result, women haven't been too eager to take the medication--nor have many doctors been all that enthusiastic...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that raloxifene is currently available for use in post-menopausal women to prevent osteoporosis and that use in chemoprevention has only been in clinical trials\u2013more data is needed prior to FDA approval for use as chemoprevention. Use as chemoprevention would be off-label and only women with an increased risk of breast cancer.", "answer": 1}, {"article": "This test will most definitely save lives.\"\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\nAn FDA spokeswoman said the agency had just become aware of the new test and could not say whether it would take any action, though she noted that in August the agency sent a letter expressing concern to another company marketing a questionable genetic test for ovarian cancer.\nThe test comes as concern has been rising about the proliferation of genetic tests.\nA biotech company today will begin offering the first genetic test to assess a woman's risk for the most common forms of breast cancer, reigniting debate about the growing number of unregulated genetic tests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman\u2019s risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review.\u00a0 ", "answer": 1}, {"article": "\u2022 Khin NA, et.al.\nEsketamine nasal spray has an acceptable safety and tolerability profile, based on the adverse event data from both Phase 3 studies.\nIf approved by the U.S. Food and Drug Administration (FDA), esketamine would be one of the first new approaches to treat refractory major depressive disorder available to patients in the last 50 years.\nIt has a novel mechanism of action, meaning it works differently than currently available therapies for depression.\nA bittering agent was added to placebo to simulate the taste of esketamine, to help mask the treatment assignment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is fairly clear that esketamine is still under investigation and is not yet clinically available.", "answer": 1}, {"article": "Six months after treatment, 54 percent of patients in the YAG group reported significantly greater improvement in floater-related visual disturbances, compared with only 9 percent of those in the placebo group.\nTHURSDAY, July 20, 2017 (HealthDay News) -- A laser treatment can reduce spots in people's vision known as \"floaters,\" a new study finds.\nA limitation of the study was its small size and short follow-up period, the researchers said.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss the availability of this laser treatment approach. Is it available through most ophthalmic practices? Is the equipment standard in most eye hospitals?", "answer": 0}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story makes clear that while this drug is available as a muscle relaxant, the dose used in this fibromyalgia trial is not available. The story also reports that the drug is not approved for treatment of fibromyalgia, but it is being prescribed \u201coff-label\u201d by some doctors. Near the bottom of the story, the researcher and company president predicts the low-dose version of the drug could be available for fibromyalgia treatment by 2015. It is hard to see what support there is for such a prediction, given the preliminary nature of this small trial.", "answer": 1}, {"article": "About Milken Institute School of Public Health at the George Washington University: Established in July 1997 as the School of Public Health and Health Services, Milken Institute School of Public Health is the only school of public health in the nation's capital.\nThe researchers recruited pregnant women who were already enrolled in an established text messaging program called Text4baby.\nAbroms and her team wanted to find out if a more intensive mobile phone program called Quit4baby would be more effective.\nHowever, the difference between the two groups did not reach statistical significance, the authors say.\n\"The study's findings suggest a potential new quitting strategy, especially for those later in their pregnancies and older pregnant women.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release notes that this experiment took place within the confines of an \u201cestablished\u201d text messaging program (Text4baby), the availability of the \u201cQuit4baby\u201d sub-program, which is the focus of the research, is not clear.", "answer": 0}, {"article": "They include people like Danielle Denlein, who, to her total shock, developed a serious heart problem.On October 20, 2008, at 1:50 p.m., Ms. Denlein was driving to a drug store to buy formula for her 5-day-old baby girl.\nInstead, she simply went near a small box, which is attached to a phone jack near her bed.\nDr. Richard Page, president of the Heart Rhythm Society, said doctors wonder if they can be held liable if they do not look at all the data.\nOne solution, being tested by St. Jude Medical, a medical device company in St. Paul, is to let patients deal with important data.\nThe big leap forward came a few years ago when device companies figured out how to make transmitters that send data over a broader range, 20 or 30 feet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was a tapestry of information about devices that are currently available, devices in clinical studies, and the potential benefit from devices to be developed in the future. \u00a0The story could have been clearer about products that are and are not readily available to patients.\u00a0 We had to read the piece several times in order to reflect on which device, from which company, was at which stage of research or development. ", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study provides the names of products that are available over the counter. Readers should be able to use this information to track down the products if they want to buy them.", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\nFruits, vegetables, beans, and whole grains are all high in fiber.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nThat was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.\nSo to get more clarity, the researchers combined 10 earlier studies that looked at women\u2019s diets and followed them over seven to 18 years to see who developed cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that fruits, vegetables, beans and whole grains are all high in fiber.", "answer": 1}, {"article": ".\nAfter 18 months, the women who received the placebo halted the injections.\nThe researchers continued to follow up with the women for seven years after the growth hormone treatment was halted to monitor their bone density, fractures and perception of their quality of life.\n\"The findings indicate the beneficial effects of growth hormone remained long after the treatment ceased,\" Krantz said.\nA decade after the study began, the women who received the larger growth hormone dose still had higher bone mineral density levels than the participants who received the lower dose or the placebo.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Many readers may know that growth hormones are available and already used for the treatment of short stature in children. But the release doesn\u2019t establish this for those who might not know. Are these hormones prescription-only? Over the counter? Was it a new formulation developed for use in the study? It\u2019s impossible to tell.", "answer": 0}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nThese markers, including structural, functional, and molecular imaging are being used in the AD diagnositc criteria [AA/NIA], (1)\" says Howard Aizenstein, M.D., Ph.D., a psychiatrist at University of Pittsburgh.\n\"Patients seem to enjoy reviewing results of their imaging studies, more so than reading the results of their blood tests or other clinical evaluations.\n\"Recent advances have improved the ability to characterize imaging markers along the trajectory of Alzheimers disease, starting in the pre-clinical phase.\nSuch work is already happening at UCLA and other institutions that meld these approaches into novel ways to improve patient care.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address the availability of quantitative MRIs of the brain. MRI in general has been used since the 1970s, and its availability is not in question. But since the issue is not specifically addressed by the release, we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "\"This could be an important tool worldwide, and even here in the United States.\"\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nTHURSDAY, Sept. 2, 2010 (HealthDay News) -- An experimental test that can diagnose tuberculosis in less than two hours, making only one doctor visit necessary before treatment starts, is being hailed as a potentially significant advance against a disease that kills nearly 2 million people annually, most of them in developing countries.\nBut Siegel said such testing, which has been in use for more than a century, isn't always accurate.\nFor the study, a research team led by Dr. Catharina C. Boehme, of the Foundation for Innovative New Diagnostics in Geneva, Switzerland, used the Xpert MTB/RIF test on 1,730 patients suspected of having drug-sensitive or multidrug-resistant pulmonary tuberculosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the new test is available in Europe and will soon be submitted for FDA approval in the U.S. But this information doesn\u2019t tell readers\u00a0when or if the test will be available in the developing world, where need for it is greatest. In developing countries, which often have rudimentary health care systems, deployment of this test may\u00a0be hampered by any\u00a0number of systemic barriers.\u00a0Cost is\u00a0certainly\u00a0one important issue. but so are management expertise and human resources and availability of reliable electricity.\u00a0The importance of these issues is demonstrated in our experience with malaria and HIV, where fast and accurate tests are\u00a0available but significant segments of the population do not have access to them.\u00a0The story doesn\u2019t do enough to provide this context.\u00a0", "answer": 0}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the fifth paragraph, the story says, \u201cStill, much larger studies, taking at least two or three years, are likely to be needed before the drug could reach the market.\u201d", "answer": 1}, {"article": "He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\nMONDAY, June 19, 2017 (HealthDay News) -- Acupuncture is a safe and effective alternative to pain medications for some emergency room patients, a new study reports.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While acupuncture is becoming more widely available in most communities, there is no information in the story that suggests how available it might be in large hospital emergency departments. Also, would it be available in a timely manner?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focuses largely on the increasing availability of new sunscreen formulations that are believed to protect sun lovers from harmful ultraviolet rays.", "answer": 1}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\nThe study results were reported on Monday at the American Society of Clinical Oncology\u2019s annual meeting.\n\u201cFor the first time, cabo is showing dramatic activity against both soft tissue and metastatic bone lesions,\u201d said Exelixis Chief Executive Officer Michael Morrissey.\nThe drug reduced by 87 percent the risk of disease progression or death.\nExelixis expects to have initial results around midyear from a pivotal trial of the drug as a treatment for thyroid cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the drug is \u201cexperimental.\u201d\u00a0 We wish it had provided more details than that.\u00a0 But we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nWhile both Children's Hospital Boston and Montefiore have offered CMA testing for several years, not all hospitals do, nor does all insurance pay for it, the researchers noted.\nThere are a few other genetic tests that can explain another few percentage points of autism cases.\nResearchers offered about 933 people aged 13 months to 22 years who had been diagnosed with an autism spectrum disorder three genetic tests: G-banded karyotype testing, fragile X testing or chromosomal microarray analysis (CMA), which has been available only for the past few years.\nCMA detected chromosomal abnormalities in slightly more than 7 percent of patients, making it the best available genetic test for autism spectrum disorders, the study authors said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that not all hospitals offer the newer chromosomal microarray analysis (CMA) test. It could have also mentioned that genetic counseling services are not widely available in some geographic areas. ", "answer": 1}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story points out that the drug is experimental and is not available. However, it says the manufacturer intends to file for approval later this year, \u201craising prospects that the drug could be on the market next year.\u201d While that statement is only a tentative prediction of what could happen, it still gives readers the impression that approval is likely, even though the full data from this trial has yet to be inspected by anyone other than the investigators. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains it is not widely available as a therapeutic in clinics.\n\u201cExperts theorize that sleep deprivation may reset the circadian clock. But it is rarely used for treatment because it wears off so fast.\n\u201cI know of about three clinics worldwide that routinely use it,\u201d Gehrman said. There are some studies showing that it can be helpful when combined with light or antidepressant medication treatment.\u201d", "answer": 1}, {"article": "Because this important step is out of the way in advance, it completely changes the patient\u2019s day of surgery experience.\u201d\n\nRadar can target abnormality within 1 mm, sparing more healthy tissue\n\nUnlike mastectomy, which treats breast cancer by removing an entire breast, lumpectomy surgery \u2014 also known as breast-conserving surgery \u2014 is used to remove only the tumor and a small amount of tissue surrounding the tumor.\nUsing the SAVI SCOUT system technology, which emits 50 million radar pulses per second, surgeons can target the affected tissue within 1 millimeter of the reflector.\nRush began offering SAVI SCOUT, which has been used in more than 50 lumpectomy surgeries, in July.\nI was glad it was done a week before and not the same day as the lumpectomy surgery.\n\u201cUntil now, a patient would go to the imaging center to have the thin wire precisely placed in the breast.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that Rush Medical Center is now making the device available to its patients. Beyond that facility, it\u2019s unclear if the device is widely available.", "answer": 1}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\nAll are approved for use in humans.\nThis work was supported by the NINDS (NS085246, NS030800, NS026543), the New York Stem Cell Foundation and the Myelin Repair Foundation, New York City.\n\u201cThe ability to activate white matter cells in the brain, as shown in this study, opens up an exciting new avenue of therapy development for myelin disorders such as multiple sclerosis,\u201d said Ursula Utz, Ph.D., program director at the NINDS.\nOur ultimate goal was to enhance the body\u2019s ability to repair itself,\u201d said Paul J. Tesar, Ph.D., associate professor at Case Western Reserve School of Medicine in Cleveland, and senior author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the two drugs highlighted (clobetasol and miconazole) are available and adds the important precatuionary note, \u201c\u2026are currently approved for use as creams or powders on the surfaces of the body but their safety administered in other forms, such as injections, in humans is unknown.\u201d", "answer": 1}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\n\u201cThis research has been tested on human tissue, which is promising, but not on humans themselves, so there is still some way to go.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\nFor that reason new treatments are exciting as they give people more treatment options that may be effective.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that this is early research and human testing hasn\u2019t even begun yet.", "answer": 1}, {"article": "This is a way of getting closer to an answer,\" said Weiner.\nThe FDA says that Amyvid \"is not a test to predict the development of AD-associated dementia\" in those who have no problematic symptoms.\nFor now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nLast week, the FDA approved an agent called Florbetapir F 18 injection (to be marketed as Amyvid), which will allow physicians using a positron emissions tomography (PET) scan to detect the presence and extent of amyloid plaques in patients concerned about declining mental function.\nBoth Florbetapir F 18 and florbetaben help diagnose Alzheimer's by sticking to beta amyloid clumps and emitting radioactivity, which can then be picked up by a PET scan.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The product\u2019s approval by the FDA does not mean that testing will be widely accessible in the near future. The statement from Eli Lilly explains why: \u201cBecause Amyvid loses over half of its radioactivity every two hours, Amyvid must be distributed directly from a radiopharmacy to the imaging centers where it will be administered within several hours. Beginning in June, a limited number of radiopharmacies will be distributing Amyvid with the goal of making the product available in more areas as soon as possible.\u201d", "answer": 0}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nThe patient, who had both HIV infection and leukemia, received the bone marrow transplant in 2007 from a donor who had a genetic mutation known to give patients a natural immunity to the virus.\nNearly four years after the transplant, the patient is free of the virus and it does not appear to be hiding anywhere in his body, Thomas Schneider of Berlin Charite hospital and colleagues said.\nIt requires destruction of a patient\u2019s own bone marrow \u2014 itself a harrowing process \u2014 and then a transplant from a donor who has a near-exact blood and immune system type.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that it is based on the findings in one patient and that it couldn\u2019t be applied broadly.\u00a0The story shows that bone marrow transplants are available and points out the unique aspects of the procedure in this single patient; that is, while bone marrow transplants are available, marrow from recipients with the CCR5 mutation is not.", "answer": 1}, {"article": "Pernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nNow, new research from Chalmers has shown that the protein parvalbumin, which is very common in many fish species, may be contributing to this effect.\nWith the parvalbumin protein so highly abundant in certain fish species, increasing the amount of fish in our diet might be a simple way to fight off Parkinson's disease.\n\"Because Nathalie had previously shown that parvalbumin passes into the body of the person eating fish, it made sense to study its interaction with human proteins.\nMore About: Fish and Better Neurological Health\n\nThe link between higher consumption of fish and better long-term health for the brain has been long established.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fish is widely available. We\u2019re told the protein of interest, parvalbumin, is found in higher concentrations in certain species, and that this concentration is seasonal and tends to peak in late summer.", "answer": 1}, {"article": "While the study offers insights on managing the disease, there's not enough evidence yet on whether HGH treatments could extend the lives of those with cystic fibrosis.\nThe disease also affects the pancreas, making it difficult for the body to absorb food, which significantly stunts growth and often leads to early deaths.\nThat growth also resulted in larger internal organs, particularly the lungs, making breathing easier.\nThe study, published Monday in the journal Pediatrics, was produced by the UConn/Hartford Hospital Evidence-based Practice Center and was funded by the U.S. Department of Health and Human Services.\nLungs are clogged with a thick mucus, which can lead to lung infections.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nThe device makes a clicking noise while delivering the magnetic pulses.\nThe NeuroStar system resembles a dentist's chair.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the device and thus the treatment is available. \u00a0The story does provide some insight into insurance coverage as well.", "answer": 1}, {"article": "\u201cThe goal for most practicing allergists and for most parents is to get a child to the point where if there is an accidental ingestion of peanut it would not be as risky or life-threatening,\u201d said Dr. Amy Stallings, an assistant professor of pediatrics in the division of allergy and immunology at the Duke University Medical Center who is not affiliated with the new study.\nThat's a potentially life-saving development.\nIt could be several more years before the patch will be available for consumers.\n\"So it\u2019s tough to get them to take it.\nJust two dropped out because of flare-ups of eczema.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lede uses cautionary wording\u2013\u201cprotection may eventually come\u201d\u2013and then, at the bottom of the text, gets reasonably specific about the \u201cseveral more years\u201d needed before a product could become available.", "answer": 1}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nThe benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\nOther healthy people interested in taking aspirin to prevent cancer should consult their doctors, experts say, and possibly await further evidence.\nA British study offers compelling -- though not clinching -- evidence that the humble aspirin tablet can prevent death from a variety of cancers, if you take the medicine long enough in middle age.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is widely known. What is unique here is how common is it to be used as a cancer prevention method. This story, like others, makes clear that it is commonly used for other reasons but not for cancer prevention. \u201cTo be sure, the U.S. Preventive Services Task Force\u2019s currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work. The benefits of daily low-dose aspirin can exceed the risks for many middle-aged and older people when it comes to preventing heart attacks and strokes, the task force says.\u00a0So for those already taking prophylactic aspirin for this reason, the possible anticancer effects are just icing on the cake.\u201d\u00a0", "answer": 1}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The supplements are already on the market and the story makes that clear.", "answer": 1}, {"article": "Some recreational swimming pools and homeowners with backyard pools have manual treadmills that are water-safe and can be plunked right in the water.\nWhether you call it water running, aqua jogging or hydrotherapy, you can\u2019t beat a workout in water for an array of health benefits, many experts say.\nSo, even older patients with limited mobility and balance don\u2019t have to negotiate getting down into a pool.\n\u201cIn water, we can teach them sooner.\n\u201cI personally prescribe it for knee issues and low back issues.\u201d\n\nHydrotherapy uses a water-friendly treadmill that can be placed in a pool.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the story how widely available underwater treadmills are for the general public.", "answer": 0}, {"article": "Noting that most of his Down syndrome patients say they lead fulfilling lives, Skotko said, \"The overwhelming majority of family members say they can't imagine their life without their family member with Down syndrome.\"\n\"We estimate we can introduce this to clinical practice in a couple of years.\"\n\"This is due to an extra chromosome 21, and that leads to physical and mental impairment.\"\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\n\"The cost is much lower than the invasive procedures,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "More reserved than its Reuters competitor, this story emphasizes the test \u201cmay one day\u201d be available\u2026 \u201cif larger clinical trials confirm the results.\u201d\n\u201cSmall study\u201d and \u201cexperimental\u201d stressed in second sentence.", "answer": 1}, {"article": "The Lancet.\nWASHINGTON, March 5, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ\u00ae, a circadian regulator, demonstrated significant and clinically meaningful benefits in nighttime and daytime symptoms of jet lag disorder.\nThe clinical efficacy results reported today are from the JET8 Phase-III clinical study (3107) (the JET8 study).\nIn addition to the risks described above and in Vanda's annual report on Form 10-K, other unknown or unpredictable factors also could affect Vanda's results.\nVanda believes that if HETLIOZ\u00ae is approved by regulatory authorities for the treatment of jet lag disorder it will potentially offer a therapeutic solution to many travelers and will likely represent an important commercial opportunity for the company.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the drug has not been approved anywhere in the world for treatment of jet lag. However, there is a statement at the end of the news release that the company has been granted \u201cmarket authorization\u201d by the U.S. Food and Drug Administration and the European Medicines Agency. Does this mean that they have approval to start selling the drug? The Hetlioz website only lists \u201cNon-24-Hour Sleep-Wake Disorder\u201d as an indication for the use of the drug. \u00a0This is very confusing for readers.", "answer": 1}, {"article": "Colorectal cancer is the third most common cancer diagnosed in both men and women (excluding skin cancers) and a leading cause of cancer death, the American Cancer Society reports.\nWhen it comes to dosing, experts say sticking to a low-dose baby aspirin is best.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nAt this time, the task force reports that more research is needed to assess whether taking aspirin is beneficial for people who are younger than 50 or those who are 70 and older.\nA government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that aspirin is ubiquitous and sold almost everywhere as an over-the-counter drug, so we\u2019ll rate this one N/A. This story, and the other we reviewed, might have benefited from mentioning that the drug has a generic name (known as ASA or acetylsalicylic acid). Generic versions of the drug do exist, are likely cheaper than the brand name, and equally effective.", "answer": 2}, {"article": "\"It makes you feel so much better,\" Wade says.\nThe setbacks put a spotlight on how the FDA handles these drugs.\nAs the FDA works through this, many are watching how the agency handles Qnexa.\nPart of what's going on is that the FDA has gotten a lot more cautious about approving new drugs in general after some serious drug-safety problems, such as heart problems linked to the painkiller Vioxx.\nBut some say the agency's aversion to accepting any risks is outdated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole story was about the FDA review of the drug and its meeting next week.\nAs noted above, the New York Times reported, \u201cThrough a regulatory loophole of sorts, many obesity doctors prescribe two separate drugs that, when taken together, are essentially the same medicine.\u201d This was an interesting perspective that the NPR post didn\u2019t include.", "answer": 1}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these products is clear from the story.", "answer": 1}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nThis study is filling in a missing bit of the jigsaw -- and shows that this supplement can decrease activity in brain areas associated with food reward at the same time as reducing the amount of food they eat.\"\nTo get the same increase from fibre alone, we would need to eat around 60g a day.\nIn a second part of the study, which is published in July edition of the American Journal of Clinical Nutrition, the volunteers were given a bowl of pasta with tomato sauce, and asked to eat as much as they like.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implicitly makes the point that the powder used in the experiment is not available to the public, but the release would have been better if this had been explicit.", "answer": 1}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nStill, some researchers not involved in the study said the topic required more work.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\nOne got Chantix, the brand name of the drug varenicline, which is taken twice a day by mouth as a pill; the other group got a placebo.\nThey were randomly assigned to two groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Chantix is already on the market.", "answer": 1}, {"article": "\"Our results suggest that nonsteroidal anti-inflammatory drug use is associated with lower colorectal cancer mortality among postmenopausal women who use these medications more consistently and for longer periods of time,\" Anna Coghill, a doctoral student in epidemiology at the University of Washington and Fred Hutchinson Cancer Research Center, said in the news release.\nThe U.S. National Cancer Institute has more about colon and rectal cancer.\nExperts say that for studies presented at medical meetings, data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nIn the study, researchers examined the use of aspirin and non-aspirin NSAIDs among more than 160,000 postmenopausal women in relation to deaths from colorectal cancer.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Aspirin and ibuprofen are widely available in US pharmacies.", "answer": 2}, {"article": "People taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nThe volunteers took pills once a day for six weeks.\nThe researchers signed up 20 people and put them at random into two groups, one receiving a placebo and the other a supplement containing 40 milligrams of resveratrol.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nFasting blood samples were taken at the start of the trial and then at intervals of one, three, and six weeks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that resveratrol can be found in common food sources.\u00a0 But the study was about resveratrol supplements in pill form and the story never explained to readers whether these were available.\u00a0 Are they at the corner drug store or health food store?\u00a0 Are they experimental?\u00a0 The story should have explained. ", "answer": 0}, {"article": "When researchers compared patients who had gastric bypass surgery to those who lost the same amount of weight by dieting, they found that the surgery patients had lower levels of amino acids that have been linked to insulin resistance.\nNow a new study from Duke University Medical Center and Columbia University may help explain why.\n\u201cSurgery puts the diabetes into remission.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that gastric bypass is a readily available surgical procedure.", "answer": 1}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided a very complete discussion about the various venues at which gastric banding was available.", "answer": 1}, {"article": "The most common drugs before treatment were metformin, a generic taken by about half of patients, followed by the medicines Avandia and Actos, taken by more than one-third of patients.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nThe researchers argue that the findings, drawn from data on four years of claims made in seven states, support coverage of bariatric surgery by insurers because of the savings and improvements in patients' health.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nAlso, at two years after surgery, data were available for less than half the patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story says the researchers argue that the results support coverage of the surgery by insurers. That at least implied that not every plan covers the surgery now for this type of patient \u2013 which is at least indirectly a comment on availability.\u00a0 It could have been more explicit. ", "answer": 1}, {"article": "Today, the United States is the third largest pear-producing country in the world, and Oregon and Washington comprise the nation's largest pear growing region with 1,600 growers producing 84% of all fresh pears grown in the United States.\nIf that isn't reason enough to fill your shopping basket, there's another reason to add this fruit to your grocery list.\n, and follow @USApears on Twitter.\nThe USA Pear Bureau continues to collaborate with researchers to commission additional studies that show the relationship between pears and positive health outcomes.\n, http://www.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release goes into some detail about the wide availability of pears in the United States.", "answer": 1}, {"article": ".\nThe article is available free on the Journal of Child and Adolescent Psychopharmacology website.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nA complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website: http://www.\nChildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening, according to the study results published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release offers no information about the possible availability of the new formulation of methylphenidate. It only mentions that the research was a \u201cphase 3 trial,\u201d which some readers will recognize must occur before a drug gets FDA approval for its use. In this case, it\u2019s unclear whether the new formulation is in the drug approval process.", "answer": 0}, {"article": "Immunotherapy moves to the front lines in fight against lung cancer\n\nThe cancer death rate has dropped again.\nDrew Pardoll, director of Hopkins\u2019 Bloomberg-Kimmel Institute for Cancer Immunotherapy, said that it is too early to know whether the findings will translate into longer survival.\nThe trial that grabbed much of the spotlight Monday is a randomized effectiveness study that involved more than 600 untreated patients with advanced nonsquamous non-small cell lung cancer \u2014 a common type of the disease.\nExperts said it was especially significant that the study showed that patients benefited from the Keytruda-chemo combination regardless of the levels of a protein, called PD-L1, found on their cancer cells.\nAnd he said the trial showed that \u201ctumor mutational burden\u201d is a reliable way to predict who will benefit from the medications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the FDA approved the Keytruda-chemo combination last May based on an early-stage trial, but many doctors did not adopt it because the trial was small and didn\u2019t initially show a survival benefit.", "answer": 1}, {"article": "It also triggers the release of the stress hormone norepinephrine, as well as the mood regulator serotonin.\nThere's more on cancer and hot flashes at the U.S. National Cancer Institute.\nDr. Courtney Vito, a breast oncologic surgeon at the City of Hope Comprehensive Cancer Center in Duarte, Calif., was pleased that a serious issue in breast cancer treatment is getting a closer look.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\nMONDAY, March 28, 2016 (HealthDay News) -- Acupuncture can help alleviate the often-debilitating hot flashes that afflict many breast cancer patients, new Italian research says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One can infer from the story that acupuncture treatment is available for breast cancer patients, particularly given that the independent source says her patients have used acupuncture in the past. And because most people are generally aware that acupuncture is available, we\u2019re giving this a Satisfactory rating.\nBut, the story would have been stronger if it had told readers whether any certified acupuncturist can provide the relevant therapy, or if a specialist in hot flashes is necessary.", "answer": 1}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\nThis is the first to correct an inherited genetic mutation.\n\"Spark Therapeutics is charging as much for Luxturna as they think they can get away with.\"\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t discuss where one can have access to this treatment. It likely will be very limited. And will it be available to anyone with this condition, or will some people be ruled out?", "answer": 0}, {"article": "Inflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nThey treated MS mice with a drug that increased expression in cholesterol synthesis genes - and this resulted in improved walking ability.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\nThe study is published in the Proceedings of the National Academy of Sciences.\nThe work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This experimental treatment on mice is clearly not available to humans yet.", "answer": 2}, {"article": "About CVS Health \n\nCVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health.\nHome infusion services are a rapidly growing delivery model in the health care system with rising rates of chronic and acute conditions that require intravenous therapy.\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\nThe costs associated with home infusion were also consistently lower than services provided in a health care facility, with savings ranging between $1,928 and $2,974 per course of treatment.\nResearchers compared measures of quality, safety, clinical outcomes, quality of life and costs of home infusion services to those provided in medical settings.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Home infusion services are widely available. Their reimbursement is not widely available.", "answer": 1}, {"article": "The task becomes more difficult, especially for people with early stages of dementia, as the dots move around, changing their direction, speed and intensity.\nThe Pittsford, N.Y.-based company\u2019s FDA application included data from a comparative study involving 401 people recruited from 13 communities for older adults.\nThe device would be available only for use by medical professionals as part of a more comprehensive assessment of cognitive function.\nCerebral Assessment Systems\u2019 device received de novo approval from the FDA, a streamlined process for reviewing medical devices that appear to be new enough to have no equivalent and pose little risk.\nIt is not intended to be a standalone diagnostic tool, and its effectiveness for people with less than 12 years of education is not proven.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the device/test was approved by the FDA and that it is available for use.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the patches are popular in Europe but not used as widely in the U.S.", "answer": 1}, {"article": "Some people (about 1 percent of whites; fewer of minorities) lack both copies of the CCR5 gene and are naturally resistant to HIV.\nThe results announced Monday at a conference in Boston left experts cautiously excited.\nThe research was only meant to show that, so far, it seems feasible and safe.\n\"It's an overreach of the data.\nThere are a lot of people out there with hopes and dreams around the C-word,\" so caution is needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0 made it clear that this was a very preliminary report.", "answer": 1}, {"article": "\"I've been through it, it was the past, time to move on,\" he said.\nAfter two years, 46 percent receiving standard treatment alone were free of tumor recurrence versus 66 percent of those like Brian who also received the antibody.\nBut then his doctor offered an additional step: an experimental treatment called immunotherapy, in which antibodies that target the cancer are injected into the bloodstream and attach to the tumor cell.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\n\"They tested it on me and it was a success, so I hope it works on all other kids,\" Brian said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ended by informing viewers that the treatment was experimental.\u00a0 There could have been more emphasis on the early nature of the findings \u2013 i.e. so far \u2013 the results have only been presented at a meeting, meaning that they have not yet undergone peer review.", "answer": 1}, {"article": "Autism is characterized by difficulties in social interaction, communication, and understanding other people\u2019s emotions and behavior.\n\u201cThe basis of autism in the brain is very deep.\nThis is performed around the world,\u201d Lange said in a telephone interview.\nThere may be very little that one can actually change about the disorder for an individual with a severe case,\u201d Lange said.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes this odd claim:\u00a0\u201cYou don\u2019t need any fancy equipment. This is performed around the world,\u201d Lange said in a telephone interview.\u00a0Interestingly, neither the actual published study nor the McLean press release provides any explicit information about the MRI scanner used or the way in which its programming may have been altered. And neither does the story. ", "answer": 0}, {"article": "March 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\nThe Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that boceprevir and telaprevir are not yet available, but they may be reviewed by the FDA at the end of April.\n ", "answer": 1}, {"article": "Researchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\nThe community-based approach and the fact that data on breast-feeding was collected before the onset of disease give the study strength.\nThe authors acknowledge that it is difficult to separate the effect of breast-feeding from childbirth itself.\nBut they found that the number of children born to a mother did not affect the results.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nMost readers will be familiar with the \"availability\" of breast-feeding. \n", "answer": 1}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\n\"Folate intake had a positive association with academic achievement\" in the students studied, the authors wrote in the report published in the July 11 online edition and the August print issue of Pediatrics.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\nThe researchers also looked at any possible effects of socioeconomic status and genetics.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported on the results of the study without helping readers understand that it was conducted on a population of youngsters without access to a folic acid supplemented food supply.\u00a0 The competing Reuters story made this point clearly.", "answer": 0}, {"article": "Some critics say Medicare would not be doing a review of a drug already approved by the F.D.A.\nBut some analysts said that should be enough for reimbursement.\nwere it not for its high cost.\nA late-stage trial could begin as early as next year, he said.\nSo it cannot be completely ruled out that XL184 somehow stopped bone growth without killing the cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided clear information about the availability of Provenge and XL184.", "answer": 1}, {"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nThe scientists bought fish oil from a company that makes it, but they said the company had no role in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the\u00a0\u201ccapsules were an over-the-counter product called Incromega TG33/22, a fish extract made by the British chemical company Croda Health Care.\u201d\nAnd in regard to whether women should start taking the supplement to lower asthma risk in their babies, the story lets us know researchers \u201care not ready to recommend that pregnant women routinely take fish oil\u201d due to the very high dose used in this study. Further research is needed first\u00a0to establish safety and confirm benefit.", "answer": 1}, {"article": "LONDON -- Sanofi-Aventis SA's obesity drug Acomplia can improve blood-sugar levels and weight loss in diabetic patients, according to a study presented at the World Diabetes Congress in South Africa.\n\nThe findings from the clinical trial have shown newly diagnosed patients with type-two diabetes who weren't taking antidiabetic drugs had significantly improved blood-sugar levels and lost more weight with Acomplia, compared with a dummy pill over a period of six months. In addition, Acomplia -- also known as rimonabant -- helped...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that the drug discussed in this story is not currently available in the US is not completely clear in this story.\u00a0 The article does mention that this drug is available in Europe, but doesn't clearly state it isn't available in the US.\u00a0 It ends with the prediction that the new data should result in eventual approval of rimonabant by the FDA, though the time frame for such approval is not predictable.", "answer": 0}, {"article": "Todd McAllister of Cytograft Tissue Engineering in California and colleagues implanted lab-grown blood vessels into 10 patients with advanced kidney disease in Argentina and Poland from 2004 to 2007.\nIn the study, doctors took a small snippet of skin from patients.\nIn 2007, the scientists published preliminary findings for another 4 patients in the New England Journal of Medicine.\nThe study was was paid for by Cytograft Tissue Engineering.\nAll of the vessels were implanted into patients' upper arms, to connect them to dialysis machines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the tissue-engineered blood vessel grafts are still experimental. It says only that this sort of lab-grown blood might help patients \"one day,\" without predicting success within a specific time period.", "answer": 1}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\n\u201cThat would be one compassionate use of it, a very serious application.\nIt was cleared by European regulators even though large so-called pivotal trials have not yet been conducted on the product.\nIt hopes to seek U.S. approval for the product in 2015, several years before any competitor.\nHe said bioresorbable materials have great potential for other uses, particularly for stents to repair the pulmonary arteries and aortas of babies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the device is available in Europe but not in the US.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment highlighted in this piece is about expanding the use of \u00a0a material already approved for other medical problems as a means for dealing with a variety of problems with heart muscle. \u00a0So although the piece mentioned that the material was currently being tested in animals for this new purpose, the story blurs this distinction because it goes on to include a quote from a patient in whom the material was used to repair a leak due to valve repair.\nSo\u00a0the CorMatrix Extracellular Matrix may be able to solve more problems than it is currently applied to, but we don\u2019t yet know. \u00a0This means the treatment is available for some medical problems, though not the one highlighted in the story. \u00a0The story was a little confusing on this one.\u00a0", "answer": 0}, {"article": "Though randomized controlled clinical trials of bright light are difficult to do properly \u2014 one expert is fond of saying that it is difficult to \u201cblind\u201d studies of bright light \u2014 the American Psychiatric Association considers bright-light therapy an effective low-risk treatment for both S.A.D.\nCOSTS Light boxes can be purchased for about $200 online; they are also available for rent.\nPatients generally sit in front of the light box, which can be as small as 9 by 11 inches and 5 inches deep, with the bright light emanating from the square surface, in the morning.\nSome say their patients don\u2019t have the patience to sit in front of a light for 30 to 45 minutes every morning.\nBut while bright-light treatment is helpful, he said, it is not sufficient for him.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear how widely used are the light boxes and that they are sold online and available for rent.", "answer": 1}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nDoctors and researchers will now explore how to best use these drugs -- give one before the other, or simultaneously.\n\"This is an unprecedented time of clinical options -- it is truly practice-changing,\" said Dr. Lynn Schuchter, who heads the Melanoma Center at the University of Pennsylvania and is not involved with the research.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nThis is very unusual in the world of drug development, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that vemurafenib is experimental and Yervoy is commercially available. Unfortunately, the story includes a prediction from the ASCO President and others that , \u201c\u2026vemurafenib will almost certainly get FDA approval this year.\u201d While this may occur, it is not certain. And a little shoe leather journalism would easily find someone who would remind readers that FDA approval is not a fait accompli.\u00a0 Because of this, we judge this unsatisfactory.", "answer": 0}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\nVitrakvi will run further tests of the drug's safety and effectiveness.\nThe FDA announced Monday that it had approved Vitrakvi (larotrectinib), a treatment for both adult and pediatric cancer patients.\nIts approval reflects advances in the use of biomarkers to guide drug development and the more targeted delivery of medicine.\"\nThe search for a cancer cure goes on, but in the meantime, there is hope for more effective treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the drug has received FDA approval.", "answer": 1}, {"article": "That was longer than we expected, and it's great news for this group of women.\"\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\n\"If a woman's bone density at age 67 is very good, then she doesn't need to be re-screened in two years or three years, because we're not likely to see much change,\" says study author Margaret L. Gourlay, MD, MPH, of the University of North Carolina at Chapel Hill, in a news release.\nTheir findings are based on the women's T-score, which is a measure of bone density.\nThe new findings are slated to be presented at the annual meeting of the American Society for Bone Mineral Research in Toronto.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story talks about \"women\u2019s T-score, which is a measure of bone density\", but it never explains how a bone density test is conducted or who might conduct it. Does a woman have to go to a specialist? What kind of equipment is involved? It doesn\u2019t take much to address these questions. ", "answer": 0}, {"article": "Kisco, N.Y.\nAn editorial accompanying the studies noted the results should be interpreted with caution since longer-term data is not yet available.\nBut obese patients should be careful to choose surgeons who have performed a high volume of these procedures before committing, said Dr. Guilherme M. Campos, lead author of one of two papers appearing in the February issue of the Archives of Surgery.\nMore people in the bypass group had complications right after the surgery.\nMore of those undergoing lap-banding, however, needed repeat surgeries (13 percent vs. 2 percent).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did not fully explain who might be a candidate for these procedures \u2013 which is a matter of availability. A brief explanation of the criteria for weight loss surgery would have dispelled any confusion.", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The journalist probably assumed that yoga and stretching programs are widely available in the U.S.\u2014which is a reasonable assumption. So the article wins a \u201csatisfatory\u201d on this point.\nBut in fact, it is not all that clear that similarly standardized \u201cviniyoga\u201d classes designed to accommodate back pain patients are widely available\u2014or whether most health insurance plans will cover them.\u00a0 Intensive stretching classes would appear to be uncommon. So physical therapists or exercise physiologists might have to create them based on the study model.\n\n\n\n ", "answer": 1}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\nZaidi said that both vitamin D and calcium are extremely important for human health, so people should follow the previous vitamin D and calcium recommendations.\nTo build bone density, weight-bearing exercise is needed, such as running or weight-lifting, according to the NIH.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of calciium and vitamin D are not in question.", "answer": 2}, {"article": "Labovitz also points out that the group of men who had fewer strokes were younger, had lower blood pressure and smoked less than the group more prone to stroke.\nTomatoes could contribute to reducing stroke in other ways, Willett says, because they are a good source of potassium, which is known to reduce blood pressure.\nHowever, daily intake of tomatoes may give better protection.\"\nIt seems the jury is still out, but researchers suggest we eat healthy as they continue to search for answers.\nLycopene has attracted a lot of attention in recent years because it's such a powerful antioxidant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes is not in question.", "answer": 2}, {"article": "The U.S. Food and Drug Administration has not yet approved its use.\nMONDAY, Dec. 17, 2012 (HealthDay News) -- For patients whose high blood pressure cannot be controlled despite taking several medications, a short burst of radio waves at the nerves around the kidneys may do the trick, a small new study says.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\nThe procedure is safe as well as effective, the study authors said.\nFonarow added: \"While this study demonstrates that renal denervation provides sustained reduction of blood pressure up to one year and appears safe, additional studies with longer-term follow-up are needed.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that the procedure is used in other countries but not yet approved in the US.\nHowever suggesting it is used in other countries doesn\u2019t really provide the reader with enough information.\u00a0 Here is what the UK\u2019s National Institute for Health and Clinical Excellence (IPG418 Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension: guidance ) had to say about the approach:\n\u201cCurrent evidence on percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for resistant hypertension is from limited numbers of patients, but there is evidence of efficacy in the short and medium term. There is inadequate evidence on efficacy in the long term; this is particularly important for a procedure aimed at treating resistant hypertension. The limited evidence suggests a low incidence of serious periprocedural complications, but there is inadequate evidence on long-term safety. Therefore this procedure should only be used with special arrangements for clinical governance, consent, and audit or research.\u201d\nThese evidence-based questions will have some impact on availability \u2013 whether in other countries or in the US.\u00a0 And the story should have dug a bit deeper.", "answer": 0}, {"article": "The National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nThe new study was presented at the annual meeting of the American Pain Society.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is not approved for use in fibromyalgia but is indicated for use in narcolepsy.", "answer": 1}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nBut the picture isn't so clear for women in their 40s.\nThese women will suffer the harms of early screening.\nFor women in their 50s and 60s, the benefits of getting regular mammograms clearly outweigh the risks.\nBut the vast majority of women will never develop breast cancer during their 40s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Mammograms are widely available (if you have access to the proper facility and a way to pay for it). So we don\u2019t expect that the story directly address availability.", "answer": 2}, {"article": "Other texts might include something like, \"Hi, Elizabeth.\nNot only does this research provide evidence that a text-based program can improve heart disease risk factors, but it also shows that a bunch of bells and whistles aren't required for successful health outcomes.\nYet patients in Chow's study resoundingly said that the text messaging helped them make the necessary changes \u2013 more than 90 percent of the participants found the program useful.\nAnd although Chow and her colleagues told study participants that they did not need to reply to the text messages, many of them still did.\nThe texts that patients received were semi-personalized, based on background information about each person, such as smoking status and preferred name.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was fairly clear from the story that this was a clinical trial, and that this particular service doesn\u2019t seem to be available to offer customized, encouraging text messages for heart disease patients.", "answer": 1}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Sonata is undergoing clinical trials and is otherwise unavailable in the United States \u2014 though it is approved in Europe.", "answer": 1}, {"article": "Androgens, including testosterone, are thought to contribute to the growth and development of prostate cancer.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nBut the new finding indicates it could also be a valuable add-on treatment to surgery if the cancer returns.\nA commonly used drug could dramatically increase survival rates for men who have to fight prostate cancer twice.\nThe drug, a type of androgen-depleting therapy, is a frontline treatment for men who opt not to have surgery for the cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies hormone blockers have been around as a technique for decades, but have not been widely used due to their side effects and uncertainty surrounding their actual efficacy.", "answer": 1}, {"article": "Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry.\nHowever, most studies evaluating migraine surgery have relied on migraine-specific questionnaires.\nPreoperative pain coping scores in migraine patients were substantially lower than reported for patients with other types of chronic pain--for example, neuropathic (related to nerve damage) pain, arthritis, or lower back pain.\nDeveloped by plastic surgeons who noticed that some migraine patients had fewer headaches after cosmetic forehead-lift, migraine surgery procedures address trigger sites linked to certain headache patterns.\nJanuary 2, 2018 - In addition to reducing headache frequency and severity, surgical treatment for migraine leads to significant improvements in everyday functioning and coping ability, according to a study in the January issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release made no mention of how or where patients could obtain migraine surgery. Online it seems that these surgeries are offered at many boutique plastic surgery centers around the country\u2013though interestingly it is only plastic surgeons who seem to offer this treatment, not neurologists (the doctors that most often treat migraine sufferers). The news release and the study also did not mention that not all migraine patients will be eligible for the procedure. Although we know little about migraines, it is known that they are triggered in different people through different mechanisms. A woman who has hormonal migraines, for example, might not benefit from nerve decompression.", "answer": 0}, {"article": "Medicare typically follows USPSTF guidelines in determining coverage and the Affordable Care Act specifies that USPSTF recommendations rated at the strongest levels must be used as a floor for coverage for private insurers.\nAnother (more costly) drug may get around the problem.\nThis post has been updated.\n\u201cIn deciding on any therapy, it is important to understand the risks and benefits, particularly for healthy people,\u201d they wrote.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear and obvious that statins are available via\u00a0a doctor\u2019s prescription.", "answer": 2}, {"article": "Impaired insulin sensitivity is one risk factor for type 2 diabetes, which is associated with age and obesity and happens when the body can\u2019t properly convert blood sugar into energy.\nAnd it doesn\u2019t prove that catching up on sleep will prevent diabetes.\n\u201cIdeally, we would all get sufficient sleep on a nightly basis.\u201d\nThe researchers did two brief sleep experiments.\nThe study doesn\u2019t prove sleeping late every weekend can counter the ill effects of insufficient rest every other night of the week, Broussard cautioned.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of sleep is not in question.", "answer": 2}, {"article": "But for relapsed ovarian cancer, surgery is usually not an option.\nMoreover, the extra chemotherapy seemed to worsen the quality of life.\nBut others would prefer to know.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CA-125 is available.", "answer": 1}, {"article": ".\nThe investigators noted that they examined only naturally occurring dietary isoflavones, not isoflavones from supplements.\nTo provide some clarity, Dr. Zhang and her colleagues looked at the relationship between dietary intake of isoflavones and death from any cause in 6235 American and Canadian women diagnosed with breast cancer.\nA free abstract of this article will be available via the Cancer News Room upon online publication.\nTherefore, we can recommend women to consume soy foods because of soy's many health benefits,\" he wrote.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It would have been interesting and helpful for the release to note what kinds of soy foods the participants said they ate, and which ones were most popular.", "answer": 2}, {"article": "Thirty-five percent were white, 32 percent were African-American, 22 percent were Hispanic and 11 percent were Chinese-American.\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\n\"It may be that if patients are in that blood pressure treatment gray zone with a high risk score but their coronary artery calcium score is zero, then they don't need to be treated aggressively to 120 millimeters of mercury and can be treated to 140 instead,\" says McEvoy.\nBut not all people deemed \"higher risk\" by traditional methods may need to be aggressively treated, McEvoy says.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Though CT scans are widely available, the news release mentions that coronary artery calcium scans aren\u2019t usually covered by insurance. This seems to be an important stumbling block to widespread adoption. Could insurers be persuaded to pay for scans if the cost is outweighed by better targeting of treatments? Addressing this point would have added value to the news release.", "answer": 1}, {"article": "Anderson Cancer Center.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article is clear that the test is not yet available. In reporting on the finding, the story states that \u201cIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer\u201d and adds that it still needs to be shown that the screening would improve outcomes for patients with pancreatic cancer. The story contains a lot of conjecture for a test not yet developed.", "answer": 1}, {"article": "\"Perhaps most importantly reducing pain medication use.\"\n\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\nOpiate overdoses are now the leading cause of death for adults under age 50 -- an especially compelling reason to find approaches to chronic pain that don't involve narcotics.\nDr. Robert Saper at Boston Medical Center is one of the authors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yoga is widely available, although it may be harder to find for rural and low-income neighborhoods. Ironically, the story does not tell us that the 320 patients in this research study were primarily low-income. The study publication itself does say that.", "answer": 1}, {"article": "Foxman B, Barlow R, D'Arcy H, Gillespie B and Sobel JD.\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\na total of 28 studies showing results from nearly 5,000 patients were considered.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address this, but it can be assumed that most (if not all) readers will be familiar with the availability of products containing cranberries. Ergo, we\u2019ll rate this as not applicable. It\u2019s worth noting that the release gives readers little idea of what sort of cranberry products a patient could \u2014 or should \u2014 use to lower their risk of a UTI.", "answer": 2}, {"article": "\"Chantix increased the unpleasant effects of alcohol, for example feeling drowsy and irritable, [and] participants also reported that they didn't like the alcohol effects as much,\" Childs said.\nChantix costs roughly $3 per pill.\nWEDNESDAY, Feb. 15, 2012 (HealthDay News) -- The quit-smoking drug Chantix may also help problem drinkers cut their alcohol consumption, a small new study suggests.\nApproved to help smokers quit in 2006, Chantix (varenicline) has its share of potential side effects.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Chantix is currently available to help smokers quit.", "answer": 1}, {"article": "Kids with August birthdays are more likely to get an ADHD diagnosis.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\nThe results of one of those studies are out Tuesday in JAMA.\nMIT scientists find evidence that Alzheimer\u2019s \u2018lost memories\u2019 may one day be recoverable\n\n\u2019Siri, I want to commit suicide\u2019 and other statements likely to yield unhelpful responses from your phone\n\nRoots of Napoleon complex may be justified: Study finds short men get short of end stick in life.\nThe two wrote that despite this and other unknowns, the study provides \"a compelling argument for ensuring that an evidence-based health care system should provide access to affordable mind-body therapies.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the story whether MBSR is widely available, is available in mainly metropolitan areas, or is a relatively new field that is still uncommon. The story does quote from a separate editorial in JAMA that says health care systems \u201cshould provide access to affordable mind-body therapies,\u201d\u00a0implying that it\u2019s not widely available. Is this the case, or can it be easily accessed?", "answer": 0}, {"article": "score of 0.9 or higher at the age of 50.\nBut the advice continues to be murky for younger men.\nStill, the absolute risks for men with elevated scores were lower than might be expected.\nFinally, some new research offers simple, practical advice \u2014 at least for men 60 and older.\n\u201cWe are in the midst of a paradigm shift in screening and risk assessment that no longer relies on a simple P.S.A.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0While not being explicit, the story strongly implied (correctly) that the PSA test is readily available.", "answer": 1}, {"article": "\"What was unique about this study is the very large number of children studied,\" Dawson noted.\nTUESDAY, June 26, 2012 (HealthDay News) -- Electroencephalogram (EEG), a test that shows the electrical activity of the brain, might be used to spot autism in children, a new study suggests.\n\"Although autism is still principally a clinical diagnosis, this study ... may allow for a new approach to classifying children with autism and may even assist in the early identification of affected children at a younger age,\" said Dr. Andrew Adesman, chief of developmental and behavioral pediatrics at the Steven & Alexandra Cohen Children's Medical Center of New York in New Hyde Park, NY.\nThe study, conducted by researchers at Harvard University Medical School, looked at the synchronization of brain activity across different brain regions, as measured by EEG.\n\"Consistent with many previous studies using EEG and functional MRI with both children and adults with autism, these investigators found that, overall, children with autism show reduced coordination (coherence) across brain regions.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from this story that EEGs are widely used in research or whether they currently have other clinical applications. We can\u2019t assume that consumers know this. If my chlid is not speaking by a certain age, can I go to my doctor and ask for an EEG? And, if I do, what would be the next steps?\n\u00a0\n\u00a0", "answer": 0}, {"article": "Result: people drinking 1.1 to 3 cups a day had an 8 percent lower mortality risk, while the 3.1-5-cup crowd had a 15 percent lower mortality risk, mostly due to lower risk of deaths from cardiovascular disease, neurological diseases, type 2 diabetes, and suicide.\nThe Claim: If you drink coffee you\u2019ll live forever!\nThat turned out to be wrong.\nThat is, each year, coffee would be keeping 1 person in 1,000 from dying.\nThat eliminated the stereotypical coffee-swilling, cigarette-sucking types.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is widely available, and that\u2019s obvious from the story.", "answer": 1}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the Heartmate II device is currently in limited use, to keep patients alive until a heart is available for transplant. The Heartmate II clearly is available only at advanced cardiac care centers. \nYet the story fails under this criterion because it stumbles across one of the most durable trip-wires on the field of health journalism: Predicting the device is \"widely expected\" to be approved for broader use, \"possibly\" early next year. This invites the reader to assume imminent wide availability.\u00a0 ", "answer": 0}, {"article": "The Kennedy Institute's Professor Kim Midwood said: 'What is particularly exciting is that when we looked at samples taken from people before their arthritis began, we could see these antibodies to cTNC up to 16 years before the disease occurred - on average the antibodies could be found seven years before the disease appeared.\nThis latest research provides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\nThat might also indicate whether it could be used in tests to indicate the disease.\nWe decided to see if it could be citrullinated and, if so, whether it was a target for the autoantibodies that attack the body in RA.\nScientists have found a marker that can indicate your likelihood of suffering from rheumatoid arthritis (RA) even sixteen years before the condition takes effect.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above under \u201cCost,\u201d if the test is promising enough to issue a news release about it, readers should be given some idea of when and where it might be available.\nWe aren\u2019t told until the very last paragraph that the research \u201cprovides the basis of tests that could improve diagnosis and, importantly, detect disease at a very early stage, with the promise even that people at risk of developing rheumatoid arthritis can be followed before the disease begins.\u201d In other words, it could be a very long way off. We think there should have been a caveat that more studies are needed or that this test may be years off before it will be ready for routine practice.", "answer": 0}, {"article": "Necator americanus, the New World hookworm, is as long and thin as a vermicelli noodle.\nThis study would also suggest that humans lost something when we rid ourselves of the microbes and parasites that had evolved alongside us for tens of thousands of years.\nThese benefits persisted for 10 weeks after the mice stopped getting the treatment \u2014 \u201cI don't even know how much that is in mouse years,\u201d Navarro said.\n\u201cIt is basically rewiring the cells in that tissue into promoting very efficient regulatory T cells,\u201d Navarro said, describing the cells that help modulate the immune system.\nIt was important that the participants be adults, because even relatively benign parasites can cause serious problems for children, pregnant women and others.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does\u2019t address availability. As we explain in the quantified benefits criterion above, the most readers get is an\u00a0erroneous statement about the next steps: \u201cNavarro said their next step is a phase one clinical trial, which would test the effectiveness of an AIP-2 pill.\u201d A phase one trial is actually to test safety\u2013not effectiveness\u2013and this error may have the effect of making this pill seem closer to reality than it is.", "answer": 0}, {"article": "The risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\n\u201cThere\u2019s been a lot of work over the years showing that certain compounds can increase the risk of cancer, but it\u2019s not been shown before that we can reduce the risk with something as simple as aspirin.\u201d\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that \u201cMany Americans take aspirin to lower their risk of heart disease\u201d but not necessarily for a cancer benefit.", "answer": 1}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\n\"It also marks a major milestone for Celator, for VYXEOS, and for our CombiPlex\u00ae platform.\nThe Company is advancing its CombiPlex platform and broadening its application to include molecularly targeted therapies.\nAn archived webcast will be available on Celator's website beginning approximately two hours after the event.\n\"The successful outcome of this Phase 3 trial represents an important advance for AML patients, their families and clinicians,\" said Scott Jackson, Chief Executive Officer of Celator Pharmaceuticals.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that the company hasn\u2019t yet sought regulatory and marketing approval for the new drug but will be doing so soon.", "answer": 1}, {"article": "Having a large waistline, high blood pressure, high blood sugar, low levels of HDL (good) cholesterol and high levels of triglycerides, are among the factors that make up metabolic syndrome.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\n\u201cCurcumin is the active ingredient of the famous spice turmeric and has a long history of culinary and medicinal use in the Asian countries,\u201d said the study\u2019s senior author Amirhossein Sahebkar.\nThe study team also analyzed data from eight previous studies and confirmed that curcumin had shown a significant reduction of CRP concentrations in a total of 281 patients.\nAt the beginning of the study and again at the end, the researchers measured levels of three blood markers of inflammation, including C-reactive protein (CRP), which even on its own has been linked with heart disease risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that one of the study co-authors is affiliated with companies that make curcumin supplements, so it is easily inferred that such supplements are available.", "answer": 1}, {"article": "Eat as you dare.\nScientists believe this style of eating offers some protection against mental aging, and, above all else, it is heart healthy.\nThis classic diet does not exclude a dinnertime glass of wine, however, sugary drinks, fried food, and sweets are not on the menu.\nInstead of avoiding unhealthy foods, people with weak hearts might focus more on consuming healthy foods.\nA new study of over 15,000 people in 39 countries explored the benefits of this diet for one special group: those already diagnosed with heart disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both Western and Mediterranean foods are widely available. However, Western foods are known to be\u00a0cheaper and more widely available in low-income areas, and that could have been mentioned.\u00a0", "answer": 2}, {"article": "The study\u2019s median follow-up was 18.5 months.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nMerck announced in October that the second-line bladder cancer study met its main goal and was stopped early.\nAccording to the FDA approval letter, the company has until December to submit the full trial data to the agency.\nAll five drugs are part of a new class of treatments designed to unleash the body\u2019s immune system to fight cancer by interfering with proteins known as PD-1 or PD-L1 that help malignant cells evade immune attack.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is not currently approved for this type of cancer, but is approved for other types.", "answer": 1}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Though it would seem reasonable to think that the Hershey\u2019s cocoa mixes used in this study are available on grocery store shelves, it\u2019s impossible to know. (It\u2019s not readily clear from Hershey\u2019s web site either.) Nonethless, we'll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states correctly that about 25 percent of spinal fusion surgeries use bone-growth proteins [BMPs].", "answer": 1}, {"article": "More than 20 percent of Americans have significant symptoms of depression or anxiety each year, but only around 20 percent of people with a mental health problem get adequate treatment.\nIndividuals can download the apps free with no financial obligation.\nSome also will have access to an IntelliCare coach via text messaging and phone calls, who are available to support them in using the apps.\nThe apps offer exercises to de-stress, reduce self-criticism and worrying, methods to help your life feel more meaningful, mantras to highlight your strengths, strategies for a good night's sleep and more.\nAlthough the apps are not validated, each one was designed by Northwestern clinicians and based on validated techniques used by therapists.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release invites people to download the apps for free.", "answer": 1}, {"article": "CDE causes inflammation that can prevent tear production, according to Allergan.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\nWhen you visit the website, you\u2019ll see a pop-up window with a portal to take the quiz.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s available and as \u201csimple as going to your doctor,\u201d according to the celebrity spokesperson. (But as we discuss in the Costs criterion, it\u2019s not free nor necessarily covered by insurance.)", "answer": 1}, {"article": "\"I thought I was cured,\" she says.\nThere are no significant side effects to the surgery, and patients can return to work the day after they have the procedure.\nIt's one of several procedures designed to help people maintain the benefits of bariatric surgery.\nAbout one in three patients regain significant amounts of weight a few years after surgery to reduce the size of the stomach pouch.\nAnd research conducted over the past decade suggests it works.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, it is apparent that the TORe procedure is available since cost and insurance coverage are noted. It would have been useful to include additional details on how widely the procedure is used, whether it\u2019s used by both gastroenterologists and bariatric surgeons, and whether patients should look for doctors who have special training or credentials for performing this procedure.", "answer": 1}, {"article": "Dr. Henderson stated, \"Misconceptions about ketamine abound among psychiatrists, particularly related to possible chemical dependence problems.\nIts findings stand in direct contrast to warnings from the American Psychiatric Association (APA).\nCiting over 60 published scientific research studies, the new research article also reviews the molecular mechanisms by which ketamine invokes a robust activation of the brain's own repair mechanisms.\n\"The wealth of clinical experience from treating hundreds of patients with ketamine has supplanted the preliminary data that emerged from the initial open-label and small double-blinded studies,\" said Dr. Henderson, who is a board certified psychiatrist, specializing in diagnosing and treating complex conditions, based in Denver, Colorado.\nPatients in the study completed the Quick Inventory of Depressive Symptoms (QIDS-SR), among other scales, and 80% showed persistent positive response to the ketamine infusions treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Other than to note that the author of the study is co-founder of an unspecified number of ketamine infusion centers, the news release does not address where to access the treatment.", "answer": 0}, {"article": "\u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study,\u201d Smith said.\nSmith said FDA approval could come sometime in 2018.\nOn Monday, Horizon Pharma announced that it was acquiring River Vision, which paid for the new study.\nThe study \u201cincluded some of the worst cases imaginable and we\u2019re now wondering whether the drug might find expanded utility in much-less-severe disease,\u201d Smith told Reuters Health in a telephone interview.\nMore people who received the drug had sizeable reductions in disease activity and reductions of 3 mm or more in eye bulge compared to the placebo group, the researchers note.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that FDA approval for this use of the drug could come sometime in 2018 so readers can easily assume the drug is not available now and won\u2019t be for the immediate future.\u00a0 It said that the next phase of the clinical trial is expected to begin within a month or two.", "answer": 1}, {"article": "Chronic diseases of aging, like diabetes, hypertension, heart problems, cancer, joint disorders and Alzheimer\u2019s, are all believed to have inflammation in common.\nIn the meantime, following the example of caffeine-drinking adults with lower levels of inflammation \u2014 by having a cup of joe or two \u2014 might be a good idea.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\nThe goal isn\u2019t to make every trace of inflammation disappear, the scientists stress.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As with cost, it can be assumed that most readers are familiar with how to make or purchase coffee. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article helpfully states that \u201cIt could be years, if ever, before any vaccines to treat addiction reach the market.\u201d The article does a good job of describing how far along the various experimental vaccines mentioned in the article are in their development.", "answer": 1}, {"article": "They should try medical therapy, and if medical therapy fails and the surgeon feels that part of the problem is anatomic, then surgery would be a good tool for them to use,\" Josephson said.\nNone of which is to say that patients shouldn't try medical therapies first, he added.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\nPatients with worse disease at the outset seemed to fare the best after the procedure, as did those undergoing surgery for the first time.\n\"I don't think it means everyone with CRS should consider surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that endoscopic sinus surgery has been used for a long time and the reader can infer that it\u2019s been in widespread use. ", "answer": 1}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nDr. High is listed as a co-author of the report because her laboratory helped monitor the patients and provided proof for regulators that the virus would not insert its human gene into the patients\u2019 sperm and make the change hereditary.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\nHigh of Children\u2019s Hospital of Philadelphia, said the new therapy had worked because the delivery virus had been made more efficient and because the research team had treated the patients with steroids to suppress immune system attacks on the virus.\nOne patient, a geologist, had a good response at first, but his level of Factor IX has declined to 1 percent of normal, the level at which the disease kicks in.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this is an experimental approach, but the story didn\u2019t challenge a researcher\u2019s claim that a genetic treatment for hemophilia B \u201ccould be available for widespread use in a couple of years.\u201d\u00a0 That kind of statement requires some kind of explanation of what the road to widespread use may look like\u2026and how unpredictable such a prediction can be.", "answer": 0}, {"article": "The F.D.A.\napproval late next year.\nhas also tentatively approved a stent system from the Cordis division of Johnson & Johnson.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\nClearance is being delayed until Cordis convinces the government it has dealt with unrelated manufacturing and record-keeping problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Very clear presentation of FDA \napproval of devices made by two manufacturers and that others are awaiting full approval.", "answer": 1}, {"article": "Both groups went to their V.A.\nBased on the study results, it could be that patients need to renew their regimen with the cream every year.\nThe dose is the same as dermatologists currently employ to treat actinic keratosis.\nHe and colleagues are planning further studies, including one to determine the cost-effectiveness of 5-FU treatment.\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the cream, available as a generic, has been used to treat other conditions. That suggests the cream is widely available.", "answer": 1}, {"article": "The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe.\nEating fish is not a guarantee of having high levels of DHA.\nFatty fish, he said, is best, and frying will cause DHA to deteriorate.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\nDr. Schaefer pointed out that the kind of fish consumed is important.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mentioned that omega-3 fatty acid docosaheaenoic acid (DHA) was found in fatty fish, as well as supplements in the form of fish oil or DHA.\u00a0 It was good to point out that neither DHA or fish oild supplements have FDA approval for prevention of dementia.\nThe story curiously mentioned that it was also found in some meats.\u00a0However, the only tissues in which DHA is found in significant quantities are the brain, retina, and testes \u2013 which are not frequently consumed by people.\u00a0 Thus the story ought not to have included 'some meats' as a source of DHA. ", "answer": 1}, {"article": "Women who undergo Caesarean sectionsmore than seven days before their due dates put their babies at higher risk of respiratory problems, longer hospital stays and other complications.\nOf those, more than 13,000 had elective C-sections.\nAll of the women had previously had C-sections.\nThe Associated Press and McClatchy Newspapers contributed to this story.\n\"I think it points to a role for the baby in the initiation of labor and the baby's readiness to make the transition.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \"growing number of planned C-sections\" is clear from the story. ", "answer": 1}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nAnd for one patient, it is promising.\nDr. Jenkins, who is not affiliated with the company, has continued to monitor Mason.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\nCBS News spoke with Mason just before he underwent delicate neck surgery to try and repair the demaged part of his spinal cord by injecting stem cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the treatment is experimental, and correspondent LaPook acknowledges at the end, \u201cMore research will be needed to try to establish whether (stem cells) actually repair damage to the spinal cord.\u201d But that strikes us as too little, too late. The story does not explain that it takes years to gain FDA approval for a new treatment, and many therapies particularly in the stem cell field never reach the finish line due to cost, safety, and efficacy hurdles.", "answer": 0}, {"article": "Dr. George Williams is an ophthalmologist and retinal surgeon associated with the American Academy of Ophthalmology.\nSo the take-home message: If you're over 60 and you begin to experience visual loss, get yourself to an eye specialist as soon as possible to see if you can be treated with medication to stabilize and even reverse the vision loss you've experienced.\nFor one, the treatment doesn't work for those who have had cataract surgery.\nThe treatment doesn't work for those who have had cataract surgery.\nDespite its terrific potential, the new eye telescope isn't for everyone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental study and says that the FDA\u00a0plans to monitor the side effects for five years. We\u2019re not quite sure why this story was coming out now given that the FDA approved this device at\u00a0the beginning of the month.\u00a0(Read about it.)\u00a0How widely available is it? Never made crystal clear. ", "answer": 1}, {"article": "For ella, \u201cwhile you\u2019re going to have to go and get a prescription for it, it gives you a little bit more leeway in terms of putting your ability to put your life on hold and get this healthcare need taken care of,\u201d said Amy Allina, program and policy director for the National Women\u2019s Health Network.\nHRA is not seeking to sell ella without a doctor\u2019s prescription.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\nIf approved, Watson Pharmaceuticals Inc would sell the drug in the United States.\nData shows the one-pill treatment, called ella and made by French drugmaker HRA Pharma, is effective when taken as many as five days after unprotected sex, Food and Drug Administration staff reviewers said in documents released ahead of a public meeting on the drug scheduled for Thursday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that the FDA is now reviewing the drug and that it is not yet available in the US but is available in Europe.", "answer": 1}, {"article": "To address this gap, researchers conducted a randomized controlled trial including 352 healthy infants from 3 pediatric outpatient clinics, including 7 physician practices, who received scheduled vaccinations in their first year of life.\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\nThe infants were randomized to 1 of 4 groups: placebo control; video instruction to parents on how to soothe their baby; video plus oral sugar solution; and video, oral sugar solution and lidocaine applied to the skin.\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Lidocaine creams come in many different over-the-counter products but it\u2019s unclear whether the lidocaine formulation used in the study is the same as one might find over-the-counter, or if it\u2019s EMLA (a cream using equal parts lidocaine and prilocaine) or another prescription product.", "answer": 2}, {"article": ".\nAn advantage of small-molecule PPF -- which has been previously used in clinical trials in an attempt to treat Alzheimer's disease and dementia -- is that it can penetrate the blood-brain barrier and reach the tumor.\n\"PPF could be easily translated to the clinic as an adjuvant therapy in combination with standard of care treatment for GBM patients.\"\nIn addition, TGen laboratory research also found that PPF increases the effectiveness of a standard-of-care chemotherapy drug called temozolomide (TMZ), and radiation, to treat glioblastoma.\nThis study -- Propentofylline inhibits glioblastoma cell invasion and survival by targeting the TROY signaling pathway -- also was funded by the National Institutes of Health under grants NS86853 and P50 CA108961.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release is clear that this approach is experimental, by failing to clearly point out the fact that the drug has yet to be tested in a single glioblastoma multiforme patient, it obscures just how preliminary and tentative these results are.The release gives the reader the false impression that PPF has already been approved for this purpose with this statement:\n\u201cAn advantage of small-molecule PPF \u2014 which has been previously used in clinical trials in an attempt to treat Alzheimer\u2019s disease and dementia \u2014 is that it can penetrate the blood-brain barrier and reach the tumor. And, the FDA has already approved it.\u201d", "answer": 0}, {"article": "Their systolic blood pressure, which was in the normal range when the study began, dropped by 4.5 mmHG, while their diastolic blood pressure dropped by 3.1 mmHg.\nThe researchers said further investigation will determine whether the benefits of the diet can continue for several months.\nThe phase II trial, conducted by researchers at the USC Leonard Davis School of Gerontology, demonstrated a host of benefits from the regimen.\n\"Prior studies have indicated a range of health benefits in mice, but this is the first randomized clinical trial with enough participants to demonstrate that the diet is feasible, effective and safe for humans.\n\"Larger FDA studies are necessary to confirm its effects on disease prevention and treatment,\" he added.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not explain whether materials used in the clinical study are widely available. The product website, however, is actively promoting the kits.", "answer": 0}, {"article": "For those with early stage breast cancer, \"lumpectomy is just as effective if not more effective than mastectomy,\" said researcher Dr. Shelley Hwang, chief of breast surgery at Duke Cancer Institute in Durham, N.C.\n\n\"There are lots of women who think the more [treatment] they do, the better they will do,\" she said.\nThe study is scientifically sound in many ways, Kruper said.\nThe study was observational, Hwang stressed.\n\"At the end of the day, personal preference trumps everything else.\nI fully support the patient's options to choose the best treatment for themselves.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No discussion of availability of either approach, but we don\u2019t think that was necessary in this case.", "answer": 2}, {"article": "Because a gene mutation impairs normal production of a blood clotting factor, patients may suffer excessive bleeding in the central nervous system or GI tract, or after surgery or an injury.\nThe current study sets the stage for clinical trials in humans.\nThis success in large animals holds considerable potential for a safe, effective and long-lasting new treatment in humans with the same bleeding disorder.\nBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\nThe Margaritis team collaborated with University of North Carolina (UNC) scientists, led by Tim Nichols, M.D., professor of Medicine and Pathology at the UNC School of Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this treatment will not be available until human clinical trials are conducted.", "answer": 1}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think it\u2019s safe to presume that readers know that vitamin and mineral supplements are widely available.", "answer": 2}, {"article": "\u2022 Try to stay indoors, and avoid mowing lawns or raking leaves.\nBut you can also tell by the ads: TV spots selling remedies for drippy, congested noses, itchy eyes and other symptoms are in heavy rotation.\nYou can tell by the sniffles and sneezes of the afflicted.\nThe various sprays have never been studied head to head, so it's impossible to say whether they vary in effectiveness, she says.\nAnd they both sit on store shelves next to antihistamines such as Claritin, Allegra and Zyrtec that were prescription drugs just a few years ago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All these drugs are available over the counter, which the article mentions early in the story.", "answer": 1}, {"article": ", follow us on Twitter @H_SeniorLife, like us on Facebook or read our blog.\nThey graded the severity of these calcium deposits using scans done for osteoporosis screening.\nResearchers analyzed the bone density scans of over 1000 older women from Australia for the presence of calcium deposits in the large artery in the abdomen called the aorta.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that bone density scanning is routinely used to diagnose osteoporosis and presumably it is widely available. What is not clear is whether bone density scanning to determine the degree of aortic calcification is generally available.", "answer": 0}, {"article": "\"That's where the money is,\" Malmgren said.\nAmong them, according to the 2009 guidelines, are false-positives, which can lead to anxiety and unnecessary biopsies.\nThey also took these into account: the cancer's stage at diagnosis; type of treatment; annual follow-up; recurrence; and survival.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\nIn 2009, the U.S. Preventive Services Task Force issued mammogram recommendations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Availability of mammograms is not in question although access to care is dependent upon many factors including distance to facility with instrument, insurance coverage, etc.", "answer": 2}, {"article": "\"And I thought, 'If we could do that in people, this is going to be amazing.'\nA clinical trial to study the drug \u2014 now called ipilimumab, or Ippy for short \u2014 was set up at Memorial Sloan Kettering Cancer Center in New York City.\nIppy is now sold under the brand name Yervoy by Bristol-Myers Squibb, which bought Medarex in 2009.\nWhat Belvin didn't know at the time was that a revolutionary treatment for melanoma had begun testing in clinical trials.\nAllison's treatment was still experimental, but if it worked, it had the potential to save Belvin's life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that ipilimumab is currently available for clinical use, marketed under the name Yervoy.", "answer": 1}, {"article": "The researchers employed a 32-point scale to assess tremor severity, and they found that mean tremor scores improved by 47 percent at three months and 40 percent at 12 months.\nBecause the approach is so new, insurance plans will not yet cover the procedure, though that may change in the coming months.\nThe site includes a list of frequently asked questions and will be updated as UVA prepares to make the treatment available.\nThe procedure is not for everyone with essential tremor.\nThe FDA approval means UVA can make the procedure available to eligible patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is clear in that the medical center is preparing to make the procedure available to qualified patients but it certainly is not available to the public at this time. It also mentions the uncertainty of insurance coverage.", "answer": 1}, {"article": "One group of researchers, for example, recently worked backward to take on the problematic overlap between depression and bipolar disorder\u2014many bipolar patients are initially and incorrectly diagnosed with depression.\nIt took a few years to find the right \u2018formula\u2019 of meds.\u201d While the doctors recommended some medication that helped, it was a matter of trial and error, since Orlando still doesn\u2019t have a concrete diagnosis today.\nDespite these exciting preliminary findings, there aren\u2019t yet any biological tests for mental illness widely used in medical practice.\nA tumor seen on a scan, bacteria identified by a throat culture, a fracture captured on an X-ray: They\u2019re all clear signs something is wrong.\nBut, if biological tests for mental illness do come to fruition, even those already living with a condition could benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story goes into some detail about how experimental these diagnostic tests are and even some of the difficulties entailed in bringing them to market.", "answer": 1}, {"article": "Past studies have found that compared with people without fibromyalgia, those with the disorder have higher rates of stressful life events, such as childhood abuse, marital problems and high levels of job stress.\nHe said that he and his colleagues have applied for funding to conduct a larger clinical trial comparing affective self-awareness with standard cognitive-behavioral therapy.\nAnother difference is that, right now, only a small number of healthcare providers practice affective self-awareness, according to Schubiner.\nIt is estimated to affect up to 5 million U.S. adults, most commonly middle-aged women.\nThe therapy involves an educational component where patients learn about the emotion-pain connection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that only a small number of healthcare providers practice affective self-awareness, suggesting that the treatment is not widely available. ", "answer": 1}, {"article": "Symptoms of lung cancer include persistent, intense coughing, shortness of breath, pain in the chest, shoulder or back and changes in the color and/or volume of phlegm or mucus, hoarseness and coughing up blood.\nSix of the eight cases found in the screening were considered potentially curable with surgery.\nAlso, about half of patients screened continue to smoke so screening might also be a logical point for smoking intervention, Schroeder said.\nA total of 398 individuals signed up for the Augusta area screening, 350 qualified and 264 actually had LDCT.\nThat means the machine is staffed at times when it is not able to be fully used for other diagnostic procedures, time that provides a natural window for lung screening using just the CT imaging capability in under five minutes from arrival to exit, Thomson said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the relevant diagnostic techniques are in widespread use; that there is limited access to the screening initiative (based on availability); and that there is an effort underway to expand the screening initiative.", "answer": 1}, {"article": "Kite Pharma is racing to get the first FDA approval of an experimental gene therapy to fight cancer.\n\nAn experimental gene therapy that turns a patient\u2019s own blood cells into cancer killers worked in a major study, with more than one-third of very sick lymphoma patients showing no sign of disease six months after a single treatment, its maker said Tuesday.\n\nIn all, 82 percent of patients had their cancer shrink at least by half at some point in the study.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0mentions this is an \u201cexperimental gene therapy\u201d and that, if approved, it could become the first such treatment to be available\u00a0in the United States. The story notes that the company is seeking approval for the drug by the end of March. While this is sufficient for a satisfactory grade, we think the story could have elaborated on this a bit, and noted that the approval would be based on preliminary phase 2 data \u2014 not the typical phase 3 study data that the FDA normally requires for approval. The drug appears to be eligible for expedited approval based on the FDA\u2019s \u201cbreakthrough\u201d therapies program.", "answer": 1}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\nAll had high blood pressure.\nThe finding stems from a study of 700 people, who averaged 56 years old.\nShe's a researcher with the George Institute for Global Health at the University of New South Wales in Sydney, Australia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t explain where or even whether the \u201ctriple pill\u201d is available.\u00a0", "answer": 0}, {"article": "BOSTON -- In 2006, the FDA warned the public that the use of common antidepressants, like Prozac and Paxil, late in pregnancy could put a baby at risk for respiratory failure.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\nIt's certainly reassuring news for Dr. Katherine Economy, a maternal fetal medicine specialist at the Brigham who cares for many pregnant women on antidepressants.\n\"So for women with severe debilitating depression that is not responsive to other non-pharmacological treatments, this should be reassuring information.\"\n\"And for many women, they cannot get through their daily activities, getting out of bed, taking a shower, and preparing food for themselves.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told\u00a0this study applies to \u201ccommon\u201d antidepressants, and a few widely known prescription name brands are mentioned. The availability (through diagnosis and a medical professional\u2019s prescription) isn\u2019t overtly established, but it\u2019s implied.", "answer": 1}, {"article": "In the study entitled \"Long-term physiological T3 supplementation in hypertensive heart disease in rats,\" aging female rats with hypertension progressing to heart failure were treated for one year (half their lifetime) with a low oral dose of the active form of thyroid hormone, T3.\nBut, they were proven to be wrong and these life-saving drugs are now standard therapy for heart failure treatment.\n\"The studies demonstrate that we should be able to implement a similar, safe treatment and monitoring program for use in human clinical trials.\nI predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients.\n\"Thus, T3 treatment inhibited the major cause of stiffening of the heart in hypertension.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does an excellent job of making clear that this was an animal model study and that clinical trials have not yet been approved for this treatment technique \u2014 meaning that this work is at least years away from widespread clinical use.", "answer": 1}, {"article": "They are packed full of growth factors, of healing factors, and when given into a specific area, you get a hyper-healing response,\" Gearhart says.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\nThe hope is that the same technology that allowed Bornstein to get back on the field so quickly can now be used to treat injuries in weekend warriors as well.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nDoctor are taking the first steps to move this treatment beyond the world of the elite athlete.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story only hinted at the limited availability of the Platelet Rich Plasma Therapy procedure.\u00a0 While it said that \"doctors have now taken first steps tomove this treatment beyond the world for elite athlete,\" and mentioned that clinical trials had begun, it did not answer viewers\u2019 probable questions of \"Where can I get it?\" or \"Is it being tried at my local hospital?\"\u00a0 And when the story lead-in frames the problem as one pertinent to 15-million American medical visits per year, this is an oversight.\u00a0 The very limited availability and preliminary nature of the research should have been emphasized STRONGLY. ", "answer": 0}, {"article": "Jay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\nThe researchers presented earlier findings on the gene therapy a year ago at the American Society of Hematology's annual meeting, but the latest data covers a larger patient group and a longer time period.\nThe results, published Wednesday online in the New England Journal of Medicine, represent \u201canother example of the gene-therapy renaissance,\u201d Matthew Porteus, a pediatrician at Stanford University, wrote in an accompanying editorial.\nThe follow-up period was relatively short, from 28 to 78 weeks in the new report; longer-term studies are needed to prove safety and effectiveness over extended periods.\nThe treatment also \u201cnearly universally eliminated\u201d the need for preventive infusions of clotting factor a few times a week, the scientists said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the story notes that the research is at an early stage with only 10 participants, a reader can easily infer that the treatment is not yet available. However, additional information about remaining evaluation stages for this treatment would have been a useful reinforcing addition. Hemophilia B sufferers who see this story will likely be contacting their doctors.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It's clear that hormone therapy is readily available and has been for many years.", "answer": 1}, {"article": "But collagenase by itself does not cause gangrene.\nIt now has only five employees and a business of collecting a roughly 11 to 12 percent royalty on sales of Xiaflex.\nShares of BioSpecifics closed Monday at $27.61, up from $1 as recently as late 2006.\nWith its belated success, BioSpecifics has sold off its ointment business.\nLast year, when BioSpecifics stock rose above $30, she sold the last 1,000 shares she had been given for serving as a consultant to the company over the years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that Xiaflex was approved last month and will go on sale later this month.", "answer": 1}, {"article": "The F.D.A.\nBut such talks, while encouraging, are still in the early stages, a Novartis spokesman said.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\nBlacks and those with a previous history of the condition were at increased risk, it said.\nNovartis said that about 2.2 million Americans would be eligible for the drug, which was approved for patients with so-called Class II to Class IV chronic heart failure with so-called reduced ejection fraction.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about the FDA approval of the drug, which suggests that it will shortly be available for purchase. Novartis says as much in its news release which indicates the drug will begin shipping this week. The story doesn\u2019t explicitly address this, but we\u2019ll give the benefit of the doubt. Again, we\u2019d add that half of this drug combination is already widely available.", "answer": 1}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nHowever, experts cautioned that while the results are encouraging, there's a lot of work left ahead before stem cells can be used to treat heart failure.\nThe message for patients, he added, is that heart failure can be treated, and researchers are looking for \"innovative\" ways to improve that treatment.\nBut it's not clear whether the stem-cell tactic was actually effective, said Gorodeski, who was not involved in the study.\nThe tactic appeared safe, the researchers said, and there were signs of symptom improvements over the next six months to a year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is another strong point, with the story making it very clear that this is not a viable treatment option for the foreseeable future. \u201cAll stem-cell therapies remain experimental,\u201d the story says at one point. Shortly thereafter, the story quotes a heart failure specialist as saying: \u201cThere\u2019s no cell therapy we can offer patients right now.\u201d", "answer": 1}, {"article": "Follow us: twitter.com/CocoaHealthSci\n\nIn 1911, Frank C. Mars made the first Mars candies in his Tacoma, Washington kitchen and established Mars' first roots as a confectionery company.\nThis test product is currently not commercially available.\nThis second study just published in the AJCN looked to address this question.\nThe nutritionally matched drinks were specially prepared.\nExcitingly, there was also evidence of improvements in these cardiometabolic outcomes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states in an editor\u2019s note that this test product is not commercially available.", "answer": 1}, {"article": "I weigh 160 pounds, and when I do this I put about half my weight into it,\" he said.\nThe bystander who needs to provide those chest compressions is often a loved one of the victim.\nStudies show that either mouth-to-mouth or hands-only CPR may double the survival rate from cardiac arrest, but bystanders typically step in to provide the potentially life-saving intervention in only about one-third of cases.\nThat hesitation is rooted not only in reluctance to lock lips with a stranger, but by anxiety over how to perform conventional CPR, in which the rescuer breathes into the victim twice after every 30 chest compressions.\nTwo years ago, after considering multiple studies, the Heart Association recommended hands-only CPR only in cases where people were unwilling or unable to provide the rescue breaths as well.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news article makes it clear that virtually anyone can perform hands-only cardiopulmonary resuscitation (CPR). It requires no devices or drugs. The major barrier to treatment appears to be fear\u2013of harm to the victim or rescuer, and/or and fear of failing to perform CPR correctly.", "answer": 1}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nHowever, the U.S. Preventive Services Task Force stopped short of saying any one screening method was better than another.\n\"There are multiple screening options for colorectal cancer that reduce the risk of dying from the disease.\nThere are varying amounts of proof supporting the effectiveness of each, and each method has its advantages and limitations, the panelists said.\nAnd what about colon cancer screening for the elderly?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that all of the screening tests mentioned in the story are generally available.", "answer": 1}, {"article": "The World Health Organization estimates that more than 300 million people suffer from clinical depression world-wide. But cost, time, stigma, distance to travel, language barriers and other factors prevent many from seeking help.\n\nNow, a growing group of health-care providers are betting that technology\u2014from web-based courses to mobile apps that send prompts via text\u2014can help bridge that gap.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story identifies several therapeutic apps and, in a video, shows one individual using a \u201cmobile therapy platform\u201d to text and videochat with a therapist.\u00a0 Several comments in the story about the continuing evolution of these applications suggest that these strategies remain works in progress.", "answer": 1}, {"article": "\"Started looking in the cupboard and I saw pie pans and I said, 'These are perfect.\nHere's the important part: if clinical trials pan out - and there's still a long way to go - the Kanzius machine will zap cancer cells all through your body without the need for drugs or surgery and without side effects.\nWell it's true, and if you think it sounds improbable, consider this: he did it with his wife's pie pans and hot dogs.\nThe last thing John Kanzius thought he'd ever do was try to cure cancer.\nKanzius told Stahl.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that the technique is not available for human use. It says it is at least four years away from human trials, assuming all goes well.", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on hepatitis C.\nThe side effects, particularly of the treatment component known as interferon, can be \"pretty hard to deal with,\" said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.\nThe study, published online April 21 in Nature, examines an experimental drug designed to combat the hepatitis C virus.\nHowever, Meanwell said, it could become part of a combination treatment of several drugs.\nIn a phase 1 trial, the first of three types of studies that new drugs must go through, researchers gave doses of the drug to a small number of people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story\u00a0points out that BMS-790052 is in an early phase testing and nowhere near being available to patients, it improperly relayed\u00a0the prediction of a researcher who said that\u00a0two other investigational drugs were expected to become available by 2011. The prediction is especially troubling given the undisclosed financial ties between the researcher and the manufacturers of the investigational agents (see source/conflict of interest criterion below). ", "answer": 0}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\nThe drink contains \"Fortasyn Connect\", a specific combination of fatty acids, vitamins and other nutrients.\nIn addition, earlier randomised controlled trials (RCTs) with the product have shown an improved memory performance in drug-na\u00efve mild AD patients, along with a good safety profile.\nIt is a Food for Special Medical Purpose (FSMP), clinically proven for the dietary management of early Alzheimer's disease.\nProject coordinator Professor Tobias Hartmann, Saarland University Germany, explained that this is the most likely reason the primary endpoint was not met.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t state whether the product is available in the United States. It is not. However, the product is marketed widely in Europe under the brand name Souvenaid.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article offers no information on availability of the supplement, nor does it reflect on the type of intervention that might make sense to people (i.e., eat lots of cruciferous veggies, take sulforaphane supplements). The basic nature of the research likely makes all of that premature, but that then raises the question of why a media outlet would publicize research at such an early stage.\nAnd this is an important question to ask, because it\u2019s not hard to envision that based on this story alone, companies that make supplements (which are held to a much lower standard of efficacy compared to medication classified as drugs) could start marketing this supplement, and use this single study and news story to back up its usefulness.", "answer": 0}, {"article": ".\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nThe association has strict policies to prevent these relationships from influencing the science content.\nIt is already well-established that the benefit of clot removal declines each hour during the first 6 hours after symptoms are detected.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Unfortunately, this news release did not mention that the results from the DAWN trial contributed to updated guidelines for treatment issued by the AHA and the ASA. While thrombectomy after a stroke is already practiced in many larger centers across the country, it is unclear whether this treatment \u2014 actually an expanded indication for an existing treatment \u2014 will now be offered in more hospitals as a result. The release should have addressed that issue as well as described where the procedure is currently offered.", "answer": 0}, {"article": "Compared to women who received inactive placebo pills, those who took flibanserin at bedtime were more likely to get relief from self-reported sexual distress, to experience more sexual desire, and to have more sexually satisfying experiences.\nHowever, it's not an on-demand treatment.\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\nUpdated reports on data from the North American \"Daisy\" and \"Violet\" studies were made by Krychman and other researchers at this week's annual meeting of the American College of Obstetricians and Gynecologists in San Francisco.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indirectly informs that reader that flibanserin is not available by noting that it is in phase III clinical trials and that the manufacturer\u00a0is seeking FDA approval (despite early direct to consumer marketing campaigns).\u00a0 ", "answer": 1}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nA lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that the highlighted treatment, deep-brain stimulation (DBS) , is a technology used to treat the tremors of Parkinson\u2019s disease, and provides a list of other conditions for which it\u2019s use is being investigated.\u00a0 \nIt would have been best to\u00a0be absolutely clear\u00a0that its use for patients with minimally conscious state is investigational.\u00a0 In the publication describing this case study, the authors state \"\u2026the generalizability of the results is unknown, and expectations raised by this report should be tempered.\" (Nature (2007)448:600-604.\nThe article mentions many conditions for which there does not appear to be FDA approval for the use of this technology.\u00a0 ", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nCWC is an equal opportunity employer and provider.\nFor more industry information, health research and recipe ideas, visit http://www.\nshould contact the CWC offices at (916) 922-5888.\nCo-authors with Dr. Falk are Liana C. Del Gobbo, PhD, Robin Feldman, MBA, Kara Lewis, PhD, and Dariush Mozaffarian, MD, PhD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are widely available so we won\u2019t ding the story for not saying so.", "answer": 2}, {"article": "New vertebral fractures occurred less frequently in the active treatment groups vs placebo: in 0.58 percent (n = 4) of participants in the abaloparatide group; in 0.84 percent (n = 6) of participants in the teriparatide group; and in 4.22 percent (n = 30) of those in the placebo group.\nThe trial was conducted at 28 sites in 10 countries.\n: This study was funded by Radius Health.\n\u201cFurther research is needed to understand the clinical importance of risk difference, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments,\u201d the authors write.\nOverall, there were no differences in serious adverse events between the treatment groups.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make it clear whether the drugs being studied are on the market.", "answer": 0}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nFreedman said that the overall research on antidepressants and hot flashes is still inconsistent.\nSo far, Freedman noted, the only hot-flash treatment that has consistently worked in studies is hormone replacement therapy (HRT).\nIn fact, Freedman said, there\u2019s some evidence that lowering serotonin levels does not worsen hot flashes \u2014 which would be expected if the \u201cserotonin theory\u201d is correct.\nThose findings appear in a separate report in the journal Menopause.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article made it clear that the use of antidepressants to treat hot flashes was off-label use of the drug. \u00a0Even though the article presented results from studies, it is not clear how widespread is the off-label use of antidepressants to treat hot flashes.", "answer": 1}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nOverall, the studies involved nearly a million participants.\n\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\nTea drinkers who drank more than three to four cups of tea per day had about a one-fifth lower risk of diabetes than those who didn\u2019t drink tea.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The availability of coffee and tea is not in question.\u00a0 ", "answer": 2}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nShapiro also advised against making any changes to your medications, including cholesterol-lowering drugs, without talking to your doctor first.\nAlso, she cautioned, when increasing the fiber in your diet, do it slowly.\nArjmandi was to present the findings Tuesday at the Experimental Biology meeting in Washington D.C.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of apples is not in question.", "answer": 2}, {"article": "Doppler ultrasound, done in the third trimester, is an established way to monitor high-risk pregnancies \u2014 those complicated by problems like poor fetal growth or health conditions in the mother, such as high blood pressure and heart and kidney diseases.\nBut there is not yet strong evidence that these women benefit, Alfirevic said.\nAnother question, Alfirevic said, is whether ultrasounds of blood vessels other than the umbilical artery might improve pregnancy outcomes.\nThe review assessed a technology called Doppler ultrasound, which measures blood flow through the umbilical cord.\n\u201cThere is no evidence to suggest that it should be done in low-risk women,\u201d Alfirevic said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story notes that Doppler is an established technique used to monitor high-risk pregnancies.", "answer": 1}, {"article": "Dr. Eric A. Klein, chairman of the Cleveland Clinic Glickman Urological and Kidney Institute, said that the study \"is confirmatory of a lot of other, smaller studies.\nAnti-hormone therapy was developed to treat the pain and other problems of advanced prostate cancer, Albertsen said, and so it was generally used for only three to five years.\nPrevious studies have shown potential dangers related to androgen deprivation therapy in older men, Keating said.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\nHormone deprivation therapy is started, Keating said, when levels of cancer-associated prostate-specific antigen (PSA) increase after surgery or radiation therapy, but there are no other indicators of danger.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story accurately indicates that androgen deprivation therapy is commonly used in men with prostate cancer.", "answer": 1}, {"article": "\u201cOurs is probably a bottom estimate,\u201d Dr. Cahill said.\nBy 2006, just four years after such products were first sold, the proteins were used in about 25 percent of all spinal fusions, the review found.\nDr. Kevin S. Cahill, a neurosurgeon at Brigham and Women\u2019s, who led the study released Tuesday, said he believed the complication rates for the cervical fusion procedures were actually higher than those reported in the study because complications often occurred after a patient left the hospital.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nDr. Richard A. Deyo, a spine expert who is a professor at Oregon Health and Science University in Portland, said the new study also suggested that the F.D.A could do a better job monitoring problems by analyzing hospitals records, just as Dr. Cahill and his colleagues had done.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n \nThe story notes that bone-growth protein infusion received FDA approval in 2002 for use in spinal fusions to treat lower back pain. It reports that by 2006 the proteins were used in about one-quarter of all spinal fusion procedures in the hospitals included in the study, including procedures in other regions of the spine\u00a0\nThe story also states that the use of these proteins in upper spine fusion procedures has dropped following reports of complications.", "answer": 1}, {"article": "If green coffee extract were a medication seeking approval from the Food and Drug Administration, these results would make it a viable candidate \u2014 more than 35% of subjects lost more than 5% of their body weight, and weight loss appeared to be greater while subjects were taking the pills than when they were on the placebo.\nThere were no signs of ill effects on any subjects, Vinson reported Tuesday.\nBut questions remain, experts say.\nIn the meantime, he said, consuming an extract that contains both good and bad chemicals in dense concentration seems an unwise thing to do.\nA larger trial involving 60 people is being planned.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One can infer the availability of the extract from the story.", "answer": 1}, {"article": "The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences.\nThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps.\nBut Boger calls this the \u201ceasy part\u201d of the project, compared with the challenge of designing the molecule in the first place.\n\u201cMaking this molecule is important, even by the current approach, if the failure of antibiotics continues.\u201d\n\nIn addition to Boger, authors of the study, \u201cPeripheral modifications of [\u03a8[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics,\u201d included first author Akinori Okano and Nicholas A. Isley, both of TSRI.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release says that \u201cThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps. But [lead researcher Dale] Boger calls this the \u2018easy part\u2019 of the project, compared with the challenge of designing the molecule in the first place.\u201d Readers could be forgiven for thinking that this modified antibiotic could be in pharmacies by Christmas. But a lot of work remains to be done, in terms of both additional studies on safety and efficacy and (presumably) finding pharmaceutical industry partners who want to help this discovery move beyond the lab bench. We say presumably, because the release doesn\u2019t address either of these hurdles.", "answer": 0}, {"article": "\"What we found was a very coherent pattern of less cervical cancer among people who\u2019ve used the IUD based on thousands of women \u2014 and the pattern wasn't subtle at all, it was stunning,\" Dr. Victoria Cortessis, the study's lead author and associate professor of clinical preventive medicine at the Keck School of Medicine at the University of Southern California, told BuzzFeed Health.\n\nIUDs are small, T-shaped devices that are placed in the uterus to prevent sperm from reaching an egg. They are a highly effective form of birth control and they can offer protection against pregnancy for up to three, five, or ten years.\n\nThe study is the first of its kind to combine and analyze data from multiple studies to look at the issue. \"We went through all of the relevant human epidemiological data on this topic and narrowed it down to 16 high-quality observational studies of over 12,000 women from all over the world,\" Cortessis says.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "IUDs have been available to women for decades. The only issue the story might have considered further is how available they are in low-income nations where vaccines and regular screening are not accessible to many women.", "answer": 1}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story basically used sales information to indicate availability. We did appreciate that this story mentioned a wide variety of nicotine products, including nasal sprays.", "answer": 1}, {"article": "Patients getting canakinumab also suffered significantly more deaths from infections than those on placebo - but, on the positive side, they appeared to be at lower risk of cancer.\nOne leading expert described the benefit as \u201cmodest\u201d.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\nCanakinumab had stirred considerable scientific interest because it appears to finally deliver proof that fighting inflammation offers a promising new way to counter heart disease in patients who already get cholesterol-lowering treatment.\n\u201cWe are not hopeful here.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The lede graph says \u201cNovartis will seek regulatory approval\u201d for the drug\u2019s use against heart disease, \u201cthough some experts fear fatal infection risks and a high price may overshadow the medicine\u2019s limited scientific benefits.\u201d At least for now.", "answer": 1}, {"article": "The meeting is jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research.\nPatients in this clinical trial were left with the bacterial infection for one week, and then everyone was given antibiotics to kill off the Clostridium novyi-NT, Janku said.\nA potentially dangerous bacteria appears to target malignant cells and could provide a new means of fighting cancer, a small, preliminary study reports.\nSUNDAY, Sept. 30, 2018 (HealthDay News) -- It's a perfect case of the enemy of my enemy is my friend.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that researchers are still studying this approach, implying it\u2019s not available widely.", "answer": 1}, {"article": "\"In most cases, a recall doesn't mean you have cancer,\" says Hubbard, a biostatistician at the Group Health Research Institute in Seattle.\nAfter 10 years of annual screening, more than half of women will be called back at least once for another mammogram.\nMeanwhile, the American Cancer Society continues to recommend that women get mammograms every year beginning at age 40.\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\nThe task force says the decision to start regular, biennial mammograms before age 50 should be an individual choice based on each patient's situation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Screening mammography is widely available throughout the United States.", "answer": 2}, {"article": "\"My impression is, even with the newer band, the results are not significantly better,\" he says.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nHis study findings, he tells WebMD, are ''a reality call.\"\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the gastric banding procedure is available and provides a link to information from the National Institutes of Health.", "answer": 1}, {"article": "\"There is no magic bullet,\" Dr. Venditti said.\nThat means lifestyle changes were twice as effective as medicine in delaying or preventing diabetes.\nThe prevalence of diagnosed diabetes has more than doubled in three decades due in large part to an upsurge in obesity, the study states.\nFirst published on October 29, 2009 at 12:00 am\n\nCorrection/Clarification: (Published Oct. 30, 2009) The educational position of Elizabeth M. Venditti was reported incorrectly in this story as originally published Oct. 29, 2009, \"Pitt program to prevent diabetes shows promise.\"\nThat was 10 years ago, when he joined the Diabetes Prevention Program Outcomes Study with the University of Pittsburgh Graduate School of Public Health, one of 27 institutions participating in the research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reporter fails to mention how and where diabetes prevention programs are available.\nLifestyle-modification diabetes prevention programs are a staple offering of hospitals, community centers, insurance companies and corporate wellness programs. The article could at least have mentioned this\u2013and provides a local resource\u2013to allow readers to follow up if they wanted to.\nMany people with high blood sugar but not diabetes take metformin as prevention. It would be useful to know how widely used the treatment is. ", "answer": 0}, {"article": ".\nTUESDAY, Nov. 2, 2010 (HealthDay News) -- MRI images can serve as a \"surrogate clock\" to pinpoint stroke onset in patients whose symptoms began during sleep, increasing the number of patients eligible for highly effective clot-busting therapy, according to a new study.\n\"A tool that can estimate the age of stroke would be of great value in cases of unknown stroke onset time,\" said lead researcher Dr. Catherine Oppenheim, professor of radiology at Universite Paris Descartes in France.\nWith the MRI data, radiologists could predict with more than 90 percent accuracy which patients had experienced stroke symptoms for longer than three hours.\nDr. Wally Ghurabi, emergency department director at Santa Monica-UCLA Medical Center, said a group of ongoing studies there include a similar focus on MRIs and stroke.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have done a better job raising the question of availability of MRI around the US for urgent use at times like those described in the story or in the study \u2013 when there is a question about the 3 hour window. \u00a0The story alluded to this but was not fully discussed in the context of availability of treatment. Do 80% of hospitals or hospital regions have MRIs ready for this use?\u00a0 50%?\u00a0 10%? Availability of the technology in question is a key concern \u2013 with huge cost implications.", "answer": 0}, {"article": "They can go to their grandchild\u2019s wedding and get up and have a dance.\u201d\nEven with a successful implantation, patients should not necessarily expect to have the same ankles they did at 18.\nThe procedure is among the most difficult that foot and ankle surgeons perform, and one of the biggest challenges is getting proper alignment of the replacement joint.\nDr. Deland cited data showing that for some recent models, 90 percent of ankle replacements were still in place after an average of eight and a half years.\nStill, Dr. Deland said, \u201cwe\u2019re getting fewer and fewer failures.\u201d\n\nThe new models require that less bone be removed, so the bone to which the device is affixed is stronger.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story correctly notes that ankle replacement has been available for\u00a0several\u00a0decades but is not\u00a0widely performed.\u00a0 However, there was an omission in not indicating that\u00a0that knee and hip replacement are\u00a0most often associated with osteoarthritis, the most common form of arthritis, while ankle replacement is largely\u00a0performed in patients with post-traumatic osteoarthritis and the much less common rheumatoid arthritis.\u00a0\u00a0 In addition, the article inaccurately states that 4 models are FDA\u00a0approved.\u00a0 A fifth model, the STAR,\u00a0which has\u00a0a unique design, was FDA approved in May 2009.", "answer": 1}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\nWhile the good results in two patients are encouraging, \"in terms of response rates, the overwhelming data is that T cells, even in high numbers, are inadequate to mediate sufficient anti-tumor effects,\" Lotze said.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nResponse by others in the field was positive but not effusive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that for now only 17 patients have undergone the experimental approach as part of an ongoing and novel study and mentions that the researchers have recently applied to the FDA for approval to conduct a clinical trial in several hundred patients. If approval is obtained, then it is possible that patients without other treatment options might be able to participate in the trial. The article did not specifically state that the approach is not widely available yet, but this can be inferred. However it is important for patients to understand that participation in a trial is not the same as receiving treatment. ", "answer": 1}, {"article": "The F.D.A.\ninstead said it wanted more proof that the drug worked and would await results from a trial that was then under way.\nAnd the drug failed to do that by a statistically significant measure.\nJudy Leon, a spokeswoman for the F.D.A., said the agency sympathized with patients but that it was necessary for drugs to meet agency standards for safety and efficacy.\nBased on those results, an advisory panel to the F.D.A., meeting in March 2007, voted 13 to 4 that there was \"substantial evidence\" that the drug worked and 17-0 that the drug was safe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the findings of the clinical trial as \"decisive,\" and speculates the \"widely anticipated results could pave the way\" for the drug\u2019s approval. \nThe result is to imply imminent availability, an outcome that is by no means certain.\u00a0 ", "answer": 0}, {"article": "But when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nA next-generation visor from eSight can improve vision for many legally blind people.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the eSight is cleared by the FDA as a Class I\u00a0device \u2014 something that\u2019s presumably about as safe as dental floss (which is also a Class I device, according to the FDA). The story mentions that most insurance carriers reject compensation, which itself implies the eSight 3 is freely available to anyone as long as they have $10,000.", "answer": 1}, {"article": "Jan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nThe findings are published in TheJournal of the American Medical Association.\nPrevious studies of other antidepressants have yielded mixed results, according to Freeman.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Barley reduced both low-density lipoprotein, or LDL, and non-high-density lipoprotein, or non-HDL, by seven per cent.\nDr. Vuksan said barley can be enjoyed in a variety of ways.\nHe recommends trying to incorporate barley into existing recipes, using it as a substitute for rice or even on its own -- just like oatmeal.\nSt. Michael's Hospital provides compassionate care to all who enter its doors.\nDespite its benefits Dr. Vuksan said barley is not as well-established as some other health-recommended foods -- such as oats.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that barley is everywhere, readily available and ready to add to your food.", "answer": 1}, {"article": "So patients are caught in the middle.\"\nANN ARBOR, Mich. -- It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.\nThe larger ongoing study, based in an abstinence-based treatment facility in Michigan and funded by the National Institute on Drug Abuse, has largely avoided that issue by decreasing the delay between study recruitment and the start of the treatment groups, Ilgen says.\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that researchers have launched a larger, follow-up study of ImPAT, and that ImPAT could potentially be widely adopted. That seems to infer that ImPAT is not currently available outside of the treatment facility where the researchers work. However, it\u2019s not clear whether that\u2019s the case. Are other facilities offering this treatment technique, or something like it? Readers really have no way of knowing.", "answer": 0}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nPatches were provided by the manufacturer, Pfizer.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\nMORE: Is Nicotine a \u2018Gateway\u2019 to Cocaine Addiction (and Cancer)?\nWas the nicotine actually having an effect on memory?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re going to rule this one Not Applicable because \u2013 while availability was not explicitly addressed \u2013 this is a product that\u2019s probably well known to most readers.\u00a0 However, both stories we reviewed could have been more specific about the exact types of patches that were studied and in what doses.", "answer": 2}, {"article": "(\u201cEnjoyed\u201d?\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nSo maybe women who won\u2019t exercise for their own sake will do it for the baby.\nThe research in question involved mice, not women.\nHow does this relate to our own species?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Running as an activity is presumably accessible to\u00a0women.", "answer": 2}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nDoctors used the self-learning computer to detect changes in brain scans too subtle for humans to see.\nThe Alzheimer's algorithm was able to teach itself to recognize patterns in brain scans that indicated disease.\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\nClick for more from The Sun.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this machine-learning technology is not yet available and needs further study.", "answer": 1}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nIf the drug succeeds in a second Phase 3 trial, with results expected by the end of the year, Ironwood plans to file for regulatory approval next year.\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\nAn experimental drug can reduce abdominal pain and increase bowel movements in people with irritable bowel syndrome, a condition that affects millions of Americans, the drug\u2019s developer said Monday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental drug that is not yet approved by the FDA. It notes that the drug will have to succeed in another phase 3 trial before the manufacturer plans to submit an application for approval to the FDA. It doesn\u2019t speculate inappropriately about when the drug is expected to be approved.", "answer": 1}, {"article": "We were pleased to find that two thirds of people in the study were able to tolerate the equivalent of two peanuts per day after nine to 12 months of treatment, and half the patients tolerated the equivalent of four peanuts.\u201d\n\nFDA WARNS AGAINST HONEY PACIFIERS AFTER TEXAS INFANTS HOSPITALIZED WITH 'RARE' ILLNESS\n\nThe results, which were presented Sunday at the College of Allergy, Asthma and Immunology Annual Scientific Meeting and published in the New England Journal of Medicine, were based on study participants ranging in age from 4 to 55 years old.\nWhile the drug is not being hailed as a cure for peanut allergy, it has proven successful in building up patients\u2019 tolerance to peanuts over time, lessening the potential for life-threatening complications.\nThe study\u2019s authors noted that patients would need to stay on the drug in order to receive protection against the allergy.\nThe hope would be to have a treatment available in the second half of 2019.\n\u201cReactions from the oral challenges at the end of the study were much milder than prior to treatment,\u201d Tilles said, according to EurekAlert.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the treatment is not yet FDA-approved, and is not currently commercially available.", "answer": 1}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\nA five-point scale was used to measure the severity of hot flashes, vaginal dryness, urinary symptoms, mood swings, and other symptoms in the postmenopausal women.\nHalf of them received traditional acupuncture treatment.\nLevels of estrogen and other hormones were measured before the study and after the first and last acupuncture sessions in both those receiving real and sham treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No discussion of the availability of acupuncture.\u00a0 Picture a woman who\u2019s just begun experiencing menopause and has never had any reason to think about acupuncture.\u00a0 She reads this story about Turkish research on Chinese acupuncture.\u00a0 Even if she\u2019s interested, she is not given any clue about the availability of the approach in the U.S.", "answer": 0}, {"article": "Hot flashes and night sweats are the most common symptoms of menopause, affecting some 80% of women.\nThe progression is familiar to most women of a certain age.\n\u201cIf you compare this treatment with off-label use of antidepressants or other non-hormonal therapies, it works as well or better,\u201d he says.\nDuring the sessions they received suggestions for mental imagery designed to minimize the intensity of their hot flashes, such as images of a cool place.\nHalf the women were given self-hypnosis training that consisted of five, 45-minute weekly sessions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It wasn\u2019t clear whether a clinician could conduct the self-hypnosis trainings, or whether the patient needed to find another certified professional. And how were the hypnotic recordings obtained?\u00a0 Towards the end, the story does include the comment about finding a qualified hypotherapist. But readers aren\u2019t given any sense of how easy/difficult that might be.", "answer": 0}, {"article": ".\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\nIn this small trial of 79 Iranian women aged 45 to 60 years, soft capsules containing 100 mg of fennel were administered twice daily for eight weeks.\n\"A larger, longer, randomized study is still needed to help determine its long-term benefits and side effect profile.\"\nImprovements were compared between the intervention and placebo groups at four, eight, and 10 weeks, with a significant statistical difference documented.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Not Applicable since most readers will likely be aware that fennel can be purchased and that supplements are available. However, as noted above, it\u2019s not clear at all how 100 mg doses are formulated.", "answer": 2}, {"article": "However, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\nAn early step in the right direction\n\nMcKee also cautioned that this is still early research.\n\"The findings of this study are the early steps toward identifying CTE during life.\nNew research released Tuesday may make that possible.\nWhile it is hoped that this will be one avenue to help detect the disease in the living, McKee believes that it will just be one part of a larger process.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Once readers get past the first couple paragraphs, the story makes clear that this research is far removed from clinical applications.", "answer": 1}, {"article": "Inflammation can make urination difficult.\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\nThe dental school has previously found a link between gum disease and fetal deaths, rheumatoid arthritis and heart disease.\nCase Western Reserve dental researchers Nishant Joshi, Catherine Demko and Robert Skillicorn; and University Hospitals Case Medical Center researchers Donald Bodner, Lee Ponsky, Sanjay Gupta and Gregory T. MacLennan contributed to the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests that dental care should probably be a routine part of efforts to control prostate disease, but doesn\u2019t address the issue of financial barriers\u00a0to such care, particularly for the uninsured. But we\u2019re inclined to overlook this because of the nature of the study: it\u2019s a pilot; it was designed to add to evidence for a relationship between gum and prostate disease via an inflammatory process; and the dental care involved is widely available and commonly provided to those who have regular dental care.", "answer": 1}, {"article": "In the study, four groups of mice received different diets -- two of which were supplemented with green tea or black tea extracts:\n\nAfter four weeks, the weights of the mice that were given green or black tea extracts dropped to the same levels as those of the mice that received the low-fat diet throughout the study.\nBenefits of green tea were already known; new UCLA study shows that polyphenols in both varieties alter gut bacteria\n\nUCLA researchers have demonstrated for the first time that black tea may promote weight loss and other health benefits by changing bacteria in the gut.\n\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\nThe research is published in the European Journal of Nutrition.\n\"Our new findings suggest that black tea, through a specific mechanism through the gut microbiome, may also contribute to good health and weight loss in humans.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Black and green tea are widely available so mentioning that fact is unnecessary.", "answer": 2}, {"article": "And young, healthy patients may not want to bother with creams or gels, which have their maximum effect if applied four times a day.\n\u201cFuture research needs to be done using patients with co-morbidities to know that these agents are safe in the highest-risk population,\u201d said the author of the analysis, Dr. Una Makris, an associate research scientist at the Yale School of Medicine.\n\u201cNow that you can just write a prescription, I use them in my practice a lot more.\u201d\n\nSince the Food and Drug Administration approved the first topical Nsaid in 2007, sales in the United States have soared \u2014 to more than $264 million in 2009, according to IMS Health, a health care research company.\nThe topical painkillers are not for everyone.\nThe American College of Rheumatology is rewriting its guidelines for osteoarthritis management and will include topical Nsaids in the recommendations, said Dr. Altman, who is on the guidelines committee.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n\nThe story reports that only three topical NSAIDs (nonsteroidal anti-inflammatory drugs) are approved for sale with a prescription in the United States, while several brands are sold over the counter in Europe. ", "answer": 1}, {"article": "that its retinal cells contained virtually no residual embryonic stem cells.\nRegeneron and its partner, Bayer, said they planned to apply for approval of the drug in the first half of 2011.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nIt is likely to be several years before such a treatment can reach the market, if it works.\nThe hope is that the implanted cells will replace those injured by the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls VEGF Trap-Eye \u201cexperimental\u201d and says the drug\u2019s developers\u00a0plan to\u00a0apply for approval of the drug in the first half of 2011.", "answer": 1}, {"article": "\"These cells proliferated rapidly, and were susceptible to damage to their DNA - both factors that help them transition towards cancer,\" she said.\nIf confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.\nAustralian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\nThe research team showed that RANK inhibition switched off cell growth in breast tissue from women with a faulty BRCA1 gene and curtailed breast cancer development in laboratory models.\nBy pinpointing the cells that give rise to breast cancers in women who have inherited a faulty version of the BRCA1 gene, Walter and Eliza Hall Institute researchers have identified that the drug denosumab may have potential to prevent breast cancer from developing.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that denosumab is already used to treat other conditions, but that clinical trials are needed to determine whether denosumab should be used to reduce breast cancer risk for women with the BRCA1 mutation.", "answer": 1}, {"article": "Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City, noted that this was a \"huge study that followed women for a long period of time.\nOne serving of blueberries or strawberries equals about one cup.\nWhat does a heart attack look like in women?\nThis held true even among women who ate a diet rich in other fruits and vegetables.\nFind out at the American Heart Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of strawberries and blueberries is not in question.", "answer": 2}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drinks are widely available. ", "answer": 1}, {"article": "Mice that got the drug orally had 40 to 50 percent fewer tumors, while those injected with the drug had 72 percent fewer tumors.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\nThey said metformin prevented lung tumor growth in mice exposed to a cancer-causing agent found in tobacco smoke, and because it is already widely used in people, it may be worth further study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says metformin \"is already widely used in people.\" ", "answer": 1}, {"article": "\"We associated these water dispensers with almost a one percentage point reduction in the likelihood of being overweight for boys and a little over a half a percentage point reduction for girls,\" said lead researcher Brian Elbel, an associate professor of population health and health policy at NYU School of Medicine.\n\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\nIn this study, the findings demonstrate that water access in schools can promote healthy weight outcomes among students,\" Turner and Hager said.\n\"Even a small, straightforward, relatively inexpensive policy intervention was associated with a small but statistically significant drop,\" Elbel told CBS News.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of water dispensers is not in question, which is why we rate this Not Applicable.", "answer": 2}, {"article": "Lowering A1C levels helps reduce the risk of long-term complications from diabetes such as eye, kidney and heart disease.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\n* Average reductions of 0.8 pct seen in levels of A1C\n\nCHICAGO, June 29 (Reuters) - Medtronic Inc\u2019s (MDT.N) insulin pump and monitoring device controlled blood glucose levels better than multiple daily injections in patients with Type 1 diabetes, according to a large post-market study.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe story points out that these results are from a post-market study, thus indicating the device is already available. However, an editorial in the New England Journal of Medicine accompanying the research article made an important point that was not included in the study: devices are not enough, effective glucose management requires effective management\u2026 and the \u201cexpert training and guidance received by patients in clinical trials cannot be readily duplicated in a busy clinical practice.\u201d In other words, the results of this trial may not necessarily be achieved in general clinical practice because while the devices tested are widely available, expert support services are not.\n", "answer": 1}, {"article": "Feb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nBut people with mild strokes are typically denied tPA because the studies that established its effectiveness excluded mild cases, says Pooja Khatri, MD, of the University of Cincinnati.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story isn\u2019t crystal clear on the widespread availability of the drug tPA but it can be inferred from the story.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that cupping treatment is available through acupuncturists, chiropractors and massage therapists.", "answer": 1}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\n\"Replication of these findings in Alzheon's planned Phase 3 study would provide a meaningful therapeutic advance for AD patients with the APOE4/4 genotype, and we are now preparing to carry forward these results into the development of ALZ-801.\"\nBased on the analyses in the publication, Alzheon is developing ALZ-801, an optimized oral prodrug of tramiprosate, and has refined the design of the pivotal clinical trial to evaluate ALZ-801 as a potential disease-modifying agent in symptomatic AD patients who are APOE4/4 homozygotes.\nWe are preparing to advance ALZ-801, a promising new treatment for Alzheimer's disease, into confirmatory clinical studies in 2017.\"\nOur lead Alzheimer's clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity - hallmarks of Alzheimer's disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states the drug is in on-going trials and one can infer the drug is not and will not be available in the foreseeable future. It describes next steps: \u201cWe are preparing to advance ALZ-801, a promising new treatment for Alzheimer\u2019s disease, into confirmatory clinical studies in 2017.\u201d", "answer": 1}, {"article": "Flu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nThe first new flu drug in 20 years won approval Wednesday from the Food and Drug Administration.\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Xofluza has received FDA approval.", "answer": 1}, {"article": "A health claim, in the language of the FDA, characterizes the relationship between a substance and a reduction in the risk of contracting a particular disease.\nNonetheless, the belief that drinking green tea confers health benefits has driven its popularity over the past decade, the Tea Association of the United States has said.\n\"There is no credible evidence to support qualified health claims for green tea or green tea extract and a reduction of a number of risk factors associated with (cardiovascular disease),\" the FDA said on its Web site last week.\nThe Food and Drug Administration said it reviewed 105 articles and other publications submitted as part of the petition but could find no evidence to support claims of the beverage's health benefits.\nIto En Ltd., a Japanese company that bills itself as the world's largest green tea company, and its U.S. subsidiary, Ito En (North America) Inc., petitioned the FDA in June, seeking to make the claim that drinking at least five ounces of green tea a day may reduce the risk of heart disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explained that green tea is made from unfermented tea leaves and mentioned that its popularity had grown over the last decade. ", "answer": 1}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\nSo-called Mediterranean-style diets, with plenty of fresh vegetables and fruit, olive oil instead of saturated fat, whole grains and more fish than meat, ward off these same diseases.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\nMany studies have shown it doesn\u2019t take a whole lot of adjustment to greatly lower the risks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "With some notable exceptions, such as \u201cfood deserts\u201d in areas of high poverty, prudent diets are widely accessible and the article spells this out pretty well.", "answer": 1}, {"article": "Researchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "I'm proof.\"\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\nRelated: Heart Attack Risk With Painkillers Starts Within a Week: Study Says\n\nA personalized approach pioneered by vascular surgeon and lead researcher, Dr. Gustavo Oderich, at the Mayo Clinic in Rochester, Minnesota creates customized stents that are specifically designed for each patient.\nBy using 3-D printing technology, Oderich's team can create an individualized model of the patient's aorta.\nAnd even if the stent does fit, patients often undergo a long, painful recovery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201cSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients. They are now training doctors nationally.\u201d It\u2019s not clear how many doctors are being trained.\nAlso, we\u2019re assuming they\u2019re referring to the 3-D printing aspect of this procedure. But regarding the endoscopic procedure, it\u2019s not clear how widely available it is. It\u2019s also not clear if this custom-printed device is\u00a0still being tested in clinical trials.", "answer": 0}, {"article": "In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\nThis work was supported by the Simon and Beathrice Apple Stem Cell Fund for Eye Research, the David and Janet Polak Foundation Stem Cell Core Laboratory; National Institutes of Health (R01 EY020488), Department of Defense (W81XWH-12-1-0617), Foundation Fighting Blindness and the Knights Templar Eye Foundation Inc.\nNewswise \u2014 LOS ANGELES (EMBARGOED UNTIL 7 A.M. EDT on APRIL 14, 2015) \u2013 An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests, through researcher quotes and other descriptions that this treatment may be just around the corner.\u00a0 That is clearly an exaggeration.\u00a0 The researchers still need more work in animal models.\u00a0\u00a0 Then they will require FDA approval for an investigational drug.\u00a0 If that comes about, then substantial clinical trials in humans will be needed.\u00a0 All told, that could mean\u00a0years of additional wor, before the procedure might be available for people.\nIs that how you would define \u201csoon\u201d or \u201cclose to a time\u201d?", "answer": 0}, {"article": "(That\u2019s a high dose; a 3 oz.\nfor more on that).\nportion of salmon contains anywhere from half a gram to 1g of omega-3.)\nThese are questions Kwong and others hope to answer with more studies.\nIt\u2019s the first encouraging strategy for protecting the heart a heart attack; the more remaining healthy tissue that can be saved, the stronger the heart will be.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people understand that fish oil is available over the counter, so we\u2019ll rate this Satisfactory\u2013though just marginally, because the fish oil prescribed to people in the treatment arm of the study was not standard over-the-counter fish oil pills; see our discussion on\u00a0this in the \u201cDiscuss costs\u201d section\u00a0above.", "answer": 1}, {"article": "Over the last decade, the makers of medical devices have developed techniques that have widened diabetes management options beyond pricking the finger several times a day to test blood glucose levels.\nAlthough the Lancet study was small \u2014 only 17 children completed the entire protocol \u2014 it is significant because it demonstrated that a computer algorithm could safely interpret glucose data and calculate appropriate insulin doses for a pump, he said.\nThe study not only indicated that the algorithm system prevented very low glucose overnight, Dr. Hovorka said, but it also indicated that the experimental system was better able to keep blood glucose in an acceptable range.\n\u201cThe significance is in showing that the existing devices, which are available commercially, can be combined to create the first version of an artificial pancreas,\u201d said Dr. Roman Hovorka, the lead author of the study.\nAfter midnight, about 80 percent of the measured glucose levels fell in a target range in children treated with the computer-adjusted system \u2014 compared to only 35 percent in the target range for those treated with a standard preprogrammed pump system, according to the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Times did a good job of describing the system used in this study and how close it is to being commercially available.\u00a0\u00a0It called the system \"experimental\"\u00a0and said that it was \"not\u00a0fully automated.\" It said that a fully\u00a0automated glucose monitor/insulin\u00a0delivery system was still \"hypothetical\" and would face regulatory hurdles before it could be marketed to the public.", "answer": 1}, {"article": "When Ali Andrew Li was born on Jan. 7, he was gently placed on his mother's chest, where doctors cleaned and examined him and covered him with a warm blanket.\nAnd if mothers or babies are very sick and have to be isolated, Gray suggests mothers take any opportunity to hold their infant skin to skin.\nThere, hospitals with no access to incubators and other equipment often sent home preemies with no expectation that they would live.\nKangaroo mother care has been widely used worldwide to care for premature babies, and it's gaining popularity in caring for healthy full term babies like Ali as well.\nOne of the first places to show how this technique can help preemies was Colombia in the 1990s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We would have liked to see more information, such as how widely this approach is used to treat premature infants, and what some of the barriers might be in high-income countries where incubator care has been the norm. For example, how many U.S. neonatal intensive care units incorporate skin-to-skin contact in their care? Which babies don\u2019t or can\u2019t get this kind of care?\u00a0Given how many births are delivered via c-section these days, is kangaroo care an option for these moms?", "answer": 0}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nImmunochemical FOBT is now largely replacing the older test.\nAnd it\u2019s much cheaper: iFOBT is more expensive than the older stool tests, but it is still roughly $30.\nA newer version called immunochemical FOBT (iFOBT) is supposed to zero in on colon growths better than an older version known as guaiac FOBT \u2014 which often picked up bleeding originating in the upper digestive tract, such as from a stomach ulcer.\n\u201cIt means that almost every case with colon cancer can be identified by iFOBT,\u201d Lee told Reuters Health in an email.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that immunochemical FOBT is now largely replacing the older blood stool test.", "answer": 1}, {"article": "\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\nThe results of the phase III randomized, controlled trial will be presented Saturday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.\nThe study was selected for the society's \"Best of ASCO,\" an effort to condense the research \"most relevant and significant to oncology\" into a two-day program to increase global access to cutting-edge science.\n\"Our findings will change the standard of care for women newly diagnosed with stage IV breast cancer,\" said principal investigator Atilla Soran, M.D., M.P.H., clinical professor of surgery, University of Pittsburgh School of Medicine, and breast surgical oncologist with UPMC CancerCenter.\nThis research was primarily funded by the Turkish Federation of Societies for Breast Diseases.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It should be clear to any audience that these types of basic surgeries are available, and so we are giving this criteria a pass.", "answer": 2}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\n\u201cThis is a clue which can be used in practice by GPs to help them select patients for further investigation \u2026 most excitingly in some patients who may not already have other symptoms of cancer to achieve earlier diagnosis,\u201d said Sarah Bailey, co-author of the research from the University of Exeter.\nRichard Neal, professor of primary care oncology at the University of Leeds who was not involved in the research, welcomed the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "They did mention blood tests being ordered by GP\u2019s making assumptions that it is widely available.", "answer": 2}, {"article": "\"You've got to turn off all the stimulants and also get into a natural sleep cycle.\"\nThe relaxation drink market is tiny compared with the energy drink market, says Garima Goel Lal, a senior analyst at the consumer research firm Mintel.\nJason Healy, the head of InterMark Brands, which markets Snooz'n, says he drinks his product on nights when he is stressed-out or when he is traveling internationally.\nThe number of nonalcoholic beverages making relaxation claims continues to rise; 40 new ones came on the market in 2010, according to Mintel.\nWhen it launches nationally in March, Snooz'n will be available in grocery and convenience stores and pharmacies, like most of these drinks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provided some good information on the regulatory differences between beverages and dietary supplements and how manufacturers who don\u2019t follow the rules can run afoul of the FDA.\u00a0As to the more basic question \u2014 where do I buy this stuff?\u00a0\u2014 the story says the drinks are available\u00a0in grocery and convenience stores and pharmacies.", "answer": 1}, {"article": "The difference?\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\nIt\u2019s an unfortunate thing that that\u2019s out there,\u201d Firouzbakht says, \u201cbecause women also need to know: You don\u2019t have to suffer, you don\u2019t have to have incontinence or vaginal prolapse or hot flashes.\nIt\u2019s a process, but hormone replacement therapy is helping women have a better life in an era when they live longer.\u201d\n\nJohnson, Firouzbakht and other experts will tell you that hormone therapy protects against heart disease, a much more common killer of women than breast cancer, as well as against dementia, colon cancer, osteoporosis and other health issues.\nJohnson, who runs the Institute of Endocrinology and Preventive Medicine in Dallas, says she only trusts the quality-controlled, safety-tested pharmaceutical bio-identical hormones that are made by drug companies and approved by the Food and Drug Administration.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "HRT is available from your doctor, but at the end of the article, there is a statement that Dr Firouzbakht \u201cprescribes pharmaceutical hormones and also works with a pharmacy she trusts to develop bio-identical hormone combinations for some patients. Such custom compounds are not FDA-approved.\u201d The article goes on to state:\n\u201cIt doesn\u2019t matter what formulation of the hormones you are using, it\u2019s the surveillance of it all that is very important,\u201d Firouzbakht says.\nThese statements are confusing about the actual availability of HRT and hormones and dismisses the importance of FDA approval.", "answer": 0}, {"article": "\u201cI used to be so irritable because I was so uncomfortable,\u201d Joyce said.\nAllerdent is not covered by insurance, meaning Joyce spends about $400 every three months but said the cost is worth it.\nThe toothpaste, called Allerdent, works to keep breath fresh and fight cavities while also offering the same benefits as an allergy shot or drops.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nVolunteers using the toothpaste were also required to log their usage in a journal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions the product price tag, the fact that it\u2019s not covered by insurance, and includes a link to the company website that can link readers to a prescribing doctor.\nWhile the promotional aspect of this information in a news story is somewhat troubling, it does satisfy the criterion.", "answer": 1}, {"article": "Researchers at Italy's Institute of Neuroscience injected rats and mice with botulinum neurotoxin A in doses comparable to those used in people.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nOne of the deadliest poisons in nature and a possible bioterrorism agent, this neurotoxin reached the market, in very dilute doses, starting in 1989 as Botox.\nIn a reversal of the usual sequence in science, researchers have discovered, after millions of people have received the drug, something fundamental about how Botox can act.\nThose unapproved uses are another concern of the agency.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that Botox reached the market in 1989. ", "answer": 1}, {"article": "Researchers from the University of Pittsburgh Medical Center and Rutgers University studied 408 males from adolescence to their mid-30s.\nYesterday\u2019s coffee science: It\u2019s good for the brain.\n\"Therefore, continued data collection and longer follow-ups are needed.\"\nBut there were none.\nHere's the scientific proof.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story leads with the \u201cwidespread availability of marijuana in recent years\u201d \u2013 especially \u201cthanks to its legalization in a growing number of states.\u201d", "answer": 1}, {"article": "Hot flashes typically begin in the year or so before menopause and tend to abate in the years afterward.\nThat doesn't surprise Adriane Fugh-Berman, associate professor in the complementary medicine program at Georgetown University School of Medicine.\nThe 2,000-year-old treatment is widely used around the world, according to the National Center for Complementary and Alternative Medicine (NCCAM), part of the National Institutes of Health (NIH).\nThat requirement has hobbled other alternative treatments, including the herb red clover and vitamin E supplements.\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that acupuncture is used worldwide.", "answer": 1}, {"article": "Shoulder movement and strength increased, while pain decreased.\nWith refinements in technique and components in more recent years, the procedure has been used in younger, more active patients.\nThe RTSA technique--using an implant in which the natural locations of the shoulder \"ball and socket\" are reversed--uses other muscles to move the shoulder, providing an alternative when the rotator cuff is severely damaged or destroyed.\nBut there are concerns about how well the results of RTSA will hold up over time in this group of patients.\nThis group of patients typically gets limited benefit from shoulder replacement with conventional implants, which rely on the rotator cuff muscles to provide shoulder movement.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the study is reporting the long-term results of this form of surgery in patients, readers can assume that it is available.\nThe implant is widely available to be used at the surgeon\u2019s discretion.", "answer": 1}, {"article": "Chinese herbal medicine increased IELT by about two minutes, Ayurvedic herbal medicine increased IELT by nearly a minute and topical cream increased IELT by more than eight minutes.\nIn addition, the authors write, the studies are so different, it\u2019s tough to draw conclusions about the different options.\nThe main limitation of the study is the underlying weakness of the studies evaluated.\nIn some instances, a combination of traditional and alternative options was the most effective.\nWhen they were reported, the adverse effects were generally mild, the study team writes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear how available these products are.\u00a0Considering how many products are sold online for this problem, some information on what these products are, and how available they are, would be useful.", "answer": 0}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\nThe Science: For decades, parents looking for an over-the-counter medicine to cure a child\u2019s sickness and coughing have turned to syrupy medicines containing dextromethorphan, a popular cough suppressant found in products like Children\u2019s Dimetapp DM and Robitussin DM.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the standard treatment for colds in kids was the subject of a 2007 ban by the FDA, and that the other standard remedy \u2013 honey \u2013 is a grocery store staple.", "answer": 1}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nWhen the researchers looked at information from a different, more in-depth sleep monitoring system, however, they failed to find significantly better outcomes with the behavioral therapy.\n\u201cThis (therapy) has the effect of compressing your sleep into a more solid block,\u201d Buysse told Reuters Health in an e-mail.\n\u201cMore consolidated sleep is more refreshing.\u201d\n\nBased on questionnaires and sleep diaries, the researchers found that two out of every three participants receiving the behavioral intervention responded favorably by the end of 4 weeks, while just one out of every four receiving the printed material experienced substantial improvement in their sleep.\nAnd the risks may be even more pronounced among older patients, added senior author Timothy Monk, also of the University of Pittsburgh.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story says this form of \u201cbrief behavioral treatment for insomnia is not yet generally available\u201d. It also described this study as being a first step in the process of making such an intervention available without making predictions about a timetable.", "answer": 1}, {"article": "Though these children are larger, they do not have increased rates of obesity,\" Wu added.\nThose whose mothers took the fish oil supplements during pregnancy sustained a higher body mass index (BMI) from the age of 1 to 6 years.\nAccording to Dr. Jill Rabin, co-chief of the division of ambulatory care, Women's Health Programs-PCAP Services at Northwell Health, in New Hyde Park, N.Y., \"In pregnancy and beyond, adequate intake of fish is important for normal human development, and this paper certainly adds to the literature.\"\nThe American Academy of Pediatrics has more on healthy growth.\nThe children were assessed 11 times between birth and the age of 6 years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fish oil supplements are readily available.", "answer": 1}, {"article": "The study was funded by The National Heart, Lung and Blood Institute's Asthma Network (AsthmaNet) and grants from the National Institutes of Health (HL098102, HL098096, HL098075, HL098090, HL098177, HL098098, HL098107, HL098112, HL098103, HL098115, TR001082, TR000439, TR000448, TR000454, K23AI104780, and K24AI106822).\nFurther studies will be necessary to answer those questions.\n(The asthma therapies were given in varying order as part of a concurrent randomized trial, making this, in effect, a \"trial within a trial.\")\nWhile the study was modest in size, it was powered to detect any clinically significant differences, more so than past retrospective studies, Phipatanakul notes.\n\u2022 Use of \"rescue\" medication (albuterol) was essentially the same: 2.8 vs. 3.0 puffs per week.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of acetaminophen and ibuprofen is not in question, since these are well-known, over-the-counter drugs. We rate this one Not Applicable.", "answer": 2}, {"article": "They found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n\u201cThe role of cholesterol in causing heart disease has been disputed by some, but this paper provides yet more evidence of the link, and the benefits of statins to prevent heart disease.\u201d\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\n\u201cOur analysis firmly establishes that controlling LDL over time translates to fewer deaths in this population.\u201d\n\nProfessor Sir Nilesh Samani, medical director at the British Heart Foundation, said: \u201cThis research further demonstrates the benefits of statins for people who have high levels of cholesterol in their blood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are widely available drugs, and the story tacitly implies they\u2019ve been available for about 20 years.", "answer": 1}, {"article": "\"Can't say,\" replies Dendreon COO Hans Bishop.\nThe company estimates 100,000 American men have the kind of hormone-resistant, metastatic cancer the drug is approved to treat.\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nBut, as the study's lead author Dr. Philip Kantoff acknowledges, \"It's not a home run; this is not going to cure prostate cancer.\"\nThe Food and Drug Administration approved Provenge this spring to treat advanced prostate cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear the drug was just approved by the FDA and that \"Dendreon, the Seattle-based company that makes Provenge, says there\u2019s a waiting list for the drug. The company estimates 100,000 American men have the kind of hormone-resistant, metastatic cancer the drug is approved to treat. But the company can only make enough at this point for 2,000 patients in the first year.\"", "answer": 1}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nThe researchers hypothesize that the prebiotics may alter levels of tryptophan, serotonin's amino acid precursor, but it's too early to say.\nThe article, \"Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig,\" is published in Nutritional Neuroscience.\nAnother surprise was a decrease in serotonin in brains of pigs fed the prebiotic.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This published study (but not the release) mentions that infant formula supplemented with prebiotics are currently available.", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides a website link and features one practitioner in the Philadelphia Inquirers\u2019s readership area. Readers will get the hint that there aren\u2019t a lot of front-line gynecologists and urologists offering this therapy, especially since the story explains that\u00a0insurance will not pay for it.", "answer": 1}, {"article": "Using the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\nThe paper is currently available in Chronic Respiratory Disease.\n\"We found that testosterone users had a greater decrease in respiratory hospitalizations compared with non-users.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is pretty obvious that TRT is available to men, so the fact it wasn\u2019t mentioned as available is a moot point.", "answer": 1}, {"article": "Researchers also found that rhabdomyolysis -- the most severe form of the muscle disease associated with statins -- was diagnosed in seven participants given 80 mg of Zocor (simvastatin), compared to none who were given 20 mg of simvastatin.\nTheir doctors should consider prescribing a statin, either at a high dose or using a more powerful statin, he said.\nTwo died within a few weeks of developing the disorder, with one cause of death mentioning the muscle disorder as a contributing factor.\n\"But if you are at risk from those diseases, you would need intensive treatment to lower LDL cholesterol, even if your LDL cholesterol level is not very high,\" he added.\nThe study was supported by a grant from Merck (manufacturer of the simvastatin).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The class of medications, statins, discussed in the story are commercially available as indicated.", "answer": 1}, {"article": "Chemotherapy deals heavy damage to tumors \u2014 but often, the cancer cells are able to regroup and repair themselves.\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nBut the data it presented at the European conference showed that the drug may not actually be more effective than Lynparza, the PARP inhibitor that\u2019s been marketed by AstraZeneca since 2014.\nThe company is now planning trials in lung cancer, and is considering other cancers to pursue.\nAt the European conference this weekend, Tesaro added a few more details to that data:\n\nThe study looked at 553 patients whose cancer responds to a certain type of chemotherapy, known as platinum chemo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As said above, Lynparza is approved and already being used. And the information provided on the other three newer drugs makes clear they are in various stages of clinical trials and not yet on the market.", "answer": 1}, {"article": "\u201cIt\u2019s just not a good operation,\u201d he asserted.\nIn a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\nThe technique is often reserved for \u201csuperobese\u201d patients with a body mass index (BMI) of 50 or higher \u2014 though some surgeons perform it with less severely obese patients too, explained Dr. Torgeir T. Sovik of Oslo University in Norway, the lead researcher on the new study.\nTwo years after surgery, duodenal switch patients had lost more weight: about 50 pounds more, on average.\nIn this study, one-quarter of gastric bypass patients still had a BMI that high two years after surgery \u2014 versus none of the duodenal switch patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that duodenal switch is \u201cless common\u201d and that \u201cDuodenal switch is not a popular procedure.\u201d In a 2008 study, it accounted for just 1 percent of weight-loss, or bariatric, surgeries done in the U.S., and 5 percent in Europe.\u201d", "answer": 1}, {"article": "Journal of Child and Adolescent Psychopharmacology.\n\"Increasingly, patients and families are asking for additional therapeutic options, in addition to traditional medication-based treatments, that have proven effectiveness for improved symptom reduction.\n\"Mindfulness-based therapeutic interventions promote the use of meditative practices to increase present-moment awareness of conscious thoughts, feelings, and body sensations in an effort to manage negative experiences more effectively.\u201d\n\nChildren who are at a high risk for bipolar disorder or other anxiety disorders, such as the participants, often have poor coping skills when confronted by stress, and only a lucky few get help.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\nBut a team of researchers from the University of Cincinnati set out to explore other treatment options that focus more on the mind and less on pharmaceutical solutions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear to readers whether mindfulness-based cognitive therapy for children with anxiety disorders is still in experimental development by a select group of researchers or is widely available. Can local therapists learn this technique?", "answer": 0}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "\"Just absolutely furious.\"\nAs as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.\nPart of the challenge, researchers say, is that many drinkers don't realize that a medicine long used to help people addicted to opioids quit their drug habit can help alcoholics and other heavy drinkers cut back, too.\nBut there's good evidence that the combination of counseling and drugs such as naltrexone can help people cut back on drinking, or move toward abstinence.\nAny health care provider who is licensed to prescribe medicine can prescribe naltrexone \u2014 not just mental health professionals or addiction specialists.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a strong point of the story:\nAny health care provider who is licensed to prescribe medicine can prescribe naltrexone \u2014 not just mental health professionals or addiction specialists. As as long ago as 1997, a published study showed that treatment of alcohol dependence with naltrexone by primary care doctors can be effective; follow-up research has confirmed that the primary care approach not only works, but makes treatment much more accessible.", "answer": 1}, {"article": ".\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\nThis study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals.\nResults of the fecal analysis demonstrated that, after five weeks, dTMS-treated subjects had greatly increased quantities of several beneficial bacterial species with anti-inflammatory properties, such as are found in healthy people.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not discuss the availability of this treatment and the treatment does not appear to be available for obesity at this time. Since dTMS is only approved in the U.S. for treatment of depression, it\u2019s unlikely that it would be available to people without a formal diagnosis of depression.", "answer": 0}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nKnowing more about the genetic mutations of a tumor enables doctors to find a potentially effective drug much more quickly and accurately.\nAs this kind of genetic sequencing of tumors has become faster and cheaper, more patients have access to this technology.\nCalled a basket trial, the study is designed to include people whose tumors have the same kind of genetic fingerprint regardless of where in the body the tumors are found.\nAt some point the drug that is keeping Anselmo's cancer at bay could stop working.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The skin cancer drug this patient received is stated to be available through a clinical trial, at least for GBM. The article also links to NIH-curated information about the drug. But this story is mainly about cancer treatment that is guided by genetic testing of the tumor, and the availability of that testing and related treatment is not satisfactorily established. The story states that the patient\u2019s\u00a0family sent samples of her tumor to several leading cancer hospitals, suggesting that this is not something that would\u2019ve been done as a routine part of her care. But what about patients whose families may not be savvy enough to coordinate this kind of testing? And how much does it cost and would the testing be covered by insurance? This story is going to create interest and demand for such testing, so a few more details about the logistics of having it carried out would have been very useful.", "answer": 0}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\n\"This important study demonstrates that many men with high-risk prostate cancer derive a survival advantage through a multi-modality approach to their disease.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\nThe research was published September 25th in the journal Cancer.\nIt was surprising to see only 29 percent of patients received the recommended combination therapies, and as many as 20 percent are not getting any treatment six months after their diagnosis,\" said Dr. Lu-Yao.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s evident these treatment options are widely available. However, the news release said researchers found many men aren\u2019t getting treatment that\u2019s recommended in medical guidelines.", "answer": 1}, {"article": "Most experts believe that the build up of beta amyloid proteins, which accumulate as plaque, is responsible for Alzheimer's.\nThe researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.\nBecause this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThe studies were funded by Pfizer Inc. and Janssen Alzheimer Immunotherapy.\nThe Alzheimer's Association has more on this condition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The subject of the story is the drug bapineuzumab, which was reported as not yet available to consumers.\nIt would have been useful to include a link to Clinicaltrials.gov so that readers who might be interested could learn about the other trials being conducted.\nhttp://clinicaltrials.gov/ct2/results?term=Bapineuzumab", "answer": 1}, {"article": "Members of one group ate food they normally ate but were instructed to cut their calories by 30 percent, primarily by eating smaller portions, said Dr. Agnes Fl\u00f6el of the University of M\u00fcnster in Germany, a neurologist and one of the researchers.\nA third group made no dietary changes.\nThe other groups showed no significant change.\nThe calorie-restricted group averaged 20 percent improvement in memory performance.\nParticipants were advised by dietitians but monitored their own eating over three months, Dr. Fl\u00f6el said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of caloric restriction is not in question.", "answer": 2}, {"article": "Two studies published Tuesday lend support to controversial new cholesterol guidelines that could vastly increase the number of Americans advised to take cholesterol-lowering drugs called statins.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe editorial was written by Dr. Philip Greenland of Northwestern University, who is also a senior editor of JAMA, and Dr. Michael S. Lauer of the National Heart, Lung and Blood Institute.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that statins are widely prescribed. One in four Americans take them by some estimates.", "answer": 1}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\n\"These are the only treatments approved by the [U.S. Food and Drug Administration],\" he added.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\nNonetheless, for people with moderate to severe restless legs syndrome symptoms, these medications provided important benefits, at least in the short term, Wilt said.\nThe report was published in the March 4 online issue of JAMA Internal Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drugs discussed are all approved by the FDA.", "answer": 1}, {"article": "Still, little is known about its cause.\nA separate analysis of 15 studies found that ever being breastfed compared with never being breastfed was associated with an 11 percent lower risk of childhood leukemia.\nBreast milk is meant to exclusively supply all the nutritional needs of infants and current recommendations include exclusively breastfeeding for the first six months of life to optimize growth, development and health.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\nIn a review of all 18 studies, the authors found breastfeeding for six months or longer was associated with a 19 percent lower risk compared with no breastfeeding or breastfeeding for a shorter period of time.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While it may be assumed that breastfeeding is available to all, this is an oversimplification. Many women have trouble initiating breastfeeding and may have jobs or other limitations that make it difficult to breastfeed. The public can be hostile to breastfeeding women. Some women do not produce enough milk to exclusively breastfeed their babies. Studies have found that while about 75% of women attempt to breastfeed in the first week, only about 30% are still exclusively breastfeeding by three months. Some acknowledgment of the difficulties involved would have provided an opportunity to mention programs and interventions, including postpartum skin-to-skin contact, partner education, lactation consultants, etc, that may improve breastfeeding success.", "answer": 0}, {"article": "Tan said the MRI images showed those with lower levels of omega-3 fatty acids were also more likely to have minute but significant structural changes in the brain.\nDHA has the added benefit of improving mood and reducing symptoms of depression, he said.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nBoth types are thought to be beneficial.\nThe study was published Tuesday in the print edition of the journal Neurology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish and fish oil supplements is not in question.", "answer": 2}, {"article": "A birth-control pill that eliminates women's monthly periods could hit pharmacy shelves later this year, marking the latest effort by a drug company to expand a contraceptive's features beyond preventing pregnancy.\n\nSince \"The Pill\" was introduced nearly a half-century ago, most regimens have mimicked a woman's cycle by having a pill-free week each month when women can have bleeding and other symptoms.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the drug maker has applied to FDA for approval, and expects a response by the end of June. The story also claims that the new birth control pill could be on the market by year\u2019s end. However, there is no independent source cited in support of these claims. The trail of past baseless predictions of FDA approval and market availability is long. ", "answer": 0}, {"article": "European Journal of Gastroenterology & Hepatology, 22, 1402\u20131411.\nThe company is dedicated to developing products to address gastrointestinal issues where there is a high unmet need.\nAn international scientific and medical review team reported that there are a range of agents available to treat IBS and physicians should be knowledgeable about the efficacy and risk profile of any option they are about to prescribe.\nIt is a privately held company based in Boca Raton, Florida, that is also the innovator of FDgard\u00ae for the dietary management of functional dyspepsia.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that IBgard is for sale without a prescription at many pharmacies and other stores.", "answer": 1}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nThere's no evidence drinking in your 20s or 30s has any health benefits.\nThe only possible exception: women over age 65.\nStudies have failed to prove any difference.\nNo health agency or major medical group recommends drinking for health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcohol is not in question.", "answer": 2}, {"article": "AMHERST, Mass.\nDiet was assessed five times over the 20-year study, allowing the researchers to capture within-person variation in changes in food and nutrient intake over times, Boutot explains.\nFor a woman with a 2,000 calorie per day diet, the authors explain, this is equal to three to four servings of such foods as enriched pasta, breakfast cereal, tofu and nuts, or about 32.5 grams a day.\nBoutot and Bertone-Johnson add, \"Though relatively few women in our study consumed very high levels of vegetable protein and our power for analyses of more extreme intake levels was limited, women consuming 9 or more percent of their calories from vegetable protein had a hazard ratio of 0.41 (95 percent confidence interval = 0.19-0.88)\" compared to those eating less than 4 percent.\nBoutot and Bertone-Johnson suggest that more prospective studies of their findings are warranted, including studies that compare soy-based and non-soy vegetable proteins.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability isn\u2019t an issue. Adding vegetable protein to your diet in the modest amounts involved in this study is a fairly easy thing to do. A completely vegetarian diet is more challenging, but that\u2019s not what the study suggests.", "answer": 2}, {"article": "It has also been linked to vulvar, anal and throat cancers.\nWEDNESDAY, Feb. 2, 2011 (HealthDay News) -- A large international trial finds that the Gardasil vaccine shields young men from human papillomavirus (HPV) as well as it protects young women.\n\"This well-designed study reinforces the idea that there is value in vaccinating young men against a virus that is nearly ubiquitous among sexually active individuals.\"\nAccording to a study presented last year by researchers at the University of Maryland, just one-third of teen girls and young women who start the three-dose series actually finish, and almost three-quarters don't start it at all.\nThis study involved more than 4,000 boys and men aged 16-to-26 from 18 different countries who were randomly assigned to get the vaccine or not.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story met this standard by telling us the vaccination is \"approved\" by the FDA, but not \"recommended\" by the CDC advisory board. Some readers will be a bit confused processing that seeming contradiction. \nEven better would be telling us why these two \"expert\" bodies appear to disagree about the widespread benefits to most young men. How about saying: \"While the FDA labeled the vaccine as safe, the CDC\u2019s advisers do not recommend it for routine use.\" Why not? Even better would be a quote from one of those advisors about the why not, and whether this new evidence has the potential to change CDC recommendations.", "answer": 1}, {"article": "WASHINGTON\u2014The Food and Drug Administration questioned the clinical benefit of using GlaxoSmithKline PLC's Avodart to cut the risk of prostate cancer.\n\nAvodart is currently approved to treat benign enlargement of the prostate. The company is seeking FDA approval to market the drug to certain men to reduce the risk of prostate cancer. The drug will be reviewed by an FDA advisory panel on Wednesday along with Merck & Co.'s Proscar, a drug similar to Avodart.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that\u00a0Avodart\u00a0is approved by the FDA for treatment of non-cancerous enlargement of the prostate.\u00a0It also explains that\u00a0Glaxo Smithkline\u00a0is seeking\u00a0new approval to\u00a0market Avodart for the prevention of prostate cancer. The story could have been more clear about the fact that Avodart can\u00a0already be\u00a0prescribed off-label for cancer prevention (even though it is not officially approved for this), and that the FDA approval would\u00a0sanction this\u00a0existing use as well as\u00a0expand it to other clinicians and patients.", "answer": 1}, {"article": "\"We only need to increase concentration beyond levels found in a healthy diet for an effect on prostate cancer cells.\"\nNew research from The University of Texas at Austin identifies several natural compounds found in food, including turmeric, apple peels and red grapes, as key ingredients that could thwart the growth of prostate cancer, the most common cancer afflicting U.S. men.\nThis is a neat solution: blocking the uptake of a nutrient needed by prostate cancer cells with nutrients that are commonly in the human diet.\nDuring the past decade, some cancer research has highlighted the potential therapies found in plants, including chemicals found in foods such as turmeric, apple peels and green tea.\nPublished online this week in Precision Oncology, the new paper uses a novel analytical approach to screen numerous plant-based chemicals instead of testing a single agent as many studies do, discovering specific combinations that shrink prostate cancer tumors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These foods can be obtained at most grocery stores; availability is not a question. The release could have lent more clarity by telling readers whether supplements are available. For example, resveratrol supplements are available and have been extensively studied for diabetes, obesity, and cardiovascular disease.", "answer": 2}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nThe FDA only approved Gardasil in June and already, there is talk of making the $360 vaccine mandatory for the 2 million American girls who enter the sixth grade every year.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\nHe agrees Gardasil is a breakthrough, but says the final decision should be made by the parents.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the FDA only recently approved the vaccine.", "answer": 1}, {"article": "\"They say, 'Oh my God, this has changed my life.\nThe drug, Addyi, or flibanserin , has been on the market since October.\nIn their editorial, Woloshine and Schwartz said Sprout and others put pressure on FDA to approve the drug.\n(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\nSome doctors and patients who've been using Addyi say the drug has been helpful.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug has been on the market since October, 2015.", "answer": 1}, {"article": "Enlarged prostate is characterized by a host of unpleasant symptoms, including weak or slow urine flow, an urgent need to urinate frequently, incomplete bladder emptying and having to get up repeatedly at night to urinate.\nAnd while this study showed some symptomatic improvement, it didn't have enough objective data to show that the new technique would surpass surgery, she said.\n\"PAE is potentially fraught with complications,\" Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\nCurrent surgical procedures typically require no more than one night in the hospital and complications such as incontinence and impotence are uncommon, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story allowed the lead researcher to boast that prostatic artery emoblization was \u2018ready to be used in certain patients\u2019.\u00a0 But then it quickly countered that with \u201cbut other experts aren\u2019t so sure.\u201d\nThe story could have stated much more emphatically that it is a stretch to think that PAE would be utilized in this new population on the basis of a single, small scale study, presented as an oral presentation at a meeting. \u00a0Given that the procedure is still experimental at this point, it is unlikely to be widely available.\nAnd although the story noted that few physicians are \u2018trained to perform the procedure\u2019 it should have been explicit that this is currently not an option for most men.\nNonetheless, we\u2019ll give the story a BARELY satisfactory on this criterion.", "answer": 1}, {"article": "SpermCheck, which is approved by the U.S. Food and Drug Administration, assesses sperm count with 98% accuracy in 10 minutes and does away with the unpleasantness of conjuring up a sperm sample in a doctor\u2019s office.\nHard to believe.\nMORE: How Better Habits Can Make Your Day\nWhy should women bear the brunt of infertility testing?\n\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The entire story is based on the pending \u201cdebut\u201d of the test.\n\u00a0", "answer": 1}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nOur Knowledge Center article on the health benefits of avocado reveals some of the other ways the food may be good for us, as well as the potential risks of avocado consumption.\nIt should be noted that this research was supported by the Hass Avocado Board, but the researchers say the organization played no other role in the study.\nAvocados, however, can also be eaten with salads, vegetables, sandwiches, lean protein foods (like chicken or fish) or even whole.\"\nStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does note that avocados are available but somewhat expensive at certain times of the year. We\u2019ll call this satisfactory, although the story could have noted that some areas may lack access to more exotic fresh produce such as avocados.\n\u00a0", "answer": 1}, {"article": "\"In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion.\nLarotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nBriana enrolled in the phase 1 clinical trial of larotrectinib and began taking the drug twice a day.\nDr. Laetsch will be the national leader for that clinical trial in children.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make it clear that the drug is not yet available in the US beyond clinical trials.\nThe company recently completed its application for fast track approval from the FDA but it is not yet approved.", "answer": 0}, {"article": "Vericel shares were down $2.01, or 33 percent, at $4.02 on Nasdaq.\n\u201cFor patients, this is a really hopeful thing.\u201d\n\nHenry, who presented the data at the ACC meeting, stressed the need for larger trials to prove the benefit of ixmyelocel-T\n\nFor the treatment, bone marrow is taken from the patient and enhanced over two weeks to increase two types of cells associated with healing.\nHowever, the treatment failed to improve secondary goals of the trial, such as heart-pumping efficiency and six-minute walking distance, and Vericel shares fell more than 31 percent by afternoon trading on Monday.\n\u201cThis is strong evidence in a well-designed trial that we can decrease events,\u201d said Dr. Timothy Henry, the study\u2019s lead investigator and chief of cardiology at Cedars Sinai Heart Institute in Los Angeles.\n\u201cPeople were looking for downside and they had one.\u201d\n\nThe data compared Vericel\u2019s bone marrow-derived ixmyelocel-T stem cells with placebo in 109 well-treated patients with advanced heart failure who had exhausted medical and device therapies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The doctor and lead investigator who was interviewed in the story noted the need for larger trials, meaning this therapy is nowhere close to being available to the general public. Although the audience is aware this is early testing, it would have been helpful to know how the study will address the limitations of failing to meet the secondary goals, such as the walk test and heart pumping efficiency.", "answer": 1}, {"article": "\u2022 In the randomized controlled trial, 38 men with abdominal obesity followed a dietary pattern high in either carbohydrates (53 % of total energy, in line with typical official recommendations) or fat (71 % of total energy, of which about half was saturated).\nThe researchers found strikingly similar health effects of diets based on either lowly processed carbohydrates or fats.\nSaturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\n\"But the alleged health risks of eating good-quality fats have been greatly exaggerated.\n\"The fat sources were also lowly processed, mainly butter, cream and cold-pressed oils.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both high-carbohydrate and high-fat foods are widely available.", "answer": 2}, {"article": "So, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nOnce on either of the medications, people fared equally well.\nWhat was important, Lee said, was for opioid addicts as well as treatment providers to understand that addiction isn't one-size-fits-all.\nWhat is key, said Dr. Miriam Komaromy, is meeting a patient where they are and understanding what best meets their needs.\nWithout the opioids, people can go into withdrawal, all contributing to a cycle of dependency.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All three drugs mentioned in the story are available, though more could have been said about how accessible they are to people who are trying to overcome addiction.", "answer": 1}, {"article": "African-American women are more likely than white women to report hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nLexapro seemed to work even among women who were not anxious or depressed.\nThe hot flashes increased after the women stopped taking the drug but not among those taking a placebo.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not comment on the availability of Lexapro to treat hot flashes. Although many readers may be aware that\u00a0this drug is approved to treat depression and may therefore be\u00a0used to treat other conditions off-label, the story\u00a0should have spelled this out as the competing WebMD coverage did. \u00a0", "answer": 0}, {"article": "The caveat is that VX-770 is designed to counter one specific genetic mutation that accounts for about 4 percent of cases of cystic fibrosis.\nmay have a profound effect on the disease.\u2019\u2019\nMany do not live past age 40.\nShe said other results of the trial were encouraging.\nThe drug also reduced the frequency of disease exacerbations that required treatment with antibiotics.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAlso, there was no difference in deaths from clots blocking blood vessels in either group, a potential safety concern for the medicine.\nAnd the result is a life saved.\nThat means 66 people would have to get tranexamic acid to prevent one death.\nThe drug is used to reduce bleeding during surgery and is also approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that TXA is a 25-year-old medicine that is approved in the U.S. to prevent bleeding in hemophiliacs who have teeth pulled.", "answer": 1}, {"article": "CHICAGO (Reuters) - Pathway Genomics, a company known for pushing the boundaries of direct-to-consumer genetic testing, on Thursday will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.\nThe cost to consumers begins at $299 to periodically check for DNA in their blood that could act as an early warning sign of cancer.\nSeveral oncology experts said liquid biopsy tests like Pathway\u2019s, while exciting, still require large clinical studies proving they help people beat cancer through early detection.\nRoche-backed Foundation Medicine Inc, Genomic Health Inc, Illumina Inc and Sequenom Inc say they have similar tests in the works.\nPathway\u2019s screening test looks at 96 genetic markers associated with major cancer types such as breast, ovarian, lung, colon and melanoma.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that \u201cThe tests must be ordered by a doctor, based on a patient\u2019s risk profile.\u201d However, it\u2019s not clear that this fully describes the process. While the tests can be ordered through the patient\u2019s physician, the Pathway website also suggests that patients can order them autonomously online through Pathway\u2019s \u201conline physician network.\u201d Here\u2019s the text:\nPatients can also order CancerIntercept\u2122 Detect online through Pathway Genomics\u2019 online physician network.\u00a0After speaking with a client services representative, the patient must create a personal account with Pathway\u00a0Genomics Member Site (members.pathway.com) and enter all personal health information into the website for\u00a0physician review. It will take up to 1-2 business days for physician review, at which time a sample collection kit\u00a0will be sent to the patient\u2019s provided shipping address if the test is approved.\nThis process seems essentially to be a direct consumer purchase with the involvement of an online physician middleman \u2014 something which is not fully conveyed by the text. We\u2019ll give the benefit of the doubt since it\u2019s debatable whether the story is technically wrong on this point or not. But we wish more detail had been provided.", "answer": 1}, {"article": "Dupuytren's disease is a common condition of the hand that affects 4% of the UK population and causes the fingers to curl irreversibly into the palm.\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nIn conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.\n\"This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years\".\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s noted that this treatment approach is in phase IIa trial; that is, preliminary evaluation of short-term safety and efficacy.\nHowever, the language used in the release: \u201cThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection\u201d\u00a0suggests this drug (which is commercially available for other conditions) could be used to stop the growth of disease causing myofibroblast cells. A simple statement in the release noting the preliminary nature of the research would have gone a long way into placing the the drug\u2019s availability into proper perspective.", "answer": 1}, {"article": "Doctors often recommend a \"watch and wait\" period for men with low-grade, or less aggressive, prostate tumors.\nHowever, the study was small, and results from a larger trial aren't expected for several years, he added.\nThe findings also need to be replicated in a much larger number of patients, D'Amico said.\nThe study results were scheduled for presentation Monday at the annual meeting of the American Chemical Society in Denver.\nD'Amico stressed that men should not start taking vitamin D supplements in hopes of slowing or curing prostate cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin D is ubiquitous in stores, food and sun exposure, and that fact was made clear.", "answer": 1}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nP-Cure\u2019s first product was cleared by the FDA in 2010.\nBecause of the high capital costs, proton therapy is currently only available to less than one percent of patients who could potentially benefit from it.\nThe P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment planning, positioning and treatment delivery for cancer patients in a seated position.\nP-Cure (P-Cure, Ltd.), a leading provider of Patient-Centric solutions for proton therapy, has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that this therapy has just been cleared and that proton therapy is currently not widely available.", "answer": 1}, {"article": "First published on June 22, 2006 at 12:00 am\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nBut it is also used by athletes seeking to enhance their performance and prescribed by anti-aging clinics.\nCompared to placebo, the medication stimulated growth hormone secretion and was associated with an increase in lean muscle mass, improved balance as demonstrated by heel-to-toe walking, and a better ability to climb stairs.\nA tablet that stimulates the production of growth hormone may help older adults improve their physical functioning and lower their body fat percentage, a researcher said yesterday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that growth hormone to counteract the effects of aging is controversial and it is not FDA approved for this use. However, the story also subtly suggests it is available for non-approved use. \u201cAnti-aging\u201d clinics may administer growth hormone, but federal law states that distributing or administering human growth hormone for age-related health problems or for cosmetic use is illegal. Growth hormone is currently only approved for adults with Growth Hormone Deficiency (GHD) and for children with pituitary disorders. The American Association of Clinical Endocrinologists does not recommend growth hormone to prevent age-related muscle loss in otherwise healthy adults, due to a lack of information on long-term safety: http://www.aace.com/pub/pdf/guidelines/hgh.pdf ", "answer": 0}, {"article": "\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nThe new drug, called T-DM1, combines Herceptin with a potent chemotherapy drug.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nIn another 12%, tumors stopped growing for at least six months.\nTumors shrank in one-third of women with metastatic breast cancer given T-DM1, says Ian Krop, MD, of the Dana-Farber Cancer Institute in Boston.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "By not mentioning that this was a Phase II trial \u2014 an early stage, uncontrolled, non-randomized study \u2014 and that the compound is still investigational, the\u00a0article is unclear about T-DM1\u2019s development status and prospects for becoming available in the future.\u00a0In addition, some of the results are preliminary, or \"immature\" according to\u00a0Genentech press release, with final results to be presented at a future meeting. The fact that these are early data is also not mentioned.\nThe article does mention that other studies of T-DM1 are ongoing and are comparing T-DM1 to other treatments. However, the key explanation is missing that the other ongoing trial is Phase III, and comparisons of T-DM1 to other treatments is the key to its FDA approval for use in patients.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is clear from the statement that nevirapine \u201chas become a mainstay in the effort to prevent mother-to-child HIV transmission in poor countries\u201d. ", "answer": 1}, {"article": "Disease-free survival and overall survival three years after treatment were 48.3% and 55.8%, respectively.\nThis type of radiation therapy has not yet been approved by the FDA as a lung cancer treatment, but this study brings it one step closer.\nThree years after the treatment, the study showed that 28 participants had a complete response to the therapy and 21 had a partial response.\nIn the study, researchers evaluated the safety and effectiveness of SBRT in treating 55 people with early-stage but medically inoperable lung cancer.\nMore than half of patients ultimately die specifically from progressive lung cancer with observation, and 2-year survival is less than 40 percent with either approach,\" write researcher Robert Timmerman, MD, of the University of Texas Southwestern Medical Center, Dallas, and colleagues in the Journal of the American Medical Association.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that SBRT is not FDA approved and is still \"experimental\" and in clinical trials. The story could have provided some information on how someone with inoperable lung tumors\u00a0could get access to the clinical trial. ", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nIdeS is still experimental, and the only way patients could receive it is through a clinical trial.\nThose patients were all successfully treated with standard anti-rejection drugs, according to the researchers.\nLead researcher Dr. Stanley Jordan agreed that more work is necessary.\nBut the findings mark another step forward for patients like these, according to Jordan, who is medical director of the kidney transplant program at Cedars-Sinai, in Los Angeles.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the only way for patients to receive the experimental therapy at present is through a clinical trial, although it does not say where such trials are taking place or recruiting patients.", "answer": 1}, {"article": "For weeks 21 through 52 of the study, 27 percent of the people who had previously taken the drug successfully avoided smoking, compared with less than 10 percent of those who received the placebo.\nThis held true even after treatment stopped.\nThe U.S. Food and Drug Administration placed a black box warning - its most severe and restrictive warning - on the product in 2009, highlighting the drug\u2019s adverse neuropsychological effects.\nBut even though the approach helped some hard-to-reach smokers, the majority of them still failed to quit, noted Lerman, who wasn\u2019t involved in the study.\n\u201cIt offers compelling evidence that gradual reduction should be considered to facilitate quitting,\u201d she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that Chantix is already available in the U.S. and elsewhere.", "answer": 1}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nNow here are the five food groups it says you should avoid to reduce your risk of developing dementia...\n\nYou already know they're not so good for your waistline, and it turns out pastries and other sweets could have a negative effect on brain health as well.\nBut even if you slip up on the diet from time to time, the researchers say it can still have benefits.\nNow there's growing evidence that the same is true for your brain.\nEven \"modest adherence\" to the MIND diet measurably reduced a person's chances of developing Alzheimer's disease, and the longer you stick with it, the greater the benefits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Certainly all of the components of the MIND diet are available in most supermarkets.\u00a0 While there might be a problem in areas where supermarkets are scarce, overall the diet\u2019s foods are available. This would have been easy to mention in the story. Since the story did not touch on availability, however, we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\u201cIt started out so innocent,\u201d his mother, Betty Vertin, told Newsweek.\nUntil then, Betty and her sons are living with a lot of uncertainty.\nFor that, Betty credits ataluren, which Max started three years ago.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nInstead of having an error in the protein, the protein is accidentally cut short.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A main point of narrative tension in the story is the family\u2019s wait to see if the FDA will approve the drug. So it is clear that the drug is not yet available.", "answer": 1}, {"article": "Dr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\nThe trial is still ongoing, so results are not available yet.\nResearchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.\nProfessor Tony Barrett, from the Department of Chemistry, said: \"This work is the result of extensive collaboration between chemists, biologists and clinicians, which has helped to bring a new treatment from discovery to clinical testing in record time, streamlining the process.\"\nFrom early attempts, a large collaborative team was eventually founded for drug discovery from 'bench to bedside', directed by Dr Matthew Fuchter in the Department of Chemistry.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We applaud the news release for stating in the second paragraph that the \u201cdrug may not become available to patients for a number of years yet.\u201d Of course, the \u201cyet\u201d is optimistic; it remains to be seen whether this will ever become available.", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Glaxo expects to submit the vaccine for FDA approval in the future. ", "answer": 1}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nDr. Cohen, Professor of Internal Medicine and with the McDermott Center, holds the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.\nTwo of these drugs, in a category known as PCSK9 inhibitors, were approved by the Food and Drug Administration last summer for use by some individuals with extremely high cholesterol levels.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drugs have been approved by the FDA, and that at least one of them was available to the patient described in the release. The reader can infer that the drugs are available to the public.", "answer": 1}, {"article": "\"By actually (measuring) the brain network activity directly, you can look at really what is the functional health of the brain,\" he said.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\nThe study was funded in part by Quadrant Biosciences, a biotech company that hopes to bring a saliva test for concussion to market in the next 12 to 24 months, Hicks said.\n\"It's frustrating for both parents and physicians that we can't accurately and objectively predict how long a child's concussion symptoms might last, what those symptoms are likely to consist of and when it might be safe for them to return to sports or school,\" said Hicks, who, as a practicing pediatrician, has routinely cared for kids with concussions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes the lead author of the saliva test study as saying that many hospitals and clinics already use the technology that would be needed to assess microRNAs in saliva. This implies that the saliva test could be readily available to patients if further research confirmed the association between specific microRNAs and prolonged concussion symptoms. The story does not provide any specific discussion of how long it could take or how much further study would be needed before the saliva test would be available for use. However, the story does communicate that the saliva test is not yet available.", "answer": 1}, {"article": "The hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\nIt is effective for up to five days after unprotected sex.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that EllaOne is available for emergency contraception only in Europe but is being considered for approval in the US.", "answer": 1}, {"article": "...\nThe U.S. Food and Drug Administration has not approved pharmacologic treatments for BED, according to background information in the study.\nThis study was supported by Shire Development, LLC, including funding to Scientific Communications & Information and Complete Healthcare Communications, Inc., for support in writing and editing the manuscript.\nThe medication was administered in dosages of 30, 50 or 70 mg/day or placebo.\nThe one-week BE episode response status was improved in the 50- and 70-mg/d treatment groups, and a greater proportion of participants achieved four-week cessation of BE episodes and global improvement of symptom severity with all lisdexamfetamine dosages.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release\u00a0clearly indicates that the drug is already approved to treat other medical problems. It also indicates that the next step in making the drug available for the need at hand rests on \u201cconfirmation of these findings\u201d in additional clinical trials. This release was issued in January 2015, and the drug has subsequently been approved for the treatment of binge-eating disorder.", "answer": 1}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nBut more research is needed before the drink could be made available to the public.\nWhether Souvenaid will slow the progression of Alzheimer's isn't known.\nAn ongoing study will evaluate the product over two years.\nThere is, however, a longer trial going on that might answer that question, Wurtman said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The fact that there were no plans yet to market the product was explained.", "answer": 1}, {"article": "But from other research \"we know it's safe to place an electrode in the nucleus accumbens, it's safe to stimulate it electrically, and we expect to be able to tune [the electrode] as we already do with DBS.\nThe current study used a brain stimulation device already approved for hard-to-treat epilepsy.\nWhether this strategy could block harmful impulses in people remains unclear.\nHe thinks the approach could also work for eating disorders and a range of other addictive or potentially life-threatening urges.\nAnother study published Monday in PNAS suggests that DBS could help boost memory and other research is exploring its use for substance abuse and other reward-seeking behaviors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that this is very early research and that the treatment is not clinically available for behavioral problems.", "answer": 1}, {"article": "Nov. 24, 2016.\n\u201cWith standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.\nBut new research indicates that such patients, paradoxically, may live longer if they receive a milder chemotherapy drug.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\nThe results of the current trial, he said, point to the inevitable need to replace large cancer clinical trials evaluating homogeneous drug treatments with smaller trials that involve subgroups of patients, with treatments targeted to their specific mutations.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that decitabine is an existing FDA-approved drug. However, its off-label use in this trial does not mean that it is now available for other AML patients. The researchers note repeatedly that larger trials are required.", "answer": 1}, {"article": "Studies have found that runners have significantly higher injury rates than walkers (one study found that young men who run or jog had a 25 percent higher risk of injuries than walkers), and that ultramarathoners are at an even greater risk.\nSo the answer to the running versus walking question will probably vary from person to person.\nInterestingly, it seems you can walk pretty much endlessly without any increased risk of hurting yourself.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\nI wanted to see what the highest-quality evidence \u2014 trials and reviews are the gold standard \u2014 said about the relative risks and benefits of these two forms of exercise.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it\u2019s certainly true that some people in the United States\u00a0might have a harder time finding space places to run or walk, it\u2019s reasonable to argue that both activities are available to most everyone.", "answer": 2}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\n\"This innovation has the potential to provide many people with an improved quality of life,\" Jeffrey Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health, says in the news release.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The focus of the story was on FDA approval of the device. ", "answer": 1}, {"article": "Nov. 14, 2011 -- The first use of heart stem cells in humans looks like a major breakthrough for people suffering heart failure after heart attacks.\nIt is stories like that that makes these results really encouraging.\"\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\n\"The reported benefits are of an unexpected magnitude,\" writes Gerd Heusch, MD, PhD, chair of the Institute of Pathophysiology at the University of Essen, Germany, in an editorial in the Nov. 14 online issue of The Lancet.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that these findings are from a small study early in the development of a stem cell therapy and that the treatment is not going to be available in the near term. It says that a \u201clarger, phase II study is planned.\u201d More important, it clearly states \u201cthe experimental treatment simply will not be available to other patients in the near future.\u201d ", "answer": 1}, {"article": "With this information in hand, the researchers took the next step.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nHER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release didn\u2019t make it clear that more research is needed following the phase 2 trial. The release could have mentioned that neratinib has already been approved by the FDA for women with early-stage HER2+ breast cancers as a follow-on therapy.", "answer": 0}, {"article": "\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\nThe study is published in Drug and Alcohol Dependence.\n\"They still drank, but they drank less.\"\nIt is one of the substances known as isoflavones found in kudzu.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the story had been clearer about the difference between the standardized kudzu extract that was tested in the study, which apparently is not yet approved for sale, and the other kudzu supplements that are widely available. Why is it ok to sell some kudzu root preparations as dietary supplements, while other extracts need approval from the FDA as though they were drugs? The story never tells us.\nThis confusion notwithstanding, the info needed to fulfill the criterion was presented in the article for those willing to puzzle it out, so we\u2019ll award a grudging satisfactory.", "answer": 1}, {"article": "Diet has been extensively studied as a modifiable risk factor in the development of breast cancer but epidemiologic evidence on the effect of specific dietary factors is inconsistent.\n\"The results of the PREDIMED trial suggest a beneficial effect of a MeDiet [Mediterranean diet] supplemented with EVOO in the primary prevention of breast cancer.\nWe hope to see more emphasis on Mediterranean diet to reduce cancer and cardiovascular disease and improve health and well-being.\"\nNevertheless, these results need confirmation by long-term studies with a higher number of incident cases,\" the authors conclude.\nThe study was conducted within the framework of the large PREDIMED (Prevenci\u00f3n con Dieta Mediterr\u00e1nea) trial, which was designed to test the effects of the Mediterranean diet on the primary prevention of cardiovascular disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that the foods in the Mediterranean diet are widely available. However, it might be harder to find certain component foods like fish, fresh fruits and vegetables, and extra virgin olive oil in some places in the U.S. (i.e. \u201cfood deserts\u201d). The release could have acknowledged this.", "answer": 1}, {"article": "Colic occurs during the first three months of an infant's life in which an otherwise healthy child cries and cannot be comforted for three hours or more every day.\nAll the infants were diagnosed with colic, born full-term at a healthy gestational weight, had no history of gastrointestinal disorders, were breastfed, not formula fed, and did not receive any other probiotic supplements during the week prior to the study.\nTo test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nResearchers from the University of Turin, Italy, found that a few daily drops of Lactobacillus reuteri, a bacterium that can help improve digestion, significantly reduced crying among infants with colic.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not enough information here. The probiotic tested in this study is actually a commercially available product distributed by the study\u2019s sponsor, BioGaia\u2013information which was never provided to readers.\u00a0(More on this later under the \"Sources\" criterion below.) Moreover, the story\u00a0attributed the benefits\u00a0observed in the study to\u00a0the Lactobacillus reuteri\u00a0species of probiotic; it should have pointed\u00a0out\u00a0that the researchers\u00a0tested a specific commercial strain of\u00a0L. reuteri\u00a0known as\u00a0Lactobacillus\u00a0reuteri DSM 17 938. Different strains of the same probiotic are known to produce widely varying effects, so the\u00a0reduction in crying\u00a0observed in the study might not be seen with other strains of L. reuteri. \u00a0\u00a0\u00a0\u00a0", "answer": 0}, {"article": "The vegetarian diet consisted of vegetables, grains, legumes, fruits and nuts, with animal products limited to a maximum of one portion of low-fat yoghurt per day; the conventional diabetic diet followed the official recommendations of the European Association for the Study of Diabetes (EASD).\nLosing muscle fat improves glucose and lipid metabolism so this finding is particularly important for people with metabolic syndrome and type 2 diabetes, says lead author, Dr. Hana Kahleov\u00e1, Director of Clinical Research at the Physicians Committee for Responsible Medicine in Washington DC.\nHowever, we also showed that a vegetarian diet is much more effective at reducing muscle fat, thus improving metabolism.\nDr. Kahleov\u00e1 said: \"Vegetarian diets proved to be the most effective diets for weight loss.\nUsing magnetic resonance imaging, Dr. Kahleov\u00e1 and colleagues then studied adipose (fat-storage) tissue in the subjects' thighs to see how the two different diets had affected subcutaneous, subfascial and intramuscular fat (that is, fat under the skin, on the surface of muscles and inside muscles).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes no statement about availability, but it seems at first blush that the\u00a0diet would be readily available. Then again, perhaps that\u2019s not the case since people who eat a conventional diet containing a lot of processed foods are very likely to turn to processed foods for their vegan or vegetarian meals, as well. Prepared vegetarian foods might be hard to find and expensive, not to mention not very tasty to everyone. To help clarify, the release could have pointed to resources that would help readers eat like participants in the study.", "answer": 2}, {"article": "Knee replacements were first offered in the 1960s, and hip replacements began in the 1940s, so many boomers are facing the same surgeries their fathers and mothers underwent.\n\u201cThe baby boomer explosion is a big deal in health care,\u201d said ConforMIS chief executive Mark Augusti.\nNadworny, who now works as a public policy advocate for people with disabilities, had knee replacement surgery last April.\nBut he has already resumed golfing \u2014 on a March trip to visit his son and his family in Atlanta.\nSome took multiple cortisone shots, hoping to avoid surgeries.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that knee replacements are widely available and covered by insurers.", "answer": 1}, {"article": "Among 46 chronic pain sufferers, those who spent time each day in a sauna for four weeks enjoyed a 54% improvement in sleep quality and were 27% more likely to return to work compared to a no-sauna group.\nBut if you\u2019re wondering whether an infrared sauna is worth a try, the evidence suggests you have little to lose and possibly something to gain by checking one out.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\nAnd, for now, there don\u2019t seem to be any significant health risks.\nBeever makes it clear all of these reports were based on small groups and require further study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Saunas\u00a0can be found in many health gyms\u2013but what about infrared saunas, which is the focus of the piece? We\u2019re not told.", "answer": 0}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nThe boy is currently on chemotherapy, the study authors noted.\nIn fact, the experiment was largely successful, with cells now able to produce WAS protein, resulting in increased platelet counts and improvement of some immune-system cells.\nNeither Conley nor Sanberg were involved in the study, which is scheduled to be presented Sunday at the annual meeting of the American Society of Hematology in Orlando, Fla.\nSUNDAY, Dec. 5, 2010 (HealthDay News) -- Using gene therapy, German researchers report that they managed to \"correct\" a malfunctioning gene responsible for Wiskott-Aldrich syndrome, a rare but devastating childhood disorder that leads to prolonged bleeding from even minor hits or scrapes, and also leaves these children vulnerable to certain cancers and dangerous infections.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never explicitly addresses the availability of this new technique or how close it may be to approval. However, it does\u00a0note that the research represents just\u00a0a \u201cfirst step\u201d and \u201cproof of concept\u201d for the new approach. Although we would like to have seen\u00a0a more direct comment about the many years of testing that lie ahead for any therapy based on this technique, we think most readers\u00a0will understand that this is preliminary research and not something they\u2019re likely to have access to anytime soon.", "answer": 1}, {"article": "Gregg Gordon, 44, developed leukemia in 2011.\nEverybody now has a donor, and that is a major advance.\u201d\n\nYet doctors and patients may not be aware there are choices other than conventional bone-marrow transplants, Jones said.\nQuinn, who has a science background, knew that finding a donor would be difficult.\nIt\u2019s an indescribable feeling.\u201d\n\nIn haploidential transplants, rather than wiping out the patient\u2019s immune system, doctors use just enough drugs to suppress it.\nUmbilical-cord stem cells, however, are sort of a blank slate because they haven\u2019t been exposed to much life \u2014 such as bacteria and viruses \u2014 and thus are more easily accepted even if they aren\u2019t a perfect match.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make it clear how frequently these treatments are performed or how widespread they are. Does one have to travel to Seattle to have this treatment? It\u2019s unclear.", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\nCanfield worked closely with Halas and Nanospectra Biosciences, the company where the shells are licensed, to incorporate the state-of-the-art technology into the trial that is also underway at the Icahn School of Medicine at Mount Sinai and the University of Michigan to test the efficacy of the therapy.\nThis procedure is the first in the world that is precise enough to potentially avoid negative ramifications like urinary incontinence or sexual impotency.\n\u201cIn fact, the first patient in the trial was actually riding a bike within a week of his treatment.\nIt is the first trial of its kind in the world.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gives the sense that this new technique is very experimental, and being done inside the bounds of a trial, but that is never made very clear. The trial will enroll only 45 patients and the follow up (a repeat biopsy) is only for 3 months.", "answer": 0}, {"article": "His doctor prescribed a C.P.A.P.\nBut not everyone finds that Provent alleviates their apnea.\nIn those people, Provent typically doesn\u2019t work.\nIt is also more expensive, and it doesn\u2019t work for every patient.\nBut the mask is like something from a bad science fiction movie: big, bulky and obtrusive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this device is becoming more widely prescribed but is not necessarily found everywhere.", "answer": 1}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\nIt wouldn\u2019t be difficult to eat enough soy to be protected, Patel noted.\n\u201cPeople should consider eating a diet that is healthy.\nHow can people add soy to their diets?\nStudies have shown that supplements containing soy protein don\u2019t have much health benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of soy foods is not in question.", "answer": 2}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nNOTE: The full title of this release is \"Scientists discover brain area which can be targeted for treatment in patients with schizophrenia who 'hear voices'\" It has been shortened in some versions to comply with Eurekalert title limits.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nSecondly, we have shown that treatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term\".\nThis is the first controlled trial to show an improvement in these patients by targeting a specific area of the brain and using high frequency TMS.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address availability of TMS for treatment of AVHs specifically. The release does note that TMS \u201chas been shown to be effective in several psychiatric conditions.\u201d However, it\u2019s not clear from the release how widely available TMS is, or even whether it is clinically available at all. This may be because the release is aimed more at practitioners (who are aware of TMS\u2019s availability) than at a more general audience. However, since many reporters and news consumers don\u2019t have that professional background and insight, it would be much better to simply address the issue of availability head on.", "answer": 0}, {"article": "Hair changes about as fast as grass grows, which is to say it\u2019s extraordinarily slow and not visible to anyone checking impatiently in the mirror every day.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\n(Mr. Skjoth, who has a master\u2019s degree in nutrition and chemistry but is not a doctor, said this is because other products may clog the scalp, causing hair loss.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the company \u201cis beginning an aggressive expansion into the $3.6 billion hair-loss market in the United States, meaning you\u2019re likely to hear a lot more about it.\u201d It also mentions clinics has a physical presence in New York City, Florida and Beverly Hills, Calif., and plans to \u201chave a presence in every state in the next two years.\u201d The product also appears to be available online.\nThe story also says that the company is \u201coffering a customized hair extract that\u2019s given only to those who pass a fairly rigorous selection process,\u201d and its products \u201care not available to anyone with autoimmune illnesses like alopecia or baldness from scarring, or anyone who is unlikely to see at least a 30 percent increase in growth.\u201d\nThe story also mentions that the treatment requires nightly six-hour applications, which could be prohibitive for some people.", "answer": 1}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nThe message here, Senay says, is that calcium supplements are useful for bone health \u2014 but you should only take them if you do so regularly, as directed by a doctor.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nAnyone over 50 will need an additional 200 milligrams.\nSupplements are an additional tool to be used when needed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the supplements are available, if they are available over the counter and if you can buy them in the formulation used in the study (600mg 2x/day).", "answer": 0}, {"article": "Their average age was 69.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\nAbaloparatide works differently from Forteo and improves bone density more than Forteo, Miller said.\nHe predicts that when abaloparatide is on the market, it will compete with Forteo, driving down the price of both drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that abaloparatide is currently in a Phase 3 trial stage.", "answer": 1}, {"article": "\"Your eyes look like they're responding beautifully!\"\nMaguire says he practiced the procedure in a lab over 10,000 times before trying it on a human.\nBefore the surgery, Manuela said she would most like to see her family and friends' faces clearly, particularly her sister's.\nThe medical procedure was developed by a husband-and-wife team \u2014 eye surgeon Dr. Al Maguire and gene therapy expert Dr. Jean Bennett.\nBefore the surgery, Manuela's pupil gave no response to or recognition of light.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explain that the procedure is not ready for general application.\u00a0 It does not make clear\u00a0 that this is part of an on-going clinical trial currently recruiting study subjects.\u00a0 Instead, it referred to the experiment as \"a medical milestone\" and as \"a cutting-edge therapy.\"\u00a0 It\u2019s not yet a therapy.\u00a0 It\u2019s an experiment. \n\u00a0", "answer": 0}, {"article": "It will still grow shorter and slower than scalp hair,\u201d he said.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nIn each case, Dr. Umar and his team extracted about 1,000 leg hair follicles and grafted them, one by one, to the patients\u2019 hairlines.\nAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the claims made at the top of the story, one would think that there is only one place in the world to undergo this technique: a clinic in Redondo Beach, California. That does not appear to be the case. In a brief online search, we were able to identify multiple dermatologists who suggest transplanting of hair from legs, chest and pubic region.", "answer": 0}, {"article": "Pfizer last week announced a deal with Canadian biotech Tekmira Pharmaceuticals Corp for this type of delivery vehicle for its RNAi drugs, joining Roche and Alnylam.\nBut getting the treatment to the right target in the body has presented a challenge.\nDavis said that part of the study will be presented at the American Society of Clinical Oncology meeting in June.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\n\u201cThis is the first study to be able to go in there and show it\u2019s doing its mechanism of action,\u201d said Mark Davis, a professor of chemical engineering, who led the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "An astute reader can probably figure out that this experimental approach isn\u2019t available yet.\u00a0 But the story never really says that.\u00a0 Instead, rather than calling it an \"experimental approach,\" the story calls it a treatment approach.\u00a0 We think the semantics are important.\u00a0 It\u2019s not a treatment yet.\u00a0 It\u2019s an experiment. ", "answer": 0}, {"article": "In the United States, the National Heart, Lung and Blood Institute, a unit of the National Institutes of Health, is supporting efforts by two separate groups, one led by Dr. O. H. Frazier of the Texas Heart Institute in Houston, the other by Dr. Leonard A. R. Golding of the Cleveland Clinic.\nOthers are in development.\nCiting World Health Organization data that shows heart disease is the world\u2019s leading cause of death, Mr. Conviti, the Carmat chief executive, estimated the potential market at \u201ca minimum\u201d of 100,000 patients a year in the United States and Europe.\nAnother device is being developed by scientists at the Helmholtz-Institute for Biomedical Engineering at the University of Aachen in Germany.\nGray Jr., the University of Louisville professor of surgery who implanted the first AbioCor heart in 2001, said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that human testing is far off:\u00a0 \"The company hopes to start human testing in France by the end of next year.\"", "answer": 1}, {"article": "\"There's a variety of methods you can use to achieve the strengthening technique,\" says Jason Grandeo, a physical therapist at Body Dynamics, Inc. in Arlington, Va.\nNot all physical therapists are sold on the FlexBar.\nBut he understands the appeal: The FlexBar is easy to use and you can do it at home.\nAnd the FlexBar makes it simple to do this kind of stretch.\nAnd he didn't want to give it all up due to a \"spot of pain\" in his elbow.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that the FlexBar is commercially available.", "answer": 1}, {"article": "Related: Common Knee Surgery May Not Help You\n\nOsteoarthritis can affect any joint when the cartilage wears off over time, often striking big joints like the knee, causing pain, swelling and stiffness.\nCoolief can be repeated if necessary, but it's not a permanent solution.\nBecause it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.\nThe Answer May Surprise You\n\nIn May, McCloden underwent the Coolief treatment and the result was instant.\n\"Though patients have a risk of the physician hitting the wrong nerve, that is extremely rare in the hands of an experienced professional\u201d, Amin said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Recent approval by the Federal Drug Administration means that the technique is not yet widely available, the story notes.", "answer": 1}, {"article": "Angioplasty, which uses a balloon to open blocked arteries, has been a popular alternative to bypass surgery in part because it brings less trauma to the patient.\nUsing robotics to bypass major blocked arteries and putting stents in other blocked arteries is gaining some currency, Rabbitt said, although few surgeons have come close to Srivastava's familiarity with the robot.\nFor Mary Lou Coulter, 77, of Westville, Ind., the main aftereffect of her robotic procedure was some soreness and numbness.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\nEven though they cost, on average, $1.5 million, the robot systems are gaining popularity.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not clearly\u00a0state how widely robotic treatments are available, either for bypass surgery or other operations. The article reports 504 units are in use in the U.S., but it\u2019s not clear how they are distributed or what they are used for, even in the Chicago area. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Co-authors are Evgeny Pokushalov, M.D.\nIf confirmed in heart bypass patients, Botox injections could also help prevent AF in people undergoing valve repair or replacement.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\nDALLAS, Oct. 20, 2015 -- Botox -- known for reducing facial wrinkles -- may also prevent irregular heart rhythms when injected into fat surrounding the heart after bypass surgery, according to research in the American Heart Association journal Circulation: Arrhythmia and Electrophysiology.\nAbout half of those patients will develop AF after surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since the release makes no claim that this therapy is ready to be used outside of clinical trials we\u2019ll give this a satisfactory. The story makes it clear that botulinum toxin is available and is routinely used in cosmetic dermatology. For that use it\u2019s sold under the trade name Botox Cosmetic. However, there are four different FDA approved strains of the toxin. Various formulations of the toxin have received\u00a0 FDA approval for use in treating excessive sweating, migraines, dystonia, bladder control issues, and several other non-cosmetic conditions. Those formulations have been available for many years as well. Since this is the first time botulinum toxin has been tested in human hearts, it\u2019s safe to say that it could be several years before it receives approval as a preventative for heart complications. The release is clear that larger studies are needed.", "answer": 1}, {"article": "When that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\nJan. 13, 2010 (Coronado, Calif.) -- A blood test under study to help diagnose lung cancer looks promising, researchers reported Tuesday at a cancer meeting in California.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story acknowledges that the results are preliminary and the test is [in the best-case scenario] a few years away from being clinically available. The investigator\u2019s quote that \"It might take three or four more years before these tests are clinically available\" assumes the test will be proven valuable in trials, which is a premature claim. Availability is not inevitable.", "answer": 1}, {"article": "\"Migraine is one of the most disabling conditions known to man, but patients need to know that there is hope,\" says Stephen Silberstein, a neurologist at Thomas Jefferson University in Philadelphia and lead author of the guidelines from the American Academy of Neurology and the American Headache Society.\nNot everyone with migraines needs prevention medicine.\nStill others try the treatments and decide they don't work or have unacceptable side effects.\nThese preventive treatments usually are used daily.\nThat's what happened to Emily Guzan, 26, a lawyer from Pittsburgh who was diagnosed with migraine in 2008.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s apparent from the story that these drugs are widely available.", "answer": 1}, {"article": "\"During immersion in water, particularly cold water, susceptible people have an exaggerated degree of the normal redistribution of blood from the extremities to the chest area, causing increased pressure in the blood vessels of the lungs and leakage of fluid into the lungs,\" said Richard Moon, M.D., an anesthesiologist and medical director of the Duke Center for Hyperbaric Medicine & Environmental Physiology.\nShe coughed up blood and was once hospitalized.\nHe also said research is ongoing to further illuminate the causes of SIPE and potential ways of diagnosing it early.\nIn addition to Moon, study authors include Stefanie D. Martina, Dionne F. Peacher, Jennifer F. Potter, Tracy E. Wester, Anne D. Cherry, Michael J. Natoli, Claire E. Otteni, Dawn N. Kernagis, William D. White, and John J. Freiberger.\n\"I have not had an incident since then.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The very first sentence of the release characterizes sildenafil as \u201creadily available.\u201d Indeed it is. It is Viagra \u2122.", "answer": 1}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\nCurrent treatments include Pfizer Inc\u2019s Xelijanz, an oral treatment for adults patients with moderate-to-severe UC, and Merck & Co\u2019s Renflexis.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Stelara is already on the market. However, it\u2019s not clear whether Stelara could currently be prescribed \u201coff label\u201d to patients suffering from UC. Nor is it clear whether the \u201clate-stage\u201d trial is still ongoing or has been completed. Is there a pathway to FDA approval? If so, what might the timeframe be?\nThe complexity of the drug approval process is such that news reports should help the public understand that this use of the drug is still experimental. that although the drug may be used \u201coff-label,\u201d it is not clear whether the company is seeking to broaden the FDA-approved indications or drum up interest among clinician researchers to design their own clinical trials.", "answer": 0}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug detailed in the story was described as heavily marketed direct to consumers and several clinicians\u2019 quotes included in the story questioned the wisdom of prescribing this medication. \u00a0", "answer": 1}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nThe company hopes to win FDA approval to market the new drug later this year.\nThe study appears in the July 15 issue of the New England Journal of Medicine.\nBy the end of year one, 55% of the patients in the placebo group and 45% of those taking the diet drug had dropped out of the study.\nAll the participants were counseled about diet and exercise.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is still in trials although it could have done a better job explaining how far it has come and what steps it still has to take to win approval. ", "answer": 1}, {"article": "Oxytocin,which is produced in abundance when a mother is breast-feeding her baby, is known as the \"bonding\" hormone.\nAlso, scientists would need to come up with a different method of delivery, Young said.\nAlthough there are many kinks to be worked out, experts feel the strategy holds promise to treat one of the core symptoms of autism spectrum disorder.\nThere were, however, wide variations in individual responses, the team noted.\nThe new study, led by Angela Sirigu at the Center for Cognitive Neuroscience in Lyon, France, was published in this week's issue of Proceedings of the National Academy of Sciences.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that the strategy used in this laboratory study is uNPRoven in the real world, particularly in children and young adults. They even note the issues in translating the delivery method to clinical practice.", "answer": 1}, {"article": "June 28, 2010 -- Cholesterol-lowering statin drugs appear to reduce the risk for prostate cancer recurrence in patients who have had a surgical procedure called radical prostatectomy.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\nThose who took the highest doses saw their recurrence risk drop by half.\nThe research does not prove that taking cholesterol-lowering drugs directly slows the growth and progression of prostate cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are widely available under several brands, many of which are mentioned in the story. At the same time, the reporter does explain that additional study would be needed before doctors would know whether to prescribe statins to prostate cancer patients and at what point in their treatment regimen.", "answer": 1}, {"article": "American veterans coping with PTSD are traveling to lodges in the Amazon that offer ayahuasca, a hallucinogenic brew. Some say it has helped them manage emotional trauma from war, but others say it\u2019s not worth the journey. Photo: Ryan Dube/WSJ\n\nAfter surviving firefights and a roadside bomb in Afghanistan, U.S. Army veteran Asa Barrett tried antidepressant drugs and therapy to overcome depression and bouts of anger. Nothing worked.\n\nBut then, like many other foreigners, he journeyed to Peru\u2019s remote Amazonian jungle to drink ayahuasca, a centuries-old, sacred indigenous brew that some Western scientists think can help to heal psychological traumas.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes numerous \u201cayahuasca centers\u201d that have cropped up around the city of Iquitos in Peru\u2019s northeastern Amazon.", "answer": 1}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is widely understood that these vaccines are available to almost everyone. The story notes only half of pregnant mothers receive the vaccine, which is important and why the CDC is researching the topic.", "answer": 1}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story included an outline of the foods that are included in a \u2018Mediterranean diet\u2019 , enabling readers to appreciate that these foods are available in grocery stores.", "answer": 1}, {"article": "\"Regorafenib has shown it can improve survival in patients with advanced hepatocellular carcinoma progressing on sorafenib.\nIn January, Bayer announced that the U.S. Food and Drug Administration (FDA) had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\nThis trial provides evidence that regorafenib is the first systemic treatment for patients whose HCC progressed during treatment with sorafenib, the only other drug with proven clinical benefit.\nThe success of this trial opens the field for testing drugs in third-line treatment of HCC and provides a rationale to test regorafenib as a first-line treatment or in combination with therapies administered directly into the tumor or diseased liver in patients in an earlier stage of HCC, according to Dr. Llovet.\n(New York, NY - January 18, 2017) An international phase 3 trial has found that the drug regorafenib improved survival in patients with advanced hepatocellular carcinoma (HCC), a form of liver cancer, giving people who previously had no other options a better chance at survival.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does tell readers that \u201cIn January, Bayer announced that the U.S. Food and Drug Administration had granted priority review status for Stivarga (regorafenib) as a second-line systemic treatment for patients with hepatocellular carcinoma.\u201d However, the release doesn\u2019t tell readers that regorafenib has already passed FDA review for treatment of other cancers, nor does it explain to readers what \u201cpriority review status\u201d means in terms of when the drug might be used for HCC treatment on a widespread basis.", "answer": 0}, {"article": "The fibers within the tendons fray.\nBut if he were to dispense advice based on his findings and that of his colleagues\u2019 systematic review, Dr. Vicenzino said, he would suggest that athletes with tennis elbow (and possibly other tendinopathies) think not just once or twice about the wisdom of cortisone shots but \u201cthree or four times.\u201d\nFor many years it was widely believed that tendon-overuse injuries were caused by inflammation, said Dr. Karim Khan, a professor at the School of Human Kinetics at the University of British Columbia and the co-author of a commentary in The Lancet accompanying the new review article.\nThe injections seem to have \u201can effect on the neural receptors\u201d involved in creating the pain in the sore tendon, Dr. Khan said.\nIt soon became a safe, reliable means to treat the pain and inflammation associated with sports injuries (as well as other conditions).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story explained the history of steroid injections, hinting at trends in availability. Steroid injections are widely available in both primary care and specialty settings. .\n", "answer": 1}, {"article": "The Web site naturalaugmentation.com lists several doctors, mostly ob-gyns and family medicine physicians, not plastic surgeons, who offer coupons for \u201cnatural augmentation\u201d and even something called \u201cstem-cell breast augmentation.\u201d\n\nA company called makes a machine used in that concentrates the cells within fat tissue that aren\u2019t strictly fat cells, including .\n\u201cAnyone can take fat and inject it into the breast, and the patient will look good immediately afterwards,\u201d Dr. Khouri said, but a few months later, the fat injected by a doctor with sub-par skills may result in \u201coil cysts, masses, and scarring.\u201d\n\nTo some, this kind of fat recycling seems simple.\nThat hasn\u2019t stopped Dr. Todd Malan, a board-certified ob-gyn in , Ariz., who is the surgeon in the ABC news clip, from anointing himself the \u201cFirst in U.S. to perform Stem Cell Enhanced Breast Augmentation!\u201d on his Web site.\nBut a far worse scenario is that a doctor\u2019s technique is so wanting that much of the transplanted fat dies and complications ensue.\nThe study, which Dr. Khouri plans to publish in a peer-reviewed journal, found that the procedure does not impede the reading of mammograms and that on average, 85 percent of transplanted fat survived to give patients natural-feeling larger breasts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThis story points out that only a handful of surgeons across the country offer breast augmentation using fat grafts and that the results are highly dependent on the skill and experience of the surgeon. The story also warns about doctors who promise unrealistic results.\n However, the story offers readers no information about how to locate a surgeon who has a good track record.", "answer": 1}, {"article": "Normally it's the very old or very young that die from flu, but every year there are deaths from influenza A,\" said Gilbert.\nThe initial results are positive, says Peter Palese, professor and chair of microbiology at Mount Sinai School of Medicine, New York, but more research is needed before the new treatment is approved.\n\"With this type of vaccine, you would at least be able to start using the vaccine as soon as you knew a new pandemic was starting.\nThe vaccine would be an important step in treating seasonal flu, not just pandemics.\n\"It took a further six months before it was possible to vaccinate a large number of people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the vaccine is in the early stage of development and will not be available for at least several more years. ", "answer": 1}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nThere are few circumstances when a single study should change our practice.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nThe researchers argue that the evidence is strong enough to change standard skin-prep practices for C-sections.\nBut based on the biological plausibility and the striking reduction in surgical-site infections with chlorhexidine, this is one of those circumstances.\u201d\n\nThis work was supported by a Women\u2019s Reproductive Health Research Career Development grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, of the National Institutes of Health (NIH), grant number 1K12HD063086-01; and by the Department of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We believe both skin-cleaning agents are widely available. So while the release never explicitly addresses availability, we don\u2019t dock points for this.", "answer": 2}, {"article": "Eating more fiber during adolescence was linked to a 16 percent lower risk of breast cancer overall, and a 24 percent lower risk of breast cancer before menopause.\n\"The results of this study emphasize the role of an early life high-fiber diet on prevention of breast cancer in later life.\n\u2022 Lesser-known signs of breast cancer women should watch out for\n\nDr. Deanna Attai, assistant clinical professor of surgery at the David Geffen School of Medicine at the University of California Los Angeles, said that while it's an observational study, not a clinical intervention, its larger point about diet and health is important.\nEating more fruits and vegetables was especially beneficial, the researchers said.\nDr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital, in New York, told CBS News, \"It lends support to the fact that we need to encourage people to start healthy habits earlier on.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are no new products or services at issue in this story, and we addressed access to healthy foods under \u201cCost,\u201d so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nAnd they pointed out that the study offers no reassurance about the safety of smoking or the advisability of CT scans for younger smokers or nonsmokers.\nBut health officials involved in the study refused to endorse widespread screening of current or former smokers, saying more analysis of the study\u2019s results is needed to further identify who benefited most.\nDr. Claudia Henschke, a clinical professor of radiology at Mount Sinai Medical Center and a longtime advocate for use of CT to screen for lung cancer, said the study was likely to have underestimated the benefits of CT scans because participants were screened only three times.\nThe study found that for every 300 people who were screened, one person lived who would otherwise have died during the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nWhile it may seem obvious that CT scanning is widely available, this trial used a specific and rigorous protocol for selecting the type of low-dose CT scanners used, how they were maintained and operated, as well as certifying the training and practices of the radiologists who interpreted the scans. The sort of CT machines, operators and radiologists generally available to smokers may not meet the demanding standards of this trial and thus may not be able to match the results.", "answer": 0}, {"article": "The home self-collection test indicated that 12.4 percent of women were infected with high-risk HPV, the self-collection tests used in the clinic found 15.5 of the women had high-risk HPV infection, and the clinician-collected test identified 11.4 percent of the women had high-risk HPV infection.\n\"HPV tests are being widely used now in the United States, but only through physician collection in clinical practice, which requires that women come to a clinic.\n\"We are already working on the next step, which is a clinical trial in which women who aren't up-to-date on screening get either a referral to a free clinic appointment to receive a screening, or receive a self-collection kit in the mail, followed by referral to a free clinic appointment.\nThe brush samples were then tested in a lab for HPV and other sexually transmitted infections.\nSome travel expenses for Des Marais were paid by Hologic, and others have consulted for the company.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that at-home, self-collected screening samples are not even close to being adopted for widespread use.", "answer": 1}, {"article": "He explained: \"When teixobactin was discovered it was ground breaking in itself as a new antibiotic which kills bacteria without detectable resistance including superbugs such as MRSA.\nThe Lincoln team has successfully synthesized new simplified versions of teixobactin which harness the same powerful antibiotic effects in a way that could be produced on a commercial scale.\nThe work builds on the success of the team's pioneering research to tackle antimicrobial resistance over the past 18 months.\nWe have been investigating a way to simplify the design while retaining the high potency against resistant bacteria such as MRSA.\nThe breakthrough by researchers at the University of Lincoln, UK, marks another important step to realising the potential of teixobactin in aiding the global fight against antibiotic-resistant pathogens.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that this work is a step closer toward creating drug treatments. There are no claims about how long subsequent testing and development may take. However, the failure to point out that this work is confined to laboratory tests and that human clinical trials have yet to begin implies a shorter path to potential clinical use than seems likely.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The story didn\u2019t discuss availability of multivitamins but this is common knowledge.\u00a0 ", "answer": 2}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The higher cost of IUDs and implants can be a significant barrier to availability, as can access to health care providers trained to insert these devices. The story briefly mentions cost issues and lack of insurance coverage for these two options, but it is not clear how often lack of access to care affects availability.\u00a0 We\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address any of the health problems or other issues that can make sex less available or fulfilling for older adults. For example, the death of a spouse, erectile dysfunction, arthritis, chronic pain, etc. Then again, these factors may not affect availability of sex for the elderly as much as we think \u2014 what goes on in assisting living facilities may surprise us all.\u00a0Regardless, we\u2019d like to see the story explore this. We\u2019d reiterate that people in worse overall health are also likely to have worse brain function and have less ability to perform sexually. This is an example of where our EVIDENCE and AVAILABILITY criteria comments overlap, but build on each other.", "answer": 0}, {"article": "\"Cancer patients tend to develop clots in their legs and lungs more frequently and also patients who develop clots in their legs and lungs tend to develop cancer more frequently,\" Choe noted.\nOf the almost 2,000 patients on anticoagulants in the study, 1,649 were taking aspirin, 428 warfarin, 287 clopidogrel (Plavix), 26 enoxaparin, and 408 a combination of blood thinners.\nThis trial, the largest of its kind, involved about 1,200 men who were randomly chosen to receive hormone therapy alone or a combination of that and radiation.\n\"This benefit was seen whether these patients were treated with surgery or radiotherapy,\" Choe added.\nAt 10 years, 4 percent of those taking one of these medications had died versus 10 percent in no-blood thinner group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe study looked at the use of available anticoagulant medications.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the Gender Knee is generally available to women who are candidates for total knee replacement.", "answer": 1}, {"article": "Other types of retinal implants, known as epiretinal implants, sit outside the retina and because they bypass the intact light-sensitive structures in the eyes they require the patient to wear an external camera and processor unit.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\n\u201cIt proves the concept that in a patient who has been blind for many years and is unable to see anything, the optic nerves can be re-awakened for them to be able to see again.\nEberhart Zrenner, chairman of the University of Tuebingen Eye Hospital in Germany and director of a small company called Retinal Implant AG which is developing the device, said the trial results were a \u201cproof of concept\u201d and would now be taken into further trials in around 25 to 50 patients in Europe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a credible job noting that the device is under study and not commercially available. Unfortunately it also suggests, based on the manufacturer\u2019s statement, that the device in a very early stage of development will be available in 5 years. The hyperbole used is indefensible \u2013 \u201cthe device could become routine for some kinds of blindness in five years\u201d\u00a0and \u201ccould eventually change the lives of up to 200,000 people worldwide.\u201d\u00a0 This comes after a test in 3 people.", "answer": 0}, {"article": "\u201cWe didn\u2019t put the weight on overnight,\u201d Surampudi said.\nBut with America growing fatter with each passing year \u2014 two-thirds of Americans are now overweight or obese \u2014 doctors believed that they had no choice but to continue their quest for a safe, and at least moderately effective, medicine that would help patients drop excess pounds and keep them off.\nFor decades, doctors have sought every dieter's dream of weight loss: a pill that could pare away the pounds without any harmful effects.\nNo one medication for hypertension works for every single person.\nI think a lot of physicians are uncomfortable prescribing weight loss medications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that, in general, the \u201clatest generation\u201d of weight loss drugs are FDA approved. But it never explains which ones fall under that category. There are at least nine weight loss drugs on the market.", "answer": 1}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a tricky one. Because the study was funded by Jenny Craig, it seems some mention of how widespread Jenny Criag programs are would have been warranted. Absent that, the story could have said how easy it might be for the typical person to find a diet program of any sourt that would provide people once-weekly face-to-face counseling, which was the regimen that had the best results \u2013 and for free! It might seem obvious that these programs are popping up all over the place, but they are not uniformly available, especially in rural and poor areas in counties that have high concentrations of obesity. If the story had even mentioned how many Jenny Craig centers (according to the company\u2019s website it is 565) we would have given this one a passing grade.", "answer": 0}, {"article": "The researchers found that women who consumed high levels of fiber (28 grams per day, on average) had a 24 percent lower risk of developing breast cancer before menopause, compared with women who ate low levels of fiber (14 grams per day, on average).\nThis new study provides some evidence of yet another potential benefit.\nThis is a question Kristi King, a dietitian at Texas Children's Hospital, has thought about a lot.\nA Diet High In Fiber May Help Protect Against Breast Cancer\n\nIf the advice to eat more fiber seems easy to ignore, you're not alone.\nOf course, the idea that high-fiber diets can help keep us healthy is not new.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are no new products or services at issue in this story, and we addressed access to healthy foods under \u201cCost,\u201d so we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nThey also plan to look at how the video game can be integrated into a rehabilitation program together with other rehabilitative techniques.\nThey used a collection of video games from the Nintendo Corporation, called Dr. Kawashima's Brain Training, which train the brain using puzzles, word memory and other mental challenges.\nAt follow-up, the 12 patients in the video-game group had significant increases in thalamic functional connectivity in brain areas corresponding to the posterior component of the default mode network, which is one of the most important brain networks involved in cognition.\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does identify the specific video game used in the study and its manufacturer, Nintendo, allowing readers to do a quick web search showing both it and accompanying equipment are readily available on the market.", "answer": 1}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nAmong them: bringing out Lipovitan Junior, a caffeine-free version for children.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nMs. Lutz, the Living Essentials spokeswoman, said the bold \u201cNo Crash Later\u201d statement on product labels was followed by a special mark.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of energy drinks is not in question.", "answer": 2}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nThe laser treatment reduces the light absorption and also helps restore the lens proteins to their proper structure.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The final line \"much more research and development work remains\" may help readers understand that this is not a readily available approach. ", "answer": 1}, {"article": "Fifteen percent of these individuals had a relapse and 10 percent died during a five-year follow-up, compared with 3 percent and 2 percent, respectively, of patients who did not have circulating tumor cells.\nAlthough the test may not be far off in terms of clinical practice, \"we need additional studies,\" Lucci said.\nThe problem is that just having circulating tumor cells may not be enough information to foretell the future, she noted.\nThe more tumor cells a woman had in her bloodstream, the higher the likelihood of relapsing or dying, according to the report.\nIn the new study, if even one cell was detected in the bloodstream, a woman had a greater chance of her cancer recurring and of dying.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No information about the availability of the blood test is given.\u00a0 There\u2019s only the line about \u201cmay not be far off in terms of clinical practice.\u201d\u00a0 But readers might not pick up on that subtle note.", "answer": 0}, {"article": "The researchers thank the Biotechnology and Biological Sciences Research Council (Grant 324594, Systems Biology studentship for J.M.H.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\nSimilar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.\nOur new compounds work by attacking the energy balance in cancer cells\u201d.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the compounds are not available to human patients yet.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of cigarettes or smoking cessation products is not in question, which is why we rate this one Not Applicable.", "answer": 2}, {"article": "In MS, it\u2019s the fatty protective sheath around the nerves; in type-1 or juvenile diabetes it\u2019s cells in the pancreas that make insulin; in rheumatoid arthritis it\u2019s tissue in the joint.\nSo far the team has only shown the process is safe \u2013 a phase 1 clinical trial.\nBut polystyrene is no good to use in people.\nBut Miller says the experiment also seemed to show they were beginning to repair the patients\u2019 immune systems.\nNow the researchers are looking for funding so they can test this new approach in people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is not currently available.", "answer": 1}, {"article": "Mpourmpakis and Taylor applied density functional theory (DFT) - a highly accurate computational method used to study the structure and properties of materials - to address how HCA and CA bind to calcium and to calcium oxalate crystals.\nHCA is chemically similar to CA and is also available as a dietary supplement.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\n\"HCA may be preferred as a therapy over CA (potassium citrate).\"\nThey often recommend taking citrate (CA), in the form of potassium citrate, a supplement that can slow crystal growth, but some people are unable to tolerate the side effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that, like citrate, hydroxycitrate is available as a dietary supplement.", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that fish oil is widely available and has been widely used for the described uses.\u00a0 However, it would have been helpful for readers/consumers if the story had discussed the challenge of assessing product purity, quality control, etc. \u2013 that it\u2019s not just a simple matter of \"just take fish oil.\"\u00a0", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that Lucentis was approved last June for wet AMD, but doesn't tell the reader how available it is \u2013 that is, is it in widespread use?", "answer": 1}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nAnyone considering changing or beginning treatment of any kind should consult with a physician.\nWHO MAY BE AFFECTED?\nTHE QUESTION Eating fish can be good for the heart, thanks to the presence of omega-3 fatty acids.\nExcept for trout, freshwater fish usually are lower in omega-3s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish and fish oil is not in question.", "answer": 2}, {"article": "Proton therapy is a precise form of radiation therapy that deposits all of its energy within the tumor and allows for less irradiation of noncancerous tissue.\n\u201cBy continuing to develop a comprehensive thermal oncology program, we are giving patients more effective treatment options and therefore another reason to hope for better outcomes.\u201d\n\n\u201cThe Maryland Proton Treatment Center has achieved another milestone by becoming the first center to offer both deep-thermal therapy and proton therapy,\u201d says E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs at UM Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and dean at UMSOM.\nThe acquisition of the deep-tissue thermal therapy system was made possible by donations from Jack and Emily Howell and the Middendorf Foundation, Inc.\n\n\u201cWithin the Department of Radiation Oncology and throughout our cancer center, we strive to make every available tool in the cancer-fighting toolbox available to our patients,\u201d says William F. Regine, MD, FACR, FACRO, the Isadore & Fannie Schneider Foxman Endowed Chair and Professor of radiation oncology at UMSOM and chair of radiation oncology at UMGCCC.\n\u201cEarly research suggests that adding thermal therapy to proton-beam therapy may be associated with an even greater benefit than when combined with standard radiation therapy, and we are excited to be at the forefront of making this combination therapy available to cancer patients,\u201d says Dr. Vujaskovic, an internationally recognized expert in hyperthermic oncology.\nVisit medschool.umaryland.edu/\n\nThe Maryland Proton Treatment Center (MPTC) offers proton therapy \u2013 a highly advanced and precise form of radiation therapy that can increase radiation dose to tumor while decreasing dose to healthy, surrounding tissue \u2013 to the Baltimore/Washington region and beyond.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says that the Maryland Proton Treatment Center, \u201cis the only proton treatment center in Maryland.\u201d While this is technically true, they neglect to mention that there is another proton treatment center in the region, an hour\u2019s drive away in Washington, D.C. Nor do they mention any of the other 28 proton centers currently open around the country, or the 10 more under development.\u00a0", "answer": 0}, {"article": "Eaton's part of the testing is finished.\n\u201cAlmost certainly, I would be deceased or in much worse shape had I not had the opportunity to be in this program.\u201d\n\nHare stressed that the current trial is only a small, run-up phase of extensive testing that will take up to five years and involve dozens of hospitals and hundreds of patients before winning U.S. Food and Drug Administration approval for routine use.\nLater, researchers will conduct a study involving 50 to 100 hospitals and many hundreds of patients aimed at winning final FDA approval.\nThe first, which started in 2009, is a double-blind, placebo-controlled study of 60 patients designed further to test the safety of the procedure, but primarily its efficacy, or how well it works.\nUniversity of Miami cardiologists last week reported success in a small, preliminary human clinical trial of a new stem cell therapy they hope some day will routinely mend human hearts and reduce the need for lifelong medication, even for transplants.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story stands out for taking readers through the application and approval process instead of just leading readers to believe that a therapy is around the corner. It says: \u201cThe next step is two more near-term studies. The first, which started in 2009, is a double-blind, placebo-controlled study of 60 patients designed further to test the safety of the procedure, but primarily its efficacy, or how well it works. Another study about to get underway will see whether bone marrow from a donor can work as well as the patient\u2019s own bone marrow. Later, researchers will conduct a study involving 50 to 100 hospitals and many hundreds of patients aimed at winning final FDA approval.\u201d\n", "answer": 1}, {"article": "Most men with prostate cancer do not experience symptoms.\nIf it is found to be effective, it could be an important tool for physicians.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nThe new method is being trialed on 300 men in doctors' offices across London, and is due to be expanded to 5,000 next year, according to BBC News.\nThe majority of cases are caught at around 66.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear this test isn\u2019t available but would have served readers better by explaining that higher. It stated the test \u201cis being trialed on 300 men in doctor\u00a0surgeries across London, and is due to be expanded to 5,000 next year.\u201d\nIt also provided this quote: \u201cIf it is found to be effective, it could be an important tool for physicians.\u201d [emphasis ours]", "answer": 1}, {"article": "Commenting on the study, Oliver Sartor, MD, Cancer Research, Department of Medicine and Urology, Tulane University School of Medicine, New Orleans, LA, stated, \"The end point deserves special mention, as the end point of undetectable PSA after testosterone recovery has been previously discussed but rarely studied.\nThe combined treatment regimen including surgery was well tolerated.\nIt is expected that an upcoming Phase 2 trial will further test this endpoint and combined modality approach.\nSuch results could not have been achieved with any single therapy alone.\nThe authors proposed that this end point may serve as a first step toward establishing a curative paradigm.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that all of the treatment options are currently available.", "answer": 1}, {"article": "They also lost substantial inches from their waistlines, which may be an important consideration for heart health, said Shane Phillips, an assistant professor in the department of physical therapy at the University of Illinois at Chicago.\n(In the current study, participants followed a diet based on the New Atkins for Life approach, which includes more vegetables than the original Atkins diet, Dr. Stewart said, adding that he and his colleagues have no ties to and receive no financing from the Atkins diet organization.)\nSuch fatty, low-carbohydrate Atkins-type diets are well established as a means of successful weight reduction, Dr. Stewart said.\n\u201cThere was no evidence of any harmful vascular effects from the low-carb diet,\u201d Dr. Stewart said.\nThe study did not include a control group of men and women who performed no exercise, making it impossible to tease out the exact physiological role that exercise played, Dr. Stewart said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story referred to the diets studied in broad terms including avoidance of trans fats and indicated that study participants reduced their daily caloric intake by about 750 calories. The Atkins diet is broadly available and widely recognized.", "answer": 1}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\n\"There are some serious concerns about the methodology used,\" but the authors \"have brought to attention some real serious potential public health issues,\" said Dr. Arl Van Moore, head of the American College of Radiology's board of chancellors.\nThe report estimates the percentage of cancers caused by CT scans -- currently 0.4 percent -- will increase to as much as 2 percent in a few decades because the number of scans has increased so dramatically, reports CBS News medical correspondent Dr. Jon LaPook.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\nIt's also a good idea to keep a diary of X-ray exposure, especially for children.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not include information about availability of CT scans (i.e. in hospital setting, in free standing imaging centers).\u00a0 However, the point of the story was that the technology is over used.\u00a0 While not meeting our usual standard of describing availability, the context of the news spot makes this less important.\nAlthough the story mentioned that patients ought to make sure that the doctor gives you \u2018the least possible dose\u2019, it did not inform the viewer that this option is not available on all CT equipment.", "answer": 1}, {"article": "Achillion\u2019s ongoing mid-stage study tests its NS5A inhibitor, ACH-3102, with Sovaldi in previously untreated genotype 1 hepatitis C patients over six and eight weeks of therapy.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\nThe all-Achillion regimen could hit the U.S. market by 2020 in a conservative scenario, Deutsche Bank\u2019s Alethia Young estimated.\nAchillion\u2019s shares rose as much as 19 percent to $12.85 on Monday on investor\u2019s hopes that an all-Achillion combination could be as effective as Gilead\u2019s and AbbVie Inc\u2019s current therapies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls the new drug \u201cexperimental,\u201d suggesting it\u2019s not yet available. But the story doesn\u2019t really address what will be the major obstacle to availability should the drug make it to approval: the cost and who will pay for it. What will be the limitations put on coverage by insurance companies looking at a huge potential total cost?", "answer": 0}, {"article": "For their analysis, Gibbons and his colleagues looked at outcomes for each individual patient in published and unpublished trials testing the effects of six weeks of treatment with antidepressants versus placebo pills.\nAbout 9,000 participants were included.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\nThe benefits were seen regardless of how severe patients\u2019 symptoms were before starting treatment.\n\u201cThere are alternative treatments for depression that also produce about the same symptom reduction as the drugs do, but without the risk of side effects,\u201d Kirsch added, including psychotherapy and exercise.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antidepressants was not in question.", "answer": 2}, {"article": "Both show that antibiotics are more effective than placebos in relieving ear-infection symptoms such as fever, poor appetite, decreased activity and irritability and suggested that their benefits warrant their being administered early on, regardless of the seeming severity of a child's symptoms.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\nStill, some of the placebo-group kids required \"rescue treatment\" when their symptoms grew markedly worse.\nEar infections hurt, and waiting for them to run their course can be excruciating.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antibiotics isn\u2019t in question, so this is not applicable.", "answer": 2}, {"article": "\"Dark chocolate may be a pleasant and effective way of delivering important dietary components that can provide health benefits to the ever increasing numbers of people at increased risk of cardiovascular disease,\" says researcher Christopher M. Reid, PhD, professor of cardiovascular epidemiology and preventive medicine at Monash University in Australia.\nMaybe, according to a new study from Australia.\nThey did not study actual people eating actual chocolate.\nThe study is published in the journal BMJ.\nThey found it would be.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of dark chocolate is not in question.", "answer": 2}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is general knowledge that estrogen and progesterone hormone therapies are common and widely available. The story cited some data on the decline in estrogen and progesterone use in the US.\n\u00a0", "answer": 1}, {"article": "Partial replacements, also known as unicompartmental replacements, are suitable for people who have arthritis in just one side of the knee, usually the inner.\nThe main reason for the surgery is osteoarthritis.\n\u201cThis is an important finding,\u201d said co-lead researcher Prof David Murray.\nThe NHS, however, needs to get the support of surgeons, many of whom rarely carry out the less invasive procedure.\nIn addition, more partial knee replacements will be done and more patients will benefit from this procedure.\u201d\n\nEd Burn, first author of the paper, said they needed to get surgeons on board.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that partial knee replacement surgery is available.", "answer": 1}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that whole-brain radiation treatment was prevalent for many years and is now declining in popularity.", "answer": 1}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\nHyldahl said the study results indicate running is chondroprotective, which means exercise may help delay the onset of joint degenerative diseases such as osteoarthritis.\nIn other words, it appears running can reduce joint inflammation.\nRunning may also slow the process that leads to osteoarthritis\n\nWe all know that running causes a bit of inflammation and soreness, and that's just the price you pay for cardiovascular health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Obviously, running is available to anyone who\u2019s able to do it for no cost. The release could have pointed out that areas with sidewalks and dedicated trails make this activity more accessible.", "answer": 2}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\nThe study is published in the New England Journal of Medicine.\nAbbott, the company that makes briakinumab, announced in January that it was withdrawing its bid to get the drug approved in the U.S. and Europe after regulators asked to see more robust proof that the medication was safe.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of briakinumab was made clear in the story.", "answer": 1}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described a recommendation to \u2018pick up a multivitamin\u2019 with a given level of vitamin D, suggesting that this is a simple over the counter purchase. \u00a0That said \u2013 the article failed to distinguish among the types of vitamin D available and whether this made any difference.", "answer": 1}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\n\"And screening not only in a way that would not only detect cancer, but pre-cancer.\nAhlquist noted that the test still needs to be refined.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nOne more advantage: patients do not need to do any special preparation before taking the test, something that other tests require, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \u201cCologuard is not yet available for sale. Clinical trials comparing the test with colonoscopy are slated to start next year.\u201d\u00a0But then it allows the lead researcher to get away with saying he \u201chopes that the test will be approved and available within two years.\u201d\u00a0 Sure he does.\u00a0 That doesn\u2019t make it a prediction you can bank on.", "answer": 1}, {"article": "\"We believe that finding ways to use CRISPR to improve existing treatments will lead to some of the first benefits for patients while we tackle the vital ethical issues around the use of CRISPR for edits that can be passed on through DNA.\nBut he said there continues to be significant safety concerns around this type of CRISPR application.\nThis multidisciplinary clinical/scientific team has been working together to develop a compassionate bench-to-bedside approach.\nDr. Kmiec said there are chemotherapies that have helped patients achieve remission or at least live longer and enjoy a better quality of life by significantly slowing the progress of the disease.\nThat was the conclusion of a new study published today in the journal Molecular Therapy Oncolytics by scientists from The Gene Editing Institute of the Helen F. Graham Cancer Center & Research Institute at Christiana Care Health System.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that this is not yet a treatment option.", "answer": 1}, {"article": "A second study, presented at the American Society for Radiation Oncology (ASTRO) 2016 annual conference, describes the extra utility that BioZorb can provide, by significantly reducing the amount of normal breast and surrounding tissues that are exposed to radiation treatment.\nThe study also noted that the device provides a helpful guide for post-treatment mammograms and other long-term follow-up to check for any cancer recurrence in these patients.\n\"We were also pleased to note in our research that there were no device-related complications in this group of patients, and that none of them had a recurrence of cancer.\"\nThe article reports that the device provides clear visualization of the surgical site where the tumor was removed, thereby improving communication between the surgeon and radiation oncologist.\n\"The marker tells us where the tumor was and helps us determine appropriate forms of treatment, whether with partial breast irradiation or standard whole breast irradiation and a boost dose at the end of the treatment process.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We aren\u2019t told where the device is available or whether it\u2019s covered under most insurance plans. It was noted that the implant has received clearance by the FDA.", "answer": 0}, {"article": "After 78 weeks, they found that patients given bapineuzumab had about a 25 percent reduction in plaque compared with those on placebo.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\nBapineuzumab \u2014 being developed by Pfizer Inc (PFE.N), Irish drugmaker Elan Corp ELN.I and Johnson & Johnson (JNJ.N) \u2014 is a potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\nRinne\u2019s imaging study was funded by Elan and Wyeth, which is now part of Pfizer.\n* Drug being developed by Pfizer, Elan and Johnson & Johnson\n\nLONDON, March 1 (Reuters) - New imaging technology suggests an experimental drug for Alzheimer\u2019s reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Bapineuzumab, the drug reported on, is experimental and not available for use outside of clinical trials. \u00a0The story mentioned the experimental status once, but the fact that it is not available was probably lost on many readers who may have been swept away by the enthusiastic reporting: \"potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\"", "answer": 0}, {"article": "And we know there are certain basic mechanisms which seem to be common to both inflammation and cancer,\" he said.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nGinger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nAs for cost, she said that a month's supply of similar ginger supplements typically runs about $10 to $30.\nThe amount of ginger in the pills is equivalent to 20 grams of raw ginger root, the authors said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says ginger is found in supplements and in many foods. The availability of ginger supplements is implied elsewhere in the story.", "answer": 1}, {"article": "\u201cDid you somehow get a biased sample of people, and is that why you\u2019re seeing this difference?\u201d\n\nHer 2008 study analyzed data from nearly 64,000 people who were melanoma-free at the beginning of the investigation, then followed them for a few years to see who developed the disease.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\n\u201cI think it\u2019s just too early\u201d to say NSAIDs offer any protection, she said.\nPeople with a family history of melanoma are better off wearing sunscreen and getting regular skin checks from a dermatologist, Asgari recommended.\n\u201cI think the jury is still out.\u201d\n\nThere\u2019s reason to hope NSAIDs might offer some protection against this type of cancer, however - earlier this year, a review found that people who use painkillers such as ibuprofen on a regular basis may be less likely to get bladder cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There isn\u2019t any question about the availability of aspirin, ibuprofen or related painkillers.", "answer": 2}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\nAll patients received a single, 19 Gy fraction of HDR brachytherapy.\nNewswise \u2014 ARLINGTON, Va., March 1, 2017 \u2013 Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer.\nAt an average of nearly three years following treatment, cancer control rates were favorable and the toxicity profile was highly favorable.\nReducing this exposure is of particular concern for treating tumors in the prostate, which is surrounded by multiple critical structures.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability but high dose brachytherapy has been available for years\u2013and a Google search reveals many sites offering this treatment.", "answer": 2}, {"article": "By using dynamic contrast magnetic resonance imaging (MRI) to image the brain\u2019s glymphatic pathway, a complex system that clears wastes and other harmful chemical solutes from the brain, Stony Brook University researchers Hedok Lee, PhD, Helene Benveniste, MD, PhD, and colleagues, discovered that a lateral sleeping position is the best position to most efficiently remove waste from the brain.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\nOur findng brings new insight into this topic by showing it is also important what position you sleep in,\u201d she explained.\nTheir finding is published in the Journal of Neuroscience.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Because everyone sleeps this criteria doesn\u2019t apply for this particular release.", "answer": 2}, {"article": "Serotonin imbalances have also been linked to depression.\nStudy results were also endorsed in 11 accompanying editorials from leading experts in psychiatry, addiction, and palliative care.\nThe drug used in the study was manufactured by Organix Inc. in Woburn, Mass.\nStudy participants, he says, experienced no serious negative effects, such as hospitalization or more serious mental health conditions.\nApproximately half way through the study\u2019s monitoring period (after seven weeks), all participants switched treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not specifically address drug availability. However, the release does note that psilocybin is a banned substance, and makes clear that larger clinical trials would have to be successful before psilocybin could be used as a \u201csafe, effective and inexpensive medication \u2014 dispensed under strict control.\u201d That\u2019s sufficient to merit a satisfactory rating.", "answer": 1}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the company that produces the drug is planning on seeking FDA approval for a new indication.\u00a0 It also reported that the drug is currently available and used for the treatment of Paget\u2019s disease and for treating osteoporosis in wpmen after menopause.\nIt is noteworthy that this story accurately reported on both of these aspects about availability.", "answer": 1}, {"article": "Feb. 9, 2010 -- Pregnant women who drink plenty of milk may be protecting their child from developing multiple sclerosis (MS) in the future.\nThe study involved more than 35,000 female nurses whose mothers answered questions about their diet habits during pregnancy.\nThe disease most often strikes adults after age 20, but it can develop in children.\nAmong the nurses studied, 199 developed MS over the 16-year study period.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story lists common sources of vitamin D, all of which are widely available.", "answer": 1}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nFurther benefits are expected with the advent of newborn screening programs that have resulted in early detection.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear how far these research findings are from making their way into clinical use.", "answer": 0}, {"article": "By measuring the sternal notch-nipple distance and the nipple-inframammary fold distance ( proxies for upper and lower sensory ligament strength, respectively), the study found a differential rate of stretch - for every 1 cm in upper sensory ligament stretch, the lower sensory ligament length increases by 0.45 cm.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\nThis study provides an anatomical foundation for why our technique may yield better, longer-lasting results.\"\nOther advantages of the Boston modification of Robertson technique include decreased operative time and elimination of the \"triple point,\" the most common site of postoperative incision rupture.\nIn all patients, only one reduction technique was performed per patient.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release mentions standard therapy and a modified technique but doesn\u2019t tell us how widely available the modified technique is, whether it is new or how many plastic surgeons are skilled in the procedure.", "answer": 0}, {"article": "Immunotherapy usually starts with clinicians harvesting immune system cells called T cells that have attached themselves to a tumor in an effort to attack.\nYee's team tried to do this more precisely.\nBut Yee bet that the extra effort would pay off with better results and fewer side effects.\nThe only side effect, he said, was a raging rash that lasted for three days.\nNow he says he is optimistic he may live to see retirement age, though he's not sure he'll ever stop teaching.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think it\u2019s clear from the story that this is only an experimental approach right now.", "answer": 1}, {"article": "Both found that drinking coffee was associated with a significantly reduced chance of death.\nI grant you that pretty much none of the research I\u2019m citing above contains randomized controlled trials.\nI\u2019m not suggesting that we start serving coffee to little kids.\nFinally, while the coffee may be healthy, that\u2019s not necessarily true of the added sugar and fat that many people put into coffee-based beverages.\nI can\u2019t think of any other product that has this much positive epidemiologic evidence going for it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is everywhere, in every culture, and in every corner of the planet \u2014 and the story mentions places you can get it.\nThere is an intersection in Vancouver with a Starbucks on EVERY corner.\nHave you heard about the new Starbucks that opened in the bathroom of an existing Starbucks?", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\n\u201cSingle-institution studies on the use of SBRT as the primary treatment for prostate cancer have illuminated the treatment as a cost-effective and faster alternative to IMRT,\u201d said Robert Meier, MD, lead author of the study and a radiation oncologist at Swedish Medical Center in Seattle.\nThe study is the first large, multi-institutional study of SBRT in prostate cancer with long-term follow-up.\nFewer than two percent of all patients experienced serious side effects in the five years following SBRT.\nBiochemical failure was assessed using the ASTRO-consensus and the nadir+2 definitions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that patients in the trial were treated at 21 academic, regional, and community medical centers, which suggests that SRBT is widely available.", "answer": 1}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of an Ebola vaccine would be reasonable to address. For example, it a new epidemic developed today, would one of these vaccines be used? This is an important clinical point that researchers might have been able to provide information about.", "answer": 0}, {"article": "\u201cWe can\u2019t tell from the existing study if that is going to hold up or not,\u201d he said.\nThe task force advises that men age 45 to 79 take aspirin to stave off heart attacks, as long as the benefit outweighs the risk of bleeding.\nFor women age 55 to 79, aspirin is recommended to prevent strokes, with the same caveat.\nThe question then becomes finding out what your risk of heart attack is in the first place, which your doctor can help with.\nOne recent study has suggested that despite the increase in bleeding ulcers from aspirin, the reduction in heart attacks might make the cheap drug cost-effective for men over 45.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of aspirin is not in question.", "answer": 2}, {"article": "\"Here, fertility is very important to many young women,\" he said.\nThis new study shows that ovarian tissue transplants are safe and effective and pose little risk of the cancer coming back, the Danish researchers said.\nAnd no cancer developed in the transplanted tissue, Jensen said.\nThe women's average age when the tissue was removed and frozen was nearly 30.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not say whether this approach, which requires a lot of planning ahead for a cancer patient, is widely available outside of research centers. The research was done in Denmark and it\u2019s not clear if it\u2019s offered here in the United States or how widely.", "answer": 0}, {"article": "Milo A. Puhan, MD, is director of the Epidemiology, Biostatistics and Prevention Institute and professor of epidemiology and public health at the University of Zurich.\nAs I showed in a commentary in the Journal of the American College of Cardiology, when combined with a statin, aspirin\u2019s net benefit in primary prevention is almost completely lost.\nIf there was a foolproof way to identify individuals at high risk for a future heart attack or stroke, as well as those at high risk for developing complications, we would know who should be taking aspirin for primary prevention and who should not.\nHere\u2019s the problem: The lower an individual\u2019s risk of a future heart attack or ischemic stroke, the less he or she will benefit from taking daily low-dose aspirin.\nThat\u2019s ironic because aspirin is ubiquitous and most patients perceive it to be safe and harmless.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that aspirin is ubiquitous and sold almost everywhere as an over-the-counter drug, so we\u2019ll rate this one N/A. This story, and the other we reviewed, might have benefited from mentioning that the drug has a generic name (known as ASA or acetylsalicylic acid). Generic versions of the drug do exist, are likely cheaper than the brand name, and equally effective.", "answer": 2}, {"article": "\u2022 Gaziano TA, Fonarow GC, et al.\nPlease see full Prescribing Information, including Boxed WARNING available at http://www.pharma.us.novartis.com/product/pi/pdf/entresto.pdf.\nYou should not place undue reliance on these statements.\nFor more information, please visit http://www.novartis.com\n\nNovartis is on Twitter.\nThey should not do both.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s noted that the drug is FDA approved.", "answer": 1}, {"article": "\u201cWhat we\u2019ve been able to show in our advanced cancer studies of men with prostate cancer and women with breast cancer, is when they have tumor in their bone that Prolia is more effective than the best available therapy at delaying significant fractures or other skeletal-related events,\u201d Perlmutter said.\nAmgen shares rose to $52.92 in extended trading from their Nasdaq close at $50.76.\nThe approval comes with a risk evaluation and mitigation strategy (REMS) that includes a medication guide for patients and information for healthcare providers that explains the risks and benefits of the drug, the FDA said.\nInvestors greeted the good news by sending Amgen shares more than 4 percent higher in after-hours trading.\nProlia, or denosumab, was compared with Novartis\u2019 Zometa in late stage clinical trials of advanced cancer patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Too much LDL cholesterol circulating in the blood can lead to the thickening of artery walls, making them less flexible and therefore impairing their function and increasing the risk of heart disease.\nStein said.\n\u201cThis is a hot research area and everybody is so close together.\"\nWith statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nIf the results are confirmed, \u201cThis is game changing science,\u201d said Dr. Richard A. Stein, a spokesman for the American Heart Association who's not related to the study author or involved in the research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this is an experimental approach.", "answer": 1}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nThe FDA granted the Tecentriq application breakthrough therapy designation, priority review status and accelerated approval for this indication.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nTecentriq is the first FDA-approved PD-L1 inhibitor and the latest in the broader class of PD-1/PD-L1 targeted biologics approved by the FDA in the last two years.\nThis trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA\u2019s approval of a drug clears the way for the drug sponsor to scale up production and begin marketing and selling the product. (The FDA doesn\u2019t state this explicitly but it can be inferred.)\u00a0 A NYT article said the drug would be available in about two months.", "answer": 1}, {"article": "Many back patients are afraid certain movements will cause them pain, so they avoid them.\nThe program led to a significant and clinically important reduction of pain, she said.\nThe regimen included the best known exercises for back pain and general exercises, she said.\n\"They should also avoid the use of scary, unreassuring labels or diagnoses,\" and not limit movement in therapy, she said.\nWhat does that mean?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that this is an experimental therapy.", "answer": 1}, {"article": "Aggression scores declined to 3.8 from 7.1 in the dextromethorphan-quinidine group and to 5.3 from 7.0 in those who took a placebo.\n\u201cThat\u2019s a lot when a patient is striking and hitting and cussing.\nThere are no currently approved treatments for agitation, and we\u2019re very enthusiastic about this finding.\u201d\n\nCorrection: October 8, 2015 \n\nA report in the In Brief column on Sept. 29 about a combination drug that could ease the agitation of Alzheimer\u2019s disease described incorrectly a disorder treated with the combination drug, dextromethorphan and quinidine.\nNow researchers report that a combination drug already in use for treating certain neurological problems may be a better remedy.\n\u201cFifty-five percent of the people who were on drugs had a 50 percent reduction in their agitation,\u201d said the lead author, Dr. Jeffrey L. Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug tested is \u201calready in use for treating certain neurological problems,\u201d and we think most readers can work out from that that the drug is available.", "answer": 1}, {"article": "\u201cI couldn\u2019t wear a brassiere for three months,\u201d she recalled.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\nIn fact, if screening finds cancer, some seniors won\u2019t withstand the surgery, usually a lobectomy, that may cure it.\nAnd Medicare has established a registry to see how well large-scale screening works.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The issue of interest here is whether low-dose CT scans are available for older, heavy smokers to screen for lung cancer. While this is satisfactorily addressed (it\u2019s the main topic of the story), it isn\u2019t entirely clear from the story if screening has actually begun or when it will. Programs to do the shared decision-making for Medicare patients haven\u2019t been established and Medicare hasn\u2019t yet released codes for billing for the initial visit where the issue is reviewed. It\u2019s also unclear if commercial insurers are covering and for whom.", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\n\u201cThis technique will change the landscape of organ donation by improving organ preservation, allowing us to better assess and regenerate the donor organ on the device before we transplant it into a patient.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\nSince the kidney did not \u201cstruggle\u201d after transplant, there is a greater likelihood that its long-term outcome will be better, he adds.\nThe technique, unique solution, and device are part of a Phase I clinical trial at Toronto General Hospital (TG), University Health Network (UHN), assessing the safety of the device, with subsequent phases examining its efficacy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the release does tell readers that this work was done as part of a phase 1 clinical trial, so we\u2019ll rate this Satisfactory. However, many \u2014 if not most \u2014 readers are not familiar with clinical trials, and we think the release would have been stronger had it translated that.", "answer": 1}, {"article": "\u201cThe studies are small and the longest of them lasted only three years.\nBefore the most recent study, at doses considered normal, the testosterone gel showed little or no effect on cardiovascular risk, the two doctors reported.\nAlthough low hormone levels are widely thought to increase a man\u2019s risk of depression, the researchers found that \u201cpsychological symptoms had little or no association with the testosterone level.\u201d\n\nThere are four main approaches to testosterone therapy available in this country: intramuscular injections every one to three weeks; skin applications through a patch or gel; and pellets implanted under the skin that last for months.\nDr. Abraham Morgentaler, a urologist at Harvard Medical School and author of \u201cTestosterone for Life\u201d (McGraw-Hill, 2009), said in an interview that other noted benefits include a decrease in body fat and total cholesterol and improved blood sugar metabolism.\nA $45 million study financed by the National Institute on Aging is under way at 12 medical centers to see if a year of treatment with testosterone will help 800 men aged 65 and older with low levels of the hormone and problems with physical functioning, fatigue and sexual or cognitive performance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study notes that testosterone therapy is available in the U.S. as an\u00a0intramuscular injection, a skin patch\u00a0or gel,\u00a0pellets inserted under the skin, and in oral preparations. \u00a0", "answer": 1}, {"article": "According to the findings, people older than 65 who had higher blood levels of caffeine developed Alzheimer's disease two to four years later than their counterparts with lower caffeine levels.\nCoffee was the main, or only source, of caffeine among people in the study.\nThere may even be a reason to start for people in their late 30s and up, he says.\n\"There is no reason to stop if you are experiencing memory problems.\"\nThis is equivalent to drinking several cups of coffee a few hours before giving blood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of coffee is not in question.", "answer": 2}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the test is available in the U.S. and is being used with increasing frequency.\u00a0 It is actually not clear how often it is being used \u2013 the article said \u201cSome anecdotal evidence suggests such screening is happening and becoming more common.\u201d", "answer": 1}, {"article": "High intake of fiber during adolescence was also associated with 16% lower risk of overall breast cancer and 24% lower risk of breast cancer before menopause.\nThe greatest apparent benefit came from fruit and vegetable fiber.\n\"We now have evidence that what we feed our children during this period of life is also an important factor in future cancer risk.\"\nThe study will be published online February 1, 2016 in Pediatrics.\n\"From many other studies we know that breast tissue is particularly influenced by carcinogens and anticarcinogens during childhood and adolescence,\" said Walter Willett, Fredrick John Stare Professor of Epidemiology and Nutrition at Harvard Chan School and senior author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this a Not Applicable since it\u2019s commonly assumed that fresh dietary fiber is widely available in various products at many grocery stores.\u00a0 We discussed problems with this assumption under the \u201ccosts\u201d criteria.", "answer": 2}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\nHowever, more research is needed to clarify the nature of the beneficial association between the EGCG and cognitive training intervention (ie, synergistic or additive).\"\n\"It's an important trial,\" says Dr. Steven Hirsh, director of clinical research for Life Extension in Fort Lauderdale, Fla. \"The findings are very noteworthy and support further study in randomized controlled trials with larger sample sizes and durations.\nIt is very encouraging that this catechin, EGCG, from green tea extract, has the potential to benefit people with Down syndrome.\"\n\"This new research adds to the growing body of evidence that suggests compounds in green tea, such as EGCG, may support cognitive health.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release could have been more explicit in pointing out that green tea extract supplements are easily available online or at the local health foods store. However, we give it here the benefit of the doubt, since it disclosed Life Extension\u2019s support in this study. Furthermore, the availability of green tea is not in question.\nWe rate this one Not Applicable.", "answer": 2}, {"article": "Cocoa contains flavanols, plant-based compounds that also are credited with giving red wine its heart-healthy benefits.\nChocolate-makers have embraced these findings and have developed new ways to satisfy the sweet tooth and curb the guilt by introducing more varieties of dark chocolates, fortifying them with vitamins and anti-oxidants, reports Miller.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nIn the journal, none of the researchers report financial ties to any chocolate companies.\nCocoa confectioner Jacques Torres told CBS News Correspondent Michelle Miller that dark chocolate is wholesome goodness to its very core.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study that this story reported on found\u00a0one particular type of dark chocolate (Ritter Sport Halbbitter) had an effect on blood pressure.\u00a0 While the story was helpful in that it included information about portion size in terms a typical consumer could understand (i.e. about one and a half Hershey\u2019s dark chocolate kisses), it failed to provide information about the availability of the chocolate used in this study. Is it common?\u00a0 Is it found in many other products?\u00a0 ", "answer": 0}, {"article": "The F.D.A.\nThe result was a requirement that a hospital should be doing at least 50 surgical aortic valve replacements a year to have access to the technology.\nAnd new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story summarizes the approval status of several devices. However, it doesn\u2019t explore important caveats about which patients are eligible for TAVR and implies that all comers who are too sick for surgery are eligible.", "answer": 1}, {"article": "And if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nThere is no such screening tool currently in use.\nBut she added that an ongoing study in the United Kingdom involving 200,000 women should more definitively determine the test's value.\nBut none proved as accurate as CA-125 after a Harvard scientist developed a mathematical model combining trends in test results and a patient's age.\nMore than half of the women in the study came from Houston.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The CA-125 test is clearly available. What is not clear is whether the clinical algorithm used in this study to identify high risk women is available widely or only in a research setting.", "answer": 1}, {"article": "We are excited to announce that FibromyalgiaTreating.com is now part of RedOrbit.com. All of the same great people, writers and editors but now with more firepower. We now have access to an enormous amount of additional research information from doctors and scientists. We can now extend to other conditions that may be part of your everyday lives and help you on a broad level if that is what you need. We are here for you and now, better than ever so sit back and enjoy the new Fibromyalgia Treating by RedOrbit!", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that about 30% of mammography centers use computer-aided detection (CAD) technology. ", "answer": 1}, {"article": ".\nStudy results also revealed that urban academic or teaching hospitals performed laparoscopic anti-reflux surgery at a higher rate than open procedures, 54.4 percent versus 45.6 percent.\n\"Anti-reflux surgery should be considered in patients who do not achieve complete control of their symptoms [regurgitation or cough] with medications; who do not want to take medications for the rest of their lives; or who experience complications of medical therapy.\"\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\n\"Our study highlights the fact that laparoscopic anti-reflux surgery is as effective as the open approach, and in 2017, with all its advantages, should be the standard of care,\" said senior study author Marco G. Patti, MD, FACS, a surgeon and Director of the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that both methods of surgery have been widely available nationally and the outcomes of 75,000 surgeries were tracked by the National Inpatient Sample (NIS) database.\nThe release also notes that \u201curban academic or teaching hospitals\u201d perform laparoscopic anti-reflux surgery more often than \u201copen\u201d procedures, 54.4 percent versus 45.6 percent. And it recommends that anti-reflux surgery should be performed laparoscopically in specialized centers.", "answer": 1}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nThe treatment, called Icon, is one of several new cavity treatments that avoid drilling.\nWolff says that while the no-drill approach to treating this type of tooth decay has promise, fluoride treatments and other patient-applied methods are still more inexpensive, less invasive and have a much longer track record of success.\nTo Drill Or Not To Drill\n\nPhark says that when decay is caught very early or very late, dentists have a clear course of action: Early problems can often be reversed with better brushing, fluoride or calcium-containing toothpastes -- and late-stage cavities need to be filled.\nIcon was developed in Germany and has been available in the U.S. for just over a year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story reports that this product has been available in the United States for just over a year. However, it does not say whether dentists need to be trained to use the product.", "answer": 1}, {"article": "The hormone, a form of progesterone, prevents ovulation and thickens the cervical mucus, making it harder for sperm to reach and fertilize an egg.\nOf the many embarrassing health statistics in this country, the huge number of unwanted pregnancies is perhaps the easiest to rectify.\nWith both implants and IUDs, fertility returns quickly as soon as the devices are removed.\nThese facts prompted a committee of the American College of Obstetricians and Gynecologists this month to urge its members to introduce women of all ages to the most effective and underused methods of reversible contraception: IUDs and hormonal implants.\nFurthermore, the committee stated, \u201calmost all women are appropriate candidates\u201d for the LARC methods currently available.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "You could say this story was about availability itself, and especially about why things that are widely available are not prescribed by doctors more often. All of these long-term contraceptives are available.", "answer": 1}, {"article": "In the cognitive behavioral therapy, participants were asked to identify positive activities they used to engage in and then are asked to actively plan those activities again.\nIt's also not clear if this kind of program could be scaled up.\nLead author Claudia Buntrock, a PhD candidate in clinical psychology at Leuphana, says that because the study only tracked participants' mental health over the course of 12 months, the long-term effectiveness of the intervention is unknown.\nSimilar programs have been used to treat depression, but this may be the first one tested to prevent it, the researchers say.\nOther experiments with online therapy have found that people didn't continue it if it wasn't guided by an actual human.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story not only makes clear that this preventive approach to online interventions is fairly novel, but that there are significant questions about whether it could be scaled up.", "answer": 1}, {"article": "The women were then followed for an average of three years.\nLight physical activity includes just about any type of behavior that isn\u2019t sitting down: walking to the mailbox, strolling around the neighborhood and doing laundry.\nAs adults get older, they expend more energy doing the same activities they did when they were younger, LaCroix says\u2014so they don\u2019t need to exercise as much, or as intensely, to burn the same amount of calories or get their heart rate up.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\nYou don\u2019t have to break a sweat to reap the health benefits of physical activity, according to new research in the Journal of the American Geriatrics Society.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job of defining what light activity means, which is important for understanding how accessible it is. Bike riding is a moderate activity, for example, whereas \u201cstrolling around the neighborhood\u201d is a light activity.", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\nThis amount of zinc is equivalent to what biofortified crops like zinc rice and zinc wheat can add to the diet of vulnerable, nutrient deficient populations.\nIn the absence of sufficient zinc, our ability to repair everyday wear and tear on our DNA is compromised.\n\"These results present a new strategy for measuring the impact of zinc on health and reinforce the evidence that food-based interventions can improve micronutrient deficiencies worldwide.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We wish the news release could have talked more about existing zinc fortification efforts around the world, since it\u2019s not clear in the release whether zinc fortification practices are already in place.\nIn the original journal article, researchers mention the zinc fortification programs initiated in more than 30 countries and point out how Bangladesh increased its rice zinc concentration by 50 percent through its biofortification methods.\nFor this reason, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "The watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\nWatson erupts in tears as she calls her mother to say this is the first time she's been able to write her name in ages.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nThe video showed Lawton trying to draw a square with her shaky right hand, and then again, wearing Emma.\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states the device is just a prototype. More could have been said about what this means, but it\u2019s enough to rate satisfactory.", "answer": 1}, {"article": "\"We feel fatty-acid consumption exerts a beneficial effect on brain aging by promoting vascular health,\" said the study's lead author, Dr. Zaldy Tan, associate professor at the Easton Center for Alzheimer's Disease Research and the division of geriatrics at the University of California, Los Angeles.\nThis might include reducing blood pressure and inflammation, he added.\nA clinical trial comparing high and low intake of omega-3s in relation to brain imaging would help answer those questions, he said.\nFind out more about brain health at the Alzheimer's Association.\nBut questions remain over whether fatty-acid levels really influence changes in brain size, Scarmeas added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish isn\u2019t in question.", "answer": 2}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nBut that decision does remain a judgment call.\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nThat test can have side effects.\nOn the first issue, there is still some uncertainty.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that PSA screening is widely available.", "answer": 1}, {"article": "\"Done haphazardly and irregularly, it is probably worse than no breast self-exam at all,\" Steiner said.\nLitt, the breast cancer survivor, has another piece of advice: \"Do not ignore your own judgment; and be assertive,\" she said.\nShe encourages women to schedule an appointment devoted to learning the technique, which should take at least a half-hour.\nA small study in Canada in 1997 found that self-exams seemed to improve survival among a subset of women using proper technique.\nIt defies common sense, she says, for scientists to conclude that breast self-exams do women more harm than good.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of breast self-exams (BSE) is implicit; however, the story appropriately notes that not all physicians or health educators know current BSE technique, and there is a suggestion that inappropriate technique may influence the sensitivity of the self-exam. The story mentions a more sensitive technique\u2013the vertical-strip, three pressure test\u2013 used in Canada, which has been validated in a small subset of women. ", "answer": 1}, {"article": "Nov. 8, 2011 -- A vaccine for breast and ovarian cancer that has spread to other parts of the body shows promise, according to a preliminary study of 26 patients.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\nAs exciting as that is, he says, \"a lot of work needs to be done to prove whether this can be effective [for more patients].\"\nOne woman who got the investigational vaccine now has no X-ray evidence of cancer, says study researcher James Gulley, MD, PhD.\nThe study, funded by the National Cancer Institute, is published in Clinical Cancer Research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We give high marks to the story for saying right in the lead that the findings are from \u201ca preliminary study in 26 patients.\u201d That tells readers both that the findings need to be interpreted with caution and that the treatment is not available to most people.", "answer": 1}, {"article": "Researchers have two main theories on why light therapy works.\nThere's some evidence that depression, like jet lag, occurs when the biological clock is out of sync, and light helps to correct that, Lam said.\nAlthough the light therapy helped many patients, it provided the most benefit to those who were also taking the antidepressant.\nOne is that it affects the biological clock in the brain.\nThe researchers said enough clinical evidence now supports mental health professionals recommending light therapy as a treatment for depression.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since these lights probably aren\u2019t very difficult to find, we\u2019ll rate the story Not Applicable here.\u00a0The story doesn\u2019t specifically address availability and it could have noted what kind of light is needed and whether these lights are widely available. But we won\u2019t ding the story for not mentioning this.", "answer": 2}, {"article": "The researchers do not make any recommendation in their study about whether women who suffer from PMS should increase their intake of essential fatty acids or, instead, consult with their doctor.\nThe study cites research dating back to 1983 examining such a possible link.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nOther treatments studied for PMS include vitamin B6, ascorbic acid and niacin.\nEggs, nuts, vegetable oils and fish are examples of foods that provide such acids, which are also available in supplement form.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described the availability of essential fatty acids in diet and in supplement form.", "answer": 1}, {"article": "Dr Golam Khandaker, who led the study, says: \"It's becoming increasingly clear to us that inflammation plays a role in depression, at least for some individuals, and now our review suggests that it may be possible to treat these individuals using some anti-inflammatory drugs.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nMeta-analyses of the other types of clinical trials showed similar results.\nBy looking at additional beneficial side-effects of the treatments, the researchers were able to show that there was a significant antidepressant effect from the drugs compared to a placebo based on a meta-analysis of seven randomised controlled trials.\nThe team of researchers carried out a meta-analysis of these clinical trials and found that the drugs led to an improvement in the severity of depressive symptoms independently of improvements in physical illness.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While this meta-analysis was done on clinical trials data, all of the drugs involved are currently available for treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis, and the release makes this clear.\n\u00a0", "answer": 1}, {"article": "In 2016, he was ranked the No.\nFAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching.\ndegree.\nJust a few months ago, the FDA removed the black box warning from varenicline.\nSuch a large randomized trial was recently completed that included both apparently healthy individuals as well as those with severe mental illness.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Chantix is commercially available.", "answer": 2}, {"article": "According to the researchers, apixaban reduced this risk by 50 percent, preventing four patients from having this type of stroke and two patients from having an ischemic stroke (cause by a vessel blockage) or stroke of uncertain origin.\nThe study was funded by Bristol-Myers Squibb and Pfizer, the makers of apixaban.\n\"Sometimes it impairs the patient's quality of life and the outcomes are very dependent on how well the drug dosing is managed,\" he added.\nWhile generic warfarin is just pennies a dose, any new brand-name drug is likely to be much more expensive.\n\"The three of them together showed that the risk of bleeding was just too high and there was no real benefit in that population.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that apixabane, the medication reported on, was experimental.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions LASIK is a common surgery, accounting for 87% of all laser eye surgeries last year. The story notes that more surgeons are tailoring techniques and procedures as laser eye surgery grows in popularity,\u00a0but the story also notes that\u00a0corrective eye surgery is not a \"one size fits all\".\u00a0 The story\u00a0 mentions newer tools to improve the LASIK and PRK procedures, but it does not mention if these are widely available. ", "answer": 1}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\nAnd they are already moving forward with new clinical studies using 10-1074 together with 3BNC117, with the hope that combining two antibodies targeting different parts of HIV will be more effective than either antibody on its own.\nThis is why researchers continue to look for other ways to control the virus--and broadly neutralizing antibodies could prove to be part of an alternate treatment strategy.\nA new biologic agent--the most potent of its kind so far--is showing early promise as part of a potential new strategy for treating HIV.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can assume that this is preliminary data collection but it would have been useful if the release included information about how long the research process may be before eligible patients might have access to this new therapy. Next steps regarding future clinical trials are mentioned in the last paragraph.", "answer": 1}, {"article": "Commenting on the next stage of the research, she said: \u201cIn the larger phase II trial we\u2019ve recruited 140 women with relapsed ovarian cancer across the U.K. to standard chemotherapy (paclitaxel) or paclitaxel in combination with vistusertib.\nDr. Dean A. Fennell, professor and consultant in thoracic medical oncology at the University of Leicester, who was not involved in the study, told Newsweek the study presents an \u201cexciting result.\u201d\n\nHe was particularly surprised by the magnitude of the response triggered by vistusertib combined with paclitaxel, which is closely related to standard chemotherapy.\nThe cocktail also stopped the cancer growing for almost six months, which is unexpected for patients with advanced-stage cancers who were unresponsive to currently available treatments, including chemotherapy, the authors said.\nThat is why the patients\u2019 tumors shrunk, the study suggests.\nWe need to wait for these results, expected later this year, to see how effective this approach is compared to chemotherapy alone.\u201d\n\nProfessor Udai Banerji\u200b, author of the study and deputy director of the Drug Development Unit at The ICR and Royal Marsden, acknowledged in an interview with Newsweek the cohort of patients was small, \"however anything more than 20 patients usually gives one a rough idea [of the effectiveness of a treatment].\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned a larger trial with 140 ovarian cancer patients that will test the drug\u2019s effectiveness versus chemotherapy alone, with results \u201cexpected later this year.\u201d This is enough information that a reader can infer that it\u2019s not available yet.\nHowever, the story didn\u2019t explain what scientific and regulatory hurdles would have to be overcome for this drug to become available.", "answer": 1}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nThe work was supported by the Department of Defense, the Meadows Foundation and the Friends of BrainHealth Distinguished New Scientist Award.\nThe knowledge-based training group learned information about the structure and function of the brain as well as the effects of sleep and exercise on brain performance.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "From the news release alone, it is not entirely clear if the brain training program already existed and was simply now applied to those with chronic TBI for the first time.", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\n\u201cLucentis should be considered a viable treatment option for people with PDR, especially for individuals needing anti-VEGF for DME,\u201d said Jeffrey G. Gross, M.D., of the Carolina Retina Center in Columbia, South Carolina, who chaired the clinical study.\nOverall, the drug\u2019s benefits are particularly clear for people with both PDR and DME.\nThe study also suggested that Lucentis may help prevent DME.\nThe results, published by the Journal of the American Medical Association, demonstrate the first major therapy advance for the condition in nearly 40 years.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that Lucentis is already used to treat other diabetes-related eye problems, and \u201cshould be considered a viable treatment option for people with PDR.\u201d", "answer": 1}, {"article": "\"We've got a lot of repeat customers, unfortunately,\" Shah said.\nBut in Europe, Canada and Japan, about 50 percent of catheterizations are performed using the technique devised in the early 1990s.\nLed by Sunil V. Rao at the Duke Clinical Research Institute, the authors found that outcomes were similar but that bleeding complications were 58 percent lower in the wrist group.\nShah and Mazhari say that their patients, many of whom have undergone both kinds of catheterizations, much prefer the wrist approach.\nSome senior interventional cardiologists say they worry that the method may be hyped.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that radial catheterization is most likely not routinely available and that a low percentage (1%) of catheterizations are performed this way.", "answer": 1}, {"article": "For more on obesity, visit the U.S. National Institutes of Health.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\n\"The important thing to keep in mind is that although we diagnose obesity on the basis of a mathematical formula -- a BMI of 30 and up -- the basis for obesity may differ from one individual to another.\"\nPsychological factors or lifestyle factors may play a role, he said.\nAll study participants followed their treatment plan for one year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that zonisamide is already used as an anti-seizure drug.\u00a0 It did not discuss whether it\u2019s used off-label for weight loss.\nFrom an availability perspective, it also didn\u2019t provide enough detail about this statement:\n\u201cAll study participants followed their treatment plan for one year. During this time, they all also received monthly individualized nutritional counseling, which Gadde described as \u201cnot intensive,\u201d to help them reduce their overall caloric intake.\u201d\nWhat does \u201cnot intensive\u201d actually mean?\u00a0 Since this was part of the treatment \u201cpackage,\u201d how generalizable is this approach?\u00a0 What kind of setting would be capable of delivering it?\u00a0 The vague \u201cnot intensive\u201d comment just isn\u2019t helpful at all.", "answer": 0}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Plavix (clopidogrel) is a medication already on the market. \u00a0While the story did not state this explicitly, it was implied.", "answer": 1}, {"article": "Dr Arthur Roach, Director of Research at Parkinson's UK, which funded the study said:\n\n\"People affected by Parkinson's, their carers, and health and social care professionals have said that preventing falls and improving balance is the biggest unmet need for people living with the condition, other than finding a cure.\nIt affects 127,000 people in the UK - which is around one in 500 of the population.\nScientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson's.\nParkinson's UK is the UK's leading charity supporting those with the condition.\nHalf the group were given rivastigmine capsules and the other half a placebo for an eight month period.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is already available as a treatment for Alzheimer\u2019s disease patients.", "answer": 1}, {"article": "Worldwide, more than 10 million people have impaired vision or blindness as a result of corneal damage, but only a small fraction ever receive transplants from cadaver donors.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nAfter several years of testing in her lab, Griffith began collaborating with Swedish eye surgeon Per Fagerholm of Linkoping University, who implanted the engineered collagen corneas into the 10 patients in Sweden.\nNine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant.\n\u201cThis is the first time we have been able to regenerate a cornea in humans,\u201d researcher May Griffith, PhD, of the Ottawa Hospital Research Institute and the University of Ottawa tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Of the three stories, this one does the best job making it clear how preliminary this study is. The second sentence says that the results are from \"the first 10 people in the world treated with the biosynthetic corneas,\" signaling that much more work needs to be done. To underscore that point, two paragraphs later the first quote in the story, from one of the lead researchers in the study, says \"We are still in the prototype stage, but this shows that regenerating a human cornea is possible.\" This is the best quote in any of the stories.", "answer": 1}, {"article": "\u201cWho doesn\u2019t want to maximize their cognitive ability?\nA number of companies now market nootropic \u201cstacks,\u201d or formulas, some of which include piracetam, herbal remedies, amino acids and citicoline, a naturally occurring brain chemical that can be taken orally as a supplement, intravenously or as a shot.\nMost often they mean piracetam, which Giurgea first synthesized in 1964 and which is approved for therapeutic use in dozens of countries for use in adults and the elderly.\n\u201cIt\u2019s the few who are getting ahead who are using supplements to do that.\u201d\n\nThe word \u201cnootropic\u201d was coined in 1972 by a Romanian scientist, Corneliu Giurgea, who combined the Greek words for \u201cmind\u201d and \u201cbending.\u201d Caffeine and nicotine can be considered mild nootropics, while prescription Ritalin, Adderall and Provigil (modafinil, a drug for treating narcolepsy) lie at the far end of the spectrum when prescribed off-label as cognitive enhancers.\nBut it\u2019s only one of many formulations in the racetam drug family.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job here, although it injects confusion when it states that in the U.S. piracetam \u201ccan be sold only for research purposes,\u201d but later says that piracetam and similar drugs are available online. In fact, the FDA at least twice warned suppliers, in 2010 and 2012, that piracetam was classified as a drug and could not be sold as a supplement. According to online accounts, that FDA action prompted major retailers to stop carrying it, which could explain why it\u2019s not present in some products marketed as nootropics.\nThe story also states: \u201cA number of companies now market nootropic \u2018stacks,\u2019 or formulas, some of which include piracetam, herbal remedies, amino acids and citicoline, a naturally occurring brain chemical that can be taken orally as a supplement, intravenously or as a shot.\u201d", "answer": 1}, {"article": "A surgically implanted electrical device that stimulates the sacral nerve can calm an overactive bladder, according to a company that sells it. Physicians say sacral neural stimulation works well for many patients, but a test period with an external device is recommended first.\n\nMillions of Americans suffer from \"urge incontinence,\" accidents caused by a strong, sudden need to get to the bathroom, or overly frequent urination, defined as eight or more times a day. Quality of life is affected, as sufferers must...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly the device is available, but it is not clear how widely and how many practitioners are trained in implanting the device.", "answer": 0}, {"article": "The group that received standard education lowered their scores by an average of 1 point.\nThere are still plenty of questions about the effects of mindfulness meditation on sleep quality.\nThe problem, Spira said, is that behavioral therapy for sleep problems is not always easily found -- and even when it's available, the process takes some effort.\nBy learning \"non-judgmental mindful awareness,\" Black said, people can begin to see their thoughts and feelings without reacting to them.\nThe caveat, according to Spira, is that this study tested that specific program.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the type of meditation therapy is available in various forms and even includes a link to the specific therapy from UCLA that was included in the study. In addition, there was a very nice general description of the technique to help readers imagine how it works: \u201cIn general, \u2018mindfulness\u2019 practices encourage people to focus their attention on the present moment, instead of the past or future, and to take an objective look at their thoughts and emotions.", "answer": 1}, {"article": ".\n\"Our study shows pre-hospital clot-busting is a promising, evolving approach to providing tPA stroke therapy.\n\"Time is brain in acute stroke after vascular collaterals fail, and faster treatment yields better outcomes,\" said May Nour, M.D., Ph.D., lead researcher, interventional neurologist and director of UCLA's Mobile Stroke Rescue Program.\nEvery second counts, in the current standard of care, patients who experience stroke-like symptoms and call 9-1-1 arriving to the hospital by ambulance are assessed by clinical examination and imaging (CT or MRI scan) in the Emergency Department.\nResearchers analyzed information about patients' disabilities to determine how many needed to be treated in the mobile stroke unit to yield a greater benefit in disability outcomes when compared to patients who received tPA at the hospital.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is not addressed beyond UCLA\u2019s Mobile Stroke Rescue Program, which collected the data for the study.\nIt would have been good to mention that specialist-staffed mobile stroke units have been popping up in different parts of the country over the last 3-4 years. They are mainly affiliated with larger medical centers and funded by private donations. ", "answer": 0}, {"article": "\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nThe study began in the 1980s, and along the way has recorded valuable data from participants, including diabetes test data.\nThe study was published June 19 in the journal Annals of Internal Medicine.\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\nThe new study \"helps us move quicker to treat diabetes,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that both blood tests are routinely performed for diabetes.", "answer": 1}, {"article": "Previous recommendations from the Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) had previously called for nasal sprays, or live attenuated influenza vaccine (LAIV), not be used during the 2016-2017 flu season.\nThen, subsequently, it was no longer preferred and now not recommended at all.\nPublished today in the scientific journal Annals of Internal Medicine, the study shows that the nose spray had a similar effect to the standard flu shot.\nThis study was funded by the Canadian Institutes for Health Research.\nThey are also looking at the effect of repeated vaccination of children.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both forms of immunization \u2014 shots and nasal spray \u2014 have been around for some time, their availability is widely known, earning the release a Satisfactory in this category.", "answer": 1}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story does not tell us whether what it calls the \u201cmini-open\u201d and other less invasive surgical techniques are widely available. \u00a0It implies that they are, but by calling them \u201cnew\u201d it likewise makes one wonder whether it may take time for them to penetrate to all surgical practices.", "answer": 0}, {"article": "Bernstein and her colleagues saw an overall 16 percent lower risk of breast cancer in women who reported using low-dose aspirin at least three times per week.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\nCity of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nWe also did not find associations with regular aspirin since this type of medication is taken sporadically for headaches or other pain, and not daily for prevention of cardiovascular disease.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release explicitly states that low-dose aspirin is \u201creadily available\u201d and that\u2019s widely known to be the case.", "answer": 1}, {"article": "In those scenarios, a woman age 30 to 60 has had two consecutive normal Pap tests but no HPV tests; two normal Paps and a negative HPV test; or a negative HPV test but no recent Pap tests.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\n\u201cOften a provider just does the HPV test\u201d without telling the patient.\n\u201cWe need to shift toward the wellness visit as opposed to, \u2018You have to come in here every year for a Pap,\u2019\u201d Castle said.\nThat\u2019s because HPV \u2014 which causes changes in the cervix that can lead to cancer \u2014 may take a decade to progress to that point.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The entire story was about cervical cancer screening being made TOO available too often.", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that stent insertion is widely available and frequently done.", "answer": 1}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\n\"In 2010, our research group published an article providing the first evidence for the existence of Alzheimer's-specific plaques in the human retina, and we demonstrated the ability to detect individual plaques in live mouse models using a modified ophthalmic device.\"\n\"We know that Alzheimer's begins as many as 10 or 20 years before cognitive decline becomes evident, and we believe that potential treatments may be more effective if they can be started early in the process.\nFindings from this study strongly suggest that retinal imaging can serve as a surrogate biomarker to investigate and monitor Alzheimer's disease,\" said Maya Koronyo-Hamaoui, Ph.D., an associate professor of Neurosurgery and Biomedical Sciences and a research scientist at the Maxine Dunitz Neurosurgical Institute at Cedars-Sinai, and a co-founder, inventor and scientist at NeuroVision.\nWe look forward to the potential of retinal imaging playing a vital role in solving the problem of Alzheimer's, both in identifying and monitoring those who may be affected by the disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although not as clearly stated as it could be, it does come across in one of the quotes that this is a technology that is not yet available for use.\n\u201cIt\u2019s exciting to see these studies demonstrating the power of the technology applied to the Alzheimer\u2019s field. Our goal is to develop a product that is easy to use, affordable and widely accessible. We look forward to the potential of retinal imaging playing a vital role in solving the problem of Alzheimer\u2019s, both in identifying and monitoring those who may be affected by the disease. Our next step is to continue with clinical trials, building upon the existing pharmaceutical company collaborations, to ensure our technology is ready for the medical community to help manage this disease.\u201d", "answer": 1}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In the lead-in to her interview with the reporter, the CNN anchor states in passing that \"as always with things that are seeking approval, and there are benefits and there are of course risks.\"\u00a0She is alluding to the fact that this\u00a0asthma treatment involves an investigational device that has not yet been approved by the FDA. However,\u00a0this is never directly stated. We\u00a0think there\u2019s a good chance the average\u00a0viewer will think that this\u00a0treatment\u00a0is already available, but it isn\u2019t.\u00a0\u00a0", "answer": 0}, {"article": "Nathan Mumford, who is African-American, tried to find a bone marrow donor after his leukemia was diagnosed not long after he graduated from college.\nAt that point, Mumford said, his choices were to continue chemotherapy and live for, maybe, another year and a half.\nEven siblings are not a sure thing, with the chance of matching a brother or sister only 25 percent.\nBut Tirpak's physician, Dr. Mary Laughlin, turned to something deemed medical waste until recently: umbilical cord blood.\nCord blood transplants among unrelated donors have risen from 1 percent in 2001 to 24 percent last year, Laughlin says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This topic was unclear. The story implies that the chain of events from cord blood donation, national registration, and transplantation is currently available. We would like to have seen a clearer, more direct discussion on its current availability, and the statistics were vague. \"Cord blood transplants among unrelated donors have risen from 1 percent in 2001 to 24 percent last year.\" 24 percent of what? Of all stem cell transplants? How many of those recipients were children?\nThe important distinction between use of this procedure in children and in adults should have been discussed.", "answer": 0}, {"article": "The researchers conclude that the added sensitivity of cotesting versus HPV alone for detection of treatable cancer affected extremely few women.?\nThis remains the most extensive experience of HPV testing incorporated into routine screening in the world.\nBut improved screening methods have also introduced some confusion, even controversy.\nHowever, reports of rare HPV-negative, Pap-test-positive cancers are motivating continued use of both tests (cotesting) despite increased testing costs.\nHPV testing is more sensitive than the Pap test for detecting precancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is implied that these tests are widely available in the US.", "answer": 1}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nSo when the implant is turned on, it electrically stimulates the nerves in order to cause the muscles to move in motions, for example, to open and close the hands.\nAnd functional electrical stimulation is using low levels of electricity in order to activate nerves and muscles in order to restore movement,\" explains Dr. Hunter Peckham, director of the Cleveland F.E.S.\nWith the touch of a button, Annette turns on a device much like a pacemaker that's implanted in her chest.\nis functional electrical stimulation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the device is available anywhere other than this clinic in Cleveland. In addition, it isn\u2019t clear whether it is investigational or FDA-approved. Is the woman in the story a study subject or is this part of routine care?", "answer": 0}, {"article": "The amygdala and hypothalamus are regions of the brain that control several memory and emotional functions.\nNewswise \u2014 Lovers of Indian food, give yourselves a second helping: Daily consumption of a certain form of curcumin \u2014 the substance that gives Indian curry its bright color \u2014 improved memory and mood in people with mild, age-related memory loss, according to the results of a study conducted by UCLA researchers.\n\u201cThese results suggest that taking this relatively safe form of curcumin could provide meaningful cognitive benefits over the years,\u201d said Small, UCLA\u2019s Parlow\u2013Solomon Professor on Aging.\n\u201cExactly how curcumin exerts its effects is not certain, but it may be due to its ability to reduce brain in\ufb02ammation, which has been linked to both Alzheimer\u2019s disease and major depression,\u201d said Dr. Gary Small, director of geriatric psychiatry at UCLA\u2019s Longevity Center and of the geriatric psychiatry division at the Semel Institute for Neuroscience and Human Behavior at UCLA, and the study\u2019s first author.\nThe paper\u2019s authors, in addition to Small, are Prabha Siddarth, Dr. Zhaoping Li, Karen Miller, Linda Ercoli, Natacha Emerson, Jacqueline Martinez, Koon-Pong Wong, Jie Liu, Dr. David Merrill, Dr. Stephen Chen, Susanne Henning, Nagichettiar Satyamurthy, Sung-Cheng Huang, Dr. David Heber and Jorge Barrio, all of UCLA.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Theracurmin is available from several sources not mentioned in the news release. The initial comments in the release give the reader the erroneous impression that eating Indian food is equal to the form used in the study. (We also discuss this under Unjustified Language.)\nThe lead sentence of the news release \u2014 \u201cLovers of Indian food, give yourselves a second helping \u2026\u201d \u2014 implies that the alleged benefits of curcumin might be achieved through diet alone, thus making availability a no-brainer. But the dosages used in the study (which we\u2019re not told are about three times the commonly recommended dose) require oral supplements, which certainly are widely available in health stores and online, but at a much greater cost than the kitchen spice.", "answer": 0}, {"article": "\u2022 Swelling or thickening in part of the breast.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\n\"With today's state-of-the-art treatment options and less extensive surgery, patients are experiencing better outcomes.\"\nThese tests can help find breast cancer in its early stages, even before symptoms appear.\"\nIn some cases, women never develop any of these symptoms, Evers noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that all of these screening methods are available.", "answer": 1}, {"article": "As Alzheimer\u2019s disease progresses, cognitive impairment can take an ever greater toll on communication and relationships.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\nSome of the caregivers did voice frustration or tried to teach their partners information they had forgotten.\nA relationship is obviously so much more than that.\u201d\n\nMembers of Williams\u2019s research team visited 15 couples in their home once a week for 10 weeks.\n\u201cAt the same time, people with Alzheimer\u2019s do have moments of clarity or show affection when it\u2019s unexpected.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The behavioral approaches derived from this study seem to be easily adoptable by caregivers. However, the story mention that the couples were receiving specific training on these communication techniques. Is such training widely available? The story doesn\u2019t say, and the average reader probably doesn\u2019t know.", "answer": 0}, {"article": "If doctors know someone is at risk for premature labor earlier in pregnancy, they might start efforts to help delay labor, such as recommending bed rest.\nThe test, if it does turn out to work in clinical trials, would be cheaper than ultrasound, said Quake.\nThere's a lot more work to be done before these tests becomes available, including clinical trials.\nBut the findings are promising, particularly because premature delivery is such a serious problem.\nThis test might help.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear about the test\u2019s availability in above-the-fold copy, stating it \u201cis still experimental and not yet available outside of a research lab.\u201d There\u2019s even a reference to it being experimental in the story summary. (But why not include \u201cexperimental\u201d in the headline, too?)", "answer": 1}, {"article": "To see if healthy tissue surrounding the cavity could be coaxed into healing the stroke injury, Segura engineered a gel to inject into the stroke cavity that thickens to mimic the properties of brain tissue, creating a scaffolding for new growth.\nIn addition to Carmichael and Segura, other authors of the paper are Lina Nih and Shiva Gojgini, both of UCLA.\nThe study was supported by funds from the National Institutes of Health.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\nCarmichael and Segura collaborated on the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made fairly clear that the gel used in this study was developed by the authors, is experimental, and most likely not available for widespread use.", "answer": 1}, {"article": "Lactoferrin supplementation also enhances the expression of salivary immune proteins, which may help reduce oxidative stress and resulting side effects.\n\"The prevailing symptom described by patients undergoing chemotherapy is a persistent metallic flavor or aftertaste, with or without food intake.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\nTheir findings could bring relief to millions of patients undergoing cancer treatment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It wasn\u2019t made clear enough in the release that lactoferrin supplements are available online. Many readers might erroneously think the only source is drinking milk.", "answer": 0}, {"article": "It will also help remove the uncertainty surrounding which sub type of the disease an individual has and therefore be a catalyst for better outcomes for all people with MS.\"\n\nMultiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS).\nPublished today in Scientific Reports, the discovery identifies tiny 'dysregulated' micro-RNA molecules that correctly diagnose MS and discriminate between patients at different disease stages - all in a simple blood test.\nThe research was made possible through the generosity of patients at the Brain & Mind Centre's multidisciplinary Multiple Sclerosis Clinic, a collaborative service offered by Royal Prince Alfred Hospital, and the University of Sydney.\nCurrently, there is no definitive test for MS.\n\"This is the first demonstration that micro-RNAs associated with circulating exosomes in blood are informative biomarkers not only for the diagnosis of MS, but in predicting disease subtypes with a high degree of accuracy,\" said Associate Professor Michael Buckland, Head of the Department of Neuropathology at RPA Hospital and the Brain and Mind Centre, University of Sydney.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This research is basic, so one might expect a reader to infer that the blood test is not yet available.\u00a0 But the text could have reinforced that by indicating what next steps need to be taken in order to validate this discovery and move it into clinical use.", "answer": 2}, {"article": "Strawberries have the potential to prevent esophageal cancer, according to a preliminary study released Wednesday.\n\nResearchers, led by Ohio State University, were able to show that freeze-dried strawberries slowed the growth of dysplastic, or precancerous, lesions in about 30 people who consumed the fruit for six months.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of strawberries is not in question. The story notes that a strawberry-industry-funded agency supplied the fruit for the study.\u00a0 One online commenter on the WSJ site wrote, \u201cIf you need someone to \u2018contribute\u2019 strawberries for research .. you already know the outcome.\u201d", "answer": 2}, {"article": "Please see paper for the complete list.\n\u201cEven though we see the far-reaching implications of this success, we also realize that this is a very small study that needs to be replicated in larger numbers at various sites.\u201d Plans for larger studies are underway.\nWithout effective prevention and treatment, the prospects for the future are bleak.\n\u201cWe think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well.\u201d\n\nWhile encouraged by the results of the study, Bredesen admits more needs to be done.\nNow we\u2019re recommending that people find out their genetic status as early as possible so they can go on prevention.\u201d Sixty-five percent of the Alzheimer\u2019s cases in this country involve APOE4; with seven million people carrying two copies of the ApoE4 allele.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Some of the MEND interventions, such as dietary changes and exercise, may be readily available. But the intensiveness that this approach requires would make it hard for most people to access financially and logistically. Perhaps the book about the program, when it publishes, will make this clear, but the news release does not.", "answer": 0}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nSo researchers have been trying for decades to figure out how to build an inexpensive odor sensor for quick, reliable and noninvasive diagnoses.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nModern medical research, too, confirms that the smell of someone\u2019s skin, breath and bodily fluids can be suggestive of illness.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told we\u2019re 3-5 years away from seeing this technology on the street, so that establishes\u00a0its current (lack of) availability.\nBut the certainty with which this estimate is passed along by a researcher who\u2019s developing such products should have received more scrutiny. This assumes that current testing will work out as planned. Moreover, three to five\u00a0years is likely\u00a0only enough time to show that the detection of cancer may be earlier by using the odor technology, and not the needed outcomes that we discussed above.\n5-year predictions in medicine generally have a poor track record.", "answer": 0}, {"article": "A drug-coated stent made by Abbott Laboratories that is awaiting U.S. regulatory approval is as safe as, and potentially more effective than, the market-leading version of the heart device made by Boston Scientific Corp., according to findings presented Tuesday at the EuroPCR conference in Barcelona.\n\nClinical-trial data analyzed by Abbott two years after its Xience V stents were implanted in patients are likely to reassure investors and regulators about the product's long-term safety and could restore some investor confidence...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the stent in question is not yet approved by the FDA. ", "answer": 1}, {"article": "Subsequently, a clinician will help a patient learn to slow down or speed up those brain waves, through a process known as operant conditioning.\nRobert Coben, a neuropsychologist in Massapequa Park, N.Y., said he had treated more than 1,000 autistic children over the past seven years and had conducted a clinical study, finding striking reductions in symptoms, as reported by parents.\nDr. Norman Doidge, a psychiatrist at the Center for Psychoanalytic Training and Research at Columbia and the author of \u201cThe Brain That Changes Itself\u201d (Viking, 2007), said he considered neurofeedback \u201ca powerful stabilizer of the brain.\u201d Practitioners make even more enthusiastic claims.\n\u201cOftentimes what people do is find a way to get one of these machines on eBay and use it at home,\u201d she said, adding that unskilled use could interfere with medications or prompt an anxiety attack or a seizure.\nWilliam E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story mentioned that there are 7,500 mental health professionals that offer neurofeedback services.", "answer": 1}, {"article": "The National Cancer Institute estimates 241,740 new cases of prostate cancer this year in the U.S. and 28,170 deaths.\nThe study was published Tuesday in the journal The Lancet Oncology.\nThe new study, designed as a proof-of-concept study, involved just 41 men.\n\u201cWhen you look at the current standard of care, there\u2019s a 1-in-3, or 1-in-2 chance of having the perfect outcome.\nDoctors used MRI and mapping biopsies to locate the cancerous tissues.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was about a British study.\u00a0 There was no mention of the availability of HIFU in the US.", "answer": 0}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nThis early-stage study represents a big step toward doctors and their patients making that decision.\nThe next step, he said, is for group members to validate the predictive power of the markers his team found.\n\u201cAnd if we can do that, then there\u2019ll be enough confidence to put it into use in the clinic.\u201d\n\nEven better, he suggested, it may one day be possible to use drugs to target the SNiPs, or the biological processes they influence, as a way to prevent damage from therapy.\nThat hope is evident to other researchers, such as Dr. Ithaar Derweesh, a urologic oncologist and associate professor of surgery at the University of California San Diego Moores Cancer Center.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article clearly indicates that this work is experimental and would require extensive validation before it could be considered for clinical practice.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\n\u201cLabor pain matters more than just for the birth experience.\nResearchers found the higher the PIP scores, the lower the EPDS scores.\nAnd, therefore, alleviating this pain might help reduce the risk for postpartum depression.\nTo learn more about the role physician anesthesiologists play in ensuring patient safety, visit asahq.org/WhenSecondsCount.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Epidurals are so widely available we don\u2019t think the availability needs to be stated.", "answer": 2}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the availability of the products discussed.", "answer": 1}, {"article": "For more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\n\"These findings allow surgeons to select which patients with microinvasive tumors may actually benefit from lymph node sampling, while sparing other patients from this procedure,\" said Tamera Lillemoe, M.D, pathologist and a study co-author.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\nPhysicians at the Virginia Piper Cancer Institute wanted to know if surgical procedures to test the lymph nodes for cancer were always necessary.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not address availability specifically but readers can glean from the release that lymph node biopsy is a common surgical procedure. The release summarizes the study\u2019s research question: Should lymph node biopsies in tumors that are 1mm or less in size remain common practice?", "answer": 1}, {"article": "But we don't know we're right yet.\"\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nThose efforts have failed to produce a single approved drug so far.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\nThe publication in Nature on Wednesday provides details about those early reports.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story calls the drug experimental and says that it will take several years for larger studies to report results. It\u2019s apparent that the drug won\u2019t be available outside of a research study any time soon.", "answer": 1}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that CBT can be provided by any trained therapist or nurse. The story could have been more\u00a0helpful if it had specified how common this training is and how a patient seeking CBT could go about finding a health care professional trained in the technique. The article also might have mentioned that systematic analysis of studies has shown that even web-based versions of cognitive behavioral therapy can effectively treat insomnia, making it even more widely available.", "answer": 1}, {"article": "Older mice treated with THC performed to the same standard as young mice that had not been given the drug.\nHuman lifespan is very extensive.\nMoving this research forward, however, will be problematic: \u201cTesting in humans is going to be difficult.\nResearchers are increasingly examining THC (tetrahydrocannabinol) for its potential medical benefits.\nIn humans it could be years before an effect is noticed.\u201d\n\n\u201cFinally, there is the issue surrounding safety.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty widely known that cannabis products are becoming increasingly available in many states, and medicinally in some.", "answer": 2}, {"article": "In the open surgery, a relatively large incision is made in the abdominal wall.\nHowever, about half as much blood was lost when robots were enlisted than with standard laparoscopy.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\n\u201cRobotic-assisted surgery is in its infancy, and it definitely has a future,\u201d said Nezhat.\nMore research is needed to be able to compare long-term outcomes, wrote the researchers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t include \u2013 and it wouldn\u2019t have taken much to do so \u2013 any estimate of the number of robotic surgery facilities in the US.\u00a0 And it didn\u2019t give any estimate of how often the open, laparoscopic or robotic procedures are done.", "answer": 0}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nAnd those issues have a huge impact on daily life, for patients and their caregivers, Scharre added.\nWhat's needed, said Fargo, is research that compares deep brain stimulation against a placebo device.\nIf DBS ever becomes an option for Alzheimer's, Scharre said it would not be for everyone.\nSo any new therapies that help address those issues would be welcome.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like the prominent placement of the caveat that \u201cit\u2019s far too early to know whether it has value for people with Alzheimer\u2019s\u201d and it\u2019s \u201cnot something patients can ask their neurologist for.\u201d It also mentions DBS \u201cwould not be for everyone\u201d including people who are frail or have other serious medical conditions.", "answer": 1}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\n\"If five types of the disease exist, how does this change popular medical opinion on prostate cancer screening?\nThe researchers said the analysis in their study is better at forecasting how prostate cancer will advance compared to the current diagnostic tests being used for prostate cancer such as the prostate specific antigen test and the Gleason score.\nFor men with a family history of the disease, contact Dr. Samadi to learn more about your risk factors and to get a baseline PSA blood test.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can\u2019t be sure if the testing protocol discussed in the release is available or not. One might reasonably assume that genetic cancer screening for the five identified genetic types of prostate cancer is available at the specialist\u2019s hospital. However, the release isn\u2019t clear on this point.", "answer": 0}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\nPhysicians can also help.\nWalking Fends Off Loss Of Mobility, And It's Not Too Late To Start\n\nPeople who have reached their later years may think it's primarily a time to relax, not to increase their physical activity.\nBut he says that many believe that older age is for relaxing and that physical activity is somehow dangerous or unnatural.\nThe exercise program pretty closely followed the government's recommendations for all adults, including older ones: 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week, plus two strength sessions that hit all the major muscle groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since walking and physical activity are available to all capable of such exercise, there is no question about availability here.", "answer": 1}, {"article": "Acetylcholinesterase inhibitors increase acetylcholine levels in the brain and, in effect, substitute nicotine's effects.\nFor both drugs, \"we were able to show a reduction in total nicotine self-administered,\" Schmidt said; however, there was a caveat.\nBefore the trial began, researchers assessed the smokers' cognitive function to get a baseline.\n\"We know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and this will limit their compliance,\" he said.\nThere's no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that galantamine is FDA approved which speaks to its availability. The release responsibly points out that \u201cThere\u2019s no data to suggest that a clinician treating a smoker should prescribe one of these AChEIs now,\u201d according to the lead investigator.", "answer": 1}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nThe women had taken another breast cancer drug, tamoxifen, for several years and then were started on an aromatase inhibitor, which doctors usually prescribe for five years.\nThere had been no research on whether that was beneficial.\nThere was no difference in survival, however: 100 women in each group died during the study.\nThe study, which was also published Sunday in the New England Journal of Medicine, was partially funded by Novartis, which sells letrozole \u2014 the aromatase inhibitor used in the trial \u2014 as the branded drug Femara.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The drug letrozole is already available, and the story makes this clear.", "answer": 1}, {"article": "Warren said.\nLike all laparoscopic procedures, a camera is inserted through a tiny incision to see into the abdomen; two other small incisions are made so that tools can be inserted to perform the surgery.\nAbout 90 percent of all gall bladder surgeries are done laparoscopically, so why not hysterectomy?\nWarren is one of relatively few surgeons who perform hysterectomy with a minimally invasive, laparoscopic technique.\nWhat frustrates Warren is that only about 15 percent of hysterectomies are done this way.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does comment on the fact that the availability of laparoscopic hysterectomy is somewhat limited. However, the story does not address the reasons why laparoscopic hysterectomy is limited, including the fact that it doesn\u2019t provide many advantages compared to vaginal hysterectomy. In fact, according to a Cochrane review, laparoscopic hysterectomy is associated with increased operating time and blood loss relative to vaginal hysterectomy.", "answer": 0}, {"article": "But there's a big \"if.\"\nStudy authors and other experts say doctors should be sure the child really is suffering from an ear infection before writing that prescription.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nTwo new studies add substantial weight to one side of a long-running controversy over whether to give antibiotics to young children suffering from ear infections.\nHoberman says they can cut through some of the fog by asking doctors if their child has the telltale \"bulging eardrum\" sign that indicates a true ear infection.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that the \u201cwait and see\u201d approach to ear infections is widely recommended. The accompanying radio piece reported that there are \u201c13 million prescriptions every year for ear infections,\u201d in part because only about 20% of doctors actually follow that approach.\n", "answer": 1}, {"article": ".\nPrevious, mostly experimental research has suggested that spices and their bioactive ingredient, capsaicin, have anti-obesity, antioxidant, anti-inflammation and anti-cancer properties.\nPeople with gastrointestinal issues, for example, should hold off on the hot sauce.\nBut experts caution that this doesn\u2019t mean everyone should pile on the spices at dinner time to improve their health and increase their longevity.\nThe authors suggest further research should investigate the benefits of other spices and the effects of certain chili pepper subtypes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Red hot chili pepper are widely available in American supermarkets.", "answer": 2}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Progestin IUD is clearly available.", "answer": 1}, {"article": "Of those 40 women, 26 had mutations carrying low to moderate risk of breast or ovarian cancer, eight had mutations associated with Lynch syndrome, which increases colon and ovarian cancer risk, and three had high-risk breast cancer genes.\nEarlier this year, 17 genetic experts argued against testing for a wider panel of breast cancer-related gene mutations until they are proven to be valid and useful in clinical practice (see Reuters story of May 27, 2015 here: reut.rs/1TvOoDf).\nAnd for many, family testing would be recommended for first-degree relatives, according to the report in JAMA Oncology.\nBut new tests for breast cancer risk mutations beyond the well-known BRCA genes would offer actionable information for many women and their doctors, a new study finds.\n\u201cMany cancer genetics experts have again urged caution, characterizing the use of multigene testing in the clinical setting as premature,\u201d Dr. Elizabeth M. Swisher of the University of Washington Medical Center in Seattle writes in a commentary accompanying the new paper.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability isn\u2019t explicitly addressed, the story does note that women and their physicians are \u201cordering a wide selection of multiplex tests daily,\u201d from which one can infer that they are available. The story could have been more specific as to which panels were tested here and what others are available from physicians and even online. A good review is included in a table in this recent article from the NEJM.", "answer": 1}, {"article": "January 30, 2018 - For older women undergoing mastectomy for breast cancer, direct-to-implant (DTI) breast reconstruction provides good outcomes in a single-step procedure, while avoiding some of the inconvenience and risks of staged approaches to breast reconstruction, reports a study in the February issue of Plastic and Reconstructive Surgery\u00ae, the official medical journal of the American Society of Plastic Surgeons (ASPS).\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nDr. Moreira and colleagues write, \"These reported cases include our learning curve patients as we familiarized ourselves with appropriate patient selection and surgical technique.\"\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\nThe researchers emphasize that DTI isn't an option for every patient, depending on breast shape and other factors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release does mention that the tissue expander approach is more established and widely used, it could have been more explicit \u2014 as the authors of the study were \u2014 in letting us know \u201cthis is relatively new technique.\u201d\nWe\u2019re told\u00a0 that DTI \u201chas emerged as a single-stage approach to immediate breast reconstruction after mastectomy\u201d and we get this quote from one of the lead authors:\nThe DTI approach is a powerful tool for breast reconstruction in elderly patients.\nTaken together these two quotes could give readers an erroneous sense that this is an established and proven option. It\u2019s not.", "answer": 0}, {"article": "Cardiac arrest involves the abrupt loss of heart function, breathing and consciousness.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\nAfter 13 minutes, patients who got CPR at the scene continued to have better survival odds but the difference was no longer statistically meaningful.\nThe biggest obstacle to bystander CPR remains that too few people know how to do it, said Dr. Peter Pons, an emergency physician in Denver and professor emeritus at the University of Colorado School of Medicine.\n\u201cClearly, if someone has been motivated to learn and has been taught CPR, they will often assist,\u201d Pons, who wasn\u2019t involved in the study, said by email.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t outright state that pretty much anybody is capable of performing CPR. However, it does imply that CPR is widely available\u00a0by explaining that the biggest barrier to bystander CPR is that too few people know how to do it. More explanation about how easy it is to learn the procedure (training can be done in just a few minutes) would have improved that aspect of the article.", "answer": 1}, {"article": "\u201cWe are not quite there yet, but it may become a real possibility for finding out real information without having to risk a pregnancy.\u201d\n\nFor example, \u201cIf this comes back negative, you don\u2019t need an amniocentesis, but if it comes back positive, we would probably still do an amniocentesis to confirm the results,\u201d she says.\nThe new test looks \u201cvery promising,\u201d says Cathy Sullivan, a genetic counselor at the University of Texas Health Sciences Center in Houston.\nIt is not a diagnostic test for Down syndrome, she says.\n\u201cIt\u2019s not ready for prime time, but researchers are actively working on methods to increase its efficiency,\u201d he says.\nIt can help women put some of the information from other tests into context.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story leans on an independent expert to say that the test is \u201cnot ready for prime time\u2026.in a year or two, this test may be available.\u201d", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focused on FDA approval.\u00a0 It also mentioned the drug company\u2019s financial assistance plan.", "answer": 1}, {"article": "JACC is ranked No.\nThe mission of the College is to transform cardiovascular care and to improve heart health.\nThe latest research and clinical practice updates in cardiology are at your fingertips with the JACC Journals app for iPhone/iPad and Android.\nThey also looked a several early indicators of heart disease.\nThe ACC leads in the formation of health policy, standards and guidelines.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "With the \u201ctreatment\u201d being physical exercise, availability is a given. There are countless ways to exercise and there need not be any cost involved.", "answer": 1}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that testosterone is available. It would have been\u00a0helpful to clearly state that this requires a prescription, but this is a minor quibble.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that these over-the-counter drugs are widely available and that Nicorette is the market leader. \u2018Glaxo products\u2014which include Nicorette gum and lozenges and NicoDerm patches\u2014account for more than half of the $835 million market in annual U.S. retail sales of over-the-counter smoking-cessation aids, according to market-research firm Euromonitor International. Pfizer Inc. and Novartis AG also market NRT.\u201d", "answer": 1}, {"article": "In 2008, Medicare paid for 480,000 injections of Avastin to treat macular degeneration and 337,000 injections of Lucentis, according to a study led by Dr. Philip Rosenfeld of the University of Miami.\nSafety of the two drugs will also be closely watched.\nSales of the drug for each company were about $1.5 billion last year.\nThe result was largely expected.\nPatients in the trial are being followed for a second year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides information on\u00a0the FDA\u00a0approval status, off-label usage, and utilization of both drugs.\n", "answer": 1}, {"article": "Niki Munk, an assistant professor of health sciences in the School of Health and Rehabilitation Sciences at Indiana University-Purdue University Indianapolis and one of the co-first authors of the study, said that the study's findings are important, given the large number of people who suffer low back pain in the U.S.\n\nLow back pain leads all disorders in years lost to disability in the U.S.\nAdditional investigation is needed to replicate the results of the initial study and to conduct a cost-benefit analysis of massage therapy, Munk said.\n\"Generally, people wonder if it is worth it.\nWill it pay to provide massage to people for an extended period of time?\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that massage is widely available. We give the release credit for noting that it\u2019s not covered by insurance and therefore not accessible to everyone.", "answer": 1}, {"article": "Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.\nThe results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.\nHalf were chosen at random to take the drug another five years, while the others were told to stop.\nWhether these differences are big enough to cause women to take the drug for twice as long remains to be seen.\nThey came from about three dozen countries.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates the drug has been available, studied, and inexpensive.", "answer": 1}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nThe next trial includes only men with these mutations in their tumours, with the aim of proving that olaparib is highly effective for them.\"\nThe trial is a milestone in cancer treatment as the first to show the benefits of 'precision medicine' in prostate cancer - with treatment matched to the particular genetic characteristics of a man's tumour.\n\"Even though the number of men surviving prostate cancer is increasing, it's still the second most common cause of cancer death in UK men.\n\"We are excited about this pioneering study because it demonstrates the tremendous crossover and wider applications in the research on these diseases.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story nods to the availability of the drug used in the study in the UK when it says it \u201cwas licensed last year for women with ovarian cancer and inherited BRCA mutations, but so far has not been approved for use on the NHS by NICE or the Cancer Drugs Fund.\u201d However, we aren\u2019t left with any idea if the gene testing carried out here is widely available. That\u2019s a critical point that should have been addressed.", "answer": 0}, {"article": "On the other hand, longer treatment was tied to a 24-percent decrease in hip fractures, which along with wrist and spine fractures affect about half of all people with osteoporosis.\nBut that\u2019s a very rare problem, experts say, which only affects about one in 100,000 people on bisphosphonates.\nThat works out to nearly three times the risk of those who\u2019d taken the drugs for roughly three months or less, after accounting for other risk factors.\nAnd the actual risk of having one of the unusual fractures was low, said Laura Y. Park-Wyllie, of St. Michael\u2019s Hospital in Toronto, who worked on the new study.\n\u201cIf you\u2019re taking the drugs and you\u2019ve been on them for a while, but aren\u2019t sure if you\u2019re at high risk, you should ask your doctor about it,\u201d Park-Wyllie advised.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that these drugs are widely available.", "answer": 1}, {"article": "Flare-ups , which involve excruciating joint pain, redness, swelling and warmth, can last days or weeks.\nGout, a debilitating and painful form of inflammatory arthritis, now affects upwards of 8.3 million Americans, according to the release.\nTHURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\nAll were placed on a chronic uric-acid lowering regimen of the standard drug allopurinol.\n\"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,\" he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are not told that the drug was approved by the FDA for use in gout in November 2011.", "answer": 0}, {"article": "Caught early, lung cancer can be cured surgically, but it causes vague symptoms and usually is not diagnosed until it has spread.\nAlmost all advanced CT scanners can perform a spiral CT, and about 60 percent of U.S. hospitals have such a machine.\nThe study sponsored by the U.S. National Cancer Institute is the first to show that people can be screened for lung cancer, akin to mammograms for breast cancer and tests for colon and prostate cancer.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\nThe trial of more than 53,000 current and former heavy smokers, aged 55 to 74, found the \u201cspiral\u201d CT scans apparently catch tumors before they have spread.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did a better job than others in actually spelling out how commonly used these spiral CT scans are, noting that \u201cAlmost all advanced CT scanners can perform a spiral CT, and about 60 percent of U.S. hospitals have such a machine. Makers include General Electric Co\u2019s GE Healthcare Siemens AG, Toshiba Corp, Hitachi and Philips.\u201d", "answer": 1}, {"article": "They compared the average number of hot flashes in 760 women who had treatment with 770 who did not.\nSoy supplements also have side effects: Nausea, bloating, and constipation, according to the NIH.\nWomen with severe or frequent hot flashes or whose hot flashes keep them up at night, should consider treatment, she said.\nAnd not every woman needs treatment, notes Bachmann, who was not involved in the study.\nHowever, a 2002 landmark study by the National Institutes of Health (NIH) found that such treatments can increase the risk of breast cancer, heart disease and stroke.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of soy supplements or of hormone replacement therapy is not in question.", "answer": 2}, {"article": "Macular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss.\nOf these, about 750,000 have DME.\nThe three drugs yielded similar gains in vision for patients with 20/32 or 20/40 vision at the start of treatment.\nTwelve percent of Lucentis participants had at least one event, compared with five percent of participants in the Eylea group and eight percent of participants in the Avastin group.\nThe other half had 20/50 or worse vision.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that all three drugs compared are available and in use. It could have noted that payers may not cover them all.", "answer": 1}, {"article": "Lower blinds and turn off lights so your room is as dark as possible.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nInstead, choose whole-wheat crackers, which can control insulin.\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\nThat means turning off all electronics, including the TV, and creating as quiet a sleep space as you can.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The criterion is not applicable. The story\u2019s focus is on the connection between sleep and weight, and the lifestyle interventions mentioned are available to everyone.", "answer": 2}, {"article": "For an early version of the study abstract, click on \u201cContents,\u201d then \u201cVolume 44, No.\nTHIS STUDY randomly assigned 60 adults with mild cognitive impairment or mild to moderate Alzheimer\u2019s disease to be given, via nasal spray, 20- or 40-milligram doses of insulin detemir (Levemir), a man-made insulin that is longer acting than natural insulin, or a placebo daily for three weeks.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Neither this story nor the competing story by Fox News explained that\u00a0this nasally administered form of insulin is currently only available as part of research studies. The story also offers no informed opinion regarding how long additional testing might take.", "answer": 0}, {"article": "The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nSurveys given to patients during follow-ups asked for information such as test for shoulder functionality, whether patients returned to sport, postoperative instability events, and if further surgery was required on the shoulder.\n\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\nThe study examined 121 patients at an average of 51 months post-surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not say how available either procedure is. The release would have been stronger if it had clarified whether all orthopedic surgeons perform this procedure or if it is a specialized procedure only available at certain clinics. ", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "In Finland, saunas are common. Since this story was published for a US audience, it should have included some mention of the relative abundance or scarcity of saunas here and where to find them. The story warned that the same benefits shouldn\u2019t be expected from hot tubs and steam rooms \u2014 a nice addition. As we mentioned above, the cost of access to sauna would have been a great addition to the story.", "answer": 0}, {"article": "Parkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\nTagliati called the study \"eye-opening.\"\nThe exact cause is unknown, but experts believe it's a combination of genetic and environmental factors.\nIt affects an estimated 1 million people in the United States, men far more often than women.\nIn a six-year span, 293 were diagnosed with the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that ibuprofen is a common anti-inflammatory drug. ", "answer": 1}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\nIn the U.S., all statins are only available by prescription.\n\u201cThey are not a magic bullet.\u201d\n\nA study in June in the Archives of Internal Medicine suggested, in fact, that statins do not save lives in patients without heart disease, although they may prevent some non-fatal heart attacks.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\n\u201cStatins don\u2019t cut out all of the unhealthy effects of a burger and fries.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that statins are widely available and only by prescription in the U.S.", "answer": 1}, {"article": "Blueberries are rich in flavonoids, which possess antioxidant and anti-inflammatory properties.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nThere was also evidence suggesting improvement in working memory.\nIn the study, healthy people aged 65-77 who drank concentrated blueberry juice every day showed improvements in cognitive function, blood flow to the brain and activation of the brain while carrying out cognitive tests.\nThe new paper, \"Enhanced task-related brain activation and resting perfusion in healthy older adults after chronic blueberry supplementation\", is published in the journal Applied Physiology, Nutrition and Metabolism.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We know blueberry juice is widely available but what about the concentrated blueberry juice used in the study?", "answer": 0}, {"article": "Yet the women with those tumors also experienced a reduction in cancer recurrence from Herceptin, in some cases as great as that in the Her2-positive women.\nBut he said the studies called attention to the inconsistent quality of Her2 testing in many small laboratories.\nIt left some doctors at the conference incredulous and uncertain how to treat their patients.\nSome experts were skeptical, saying the number of patients in the two studies was too small to draw firm conclusions.\nThe fact that this uncertainty is occurring so long after the 1998 approval of Herceptin \u2014 the paragon of \u201cpersonalized medicine\u201d \u2014 suggests that it will not be so easy to tailor other drugs to patients based on gene or protein tests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story correctly points out that Herceptin treatment has been approved and available for about ten years, and discusses testing for the presence of the HER2 receptor.\u00a0 ", "answer": 1}, {"article": "A new study shows that computer technology known as machine learning is up to 93 percent accurate in correctly classifying a suicidal person and 85 percent accurate in identifying a person who is suicidal, has a mental illness but is not suicidal, or neither.\nThe results showed that machine learning algorithms can tell the differences between the groups with up to 93 percent accuracy.\nThey then used machine learning algorithms to classify the patients into one of the three groups.\nThe researchers extracted and analyzed verbal and non-verbal language from the data.\nDr. Pestian and his colleagues enrolled 379 patients in the study between Oct. 2013 and March 2015 from emergency departments and inpatient and outpatient centers at three sites.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of the algorithm isn\u2019t made clear in the release, though the study notes that an \u201cunexpected\u201d lack of predictive power means \u201cadditional research\u201d is required.", "answer": 0}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nBut it didn\u2019t seem to matter whether people had been on aspirin for more or less than five years.\n\u201cThings are moving forward, but it is still a work in progress.\u201d\n\nMedical guidelines in the U.S. already urge people to take low doses of aspirin to prevent heart disease if the predicted benefits outweigh the risk of side effects, or if they have already suffered a heart attack.\nAnd the final chapter on the popular but controversial drug has yet to be written, experts say, because like earlier research the new work has considerable limitations.\nIt discourages the use of aspirin to stave off colorectal cancer in people at average risk for the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is not in question.", "answer": 2}, {"article": "In a study suggesting that red wine might be the next big thing in breast cancer prevention, a study has found that women who drank just under two servings of red wine daily experienced hormonal changes that mimic the effects of a drug used to prevent malignant breast tumors from coming back.\n\nThe study, published Friday in the Journal of Women's Health, found that consuming the same amount of white wine did not have the same effect in premenopausal women participating in the study.\n\nWomen intent on warding off breast cancer have been warned about alcohol consumption: as recently as November, a study found that women who consumed as few as three servings of alcohol a week increased their risk of developing the disease, which strikes one in eight American women at some point in life.\n\nWhite wine and other alcoholic beverages are believed to promote the conversion of androgens--\"male hormones\" such as testosterone, which circulate in all women's blood--into estrogen. And the greater a woman's lifetime exposure to estrogen--whether her own or estrogen that comes from medication or environmental sources--the higher her risk of developing breast cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of red wine is not in question.", "answer": 2}, {"article": "\"Joint pain associated with normal aging and over-exercising is extremely common,\" said Thomas Sullivan, Jr., Chief Executive Officer of HSRx Biopharmaceutical.\nThe clinical studies support powerful marketing claims.\nAfter 14 days of treatment, the average improvement was still nearly twice as large as the competition.\nThe proprietary formulations support long product patent lives.\nAfter 14 days of treatment, average pain reduction was more than twice as large as the competition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The point of the release appears to be an advertisement for a product that is already available. The supplement was readily found online.", "answer": 1}, {"article": "Up to 30% of men suffer some degree of premature ejaculation, defined as ejaculation that occurs within one minute of vaginal penetration.\nAll used the product for three months, for a total of 23,000 doses.\nHe consults for Shionogi Pharma Inc., which makes the spray and funded the work.\nNonetheless, doctors like Irwin Goldstein, MD, director of San Diego Sexual Medicine at Alvarado Hospital in San Diego, tell WebMD they're excited because this is the first time a drug is being rigorously tested for men with really serious premature ejaculation problems.\nPSD502, which contains two common topical painkillers, lidocaine and prilocaine, is \"slightly oily, but not objectionably so,\" Sharlip says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \"The drug is so new that the company has yet to give it a name under which it will be marketed\u2026. the company is preparing to apply for FDA approval based on the results of the new research.\"", "answer": 1}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\nOne in eight men will develop the condition at some point in their lives with more than 47,000 new cases being diagnosed every year.\nThe method is non-invasive and cheaper than current detection techniques.\n\u201cThe technique now needs to be tested in a much larger number of men to confirm just how well it can detect the aggressive cancers, while also ruling out those who do not have prostate cancer,\u201d said Simon Grieveson, head of research funding at Prostate Cancer UK, which funded the Dundee project (with support from the Movember Foundation).\n\u201cCurrent diagnosis of prostate cancer is extremely inefficient, leading to unnecessary treatments for many patients,\u201d said the Dundee University team\u2019s leader, Professor Ghulam Nabi.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story doesn\u2019t explicitly deal with the availability of shear wave elastography (SWE), it\u2019s fairly clear that the new approach is experimental, has only been used on no more than 200 patients, and would require larger clinical trials to prove its efficacy \u2014 all points that suggest that it may not be available to most patients now.\u00a0 It also states that, \u201cSWE technology is already used in diagnosing breast cancer and liver diseases.\u201d", "answer": 1}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\nThe first line of defense are anti-perspirants.\nThe Menlo Park, California-based company\u2019s shares were up 3 percent at $33.00 in extended trading on Wednesday.\nDermira said it had expected to apply for marketing approval for the drug in the second half of 2017, subject to completion of the drug\u2019s long-term safety trial.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn it is still in its experimental stages.", "answer": 1}, {"article": "Eventually, the overwhelmed system leaves these sugars, in the form of glucose, to build up in the blood, which can lead to obesity, damage the heart, and cause other metabolic problems.\nBut despite decades of research, scientists haven\u2019t found a better way to address the problem.\nThat\u2019s because experts believed that once the pancreatic islet cells, the body\u2019s insulin-making factories, were compromised, they couldn\u2019t be made to work again.\n\u201cThat\u2019s a huge difference.\u201d\n\nWhat\u2019s more, it appears the cells are relatively long-lasting, which could indicate they are robust enough to bring glucose levels in diabetics under control.\nMore work will be needed to confirm what benefit betatrophin might have on diabetic patients before that might be possible, however.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that any possible treatment resulting from this research is still a long way away.", "answer": 1}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nA larger trial that controlled for remediations would offer more conclusive results.\nOf course, the results of the study are only preliminary.\nA study led by Fumiko Hoeft, psychiatry researcher at Stanford University School of Medicine, used brain imaging to answer this question.\nIf made widely available, this kind of brain scan could be an important complement to the assessments -- based on reading and behavior -- already available for diagnosing dyslexia, Hoeft said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that the type of scan used in this study is not widely available.", "answer": 1}, {"article": "Data from nearly 9,500 people on five continents shows that amyloid can appear 20 to 30 years before symptoms of dementia, that the vast majority of Alzheimer\u2019s patients have amyloid and that the ApoE4 gene, known to increase Alzheimer\u2019s risk, greatly accelerates amyloid accumulation.\nSuch screening is increasingly used in research.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nThe largest analysis to date of amyloid plaques in people\u2019s brains confirms that the presence of the substance can help predict who will develop Alzheimer\u2019s and determine who has the disease.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Dr. Gandy\u2019s quote implied scans were available, although expensive and not covered by many insurance plans. We consider this a satisfactory recognition that the scanning technology is available now.", "answer": 1}, {"article": "Rigid artery walls are an independent predictor of cardiovascular- related disease and death and vitamin D deficiency appears to be a contributor, says Dr. Yanbin Dong, geneticist and cardiologist at the Georgia Prevention Institute at the Medical College of Georgia at Augusta University.\nThe researchers say a vitamin D supplement is an inexpensive and safe option for most of us.\nWhile just how vitamin D is good for our arteries isn't completely understood, it appears to impact blood vessel health in many ways.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\nThe varying doses, as well as the placebo participants took, were all packaged the same so neither they or the investigators knew which dose, if any, they were getting until the study was complete.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that it would be simple for almost anyone seeking to increase their vitamin D intake to do so. They can drink more milk, eat more yogurt, eat more greens like kale, take a supplement and so forth.", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is relatively clear from the story that while virtual colonoscopy is available as a treatment option, this method of preparing for a scan is not (\u201cmay become a useful alternative\u201d).", "answer": 1}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nNor is it clear if the study results are applicable to all smokers.\nThe NCI said it is not clear that all smokers should get the scans, which are not risk-free.\nThe massive National Lung Screening Trial enrolled 53,000 current or former smokers to try to settle the debate.\nThe trial enrolled people ages 55 to 74 who were or had been very heavy smokers and gave them one scan a year for three years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nWhile this story does call the CT scans used in this trial \u201cspecial\u201d and different from conventional CT scans, it does not make clear that the trial applied rigorous standards to the equipment, operators and radiologists that may not be followed by other providers who offer CT scans to smokers.", "answer": 0}, {"article": "Heart patients who took Brilinta (ticagrelor) with low-dose aspirin (less than 300 milligrams) had fewer cardiovascular complications than those taking Plavix (clopidogrel) plus low-dose aspirin, researchers found.\nOne expert said the new information is valuable.\nMONDAY, June 27, 2011 (HealthDay News) -- Brilinta, an experimental anti-clotting medication currently awaiting U.S. Food and Drug Administration approval, performed better than the industry standard, Plavix, when used in tandem with low-dose aspirin, a new study finds.\nThe data and conclusions of the research should be viewed as preliminary until published in a peer-reviewed journal.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We would have preferred a different tone that didn\u2019t suggest the drug is \u201cawaiting\u201d what then appears as almost inevitable FDA \u201capproval.\u201d The FDA panel that produced the 7-1 vote is not the panel that decides whether to approve drugs. It\u2019s an advisory panel. The FDA usually follows its recommendations, but it has not decided whether to approve the drug. That colors the caveat that the \u201capproval process is still ongoing\u201d as sounding somewhat perfunctory, like it\u2019s only a matter of time. It would be more balanced to suggest it\u2019s still under review.", "answer": 0}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nIt was funded by an \"educational grant\" from Glaxo SmithKline, which makes Paxil.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\nAfter six weeks on Paxil, his fear level dropped to a 4 -- an improvement that led him to continue the medication after the trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about the\u00a0medication Paxil, which is a\u00a0readily available prescription medication\u00a0though the piece failed to mention this and the fact that\u00a0the use of Paxil in the treatment of hypochondriasis has not been approved by the FDA.", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We have mixed feelings about this one. On the one hand, the story says, \u201cDo-it-yourself stress testing is probably not very reliable, since a physician or sports physiologist needs to be around to decide when to call a halt to the test (and therefore what maximum a test-taker has achieved).\u201d But then it encourages people to try to develop their own score at the gym or at home and gives them the formula that the researchers used. It\u2019s great to give readers all the information, but we would have preferred that the story emphasize that the validity of the results stems from how these tests were conducted in a clinical setting.", "answer": 1}, {"article": "U.S.-listed shares of Novartis closed up 1.2 percent .\nOn a media briefing following the release of J&J\u2019s trial results, Novartis said it expected the data to have \u201climited clinical relevance\u201d and no impact on plans to expand the Cosentyx label.\nTremfya, first approved in July 2017 as a plaque psoriasis treatment in the United States, is also being tested as a for psoriatic arthritis and Crohn\u2019s disease.\n\u201cThese results imply that Cosentyx remains a good option for moderate-to-severe psoriasis patients that want to achieve more rapid skin clearance,\u201d brokerage Jefferies wrote in a note following the results.\nAbout 7.5 million Americans live with plaque psoriasis, of which 20 percent have moderate-to-severe form of the disease, J&J said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is implied but it should have been made more clear when these drugs received FDA approval, and what they\u2019re approved for.", "answer": 1}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The STAT story\u00a0notes the availability of CAR-T commercially (by naming the companies) for blood cancers, and it quotes an outside source as essentially saying \u201cdon\u2019t hold your breath\u201d awaiting the viability of this treatment for glioblastoma.", "answer": 1}, {"article": "The requested URL /2011-08-30/business/29945941_1_mark-kris-cancer-cases-lung was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that crizotinib recently received FDA approval for use \u201calong with a companion diagnostic test for just a small subset of lung cancer patients.\u201d However, while the story refers to ongoing research, the actual status of the drug is not explained. The FDA approval letter warns that, \u201cIf postmarketing trials fail to verify that clinical benefit is conferred by XALKORI (crizotinib) Capsules, 200 mg and 250 mg, or are not conducted with due diligence, we may, following a hearing in accordance with 21 CFR 314.530(b), withdraw or modify approval.\u201d \nReaders should have been clearly told that this drug is still very much on trial.", "answer": 0}, {"article": "Many Type 2 diabetics become resistant to insulin and have to inject additional amounts.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nThe study also found other benefits.\nBetter yet, the drug, fexaramine, works only in the intestine, never entering the bloodstream.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does caution readers not to expect this drug to be available any time soon.", "answer": 1}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe present study is also the first to test its clinical utility in a U.S. population.\nThe new test is available to health care providers worldwide through Mayo Medical Laboratories, which offers laboratory testing and pathology services to more than 4,000 health care organizations in more than 70 countries.\nThe trial was funded by Mayo Clinic.\nThis test seems to provide such information,\u201d says Allan S. Jaffe, M.D., senior author of the study, cardiologist at Mayo Clinic and chair of the Division of Clinical Core Laboratory Services.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that the \u201cnew test is available to health care providers worldwide through Mayo Medical Laboratories.\u201d It is not entirely clear whether this is the only commercially available test of its kind.", "answer": 1}, {"article": "May 14, 2012 -- Acupuncture may allow people with the lung disease COPD (chronic obstructive pulmonary disease) to breathe a bit easier.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nThe study appears online in the Archives of Internal Medicine.\nMany people with COPD have problems getting optimal nutrition because of their condition.\nOthers got a sham acupuncture treatment, in which the needles did not enter their skin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does mention that patients \u201cmust choose a licensed and experienced acupuncturist,\u201d it does not detail how many of those professionals practice in the US.", "answer": 0}, {"article": ".\nA private company has purchased the technology and is making it available to hospitals across the country.\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nHe called the technology \"a canary in the coal mine\" for lung cancer, which kills about 160,000 people in the United States each year.\nThe current advance was a long time in coming and shows the difficulty of bringing research from the lab to the consumer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that\u00a0a company bought the test\u00a0and is \u201cmaking\u00a0it available\u201d to hospitals nationwide.", "answer": 1}, {"article": "A study published in 2015 by the Center for Cancer Research found that fusion biopsy is 30 percent more accurate in diagnosing high-risk, aggressive cancers than a TRUS biopsy.\nThat\u2019s one of our strengths.\u201d\n\nYu has seen how MRI technology has changed prostate patients\u2019 care.\nMuch like someone would have an MRI to investigate the cause of back pain, the technology gives doctors eyes on what is happening in prostate tissue.\n\u201cIf you do not have this kind of advanced imaging, sometimes a patient runs into a situation when a tumor can\u2019t be found and treated because it\u2019s too late \u2014 it has already metastasized.\n\u201cRight now, I think probably 50 or 60 percent get imaging.\u201d Sometimes, these are patients pushing their doctors for a referral as one of Yu\u2019s patients did last year.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that \u201cVCU Medical Center is one of the major teaching hospitals in the country doing advanced multiparametric MRI.\u201d That appears to be accurate.\nIt would have helped readers not in the VCU vicinity if the release had included more information about where tests could be done. Is it generally available at major teaching hospitals? If not, how many have it?", "answer": 0}, {"article": "Oct. 25, 2010 -- Aspirin , already linked in some studies to a lower risk of developing colon cancer , may also cut the risk of dying of prostate cancer by more than half, a large study suggests.\nThis study was presented at a medical conference.\nThe risk that cancer spread was also reduced by anticlotting medications, from 7% to 3%.\n\"We have to be sure the benefits outweigh the risks before we recommend this to patients.\"\nThe study involved 5,275 men with localized cancer whose disease had not spread beyond the prostate gland; 1,982 of the men were taking anticlotting medications: aspirin, Lovenox, Plavix, and/or warfarin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe study looked at the use of available anticoagulant medications.", "answer": 1}, {"article": "In macular edema, fluid from those damaged vessels leaks into the macula, the part of the retina that is responsible for the straight-ahead vision important for driving, recognizing faces and reading.\nResults of the trial were published online on Tuesday by the journal Ophthalmology.\nDr. Philip J. Rosenfeld, a professor of ophthalmology at the University of Miami, said the decision was \u201cclearly a case of pay to play\u201d since Genentech\u2019s money dictated the choice of drugs.\nThe third group got laser therapy plus injections into the eye of triamcinolone, a steroid sold by Allergan under the name Trivaris.\nHe said treatment with Lucentis in the clinical trial virtually eliminated those incidents.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was crystal clear that the drug reported on, Lucentis, is available as it is FDA approved for another condition; the story also mentioned that it is not yet FDA approved for treatment of diabetic macular edema.", "answer": 1}, {"article": "Because even a minor exposure can set off a reaction, many people at risk strictly avoid foods that contain an allergen or were prepared in places where nuts or other allergens might have been used.\nThe findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this experimental treatment for peanut allergy is in the early stages of human research, and not available. \nIdeally it would have made this plain earlier in the story.\u00a0 \n\u00a0", "answer": 1}, {"article": "\u201cWe need to look at the evidence, and we shouldn\u2019t go beyond it.\u201d\n\nThe new study matched each of 10,292 people who died of colon cancer to five people who lived in the same area and were of the same age, sex and socioeconomic status.\nHe is having a stool test, the fecal occult blood test, between colonoscopies.\n\u201cColonoscopy is a good test, but it isn\u2019t completely effective.\nPerhaps patients did not sufficiently cleanse their bowels of fecal material, a particular problem for the right side of the colon.\nThey should take at least eight minutes to withdraw an endoscope from the colon.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly colonoscopy is available.", "answer": 1}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nThe correlation of the panel blood test results with Gleason Score shows great promise in this regard.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nThe addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.\nThe assay results correlated with the Gleason Score, which is one of the main predictors for aggressive PCA determined on biopsy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this blood test is experimental and one can safely assume it is not yet available.", "answer": 1}, {"article": "\"So many people say `how can cancer screening be harmful?'\nCervical cancer is easy to prevent.\nHalf were screened annually with an ultrasound for four years and a blood test for six years.\nFew take this advice, though.\nAfter 13 years, there were no major differences in ovarian cancers found or deaths from the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "\"The rationale for using pRF on disk herniation is that we eliminate the inflammation process of the compromised nerve root,\" he explained.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\nThe American Academy of Orthopaedic Surgeons offers more information on herniated disks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mentions this treatment has been FDA-approved, but doesn\u2019t explain whether it\u2019s widely available, particularly for treating spinal disk herniation with spinal nerve compression.", "answer": 0}, {"article": "The paper, entitled: \"Longitudinal Adaptations of Bone Mass, Geometry and Metabolism in Adolescent Male Athletes.\n\"Though we focussed on aspiring professionals who played as much as nine hours a week, playing football for three hours a week might be enough for a substantial effect.\n\"Although we didn't study other sports, it's reasonable to suppose that weight-bearing, high-impact, high-intensity exercise like tennis, badminton, basketball and handball will have similar effects to football.\"\nNote to editors: Being a UK university, when we say \"football\" we mean the game otherwise known as soccer.\nPlaying football can improve bone development in adolescent boys, new research shows.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention availability. True, soccer is the world\u2019s most popular sport and there are opportunities to play \u2014 but not all families are able to invest the time and expense required for intense participation in a sport.", "answer": 2}, {"article": "Radiology is edited by Herbert Y. Kressel, M.D., Harvard Medical School, Boston, Mass., and owned and published by the Radiological Society of North America, Inc.\n\nRSNA is an association of more than 54,000 radiologists, radiation oncologists, medical physicists and related scientists promoting excellence in patient care and health care delivery through education, research and technologic innovation.\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\n\"The results show that multicentric cancer detected on breast MRI after mammography appears to represent a larger tumor burden in approximately a quarter of patients and can result in potential changes to cancer grade and treatment,\" Dr. Iacconi said.\n\"In general, it is accepted that radiation can likely treat invasive cancer less than 1 centimeter, but lesions larger than 1 centimeter, especially invasive carcinomas, may not be reliably treated with conservation.\"\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that MRI is widely used for screening high-risk patients and for pre-surgical planning.", "answer": 1}, {"article": "But the F.D.A.\nThe Avid study was complete, and the full data will be presented at the meeting next month.\nThe questions though, are who should be getting the drugs and who really has Alzheimer\u2019s or is developing it?\nBut every major drug company has new experimental drugs it hopes will work, particularly if they are started early.\nBut, they found, most patients and their families agreed and said they were grateful to have been asked.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole story is about how there is nothing available right now to accurately detect Alzheimer\u2019s and how this procedure may move the ball forward. Although, as the story rightly points out, the new scan won\u2019t necessarily answer all the questions about Alzheimer\u2019s. It should make it clear up high how long it would take for this scan to go through the FDA process.", "answer": 1}, {"article": "Of those, 25 had been admitted with a primary diagnosis of \"acute decompensated heart failure\" while another 16 patients had shown no signs of heart failure but did have other cardiovascular issues.\nDr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that if further research were able to establish its effectiveness, a breath-driven tool for identifying heart failure would be a helpful diagnostic innovation -- but more so in a doctor's office or clinic than in the hospital.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\nThis study is really a proof of concept.\nThe investigators stressed that their evaluation is based on a small group of participating patients, and that more extensive research will have to be done to confirm their initial success.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that this test is experimental and quotes a researcher saying, \u201cThere is much more work that needs to be done to get it to the point where it would become widely available.\u201d", "answer": 1}, {"article": "It was Kyle Henn, recovering from his own PTSD after surviving the plane crash, who recommended eye movement desensitization and reprocessing therapy, or EMDR.\nThis distraction had a positive effect on her, she said, allowing her to dive deeply into the therapy without freezing in the face of fear.\nEMDR, Henn said, allowed her to have a do-over \u2014 to be able to grieve properly and then to move beyond grief.\n\u201cEMDR processing is untangling the knot.\u201d\n\nOnce the memories are processed, therapists say, they are less vivid \u2014 less like the film reel Henn would see in her mind.\nShe asked a close friend to write a speech from Nate\u2019s point of view, as if he were speaking at the celebration.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that one can find clinical psychologists who will administer the therapy.", "answer": 1}, {"article": "They also were published online by the New England Journal of Medicine and will be in the April 12 issue.\nAlso, the clogs treated with angioplasty are not the really dangerous kind.\nThe new study shifts the argument from which type of stent to use to whether to do the procedure at all.\nThose patients now should try drugs first, experts say.\nAn even bigger surprise: Angioplasty gave only slight and temporary relief from chest pain, the main reason it is done.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that stenting is very common in the U.S.", "answer": 1}, {"article": "Professor Francesca Cordeiro at UCL Institute of Ophthalmology, who led the research, said: \"Detecting glaucoma early is vital as symptoms are not always obvious.\nWhile we cannot cure the disease, our test means treatment can start before symptoms begin.\nFurther studies will now be carried out to into DARC and how it can be used not only to diagnose and treat glaucoma patients but also for other neurodegenerative conditions.\nNow, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma.\nThe initial clinical trials established the safety of the test for patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Despite the enthusiasm about its future uses, it\u2019s pretty clear this test is in early trials and unavailable to the public. ", "answer": 1}, {"article": "Their symptom score dropped by 29 percent and the number of hot flashes by 35 percent, according to Dr. Yan-bin Ye of Sun Yat-sen University in Guangzhou.\nSoy supplements also have side effects such as nausea, bloating, and constipation, according to the National Institutes of Health.\nThe standard drug treatment for stubborn menopause symptoms is hormone replacement therapy.\nBut doctors and women have become increasingly wary of that option because of serious side effects such as increased risk for heart attack, stroke and breast cancer.\nNEW YORK (Reuters Health) - Middle-aged women may find some relief from hot flashes and other menopause problems with soy supplements, according to Chinese researchers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Soy supplements are over-the-counter products sold in most health stores.", "answer": 2}, {"article": "They found testosterone and two hormones needed for the production of sperm were notably suppressed in men who took the highest dose of DMAU.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nRead more: Male birth control pill could be made from heart-stopping poison in ancient African arrows\n\nThe once-daily prototype pill suppressed certain hormones to the low levels you'd expect to see with effective longer-term contraceptives, results from an ENDO 2018, the Endocrine Society\u2019s annual meeting in Chicago, abstract show.\nUpdated | Almost sixty years since the FDA approved the pill for birth control in women, a male version may finally be on the horizon.\nRead more: Side effects are not what's holding back the male contraceptive pill\n\nEighty-three men took various doses of DMAU or a placebo for a month.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that \u201cLonger-term studies are the next step toward a once-daily male contraceptive pill.\u201d However, most people are not familiar with how clinical trials work. A little additional information here would have gone a long way. Realistically, these \u201clonger-term studies\u201d will take years \u2014 and that\u2019s if everything goes perfectly. Readers expecting to see a male birth control pill in the relatively near future will certainly be disappointed.", "answer": 1}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nThe idea of a psychiatric evaluation sent chills down the spine of Caroline's mother, Mathy Milling Downing, who believed that her younger daughter, Candace, had committed suicide because of an adverse reaction linked to a psychiatric drug -- the antidepressant Zoloft.\nAfter several intensive evaluations that delved into the girl's mental and emotional history, and that obtained a family history and detailed information about Candace's death, Caroline was placed in \"art therapy,\" painting or making sculptures with a therapist who simultaneously used the sessions to draw out the teenager's emotional problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story failed to provide information about the availability of recommended treatments for major depressive disorder in adolescents. \u00a0It provided some information about vendors that provided testing for this target population, but it was unclear from the piece where someone ought to turn for help with this. \u00a0It would have been worth mentioning that therapists specializing in adolescents are in short supply.", "answer": 0}, {"article": "\u201cThat\u2019s a simple enough statement, and people are not put off by that,\u201d she said.\nThe new report shows that during the two years, those same people had increasing confidence in their skills, with no increase in embarrassment or discomfort.\nAmong people who received the skin exam training, the researchers found a steep increase in their confidence at performing skin exams between the start of the study and four months later.\nThe researchers previously found that skin cancer survivors and their partners could be trained to spot potentially cancerous moles by doing skin exams.\nOverall, the trained group found 51 early melanomas during the study, compared to 18 melanomas found by a comparison group of patients and partners who didn\u2019t receive training.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of having a partner help with mole-spotting would seem to depend on the individual patient. The writer does mention that bringing a partner program into standard practice \u201cpresents some challenges\u201d due to the need for training, and that the\u00a0researchers are looking at ways to help people learn to identify melanomas without reinforcement by physicians. This\u00a0is enough to\u00a0earn a satisfactory rating.", "answer": 1}, {"article": "Marcella and his colleagues collected the medical records of 380 men who had died of prostate cancer and another 380 of the same age and race without prostate cancer or with non-lethal cancer.\nAbout one-quarter of adults age 45 and older in the U.S. take statins to lower cholesterol and protect against heart attacks.\nResearchers agreed that until there\u2019s clearer evidence for benefit, men with healthy hearts shouldn\u2019t seek out statin prescriptions for the purpose of lowering their prostate cancer risks.\nBut they jibe with previous studies suggesting that getting cholesterol levels under control might help reduce the risk of life-threatening disease, researchers said.\nThe researchers also couldn\u2019t tell whether men started using statins before or after they were diagnosed with aggressive cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that about one-quarter of adults age 45 and older in the U.S. take statins to lower cholesterol and protect against heart attacks.", "answer": 1}, {"article": "First the science.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\nIt lasted for 16 hours before it started peeling off, and smoothed out the eye bags that become so common as people age, they wrote.\nThey demonstrate it in this video.\nThere\u2019s cross-linking and it tightens it up.\u201d\n\nCross-linking is a well-understood process.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Since the story mentions that the material has been licensed to two private companies, readers will assume that it\u2019s not on the market yet but may be in the near future.\u00a0 It\u2019s pretty clear that it is not available for public use yet.", "answer": 1}, {"article": "Cancer is the No.\nAnd then it will have to be shown that using the test allows doctors to intervene sooner and help people.\nThe genetic sequencing is also expensive right now \u2013 on the order of several thousand dollars for the 30,000 repeats the team did.\nIt\u2019s easy to find tumor mutations if you know what to look for.\nBut there\u2019s nothing yet that can detect cancer in someone who has not yet been diagnosed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that the potential use of this technology as a cancer-screening tool is some time off in the future, if its usefulness is further proven. Based on the story, readers should understand that this isn\u2019t a tool currently available.", "answer": 1}, {"article": "\"We can't say this research is definitive,\" Dr. Senay said.\n\"The next step would obviously be to do an intervention trial where one group eats the diet, the other eats a traditional American diet and then look at the outcome.\n\"Those who most closely adhered to the Mediterranean diet had a 68 percent reduction in the risk of Alzheimer's disease.\nThe Mediterranean diet can vary from country to country but the foods consumed from Greece to Spain tend to be high in fruits, vegetables, fish, legumes, nuts, bread, pasta, cereals, potatoes and unsaturated fats like olive oil.\nAs far as alcohol goes, they consume red wine in moderation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that foods that comprise the Mediterranean diet are available to many people. ", "answer": 1}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although vague, the story reports when the procedure will likely be available based on the best source available \u2014 the manufacturer. The main reference to availability is a quote by the company spokesperson stating that the company hopes to have successful negotiations with insurers and Medicare concluded \u201clater this year.\u201d We\u2019ll rate this sufficient for a satisfactory, but we\u2019d note that the availability will also hinge on patient shared costs and hospital and physician training and location. In addition, low income and minority populations have higher rates of obesity and higher rates of Medicaid use. State Medicaid programs will likely not cover this or will at least establish some pretty restrictive criteria.", "answer": 1}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that these apps are available in pilot programs and studies. It also refers to Skype, which most readers will know is generally available. One issue that remains to be seen is how accessible these apps will be to lower-income or homeless people, or those who have limited technology experience and/or limited eyesight.", "answer": 1}, {"article": "Screening all children would \u201cidentify a number of children who are of very significant risk of premature heart disease,\u201d said Dr. William Neal of West Virginia University in Morgantown, who led the new study.\nAnother existing set of guidelines doesn\u2019t call for screening in any children.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\nBut a third of those children didn\u2019t have relatives with heart disease or high cholesterol, and so wouldn\u2019t have been screened under the current guidelines, issued by the government\u2019s National Cholesterol Education Program.\nYet among the kids without heart disease in their family, the percentage of children who might benefit from treatment was closer to two percent than to one, meaning that family history didn\u2019t seem to make a difference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe availability of cholesterol screening is not at issue.\n", "answer": 2}, {"article": "We cultivate evidence-based knowledge, provide extensive educational programming, and promote emerging research that advances the science and practice of sports medicine.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nAOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nSAN DIEGO, CA - Knee pain in active patients over 40 is often difficult to treat but according to researchers presenting their work today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in San Diego utilizing a special kind of allograft may be a step in the right direction.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that \u201costeochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\u201d Readers can infer from this that the technique is already available, although it may not be available everywhere and not all insurers will cover these procedures.", "answer": 1}, {"article": "\u201cA lot of preparations have added so many things that they aren\u2019t releasing zinc properly,\u201d said Dr. Ananda Prasad, professor in the department of oncology at Wayne State University School of Medicine in Detroit and an early pioneer of research into zinc as an essential mineral.\nWhile the findings are certain to send droves of miserable cold sufferers to the drugstore in search of zinc treatments, the study authors offered no guidance on what type of zinc product to buy.\nSince that study, 18 more trials of zinc for colds have been conducted: 11 of them showed it to be a useful treatment, while seven of them showed no benefit, according to the review.\nEven so, the new report gives credence to the long-debated theory that zinc can be an effective treatment for colds.\nA sweeping new review of the medical research on zinc shows that sniffing, sneezing, coughing and stuffy-headed cold sufferers finally have a better option than just tissue and chicken soup.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no question regarding the availability of products containing zinc; however, as the writer points out, the most effective formulation and dosage for reducing cold symptoms is currently unknown. \nOf note, the story specifically mentions that zinc lozenges from Coldcure.com were used in many of the trials evaluated in the Cochrane systematic review, but failed to note that they are no longer manufactured.\u00a0", "answer": 1}, {"article": "At that point, a valve designed to open on its own, allowsthe balloon to empty and be excreted naturally from the body,eliminating the need for endoscopy or another procedure.\nAllurionTechnologies, the manufacturer of the device called Elipse\uf0d4, whichis not yet commercially available, is studyingwhat it says is the \u201cfirst procedureless gastric balloon\u201d inpatients with a body mass index (BMI) of 27 or more.\ni The ASMBS estimates about 24 million people have severe or morbidobesity.\nimmediate pastpresident of the ASMBS and vice-chair, UC Irvine Department ofSurgery and chief of gastrointestinal surgery, who was not involvedin the study said the device is not a permanent solution to weightloss, but has the potential to help those individuals who areoverweight or have obesity and are not candidates for bariatricsurgery.\n\u201cFor many struggling with theirweight, procedureless gastric balloon devices may serve as atreatment option that bridges the gap between weight-loss drugs andsurgery.\u201d\n\nTheU.S.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that the device is not yet commercially available.", "answer": 1}, {"article": "A second infection study, also reported in the journal, found that a chlorhexidine-alcohol combination produced 41 percent fewer surgical-site infections as the commonly used mixture of povidone and iodine, which gives a yellow-orange tinge to the skin.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\nAlthough his team did not evaluate enough patients to study the problem directly, \u201cWe feel this technology is capable of preventing those types of infections as well,\u201d Verbrugh said.\nHospital-acquired infections are a major problem in medicine, so doctors are always looking for the best way to reduce the risk.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is not discussed. The story should have noted that the resources used in the Bode study are currently available in US hospitals, just not routinely applied. We think this should have been noted in the story. ", "answer": 0}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nLike many patients his age, he didn't expect there would be any effective treatment.\nHe was senior author of a study published in the Journal of Clinical Oncology in October.\nThen his luck ran out.\nThat was seven years ago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The surgery is clearly already available.", "answer": 1}, {"article": "Dr. David E. Neal, a professor of surgical oncology at the University of Cambridge in the U.K. and author of an accompanying editorial, believes that, \"PSA testing detects prostate cancer early in its natural history when it causes no symptoms.\nThe report is published in the June 30 online edition of The Lancet Oncology.\nThis study adds to previous evidence that PSA testing and screening for prostate cancer saves lives, he said.\nAmbivalence over the test hasn't been confined to the United States.\nMoreover, the risk of over-diagnosis was less than previously thought, with just 12 men needed to be diagnosed to save one life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story accurately reported the widespread use of the PSA test to screen for prostate cancer in the U.S.", "answer": 1}, {"article": "During menopause, levels of estrogen decline in vaginal tissues, which may cause a condition known as VVA, leading to symptoms such as pain during sexual intercourse.\nThe safety of Intrarosa was established in four 12-week placebo-controlled trials and one 52-week open-label trial.\nThe agency also is responsible for the safety and security of our nation\u2019s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.\nWomen were randomly assigned to receive Intrarosa or a placebo vaginal insert.\n\"Intrarosa provides an additional treatment option for women seeking relief of dyspareunia caused by VVA.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t disclose how soon consumers can expect to find Intrarosa at their local drug store. However, it does make clear that DHEA is already out on the market as a dietary supplement, although these have not been FDA approved for safety and efficacy for \u201cdiagnosing, curing, mitigating, treating or preventing any disease.\u201d\nWe feel this mention is good enough for a Satisfactory rating here.", "answer": 1}, {"article": "Chronic insomnia is defined by the Diagnostic and Statistical Manual of Mental Disorders as sleeping poorly at least three nights a week for a month or longer, despite adequate opportunity for a full night's sleep.\nAdditional training in the therapy for behavioral health providers in all branches of the military is needed, he said.\nHe noted that that cognitive behavioral therapy is \"a multifaceted intervention that can be difficult to administer without the benefit of a therapist.\"\n\"About 10 percent of deployed military personnel take sleep medications, which are effective for short-term treatment of insomnia in civilian populations.\nBoth the in-person and Internet therapy had the exact same content, with the Internet lessons presented as audio recordings accompanied by visual graphics and animations.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The extent to which Internet-delivered CBTi is available for military personnel or the general public isn\u2019t mentioned.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that these tests are available through the mail from a number of companies.", "answer": 1}, {"article": "Espiritu started work at Henry Ford just as the program was starting, and she remembers the initial staff meetings: \"There was a lot of, 'How can you do this?\nThe story of the health system's success is a story of persistence, confidence, hope and a strict adherence to a very specific approach.\nThe plan it developed is intensive and thorough, an almost cookbook approach.\nBefore the zero suicide plan went into effect, says psychiatrist Doree Ann Espiritu, acting head of the zero suicide program at Henry Ford, you might make a contract with a patient where the patient agrees not to commit suicide.\nThat approach saved the life of a woman who prefers to be known only by her first name, Lynn.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that \u201cperfect depression care\u201d has been either adapted or adopted by other health systems, and names two of them. It also says that health insurers and other health systems have expressed an interest in the approach. In short, the approach is not yet in widespread use, but may eventually be adopted in additional areas. Given that the story can\u2019t be expected to incorporate a list of every health system currently using the approach, this earns a Satisfactory.", "answer": 1}, {"article": "(Reuters) - Amgen Inc said its potent cholesterol fighter Repatha significantly reduced the risk of heart attacks, strokes and death in patients with heart disease, according to initial results of a large, eagerly-anticipated trial released on Thursday.\nBut those who control budgets wanted concrete proof that the drug could actually reduce the risk of heart attacks and death before making it easier for patients to get the medicine.\nNo new safety problems cropped up in the 27,500 patient study called Fourier, Amgen said.\nThe company said Repatha would be well on its way to becoming a $1 billion seller if all prescriptions written had been filled.\nThe primary goal also included need for a new artery-clearing procedure and hospitalization for angina.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the drug Repatha is already on the market and available for use.", "answer": 1}, {"article": "And a study of men attending a fertility clinic, published in May by the journal Human Reproduction, found that high intake of omega-3 fats was linked to more normal sperm size and shape, while high intake of saturated fats was related to lower sperm concentration.\nWalnuts, that is.\nThe other men were told to continue their regular diet but not to eat any tree nuts.\nHalf the men were randomly assigned to eat 2.5 ounces of walnuts a day, along with their usual diet.\nIn the new study, most of the walnut eaters snacked on the shelled whole nuts straight out of the package, Robbins says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of walnuts is not in question.", "answer": 2}, {"article": "For more on omega-3 fatty acids, visit the National Institutes of Health.\n\"But it's also possible that the different dosing used in this study relative to previous work made a difference in the outcome.\nIn the study, researchers focused on a group of more than 4,800 Dutch heart attack patients between the ages of 60 and 80, slightly more than three-quarters of whom were men.\nThe amount of supplementation added to the various margarines was deemed to be \"low-dose.\"\nAnd they're also not just looking at preventable fatalities but all heart-related events that follow.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was not clear that the margarines used in the study reported on were formulated specifically for use in the study and are not commercially available.\u00a0 Nor did it explain \u2013 as other stories did \u2013 that there are similar products already on the market.", "answer": 0}, {"article": "The women who ate more berries also tended to eat healthier overall, consuming more vegetables and fruits than those who didn\u2019t eat as many berries; but when the scientists broke down the women\u2019s diets, they found that the highest consumers of berries even had a lower risk of heart attack compared with women who still ate plenty of fruits and vegetables but fewer berries.\nThe researchers focused on blueberries and strawberries because these are the most widely consumed varieties in the U.S.\nBoth berries contain high levels of anthocyanins, as well as other flavonoids, which fight the effects of stress and free-radical damage to cells as they age.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nIt is a powerful message that we can prevent cardiovascular disease by what we eat.\u201d Something worth remembering the next time you\u2019re in the produce aisle.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of strawberries and blueberries is not in question.", "answer": 2}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nA simple surgical extraction for a wisdom tooth that's showing through the gums should run about $230, according to Healthcare Bluebook.\nSo the question comes down to which side of the fence medical professionals fall on, and what works best for their patients.\nThe American Association of Oral and Maxillofacial surgeons says, \"There is no pat answer, cookbook recipe, or flow chart that is universally accepted regarding the decision making process\" in these cases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t acknowledge the gap in dental care access and how that might affect the numbers of people having wisdom teeth removed. Uninsured people are far less likely to pay out-of-pocket for elective surgery.\u00a0These issues could have been addressed with one additional sentence", "answer": 0}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\n\u201cSo the cancer trap is really complementary to current cancer treatments and especially beneficial at the early stages when it is difficult to see if the cancer is spreading as there are few cancer cells.\n\u201cWe are putting biological agents in a cancer trap to attract and kill cancer cells.\nCurrently, there are many treatments for primary tumors but they do little to prevent metastasis and stray cancer cells from relocating to another part of the body.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release appears to be in conflict with itself here. On the one hand, the first paragraph talks about the patenting of an implantable medical device. On the other hand, the release also tells us that the researchers are \u201choping to move toward clinical trials in the next few years.\u201d The first paragraph may make many readers think this is a prototype that may be close to the market. But the lack of a timeline for clinical trials suggests that this could be many years away from clinical use (if it reaches clinical use at all). This lack of clarity is problematic.", "answer": 0}, {"article": "They should leave it alone.\"\nTHURSDAY, April 21, 2011 (HealthDay News) -- For men who believe size matters -- and that their penises don't measure up -- success can be found in certain non-surgical penile lengthening treatments, a new study analysis by Italian researchers contends.\nDr. Elizabeth Kavaler, a urologist at Lenox Hill Hospital in New York City, said functional issues resulting from conditions such as birth defects or prostate cancer surgery may warrant penile surgery, but such cases are unusual.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\nStudy co-author Dr. Paolo Gontero said urologists are constantly approached by men concerned about their penis size, despite the fact that the majority are average, with a flaccid length of 1 to 4 inches.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests but does not makes it clear that many \u201ctreatments\u201d are available. It implies that surgical procedures are performed by urologists and plastic surgeons. We would have liked to have seen some additional comments about the availability of and a definition of traction methods. A comment on the frequency of these procedures from one of the plastic surgery societies would have been a good addition.\nBesides the comment, \u201curologists are constantly approached by men concerned about their penis size,\u201d we are not given any idea about how widespread or available are the methods to address these concerns.\nAnd cognitive behavioral therapy isn\u2019t given much attention at all.", "answer": 0}, {"article": "And sometimes we have to make decisions about using drugs that are probably a little less effective but at the same time we have to take into account the financial standpoint,\" said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge.\nRead the full guideline at the American Society of Clinical Oncology.\nThe new guidelines replace previous guidelines issued in 2002, and subsequent updates in 2003 and 2004.\nAromatase inhibitors are not effective in this age group, the experts note.\nCrystal Denlinger, assistant professor of medical oncology at Fox Chase Cancer Center in Philadelphia.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Estrogen stimulates the growth of ER+ tumors.\nTUESDAY, May 25, 2010 (HealthDay News) --Giving certain breast cancer patients estrogen-lowering drugs before surgery enhances their chances of being able to choose a breast-conserving lumpectomy instead of a full mastectomy, new research suggests.\nThe women were classified into three groups as the study began: \"marginal\", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; \"mastectomy-only\", meaning a lumpectomy was not considered possible; and \"inoperable\", meaning that doctors believed that even a mastectomy would not completely remove the cancer.\nMore than half of those women who had been categorized as mastectomy-only patients were also able to go the lumpectomy route and experience a good outcome.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story should have done a better job of explaining how the drugs discussed in this story, known as aromatase inhibitors,\u00a0are\u00a0currently used in\u00a0cancer treatment and why this study may represent an advance over current approaches.\u00a0All of the drugs\u00a0discussed are currently approved\u00a0by the FDA for breast cancer, but they are typically administered to women\u00a0only after\u00a0surgery or as\u00a0an adjunct to other drugs\u00a0in order to prevent a cancer recurrence. The new study is testing these treatments prior to surgery to see if this improves outcomes. The\u00a0story isn\u2019t explicit about most of this and\u00a0assumes that readers are already\u00a0aware of this background.\u00a0Many probably are, but others are not.\u00a0\u00a0\u00a0", "answer": 0}, {"article": "Often they get both.\nRelated: Keytruda Keeps Some Patients Alive For Three Years\n\n\"Immunotherapy is a whole new way of treating cancer, including lung cancer,\" said Janne, who was not involved in the study.\nUsually, cancer drugs are only tested at first in patients who have tried everything else available and their cancer has come back, anyway.\nThe company now can ask the Food and Drug Administration if it will approve Keytruda to use as the first treatment a lung cancer patient tries.\nIt worked at least as well if not better than the chemo, so the researchers have stopped the study to give everyone a chance to take Keytruda, Merck, the company that makes the drug, said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does establish availability, though it is confusing.\nIt calls the drug \u201cthe Jimmy Carter drug\u201d in the headline, leading readers right away to believe this is an available drug that the former president took. But then it provides a\u00a0tidy\u00a0summary of drug trials and why the halting of this particular trial matters, saying:\n\u201cCancer research goes forward in slow steps. In tests of new drugs, patients always get either the very best therapy already available, or the new drug. Often they get both. Usually, cancer drugs are only tested at first in patients who have tried everything else available and their cancer has come back, anyway. So\u00a0it\u2019s an important break for a company if its drug is the first one a patient gets and it works better than the so-called standard of care.\u00a0The company now can ask the Food and Drug Administration if it will approve Keytruda to use as the first treatment a lung cancer patient tries.\u201d\nThe nuance there might be missed by readers. But we are giving the story a pass here because later, the story says more clearly that Keytruda was \u201capproved October last year for lung cancer and in 2014 for melanoma.\u201d", "answer": 1}, {"article": "The majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London\n\nThe majority of smokers who successfully switch to vaping say they have fewer respiratory infections, according to a study led by Queen Mary University of London (QMUL).\nThe on-line survey of 941 respondents assessed subjective changes in respiratory symptoms in smokers who switched to vaping for at least two months.\nHuman trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\nDespite the limitations, the researchers say that the study provides a reasonable reassurance that vaping does not promote respiratory infections and may in fact reduce them.\nThis misinformation includes a misreported study on rats that claimed that vaping may increase vulnerability to infections.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "E-cigarettes are widely available at nearly every drug store and gas station convenience store in the United States and are widely available in the\u00a0 UK where the study was conducted. The release could have mentioned that, in the U.S. at least, new rules require buyers to be at least 18 years old to purchase them.", "answer": 2}, {"article": "As measured by an electroencephalogram (EEG), small children's brains show a specific pattern of activity when they look at a picture of a human face.\nBut that's not all, researchers Geraldine Dawson, PhD, and colleagues report.\nJust the reverse happens in children with autism.\nThis doesn't happen when they look at pictures of inanimate objects.\nWithout such interactions, language and social skills do not develop.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from the story whether this therapy is being used anywhere or whether it is something that only Dawson and her colleagues are testing out in small settings.", "answer": 0}, {"article": "People who were given the 60 mg doses saw a nearly 16 percent reduction in the amount of amyloid, and those given the 200 mg doses saw a 36 percent reduction.\nThe need for a drug to delay the onset or slow progression of Alzheimer's disease can't be underestimated, Aggrawal said.\nThat said, these experimental drugs carry the potential for serious side effects, including causing the immune system to go haywire.\nThere are approximately one dozen therapies, including vaccines, for Alzheimer's disease that are currently in the pipeline, Lyden noted.\nThe new drug was given at either 60 or 200 milligrams (mg) doses.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The early, experimental stage of the research was clear in the story.", "answer": 1}, {"article": "HRT \u2014 with either estrogen alone or a combination of estrogen and progestin \u2014 was linked to a lower colon cancer risk even when the researchers accounted for the women\u2019s age, weight, exercise levels and race.\nThe implications of that finding, if any, are not yet clear.\nThese latest findings do not alter that advice.\nThe findings are based on 56,864 menopausal women who took part in the California Teachers Study, a health study begun in 1995.\nMost of the women were past menopause at the outset, and 61 percent were currently using HRT.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of hormone replacement therapy is not in question. ", "answer": 2}, {"article": "\"I just didn't want to do that for my children.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\nWhile surgical decisions are up to patients, the findings of this study should help them decide what to do, she says.\nIn an editorial accompanying the study, Virginia Kaklamani, an oncologist at Northwestern University, says lives can be saved if women have genetic testing.\n\"We found mastectomy provided huge risk reduction of subsequent breast cancer diagnosis and death.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "\u201cMost people in the world have access to a telephone,\u201d said Meltzer-Brody, who wasn\u2019t involved in the study.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\nMothers who left the study said they no longer needed support, sought counseling from mental health professionals, or didn\u2019t have time for the phone calls.\n\u201cThis study, while small, suggests that peer phone counseling could be a very effective, widespread public health intervention.\u201d\n\u201cTraining peer counselors to do phone counseling is an effective, low-cost and non-stigmatizing way for new moms to get the help they need.\u201d\n\nParticularly for first-time mothers, postpartum depression can be hard to distinguish from the stress and fatigue that come with caring for a new infant around the clock, Letourneau said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a borderline call where we\u2019ll give the story the benefit of the doubt. The story does not explicitly address availability of peer counselors, although it implies that they are not generally available for PPD. And the story does give enough detail to help the reader understand what would be necessary to create such a system of peer counselors. A comment about availability of peer counseling for other health issues would have been useful.", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the test, marketed as GeneSight, is available.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story contained estimates of how many people are currently taking statin medication.", "answer": 1}, {"article": "S. Bagla; R. Piechowiak; T. Hartman; J. Orlando; A. Isaacson; Vascular Institute of Virginia, Woodbridge, VA; UNC Chapel Hill, Chapel Hill, NC; University of North Carolina, Chapel Hill.\n\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\nBut GAE provides another option for patients struggling with pain and may even allow patients to avoid the painful recovery of knee surgery and the need for the kind of opioid pain medications associated with the dangerous epidemic in the United States.\"\nThis prospective, multicenter clinical trial evaluated 13 patients with severe osteoarthritis pain.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is confusing for readers on this point. The release suggests that GAE is an intervention already in current use when it states:\n\u201cInterventional radiologists perform GAE for knee pain by inserting catheters through a pinhole-sized incision, blocking the very small arteries or capillaries within the lining of the knee, reducing the inflammation caused by osteoarthritis. As an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\u201d\nHowever, further down in the release its noted that the procedure has \u201conly been used in a clinical trial setting.\u201d", "answer": 0}, {"article": "It is less common than Type 2 diabetes, which is associated with obesity.\nThough too early to call it a cure, the procedure has enabled the young people, who have Type I diabetes, to live insulin-free so far, some for as long as three years.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The\u00a0story tells readers that the new treatment is still experimental and this treatment appears to have been used for the first time in a recent research study.\u00a0 One physician is quoted saying the idea \"is not ready for prime time\" so viewers should know they can not turn to their local doctor to have this treatment.\u00a0 ", "answer": 1}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\nMarkar added that the test needs to be validated in a bigger group before it could be used on patients.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\nThe researchers said they are planning a larger trial of the breath test over the next three years.\nTUESDAY, Jan. 31, 2017 (HealthDay News) -- A breath test to detect stomach and esophageal cancers shows promise, researchers say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job here. It not only notes that \u201cthe test needs to be validated in a bigger group before it could be used on patients,\u201d but makes clear that the study findings were presented at a conference. Further, the story explains that \u201cStudy results presented at meetings are generally considered preliminary until they\u2019ve been published in a peer-reviewed journal.\u201d That\u2019s valuable context for readers.", "answer": 1}, {"article": "\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\nResearchers are already kicking off a second, larger trial to better understand how the procedure works and which patients it might benefit, Bagla said.\n\"This therapy is very well-targeted to that particular mechanism, and certainly it should be investigated further,\" said Vedantham, who wasn't involved with the study.\nTUESDAY, March 20, 2018 (HealthDay News) -- Tiny pellets could treat arthritic knee pain, delaying the need for knee replacement surgery, a small study has found.\nMuch of the pain that comes from knee arthritis actually stems from inflammation in the lining of the knee joint, also called the synovium, Bagla said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does acknowledge the need for further research. But this is a bit of an extreme case, in terms of how preliminary the research is, and so we feel the story should have made it very, very clear that we have no idea how this will pan out. Another more skeptical source would have helped on this one.", "answer": 0}, {"article": "\"Strikingly, these fasting-stimulated changes in the growth of vascular cells and subsequent immune alterations occur even after a single cycle of 24-hour fasting, and are completely reversed when mice start eating again,\" adds Yun Hye Kim.\nSuch fasting already shows benefits after only six weeks.\nThe recurring regimen saw the animals being fed for two days, followed by one day without anything to eat.\nA type of white blood cell known to play a role in fighting inflammation is triggered.\nFor this reason, dietary interventions like intermittent fasting are gaining popularity to treat conditions such as obesity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fasting is widely available.", "answer": 2}, {"article": "Acute pancreatitis, a concern with some diabetes drugs, was uncommon but higher with Januvia, 23 versus 12.\nThat was not statistically significant.\n\u201cFor the heart failure concern raised by other agents in the class there is no difference (with placebo),\u201d he added.\n(Reuters) - Details of a large heart safety study presented on Monday appear to give Merck and Co\u2019s diabetes drug Januvia a clean bill of health, possibly setting the stage for a return to sales growth for the drugmaker\u2019s biggest product.\nIt was undertaken after heart safety concerns were raised over other diabetes medicines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug has been available but has been hampered in terms of sales because of safety concerns. The drug\u00a0is widely available, widely used, expensive, and of unproven value in terms of important outcomes.", "answer": 1}, {"article": "In one patient who had Alzheimer\u2019s, the pathologist and the radiologist analyzing the scan did not see much plaque, but the computerized analysis of the scan and the two autopsy reports did.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nNeither the radiologists nor the pathologists knew whether the patients had dementia.\nThat was what Avid demonstrated with its study, presented Sunday by its medical director, Dr. Christopher M. Clark.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story was clear that it was reporting on a screening test for Alzheimer\u2019s disease that is undergoing study. That said \u2013 it would have been better to state explicitly that this test is currently unavailable to patients.", "answer": 1}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nSour milk was the most commonly used low-fat fermented dairy product.\nApproximately 2,000 men participated in the study.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\nMilk was the most commonly used product in this category, and a very high consumption was defined as an average daily milk intake of 0.9 litres.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fermented dairy products are widely available and the news release does clearly outline several types.", "answer": 1}, {"article": "Their average dose of mealtime insulin decreased by seven units (30%) and their need for all-day insulin dropped by eight units (32%).\nAnd during Victoza treatment, patients needed less and less insulin.\nAdding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\nThose who continued treatment for a full year continued these improvements and felt much better overall, says study leader Paresh Dandona, MD, of the State University of New York, Buffalo.\nThis appeared to be due to reduced appetite and food intake.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the drug is not approved for use in type 1 diabetes, but that it could be used off-label in this population by a diabetologist since it is approved for use in type 2 diabetes.", "answer": 1}, {"article": "A DXA can cost a couple hundred dollars, while a CT scan can cost about $500.\n\u201cWhat we found is that there is pretty good correlation,\u201d said the study\u2019s lead author Dr. Perry Pickhardt, professor of radiology at the University of Wisconsin School of Medicine and Public Health in Madison.\nThe researchers, who published their findings in the Annals of Internal Medicine on Monday, compared patients\u2019 CT scans to their dual-energy X-ray absorptiometry (DXA), which is traditionally used to diagnose osteoporosis.\nDr. Sumit Majumdar, who wrote an editorial accompanying the new study, said a lower threshold for bone density would catch most cases of osteoporosis and limit \u201cincidentaloporosis\u201d - incorrect osteoporosis diagnoses \u201cdiscovered\u201d while doctors were looking for something else.\nDespite DXA scans being safe and cost effective, Pickhardt and his colleagues say the test is underused.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story touched on availability and use patterns in this succinct statement:\n\u201cDespite DXA scans being safe and cost effective, Pickhardt and his colleagues say the test is underused. CT scans, however, are considered overused \u2013 with more than 80 million performed in the U.S. during 2011.\u201d", "answer": 1}, {"article": "It's very exciting.\"\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nResearchers in the field, who have become accustomed to rapid advances, said they, too, were surprised by the advance.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story was clear that this highly experimental approach in mice is currently not available for humans, it provided a wholly unrealistic estimate for its application to human disease. \u00a0\nAlthough interesting from a number of perspectives, the story is about a novel but relatively untested approach to managing diabetes in mice. \u00a0The story is somewhat excessive in its language related to the potential for this approach suggesting the line of research will indeed be transferable to humans in a relatively brief period of time. While some caveats are included, we don\u2019t think balance was achieved.\u00a0 ", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the drug is already being used in sickle cell treatment and is FDA approved.", "answer": 1}, {"article": "Newly postmenopausal women who received estrogen via a skin patch had reduced beta-amyloid deposits, the sticky plaques found in the brains of people with Alzheimer\u2019s disease, a Mayo Clinic study published this month in the Journal of Alzheimer\u2019s Disease found.\nThe oral treatment was not associated with lower amyloid deposition.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\nUltimately, these deposits harm neurons, leading to cognitive problems.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that numerous estrogen supplements \u2014\u00a0 including those delivered via patch \u2014 are readily available.", "answer": 2}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the social media diagnostic model is not close to being viable for clinical use.", "answer": 1}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that cethromycin, the new antibiotic under development, is not yet approved for sale.\u00a0 ", "answer": 1}, {"article": "Parkinson\u2019s disease is a progressive neurological disease that causes symptoms including muscle tremors, shaking, and stiffness.\nNor is it clear why the results differed for men and women.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nThis was an observational study and therefore can\u2019t establish cause and effect.\nThis study will be presented at a medical conference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of the flavonoid-containing foods mentioned in the story is not in question.", "answer": 2}, {"article": "In addition, some people have implanted defibrillators or pacemakers.\nDespite the encouraging results of this first trial, a lot more testing will be needed before cimaglermin can be considered a standard treatment for heart failure, Bishopric said.\nBased on these preliminary findings, larger trials are being planned, Lenihan said.\nA phase 1 trial like this one is designed to see if a new drug is safe, not to test its effectiveness.\n\"These findings need to be replicated in larger trials, and you have to be able to predict whether improved heart function from cimaglermin will help people live longer and feel better,\" she noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this category satisfactory, given that the story admits that it is reporting on a phase one trial, and includes the following information:\n\u201cBefore cimaglermin could be used to treat patients, it must prove its worth in a series of progressively larger and challenging trials and then be approved by the U.S. Food and Drug Administration. The process can take several years.\u201d", "answer": 1}, {"article": "\u201cI just need a calculator to add a few things,\u201d said Falcone, who was not involved in the study.\nTo test this idea, they looked back at 78 minor surgeries that were done on women with endometriosis - half using the assistance of a robot, half without it.\nUsing a robot for basic surgery, like the kind studied here, would be like using a computer to do addition, he told Reuters Health.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nBecause the robot lets the surgeon get a better picture of the inside of the body, the authors had expected that surgeries using the robot would go more smoothly than those without it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was one of the missing elements. At a minimum, the story should have said how many companies even make these things, how long they have been in production and how many hospitals/surgical centers have them. As far as\u00a0we know, the major manufacturer is da Vinci, and we\u2019re sure they would be glad to provide some numbers. If you just do a search on the da Vinci site of how many surgeons in western\u00a0Washington use these machines for gynecological procedures, you come up with a list of 1,500 names. imagine what that would be like in an area like Los Angeles or New\u00a0York?", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.01.036.\nResearchers noted that the findings only pertain to consuming the nutrient through food and not vitamin supplements.\nThey also tried to find out how much environmental factors such as diet mattered versus genetics.\nHow vitamin C inhibits cataract progression may have to do with its strength as an antioxidant.\n\u201cThe most important finding was that vitamin C intake from food seemed to protect against cataract progression,\u201d said study author Christopher Hammond, M.D., FRCOphth, professor of ophthalmology at King\u2019s College London.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that Vitamin C-rich foods are widely available, although in different types and costs, so we rated that Not Applicable.", "answer": 2}, {"article": "\"The work by [first author] Price et al.\nWe should be very careful about claiming the importance of resveratrol for medical purposes.\n\"This field has been extremely controversial.\nTesting the effect of resveratrol on SIRT1 in mice was difficult, Sinclair said.\nBut don't go reaching for that Chianti yet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The preliminary nature of these findings was clear in the body of the story (although not in the headline).", "answer": 1}, {"article": "For example, 75% of all smokers reach for their first cigarette within 30 minutes of waking up.\n\"Gums and patches are designed to help manage cravings, but they are only 5 to 9 percent effective.\nThe data were presented today at the Society for Research on Nicotine & Tobacco's 22nd Annual Meeting.\nSkin irritation assessment showed no signs of irritation or erythema.\nCHICAGO, March 4, 2016 /PRNewswire/ -- Chrono Therapeutics, a pioneer in digital drug therapy, today announced that clinical data for the company's smoking cessation technology showed a statistically significant reduction in nicotine cravings in a trial of adult male smokers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of the availability of this device, such as next steps in testing or application for FDA approval. The news release also does not discuss whether this device would require a prescription.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of whether this device is still in testing or whether it has garnered FDA device approval. (In fact, the FDA has determined that the device may be marketed as of August 18, 2005; the company was FDA approved to market it for \u201cfailed diuretic therapy\u201d not as an alternative for heart failure patients \u2013 FDA Feb 2, 2006 .)", "answer": 0}, {"article": "\u201cWe start to see these correlates that we think over the course of decades in a human could lead to something problematic,\u201d he says.\n\u201cThat means if you\u2019re not eating dietary fiber, your immune system may be existing in kind of a simmering pro-inflammatory state,\u201d he says\u2014the very state that predisposes us to different Western diseases.\nLoading up on fiber-fortified processed foods isn\u2019t likely a good way to increase the kind of fiber that benefits the gut.\nThey kept a food journal throughout, and the researchers biopsied their fat tissue.\nThe diet was followed by six weeks of eating normally.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions a range of healthy dietary options for increasing fiber intake \u2014 all of which are available to consumers.", "answer": 1}, {"article": "\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nFreezing eggs now is no guarantee of a baby later.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n\u25a0 The \u201csuccess\u2019\u2019 rates of egg freezing may vary widely from one fertility center to another.\nShe owns her eggs, no question.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear about the availability:\u00a0 \"half of 282 US fertility centers surveyed offer egg freezing.\" ", "answer": 1}, {"article": "But for others, doctors may prescribe a more invasive treatment that involves injecting hyaluronic acid in to the knee, called viscosupplementation.\nThe authors of the study discourage patients from getting this treatment.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\n\"This needs to remain one of those limited treatment options and should be used appropriately by the physician giving it.\"\n\"This is not a first line treatment, but it's a reasonable treatment in those people who have been appropriately screened.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never explained the availability of the viscosupplementation approach.", "answer": 0}, {"article": "For people hoping to shed some pounds, changing the type of protein in the diet, rather than the amount of it, is an idea the researchers think deserves more study as a weight loss strategy.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\nHe is an associate professor in the department of infection and obesity at the Pennington Biomedical Research Center in Baton Rouge, La.\nOne large egg has about 70 calories, and it contains about 6 grams of protein, 5 grams of fat, and 186 milligrams of cholesterol.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of eggs and cereal is not in question.", "answer": 2}, {"article": "The median age was 75 years (range 41to 94).\nThe study evaluated safety and efficacy outcomes of 1,083 patient reports collected in a multi-institutional database.\nElekta (EKTA-B.ST) today announced new data demonstrating stereotactic body radiation therapy (SBRT) is a safe treatment option for early-stage lung cancer patients aged 80 or older.\nDisclosure: This research was partially supported by Elekta through a research grant with all institutions being members of the Elekta Lung Research Group.\nTo date, they have accumulated data on close to 1,200 such patients and identified medical and technical factors that affect tumor control and toxicity.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the treatment is available at the five sites that participated in the observational study, but whether it is available outside of major academic cancer treatment centers isn\u2019t spelled out.", "answer": 0}, {"article": "... Then a lot of guys eventually were like, 'I'll go.\nThe study, published Monday in the New England Journal of Medicine , tested whether pharmacist-led programs in barbershops could significantly lower high blood pressure in black men in the United States.\nOn the other hand, the barbershop represents a safe haven in the black community -- a no-judgment zone -- where conversations about health and other personal topics are commonplace.\nAt his barbershop, Thomas said, many customers were hesitant to open up to the pharmacists and doctors and to meet with them for health consultations.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this research was conducted in the Los Angeles area and cautions that a national study would be needed to show the approach\u2019s applicability in other locales. Readers would not assume that this kind of health care assistance was available in black-owned barber shops elsewhere.", "answer": 1}, {"article": "\"We found potentially important changes in other outcomes; in particular, fewer participants in the nasal irrigation group than in the no-irrigation group had headaches, used over-the-counter medications and intended to consult a doctor in future episodes,\" write the authors.\nTo alleviate symptoms, steam inhalation and nasal irrigation are widely suggested as an alternative to common treatment with antibiotics, which are often not effective and contribute to antibiotic resistance.\nSteam inhalation did not appear to alleviate symptoms of sinusitis.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\nResearchers from the United Kingdom conducted a randomized controlled trial on the effectiveness of advice from primary care physicians to use nasal irrigation and/or steam inhalation for chronic sinusitis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Nasal irrigation and steam are both widely available.", "answer": 2}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nIt\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\nIt found that 52% of low-FODMAP patients and 41% of patients on a less-restrictive diet reported \u201cadequate relief.\u201d The difference was not statistically significant, says study co-author William Chey, a professor of gastroenterology.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\nIn 2014, IBS treatment guidelines from the American College of Gastroenterology said the diet showed promise, but that the quality of evidence was \u201cvery low.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The text offers links to online explanations of the diet, as well as to lists of foods that would be eliminated initially as part of it. Anyone could give this a try, though the article recommends that IBS sufferers implement the diet under a dietitian\u2019s supervision.", "answer": 1}, {"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\nCosts vary widely, but the American Society for Aesthetic Plastic Surgery said the average price for a Botox treatment in 2016 was $376.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\n\u201cI had less problems with depression.\u201d\n\nEven though the study she took part in is now over, she said she will continue to get Botox injections.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No statement is made about the availability of botox, but readers can reasonably\u00a0assume that it will continue to be widely available.", "answer": 2}, {"article": "\"Here's this guy, the handwriting is on the wall, any hematologist will tell you he is a goner -- this guy was essentially cured,\" Galipeau tells WebMD.\nExcitement is spreading as oncologists learn about the findings.\n\"Our results were absolutely dramatic.\nThey kill cancer in the test tube.\nGalipeau was not involved in the Porter study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nPreviously, EDAS has been used for moyamoya disease, a rare cerebrovascular disorder that affects younger patients.\nAfter one year, 9.6 percent of the patients treated with the surgery experienced another ischemic stroke or died, compared with 21.2 percent of patients in a matched control group who received only intensive medical management.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This procedure is currently available, as explained here:\u00a0 \u201cEDAS has been used for moyamoya disease, a rare cerebrovascular disorder that affects younger patients.\u201d However,\u00a0 there are relatively\u00a0few facilities that treat moyamoya disease.\u00a0 Saying how many sites have the ability and expertise to do the EDAS procedure would\u00a0have been more helpful.", "answer": 0}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0indirectly states\u00a0that lung cancer screening is not widely available (e.g.\u00a0\"would widespread screening reduce cancer deaths?\").\u00a0\u00a0 ", "answer": 1}, {"article": "Studies conducted by the CDC through its Adult and Youth National Tobacco Surveys found increased experimentation by youth trying out e-cigarettes but not conventional cigarettes.\nBut as it seems e-cigarettes are here to stay, most calls are for informed regulation rather than prohibition.\n(CNN) It's a portable piece of technology providing seemingly bottomless access to a drug craved by more than 1 billion people worldwide -- nicotine.\nThe growing fear is the increasing domination of big tobacco in the e-cigarette market, which was once seen as a competitor.\n\"Exposure to nicotine can harm adolescent brain development.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the products discussed are readily available.", "answer": 1}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was about a study comparing two treatments for abdominal aortic aneurysms.\u00a0 Because the story mentioned that it was about aneurysm repair in 2001 and 2004, a reader could infer that both are current procedure.\u00a0", "answer": 1}, {"article": "Most recently, the F.D.A.\nThomas E. Rathjen, a spokesman for Nabi Biopharmaceuticals, said the results of the study should be available sometime next year.\nThe multishot sequences being tested are designed to extend the antibody response for many months, although eventually the body will stop producing the anti-nicotine antibodies, he said.\nIf the vaccine helps smokers quit, Dr. Reus said, a central question will be whether booster shots could help prevent relapse.\nAn effective vaccine could play a major role in reducing smoking around the world, said Dr. Vocci, who estimated that current rates of smoking would lead to one billion deaths in the 21st century.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly describes the current stage in the drug approval process: The story discusses that NicVax (Nicotine Conjugate Vaccine) has been fast-tracked for approval by the FDA, however, the story also notes that this vaccine is still in Phase 2 clinical trials (tests of safely and efficacy), and additional large-scale, randomized controlled Phase 3 trials are needed before NixVac can apply for final FDA approval. ", "answer": 1}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nThere has been research in monkeys and rabbits as well, and the researchers hope the vaccine will progress to human trials.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\nPrevious attempts to find an Alzheimer's vaccine either caused harmful side effects, such as brain inflammation, or used less effective approaches, she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the vaccine is not available and has not even begun clinical research in human patients. However, it would have been appropriate to give a sense of the time frame. Even if trials started in humans and the vaccine was shown to be safe and effective, it would be years before this became widely available.", "answer": 1}, {"article": "But \"we could never get it to sustain beyond maybe a day,\" he says.\nSince then, thousands of depressed patients have received \"off-label\" treatment with ketamine.\nIt's been used for decades as an anesthetic that can rapidly stop pain without affecting vital functions like breathing.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nBut the studies of ketamine have produced results so dramatic that some doctors, including Feifel, are bypassing the usual protocols.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that ketamine is not approved for treatment of depression, but it is widely used as an anesthetic.", "answer": 1}, {"article": "In a paper published online Tuesday by the journal PLoS Medicine, the researchers found that those who consumed 15 grams or less of alcohol a day, which is the equivalent of one drink of any alcoholic beverage, when they were about 58 years old on average were more likely to have good overall health when they were about 70 years old.\nThat was after accounting for other factors, such as smoking.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcoholic beverages isn\u2019t in question.", "answer": 2}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nDr. Gupta added that the study provides evidence demonstrating that the robotic approach performs at least as well as the open approach.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\nThe study is titled \"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomized, phase 3, non-inferiority trial.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that both techniques are available\u2026 including at the institution that issued the release. The release could have informed readers that, according to the published paper, that all of\u00a0the operators in this study had\u00a0done at least 10 robot-assisted cystectomies before being allowed to participate in the study. When widespread adoption of the robot-assisted procedure occurs, it would be possible that many surgeons would not have completed that many robotic cystectomies.", "answer": 1}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nThe research raises the possibility that singing in choir rehearsals could help to put people in the best possible position to receive treatment, maintain remission and support cancer patients.\n\u2022 At Tenovus Cancer Care our aims are simple: to help prevent, treat and find a cure for cancer.\nIn doing that we offer support, advice and treatment, information on prevention and funding for research to improve outcomes for people living with cancer.\nFollowing on from this research, Tenovus Cancer Care is launching a two year study looking in more depth at the longitudinal effect of choir singing over several months.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We think choir-singing is widely available. The news release provides a link to 17 Tenovus Cancer Care centers that offer group singing in England and Wales. However, it\u2019s worth noting that most people do not have access to choirs that are meant to support people in cancer treatment and their caregivers.", "answer": 1}, {"article": "Briakinumab works by dampening the immune system response that causes psoriasis, said Bruce Bebo, director of research and medical programs for the National Psoriasis Foundation, based in Portland, Ore.\n\nMore serious infections were seen in people taking briakinumab (2.6 percent) vs. those taking methotrexate (1.8 percent).\nThe study was funded by the drug's manufacturer, Abbott Laboratories.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\nThe study lasted one year.\nAn ongoing three-year trial involves 248 people from the current study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of briakinumab was made clear in the story.", "answer": 1}, {"article": "Compared to coffee, soft drink and iced tea drinkers, study participants who consumed a cup or more of hot caffeinated tea daily had 74 percent lower odds of having glaucoma, the study authors report in the British Journal of Ophthalmology.\n\u201cBut we are also interested in lifestyle habits and what we can do to make a difference.\u201d\n\nGlaucoma is the second leading cause of blindness worldwide, according to the World Health Organization, affecting an estimated 58 million people.\nThat includes more than three million Americans, only half of whom are aware they have the disease, according to the Glaucoma Research Foundation.\nOther studies indicate that antioxidants in tea could have similar effects, he noted.\n\u201cPatients can and should be involved and take an active role in the management of their ailments,\u201d Hecht said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Other than water, tea is the most widely consumed beverage in the world.", "answer": 2}, {"article": "GLYX-13 targets parts of the brain linked to learning and memory.\nFor his part, Bruno cautioned that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.\nThe new drug -- called GLYX-13 -- is so far given in an intravenous form and was recently tested in patients who had not responded to other antidepressants.\nGLYX-13, the new drug, is still being studied and it isn't projected to be available before some time in 2016, Moskal said.\nMoskal, however, said he is confident that this drug will be a breakthrough in treating depression.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the study is in phase II clinical trials and that results are considered preliminary. The lead researcher says that the new drug is not projected to be available before 2016. The independent expert also cautions that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.", "answer": 1}, {"article": "More women are undergoing genetic testing after a diagnosis of breast cancer, and improvements in both mastectomy and breast-reconstruction techniques have made the option of a double reconstruction less daunting.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\nHe and other experts emphasized that though the removal of the healthy breast sharply reduced the risk of a new cancer developing in that breast \u2014 the risk is not zero because some tissue can remain \u2014 it was the cancer that had already been diagnosed that posed the greatest threat to a patient\u2019s life.\nDoctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\n\u201cWe want to support women in doing what feels right to them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes surgical treatments available for women who are diagnosed with breast cancer. The story also notes via Dr. Gralow\u2019s comments\u00a0 that women should be appropriatley informed about the absolute survival benefits of their treatment choices. ", "answer": 1}, {"article": "Despite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\nThis is the first clinical study to suggest that neoadjuvant chemotherapy (treatment prior to surgery) may improve breast cancer recurrence rates and patterns in African-Americans.\nDifferences in recurrence rates and patterns between the races following various forms of treatment have not been thoroughly investigated.\nCo-authors of the study include Jun Xia, Sergey Klimov, Pranay Neema, Dr. Dora Il'yasova, Dr. Padmashree C. G. Rida, Dr. Remus Osan and Dr. Aneja of Georgia State; Dr. Guilherme Cantuaria and Dr. Mildred Jones of the Northside Hospital Cancer Institute; Dr. Uma Krishnamurti, Dr. Xiaoxian (Bill) Li and Dr. Michelle D. Reid of Emory University; and Dr. Meenakshi Gupta of West Georgia Hospitals.\nThe researchers studied rates and patterns of tumor recurrence after hormone, radiation and chemotherapy among African-American and European-American breast cancer patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "None of the treatments given are new or experimental and it\u2019s clear they\u2019re readily available within cancer treatment facilities.", "answer": 1}, {"article": "No relationship was observed between exercise and later anxiety, but the researchers did find a link between exercise and later depression.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\nMORE: A New Hope For Depression\n\nThe authors write that the combined physical and social benefits of exercise are likely responsible for its ability to help stave off depression.\n\u201cThere is good evidence that physical activity can help people recover from depression, though we recommend it be used in addition to the usual treatments we would prescribe for established depression, like medication and counseling,\u201d says Harvey.\nPeople seemed to have mental health benefits from physical activity regardless of whether they reported working out to the point of exhaustion or barely breaking a sweat.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it makes no statements about availability, most readers will realize that exercise, such as walking and cycling, are usually readily available.", "answer": 2}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\nThe muscle into which needles deliver vaccine is not nearly as active immunologically.\nBut he said it will be interesting to watch.\nFlu patch may take sting out of your fears\n\nIn what would be a boon for needle-phobes of all ages, researchers have developed a skin patch that vaccinates against the flu and could be available in five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this technology is not yet available. But why waste the introduction\u00a0predicting that the patch \"could be available in 5 years\"?\u00a0That\u00a0space\u00a0would have been better used to provide an important detail about the research: This was a mouse study!\u00a0Instead, readers have to wait 5 paragraphs to learn this. And what is that five-year prediction based on besides the hopes and prayers of a researcher and whatever company will market it? ", "answer": 0}, {"article": ".\n\u2022 Smoking cessation, weight loss (if indicated), limiting or avoiding alcohol, maintaining adequate levels of vitamin D and calcium, eating a healthy diet, and regular physical activity are suggested for all women with prior breast cancer\n\u2022 Non-pharmacologic therapies for VMS such as cognitive behavioral therapy, hypnosis, and acupuncture may be helpful as are vaginal lubricants and moisturizers\n\u2022 Several emerging approaches such as selective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors show promise as useful agents to expand options for symptom relief with less breast cancer risk but have not yet been tested to confirm safety in women with prior breast cancer\n\nOther authors of the study include: Cynthia A. Stuenkel of the University of California, San Diego in La Jolla, Calif.; Susan R. Davis of the School of Public Health and Preventative Medicine, Monash University in Australia; JoAnn V. Pinkerton of the University of Virginia in Charlottesville, Va.; Ann Gompel of Paris Descartes University in France; and Mary Ann Lumsden of the University of Glasgow School of Medicine, Dentistry, and Nursing in Scotland.\n\"Following breast cancer, women should generally not be treated with menopausal hormone therapy but should instead focus on lifestyle modifications such as smoking cessation, weight loss, and regular physical activity,\" said the study's first author, Richard J. Santen, M.D., of the University of Virginia Health System in Charlottesville, Va. \"Pharmacologic agents are also available to treat women with severe symptoms.\nA comprehensive review published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism focuses on current and future approaches to management of menopausal symptoms after breast cancer.\nHormone therapy may help relieve a woman's menopausal symptoms but is not recommended for women who have had breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although lifestyle changes are readily available, it\u2019s unclear if the emerging approaches (\u201cselective estrogen receptor modulators (SERMs), Tissue selective estrogen complex (TSECs), estetrol, and neurokinin B inhibitors\u201d) listed in the release are even available. Some of the recommended lifestyle changes aren\u2019t available to women with limited access to healthy foods which are often more costly even if they are available. \u00a0Lack of insurance coverage and lack of availability of alternative treatments like cognitive behavior therapy, acupuncture and hypnosis put these modifications out of reach for many women.", "answer": 0}, {"article": "Apixaban showed a 21 percent relative reduction in the incidence of strokes or systemic embolisms (clots) when compared to warfarin, a 31 percent relative reduction in major bleeding and an 11 percent relative reduction in overall mortality, the researchers found.\nThe drug has not yet been approved by the U.S. Food and Drug Administration.\nThe study was published online Oct. 1 in The Lancet.\nThis may simplify how physicians make decisions and also improve patient care.\"\nCurrent practice guidelines permit the use of either anti-clotting therapy with aspirin or warfarin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug has not yet been approved by the FDA.", "answer": 1}, {"article": ".\nThere was also a lower positive biopsy rate among women ages 40-49 compared with women over 50.\nMore than 41,000 screening mammography exams were examined for callbacks and recall rate, biopsies performed, cancers detected, and sensitivity and specificity of screening mammography.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\nThe number of cancers detected in women ages 40-49 was not significantly different from women ages 50-59 or 60-69.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Mammograms are a widely available intervention. However, like all medical care, women in rural areas far away from clinics or hospitals may have trouble accessing mammograms.", "answer": 2}, {"article": "Calcineurin is an enzyme that regulates communication between brain cells and memory formation.\nBecause of this, there is a large consensus that preventing this kind of toxicity would be an effective treatment strategy.\nAn early online version of this paper detailing the findings has been published and is scheduled for publication in the July 7 issue of the Journal of Alzheimer's Disease.\nUTMB's Cristiana Rastellini, Professor in the departments of Surgery and Microbiology & Immunology also was an author on this paper.\nTo bypass this issue, the UTMB team analyzed data from the medical records of 2,644 patients who received organ transplants and must take calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, for the rest of their lives to prevent rejection of the transplanted organ.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, it is clear that the drugs in question are available. That raises a possible concern, as their availability and the news release\u2019s enthusiasm may result in patient demand for access to this as-yet unproven strategy.", "answer": 1}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nIn general, dietary patterns are consistent for at least seven or eight years, Scarmeas said.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nThe bottom line for dementia is that fish oil may help in the very early stages, but more research must be done to confirm this, he said.\nIt could also help keep you thinking clearly.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of the \u2018mediterranean diet\u2019 so this criterion is not applicable for this story. ", "answer": 2}, {"article": "Five trials using zinc salts other than acetate in daily doses greater than 75 mg shortened colds by an average of 20 percent, while another five using less than 75 mg per day produced no effect.\nAllowing the lozenge to dissolve instead of swallowing it seemed to provide a therapeutic effect.\nWhile surprised to note how strong the correlation was between daily doses of zinc and its effect on colds' duration, he said he and his colleagues still don't know why it seems to work.\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\nTUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the \u201cpopularity of zinc supplements\u201d but never established how popular, widespread are their use and never explained\u00a0\u00a0 if the lozenges on market shelves are at the same dosages as discussed in the story.\nWe can\u2019t give it a satisfactory score; we\u2019ll rule it N/A.", "answer": 2}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nBut biomarkers \u2014 proteins and imaging techniques \u2014 are helping to identify the disease much earlier.\nThey can also administer simple paper-and-pencil tests.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\n[ID:nN13273900] These proposed rules included measurements of cerebral-spinal fluid.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story does not point out the hurdles that need to be cleared before this sort of spinal fluid test for Alzheimer\u2019s Disease could be considered for use outside of research trials, so readers may get an unrealistic sense of how soon it might enter routine clinical use.", "answer": 0}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nCamann says the gentle C-section is not a replacement for a vaginal birth; it's just a way to improve the surgical experience.\nIn addition, Penn says, the mother's hands were not strapped down and the intravenous line was put in her nondominant hand so she could hold the baby.\nShe says she'd like nothing more than to know that other women having C-sections are able to have the same amazing experience she had.\nBetsey Snow of Anne Arundel Medical Center says the family-centered C-section represents a cultural shift, and her hospital is helping break new ground by adopting it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a tricky one. The piece said family-centered cesareans are not routine, and it did not firmly establish if every mother who asks for the procedure would be accommodated. We\u2019ll give the benefit of the doubt, but we\u2019d note that the story could have addressed how women can find providers who are known to offer family-centered cesareans. It also could have discussed whether hospitals are generally willing to accommodate these practices if asked to do so.", "answer": 1}, {"article": "Observers measured the symmetry of their smiles, checked for drool and listened to them read sentences.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nNovalar and some dentists who advise the company said it might be useful for children, who can injure themselves by biting their lip or tongue without knowing it.\nWith about 300 million anesthesia injections given by dentists each year, company executives say the drug could easily achieve sales of hundreds of millions of dollars a year.\n\u201cWe aren\u2019t reversing the local anesthesia,\u201d said Dr. Paul A. Moore, chairman of anesthesiology at the University of Pittsburgh School of Dental Medicine, who is an adviser to Novalar.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article says the company that makes OraVerse, which has just been approved by the FDA for use in speeding the return of sensation after local dental anesthesia, expects to be selling it by the end of the year. ", "answer": 1}, {"article": "But he cautions against overdoing it.\nPeople should start with mild, gentle exercise like clearing the table, doing the dishes, or taking the dog for a short walk.\nWhen patients adopt a more positive attitude, Barsky points out, it often translates into greater confidence and more energy.\nIn the study, over 600 patients with chronic fatigue syndrome were assigned to different treatments.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions \u201ca form of talk therapy\u201d but never makes it clear how exactly the therapy works and whether any psychiatrist could provide it. This is one of many places in the story where additional detail would help. Cognitive behavior therapy (CBT) was offered for up to 14 sessions over 23 weeks. A booster session was offered at 36 weeks. CBT is a widely available and standard psychological treatment used for many conditions. Similar to CBT, details on the duration, frequency and availability of the competing interventions would be useful. Helping readers understand what might be involved in the intervention would improve understanding.", "answer": 0}, {"article": "About half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story opened by informing readers that it was about \u201ca specific bacterium, known as a probiotic\u201d and although the story did indeed name the particular bacterium used in the study, it neglected to inform readers whether it was currently available to the public. And, since this was a European study, it raises even more questions in readers\u2019 minds about how the findings relate to American products.", "answer": 0}, {"article": "\u201cPublic health ethics always has a concern to avoid any net harm to population health,\u201d explains Kozlowski, professor of community health and health behavior at UB and the paper\u2019s lead author.\n\u201cThe public is dramatically misinformed about the relative risks of substitutable tobacco and nicotine products.\n\u201cYet, such facts are being kept from adult consumers of legal tobacco/nicotine products, either by not informing or actively misinforming consumers.\nAn information quarantine functions similarly to a medical quarantine \u2013 think of your favorite zombie movie or television show in which the infected person is secluded from everyone else to protect the overall public.\n\u201cIt would be scandalous, even criminal, to keep such facts from consumers,\u201d the researchers write.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Anyone who has been to a drug or convenience store knows that smokeless tobacco products are readily available.", "answer": 1}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nGiven those findings, along with the results from this trial, a rapid change in clinical practice is expected, noted Dr. Jotte.\nResearchers are continuing to follow patients and anticipate a subsequent analysis later this year.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\nAbout the Study\n\n The IMpower131 trial enrolled 1,021 patients with stage IV squamous NSCLC.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release refers to the brand name of the immunotherapy drug, which would be enough to alert most journalists covering the ASCO meeting that that this drug is approved for other uses.\nHowever, given the cost and marginal benefit, many insurers will not pay for it which would make it prohibitive for most.", "answer": 1}, {"article": "Mice, as well as humans who have albinism or lack of pigmentation, have profound vision loss and changes in the eye structure , especially the macula, the oval-shaped area near the center of the retina associated with a person's ability to see clearly.\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\nThis work grew out of research using albino mouse models.\n\"In the end, L-DOPA may not be the drug that ends the disease but the pathway identified is likely to be a key observation as the search for a cure continues.\"\nThey then determined the age patients developed AMD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "L-DOPA is readily available to patients now and the story makes this clear.", "answer": 1}, {"article": "The other 13 received a placebo -- a pill containing no medicine -- to be taken 30 minutes before bedtime.\nMany people with prediabetes also have untreated sleep apnea, although few of them are aware of it.\nUsing a simple device for eight hours a night to treat sleep apnea can help people with prediabetes improve their blood sugar levels and may reduce the risk of progressing to diabetes, according to a new study published online in the April 21, 2015, issue of the American Journal of Respiratory and Critical Care Medicine.\nThe most widely accepted treatment for sleep apnea is continuous positive airway pressure (CPAP), a device that blows a constant pressure of air into the lungs through a tube and face mask during the night.\n\"Assessment of sleep apnea should be considered in patients at high risk for diabetes and cardiovascular disease, since our study shows that treatment of sleep apnea can reduce these risks.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does not establish how easy or difficult it is to obtain treatment with a CPAP machine. Many people with prediabetes do not know they have sleep apnea. Diagnosis requires either an expensive overnight sleep study (not widely available) or sometimes, with a cheaper home sleep monitor (becoming more available). There are many insurance limitations on testing for sleep apnea. Once the condition is diagnosed, treatment is usually covered by insurance and provided by respiratory care supply companies in the home. Some discussion of this context would have been helpful.", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was ample explanation of the Lariat being available, even though the JAMA study authors recommend that it no longer be used for the purpose of atrial fibrillation surgery. The story also discusses recent FDA approval of the Watchman device.", "answer": 1}, {"article": "He's from the cell therapy and transfusion medicine unit at Careggi University Hospital in Florence, Italy.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nThe researchers think these deaths were most likely due to the transplant technology used before 2006, which has since improved.\nMost people are diagnosed between the ages of 20 and 50, although individuals as young as 2 and as old as 75 have developed the disease, the society says.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explain if stem cell transplants are currently available to MS patients. The National MS Society states they are not FDA approved, and are considered experimental.", "answer": 0}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nThe calculator used in this study is a simplified version of that model.\nAnd right now, there is a way to go before most doctors will have those systems in place.\nOnly about 10 percent had a \u201cfully functional\u201d system that included extensive information on patients\u2019 medical history.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about the availability \u2013 or lack thereof \u2013 of the computerized risk calculator in question.\nHowever, a reader should be able to deduce from the following hints that the idea is not in widespread use:", "answer": 1}, {"article": "This month, Pennsylvania became the 24th state to legalize medical marijuana.\n\"But why take a solution off the table when people are telling us and physicians are telling us that it's working?\"\nMany medical professionals say there's not enough evidence for them to confidently prescribe it.\n\"Opioid abuse has no party, has no color, has no religion,\" Vereb said.\n\"When I see them in a six-month follow up, they are much more focused,\" Witman said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article adequately\u00a0discusses that availability varies widely from state to state.", "answer": 0}, {"article": "CHICAGO - Screening patients for diabetes based solely on their age and weight - a recommendation from a leading medical expert group - could miss more than half of high-risk patients, according to a new Northwestern Medicine study of a nationwide sample.\nO'Brien will be presenting his findings today at the Society for General Internal Medicine conference in Denver, Colorado.\nThe study was published today, Friday, April 13, in the Journal of General Internal Medicine.\nBut there has been little attention focused on this group's most recent diabetes screening guideline.\nThe other co-authors were from the CDC.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "More intensive screening is obviously available.", "answer": 2}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The\u00a0story mentioned that\u00a0orlistat, the weight loss medication tested in the study,\u00a0is the active ingredient in Xenical and\u00a0Alli. Unlike the competing piece in HealthDay, however, it did not specify that Xenical is a prescription drug and that Alli is available over the counter. Although this information would have been helpful, providing the trade names for both drugs is probably enough to orient most readers.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that Gilenya has already been approved to treat adults with MS. However, it would have been stronger it had mentioned that the expanded indication is for ages 10 and older.", "answer": 1}, {"article": "Until recently, studies of osteoporosis drugs just measured changes in bone density, assumed to equate with lower fracture risk.\nAmgen Inc. will stress that only two shots of its genetically engineered denosumab, which could be approved for sale this fall, are needed each year.\nDenosumab, an injection just under the skin, would have to compete against eight major types of pills and injected medicines, including estrogen and generic and brand-name Fosamax pills, long the market leader.\n\"Because this drug affects the immune system, the long-term effects on cancer risk or immune function is still unknown,\" she warned, saying she expects FDA will require Amgen to track risks over time if the drug is approved.\nHe expects that would be covered by insurers, who pay for multiple medicines for other conditions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the study drug, denosumab, is not yet approved by the FDA, but indicates that it could be available this fall.", "answer": 1}, {"article": "For the study, published online Feb. 7 in the Journal of Epidemiology and Community Health, Northstone's team collected data from the Avon Longitudinal Study of Parents and Children on 3,966 children born in 1991 and 1992.\nThey speculate that good nutrition may promote brain growth and cognitive development.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\nFor more information on healthful eating for kids, visit the U.S. Department of Agriculture.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of healthy foods is not generally in question, although it may\u00a0be\u00a0difficult to find fresh produce\u00a0in\u00a0urban areas\u00a0that aren\u2019t served by grocery stores.", "answer": 1}, {"article": "For nine months, the developing fetus is attached to its mother by the umbilical cord.\nThere was not enough evidence before to extend that recommendation to full-term babies, but Rabe thinks this study should tip the balance in favor of delay.\nNow, research suggests there may be benefits to keeping mom and baby attached a few minutes longer.\nImmediate clamping started about 70 years ago out of concern that leaving the delivered infant attached to the placenta could rob the mother of too much blood.\nKjersti Aagaard, vice chair of obstetrics and gynecology at Baylor College of Medicine and Texas Children's Hospital, is more skeptical.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Hypothetically, a delay in cord-clamping is something equally available to all those who deliver babies and their patients. But in the real world it\u2019s different:\u00a0A delay is only available to a woman\u00a0if her\u00a0doctor/health system decides to offer it (barring the role of patient advocacy). The story didn\u2019t explore how common delayed cord-clamping is, or how willing doctors are to consider it. But since the story does at least suggest that women can raise the issue with their doctor and make a shared decision about what to do, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Surgery for a painful, common back condition known as spinal stenosis resulted in significantly reduced back pain and better physical function than treatment with drugs and physical therapy, according to the latest findings from a large federally funded research effort.\n\nThe results from the Spine Patient Outcomes Research Trial, or Sport, echo findings it reported last April involving degenerative spondylolisthesis, another common spinal problem. A separate, earlier report from the same study found nonsurgical treatment for...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news story notes that laminectomy is one of the most common operations performed in the U.S., suggesting that it is widely available. Most readers are likely aware of the availability of nonoperative treatments such as pain medications and physical therapy.", "answer": 1}, {"article": "\u201cA.A.\nBut observational data can.\u201d\n\nIt is unlikely that substance abuse experts will widely reject A.A. on the basis of these findings.\nBut Sarah Zemore, of the Alcohol Research Group of the National Alcohol Research Center, said studies that observed the results of a treatment without setting up randomized control groups could also be informative.\n\u201cAlthough the randomized controlled trial is the gold-standard methodology in comparing between conditions,\u201d said Thomas G. Brown, an assistant professor of psychiatry at McGill University, \u201cit washes out a factor that may be important in potentiating A.A.\u2019s benefits, namely patient choice and preference.\u201d In other words, having a patient choose the form of treatment, rather than being assigned to it as in most studies, could be an important factor.\n\u201cSome of the wisdom embodied in A.A., such as the notion of persons, places and things that trigger drinking, are very much a part of cognitive-behavioral therapy, which is a scientifically driven, empirically validated treatment,\u201d Dr. Nunes said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains Alcoholics Anonymous (AA) and similar 12-step self-help programs for reducing alcohol dependence. The story does not mention that A.A. groups are widely available to anyone regardless of finances, and many groups allow people to attend any meeting without prior membership in the group. This would be important to note when discussing comparisons with more time-limited and potentially costly psychological treatments. ", "answer": 0}, {"article": "Air is suctioned through the side channels to emulate breathing.\nSome companies are already trying out the concept.\nFor some time, scientists have been searching for ways to cut down on the cost and failure rate of drug testing.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that this technology is still under development, with a recent grant from the Defense Advanced Research Projects Agency to create chips for all systems in the body. But we were concerned that the story allows a researcher who, according to this story is part of a team seeking to commercialize the technology, to speculate about FDA approval within two years and\u00a0to say that it\u2019s \u201conly a matter of time\u201d before these chips replace rodents. Those statements seem highly optimistic to us \u2014 another reason why the story should have consulted with an independent authority.", "answer": 0}, {"article": "A research team from the University of Adelaide and Griffith University have been studying the interactions between the toxin and an abnormal glycan (sugar) expressed on the surface of human cancer cells and released into the blood.\nThe team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\n\"Ovarian cancer is notoriously difficult to detect in its early stages, when there are more options for treatment and survival rates are better.\nThe new blood test has the potential to dramatically improve early detection of the disease, although it will require further testing before it is available for clinicians.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Here\u2019s the last sentence of this very brief news release:\n\u201cThe [research] team is currently seeking scientific and commercial partners to further test the technology with larger numbers of patient samples and to adapt it for mass screening.\u201d\nIt doesn\u2019t completely clarify for readers whether the test is currently available, but suggests it isn\u2019t.", "answer": 0}, {"article": "In the study, those who met the physical activity target by exercising through the week had a 35% lower risk of death than the inactive adults, with cardiovascular deaths down 41% and a 21% lower risk of cancer death.\nBut the weekend warriors also saw substantial health benefits if they met the physical activity target too.\nAs a rule of thumb, moderate exercise can be done while maintaining a conversation, whereas during vigorous exercise talking at the same time is too hard.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\n\u201cWeekend warriors are people who meet the recommended volume of physical activity each week through only one or two sessions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The ability to exercise is generally available, so this is N/A.", "answer": 2}, {"article": "Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: \"EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer.\nThe study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.\n\"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit,\" the authors wrote.\nThe Metastatic Breast Cancer Network has more about metastatic breast cancer.\nThe researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not report that eribulin, the drug studied, received approval in the United States based on the results of the study.\u00a0 Eribulin is approved for patients who have previously\u00a0been treated for metastatic breast cancer with at least two chemotherapies, including an anthracycline and a taxane.\nAs a result, the availability of the drug is unclear to readers.\u00a0 Information about drug approval and availability is valuable for patients with metastatic breast cancer.", "answer": 0}, {"article": "\u201cIf it weren\u2019t for the trial I wouldn\u2019t be here,\u201d she said.\nThe drug is expected to be approved by the Food and Drug Administration within a few months.\nRoche and Bristol-Myers said Thursday that they would conduct such tests.\nThe price of vemurafenib has not been announced, but is expected to be at least tens of thousands of dollars per year.\nThe effect was so marked that the trial was stopped early for ethical reasons, so that patients in the control group could be offered the new drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vemurafenib was described as experimental and as \u201cexpected to be approved by the FDA within a few months.\u201d\u00a0 Ipilimumab was explained to be approved in March and already on the market.", "answer": 1}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nFor now, he said, the data from this study is not strong enough to spur any changes in current screening recommendations.\nTUESDAY, Aug. 11, 2015 (HealthDay News) -- Colonoscopy can save lives, but experts agree that testing rates remain too low.\n\"While high-risk patients may ultimately require a screening colonoscopy, many average- and low-risk patients could undergo less invasive screening procedures.\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability isn\u2019t explicitly addressed, this risk calculator is now available (implicitly) by virtue of publication of the paper. \u00a0It is a simple scoring system that can be implemented based on the information in the paper, and the story makes this clear. We\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The two devices mentioned in the story were described as FDA approved, which is true. The story could have made it clear, though,\u00a0that both devices have been in use for a while and that\u00a0off-label use of devices is common. \u00a0", "answer": 1}, {"article": "Patients with Type-1 diabetes typically compensate by monitoring their blood sugar levels every few hours and injecting themselves with insulin as many as five times a day.\nThe treatment had no effect on one patient, whose disease had already progressed too far, doctors decided.\nAbout two weeks later, the patients checked into the hospital and received chemotherapy and other drugs to kill off their immune systems over five days.\nEven if patients continue to require insulin shots, the treatment should be considered a success if it halts the destruction of beta cells, said Dr. Jay Skyler, with the Diabetes Research Institute at the University of Miami Miller School of Medicine, who wrote an editorial accompanying the study.\nBut other doctors said that even if the benefits of the therapy are temporary, the research provides valuable insight into the mechanism behind the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states the treatment is experimental, letting readers know this procedure is not available at your local doctor's office just yet.\u00a0 ", "answer": 1}, {"article": "There is currently no test to predict which women will develop pre-eclampsia, which is marked by high blood pressure and high protein levels in urine.\n\u201cIt would also ensure that those women are educated about the warning signs of pre-eclampsia.\nThere\u2019s no reason why women should be caught unaware in the late stages of a pre-eclampsia\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\nThey ran the test at about 15 weeks gestation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is an experimental diagnostic test and not available beyond research settings. The story makes that clear.", "answer": 1}, {"article": "Not a single cancer was undetected that became palpable,\" she said.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nThe new study showed that, consistent with previous research, breast MRI can depict these rapidly growing cancers with high reliability.\nMRI screening has not been considered necessary for women at average risk, and there has been resistance to expansion of MRI into this population due, in part, to concern over higher costs.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that MRI screening is already available. The release notes that there\u2019s been a resistance to expand MRI screening to average risk women because of the cost.", "answer": 1}, {"article": "The most common side effects include itchiness and irritation in the mouth, ears and eyes, swelling of the mouth or tongue, headache and gastrointestinal problems like stomach pain and heartburn.\nStill, Nelson said that if sublingual products do win approval in the U.S., they will likely boost the number of hay fever sufferers who want to use under-the-tongue immunotherapy.\nThe researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\nBut longer term data are not yet available.\nThe benefits of allergy shots, by contrast, have been shown to persist for 10 years or beyond, Nelson noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n \nThis story makes it clear that sublingual immunotherapy is not available in the U.S.; however, this might have been mentioned sooner in the text.\u00a0\u00a0 \n", "answer": 1}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\n\"Our results suggest that the unique polyphenol mixture in tart cherries may help positively shape the gut microbiome, which could potentially have far-reaching health implications.\"\nThe gut microbiome holds great promise, especially related to personalized nutrition, although the research is still evolving and larger, long-term human intervention studies are needed.\nWhile the dietary intervention was based on a limited number of human volunteers and more research is needed to support these conclusions, the results help build the foundation for future research and suggest Montmorency tart cherries can play a role in positively shaping the microbiome and maintaining gut health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We can presume that tart cherry juice is widely available, and the news release does mention that Montmorency cherries are a common domestic variety \u201cavailable year-round in dried, frozen, canned, and juice forms.\u201d", "answer": 1}, {"article": "Glaucoma is a leading cause of blindness.\nBut they added that blood pressure and other factors that can contribute to vessel size would need to be considered.\nThe study appears in the latest issue of the journal Ophthalmology.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\nIn the study, researchers from the University of Sydney followed nearly 2,500 adults, aged 49 and older, for 10 years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was no discussion of what the \u201ccomputer-based imaging tool\u201d really was.\u00a0 Is it equipment already readily available and in use?\u00a0 If not, what is it, and what would it take to implement?\nNo details were provided \u2013 a weak spot in the story.\nThe story should have made the connection between retinal photography that is currently done for diabetic eye screening and this new, alternative use of the same images.", "answer": 0}, {"article": "Over more than six years of follow-up, the researchers found no evidence that ginkgo delayed or prevented normal declines in memory, language, attention, visuospatial abilities or executive functions, such as anticipating outcomes and adapting to changing situations and thinking abstractly.\nStill, Schneider won't object if someone wants to try it.\nHowever, ginkgo was safe and no serious side effects were noted, DeKosky added.\nThe American Botanical council took issue with the findings, however.\nThis age group is not typical of the age of both healthy people and those with mild cognitive impairment who use ginkgo for improving mental performance.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that ginkgo biloba is used widely. ", "answer": 1}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\n\u201cIt\u2019s maximally invasive,\u201d said Dr. Sugarbaker, who often removes the \u201cspare parts\u201d \u2014 organs a patient can live without, like the spleen, the gall bladder, the ovaries and the uterus.\nAnd critics say that since that trial was conducted, new drugs have come to market that allow patients with metastatic colorectal cancer to live two years with intravenous chemotherapy alone.\nBut Dr. Alan Venook, a colon cancer specialist at the , said that a couple of patients referred by him had \u201cdied miserable deaths.\nOne randomized trial done more than a decade ago involving 105 patients in the did show a striking benefit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that \u201can increasing number of the nation\u2019s leading medical centers has been offering the costly \u2014 and controversial \u2014 therapy to patients with the more common colorectal or ovarian cancers\u201d and names some of them.", "answer": 1}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nMcEvoy said there have been several reports of doctors doing CCTA heart scans in healthy patients, although the practice is currently discouraged by the American Heart Association.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\n\u201cTesting might lead to more harm than good,\u201d McEvoy told Reuters Health, adding that heart scans may cost $600 or more.\nIn an editorial, Dr. Michael S. Lauer of National Heart, Lung, and Blood Institute in Bethesda, Maryland, said the new study serves as a reminder of the downsides of screening.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that the scans are not currently recommended by guidelines but that \u201cthere have been several reports of doctors doing CCTA heart scans in healthy patients, although the practice is currently discouraged by the American Heart Association.\u201d", "answer": 1}, {"article": "Obesity is associated with heart disease, stroke, diabetes and some cancers, and researchers estimate that it is the second-leading cause of preventable death, after tobacco use.\n\"Our research -- the first to compare these treatments -- demonstrates that endoscopic sleeve gastroplasty is safe and effective in helping patients lead healthier lives.\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nDr. Sharaiha did not have any disclosures for DDW research.\nDr. Sharaiha noted that these findings do not suggest that endoscopic sleeve gastroplasty will replace the two surgical treatments as weight-loss interventions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "For someone reading the news release who is unfamiliar with weight loss treatment procedures, ESG may sound like an entirely novel treatment that is not yet clinically available. However, while it is relatively new, it is already in use. The release doesn\u2019t give us any idea of how many facilities perform any of these procedures.", "answer": 0}, {"article": "For Patients and the General Public:", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Both neratinib and veliptarib are described as \u201cexperimental\u201d so it is clear that neither are\u00a0currently\u00a0available outside of clinical\u00a0trials.", "answer": 1}, {"article": "Actually, nitrous is making a comeback in U.S. maternity circles. It has remained a staple of childbirth in Canada, Australia, and Britain \u2014 Catherine, Duchess of Cambridge (the former Kate Middleton), who welcomed her third royal baby, Louis Arthur Charles, last month, reportedly has used it. But it basically disappeared in the United States in the 1970s. American women preferred to be numbed below the waist with epidural anesthesia, or at least that became the gold standard for pain relief.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that currently \u201can estimated 500 U.S. hospitals and birthing centers offer nitrous \u2014 up from a handful less than a decade ago.\u201d", "answer": 1}, {"article": "Fluctuating levels of levodopa result in erratic periods of muscular control and involuntary movements throughout the day, disrupting activity at least half a dozen times a day.\nThe company said the drug is expected to be available in the fourth quarter, and formally launched in January 2018.\nThe long-acting therapy is taken once-daily at bedtime.\nWith Gocovri, which targets both dyskinesia and off time, patients will be able to reclaim about 3.6 hours of their day, CEO Gregory Went said in an interview ahead of the decision.\nAn estimated 90 percent of levodopa-treated patients, about 200,000 people in the United States, suffer from LID, the company said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes this clear: \u201cThe company said the drug is expected to be available in the fourth quarter, and formally launched in January 2018.\u201d", "answer": 1}, {"article": "Minimally invasive procedures increased to 31 percent of all radical prostatectomies in 2005 from 12.2 percent in 2003.\nThe widely advertised procedure is becoming more popular, said Dr. Jim C. Hu, the lead author of the study and an instructor in surgery at Harvard.\nBut the surgery increases the chance for longer term problems that require further therapy, the research says.\n\u201cThis paper,\u201d Dr. Hu said, \u201cdemonstrates that there are hidden risks for patients who opt for laparoscopic or robotic surgery.\u201d\n\nIn laparoscopy, a surgeon inserts instruments through small cuts in the skin instead of making large incisions to expose the organs.\nThe study, published on May 10 in The Journal of Clinical Oncology, examined a sample of 2,702 Medicare patients undergoing radical prostatectomy, the complete removal of the prostate, from 2003 to 2005.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies that laparoscopic prostatectomies are widely available, and in fact are done about a third of the time in the studied population.\nBut it would have been useful to state how difficult it is (or is not) to find a surgeon experienced with laparoscopic procedures. ", "answer": 1}, {"article": "After looking for other possibilities, those who took statins regularly had a 41 percent lower risk of developing rheumatoid arthritis compared with people who were not taking statins regularly.\nThe only way to prove the connection is with a clinical trial, Myerburg said.\nThis work received no outside or corporate finding, the researchers noted.\nFor the study, Chodick's team collected data on 1.8 million patients who got their health care through the Maccabi Healthcare Services, an HMO in Israel.\nThe report was published online Sept. 7 in PLoS Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that statins are already used to prevent heart attacks and stroke.", "answer": 1}, {"article": "\"It's known that EPA and DHA can inhibit breast tumour growth, but no one has looked directly at how effective these omega-3s are compared to ALA.\"\n\nMa found overall exposure to marine-based omega-3s reduced the size of the tumours by 60 to 70 per cent and the number of tumours by 30 per cent.\n\"There is evidence that both omega-3s from plants and marine sources are protective against cancer and we wanted to determine which form is more effective.\"\nIn North America, we don't get enough omega-3s from seafood, so there lies an opportunity to improve our diet and help prevent the risk of breast cancer.\"\nOmega-3s from fish pack a stronger punch than flaxseed and other oils when it comes to cancer prevention, according to a first-ever University of Guelph study.\nALA is plant-based and found in such edible seeds as flaxseed and in oils, such as soy, canola and hemp oil.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Fatty fish is widely available.", "answer": 2}, {"article": "A Harvard researcher hopes an old arthritis drug, which he read about in a 19th century German medical journal, could be a cheap new treatment for diabetes.\n\nIn the late 1990s, Steven Shoelson's research suggested that the drug, called salsalate, might also help diabetics. The idea sent him into the basement stacks of a Harvard library to see whether anyone else had pursued the notion.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described the drug being investigated as \u2018a cheap, generic\u2019 and as currently being sold as \u2018an inexpensive generic\u2019.\u00a0 It would have been useful to clarify whether it was available as a prescription or an over-the-counter medication.", "answer": 1}, {"article": "However, about half of patients who undergo hormone therapy suffer from hot flashes similar to those that women experience during menopause.\n\"The symptoms don't (normally) get better by that much that quickly.\"\nTheir reported level of hot flashes dropped markedly.\n\"Usually it's mild and self-limiting and improves with time.\n\"It is a definite nuisance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of acupuncture isn\u2019t in question.", "answer": 2}, {"article": "\"It's like 'Star Trek.'\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nThose factors do not prevent Campbell from dreaming.\nAnd just recently, during a vision test, Campbell was able to correctly identify a sequence of letters for the first time in decades.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story plainly says that only 14 people in the U.S. are involved with a study of the artificial retina device, making it clear it\u2019s not in clinical use. ", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nBut, he says, \u201cThose are things that can be easily worked out and can be done in the coming future.\nThe devices are only experimental prototypes with many years of additional research and development likely before they might be ready for commercial use.\nPatients were practically still blind and incapacitated as far as everyday tasks were concerned.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0makes quite clear that the new devices are not yet available and likely won\u2019t be for several years. We especially liked that this was brought up near the beginning of the story, versus at the end.", "answer": 1}, {"article": "For more on the definitive guide to alternative methods of healing the mind, body and soul, pick up a copy today.\nIts efficacy varies from patient to patient and, like most prescriptions for depression, TMS has its own set of side-effects.\nIn fact, the only clue TMS treatment contains magnets at all is that patients must remove any jewelry and stow their credit cards (to prevent demagnetization) before treatment.\nSo, in a sense, [TMS is] not a treatment...for the ultimate cause of the disorder, but it\u2019s an intervention that improves how the patient is able to function.\u201d\n\nTMS has a lot in common with a traditional MRI scan.\nOne of the leading causes of disability in the United States isn\u2019t physical\u2014it\u2019s mental.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0\u201cits use is federally restricted with exemptions only for those with severe depression.\u201d\nThis is incorrect and a misinterpretation/misunderstanding of the FDA approved indication for depression. The FDA (the \u201cfederal\u201d\u00a0we assume here) approved TMS for the treatment of depression after a patient fails to respond to one antidepressant, whatever his or her\u2019s degree of depression severity (moderate, severe\u2026). A physician makes the judgement of whether TMS is indicated and can do so even before trying a drug if there is some reason a person cannot tolerate drugs. The FDA does not regulate the practice of medicine.", "answer": 0}, {"article": "Mitochondria are the organelles within the body\u2019s cells that generate energy.\nDr. Auwerx cites evidence that resveratrol does activate sirtuin, but Dr. Evans said the case was not yet fully convincing.\nWhether much lower doses would benefit athletic performance is not clear, Dr. Evans said.\nThe two studies were started and performed independently, Dr. Auwerx said, though he obtained supplies of resveratrol from Sirtris, which was co-founded by Dr. Sinclair, and he has become a scientific advisor to the company.\nThat is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not mention that reservatrol is not a substance approved by the FDA.\u00a0 It mentioned an available capsule product but then mentioned that this product's volume of resveratrol \"would have to be gulped in almost impossible quantities for a human to obtain doses equivalent to those used in mice.\"\u00a0 So the true availability issue was unresolved. \u00a0 ", "answer": 0}, {"article": "For instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\nBut while the research is promising, yoga likely won\u2019t be a panacea for mental illness.\nThe researchers say there\u2019s enough evidence to warrant a larger study on the effects of yoga on mental health, and it should be considered as part of treatment for more disorders.\nIf a large national study were done, it could turn out that yoga is just as good and may be a low cost alternative to people with unmet needs.\u201d In the meantime, he says it doesn\u2019t hurt to add yoga to existing treatments so patients can take advantage of any potential benefits.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yoga classes are widely available, but there is no standardized curriculum. So it\u2019s not clear if classes at the local community center will provide the same benefits observed in these studies.\u00a0The story should have addressed\u00a0this uncertainty.", "answer": 0}, {"article": "Significantly greater improvements in motor function were recorded after three months in patients taking Prozac, where the average test score improved by 34.0 points, than in the placebo group, where the average improvement was 24.3 points.\n\u201cDepression after stroke is a common enough complication to have raised the question of treating with antidepressants early after stroke,\u201d he said in an emailed comment.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\nCommenting on the study, Robert Robinson and Harold Adams from the University of Iowa in the United States, said it could change the way doctors treat stroke victims in future, but more research is needed to see if the effects continue over time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear\u00a0that the story is about a new use for a medicine that has been available for many years to treat depression and anxiety.", "answer": 1}, {"article": "Repeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\n\"These results are a promising early piece of the puzzle, but the risks of ketamine use are still not wholly understood.\n\"Elderly patients with severe depression face additional barriers when seeking treatment for the condition.\nProfessor Loo will build on these promising results as part of her current work directing the world's largest trial of ketamine to treat depression, which is now recruiting participants.\nMany medications may cause more side effects or have lower efficacy as the brain ages,\" said co-author Dr Duncan George from UNSW Sydney.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address the availability of ketamine for depression head-on. We\u2019re not sure what regulatory issues may apply in Australia, where the release was issued from, but since the information is being distributed to a worldwide audience via a news wire, some comment on this issue would have been appropriate and helpful. The implication is that ketamine is not yet in general clinical use for treatment geriatric depression. But in the U.S., at least, clinics are starting to pop up around the country that offer this therapy. Are these treatment centers reputable? Readers aren\u2019t given any guidance.", "answer": 0}, {"article": "\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nBut after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\nAndrea Fagiolini, a professor who led the study and presented it at the European College of Neuropsychopharmacology conference in Vienna on Monday, said the treatment may prove useful during the Northern hemisphere\u2019s darker winter months.\nIn contrast, the control group only showed an average score of around 2.7 after treatment.\u201d\nFagiolini\u2019s team recruited 38 men diagnosed with either hypoactive sexual desire disorder or sexual arousal disorder \u2013 both characterized by a lack of interest in sex.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Many people are aware that light boxes are available and relatively commonplace, so we\u2019ll rate this N/A. However, the story would have been stronger had it discussed what kind of light box the researchers used, and if it\u2019s available, etc.", "answer": 2}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\n\"The stratification of patients by beta-blocker use and selectivity in this study makes it unique among all other studies examining the impact of these drugs on cancer.\nAccording to Sood, the preliminary data from these feasibility trials will be used to design prospective, randomized clinical trials examining NSBBs on patient outcomes.\nThis study builds on a large body of research by principal investigator Anil Sood, M.D., professor in Gynecologic Medical Oncology and Cancer Biology at MD Anderson.\nFuture trials will seek to identify patients who would benefit most from beta-blocker use and the best beta-blocker for a specific tumor type based on adrenergic receptor expression.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This is a close one. Yes, the release notes that beta blockers are already in widespread use. Yes, the release mentions the two ongoing clinical trials and how they\u2019ll be used to design additional clinical trials. But the information on clinical trials is in the penultimate paragraph and the ramifications aren\u2019t necessarily clear to lay readers \u2014 it will be years before researchers can determine whether beta blockers should be incorporated into clinical treatment of EOC patients.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nSome study limitations should be considered.\nThere are numerous possible active properties in walnuts that may be contributing factors in providing health benefits.\nThey are the only nut to contain a significant amount of ALA with 2.5 grams per one ounce serving.\nFor more industry information, health research and recipe ideas, visit http://www.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Walnuts are known to be widely available.", "answer": 2}, {"article": "\u201cThe question has been, \u2018What do you do with the rest?\u2019\u201d he says.\nThe researchers note that the study dose was \u201cgenerally well-tolerated.\u201d No new nerve symptoms were reported.\nHe says about 75% of patients with affected skin will go into remission with these standard treatments.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nSimilar to treatment with thalidomide, most of the patients had a relapse of their skin problems within weeks of stopping the drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \u201d Lenalidomide is available as Revlimid to treat people with multiple myeloma and myelodysplastic syndromes.\u201d\u00a0 But for the lupus skin conditions in question, it is unclear if some doctors were currently using it off-label.\u00a0 We think the story should have discussed this.\u00a0 Any of the doctors interviewed could have answered this.", "answer": 0}, {"article": "The first figure is systolic pressure, generated when the heart is pumping, and the second figure is diastolic pressure, created when the heart is relaxing and filling with blood.\nAs for the next step in confirming the relationship between beetroot juice and blood pressure, she says this was a small trial.\nThe trial was double-blind, which means neither the administering clinicians nor the patients knew whether the beetroot juice they were given was the placebo or the active supplement.\nMedical researchers have recently returned to this plant product to investigate its effect on blood pressure and explore opportunities to put it to use in modern medicine and the home management of conditions.\nHere is a link to a wide range of natural beetroot products.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have mentioned options for purchasing or preparing beet juice. While it didn\u2019t emphasize this or discuss the availability of beets or other nitrate-containing vegetables, we think most readers will understand that these foods and juices are available.", "answer": 2}, {"article": "In Canada, heart failure patients stay an average of almost 10 days for each hospital admission, accounting for 1.4 million hospital stays a year.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\n\u201cTraditionally we\u2019ve relied on a patient describing symptoms, and by then they may have already progressed to the point of hospitalization.\nThe system features a small butterfly-like sensor that then sits inside the pulmonary artery of a heart failure patient.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that this device is not widely available in Canada, since it\u2019s a \u201cnovel\u201d sensor and not yet approved by Health Canada.\nIn the last sentence, it states that CardioMEMS was approved by the US FDA, implying that the implantation procedure is more widespread there.\nWe rate this one Satisfactory.", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that Vascepa is available by prescription to treat high triglyceride levels.", "answer": 1}, {"article": "During the DaTscan test, an imaging drug is injected into a patient's bloodstream and the patient undergoes a single-photon emission computed tomography, or SPECT, scan.\nSince June, 25 men and women of all ages have been tested with DaTscan at Central DuPage, Rezak said.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\nApproval of DaTscan followed two Phase 3 clinical trials in which 284 adult patients with tremors were studied.\n\"DaTscan is used in difficult-to-diagnose cases and must be used in conjunction with a clinical evaluation and a patient's response to medications,\" Rezak said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe availability of the DaTscan test is the main point of the story. It reports the test was approved by the FDA in January 2011 and is now available at more than 80 hospitals in the United States. It also reports that the test was approved for use in Europe a decade ago. ", "answer": 1}, {"article": "(Reuters Health) - Exposing sleeping people to a series of short flashing lights at night might help them adjust more quickly to time zone changes, according to a new U.S. study.\n\u201cFor moving your system to an earlier time, such as would be necessary when traveling West-to-East, light during the last few hours of the night is ideal.\u201d\n\nThe night flashes require special technology and equipment, beyond just a smartphone, which are still in development, Zeitzer said.\n\u201cHowever, the treatments that are developed for jet lag can be used for less prevalent, though far more significant societal problems including delayed sleep in teens (in whom we have an ongoing clinical trial using the flash technique) and shift workers who try to flip between a night time schedule for work and a day time schedule for leisure,\u201d he told Reuters Health by email.\nAs for frequent flyers trying this themselves, it is \u201cfar too early \u2013 neither the methodology is available outside research, nor any guidance about safety, nor tests of simulated jet lag in an appropriate \u2018realistic\u2019 protocol,\u201d Wirz-Justice told Reuters Health by email.\nIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article made it fairly clear that this technology wasn\u2019t ready for consumers by mentioning that further research needed to happen and that frequent flyers shouldn\u2019t try this on their own.", "answer": 1}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nThe Australian team believe theirs would be the first to detect melanoma.\nThe test could speed up the diagnosis process, saving thousands of lives.\nHowever, she stressed the fact this new test has not undergone clinical trials.\nIf further trials are successful, Ziman estimates the test could be distributed internationally in up to five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that the tests are in the experimental stages and not available commercially.", "answer": 1}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nIn addition, these positive effects were shown quickly, at two weeks, and the supplements were well tolerated and similarly effective regardless of age, sex, or use of antidepressants, among other factors.\nNew clinical research published today in PLoS One shows that over-the-counter magnesium appears safe and effective to treat mild to moderate depression.\nHowever, few clinical trials have studied the supplement's effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release mentioned that magnesium can be found over-the-counter.", "answer": 1}, {"article": "U.S.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\nExcept as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.\nThe healed tear could not be penetrated by the probe.\nTo management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release never emphasizes the early stage nature of this work.\u00a0 Knowledgeable readers might know that news of a single case study\u00a0may be\u00a0just the beginning of a long-term research effort, but nothing in the release expresses that to readers who may be less knowledgeable.", "answer": 0}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nIf it also improves cognitive performance -- like we've seen here -- even better.\nBut they've never all been connected before.\n\"If the fish improves sleep, great.\n\"This area of research is not well-developed.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear that fish is a common food source, available everywhere.\n\u00a0", "answer": 2}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nPTSD is caused by an overactive fear memory, and the new research shows that doxycycline can reduce the fear memory response in healthy volunteers.\nThe study, published in Molecular Psychiatry, was a pre-registered, placebo-controlled, double-blind randomised controlled trial in 76 healthy volunteers.\nA week later, under no medication, participants returned to repeat the experiment.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that \u201cmore realistic models\u201d of clinical PTSD are needed and any testing of doxycycline in those models is years away.", "answer": 1}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nDr. Faber noted that Ms. Slimak's clean room work -- like much of the research on toxicity in autism -- \"hasn't been written for the main [scientific] literature\" but instead has been written mostly for the Internet.\nWith so many doubts -- and so few answers -- about effective autism treatments among the growing community of families affected by the condition, the institute said openness is vital to the experimental method's success.\nNo cause for autism has been found, and debates rage as to whether the brain development disorder is purely genetic or caused in part by environmental factors, including air and food-borne chemicals.\nEducational, physical, speech and behavioral therapies have long been the traditional treatments for autism, but a growing number of families and researchers have called for further biomedical treatments as well, suspecting there is a chemical side to the disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The pollutant-free \"clean room\" experiment, designed to attempt to detoxify the bodies of young patients with autism, is in the conceptual\u00a0and fund-raising stages, which have\u00a0yet to be completed.\u00a0 This article does not indicate that the\u00a0experimental protocol will not likely be implemented in the near future and that it will not be available to autistic children who are not enrolled in the research study. ", "answer": 0}, {"article": "Sharon Samuels was a teenager when she was first diagnosed with essential tremor.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nFor now, the treatment has had an immense impact on patients\u2019 lives.\nThat needs to be shown.\u201d\n\nThe researchers are in the process of collecting this data; the clinical trial will run until December.\nThe doctors at Brigham will follow up with Samuels \u2014 and others who undergo the treatment \u2014 for up to five years and run more MRI scans and neurological exams to find out for how long the lesion lasts and keeps the tremor suppressed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the device was approved by the FDA in July. The story could have done readers a service by giving a sense of how many medical centers around the country are geared up to perform the procedure, or will be soon.", "answer": 1}, {"article": "For example, Kramer says, what if a man got a PSA test when his prostate cancer was in the very earliest stages of metastatic disease?\nThe new study seems to make a powerful argument in favor of PSA testing.\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\nBut he would not yet have symptoms or detectable metastatic disease, so he'd be diagnosed with earlier-stage disease.\nBut it's not that simple, says Barnett Kramer, MD, MPH, associate director for disease prevention at the National Institutes of Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that PSA screening is \u201cwidespread.\u201d", "answer": 1}, {"article": "Post-operative cognitive dysfunction (POCD), a condition mostly observed in older patients following surgery under general anesthesia, is characterized by impaired memory and concentration.\n\"Our findings confirm recent evidence that the deeper the anesthesia-induced hypnosis, the higher the incidence of POCD.\n\"Little is said about rehabilitation or ways of helping patients recover pre-operative cognitive function.\"\n\"The causes of and risk factors for POCD are still being discussed,\" she said.\n\"With regard to the use of dexamethasone, more research is needed to confirm our finding, preferably in multicenter trials, but there are strong indications that it can be beneficial in many cases.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that the relevant tools involved in this particular intervention \u2014 the use of dexamethasone and avoidance of \u201cdeep\u201d anesthesia \u2014 are currently available. However, as noted above, this is a relatively small study, and we suspect that more research would be needed before this approach was considered for widespread clinical practice. Since we already dinged it for that point earlier, we\u2019ll give it a satisfactory here.", "answer": 1}, {"article": "Rheumatoid arthritis, which is felt throughout the whole body, is caused when a person's immune system attacks his or her own tissues.\nThe findings are published in the Nov. 28 online edition of Arthritis & Rheumatism.\n\"While complication rates are low, there are some cases with serious consequences that include infection, joint dislocation, blood clots and even death.\"\nThe studies included arthritis patients aged 18 or older who had hip or knee replacements.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. No details were given about the availability or widespread use of joint replacements.\u00a0 Even though no specific numbers are reported, readers should understand that joint replacement is a widely available treatment.", "answer": 2}, {"article": "Malignant mesothelioma is an aggressive and almost uniformly fatal tumor caused primarily by exposure to asbestos.\nA 510(k) application is being prepared for submission to the FDA to register the ONCOblot test as a medical device.\nThe ONCOblot Test is CLIA registered and meets all current FDA regulations as an LDT.\nThe ONCOblot\u00ae test is based on more than 20 years of basic research.\nMorNuCo Laboratories is elated to share these results with the public, as early detection is widely considered the corner stone of an effective strategy to reduce cancer-related deaths.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release notes that the ONCOblot test is FDA approved as a \u201cLaboratory Developed Test.\u201d It also includes a link to a company web site with more information on the test and how to get it.", "answer": 1}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nThe test was approved for use in Europe in 2006 but is not yet approved in the United States.\nThe Progensa test looks for a genetic material called PCA3.\n\u201cIf the PCA3 is abnormal, above about 35, you have got an 80 percent chance of having cancer,\u201d Crawford said.\n\u201cIf you had no cancer your PCA3 was at 25 or 20.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story stated that this test is approved for use in Europe but not the US.", "answer": 1}, {"article": "Paul J.D.\nThe team is in the planning stages of developing a start-up company to commercialize the technique.\nThe techniques developed by the interdisciplinary team can be used by dermatologists and will reduce safety concerns in laser dermatology by improving laser transmission through surface layers of the skin.\nWhiteside presented his technique to clinicians on April 9, 2017, at the annual conference of American Society for Laser Medicine and Surgery (ASLMS).\nThe sonoillumination research was funded in part by a 2015 Fast Track grant from the University of Missouri System.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the release is clear that the device is not yet available, there is no support for the claim that the device, which has yet to be tested on tattoos or other skin markings, \u201cwill be available widely in the near future,\u201d especially since clinical trials have yet to be performed.", "answer": 0}, {"article": "Badie and his team extracted immune cells from him, then engineered them to express proteins on their surface that would recognize and destroy glioblastoma tumor cells.\nThe patient is one of nine in the trial, and so far, many of the other people are having similar experiences on the therapy.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nBut after being treated with the immune therapy, his cancer did not grow or recur for nearly eight months.\nThis is the first time that immune cells have been injected into these brain regions, because introducing anything into the ventricles can cause dangerous and possibly deadly inflammation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the therapy is experimental, that complexities are numerous, that much is still unknown, and the trial is ongoing.", "answer": 1}, {"article": "Trials of that vaccine in people, which is also based on man-made copies of virus proteins, began on August 2, when the first study volunteer was given a vaccination through a needle free injector, said Dr. Anthony Fauci, head of the National Institute for Allergy and Infectious Diseases.\nRight now, just one of those three vaccines will be progressing to clinical trials.\nRelated: Could We Nave New Zika Vaccine Soon?\n\"So we\u2019re cautiously optimistic.\u201d\n\nAnd if problems turn up, there are the three potential vaccine described in the new study.\nThe protein/cold virus vaccine was especially effective, sparking a significant immune response after just one dose.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story offers information about possible timetables for clinical testing and availability. It could have been more emphatic that there are a lot of unknowns here, though.", "answer": 1}, {"article": "A role for dietary macroalgae in the ameliorating ration of certainement Risk Factors Associated with cardiovascular disease.\n\"We know that many people have difficulty distinguishing between healthy and unhealthy food.\nBy adding seaweed to processed foods we can make food healthier.\nIt can even enhance the flavor of the food, they argue.\n\"It is difficult to determine how much seaweed a person should consume to benefit from its good qualities.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are going to assume here that most people think seaweed is widely available as a food product.", "answer": 1}, {"article": "Regions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThis study was made available online in May 2018 ahead of peer-review and publication.\nThe authors report no other relevant potential conflict of interest.\nThis study was funded by an F. Hoffmann-La Roche Ltd. contract to The Johns Hopkins University.\nThese three most promising tracers were previously tested in nonhuman primates, and the results looked promising enough to test in people.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not make clear that this work is still far removed from widespread clinical application.", "answer": 0}, {"article": "Let's address what's going on.\"\nBut, as CBS News contributor Dr. Sanjay Gupta reports, he's willing to talk about how prescription painkillers took over his life: Ten OxyContin pills a day, costing up to $12,000 a month.\nIf left unsatisfied, the receptor sends pain signals to the brain - this is withdrawal.\nIf the receptor is satisfied with drugs, the withdrawal symptoms stop and the person gets high.\nHere's how it works: When people are addicted, new receptors are created in the brain, which crave opioids.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment states that Suboxone (sublingual buprenorphine) is available from \"any doctor, even a family physician.\" \nIt\u2019s a bit more complicated than that. In order to prescribe Suboxone, a physican without specialized training in addiction needs to be certified by submitting an application to the federal government, completing an 8-hour training course and meeting other criteria.\u00a0 \nThe segment is unclear about availability in a second case. The segment itself implies (correctly) that the drug is currently available. But then the host says the drug is currently in clinical trials. The physician-reporter\u2019s response does not clarify that these trials are for approval of an additional, specific use of the currently available drug. \u00a0", "answer": 0}, {"article": "Our scientists are dedicated to learning more about who might derive a greater benefit from Avastin,\" she explained.\nPhysicians who favor Avastin's use say the FDA is being overly cautious, and that the drug can be used safely if patients are closely monitored.\nReflecting splits in the medical community, the European Medicines Agency said Thursday that Avastin would remain an approved therapy for breast cancer in European Union countries, although only in one particular combination: with the drug paclitaxel.\nHowever, patients currently taking Avastin as part of their chemotherapy regimen will not immediately be affected, and \"doctors should use their medical judgment on whether to continue\" its use, said Dr. Janet Woodcock of the FDA's Center for Drug Evaluation and Research.\nAfter the advisory committee's decision in July, Sen. David Vitter, R-Louisiana, wrote a letter to the FDA complaining that \"the (FDA advisory) committee's concerns appear to have been based on cost-effectiveness,\" and adding that a reversal on accelerated approval would amount to \"cost-rationing.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear about Avastin\u2019s availability and the impact of the FDA decision.\nFYI: it states that the EU has decided to keep Avastin approved for breast cancer\u00a0only\u00a0in combination with paclitaxel. Just to be clear, in the US, it\u2019s only\u00a0approved\u00a0in combination with paclitaxel , too.", "answer": 1}, {"article": "We keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nWhen 57-year-old Dean Cowles suddenly suffered a heart attack, he was lucky that he worked at a company that made defibrillators,reports.\nBut what helped save his brain \u2014 and left him remarkably undamaged \u2014 was a simple procedure in the ER: chilling his body.\nIt's called induced hypothermia.\nResearch has shown it can improve the survival rate by 14 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that this treatment is not available at most hospitals.", "answer": 1}, {"article": "Got raw milk?\nSusan Mueller, a mother of two in Ithaca, N.Y., bought shares in a dairy farm so she could pick up her raw milk and yogurt at a drop-off point closer to home.\nAnd they consider themselves lucky.\nNow that's trickier.\nCarol Peterson, an IT manager at Xerox, drives almost two hours each month to her favorite farm in upstate New York for her unpasteurized supply.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story did not list the states by name, it did mention that six states allow the sale of raw milk in stores and that 28 states allow the sale of raw milk on the farms where it is produced.", "answer": 1}, {"article": ".\nImportantly, the researchers show that the prebiotic induced specific gut bacterial shifts compared to placebo.\nThe metabolic and microbial findings from this study provide a foundation for a larger clinical trial in the pediatric population.\nFor this study, researchers from the University of Calgary, Alberta, Canada, performed a double-blind, placebo-controlled trial with 42 participants.\nThis work was supported by grants from the BMO Financial Group Endowed Research Fund in Healthy Living, Alberta Children's Hospital Foundation, Alberta Children's Hospital Research Institute and the Canadian Institutes of Health Research (MOP115076-1).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability. The supplement used in the trial is from Germany and was not easy to find online, but as noted, similar products appear to be easily available.", "answer": 0}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The column explained that the lenses are marketed on a company website, which also gives a list of providers.", "answer": 1}, {"article": "In the six studies that looked at decaf coffee, the researchers found, people who consumed more than three or four cups a day were at 36 percent lower risk of diabetes.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nClinical trials are needed to investigate whether these beverages do indeed help prevent diabetes, the researchers say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availabilty of coffee and tea is not in question. ", "answer": 2}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that IVM (in vitro maturation) treatments are not widely available and this method is not as successful or widely accepted in the medical community as IVF (in vitro fertization) treatments.\u00a0 The story notes that Dr. Batzofin is one of the first doctors in Manhattan to offer the treatments and is conducting a clincal trial on IVM.\u00a0 ", "answer": 1}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\nBut drinking tequila won't help, the study authors noted.\nThe study was to be presented Tuesday at the national meeting of the American Chemical Society in San Francisco.\nThe National Osteoporosis Foundation has more about osteoporosis prevention.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of these plants is not in question. ", "answer": 2}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the story mentions some specific brands. It also provides some details about the differences between varieties of red palm oil.", "answer": 1}, {"article": "Read more at The Wall Street Journal.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nThe experimental drug, however, kicks into action earlier, working to block the virus from hijacking cells in the first place, the Journal said.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nExisting drugs, including Tamiflu, work to block these viral copies from escaping the cell, the Journal reported.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article, again as noted above, seems to assume that the FDA will automatically approve this anti-viral drug and do so quickly. Neither assumption is necessarily the case.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The results presented are acknowledged to be preliminary, with the next step being a second, larger trial. \nThis suggests that use of HSCT for treatment of lupus is not likely to be widely available for some time.", "answer": 1}, {"article": "Women taking oxybutynin also reported improvement in work, social activities, leisure activities, sleep and overall quality of life.\nDrugs in this class -- called anticholinergics -- have been linked with mental decline, he said.\nHowever, he cautioned that its long-term effects aren't known.\nBut a new study suggests an existing medication may help.\nThe drug is oxybutynin (Ditropan XL), long used to treat urinary incontinence.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that the drug, which is approved to treat incontinence, is readily available.", "answer": 1}, {"article": "Concussion is a major public health concern, often resulting in significant acute symptoms and in some individuals, long-term neurological dysfunction.\n\"There is no one metabolite that we can put a finger on but when we looked at all of them, those profiles are different enough that we could easily distinguish concussed patients from non-concussed.\nIn this latest successful attempt, the researchers took a different approach and investigated a full spectrum of 174 metabolites.\nThis new method, fully funded by the Children's Health Foundation and conducted by the Western Concussion Study Group, is unique in that previous attempts have looked unsuccessfully for a single highly accurate protein biomarker that can distinguish concussed from non-concussed adolescent patients.\nIn fact, with fine tuning we can now look at sets of as few as 20-40 specific metabolites and maintain the diagnostic accuracy level of the test over 90 per cent.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We aren\u2019t told if it is available or not or even when it might become available. The release could have been much more transparent about its availability. When we assessed the release it appears that there isn\u2019t a test per se, but a series of chemicals that could be combined into a future commercial test.", "answer": 0}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nNone of the drugs or extracts are approved by the Food and Drug Administration to treat hot flashes \u2014 only hormones are approved for that purpose \u2014 but doctors are free to prescribe medicines for any use they see fit, and many recommend the drugs or plant products for hot flashes, based on study findings and their patients' experiences.\nNow, other drugs have come into use for hot flashes, but not much is known about their effectiveness or long-term safety.\nIn the meantime, both Dr. Tice and Dr. Nelson said that for women who find their symptoms intolerable and want treatment, they would favor antidepressants over hormones.\nNeurontin causes sleepiness, and soy extracts can produce gastrointestinal troubles.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Medications listed in the story are available with a prescription, but they are not yet FDA approved for the treatment of hot flashes. Supplements such as soy and red clover are available without a prescription, however, these are not regulated and the active ingredient (i.e. plant estrogens) in these supplements may vary by manufacturer.", "answer": 1}, {"article": "MU physicians treat patients from every county in the state, and more Missouri physicians received their medical degrees from MU than from any other university.\n\"Most patients with this disease are older and tend to have other health conditions such as high cholesterol.\nOf those who do get to a health facility alive, only about 50 percent survive.\n\"This information could be beneficial to patients who are about to have elective endovascular abdominal aortic aneurysm repair,\" Vogel said.\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s assumed that the public is aware that statins are widely available as a prescription drug.", "answer": 1}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nPilot study published in the Journal of the American Osteopathic Association finds targeted pressure device significantly increased sleep for those with moderate to severe symptoms\n\nAuthors from Lake Erie Research Institute in Pennsylvania report an adjustable foot wrap caused to treat restless legs syndrome (RLS) is 1.4 times more effective than the standard pharmaceutical treatment.\nDisclosures: Dr Kuhn worked without compensation through Lake Erie Research Institute (LERI) during the 5 years of the study of the device and is now receiving compensation for that work.\nResearchers indicate that the pressure produced by the device may also stimulate a dopamine release, similar to massage therapy or acupressure.\nPatients using the RLS device also reported an 82 percent decrease in sleep loss.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Oddly, the release does not say that this foot wrap was cleared for sale by the FDA in 2013 and is already on the market (brand name restiffic).", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\nWEDNESDAY, July 29, 2015 (HealthDay News) -- The U.S. Food and Drug Administration's approval of a temporary, implanted balloon device for weight loss may have many wondering how -- and how well -- it works.\nDoctors can then go back in and retrieve the entire device.\nThe people who initially will use the ReShape are people who can afford to pay for it out-of-pocket and need to drop some pounds quickly, Roslin said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear the device has just won FDA approval, and has been available in Europe.\u00a0But the story doesn\u2019t comment on what might be the obstacles to use in the US. \u00a0What training is required? \u00a0How many physicians have been trained? \u00a0How might availability be held back if (as the story appropriately suggests) patients have to pay cash for it? Are there any lessons from Europe that would educate American consumers?\n\u00a0", "answer": 0}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear in the story that the drugs in question are available for prescription. However, the U.S.\u2019s complex behavioral health system and prescription drug payment policies makes obtaining them difficult for many, and the story would have served readers better if it discussed this barrier to access.", "answer": 1}, {"article": "CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\n\"Importantly, the fact that CAM2038 will be given in the clinic by health providers should address concerns about diversion of buprenorphine for illicit use.\nFour more trials, including two Phase 3 studies, are currently ongoing.\nNew drug products with best-in-class potential are conceived based on the proprietary FluidCrystal\u00ae drug delivery technologies and an extensive R&D expertise.\nAdditional information on the design of the trial can be found at www.clinicaltrials.gov .\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t provide a time frame for when the drug, which is still under development, will be available but suggests it will be \u201ca future treatment alternative.\u201d We don\u2019t fault them for not providing a date following a phase 2 trial. There are many steps to be completed before or if it is approved and marketed.", "answer": 1}, {"article": "In particular, it measures rhythmic patterns known as theta and beta waves.\nShe says it might have been because she and her son spent so much time going to all those sessions together, and had pizza together afterward.\n\"Because I was always wary about using meds as a single approach or for very long, it seemed to be an interesting alternative.\nIn the meantime, he says, the study has shown that it is possible to do neurofeedback research that involves a placebo.\nBut it will take better research to figure out whether neurofeedback can live up to that promise, Rabiner says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this type of treatment is available to the general public.\u00a0We like that the story cautioned readers to look out for\u00a0unqualified therapists and\u00a0gave tips\u00a0for finding reputable clinicians. The story could have been more specific about how many trained professionals there are and how easy\u00a0it is\u00a0to find them outside of large population centers.", "answer": 1}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\nIn addition, the mammoth, U.S.-government funded Women's Health Initiative (WHI) earlier found no negative link between calcium and heart health.\n\"Our own recommendation is to critically review the use of calcium supplements, since the data in this paper suggests that they do more harm than good,\" added Reid, who is professor of medicine and endocrinology at the University of Auckland in New Zealand.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated:\u00a0\u201cMany older women take calcium supplements with or without vitamin D to keep their bones strong, especially since that has long been standard medical advice.\u201d So availability and widespread use is clear.\n", "answer": 1}, {"article": "Radiotracers work by injecting a small amount of a compound tagged with a radionuclide into patients.\nSince these changes could not be detected based on a PSA blood test alone, this new test would be very helpful in determining early on which therapy to choose in a given patient.\"\nTwo prostate cancer experts said the tool, if borne out in patients, could prove very useful.\nHe noted that, as of now, doctors typically rely on results of the PSA blood test and/or standard diagnostic scans to help guide treatment decisions.\nEncouraged by their findings, the study's authors said they hope to begin a human trial next year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the researchers \u201chope to begin a human trial next year.\u201d", "answer": 1}, {"article": "Red and purple fruits owe their colors to...\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nThe juice is a beautiful wine-red color and tastes delicious.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that pomegranates are now \u2018everywhere\u2019. There has been an increased number of pomegranate-containing products available in grocery stores and other venues. However, the article mentions that there have been few good clinical studies with pomegranates and that the results from those few studies should be followed up with larger, better studies. ", "answer": 1}, {"article": "The head is attached to a spike that is driven into the femur, or thigh bone, to anchor it.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\nNow, tens of thousands of ceramic hips later \u2014 from Stryker and other makers that entered the field \u2014 many patients say their squeaking hips are interfering with daily life.\nAlready, dozens of patients have elected to endure subsequent surgeries to replace the noisy hips.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly state that ceramic hip replacements are approved by the FDA, but with \u201ctens of thousands\u201d implanted, it\u2019s clear that surgeons\u2019 adoption of the devices is widespread. The FDA\u2019s warning to implant maker Stryker about squeaking suggests the devices may not be perfect, but are approved.", "answer": 1}, {"article": "People with insomnia may have one or more sleep problems, including difficulty falling asleep, trouble staying asleep and difficulty getting back to sleep after waking in the night.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nHe said the 80 mg dose was likely more than most people need.\nThe drug also demonstrated superiority to placebo in the time it took to fall asleep and time spent awake after initially falling asleep, Merck said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The first sentence presents the information as coming from \"a mid-stage study,\" a vague term. Later, though, it says that Merck is going to apply for approval for the drug in 2012. This is satisfactory in the strictest sense of the word.\u00a0To really understand the origin of these results, you need to go read the press release, which calls the study a \"Phase IIb\" study and alludes to ongoing Phase III studies. The story seems to conflate these two things.", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make clear that Bavencio and Inlyta are already on the market, much less that Bavencio\u2019s current use is for treatment of a skin cancer called Merkel cell carcinoma.", "answer": 0}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that a hormone therapy, anastrozole (trade name Arimidex), was FDA-approved in 2005 for the treatment of early-stage breast cancer (after surgery). What is important, but is not\u00a0emphazied\u00a0is that this drug is only for post-menopausal women. ", "answer": 1}, {"article": "Dr. Stehling is a German Professor of Radiology, a former Associate Professor at Boston University and served as Research Assistant to Sir Peter Mansfield, Prof of Physics and Nobel Prize winner in Medicine in 2003 (for discoveries concerning magnetic resonance imaging).\nCHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\nThe study which was conducted at the Prostata Center of Offenbach, Germany (www.prostate-center.org) will be presented today at the annual meeting of the Radiological Society of North America (RSNA).\n\"The data from this study confirms what we see every day, we have a very attractive approach for patients who are concerned about quality of life challenges and are considering options for the treatment of localized and late stage prostate cancer,\" he said.\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "When a release is all about a \u201cnew\u201d therapy, it is important to establish whether this technology and expertise is available only in academic centers or more widely in the community or hardly at all and only in clinical research. This release does not tell us anything about when and where this might be made available.\u00a0If the investigator is just now reporting up to 4 years of data on only 265 subjects then this is not widely available.", "answer": 0}, {"article": "Among the 85,176 children in the study, 270 (or 0.32%) received an ASD diagnosis \u2013 114 (0.13%) had autistic disorder, 56 (0.07%) had Asperger syndrome and 100 (0.12%) were diagnosed with \u201cpervasive developmental disorder-not otherwise specified,\u201d or PPD-NOS.\nBut not all mothers were equally likely to take folic acid supplements.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nMothers who took folic acid supplements around the time they became pregnant were less likely to have children with an autism spectrum disorder, a new study has found.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that folic acid supplements are widely available and have long been recommended for women considering pregnancy.", "answer": 1}, {"article": "Autistic children are prone to seizures.\nShe said Geier plans to continue the Lupron for several months to see if it helps Marco's other autistic behavior.\nGeier's promotional materials said he has treated hundreds of children with Lupron and has launched nine ASD Centers in eight states.\nClayman said he would not comment until he treats patients with Lupron therapy for a year.\nHe told one parent he did not plan to comment for this story.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Lupron is already used to treat endometrial cancer and prostate cancer.\u00a0 The story might have addressed more directly its current off-label use.\u00a0\u00a0 \nIt\u2019s also clear that this is about a Maryland medical group taking its idea on the road to South Florida.\u00a0 Ideally, the story might have addressed whether it\u2019s being tried elsewhere. ", "answer": 1}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\nFurther research is needed to compare techniques for measuring anogenital distance and assess their accuracy, he and his colleagues said.\nOne expert who's done her own research in this area applauded the study.\n\"This paper also provides new data on infertile men, who have shorter (less masculine) anogenital distance.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of such a measurement approach is not in question.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does state that the availability of the new\u00a0ultrasound may be limited to academic or large city hospitals.", "answer": 1}, {"article": "AsthmaNet is a nationwide clinical research network created by the NHLBI in 2009.\nAsthmaNet studies are currently being conducted in 14 states.\n\"Results from this randomized controlled study showed that in young children with mild asthma, acetaminophen used as needed was not associated with increased asthma flares or more asthma symptoms.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\nNHLBI press releases and other materials are available online at http://www.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of acetaminophen and ibuprofen is not in question, since these are well-known, over-the-counter drugs. We rate this one Not Applicable.", "answer": 2}, {"article": "It describes circulating tumor cells as cancer cells that have detached from a tumor and are found at very low levels in the bloodstream.\nDr. Mehmet Toner, director of the BioMicroElectroMechanical Systems Resource Center in Massachusetts General's Center for Engineering in Medicine, says while it will take at least five years before the test is on the market, it's another step toward personalized medicine and the implications for patients are significant.\nVeridex launched the first commercial test using circulating tumor cell technology in 2004, the company said.\nIn fact, a tube of blood taken during an annual exam would only have a few CTCs.\nToner said you are likely to find just one circulating tumor cell in 5 to 10 billion blood cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes a researcher saying it \u201cit will take at least five years before the test is on the market\u201d but treats that as a fait accompli. But the story doesn\u2019t make clear the staggering amount of testing that remains ahead.", "answer": 1}, {"article": "But researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\n\u201cThis is the first on walnuts and diabetes.\nWomen who ate walnuts tended to weigh less, consume more fish and exercise more than those who did not.\nEating walnuts may reduce the risk for Type 2 diabetes in women, a large new study concludes.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of walnuts is not in question.", "answer": 2}, {"article": "So, indeed, there has been a strong interest in giving the best additional therapy possible,\" Choti added.\nAnd even for those, unfortunately 75 to 80 percent of those will go on to recur even after the surgery appears to be successful.\nTUESDAY, Sept. 7, 2010 (HealthDay News) -- Pancreatic cancer patients undergoing chemotherapy after surgery don't see improved long-term survival with the drug gemcitabine, compared with patients receiving a chemotherapy regimen consisting of fluorouracil and folinic acid, new research suggests.\nDr. Michael Choti, a professor of surgery and oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, described the study as \"important,\" but he does not believe it will alter the current approach to post-surgical chemotherapy.\n\"Really in the scope of things following major surgery, both are fairly tolerable regimens, and this study doesn't necessarily change the pattern of use in terms of choosing post-operative therapy,\" Choti said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not clearly establish whether gemcitabine or the other drugs mentioned are currently on the market. (They are.)", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mentioned that statins are widely used and considered safe. Mentioned that use as cancer \npreventative would be an off-label use (i.e. drugs not approved for this purpose)", "answer": 1}, {"article": "Fibrosis - where persistent inflammation causes scar tissue to form in the liver, but the liver is still able to function normally \n\n4.\nPublishing in the academic journal GUT, the Newcastle team describe the proof of principle research in which they measure specific epigenetic markers to stratify NAFLD patients into mild or severe liver scarring, known as fibrosis.\nIn this first stage of research the team developed the blood analysis in 26 patients with NAFLD.\nThe test detects chemical changes on tiny amounts of \"cell-free\" DNA that are released into the blood when liver cells are injured.\n\"We know that the presence of even mild fibrosis of the liver predicts a worse long-term outcome for patients with NAFLD and so it's important to be able to detect liver scarring at an early stage.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release includes a quote that says \u201cWe are now working on confirming these findings in a larger group of patients.\u201d Based on that, readers can infer that the technique is not yet available \u2014 so it gets a pass. However, it would have been better to state that more explicitly. As the paper itself says: \u201cWith validation, this blood-based biomarker could become an important contributory clinical tool alongside other epigenetic, genetic and biochemical biomarkers, mitigating the future need for biopsy to evaluate fibrosis.\u201d", "answer": 1}, {"article": "NEW YORK (Reuters Health) - Taking multivitamins may help women without cardiovascular disease to ward off a heart attack, new research shows.\nTo investigate the relationship between vitamin use and heart disease in women, Rautiainen and her team followed 31,671 women with no history of heart disease and 2,262 women who did have cardiovascular disease for about 10 years.\nThe women ranged in age from 49 to 83 at the study\u2019s outset, and about 60 percent in each group used some type of dietary supplement.\nAmong the women with heart disease, 13 percent of the non-supplement-users had heart attacks, compared to 14 percent of women who took multivitamins only, which wasn\u2019t a statistically significant difference (meaning it could have been due to chance).\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of multivitamins is assumed. However, the researchers did not collect deatiled data about which vitamins the women took or in what amounts, so it is unknown whether the results truly reflect on typical multivitamins or possibly other products.", "answer": 1}, {"article": "The U.S. National Institute of Neurological Disorders and Stroke has more about autism.\nHe was cautiously optimistic about the promise of the video feedback approach.\nTwo experts agreed that early intervention is key.\n\"Although it would be wonderful if a relatively simple, video-based intervention could reduce the recurrence risk of autism spectrum disorder in later offspring, further studies are needed to examine this very issue,\" he said.\n\"Children with autism typically receive treatment beginning at 3 to 4 years old,\" he explained.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although there is no mention of where and when the potential therapy might be available, the story did establish that more research would be needed before it should be used. Since the story didn\u2019t give the impression that anyone should use this approach right now, we\u2019ll rate this satisfactory.", "answer": 1}, {"article": "The disease strikes when the immune system attacks myelin, layers of fatty insulating membrane that surround nerve fibers.\n\"People thought we were absolutely crazy to launch this trial, because they thought that only in newly diagnosed cases could a drug like this be effective -- intuitively, if myelin damage is new, the chance of repair is strong.\n\"To the best of our knowledge this is the first time a therapy has been able to reverse deficits caused by MS.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nThis \"flip-flop\" technique gave the researchers the ability to compare patients to themselves -- a form of control that increased the statistical power of the study by nearly an order of magnitude, Green said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release reports that clemastine was first approved by the US FDA in 1977 for allergies and that its generic form has been available over the counter since 1993.\nWe rate this Satisfactory.", "answer": 1}, {"article": "Spinal fluid can also reveal the disease but that can be a difficult and painful test.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nBrain scans and spinal taps are helpful but they're not certain.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The report clearly states that \"plenty of lab work\" still remains before it\u2019s proven that a simple blood test can diagnose Alzheimer\u2019s.\u00a0 Even though this is tacked on as a disclaimer as the last sentence of an otherwise exuberant report, we\u2019ll give it the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "It's kind of trading in your MS for another autoimmune disease,\" Giovannoni said.\nBecause of serious side effects, the drug -- Lemtrada (alemtuzumab) -- is approved in the United States only for patients who have failed other treatments.\nThe new trial of more than 600 patients with relapsing-remitting MS was funded by Sanofi Genzyme and Bayer HealthCare Pharmaceuticals, the drug's makers.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\nGiovannoni believes the drug could offer real relief from MS symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0that the drug is approved in the U.S. for patients who have failed other treatments.", "answer": 1}, {"article": "Among the 620 adults (average age, 71 years; 74 percent women) who were randomized, 96 percent completed the study.\nThe researchers add that close contact casting may be an appropriate treatment for older adults with unstable ankle fracture.\nAlthough close contact casting may be unfamiliar to some orthopedic surgeons, it can avoid surgery for older patients with ankle fractures, yet result in equivalent functional outcomes.\nFurther studies are needed to help identify which patients will not benefit from casting.\nAmong older adults with an unstable ankle fracture, the use of a modified casting technique known as close contact casting (a molded below-knee cast with minimal padding) resulted in similar functional outcomes at 6 months compared with surgery, and with fewer wound complications and reduced intervention costs, according to a study appearing in the October 11 issue of JAMA.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes an accompanying editorial stating that \u201cclose contact casting may be unfamiliar to some orthopedic surgeons.\u201d Although that\u2019s a vague statement, we can assume it\u2019s not in widespread use.\nIn the U.S., most orthopedists are not trained in close contact casting nor do they feel comfortable using it. \u00a0Most patients will not be offered this treatment as an option for their fracture care.", "answer": 1}, {"article": "The data indicate that for every 10,000 women in their 50s, those using estrogen would experience 12 fewer heart attacks, 13 fewer deaths and 18 fewer adverse events like blood clots or stroke in a given year, compared with those taking a placebo.\n\u201cI hope that separation will become clearer now.\u201d\n\n \n\n\n\nThis article appeared in print on Wednesday, April 6, 2011 on page A1.\nThe research, part of the landmark Women\u2019s Health Initiative study, is likely to surprise women and their doctors, who for years have heard frightening news about the risks of hormone therapy.\nThe most surprising new finding relates to breast cancer.\nDr. Chlebowski previously led research that showed cancer risks associated with combination hormone therapy, but he says the new data on estrogen alone show that in certain women, estrogen use to relieve menopausal symptoms is a \u201cgood choice.\u201d\n\n\u201cWhen you look at the debate, people are saying hormones are good or not good \u2014 it\u2019s been all or nothing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Estrogen is widely available and story does not need to talk about that.", "answer": 2}, {"article": "America\u2019s ongoing battle with weight-loss that has led to fad diets and invasive surgeries like gastric bypass and stomach stapling.\nDr. Prem Chattoo, a New York based gastroenterologist, told FoxNews.com that the balloon is placed it into the stomach through the mouth.\nThe balloon would be removed in the same way it is at the six month mark.\nThe hope is that patients can train their body to eat in a much healthier fashion without feeling overly hungry.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t tell readers that Orbera is available, but it can be inferred from the patient\u2019s testimonial, so we\u2019ll give it a pass.", "answer": 1}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\nBut she cautioned that longer trials are needed to fully assess the drug.\nBut the editorial said effectiveness of dupilumab has been established in just a \u201climited subpopulation of patients with asthma\u201d because only 21 percent of those screened for enrollment in the study met its criteria.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\nSuch patients were deemed likely to benefit from treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Right in the lead, the story signals that this drug is not currently available, and, to the knowledgeable reader, shows where it is in the regulatory process, referring to a \u201cmid-stage trial.\u201d\u00a0 Later, it also says that \u201cfar larger trials will be needed to confirm findings from the \u201cproof of concept\u201d study.\u201d\nHowever, calling this \u201ca potential game changer for patients with moderate to severe disease\u201d may imply a more imminent definitive answer than actually exists.", "answer": 1}, {"article": "Dr. Heather Hayes, Director of Food Innovation with Devenish, said:\n\n\"Offering birds a natural and sustainable source of omega-3 PUFA is good for the bird and good for the consumer.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\nThey also deliver tailored nutritional products and solutions for their customers' specific requirements.\nTaste panel studies have shown that the omega-3 enriched chicken meat tastes as good, if not better than conventional chicken.\nThe results from the clinical study saw an increase in omega-3-PUFA levels in blood and a positive shift in what is described as the 'omega-3 Index'-a test that measures the amount of the omega-3 fatty acids, Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in red blood cell membranes, which reflects the levels in your heart and other tissues.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although it isn\u2019t made clear in the release whether the new chicken feed is on the market yet, one might assume that it will be shortly, based on the fact that the release seems aimed more at promoting a commercial product than it does describing actual clinical research.", "answer": 2}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nThis could be something as simple as a brisk walk or other low-impact options for vigorous exercise about 20 minutes a day.\nHe says middle-aged adults should exercise moderately during the first 12 weeks and then slowly build up to more vigorous activity.\nHowever, there are also some limitations to this study, the researchers say.\nThe information about physical activity was reported by the participants, and it\u2019s likely that many were too generous in their estimates of how much time they spent at the gym.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think that the ability to exercise is generally available, so this is N/A.", "answer": 2}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nIt is also the first clinical trial investigating the efficacy, tolerability and safety of intranasal-administered oxytocin in young children with autism.\nOver the last 10 years Brain and Mind Centre researchers have been documenting the benefits of oxytocin in humans, revealing that it enhances eye gaze, emotion recognition and memory across a range of populations.\nA five week treatment with the synthetic hormone oxytocin significantly improved social, emotional and behavioral issues among young children with autism, according to University of Sydney research published today in Molecular Psychiatry.\nThe study, led by researchers at the University's Brain and Mind Centre, is thought to be the first evidence of a medical treatment for social impairments in children with autism.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention that synthetic oxtocin (in this trial Syntocinon was used) has been widely available for many years. It was first synthesized by American Nobel prize-winning biochemist Vincent du Vigneaud in 1955. It is most frequently used as an injectable to induce labor in pregnant women.", "answer": 0}, {"article": "\"Approximately 40% of those who ought to have a colonoscopy avoid the procedure, and the top reason cited for their avoidance is the prep,\" said Dr. Rex.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\nThe company currently has two product candidates in clinical development: ECP, which is expected to enter Phase 3 clinical trials in early 2017, and the \"C-bar\", a novel product candidate for chronic constipation, which is currently being studied in a Phase 1b clinical trial.\n\"Colonoscopy is still recognized as the gold standard - the best way to catch this cancer at an early stage.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that the results reported come from a Phase 2 clinical trial and that Phase 3 trials may begin in early 2017. Put another way, the prep is not yet available.", "answer": 1}, {"article": "New Jersey and Ohio were the first to participate statewide in the program.\nParents can then take their digital or printed-out certificates to a participating hospital for their boxes.\n\u2018\u2018They do it because they want to be nurturing and they are, but it\u2019s not safe.\u2019\u2019\n\nTo get the boxes, prospective moms can register through babyboxuniversity.com, watch a handful of videos on sleep safety and pass a quiz.\nMcCans says the complimentary items like diapers and onesies are nice, but the more important objective behind the boxes is bringing down infant deaths and grounding parents on safe sleep practices: Place babies on their backs to sleep; Don\u2019t use bumpers in cribs; Keep stuffed animals and blankets out of infants\u2019 sleep spaces; Avoid sleeping in the same bed as infants.\nThe boxes can also be sent in the mail, if a nearby hospital is not designated as a distribution center.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The boxes are given away, but parents have to \u201cregister\u201d through babyboxuniversity.com.\nThey must \u201cwatch a handful of videos on sleep safety and pass a quiz. Parents can then take their digital or printed-out certificates to a participating hospital for their boxes. The boxes can also be sent in the mail, if a nearby hospital is not designated as a distribution center.\u201d\nWe are left unsure whether any parent can get a box from the company without registering or can a parent watch the educational material without registering and giving away his or her identity?", "answer": 0}, {"article": "The results have not previously been published or presented.\nRegulatory approval for C-Tb is currently being sought and Statens Serum Institute is actively seeking a commercial partner for marketing of C-Tb.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\nThe test is easy to administer but produces too many false positives to achieve the WHO's goal of reducing TB deaths by 95 percent and new cases by 90 percent by 2035, Dr. Ruhwald said.\nThere is also a dramatic price difference between the two diagnostic tests.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release informs readers that the test still faces a regulatory and commercial path, which strongly implies it is not yet available: \u201cRegulatory approval for C-Tb is currently being sought and Statens Serum Institute is actively seeking a commercial partner for marketing of C-Tb. The cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\u201d", "answer": 1}, {"article": "Along with obesity, high levels of blood fats can lead to heart disease and other health problems, including diabetes.\nThe next update of the recommendations is expected in spring 2011.\nNeal's data show that may not be the case.\n\"I think we need more effective screening tools.\nThat allowed Neal and his team to determine how many children who actually had high cholesterol would have been missed if they had been screened based on federal guidelines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe availability of cholesterol screening is not at issue.", "answer": 2}, {"article": "For clinical or PR inquiries, please call (405) 400-0680.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nOKLAHOMA CITY, Sept. 7, 2017 /PRNewswire/ -- Arthrokinex announces the release of IRAPjoint\u2122 therapy in the USA.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nFinally, a U.S. based company has a solution for America's professional and weekend athletes as well as those struggling with aching or arthritic joints.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The specific treatment in the news release is only offered at one clinic in the U.S., but the news release didn\u2019t mention if any other clinics or companies offer a similar therapy. The release also makes it sound like this treatment is available for anyone with bad joints, though theoretically there would be people who do not qualify for the treatment based on their symptoms or medical history. ", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nIt\u2019s inflammation, also.\n\u201cBut until now, there's been no way to detect inflammation in the coronary arteries.\u201d\n\nRelated: Half of People Who Have Heart Attacks Don\u2019t Even Know It\n\nDoctors run many different tests to assess someone\u2019s risk of heart disease.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that more research is needed before the technology might be available to everyone.", "answer": 1}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\nThey did so by substituting safflower oil for animal fats, common margarines and shortening oils, salad dressings, baked goods and other products, according to the study.\nDespite the fact the American Heart Association (AHA) currently recommends that 5 percent to 10 percent of all calories come from polyunsaturated fat (principally from omega-6), the NIH team found no evidence to support the notion that linoleic acid confers health benefits.\nThe original \"Sydney Diet Heart Study,\" was initially conducted between 1966 and 1973, at a time when the cholesterol-lowering benefits of all polyunsaturated vegetable acids (PUFAs) were touted with a broad brush.\nThe first group was told to consume linoleic acid, in the form of safflower oil and safflower oil polyunsaturated margarine, at levels equal to 15 percent of total calorie intake.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story mostly used terms like \u201comega-6 fat\u201d and \u201clinoleic acid.\u201d But\u00a0food fats and oils\u00a0\u2014 things like corn oil and soybean oil\u00a0that people actually look for in the grocery store \u2014\u00a0contain\u00a0differing\u00a0combinations of omega-6 linoleic acid,\u00a0omega-3 fats, and other fatty acids. Although the story notes that the study involved safflower oil, it would have been helpful to explain how much linoleic acid is found in other types of oils, and\u00a0whether these oils also include omega-3 fats.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that kratom is widely available in Philadelphia at gas stations and convenience stores, but that a number of states have banned kratom or\u00a0have legislation to ban it pending.", "answer": 1}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nTwo manufacturers, Amgen (in collaboration with Novartis) and Teva Pharmaceuticals, have completed clinical trials and expect to hear from the FDA by June whether the therapies have been approved.\nTwo more companies, Eli Lilly and Alder Biopharmaceuticals, plan to file for FDA approval later this year.\nAll of that could change in a few months when the Food and Drug Administration is expected to announce its decision about new therapies that have the potential to turn migraine treatment on its head.\nAnd so far, patients on the experimental treatments report limited side effects that consist mostly of pain at the injection site.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear these injections aren\u2019t available yet:\nTwo manufacturers, Amgen (in collaboration with Novartis) and Teva Pharmaceuticals, have completed clinical trials and expect to hear from the FDA by June whether the therapies have been approved. Two more companies, Eli Lilly and Alder Biopharmaceuticals, plan to file for FDA approval later this year.\nIt also cautions that their high cost means insurance companies might \u201crequire patients to have tried just about everything else first.\u201d", "answer": 1}, {"article": "\u201cFor now I think what this study does is to create another shade of gray in the understanding of gray matter,\u201d he said.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\nAbout 50 percent of people with such injuries recover some awareness in the first year after the injury, studies find; very few do so afterward.\nThe chances that an unresponsive, brain-damaged patient will eventually emerge depend on the type of injury suffered, and on the length of time he or she has been unresponsive.\nVery few do after that, and a 1994 review of more than 700 vegetative patients found that none had done so after two years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the functional MRI imaging is available and in use for clinical practice or if it is simply a research tool. Functional MRI is an established imaging technique but is not widely available at the present time like standard imaging studies including MRIs and CTs. Functional MRI is mainly used for research purposes, but its potential role in clinical care is likely to increase over time.", "answer": 0}, {"article": "In a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\nThe technique, known as diffusion tensor imaging (DTI) or diffusion MRI, is used to assess changes in the white matter regions of the brain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story provided no insight about whether hospitals have the facilities needed for this test.", "answer": 0}, {"article": "But overall, the median length of survival was 12.5 months for patients treated with poliovirus, compared with 11.3 months for a similar group of patients treated in the past, the researchers report.\nBut the researchers and other brain-cancer doctors caution the research is at a very early stage.\nSome other researchers praised the results.\nMuch more follow-up research is needed to better assess and hopefully improve the treatment's effectiveness, the researchers say.\nThere are substantial risks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear this is an experimental therapy and thus not yet widely available.", "answer": 1}, {"article": "One-third of the patients took aspirin alone; 54 percent took only an anticoagulant; and 13 percent took an aspirin/anticoagulant combination.\nAlthough warfarin costs a few dollars for a 30-day supply, its cost approaches that of the other anticoagulants when doctor visits for monitoring are factored in, Hallstrom says.\nThose reasons include shorter surgical times, less invasive procedures and use of regional anesthesia that allows early mobilization after surgery, Hallstrom says.\nSome patients are even going home the same day.\n\"Patients can get it over the counter for pennies, while the other anticoagulants require monitoring, injections, frequent dose adjustments and are extremely expensive.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that many knee replacements surgeries are performed every year.", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focuses on this fat injection with stem cells as a procedure for cosmetic augmentation or reconstruction following breast cancer surgery.\u00a0 The story notes that while some plastic and cosmetic surgeons are experimenting with this procedure, it is a \"biologic product\" (due to mixture of a person\u2019s own fat w. additional stem cells) which is not currently approved by the FDA.\u00a0 ", "answer": 1}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes an effort to establish the availability of night milk by\u00a0providing a hyperlink\u00a0to a company that sells night milk. But the website obviously caters to German customers and seems like it could be a headache for US consumers to navigate. And we couldn\u2019t find any other online sources of night milk besides this company that would be more accessible.", "answer": 1}, {"article": "\"It was just advice,\" Jenkins said.\nResearchers in Canada have shown that a special cholesterol-lowering diet works well \u2013 even with only two nutritional counseling sessions over six months.\nLead author Dr. David Jenkins, Canada research chair in nutrition and metabolism at the University of Toronto and St. Michael's Hospital, had previously shown the effectiveness of a cholesterol-lowering diet when all the meals were provided to participants.\nMaking dietary changes like eating oat bran for breakfast, drinking soy milk instead of dairy, soy burgers in place of hamburgers, and fruit and nuts instead of a full lunch prompted a double-digit drop in both total cholesterol and LDL or \"bad\" cholesterol.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no\u00a0discussion of the difficulty people in poor urban and rural areas may have finding some of the vegetarian foods called for in this diet, which includes some fairly exotic soy products (e.g. soy deli slices) as sources of protein. Also, considering the lack of physician reimbursement for dietary advice, patients may\u00a0have trouble finding a health professional who can\u00a0counsel them on this approach.", "answer": 0}, {"article": "The Biggest Loser diet and the DASH diet came in second and third, respectively, in the diabetes category.\nThe DASH (Dietary Approaches to Stop Hypertension) diet was designed to lower blood pressure and cholesterol levels by limiting fats, red meat and sugar in favor of healthy grains, poultry, low-fat dairy and nuts, the U.S. National Heart, Lung, and Blood Institute says.\nThe MIND diet includes some features of the DASH diet and Mediterranean diet, such as high consumption of fruits, vegetables and fish, but focuses on foods that promote brain health.\nThey also considered how easy each diet was to follow, as well as safety and nutritional value.\nTUESDAY, Jan. 5, 2016 (HealthDay News) -- For the sixth year in a row, a panel of health experts has named the heart-healthy DASH diet the best overall eating plan, according to U.S. News & World Report's 2016 Best Diets ranking.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that the DASH diet is widely available. It has been available and promoted to the public for many years. There are books, public and private websites, shopping lists and menus devoted to it. It has been named the \u201cTop Overall Diet\u201d by one magazine six years in a row.\nThe concern that a broad swath of the public does not have the financial means or a neighborhood grocery store they can walk into and acquire the menu items is another matter.", "answer": 1}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers may feel mislead about the availability of the app, given the story\u2019s headline (\u201cHow to heal head injuries? Try new app\u201d) which very strongly indicates that not only is this app publicly available, but also that it\u2019s capable of healing head injuries. Neither are true. \u00a0", "answer": 0}, {"article": "The study, conducted at the University of Texas M.D.\nAnderson's department of health disparities and the study's principal investigator here.\nBut he also acknowledged the results so far were a surprise.\nThey were followed for six to 11 years.\n\"Now we know you don't have to eat nine, 10 or 11 servings a day.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This criterion does not apply in this story. ", "answer": 2}, {"article": "Cao looked at data from over 86,000 women who were part of the Nurses' Health Study between 1980 and 2012 and over 43,000 men who were part of the Health Professionals Follow-Up Study from 1986 to 2012.\n(CNN) An aspirin a day may keep the doctor away.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\nIt may also reduce your chances of dying from cancer, according to a study on long-term regular aspirin use and different kinds of cancer.\nStudies have also found that aspirin can help patients who have had (or are at high risk for) a heart attack or stroke, and of course it is a good drug to relieve pain.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Aspirin is\u00a0widely available.", "answer": 2}, {"article": "Yet stroke patients admitted on the weekends were no more likely to die than stroke patients admitted during the week: 1,420 patients admitted on the weekend died versus 3,993 patients admitted on a weekday, which worked out to roughly the same rate of death.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\nThe current study, she added, shows that \u201chigh quality (stroke) care is available in hospitals on the weekends and weekdays.\u201d In fact, care might even be more aggressive on weekends.\n(See Reuters Health report, March 8, 2007).\n(See Reuters Health report, March 17, 2007).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Similar to the story from HealthDay, this report\u00a0emphasizes\u00a0that\u00a0an early diagnosis\u00a0is a critical\u00a0factor in the availability of\u00a0tPA for stroke patients. Although more detail could have been provided, this is the key point.", "answer": 1}, {"article": "\"This is pretty exciting,\" said Alycia Halladay, senior director for environmental and clinical sciences for Autism Speaks, an autism advocacy group.\nThe Norwegian researchers do admit that more studies should be done to confirm the link.\nBut some experts aren't quite ready to tout the benefits of folic acid too loudly, particularly for autism prevention.\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\nThe organization also recommends women of child-bearing age take 400 micrograms of folic acid daily before conceiving and 600 to 800 micrograms per day while pregnant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of folic acid supplements is not in question.", "answer": 2}, {"article": "Dr. Farah, who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown, prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains, \"Based on ASAM's definition of addiction, about half of substance abuse is due to genetic factors.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nProove\u00ae's medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers, such as the University of North Carolina at Chapel Hill, the University of Utah, and other institutions.\nThis study shows that analyzing genetics with lifestyle and behavioral variables in a predictive algorithm can accurately stratify patient risk.\"\nIRVINE, Calif., May 10, 2017 /PRNewswire/ -- Proove\u00ae Biosciences, Inc. announces a new study validating the accuracy of precision medicine technology to predict prescription opioid abuse.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release quotes one of the study authors as saying he has used the \u201ctechnology\u201d for six years, suggesting that it should be available. However, the news release does not provide information about any use of the POR algorithm by health professionals not affiliated with Proove or this specific study. The release neglects to mention whether the FDA has cleared the device for marketing.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that estriol is widely available now for other uses and that researchers have yet to complete Phase lll trials and apply for FDA approval for application in MS patients. However, it should be noted that estriol is far more commonly used in topical skin creams and not in tablet form as was the case with this study.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the intravenous (IV) zoledronic acid (Reclast) has been FDA approved or whether it is available or not.", "answer": 0}, {"article": "Using both together resulted in a 51 percent response, compared with a 30 percent response in women given Herceptin alone.\nThe researchers are continuing to evaluate that.\nThat's the effect on overall survival in using the two-drug approach.\nThe important question, however, has not been answered yet, Lichtenfeld said.\nThose given Tykerb alone had a 25 percent response.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers have to connect the dots to figure out the availability of these drugs.\u00a0 We\u2019re told that Tykerb was approved in 2007 and we\u2019re told its retail price \u2013 so you can infer that it\u2019s available. There was no overt description of the availability of Herceptin.\nWe\u2019ll call this satisfactory by a weak nod.", "answer": 1}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\nWhen the research was originally funded, Hollander says, autism was considered to be a rare condition.\nThe study was published in the American Journal of Psychiatry.\n\u201cThe clinicians could tell that people were doing better not only in terms of OCD symptoms but overall distress and ability to function.\u201d\n\nMORE: Why Are So Many Foster Care Children Taking Antipsychotics?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that Prozac is widely available and that other drugs are approved for use in autistic patients.\n\u00a0\n\u00a0", "answer": 1}, {"article": "When an ultrasound revealed she was carrying a girl, \u201cI was absolutely shocked,\u201c she said.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\nOne potential worry is that women might abort fetuses of an undesired sex.\nA typical blood test like Pink or Blue, for example, costs $25 for the kit.\nAbsence of a Y chromosome would probably mean the fetus is female, but could mean that fetal DNA was not found in that sample.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yes, the story explains there are a variety of tests that have been widely available to consumers. But the story could have done a better job of connecting the dots for readers. Exactly how does one get a blood test done for a home test kit? Raises questions like: do I go to a lab? Finger stick? Are their costs other than the test? Shipping? Do I do this at home myself? Working with my medical care team? How soon do I get the results?, etc. Process of using several common kits could have been better described.", "answer": 1}, {"article": "Median length of stay was 6 days (range, 4-58) with a median follow-up of 25 months.\n\"This new analysis of IRE could help change the standard of care for Stage III pancreatic cancer patients whose only treatment options until now were chemotherapy or a combination of chemo-radiation therapy, which will only stabilize the disease and not destroy the tumor.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nSAN DIEGO, April 24, 2015 /PRNewswire/ -- University of Louisville announced today results from the Soft Tissue Ablation Registry (STAR), demonstrating that irreversible electroporation (IRE) with the NanoKnife\u00ae System, in combination with chemotherapy, doubled the overall survival rate of locally advanced (Stage III) pancreatic cancer patients to nearly 24 months.\nWith IRE, these patients now have a surgical treatment option to augment their treatment plan.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told the NanoKnife\u00a0system \u201cis approved by the U.S. Food and Drug Administration for the surgical ablation of soft tissue\u201d and that it \u201cis not approved for use in specific cancers.\u201d So does that mean a pancreatic cancer patient could ask for this treatment? It\u2019s unclear. It\u2019s also unclear if insurance will pay for it.", "answer": 0}, {"article": "Hill called the new research \"a call to action\" and added, \"we should be studying these policies.\nAll of these states include chronic pain -- either directly or indirectly -- in the list of approved medical conditions for marijuana use, according to Bradford.\nThe impact of these laws also differed based on the class of opioid prescribed.\n\"There is a great deal of movement in the Northeast, with New Hampshire and New Jersey being well-positioned to legalize adult use,\" Moore said.\nThe details of the medical cannabis laws were found to have a significant impact on opioid prescription patterns, the researchers found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article included information about the number of states that have legalized certain types of marijuana use.", "answer": 1}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nThe American College of Medical Genetics did not respond to requests for comment on the DNA tests.\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\nBianchi said one study had estimated the blood test costs about 255 pounds in the UK (about $413), all included.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The test to determine fetal gender is available in the United States, as an unregulated procedure outside a doctor\u2019s purview. The Reuters story does not mention this. The competing NY Times story was explicit on this.", "answer": 0}, {"article": "But in this case, if anything, we're taking money out of our own pockets.\"\n\"More testing is not always more intelligent testing.\"\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of Pap testing is assumed. ", "answer": 2}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nThe results: continual muscle and fat measurements revealed that the group that took no fish oil supplementation lost an average of just over 5 pounds; the supplement group lost no weight.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\nThe authors concluded that fish oil supplementation appears to be a safe and effective way to prevent malnutrition among cancer patients, and may ultimately prove to be of benefit for other groups of people, such as elderly patients who also face a significant ongoing risk for muscle loss.\nWhat's more, blood analyses revealed that those in the fish oil group who had the biggest bump in bloodstream EPA concentrations also had the greatest muscle mass gains.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of fish oil supplements.\u00a0 More importantly, the independent perspective from dietitian Lona Sandon pointed out that the amount of concentrated fish oil supplement used in the study was much more than any recommended dietary allowane.", "answer": 1}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nshould contact the CWC offices at (916) 922-5888.\nCancer Causes Control.\nThe California Walnut Commission, established in 1987, is funded by mandatory assessments of the growers.\n#250, Folsom, CA 95630\n\n1.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We accept that walnuts are widely available.", "answer": 1}, {"article": "Meningitis is a condition \u2014 inflammation of the membranes that surround the brain and the spinal cord \u2014 that can be triggered by some viruses and several types of bacteria.\nBut the same component is one of several in the Bexsero vaccine, which was used in Quebec when the government decided to vaccinate against meningococcal B disease in a part of the province with a high relative rate of cases a few years ago.\nResearchers in Quebec say they saw the same phenomenon after a meningitis outbreak there, and previously published data from Cuba and Norway also hint of the vaccine\u2019s unexpected benefit.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the single-component vaccine used in New Zealand is no longer made but that the component is part of GSK\u2019s Bexsero vaccine, which is on the market. The story also distinguishes the B vaccine from others on the market: \u201cMeningococcal vaccines that protect against the other strains do not seem to have the same effect (on gonorrhea).\u201d", "answer": 1}, {"article": "Only children with moderate cough and severe stuffy nose were eligible, and those were divided into three groups.\nAlthough Vicks VapoRub is often used to fight colds and congestion, there has never been proof of how well it works.\nVicks VapoRub is not recommend for children under the age of 2.\nThe current study shows that Vaporub is more effective than placebo.\"\nThere were no side effects in the two other groups.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe availability of VapoRub is well known.", "answer": 1}, {"article": "Sunlight's ultraviolet (UV) rays can damage the DNA in skin cells, increasing the risk for skin cancer.\n(Another popular form of Vitamin B3 called niacin was not used in this study.)\nThey found patients who took vitamin B3 twice a day cut their chances of developing new skin cancers by 23 percent.\nOne patient who could benefit from the vitamin treatment is Charity Wiese, who has been diagnosed with skin cancer more than two dozen times in the last five years.\nShe also noted that the benefits appear to wear off when patients stop taking the supplements.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article\u2019s first paragraph establishes that nictotinamide is an \u201cover-the-counter vitamin supplement\u201d and thus readily available \u2014 at least in theory. The study\u2019s lead author also adds: \u201cIt\u2019s safe, it\u2019s almost obscenely inexpensive, and it\u2019s already widely commercially available.\u201d\nWe\u2019ll award a Satisfactory, but we\u2019d note that the competing AP story dug deeper, cautioning that \u201cA check of one major drugstore chain found only other forms of B3, such as niacin, or combination B vitamins.\u201d", "answer": 1}, {"article": "\"Emergency departments are going to have to think twice about a test like that,\" says Michael Shannon, senior physician in emergency medicine at Children's Hospital Boston.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nPhysicians say the test is accurate and the most comprehensive available, but some say its long processing time limits usefulness in emergency rooms.\nIt also needs extensive processing in the lab.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story provides good information about availability.\u00a0 The Xtag test is mainly used in hospitals and emergency rooms but can also be done in the primary care setting.\u00a0 Other important information on variability of the length of time needed to process the test, from hours to 1-2 days, was also provided. ", "answer": 1}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\nCAD is becoming more widespread, said Dr. Joshua Fenton, an associate professor of family and community medicine at the University of California, Davis, and lead study author.\nNow, with about 75 percent of mammograms adding it, it is even more common, Fenton said.\nAlthough it has rapidly become part of mammogram screening, Fenton said there is limited and conflicting research on its effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Early in the article, the study author is quoted observing that \u201cIt\u2019s an add-on and now is used in probably three-quarters of U.S. mammograms.\u201d\nWomen would have to ask if CAD is being used to read their mammograms.", "answer": 1}, {"article": "This direct antiviral approach has been used with great success in treating H.I.V.\nThe results also keep Vertex at the front of a crowded field that has made hepatitis C one of the fiercest battlegrounds in the pharmaceutical business.\nIt is not quite clear how those drugs work.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The second word in the story is \"experimental.\" It talks about the drug being in three different Phase 3 clinical trials and about the company looking forward to applying for approval from the FDA. What it does not do is make it clear how quickly the drug could be brought to market (or slowly) especially given the problems of side effects also noted in the story.", "answer": 1}, {"article": "With relaxation of the muscles, the distance between the vertebrae returns,\" Dr. Napoli explained.\nThe Society is based in Oak Brook, Ill. (RSNA.org)\n\"There's a big gap between conservative treatments for disc compression and herniation and surgical repair, which can lead to infection, bleeding and a long recovery period,\" Dr. Napoli said.\nNote: Copies of RSNA 2017 news releases and electronic images will be available online at RSNA.org/press17 beginning Monday, Nov. 27.\n\"Following this treatment, inflammation and pain go away.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does a nice job of explaining the procedure and, we feel, gives readers enough detail to understand how it would work. But it does not make it clear how widely this procedure is available and the type of technical skill necessary to administer it.", "answer": 0}, {"article": "Another approach to assessing the meaning of a PSA reading is to analyze how much antigen is traveling free in the blood and how much is bound to a companion protein, Dr. Scardino suggested.\n\u201cWe don\u2019t want to miss the possibility of a life-threatening disease, but we end up diagnosing and treating disease that would never have caused harm.\u201d\n\nThe new guidelines will lower the PSA level at which a biopsy should be considered, because, as Dr. Carter put it, \u201cthere\u2019s no level below which we can tell a man he doesn\u2019t have prostate cancer or life-threatening prostate cancer.\u201d\n\nAs one important trial showed, among men with a very low PSA \u2014 that is, a reading below the current cutoff of 4 \u2014 biopsies found that 15 percent had prostate cancer.\nCurrent guidelines recommend that all men have an annual PSA test starting at age 50 and that biopsies be conducted if the level exceeds 4 or if a \u201csignificant rise\u201d occurs between two tests.\nThe guidelines also suggest limiting screening to men with more than a 10-year life expectancy.\n\u201cPSA testing of men over 70 is not rational.\u201d\n\nHe pointed to a Scandinavian study showing that among men older than 65, to prevent one death from prostate cancer over 10 years, 330 men would have to have prostate surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that most men over 40 know that the PSA test is widely used for prostate cancer screening.\u00a0 ", "answer": 1}, {"article": "Dry eye syndrome is a multifactorial disease of the tear film and ocular surface that produces symptoms of ocular discomfort, eyesight disorders, and tear film instability with potential damage to the ocular surface.\nSylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and that has enabled the start-up of the Phase III \"Helix\" clinical trial.\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nIt must be empathized that this pathology affects more than 5 million in Spain, between 10% and 20% of the population, mostly women, and almost 100% of these being elderly , .\nWe currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "A scientist working for the drugmaker says she hopes \u201cthat tivanisiran will soon become a real alternative.\u201d Savvy readers will note that the drug is still in development and that the drug is not yet ready for patient use outside of a research setting.", "answer": 1}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\nMillions of jet-lagged and sleep-deprived Americans--citing countless self-help articles--insist they do.\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article did not mention that melatonin is sold as a dietary supplement and as such, the FDA neither approves the claims made nor monitors the content of the product.", "answer": 0}, {"article": "Fader no longer holds that role.\nFrom August 2011 through March 2017, Fader, Alessandro Santin, M.D., professor of gynecology and obstetrics at Yale University, and collaborators at 11 other cancer treatment centers in the U.S. randomly assigned 61 women with uterine serous carcinoma, being seen at the participating institutions, to receive either the standard chemotherapeutic regimen--a combination of the drugs carboplatin and paclitaxel--or those drugs plus trastuzumab.\n\"The fact that these tumors grow rapidly, but also have a propensity to spread to lymph nodes and other organs very early, is a double whammy for women,\" says Amanda Fader, M.D., associate professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine, and first author of the new study.\n\"Even an improvement of a few months may be quite meaningful for women with these cancers,\" says Fader, who is also affiliated with the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.\nAdding the monoclonal antibody drug trastuzumab--already used to treat certain breast cancers--to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that researchers have submitted their findings to the National Comprehensive Cancer Network, \u201cwhich guides the design of standard treatment plans around the country.\u201d However, it\u2019s not clear when or whether USC patients may have access to trastuzumab \u2014 either through FDA approval or via off-label prescriptions by health care providers. More importantly, though, the release could be a bit more clear on the percentage of patients with uterine cancers who may benefit from trastuzumab. There are bits and pieces of information scattered throughout the release, but it would be good to pull them together and add up what it all means. Here\u2019s what we\u2019re talking about (bear with us): according to the American Cancer Society, there are expected to be about 63,230 new cases of uterine cancer diagnosed in the U.S. in 2018; about 92 percent of those uterine cancers are likely to be endometrial, bringing the number to around 58,171; approximately 10 percent of those endometrial cancers will be USC, bringing the number to 5,817; and about 30 percent of those patients with USC test positive for HER2/neu receptor proteins that trastuzumab blocks. In other words, of the 5,817 women who may be diagnosed with USC in 2018, only 1,745 of them may be able to benefit from trastuzumab. That\u2019s an important idea to get across clearly.", "answer": 0}, {"article": "The healthiest fats, those found in olive and canola oils, contain more monounsaturated fats, which do not raise LDL cholesterol and might even help lower it.\nIt\u2019s the whole coconut that needs to be talked about.\u201d\n\nEntrepreneurs are talking about the whole coconut these days.\nIn the past couple of years a couple of brands have figured out the right angle \u2014 electrolytes and hydration.\u201d\n\nCraven estimated the coconut-water market at about $100 million annually right now, but companies are doubling their sales year after year.\nEven so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\n\u201cIt\u2019s trickling down to the mass market.\u201d\n\nThe company is growing so quickly, he said, it had to hunt for coconuts from outside of Brazil, where it previously harvested most of its fruit.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The sheer volume of people within the retail food industry who seem excited about this trend makes us believe that\u00a0a lot of stores are following this fad, which means coconut products are widely available.", "answer": 1}, {"article": "Ecstasy use can cause depression, severe anxiety, and potential cognitive problems, according to the National Institute on Drug Abuse.\nConducting a study with an illegal drug is a complex process.\n(All of the participants received additional therapy sessions that did not involve the drug.)\nOn two separate occasions, 12 of the people took a dose of MDMA and then spoke for several hours with a pair of trained therapists.\nThe drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The first sentence states that \"The drug MDMA\u2014better known by its street name, Ecstasy\u2014may be illegal, but a new study suggests that it\u2019s also a promising treatment for post-traumatic stress disorder.\" The story underscores the point several times that the drug is illegal and currently unavailable for therapeutic use.", "answer": 1}, {"article": "The sweating can occur even when the temperature is cool and the person is at rest.\nThe study was small and the findings are preliminary.\nAll had hyperhidrosis, a condition where a person sweats much more than the body needs to cool itself.\nHe presented the findings here at the annual meeting of the American Academy of Dermatology.\nIt works, he says, by heating and destroying the sweat glands under the arm.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never does state the availability of the technology for people with hyperhidrosis.\u00a0 It does state that the FDA has approved it for eyelid lifts.\u00a0 Are many dermatologists (or others) trying it for hyperhidrosis?\nA simple few additional words would have clarified the issue.", "answer": 0}, {"article": "Pulse pressure is the difference between systolic and diastolic (bottom number) in blood pressure readings.\nLonger-term studies involving other population groups are warranted.\nThe research was supported in part by funds from the National Mango Board and USDA.\nMango consumption helped relax blood vessels in as little as two hours after intake.\n\"Our results build on previous animal and cell studies that point to the potential benefits of mangos to promote health.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention this, but presumably people know that mangoes are already available to the public. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "HPV causes cervical cancer, which remains a significant health problem, particularly in less resource-rich areas of the world.\nIt could be done less frequently than the Pap test, which could be used only in women who have tested positive for HPV, they said.\nThat decline has been largely attributed to widespread use of the Pap test.\nThe previous recommendation was to start Pap tests three years after becoming sexually active or at age 21, whichever came first.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly the HPV DNA test and pap tests are both available in the US.", "answer": 1}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nIn the case of beta-carotene, scientists were surprised to find that when the results of randomized trials were in, those taking the supplement actually had a higher risk of lung cancer.\n\"It was believed that megadoses of vitamin E, beta-carotene, selenium, folic acid and the B vitamins would confer a large array of health benefits.\nDr. JoAnn Manson, chief of preventive medicine at Harvard-affiliated Brigham and Women's Hospital, points out that nearly all of the proliferating studies involving vitamin D are what scientists call \"observational.\"\nUntil those results are in, Manson advises patients and doctors to view vitamin D claims as \"promising but not yet proven.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story did mention various means to increase one\u2019s level of vitamin D including supplements, fortified foods, and exposure to sunlight. \u00a0It would have been useful to mention that vitamin D is commonly found in multivitamins, and many calcium supplements contain vitamin D as well. ", "answer": 1}, {"article": "46 babies had a brother or sister with known autism, which means they themselves are at an increased risk for the neurodevelopmental disorder that affects about one in 110 children according to the Centers for Disease Control and Prevention.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nDoctors and scientists not connected to the study are intrigued by the results but caution that this is very early research and not something concerned parents can be looking for as a screening tool for their babies any time soon.\nHe, too, is hopeful that further research will provide more concrete information.\nBut she cautions that a lot more work needs to be done.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that this was an experimental diagnostic tool and not ready for the pediatrician\u2019s office.", "answer": 1}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nOverall, pembrolizumab shows promising antitumor activity in advanced cases of follicular or papillary thyroid cancer which progressed on standard treatment.\nQ: What did you find?A: At the time we reported our results, six of the 22 patients remained on treatment.\nThe clinical benefit of pembrolizumab in advanced thyroid cancer will be further studied in a follow-up phase II clinical trial that is now ongoing to try to discover biomarkers which predict response to treatment with pembrolizumab.\nIn blocking this activity, these new immunotherapy drugs help T cells get back to work in protecting the body.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that\u00a0pembrolizumab is under study in an early clinical trial. It does not, however, point out that the drug is in fact commercially available under the trade name Keytruda, a drug we have heard a great deal about in the past few months related to its use in melanoma.", "answer": 0}, {"article": "\"It's an important step along the way,\" Dr. Hadley said.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\nThe participants, who were paid, turned out to be highly motivated, he said.\nHe called the results \"striking,\" even though the experiment was only a pilot study for a two-year trial of calorie restriction due to begin in the fall.\nA six-month study in 48 people directed by Dr. Ravussin, being published today in The Journal of the American Medical Association, is the first rigorous test of calorie restriction in people who are overweight but not obese.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions \u2018people experimenting on themselves\u2019, indicating the potential for anyone to self-impose calorie limitations on themselves. However, the article failed to explain that all the food consumed by the research subjects in the study was provided for them thus ensuring nutritional adequacy while restricting calories. That\u2019s beyond the reach of the average American. People were paid $7,000 to be in the study!", "answer": 0}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\nTo read an excerpt, click here.\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nHe says vegetables and fruits such as brussel sprouts, asparagus and raspberries can target specific cancers, at least in test tubes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly fruits and vegetables, spices and green tea, and physical activity \u2013 mentioned in the story \u2013 are all widely available.", "answer": 1}, {"article": "With the FDA's announcement, drugs like pembrolizumab have also begun to change the way that physicians, patients and government regulators think of cancer. No longer will they see all cancers of the lung, breast, colon, brain, liver, pancreas and prostate as distinct from one another. Instead, they will look for the common genetic mutations that give rise to cancers no matter where they're found. And they'll treat those cancers with a drug that uses that common signature as a homing beacon, either for the immune system or for targeted cancer drugs to attack.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that pembrolizumab is currently being sold under the brand name Keytruda.", "answer": 1}, {"article": "Behavioral counseling is widely recommended, with medication, to help smokers quit.\n\"Long term, our study would not say it would prevent relapse.\"\nRelapse rates of the quitters were similar during the study period, whether they used the products alone or with counseling, or they did not use them.\nThe new study, however, draws from the population.\nThe results of the new study are published online in Tobacco Control.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like that this story was very specific on what types of nicotine products were studied. \u201cThe participants told whether they had used a patch, gum, inhaler, or spray. They told how long they used the product continuously.\u201d", "answer": 1}, {"article": "In Israel, the treatment costs $6,000.\n\u201cWe see improvement lasting for 9-12 months and the good thing is that patients can return and undergo treatment again,\u201d Baror said.\n\u201cYou stimulate the brain on a biological level as well as on a cognitive level,\u201d Neuronix CEO Eyal Baror told Reuters, saying this double approach created longer-lasting benefits.\nThe device, which combines electromagnetic stimulation with computer-based cognitive training, is already approved for use in Europe, Israel and several Asian countries such as Singapore.\nPascual-Leone, who is principal investigator in the Harvard trial, said that of 12 patients in the study, six received the real treatment and all showed cognitive improvement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mixed bag here.\nThe story explained that the the device is approved for use in several other countries.\u00a0 But it also said the company \u201cexpects the system to be approved by the U.S. Food & Drug Administration in late 2014.\u201d\nNo basis for that projection was given.\u00a0 Later the story stated that \u201cUS trials are expected to run till the end of 2013.\u201d\nSo the entire projection of approval and availability is based on a hope and a prayer and a crystal ball of unknown clarity and certainty.", "answer": 0}, {"article": "HONG KONG (Reuters) - Boosting the effect of acupuncture needles with small electric currents may be effective in treating depression, a study in Hong Kong has found.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\n\u201cThe drop (in depression scores) among the group receiving active treatment was more significant than the placebo group,\u201d said Roger Ng, another researcher in the group, which published their findings in the journal PLoS (Public Library of Science) ONE.\n\u201cWhen the acupoints are stimulated, some brain centres responsible for producing serotonin are stimulated,\u201d explained Ng, a consultant at the department of psychiatry at the Kowloon Hospital in Hong Kong.\nThe electroacupuncture was given in addition to medication that the patients were already taking and meant to augment their treatment, Zhang told a news conference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There was no explanation of the availability of electroacupuncture. This is certainly an important issue in the USA, which is where we \u2013 and presumably many other readers \u2013 found the story online.", "answer": 0}, {"article": "Wasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\nThe discovery was a \u201cserendipitous finding\u201d in the lab of Rajan Sah, M.D., Ph.D., assistant professor of Internal Medicine and Molecular Physiology and Biophysics at the University of Iowa.\n\u201cThe treatment of cachexia just doesn\u2019t exist.\nThe intellectual property associated with this discovery was recently licensed by the UI Research Foundation to Innovus Pharma, an over-the-counter consumer goods and specialty pharmaceutical company that commercializes non-prescription medicine and consumer care products.\n\u201cWe tested these compounds in sedentary mice and found a dramatic improvement in exercise endurance and a mild increase in muscle size of certain muscle groups,\u201d Sah says.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give the release a Satisfactory in this category since it states that a company has been licensed to develop a drug based on this research, and therefore readers know that it isn\u2019t available yet.", "answer": 1}, {"article": "The stool was more solid, the diarrhea goes away, and the bloating is much less.\"\nThe study looked only at those IBS patients with the non-constipation form, he tells WebMD.\n''The major finding was that all IBS symptoms improved,\" says Mark Pimentel, MD, director of the GI Motility Program at Cedars-Sinai Medical Center, Los Angeles, who led the clinical trial of the drug at Cedars.\nWith the drug treatment, Pimentel says, those with the IBS ''can enjoy social outings without the worry of having to run to the bathroom and having diarrhea.\"\nThat can translate to big changes in the lives of those with IBS, estimated to affect about 15% of adult Americans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that\u00a0rifaximin\u00a0\u201cis approved by the FDA only for traveler\u2019s diarrhea and hepatic encephalopathy, a brain disorder caused by chronic liver failure.\u201d And it interviews a physician who\u2019s been using it off-label for the non-constipation form of IBS. But the story does not make clear how widely used it is.", "answer": 1}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that deep brain stimulation is a current therapy, though not yet for diabetes.", "answer": 1}, {"article": "Researchers found that regular coffee drinkers \u2013 those who drank more than four cups of coffee a day \u2013 had a 39 percent decreased risk of two types of head and neck cancer: oral cavity and pharynx cancers.\nHowever, coffee alone may not be the answer according to some experts.\nBut he says that newer studies suggest that drinking coffee may actually be good for you.\nCoffee did not decrease the risk of a third type of oral cancer \u2013 laryngeal cancer.\n\"Each person needs to think about how they metabolize caffeine or coffee.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable \u2013 the availability of coffee is not in question. ", "answer": 2}, {"article": "Cognitive behavioural therapy (CBT) is a talking therapy that can help a person manage problems by changing how they think and behave.\nThe study found that women who had least social support such as those who were not living with or near their mother or mother-in-law, benefited most from the therapy intervention, both in the short and long term.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\nWhile studies have highlighted the short-term benefits of CBT, until now question marks have been raised about whether it can have long-term effects.\nThe NHS website explains that it is \u201cbased on the concept that your thoughts, feelings, physical sensations and actions are interconnected, and that negative thoughts and feelings can trap you in a vicious cycle\u201d.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address availability.\nAs explained in the original clinical trial, the researchers used an existing system of Lady Health Workers who are specially trained to do the intervention, making the treatment available in an area where it normally wouldn\u2019t be.\nBut even in nations with more resources, spotty insurance coverage and lack of providers limit access to this type of care. The story should have at least touched up on the availability issue. This is an area an independent source likely could have given some context on.\n\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the folate fortification of the North American food supply; it also noted that folic acid is found in multivitamins.\u00a0 The story is mainly about recent analysis about possible consequences of folate supplementation of the food supply.\n\u00a0", "answer": 1}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this is an existing drug for osteoporosis that has not been approved by the FDA for use in breast cancer prevention. The story does not make claims about when it may be approved for that purpose.", "answer": 1}, {"article": "In another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is a variation of a drug already on the market but that it is not yet approved for use.", "answer": 1}, {"article": "As the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nTaking a combination of estrogen and progestin is associated with an increased risk of breast cancer, but advances in screening and treatment since the WHI started now mean these tumors are unlikely to be fatal, McNeil said by email.\n\u201cThe take-home message now is that for the right patient, hormone therapy is safe and effective.\u201d\nWomen were 63 years old on average when they joined the trials and had already gone through menopause.\nThey took hormones or a placebo for five to seven years and were followed for a total of 18 years altogether.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "These therapies are widely available and that\u2019s implied in the story.", "answer": 1}, {"article": "Caucasian men more commonly reported circumcision (69%) than African American men (43%).\nCircumcision, of course, removes this protective environment.\nA few potential caveats to note include the reliance on self-reporting when it comes to a man's history of STIs, as well as his sexual partners.\nA cursory review of the data suggests, for example, that the number of male sexual partners is greatly underreported.\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of circumcisions is not in question.", "answer": 2}, {"article": "This may predate the onset of other symptoms.\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\nNot all will be destined to be affected by the disease, however.\nThose who do worse in the tests will be the ones most likely to succumb to Alzheimer\u2019s later in life, scientists now believe.\nBut now scientists plan to take their tests to a new level with the use of the virtual reality sets in which wearers are immersed in simulated environments through which they must navigate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "On the one hand, the story does tell readers that there will be a forthcoming study to evaluate whether VR technology can be used to test people\u2019s navigation ability in order to determine whether it is an effective technique for diagnosing Alzheimer\u2019s. (In other words, they don\u2019t even know if this is something that will work yet.)\nOn the other hand, earlier in the story, readers run across sentences like: \u201cVirtual reality to help detect early risk of Alzheimer\u2019s\u201d and \u201cThose who do worse in the tests will be the ones most likely to succumb to Alzheimer\u2019s later in life, scientists now believe.\u201d That makes it sound like this is already a useful tool, and availability could be right around the corner. Ultimately, the story never explicitly tells readers that any possible VR tool is years away, at best. That tips the scales for us, and we lean in the direction of \u201cnot satisfactory\u201d on this criterion. One wonders how many people read this story and contacted their general practitioner about taking a VR test to assess their Alzheimer\u2019s risk.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16organ.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article discusses several consortia or organizations of hospitals that participate in paired matching of organs. Based on the limited number of participating hospitals in selected regions, it seems clear this is not widely available at present. Plus, the article mentions that legislation is needed before a federally funded organ donation organization (UNOS) could get involved, potentially making this much more widely available. ", "answer": 1}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are given no indication whether the procedure is in use in other hospitals outside the clinicians who were involved in the clinical trial.", "answer": 0}, {"article": "While skeptics may question the idea of using psychedelics as treatment for psychological distress, Hendricks emphasizes that he does not advocate for rampant recreational use of psychedelics, or widespread legalization.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\nThe data were compiled between 2008 and 2012, and drew from the experiences of 190,000 adults.\nThe UAB isn't the first study to flirt with this idea.\nA lack of resources and funding is a hindrance to continuing studies, however, as psychedelics are still classified as schedule 1 narcotics in the U.S. and criminal offenses accompany their possession.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study noted that the drugs are not available legally in the United States.", "answer": 1}, {"article": "All participants also initially received standard doses of the corticosteroid prednisone, and continued to receive it in diminishing doses over the course of 15 weeks.\nThe FDA\u2019s approval is limited to treatment of the three types of noninfectious uveitis that pose the greatest threat of vision loss.\nFurther author disclosures are available in the study\u2019s manuscript.\nJaffe said the study focused on time to treatment failure because delaying or preventing inflammation is the key to successful treatment.\nThe Food & Drug Administration recently approved the additional use of adalimumab (sold as Humira) for patients with noninfectious uveitis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The level of detail is good here, noting that the FDA recently approved adalimumab for noninfectious uveitis, how it was previously approved for other conditions, and in which types of uveitis it\u2019s generally ok to treat.", "answer": 1}, {"article": "Source: Brightling C, et al.\nThe pill may be a \u201cgame changer for future treatment of asthma,\u201d said Professor Chris Brightling, a National Institute for Health Research (NIHR) Senior Research Fellow at the University of Leicester, in a press release.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\nWe already know that using treatments to target eosinophilic airway inflammation can substantially reduce asthma attacks.\u201d\n\nUltimately, the researchers hope that the drug \u201ccould likewise help to stop preventable asthma attacks, reduce hospital admissions and improve day-to-day symptoms \u2013 making it a \u2018game changer\u2019 for future treatment,\u201d said Brightling.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The headline makes it sound as if the pill is readily available, with no mention that further trials and approvals are necessary before the drug could be marketed.", "answer": 0}, {"article": "An estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nThe research results on the new test are published online in PLoS ONE.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\nHe is also founder of Durin Technologies Inc., the company that is developing the test.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\nDeep in the story, it explains that \u201cif all goes well\u201d the developer is hopeful the test could be available within a year. That is followed by an Alzheimer\u2019s Association spokesman saying this is \u201cpreliminary.\u201d\u00a0 So the developer\u2019s optimism is tempered somewhat.\n", "answer": 1}, {"article": "Ten years ago, scientists started looking at the hormones made in the pituitary gland to see how they act on certain targets.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\nBut how do mice models translate to human treatments?\nAfter that, we would go into primates and larger animals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes all of the steps that need to be taken before the antibody could even begin human trials, in three to four years at the earliest.", "answer": 1}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nHicks and a team of researchers have been looking for an objective test that might help.\nMost samples were collected about a week after the injury.\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nBut saliva may not be the best place to measure microRNAs, Bhomia says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the spit test is still being studied. There were no predictions about when or if it would be available.", "answer": 1}, {"article": "Can a cup of blueberries keep the doctor away?\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\nThere were no significant changes in the placebo group.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not discuss or mention the availability of blueberries or blueberry products. Since the investigators were studying a freeze-dried blueberry powder that may be harder to find than typical grocery store blueberries, we would expect the story to look for and comment on the availability of this product.", "answer": 0}, {"article": "\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nMost individual tests were completed within two minutes.\nThis was the first time a portable device was used for these tests.\nA tiny skin electrode was placed on the skin under the eye to record the retina's electrical activity.\nWe and other researchers are now investigating whether retinal changes are related to brain structure and function changes in schizophrenia.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release said the device is \u201ccommon in optometrists\u2019 offices.\u201d", "answer": 1}, {"article": "It matters.\nIt turns out that the melanoma really cares if we block the gene BRAF.\nProgress in this field has essentially been stalled for decades, experts say.\nThe findings join other recent reports of potential treatments for melanoma in what appears to be an exciting time for the field.\nOne expert cautioned that it's too early to say whether the drug will actually prolong patient's lives, or if it might be helpful to patients in earlier stages of the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story specifies that the new drug is \"experimental\" and in phase 1 clinical research. Readers can conclude from this that the drug is not widely available.\u00a0", "answer": 1}, {"article": "Women taking medications may forget to take them sometimes.\nInsertion of the device may be mildly uncomfortable for some women, she said.\nGetting an intrauterine system generally just requires one office visit, Espey said.\nResults of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan. 10 issue of the New England Journal of Medicine.\n\"They also have a high continuation and a high satisfaction rate.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are only told that the IUD is \u201csold under the brand name Mirena.\u201d\nWe\u2019ll give the story the benefit of the doubt, although it didn\u2019t discuss anything about how widespread is the use of this IUD.", "answer": 1}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this \u201cmind-cleansing\u201d drug is not available. ", "answer": 1}, {"article": "The median age was 70, with a range of 50 to 88.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\n\u201cThe net benefit of pleurectomy and decortication justifies the procedure in the majority of patients with malignant pleural mesothelioma,\u201d Dr. Vigneswaran concluded.\nDr. Vigneswaran and colleagues administered a cancer quality-of-life survey known as the EORTC QLQ-C30 to 114 mesothelioma patients who underwent PD surgery.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We rated this as satisfactory, but just barely. The release notes that surgery in the opening paragraph:\u201dAlthough surgery can prolong the lives of patients with an aggressive type of cancer called malignant pleural mesothelioma, many patients avoid the operation for fear it will degrade their quality of life.\u201d\u00a0 This makes it clear that surgery is a routine option for treatment although not specifically pleurectomy and decortication. We appreciate that the release is intended for a sophisticated audience but think that the wording could have been a bit clearer. ", "answer": 1}, {"article": "Many more stroke victims than previously thought can be saved from disability or death if doctors remove blood clots that are choking off circulation to the brain, a new study has shown.\nThe study showed that the time window could be expanded to 16 hours.\nHowever, the findings do not apply to every stroke victim.\n\u201cI really cannot overstate the size of this effect.\u201d\n\nThe key finding is that there is often more time than doctors realized in which brain cells can still be rescued by a procedure to remove the clot.\nThe researchers used a special type of brain imaging to identify the patients who still had live brain tissue that could be saved if the blood supply was restored.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While it\u2019s not clear when the new 16-hour guideline will take effect, the article makes it clear that this procedure is currently available.", "answer": 1}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that locomotor training is only available in a handful of centers in the U.S.\u00a0and access is limited. The story should not have implied that the treatment has gone \"mainstream\" because it is only available in 17 hospitals in the US.", "answer": 1}, {"article": "\"Proteins are constantly moving and changing shape,\" said Lapidus, a professor in the Department of Physics and Astronomy.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\nFox and St. Mary's Foundations, funded the study.\nThe medication also treats many of the symptoms associated with the disease such as tremors and poor muscle control.\n\"What we've essentially shown is that an already FDA-approved drug that's been studied over 50 years and is relatively well tolerated could be a much simpler approach to treating the disease itself, not just the symptoms,\" Collier said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is about a \u201cproof of concept\u201d and no therapy is available based on this research. We\u2019ll rate this Not Applicable but note that the release should have been more clear in the headline and lede that this therapy hasn\u2019t been tested in humans.", "answer": 2}, {"article": "In contrast, a 2000 Singapore study of 330 adolescents found no difference in 3-month quitting rates for participants treated with real or fake laser therapy.\nThat\u2019s what Innovative Laser Therapy, a New Haven, Connecticut-based company, advertises on its website.\nStill, Laser Therapeutics\u2019 Camera said, the treatment won\u2019t work on everybody.\nAfter seeing the initial research, she\u2019s hopeful, but cautious, about low-level laser therapy as a way to help people do that.\nPinto launched Innovative Laser Therapy after he successfully quit smoking with a round of laser therapy from a clinic in Florida.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains how these laser treatments are part of an emerging trend that grew out of acupuncture.", "answer": 1}, {"article": "Similar drugs are under development at companies including Eli Lilly & Co and Teva Pharmaceutical Industries Ltd, but Amgen emphasizes that Aimovig is the only one that targets the CGRP receptor pathway, rather than CGRP itself.\nA decision by the FDA is due by May 17.\nHe said previous studies excluded patients who had tried more than two other treatments.\nThe drug, a monoclonal antibody, was given monthly by injection at a dose of 140 mg for the trial.\n\u201cThis is a trial in really difficult to treat patients,\u201d professor Uwe Reuter, trial investigator and managing medical director at Charit\u00e9 Universit\u00e4tsmedizin in Berlin, told Reuters in a telephone interview.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the drug is under review by the FDA and that a decision is expected in May.", "answer": 1}, {"article": "(Reuters) - Medtronic Inc, a manufacturer of pacemakers, heart stents and spine products, has developed a device to tackle another common health problem: erectile dysfunction.\nRogers said it could be several years before Medtronic undertakes a much larger late-stage trial.\n\u201cThis is still investigational and requires more research.\nAfter three months the results were promising, the company said.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that \u201cit could be several years before Medtronic undertakes a much larger late-stage trial\u201d and that \u201cthis is still investigational.\u201d", "answer": 1}, {"article": "A growing number of doctors who treat the estimated 6.4 million American children diagnosed with A.D.H.D.\nexperts challenge this conclusion.\nThe question is whether these effects can last once the drugs have left the bloodstream.\nYet Dr. Bertin has recently changed the way he talks about medication, offering parents a powerful argument.\nAnd other research has raised new concerns.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the medications being discussed are widely available.", "answer": 1}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nConclusions and Relevance The results of a possible cetuximab-related laryngeal preservation benefit for patients with hypopharyngeal or laryngeal cancer are intriguing; these results need to be interpreted in the context of a retrospective subset analysis with limited sample size.\nUnfortunately, there has been a lack of improvement in overall survival for patients with laryngeal carcinoma in the last 30 years.\nThis treatment approach warrants further evaluation in larger populations to fully assess the potential value of cetuximab or other molecular targeting agents to augment laryngeal preservation rates.\nAn older report31 of interviews with firefighters and executives who were asked to envision that they had advanced laryngeal cancer determined that they were willing to accept a 15% to 30% reduction in life expectancy for a laryngeal-preserving treatment compared with total laryngectomy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This release notes that more research, on a larger scale, needs to be done to \u201cassess the potential value\u201d of interventions like CRT in treating cancer while preserving the larynx. However, the release would have been much better if it had clearly noted that cetuximab is not currently eligible for insurance coverage for this particular condition and a result will not be available to many patients.", "answer": 0}, {"article": "The Lancet.\n\"While we have demonstrated clinical effectiveness of screening, we are also exploring cost-effectiveness of this approach; initial analyses also look promising in this respect.\"\nThe research, involving more than 12,000 older women and carried out in collaboration between the universities of Birmingham, East Anglia, Bristol, Leicester, York and Sheffield, found that screening through GP practices allowed patients to be targeted for treatment.\n\u2022 FRAX\u00ae is a simple calculation tool that integrates clinical information in a quantitative manner to predict a 10-year probability of major osteoporotic fracture for both women and men in different countries.\nThe study suggests that one hip fracture could be prevented for every 111 women screened and early analysis suggests the approach is likely to be cost-effective.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a clinical trial of the proposed adoption of a screening procedure which the researchers hope will contribute to national healthcare policy. The risk calculator used in screening, FRAX, is already widely available.", "answer": 2}, {"article": "Oral and injectable medications are also prescribed.\nThe authors are planning prospective efficacy studies of extended dose natalizumab.\nHowever, previous research led by Dr. Zhovtis-Ryerson's group found extending the dose up to 8 weeks did not negatively affect the medication's efficacy in a retrospective sample of 2,000 people.\n\"Our safety findings are clinically and statistically significant, and we believe that extending the dosing schedule of natalizumab is practice changing and may save lives.\"\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does mention that natalizumab is a \u2018commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect \u2026 \u201d\nIt should have been made more clear, however, that the drug has been pulled from the market before (over PML concerns) and is now FDA-approved only for\u00a0highly active, relapsing remitting MS.", "answer": 1}, {"article": "In a healthy brain, microglia act as chemical rubbish collectors, surveying the local environment, clearing up unwanted compounds, but in Alzheimer\u2019s these cells can lose this function and switch into an inflammatory state in which they secrete toxic compounds instead.\nThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\nAt 40Hz the flicker of the light is barely discernible and would be \u201cnot offensive at all\u201d for a person to have in the background.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story address availability with this\u00a0statement: \u201cThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\u201d OK, quicker and cheaper \u2014 but does that mean a year from now or five years or 10?", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story included a statement that \"a mere 10 to 15 minutes outdoors at midday gives the average fair-skinned person 10,000 international units\" which\u00a0is hyperbole because\u00a0season and latitude greatly\u00a0affect the amount of vitamin D synthesis that occurs. Even though the story included a statement about latitude a little later, the first statement is misleading for the reader.\nThe story included mention of food sources for \"relatively modest amounts\" of vitamin D, though that does little to help the reader know how much of the foods would need to be consumed.\u00a0 Although the last sentence of the article listed one mini-meal plan, which, along with supplements would supply the suggested level of Vitamin D, this was an incomplete method of telling readers how to achieve adequate vitamin D intake.\u00a0 The story also failed to mention the effect of sunscreen on vitamin D production by the body.", "answer": 0}, {"article": "\"Our idea was to find a way to do a quick examination that would allow, during a boxing or American football match for example, to determine whether the athlete can return to the field or if his condition requires hospitalization.\nThis discovery, described in PLOS ONE, will not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nABCDx's ultimate goal is to bring to market biomarkers capable of diagnosing brain trauma, stroke and aneurysms.\nIt will display the word \"positive\" or \"negative\" and send the result to the patient's or caregiver's smartphone via Bluetooth.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release stated that the device will be marketed starting in 2019 by a company called ABCDx. However, it would have been helpful to readers to point out whether or not the device must receive regulatory approvals or any details about the types of patients for whom it is recommended.", "answer": 1}, {"article": "Professor Roy Taylor said: \"What we have shown is that it is possible to reverse your diabetes, even if you have had the condition for a long time, up to around 10 years.\nA previous study led by Professor Taylor, published in 2011, showed that diabetes could be reversed by a very low calorie diet.\nThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\nParticipants in this study had Type 2 diabetes for between six months and 23 years.\nIn addition, the team found that even patients who have had Type 2 diabetes for up to 10 years can reverse their condition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Given that the approach of this study focuses on specific foods as key to maintaining weight, and that these foods are commonplace, one assumes that they are readily available in the marketplace.", "answer": 2}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Story about FDA approval for women with early-stage invasive disease.", "answer": 1}, {"article": "Shingles is a viral disease produced by the chicken pox virus, a common childhood disease, and is characterized by pain and a blistering rash along the nerves that have housed the dormant virus.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\nDespite the FDA\u2019s approval, the vaccine has not caught on as much as some had hoped.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that this shingles vaccine was approved in 2006. It also makes reference to stringent requirements for storage and handling, which have been cited (along with cost) as barriers to access.", "answer": 1}, {"article": "The findings impress Columbia University researcher Gregg W. Stone, MD.\nThat approval seems likely, given the results of a new clinical trial that compared Plavix to Brilinta in patients with acute coronary syndromes who had stents placed in their arteries to improve blood flow.\nThat's probably why the 6,732 study patients who got Brilinta were 16% less likely to die, or have a heart attack or stroke, than were the 6,676 patients who got Plavix.\nAnd in the new study, patients had less bleeding after stent installation.\n\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that ticagrelor is not yet have FDA approval.\nHowever, the story stated that \u2018approval was likely\u2019 and that the drug will be marketed as Brilinta. \u00a0Both pieces of information are more akin to marketing than reporting. \u00a0It would be more accurate to state that the drug is currently under consideration for FDA approval and that the name Brilinta has been proposed.", "answer": 1}, {"article": "Who and When: 8,385 obese patients in Israel who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) from 2005-2014; 25,155 obese patients who received nonsurgical care for obesity management from primary care physicians that may have included dietary counseling and behavior modification.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nLink will be live at the embargo time http://jamanetwork.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability. However, bariatric surgery for obesity is becoming increasingly common and is now available worldwide. The release would have been stronger had it informed readers about the eligibility criteria for the surgery.", "answer": 2}, {"article": "As many as 10 percent of children suffer from hay fever, nearly 12 percent have skin allergies, and 5 percent have food allergies, most commonly peanuts, dairy, and shellfish, according to the 2014 National Health Interview Survey.\n\u201cThat hypothetically decreases the risk for adverse events.\u201d\n\nFor all the research on allergies, none of the drugs in the pipeline is a sure thing.\nThe experimental treatment that may be closest to market is also one of the simplest.\n\u201cThere\u2019s really no doubt that there have been cold feet in the industry about this issue.\u201d\n\nBut investigators around the world have shown they can carry out these \u201cfood challenge\u201d trials safely \u2014 which could help hasten the development of new drugs.\nIt\u2019s a risky proposition to give patients the foods they\u2019re deathly allergic to \u2014 inducing anaphylactic reactions simply to test drugs in clinical trials.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article, admirably, makes clear that movement through the new drug pipeline is likely to be slow for most of the newly envisioned therapies.", "answer": 1}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that bisphosphonates are in widespread use, and the article at least implied that the generic versions were generally available at the low quoted price \u2014 giving readers the tools to select the drug and look at reasonable pricing.", "answer": 1}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not comment on the availability of PET scanners.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention that lung cancer screening is already being offered and advertised by many hospitals and imaging centers across the country. We're told the study was done in 38 centers around the world but are given no idea of the availability of spiral CT scanners.\u00a0 ", "answer": 0}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nHowever, colon cancer patients shouldn't try to boost vitamin D levels beyond the normal range, one expert said.\nIt did not prove cause and effect.\nEveryone should maintain healthy vitamin D levels anyway, to protect their bone health, Ng and Krishnamurthi said.\nThe report, scheduled for presentation this week at the Gastrointestinal Cancers Symposium in San Francisco, adds more weight to suspicions that vitamin D might be a valuable cancer-fighting supplement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people know that vitamin D supplements are widely available. A brief statement to that effect would have earned the story a satisfactory, as opposed to not applicable.", "answer": 2}, {"article": "Sumathi Reddy has details on Lunch Break.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nProbiotics, believed to help with digestion, are increasingly being studied to treat wide-ranging conditions, from colic to cholesterol and the common cold.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that probiotics are available in supplements and a variety of other products.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that carotid endarterectomy is widely available.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\n\"Although we observed that short-term use of LDX was well tolerated and effective in several subjective and objective areas, long-term studies of menopausal women receiving LDX are needed, similar to those conducted for ADHD patients,\" said Epperson.\n\"It is also important for clinicians to confirm that a woman's complaints of worsening memory are in the executive function domains, are temporally related to the transition to menopause, and are not indicative of some other pathological cognitive impairment before prescribing a trial of LDX.\"\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\nResults of the study are published online today in the journal Psychopharmacology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release establishes that the drug used in the study is now frequently prescribed for ADHD patients, suggesting that it is available and also could also be used for menopause-related symptoms..", "answer": 1}, {"article": "; Menno V. Huisman, M.D., Ph.D.; Pieter W. Kamphuisen, M.D., Ph.D.; J\u00f6rg Kreuzer, M.D.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\nIdarucizumab was approved by the U.S. Food and Drug Administration in October 2015 as the first medicine designed to reverse dabigatran.\nResearchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients' clotting systems forming dangerous blood clots.\nAn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A. Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that idarucizumab was approved by the FDA in October 2015, so readers can assume that it\u2019s available (and it is).", "answer": 1}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nUnlike on TV, in all likelihood it won't be widely used anytime soon to retrieve specific memories.\nUnfortunately, [the findings] suggest that the therapy may not be as robust as initially proposed.\"\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\nYet the fact that the therapy can in some people rescue recollections \u2013 albeit random ones \u2013 and possibly induce new neuron growth in memory regions of the brain seems reason enough to pursue it further.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story acknowledges the preliminary nature of the research, but we\u2019d have liked to see it near the top rather than in the third-to-last paragraph, which states: \u201cDBS for treatment of Alzheimer\u2019s and other dementias is a field in its infancy. Unlike on TV, in all likelihood it won\u2019t be widely used anytime soon to retrieve specific memories.\u201d", "answer": 1}, {"article": "\"Nobody has the answer at this time,\" Perle said.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\nAbout two-thirds of the studies were not included in a previous review published in 2004, and all patients had suffered from lower back pain for 12 weeks or longer.\nMore than 6,000 patients were included in the compilation of results, which the study authors said were sparse in data indicating participants' overall recovery, quality of life and ability to return to work.\nThe studies also varied in quality, with only nine of 26 considered \"low [in] bias,\" according to background information accompanying the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article gets a \u201csatisfactory\u201d because it pointed out that manipulation is commonly performed by multiple healthcare professions. \u00a0It would have been useful to mention that manipulation is not routinely available in conventional primary care medical settings.\u00a0 And despite its evidence record, it does not generally enjoy completely consistent insurance coverage.\u00a0 The same points apply to massage.\n \n", "answer": 1}, {"article": "Rhesus monkeys and rats performed just as well on memory and attention tasks shortly after being administered DORA-22 as they did on an inactive placebo.\nMerck already has one such drug, suvorexant, under review by the U.S. Food and Drug Administration (FDA).\nWEDNESDAY, April 3, 2013 (HealthDay News) -- A new class of sleep medications appears to help people fall asleep without causing grogginess the next day, researchers say.\nSo much so that the FDA recently cut recommended doses of Ambien and other drugs that contain zolpidem for fear that their use, even the night before, might impair driving or other activities the next day.\nBut many questions remain: Do the drugs truly have fewer side effects?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is under study and therefore not available. The story tells readers that Merck has applied for FDA approval to market a similar drug.", "answer": 1}, {"article": "According to Cancer Research UK, eight out of 10 children with leukemia in Britain now survive for five years or more, compared with one in 10 in the late 1960s.\n\u201cEven though this is still lab-based ... it validates the idea of developing small molecules against epigenetic switches,\u201d he said in an emailed comment.\nKevin Lee, head of epigenetics discovery research at GSK, who also worked on the study, said he too was excited about the findings, although it will probably be many years before the drug could potentially reach the market.\n\u201cIt is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.\u201d\n\nMLL leukemia is thought to account for up to 80 percent of cases of acute leukemia in children below two years old, and up to one in 10 cases in adults.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story had several reminders for readers of the early stage of this research.\u00a0 The reminder that \u201cit will probably be many years before the drug could potentially reach the market\u201d is almost premature in itself given that this is something that hasn\u2019t even been tested outside the lab yet \u2013 with not one human experiment having been conducted.", "answer": 1}, {"article": ".\nThe experience supports a growing body of research showing good outcomes with surgery for chronic temporal headaches.\nHe hopes his new technique will \"lower the bar to adoption\" of effective surgical treatment for patients with this debilitating headache condition.\nIn recent years, surgery has emerged as an effective treatment option for selected patients with chronic, severe headaches.\nThe simplified approach using the Gillies incision combines the advantages of other approaches to chronic temporal headache surgery while minimizing the disadvantages, Dr. Peled believes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release isn\u2019t clear whether or not the surgery is currently available specifically for chronic headache patients. From an online search, it seems that some centers do offer surgery to treat chronic headaches, although it isn\u2019t always clear\u00a0 what techniques the surgeons use.", "answer": 0}, {"article": "All of the babies born by C-section were slightly more likely to use an asthma inhaler at age 5: 10.3 percent of planned C-section babies and 10.19 percent of unscheduled C-section babies wound up using an inhaler, compared with 9.6 percent of vaginally born babies.\nThe findings are a reminder that although C-sections are appropriate in some circumstances, they are a poor substitute for labor.\nThe Scottish study took advantage of the small country\u2019s rich trove of linked birth and medical databases to track the long-term health of 321,287 babies.\nThe finding suggests that the arduous experience of labor \u2014 that exhausting, sweaty, utterly unpredictable yet often strangely exhilarating process \u2014 may give children a healthy start, even when it\u2019s interrupted by a surgical birth.\nNow, a groundbreaking study suggests that not all C-sections are equally risky.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All three of the birth methods described are widely available.", "answer": 1}, {"article": "Pathologists can distinguish between cancers that look particularly aggressive and those that do not, but there is a real possibility that even if tissue obtained at a biopsy has only less aggressive tumor cells, more aggressive cells might still be lurking in the prostate.\nAnd there are financial incentives.\nOften it is easier to just order the test.\nSome men say the cautions just do not apply to them.\nAnd doctors, he added, have many inducements to screen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that \u2018routine\u2019 PSA testing is readily available.", "answer": 1}, {"article": "+ Loss of fat was associated with faster walking speed, while loss of muscle was associated with reduced knee strength.\nLoss of lean mass could have important consequences given the high risk of physical disability among the growing population of older adults.\nFor older adults trying to slim down, pumping iron might be the way to go.\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\nCo-authors on this paper included W. Jack Rejeski and Anthony Marsh, co-principal investigators of the CLIP-II study, and Jessica Sheedy, Beverly Nesbit and Jill Gaukstern, all of the Wake Forest University Department of Health and Exercise Science; and Walter Ambrosius, Michael Walkup, Jonathan Burdette and Barbara Nicklas of the Wake Forest School of Medicine.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As mentioned above, weight lifting classes are offered at most gyms and there are online tutorials as well, making it extremely available. However, it would have been nice to include some organizations that specifically offer weight training for elders.", "answer": 2}, {"article": "\"[The study is] one of the first studies that evaluated the role of Mediterranean diet on metabolic syndrome, and revealed a beneficial association- quite a big influence, taking into account that the Mediterranean diet is a non-pharmacological mean,\" said study author Demosthenes Panagiotakos, from the Department of Science of Dietetics-Nutrition at Harokopio University of Athens in Greece.\nThat translates into 2.9 million young people.\nPanagiotakos concludes that this pattern of eating can be easily adopted by people of various cultures and populations.\n\"It's all these other components,\" Eckel said.\nThe syndrome is present when someone has three of those five risk factors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story opened by indicating that readers had likely heard about or even tried the\u00a0\u2018Mediterranean diet\u2019.", "answer": 1}, {"article": "The leaky mitral valve makes the heart enlarge even more, as it tries to compensate, and heart failure worsens.\n(The clip is made by Abbott, which funded the study; outside experts reviewed the trial data.)\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nThe result was to convert a valve that barely functioned into one able to regulate blood flow in and out of the heart.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a strong point.\nThe story stated: \u201cIf the device is approved by the Food and Drug Administration for treatment of severe heart failure, as expected, then insurers, including Medicare, most likely will cover it.\u201d\nIt also stated, \u201cNot every cardiologist is equipped to insert the clip.\u201d", "answer": 1}, {"article": "When ICI-associated colitis is severe, guidelines require a patient to stop ICI treatment until the colitis is in remission.\n\u201cBased on these results, this should be evaluated even as a first-line therapy for ICI-associated colitis because it\u2019s safe, quick, and the effect is durable - from one treatment.\u201d\n\nImmune checkpoint inhibitors, which release a block on the immune system to attack cancer, have been successful in providing durable responses for patients with several cancer types.\nFMT continues to be offered to MD Anderson patients on a compassionate-use basis.\n\u201cWe have a limited amount of time to fix the problem so they can resume ICI treatment, but I feel that we\u2019ve made great progress in this area.\u201d\n\nThe researchers chose to investigate the potential for FMT as an alternative, compassionate-use therapy for patients suffering from refractory, or unresponsive, ICI-associated colitis.\nStill, post-treatment gut bacteria remained distinct from their own pre-treatment microbiome.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Determining this will be confusing to someone reading this release.\u00a0 Fecal transplant procedures are in use to treat a variety of gastrointestinal issues, so this would suggest that the procedure is available.\u00a0 But its employment to subdue inflammation caused by immunotherapy treatment is just being explored and has not even been subjected to clinical testing yet.\u00a0 So whether the procedure would be available to cancer patients receiving immunotherapy is an open question.", "answer": 0}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nAt study enrollment, none had signs of dementia.\nThe study was supported by the National Institute on Aging and the Judith Zwartz Foundation.\nDuring the course of the study, each person received annual, standardized testing for cognitive ability in five areas -- episodic memory, working memory, semantic memory, visuospatial ability and perceptual speed.\nThe results were the same after researchers adjusted for other factors that could affect memory and thinking skills, such as education, physical activity, smoking and participating in mentally stimulating activities.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "People have been eating fish for rather a long time, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The I.V.\nSchwartz, though, said the supplements are completely safe.\nThere is a published review on the use of Myers\u2019 cocktail \u2014 but it\u2019s just a collection of anecdotal evidence.\nAnd though the IV lends a medical air to the procedure, the infusions suffer from the same problem as many supplements taken orally \u2014 there isn\u2019t any robust evidence to back up their health claims.\nA longitudinal study would be needed to back those claims with evidence, she added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that several different companies are selling nutritional supplements delivered by intravenous drip. But it was not clear how easy these are to obtain and the potential for insurance coverage was not mentioned, so this is a marginal satisfactory rating.", "answer": 1}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\nSuch results are why the treatment is on track to become the first gene therapy approved by the Food and Drug Administration.\nTo try to ensure patient safety, Novartis is not planning a typical product rollout, with a drug pushed as widely and aggressively as possible.\nFor the Penn team, the CAR T-cell story goes back decades, starting at the then-National Naval Medical Center in Bethesda, Md., where June and a postdoctorate fellow named Bruce Levine worked on new HIV treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly lays out where this treatment is in the FDA review process, how that process may unfold, and what this may mean for future availability. In addition, the story explains that CAR T-cell treatment would not be rolled out universally, but \u2014 if approved \u2014 would be available only through designated treatment facilities that have the relevant expertise.", "answer": 1}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nTo do this, all of the study volunteers were given all three tests.\nEach test is non-invasive, requiring only the use of exhaled air.\nBoth Appleyard and Leath noted that cost might initially limit the use of an electronic nose.\nNone of the study volunteers had a history of smoking.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story never explicitly states that the device being discussed is experimental, comments from the experts make it pretty clear that the technology\u00a0is still in development.", "answer": 1}, {"article": "Cameron Batson, 18, died a few weeks before that, while playing a game of pick-up soccer.\nIf an ongoing program of testing happens, the hospital would try to tap into third-party funding, donations and grants, Towbin says.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\nA key challenge now is making these tests affordable; most medical insurance plans won't cover them.\nCurrently, an EKG and echocardiogram would cost parents a minimum of $2,500, Anderson says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the way the tests are described in the story, they appear to be routinely available. However, there is no discussion of whether the capacity exists to test and properly interpret test results for the millions of teens who would need to undergo screening if it were demonstrated to be beneficial.", "answer": 1}, {"article": "Multiple myeloma is the second most common type of blood cancer in the U.S., impacting more than 25,000 people each year and disproportionatly affecting African-American men.\nWith a goal of enrolling 82 patients, those in the trial will be treated with a combination of anti-myeloma agents and immunotherapy that have a proven record of eliminating minimal residual disease, including the drug carfilzomib and the monoclonal antibody daratumumab, agents that are currently only approved to treat patients whose disease has returned.\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\nThe MASTER trial is supported by Amgen and Janseen, both with drug and finaincial support.\nPatients will be monitored for relapse at the molecular level, before disease becomes again symptomatic.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the trial uses drugs that are already available, though some are approved for only patients who have relapsed after initial treatment. It makes clear that the \u201cminimal residual disease\u201d testing regime to be used is not routinely available.", "answer": 1}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread use of c-sections is clear in the story. ", "answer": 1}, {"article": "\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nThe strategy is being tested in a handful of small studies that are part of a surge of research in a field that for years showed little progress.\nBurks and Jones are part of the federal consortium, which is studying the same approach for eggs at research institutions across the country, including Johns Hopkins, and conducting detailed immunological studies to try to get a better understanding of how the treatment works.\nNo one should try the approach on his own, because the treatments themselves can trigger potentially life-threatening reactions.\nAlthough the approach appears to be highly effective for some children with milk and peanut allergies, the researchers conducting the studies and others caution that much more research is needed to prove and perfect the approach and that it is far from ready for widespread use.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described positive results from a couple of studies and indicated that desensitization in this manner is the realm of research and not widely available clinically. \u00a0\nThat said \u2013 it could have provided readers with some ideas for where they could go to learn about studies in their area. (www.clinicaltrials.gov)\u00a0", "answer": 1}, {"article": "Also, mice that received the drug had slower blood clot formation than untreated mice, but the treated mice did not bleed longer than untreated mice.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nWhen mixed with blood, the new compound prevented blood cells called platelets from clotting.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates more research is needed before this compound will be available (if ever).", "answer": 1}, {"article": "\u201cNow, it\u2019s just impatience,\u201d Kefalis said.\nTeichner asked, \u201cDo you believe that gene therapy is finally coming into its own?\u201d\n\nThe MLD trial, she thinks, demonstrates what\u2019s possible -- offering promise to the 30 million Americans who suffer from some 7,000 rare diseases.\nHere\u2019s what\u2019s really amazing: That vehicle is the HIV virus, re-engineered so the children can\u2019t get AIDS.\nSo far, not a single gene replacement therapy has been approved by the FDA.\nBut then they need a vehicle to insert the good gene into the stem cells before those are put back into the patient\u2019s body.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made very clear that the treatment is not available in the U.S., and likely won\u2019t be for some time.\nWhile this deserves a Satisfactory rating, there are two ways in which the reporter might have dealt with the availability issue differently. First, it might have been worth saying the treatment may\u00a0never be available in the U.S., since the research is at too early a stage to guarantee success. Second, it would have been informative to find out from the drug company what they think will happen next.\u00a0GlaxoSmithKline are reported to have said they will seek approval in 2017\u2013is that based on this current study or are they planning to do more research?", "answer": 1}, {"article": "Chemotherapy before surgery might provide a false assurance that there's no more residual cancer, whereas microscopic tumour may remain after the surgery, leading to cancer recurrence and possibly, death.\nThe goal is to have no cancer visible to the naked eye of the surgeon after the surgery.\n\"Women need support to endure surgery and the rigours of intraperitoneal chemotherapy, but should be encouraged to do so whenever possible, considering the potential survival benefits,\" said Narod.\n\u2022 The surgery should be aggressive in an attempt to remove all visible signs of the tumour, and to avoid leaving any residual disease.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the treatment options being urged as the standard of treatment are already well established.", "answer": 1}, {"article": "Research has shown that vitamin D plays a key role in maintaining muscle integrity and strength and some studies suggest vitamin D may reduce the risk of falls.\nAt the beginning of this pilot study, the research team found that more than half of the participants had insufficient concentrations of vitamin D in the blood (less than 20 ng/ml), while less than a quarter had concentrations in the optimal range (30 ng/ml or more).\nThe study showed that the monthly vitamin D supplement was effective in increasing the concentrations of vitamin D in the blood from insufficient to sufficient levels in all but one of the 34 people who received it, and to optimal levels in all but five people.\nThe study is published in the early online edition (8/16/2015) of the Journal of the American Geriatrics Society.\n\"Falls in homebound older people often lead to disability and placement in a nursing home,\" said Denise Houston, Ph.D., R.D., associate professor of gerontology and geriatric medicine at Wake Forest Baptist and lead author of the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Not Applicable. Although no mention was made of the availability of the vitamin supplements, it is fair to assume most readers know that they are readily available in nearly any supermarket or drug store. However, the high dose vitamin D used in this study is typically available by prescription only.", "answer": 2}, {"article": "The FASEB Journal, April 2017, vol.\nFurther research is needed to support the hypothesis that the consumption of raspberry puree may change the composition of the gut microbiota.\nThis may reflect differences in varieties, origins, processing methods among other influential factors.\nNPRC's mission is to conduct nutrition research and promote the health benefits of processed raspberries.\nThe NPRC is responsible for marketing processed raspberries in the U.S. and is committed to promoting the growth of the entire industry.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability generally isn\u2019t an issue\u2014raspberries are a common fruit known to most who shop at grocery stores. However, prices (and therefore access) can fluctuate widely depending on where you live. ", "answer": 2}, {"article": "Virus levels can\u2019t be detected by routine HIV tests, which can only show whether or not a person has the virus.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\nAt the moment, testing often requires costly and complex equipment that can take a couple of days to produce a result,\u201d said Graham Cooke, who co-led the research from the Imperial\u2019s department of medicine.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re\u00a0told\u00a0the\u00a0technology\u00a0is\u00a0in\u00a0the\u00a0\u201cearly\u00a0stages\u201d and is thus not yet available.", "answer": 1}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that lapatinib is still being tested in clinical trails and is not yet available for sale. The story says that \u201cGlaxoSmithKline plans to submit the drug for regulatory approval in the U.S. and Europe by the end of this year,\u201d and later mentions Glaxo\u2019s \u201chigh hopes for Tykerb.\u201d It would have been better to get some other perspectives about these prospects, other than comments from the company or company-sponsored researchers. ", "answer": 1}, {"article": "Citation: Henry TD, Schaer GL, Traverse JH, Povisc TJ, Davidson C, Lee, JS, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Patel AN, Riedel N, Junge C, Hunt A, Kereiakes DJ, White C, Harrington RA, Schatz RA, Losordo DW, the ACT34-CMI Investigators.\nAppeared or available on-line: May 4, 2016\n\nThis study, scheduled to be published later this year in a special cardiovascular issue of Cell Transplantation, is currently freely available on-line as an unedited early e-pub at: http://www.\nOutcomes from the \"ACT-34-CMI\" study, a two-year, phase II, randomized, double-blind, placebo-controlled clinical trial, will be published in an upcoming cardiac issue of Cell Transplantation.\nAll of the 167 patients participating in the ACT34-CMI study saw significant improvement in both angina frequency and exercise at 12 months and a trend toward decreasing major cardiac events.\n\"These patients frequently have symptoms after having had standard therapies and are left with limited treatment options.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that this paper stemmed from a phase II clinical trial. It didn\u2019t tell readers how long ago the trial took place, or what the treatment\u2019s prospects are (even in general terms) for potential clinical use. In 2012, Baxter issued a news release announcing plans to launch a phase III trial for CD34+ treatment to \u201d\u00a0increase exercise capacity in patients with chronic myocardial ischemia.\u201d That trial appears to be related to this research, although that\u2019s not entirely clear. Is it related? And, if so, has that trial moved forward?", "answer": 0}, {"article": "Both are reasonable options.\u201d\nThe most common treatment for urinary incontinence is a daily dose of an anticholinergic medicine that alters the action of certain nerves.\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\nSignificantly, those who took Botox were more likely to have their symptoms completely disappear.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentions that anticholinergic medicine is the \u201cmost common treatment\u201d for urinary incontinence. It is also well-known that botox injections are readily available.", "answer": 1}, {"article": "Feb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\n''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both the HealthDay story and the WebMD story described the diet in broad strokes, allowing readers, especially parents, to understand the basic components. There are two problem with both stories, though. First, they did not say anything about food preparation. Is serving a child fried chicken the same as grilled? Are french fries as good as a baked potato?\u00a0The other key point is that a dietician has to \u201ctailor\u201d the diet for each child. If there were no experienced dietician available, that would be problematic.\u00a0Still, we thought enough detail was presented to warrant a satisfactory rating.", "answer": 1}, {"article": "Texting also played a role in helping patients feel like they were in control of their treatment, particularly during the first month.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nOne of the patients texted the program 1,217 times.\nAt the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned this was a feasibility study, signalling the system isn\u2019t available. Still, it could have explored whether any text messaging systems are being used for chemo patients.", "answer": 1}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that this supplement is available over the counter.", "answer": 1}, {"article": "And so far there's no cure.\nIt's still in the early stages, but Dr. Robert Wood of Johns Hopkins, who has been on the forefront of food allergy research, estimates the treatment could be brought to the public within six to eight years.\nSome children are allergic to many foods, and it's impossible to know based on preventive testing whether someone will have a mild or severe reaction.\nResearchers are separately looking at a drug called omalizumab (Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.\nOther research has shown that immunotherapy techniques may similarly work for children with peanut allergies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted, the story made it clear that this is preliminary research and that the approach \u201cmay one day\u201d be available.\nThen the story quoted the researcher estimating that \u201cthe treatment could be brought to the public within six to eight years.\u201d\nThis is not entirely accurate, as oral immunotherapy for food allergies (including milk allergy) is currently being administered clinically by a handful of physicians. The concept behind the treatment (basically, exposing patients to food proteins) is not FDA regulated, and so there is theoretically no barrier to physicians offering this type of therapy to their patients. Citing the potential for adverse reactions and other concerns, however, most experts say that it is much too soon to use oral immunotherapy outside of a research setting. And so the story\u2019s bottom line message about availability is correct for the vast majority of patients. Still, the estimate of availability \u201cwithin 6 to 8 years\u201d may cause confusion to parents who have heard, via allergy blogs or other media sources, that it is already available.", "answer": 0}, {"article": ".\nEdward Kim, MD, urologist at the University of Tennessee Medical Center and Professor at the University of Tennessee Graduate School of Medicine in Knoxville, and his colleagues compared such a drug, called Enclomiphene citrate, with testosterone replacement therapy (Androgel) in overweight men with low testosterone, or hypogonadism.\nFull citation: \"Oral Enclomiphene Citrate Raises Testosterone and Preserves Sperm Counts in Obese Hypogonadal Men, Unlike Topical Testosterone: Restoration Instead of Replacement.\"\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nThe investigators found that Enclomiphene citrate restored blood testosterone levels to normal after 16 weeks while maintaining sperm concentrations, whereas Androgel restored blood testosterone levels but caused marked reductions in sperm concentrations by suppressing the function of the testes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release did not explicitly describe the availability of\u00a0Enclomiphene citrate.\nThe study indicated that clomiphene, closely related to the study drug, is used \u201coff label\u201d for hypogonadal men. It has not been approved by the FDA for use in men.", "answer": 0}, {"article": "\"Artificial intelligence gives us the ability to find patterns we might not find with our own eyes,\" Bosl said.\nAlso, the study predicted who was at high risk of autism, but it's unknown if those babies actually went on to develop autism, he noted.\nThe technology has been around for awhile -- developed in the late 1920s, it has been used for more than 60 years to detect seizures in epileptics.\nWhen the babies were nine months old, researchers could predict who was in the high-risk autism group -- that is, they had a sibling with autism -- with nearly 80 percent accuracy.\nDr. Joshua Ewen, a neurologist and director of the clinical neurophysiology laboratory at the Kennedy Krieger Institute in Baltimore, said the study is well done and looks promising, but needs to be replicated.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job setting up the study by explaining that researchers already know that having a sibling with autism can be a risk factor for developing autism and goes on to explain that this method of reading an electroencephalogram (EEG) is experimental.\u00a0The story accurately states that EEGs are not new, but have been used for detecting seizures for many years.", "answer": 1}, {"article": "It is also inexpensive and easy to use.\nResearchers say that until now, the function of POPG has been unclear.\n\"Our findings demonstrate that POPG is a potent antiviral agent both as\n\na prophylactic and after infection has occurred,\" researcher Dennis Voelker, PhD, professor of medicine at National Jewish Health in Denver, says in a news release.\nIn the study, published in the Proceedings of the National Academy of Sciences, researchers examined the effects of POPG on RSV infection in human lung cells in the lab and in mice infected with the virus.\n\"While these are still early studies, several characteristics of POPG make me believe that it has real potential as both an antiviral and anti-inflammatory treatment.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not until the sixth paragraph does the story explain that this work was done in the lab \u2013 not in people.\u00a0 But later, the story says that the substance in question \"is already used in other treatments and has been safely given to millions of premature infants to protect their lungs.\" So is that a substance that doctors would use (have used?) off-label?\u00a0 This is not at all clear. ", "answer": 0}, {"article": "\u201cWe do not know for sure, and we do not know which particular aspect of olive oil is the most relevant to stroke,\u201d he says.\n\u201cMaybe olive oil improves vascular risk factors such as hypertension, dyslipidemia, diabetes, heart disease, obesity, which may in turn reduce stroke risk, or it may be that olive oil is anti-inflammatory or an antioxidant.\u201d Scarmeas writes an accompanying editorial.\nShe agrees with the study authors and editorialist that it is too early to make any recommendations about olive oil intake and stroke risk.\n\u201cOlive oil is a healthy fat and it can reduce cholesterol and inflammation, and has been shown to help reduce the incidence of heart disease,\u201d she says.\nShe calls the findings \u201cintriguing\u201d but says they \u201cdo not equate a randomized clinical trial and should be used with appropriate caution in making broad recommendations.\u201d\n\nSuzanne Steinbaum, MD, director of women and heart disease at Lenox Hill Hospital in New York, says moderate use of olive oil in cooking and on bread may help protect against stroke in people older than 65.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of olive oil is not in question.", "answer": 2}, {"article": "While this study suggests that cholesterol levels alone are not associated with longevity, it is important to emphasize that many studies show the benefit of statin medications to lower blood cholesterol, that are highly associated with a reduced risk of death.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\nA new study suggests the answer may be no.\nEat less saturated fat for better heart health: that\u2019s been the conventional wisdom based on decades of scientific study.\nDoes swapping out all of your saturated fat with unsaturated fat lead to a longer life?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The different oils are widely available; this is N/A.", "answer": 2}, {"article": "It's a substantial number of women,\" Lyman said.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\nIn the new study, Armando Giuliano of the John Wayne Cancer Institute at Saint John's Health Center in Santa Monica, Calif., and colleagues analyzed data collected from 445 women who had their nodes removed and 446 who did not, along with radiation and chemotherapy.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll address the following concern under this criterion because we\u2019re not sure where else to address it.\u00a0 Readers would have benefited from early clarity that all participants in the study\u00a0still had a sentinel lymph node biopsy and that the research focused on whether removal of all lymph nodes was necessary\u00a0if the sentinel nodes were cancerous.\nThe article pointed out that if breast cancer has spread to any lymph nodes, doctors usually recommend removing all lymph nodes in the arm.\nThe article reported that\u00a0in a phone interview, Gary Lyman of the American Society of Clinical Oncology said the group may revise its recommendations for full lymph node removal based on the results of this study.\u00a0 Since many surgeons and oncologists base their advise to patients on these recommendations, patients may soon be offered this less extensive surgery option. .", "answer": 1}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nFunctional MRI and Diffusion Tensor MRI are research tools not routinely available in community hospitals and not routinely used in clinical practice.\u00a0 The story does not provide any information on their availability.\u00a0 It also doesn\u2019t tell us anything about the two approaches and why/how they are different.\u00a0 It just name-drops fMIR\u00a0and DTI as if readers are supposed to know what that means.\n", "answer": 0}, {"article": "Those who reported longer fast durations also indicated they consumed fewer calories per day, ate fewer calories after 10 p.m. and had fewer eating episodes.\n\u201cThis is a simple dietary change that we believe most women can understand and adopt.\nIt may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\n\u201cThe dietary advice for cancer prevention usually focuses on limiting consumption of red meat, alcohol and refined grains while increasing plant-based foods,\u201d said co-author Ruth Patterson, PhD, UC San Diego Moores Cancer Center associate director for population sciences and program leader of the cancer prevention program.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Again, we\u2019ll rule this criterion Not Applicable. \u00a0Fasting is something that anyone could do, although some people should consult with a doctor before limiting their calorie intake or increasing the amount of time between meals.", "answer": 2}, {"article": "The most common form of breast cancer uses oestrogen to grow.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\n\u201cThis early study raises an interesting question of whether cholesterol-reducing treatment, such as statins, could help lower the chances of breast cancer returning for some women who have developed a resistance to hormone therapy,\u201d said Jane Murphy, clinical nurse specialist.\n\u201cWe know that many women can be consumed with fear of their breast cancer coming back, which can have a huge impact on their ability to move forward after treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says statins are currently used for lowering cholesterol. However, it should have described the clinical trials and government approval processes required for statins to become a treatment for breast cancer.\nIt\u2019s important to add that the headline says\u00a0statins\u00a0\u201ccould be\u201d added to breast cancer treatment. This sort of statement may mislead some patients who feel desperate to try anything and therefore may seek out and take statins not currently prescribed for them.", "answer": 1}, {"article": "Their metabolism slows down, they expend fewer calories when they exercise because their muscles become much more efficient, and their thyroid hormone and adrenaline levels drop.\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nBut, Dr. Rosenbaum said, it established a proof of principle.\nLeptin reversed that, too.\nWhat is hard is to keep the weight off.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Doesn\u2019t mention that there is no FDA approval for the use of \nleptin in maintenance of weight loss.", "answer": 0}, {"article": "Now she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nIn fact, Mummaneni says, stronger muscles might be the secret to Gokhale's success.\nSo the spine looks more like the letter J.\nBack pain is a tricky beast.\nSo Gokhale worked to get her spine into the J shape.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the Gokhale Method is available.", "answer": 1}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"This study adds to the literature on vaginal laser therapy for GSM.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\nHowever, more robust randomized, sham-controlled data are needed, with larger numbers of women, to evaluate long-term safety, benefits, and risks,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nAlthough there is ongoing debate regarding the safety and effectiveness of vaginal laser surgery, a new study suggests that it may be effective, especially after multiple treatments.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that vaginal laser surgery represents \u201cone of the newer and more hotly contested approaches\u201d to menopause symptoms.\nSo we\u2019ll give this a satisfactory mark, but it would have helped readers to give them a ballpark sense of how widely the surgery is being used in North America.", "answer": 1}, {"article": "Laparoscopic surgery, in which a surgeon performs the operation through small incisions, usually with the help of a surgical robot, has been touted as carrying a lower risk of incontinence and impotence than the standard \u201copen\u201d form of the surgery.\nAnd while the robot-assisted operation is now the \u201cdominant approach\u201d to this surgery in the US and is gaining popularity in other wealthy nations, there\u2019s still too little information on how patients fare after the surgery, Dr. Declan G. Murphy of the Peter MacCallum Cancer Center in Melbourne, Australia and his colleagues write.\nIn the current study, Murphy and his team looked at 68 studies of robot-assisted laparoscopic surgery to better understand its downsides.\nFinally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\nIn about one in 250 surgeries, the robot failed to work properly.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story mentioned that robotic prostatectomy was the \u2018dominant approach\u2019 to this procedure in the United States.\u00a0 But that is an erroneous statement by the physician who is from Australia. It is certainly booming in popularity, but that doesn\u2019t make it the dominant approach. ", "answer": 0}, {"article": "\u2022 Pregnant women who were hospitalized with severe cases of flu illness were half as likely to have been vaccinated as women with non-severe illness.\nA related editorial commentary by Alan T. N. Tita, MD, PhD, and William W. Andrews, PhD, MD, of the University of Alabama at Birmingham, accompanies the new study in The Journal of Infectious Diseases.\nFor an embargoed copy of the study and the commentary, please contact Emily Zaideman (312-558-1770, ezaideman@pcipr.com).\nPast studies have suggested that flu antiviral therapy is safe and beneficial for pregnant women.\nSixty-three of these patients, or about 7 percent, had severe illness.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Readers can infer that oseltamivir is available, since it was used in hospitals to treat patients.", "answer": 1}, {"article": "\"Our idea was that if you had an inexpensive test that was easy to use and wasn't invasive, you could reach a lot of people and prevent deaths from happening every day of the year,\" Markowitz said.\nUp until June 1, LabCorp of America had a product on the market.\nLabCorp has said it will come out with a new test this year.\nAnd you've probably heard about how early screening means early detection and removal of polyps before they turn into cancer.\nBut all of this hasn't been enough to convince a lot of people make those appointments.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that one stool DNA test has been commercially available since 2003. Others will be available later in 2008 and in 2009.", "answer": 1}, {"article": "Known generically as dupilumab, the drug can cause serious allergic reactions and eye inflammation.\nActual costs to patients, payers and health systems are anticipated to be lower as WAC pricing does not reflect discounts, rebates or patient assistance programs,\u201d it said.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\nIn a nod to the sensitivity around drug prices, the company stressed that there is no single price for the drug.\n\u201cScratching leads to swelling, cracking, weeping clear fluid, and finally, coarsening and thickening of the skin.\u201d\n\nThere are many treatments out there now, from simple skin lotions to steroid creams and immune suppressant drugs like tacrolimus.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the drug is now FDA approved for sale. It also says the drug \u201cis a twice-a-month injection under the skin. Patients can do it at home.\u201d However, it didn\u2019t broach the topic of how likely insurance companies are to cover this drug. Patient demand is likely to be high, but insurers may push back due to the high cost.", "answer": 1}, {"article": "More than 80% of all skin cancers are BCC, arising from the basal cells (i.e., small, round cells found in the lower layer of the epidermis).\n\"The main advantages of noninvasive treatments are good cosmetic outcome, preservation of surrounding tissue, and potential for home application of either creams,\" explained lead investigator Marieke Roozeboom of the Department of Dermatology, Maastricht University Medical Center in the Netherlands.\nThere are over two million cases a year in the U.S. and the lifetime risk of developing a BCC before the age of 85 years is one in five people.\nHowever, prior to this study there has been a lack of randomized controlled trials with a long-term follow-up that compare the effectiveness of noninvasive treatments.\n\"When choosing a treatment for an individual patient with a superficial BCC, other factors like age, compliance, and patient preferences should always be taken into account.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release implies that each of these are available treatments and the goal is to compare existing treatments.", "answer": 1}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nWomen who want to quit smoking may find it easier if they time their efforts just right.\nThey called for more studies to help understand all the factors that contribute to sex and gender differences in smoking.\nThey were asked to view photos both related and unrelated to smoking.\nAfter undergoing the brain scans they viewed the photos a second time and reported on a scale from zero to 100 if the pictures triggered cigarette cravings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ends with a call for emphasis on \u201cgender-specific programs to quit smoking.\u201d Are such programs available? \u00a0The headline and the first sentence might suggest to some readers that the proof is in and that women can already get help with this. Accordingly, we\u2019ll rate this as unsatisfactory. \u00a0", "answer": 0}, {"article": "Almost never?\nBut a closer look at the data suggests that this is probably just a statistical artifact: This intense running group contains only 36 people and two deaths, versus hundreds of people in the more casual running groups.\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nNothing in the data suggests that running more \u2014 farther, or faster \u2014 will do more to lower your risk of death.\nHowever, I\u2019d argue that the comparisons the studies make among runners are still valid.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most people are aware that walking, jogging and running are exercise options. So while no specific comment was made about availability, we\u2019ll rule it Not Applicable. The story could have touched on availability in the sense that injuries, mobility issues, and health problems might prevent some people from participating in such activities.", "answer": 2}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAnd he says other people with high blood pressure should follow his lead.\nThe pill is his blood pressure medication.\nYou Might Want to Check Your Blood Pressure\n\nEvery day, Dr. Walter Koroshetz, 65, takes a pill as part of his effort to help keep his brain healthy and sharp.\nKoroshetz is using all of these approaches.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear in the story that blood pressure medications and lifestyle changes are readily available.", "answer": 1}, {"article": "\"It's a very important trial,\" added Dr. Angeles Alvarez Secord, associate professor of gynecologic oncology at Duke Comprehensive Cancer Center in Durham, N.C. \"I've been using [the IUD] clinically for several years now for this purpose in patients who desire future fertility and some patients who cannot undergo surgery or who are at high risk for surgical complications.\nThe IUD was removed at the end of the year if there was no evidence of cancer.\nAlthough the IUD is not yet approved to treat endometrial cancer, it is approved and widely used to treat endometriosis and abnormal uterine bleeding.\nOral hormone treatment to slow down the cancer's growth is a systemic therapy, however, and can have adverse side effects such as skin rashes, nausea and vomiting, headaches and abnormal uterine bleeding, according to background material accompanying the study.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The progestin IUD is clearly available.", "answer": 1}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nThe new study, in the Annals of Surgery, doesn\u2019t settle that question.\nWhen the appendix had burst, however, the open surgery racked up a considerably higher bill.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread use of laparascopic appendectomy was clear in the story.", "answer": 1}, {"article": "Details of the cases are documented in the paper \"Artemisia annua dried leaf tablets treated malaria resistant to ACT and i.v.\nLaboratory tests showed they had no parasites remaining in their blood.\nThis small but stunningly successful trial offers hope to address the growing problem of drug-resistant malaria.\nIn effect, the dried leaves constitute a robust natural combination therapy, one whose benefits far surpass those of ACT and other combination drugs.\nIn just five days, all 18 people fully recovered.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "These tablets are only available as part of experimental compassionate use. We think the release makes it clear they aren\u2019t widely available.\u00a0  ", "answer": 1}, {"article": "Then in 2002, the results of the largest randomized clinical trial of hormone replacement, the Women\u2019s Health Initiative (W.H.I.\nDr. Manson is distressed about the large number of women \u2014 about a third of those now on hormone replacement \u2014 who are relying on \u201ccustom-compounded\u201d products that have not been reviewed for safety and effectiveness by the Food and Drug Administration.\nstudy actually had nothing to do with menopausal symptoms.\n), created a kind of menopausal panic, prompting millions of middle-age women to stop or not start hormone treatments and doctors to not prescribe them.\nThere are also lots of products now available and different ways to use them that enhance the safety of hormone replacement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the therapies in the story are widely available, and the story establishes this with this sentence:\u00a0\u201cThere are also lots of products now available and different ways to use them that enhance the safety of hormone replacement.\u201d", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\nMore trials need to be done of this unique treatment, she added.\nThe study was published online Nov. 5 in the Journal of the American Medical Association, to coincide with a planned presentation at the American Heart Association's annual meeting in Los Angeles.\nThe 12-week, phase 2 clinical trial was conducted at 33 international sites and included adults who suffered muscle problems when taking statins, a class of cholesterol-lowering drugs that includes Crestor and Lipitor.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the drug is experimental.", "answer": 1}, {"article": "Two drugs once widely used to treat Parkinson's disease sharply increase the risk of heart-valve damage, researchers have found. The studies immediately prompted calls for the treatments to be discontinued or patients more closely monitored.\n\nPatients who take the drugs, pergolide or cabergoline, are four to seven times as likely to suffer damage to their heart valves as patients who don't take either one, according to two studies published in today's New England Journal of Medicine.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Wall Street Journal article provides accurate information about the availability and stormy history of two Parkinson\u2019s drugs that may increase the risk heart valve disease.", "answer": 1}, {"article": "Alzheimer's disease is the most common cause of dementia, and two out of three Alzheimer's cases are women.\nThe newest results were published recently in Neurology and Maturitas and the earlier results in the Journal of Alzheimer's disease.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nThe research data was from the MEDALZ (Medication use and Alzheimer's disease), OSTPRE (Kuopio Osteoporosis Risk Factor and Prevention Study) and CAIDE (Cardiovascular Risk Factors, Aging and Dementia) studies.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release presumes that people know that hormone replacement therapies are available. In this particular case, there has been so much negative news around hormone replacement therapies because of their linkage to cancer risks that it would have been worth noting that the therapies are available by prescription.", "answer": 0}, {"article": "The thought that you could lose your vision is very, very depressing,\" Daniel says.\n\"These symptoms were these wavy lines \u2014 and especially on the periphery of your vision,\" says macular generation patient Daniel Davison.\nThere's a catch: it's expensive \u2014 about $2,000 per injection \u2014 although Medicare and most insurance companies cover most of it.\nAnd patients may need to continue treatment.\nHe was diagnosed with wet macular degeneration, the most acute form, affecting 1.7 million Americans.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that Lucentis was recently approved by the FDA. The story should have been more clear that the approval was for neovascular, or \u201cwet\u201d, age-related macular degeneration (AMD) and not the more common \u201cdry\u201d form of AMD.", "answer": 1}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\nThey have filed a patent and hope to move forward with clinical trials that could lead to commercialization.\nCollaboration with Ping Wang, associate professor of Pathology and Laboratory Medicine at the University of Pennsylvania's Perelman School of Medicine, enabled the design and implementation of the key clinical validation study.\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the researchers \u201chope to move forward with clinical trials that could lead to commercialization.\u201d", "answer": 1}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was very clear about availability issues and about concerns over off-label use:\n\u201cdoctors who work with Alzheimer\u2019s patients say they expect patients and families to clamor for the drug. Many say they have been asked about Gammagard for years, and this latest positive result, however small, is likely to bring an increase.\nIn February, when results in mice were published suggesting that a skin-cancer drug, bexarotene, was beneficial for Alzheimer\u2019s, many patients started calling their doctors to find out more about the drug and whether they or a family member should use it off-label.\nA spokesman for Baxter said the company \u201cdoes not support the use of its therapies for unapproved indications. Further, it remains difficult to monitor the use of our IG products for Alzheimer\u2019s disease.\u201d\nDrugs must be approved by the Food and Drug Administration for specific uses, but doctors can prescribe them to patients for other purposes. With any off-label use, there are concerns about safety and efficacy. With Gammagard, there is an additional concern about supply.\nIVIG is costly and difficult to make. Baxter says it takes 130 plasma donations to make enough to treat one patient with primary immunodeficiency today. The amount varies based on patient weight and the disease.\n\u201cThe findings are highly promising but nevertheless a double-edged sword due to the limited supply,\u201d said P. Murali Doraiswamy, an Alzheimer\u2019s researcher at Duke University who wasn\u2019t involved in the study but previously served as an adviser to Baxter. \u201cThe growing off-label demand for Alzheimer\u2019s could threaten supply for immunodeficient patients.\u201d", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story says nearly half of all total joint surgeries are now being done with so-called \u201cminimally invasive\u201d approaches.", "answer": 1}, {"article": "According to the National Cancer Institute, about 32,050 men died from prostate cancer in 2010 and 217,000 new cases were diagnosed.\nThat\u2019s what the findings of two new studies published this week suggest.\nMen who took acetaminophen for less than five years saw no protective benefit.\n\u201cThe important point was the intensity of the activity,\u201d Erin Richman, a postdoctoral fellow at UCSF, said in a statement.\nThe patients\u2019 average age at diagnosis was 65.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 There\u2019s no question about the availability of the two \u201cinterventions\u201d \u2013 walking and acetaminophen.", "answer": 2}, {"article": "\"Wow!\"\nAnd the drug hasn't been submitted for review by the Food and Drug Administration, though Vertex expects to do that later this year.\nBut these results, even with plenty of caveats, suggest the drug is on the right track.\nThe experimental medicine, taken twice a day, goes by the code name VX-770.\nBut a key takeaway is that the medicine gets at a root cause of cystic fibrosis in some people rather than just relieving their symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that the drug is experimental, and that it hasn\u2019t even been put before the FDA for review yet.", "answer": 1}, {"article": "HIV infects the body by corrupting T cells that are mobilized by the immune system when the virus enters a person's body.\nThe article recently appeared in the Journal of Controlled Release.\nThe implant is composed of a hollow tube and two pliable arms to hold it in place.\n\"By delivering the medication exactly where it's needed, we hoped to increase the chances of inducing immune quiescence.\"\n\"What we don't know yet is if this can be a stand-alone option for preventing HIV transmission or if it might be best used in conjunction with other prevention strategies.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not made clear enough that this vaginal implant is experimental, in development, and has never been tested on humans and that it could be years \u2014 if ever \u2014 before the device is available.", "answer": 0}, {"article": "\u201cHe said, \u2018I don\u2019t want to spend my time doing this,\u2019 \u201d recalled his son, Dr. Gerald A. Hladik.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nHis doctors managed his heart disease and hypertension with drugs.\n\u201cDialysis may have prolonged his life, but I suspect only by a couple of months,\u201d Dr. Hladik said.\nHis father\u2019s eventful medical history included a serious stroke and coronary bypass surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story presents it as a given that dialysis, renal clinics and so on are common in the health system.", "answer": 1}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\nThe new findings add to other evidence showing that medical testing is on the rise across the U.S., although in many cases the impact on overall health remains unclear.\n\u201cRight now, it is a difficult place for the patient to be in,\u201d Wiener said.\nUsing national data, the researchers found the rate of so-called pulmonary embolisms, or PEs, nearly doubled with the introduction of a new powerful diagnostic test more than a decade ago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that chest CT scans are \u201cbeing used in millions of patients every year in the US.\u201d", "answer": 1}, {"article": "When it comes to health, I\u2019m skeptical of willpower. Sure, I talk to my students about personal responsibility, but when it comes to the health of populations, I look for big fixes more than for small acts of will.\n\nThat\u2019s why my ears perked up when I heard that two old physician friends had decided to start taking, as a preventive measure, some of the medications often included in what the field has dubbed the \u201cpolypill.\u201d My friends are both top doctors in their 60s, with good diet and lifestyle, and this is now part of their...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a confusing point for us\u2013the author mentions having two friends who appear to be self-medicating using several of the mentioned drugs, with the aim of preventing heart disease and diabetes. Then we\u2019re told that a similar\u00a0regimen could feasibly be rolled into a one-size-fits-all\u00a0\u201cpolypill\u201d for the general public, and the story speculates what that pill \u201cmight\u201d contain. \nThe story then adds, as an aside, that there is a less comprehensive \u201cpolypill\u201d available via online ordering, and provides a link to the site. \nIt\u2019s not clear if or when a more comprehensive polypill for the masses might become available.", "answer": 0}, {"article": "In people with osteoarthritis, the cartilage in a joint wears away in some areas.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C.\nNov. 12, 2012 -- A drug used outside the U.S. to treat osteoporosis may not only lessen the everyday pain associated with knee osteoarthritis, but may even slow down the progression of osteoarthritis, researchers say.\nNearly one in 100 people have evidence of knee osteoarthritis on an X-ray.\nThe function of cartilage is to reduce friction in the joints and serve as a \"shock absorber.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that strontium ranelate\u00a0is available as a prescription drug for osteoporosis in some other countries, but is not approved in the U.S.\u00a0It explains that other strontium formulations\u00a0are available as nutritional supplements in the U.S., but that these might not work the same way that the strontium drug tested in the study works.", "answer": 1}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\nThe game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nImportantly, the patients also said they enjoyed the game and were motivated to play it across the eight hours of cognitive training.\nScientists at Cambridge University said tests on a small number of patients who played the game over four weeks found they had improvements in memory and learning.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t tell readers whether the game, called \u201cWizard,\u201d is currently available for iPad users. This is particularly problematic, because searching for an iPad game called Wizard returns a number of options. Are any of those options the correct game? What is the current stage of availability?", "answer": 0}, {"article": "AURORA, Colo. (Nov. 16, 2016) - Researchers at the University of Colorado Anschutz Medical Campus have found that high doses of vitamin D reduce the incidence of acute respiratory illness (ARI) in older, long-term care residents.\nThose with higher doses saw ARIs cut nearly in half.\nBut vitamin D seems able to potentially prevent these infections.\"\nThe findings of the clinical trial, published today in the Journal of the American Geriatrics Society, could help reduce one of the leading causes of serious illness, debilitation and death among patients in nursing homes and other long-term care facilities.\nThey also had over double the incidence of falls, the study said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of availability, but it\u2019s generally understood that vitamin D is widely available.", "answer": 2}, {"article": "\u201cBut it\u2019s piecemeal,\u201d she said.\nIt includes the options any oncologist addresses: surgery, chemotherapy and radiation and their side effects.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\nBut the National Institutes of Health is under budget pressure, and the other major source of money for medical research, the pharmaceutical industry, has little incentive to study palliative care.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Mixed bag here. The Times noted that Medicare pays for some palliative care services but that billing difficulties may deter physicians from offering\u00a0it.\u00a0However, there was no mention of the difficulty patients may have accessing\u00a0the type of outpatient palliative care services that were offered in this study. Most non-hospice palliative care is currently provided only in the inpatient / acute care hospital setting. A borderline\u00a0satisfactory.", "answer": 1}, {"article": "Those with the BRCA1 mutation also have a 36 to 63 percent higher risk of ovarian cancer and those with the BRCA2 mutation have a 10 to 27 percent higher risk of ovarian cancer.\nShe said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n\u201cMost of these women will die of ovarian cancer, so you can save 20 percent of them with the prophylactic surgery,\u201d Kaklamani said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention that the type and quality of genetic testing, genetic counseling, surgery and surveillance offered to women in this study may not be available to women in other settings.", "answer": 0}, {"article": "The researchers hypothesize that the antidepressant effects of diclofenac and minocycline may be due, at least in part, to their abilities to reduce inflammation.\nThe research team focused on patients in the database who received ketamine, narrowing their study population down to approximately 41,000.\n\"This study extends small-scale clinical evidence that ketamine can be used to alleviate depression, and provides needed solid statistical support for wider clinical applications and possibly larger scale clinical trials.\"\nThe study, published May 3 in Scientific Reports, also uncovered antidepressant effects for three other drugs typically used for other purposes -- Botox, the pain reliever diclofenac and the antibiotic minocycline.\nBut ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address availability or how many physicians currently prescribe ketamine for depression.", "answer": 0}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story refers to the growing use of cognitive rest.", "answer": 1}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nNobody looks forward to having a cavity drilled and filled by a dentist.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the use of SDF is not widespread in the U.S., but that it is becoming increasingly available.", "answer": 1}, {"article": "Vasopressin, an anti-diuretic, reduces urine production.\nThere's more on nocturia at the National Association for Continence.\nBut help could soon be at hand in the form of a nasal spray, new research suggests.\nA spritz of a synthetic hormone, already used by bed-wetting kids, might benefit older people struggling with the problem called nocturia.\nIn the United States there's no approved drug to treat the problem, the study authors said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that it\u2019s not FDA approved yet.", "answer": 1}, {"article": "But those who ate vegetable forms of protein, such as soy, and fat, such as olive oil, did reduce their risk of heart disease.\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\n\"This is a study that shows what happens if you bought the book and tried to follow\" the diets, as most dieters do.\nAll the participants reported eating about 2,000 calories a day when the study began.\n\"For all practical purposes, the programs all worked about the same,\" said Kelly D. Brownell, director of Yale University's Rudd Center for Food Policy and Obesity and creator of the Lifestyle, Exercise, Attitudes, Relationships and Nutrition (LEARN) program for weight management, one of the diets studied.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a study that compared weight loss of overweight and obese individuals who followed one of four popular weight loss diets.\u00a0 The story mentioned that the people in the study were given a book on the diet that they were assigned to follow and\u00a0the books used are available commerically.\u00a0 It would have been helpful to readers to include explicit details on the specific books used.", "answer": 1}, {"article": "The 1,788 who continued statins up to the day of surgery had a risk of death within 30 days of 1.7 percent, compared with 2.9 percent for 452 who stopped one to three days before surgery, and 3.8 percent for 781 who did not take statins or stopped more than 72 hours before their operations.\nThe scientists had no data on how long patients had been taking statins, but only on when they stopped.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no mention of whether statins are widely available, available by prescription only, etc. We might presume that everyone knows how popular statins are and how widely prescribed, but we always think it\u2019s a good idea to make it clear how someone would gain access to a particular therapy.\nA simple line saying something to the effect of \u201cthese medicines have been around for many years, are widely used and available in inexpensive generic formulations\u201d would have addressed this.", "answer": 0}, {"article": "That number was the same in younger people who had large waistlines, and even lower in those with metabolic syndrome, a combination of risk factors including belly fat, high blood pressure and high blood sugar.\nColonoscopy, used in millions of Americans every year, is just one of many methods to detect abnormalities.\n\u201cIt may be reasonable to offer colonoscopic screening to these individuals,\u201d Dr.\nSung Noh Hong and colleagues write in the journal Gastrointestinal Endoscopy.\nOne gastroenterologist said the results were \u201cimportant\u201d but should not change practice.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly colon cancer screening is available.", "answer": 1}, {"article": "\u201cIt\u2019s a survival thing,\u201d she said.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\nFor other women, a double mastectomy might eliminate another breast cancer, but it won\u2019t stop cancer from resurfacing in vital organs, Tuttle said.\nU researchers confirmed the trend using federal cancer data but could only speculate why.\nResearch has found this procedure is equally effective, particularly with smaller tumors and often when used in combination with radiation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article implies, accurately, that double mastectomy is available at any facility that provides breast cancer treatment. ", "answer": 1}, {"article": "\u201cWe\u2019ve seen individuals who have lost significant amounts of weight in the six-month period.\nZafgen has not identified the patients who died or said at which of 14 US trial sites they were taking the drug.\nSome analysts have suggested the FDA might approve the drug, despite the adverse events, if Zafgen can prove its benefits outweigh its risks to some patients.\nWhile the FDA\u2019s clinical hold prevented Zafgen from completing its trial, Dennis D. Kim, the company\u2019s chief medical officer, said it was largely finished.\nBut he conceded that Zafgen, which had once hoped to begin selling its drug candidate, Beloranib, as early as 2016, will have to conduct at least one additional study before it can apply for FDA approval.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made clear that the beloranib drug is still under experimentation and pending FDA approval.", "answer": 1}, {"article": "Seizures can be obvious, causing unconsciousness or convulsions, but often they trigger subtler changes in a person's perceptions or behavior -- like a short staring spell, confusion or an altered sense of taste or smell.\n\"We just wanted to see if this is feasible, and this study shows that it is,\" said lead researcher Dr. Mark Cook, of the University of Melbourne and St. Vincent's Hospital in Australia.\nIt may be the people who fall in the middle -- who have disabling seizures at unpredictable intervals -- who would stand to benefit the most, he said.\nBut what's still needed is evidence that this device does improve the quality of patients' lives, Mehta said.\nAnd you need to see which groups of patients might be good candidates for this.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about how far away from marketing approval such an approach might be.\u00a0 But we\u2019ll call it satisfactory for at least including this from the independent expert quoted:\n\u201cThis study is an important first step,\u201d said Mehta, who was not involved in the research. \u201cThe next step would be to implant these in a larger sample of patients. And you need to see which groups of patients might be good candidates for this.\u201d", "answer": 1}, {"article": "Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nFewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.\nSix months later, \u201cformer smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers,\u201d the researchers said.\n\u201cInterestingly, current smokers did not show any significant improvements,\u201d they added.\nThe patients who got Tarceva lived a little longer without their tumors growing \u2014 12 weeks versus 11 weeks on average and they lived a month longer on average \u2014 12 months versus 11 months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story gets a marginal satisfactory. In the first half, we\u2019re told of inhaled iloprost\u2019s availability for certain indications, which don\u2019t include the prevention of lung cancer. It could have been a lot clearer that the oral formulation is not currently available to patients; right now, we can only tell that by inference given the indications and brands mentioned for inhaled and IV formulations are mentioned.\nIn the second half, we\u2019re told that erlotinib is currently sold as Tarceva. It would have been good to note its indications, which were expanded in April to cover the approach used in this study because of the results of the study.", "answer": 1}, {"article": "What she found: The mice with the higher levels of omega 3 fatty acids seemed to have more precursors to egg cells than control mice with lower levels of the fat, meaning they had a larger reserve of eggs-to-be.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\nThere may also be other benefits linked to omega 3 fatty acids for the fetus as well, in helping nerve development \u2014 that\u2019s why many prenatal vitamins include forms of omega 3 fats.\nNow, according to scientists at the University of Colorado, there is even evidence that the healthy fat can boost your chances of getting pregnant.\n(Some people who are predisposed to bleeding problems may be at higher risk of hemorrhages with high doses of omega 3s, but those cases are relatively rare.)\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both omega 3-rich foods and omega 3 supplements are widely available.", "answer": 1}, {"article": "While Drs.\nThe present analysis was not supported by industry funding.\nThe FAME 2 trial was supported by St. Jude Medical.\nThe trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up.\n\"Our trial over its entire follow-up shows us that the longer you observe these patients, the more pronounced the benefits of the initial PCI become,\" said Dr. J\u00fcni, who is also a Canada Research Chair and a Professor of Medicine at the University of Toronto.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s apparent that PCI is widely available and that there is debate about when to use it.", "answer": 1}, {"article": "About one of every five breast cancers involves cancer cells that churn out an excess of HER2 due to a genetic mutation.\nThe science is early, Hale stressed, and it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\nThe goal of the vaccine, Hale said, is to educate the body to respond to that HER2-based peptide, so it will recognize the cancer when it recurs and attack it.\nNumerous vaccines to prevent breast cancer recurrence are currently under study, he noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated \u201d it will take at least five years before the vaccine could conceivably be available if ongoing studies bear out.\u201d", "answer": 1}, {"article": "Who and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nEvery article is free online from the day of publication.\nTo Learn More: The full study is available on the For The Media website.\nWhy The Research Is Interesting: Patients with DCIS are often treated with radiation after lumpectomy, although it has remained unclear whether this can reduce the risk of dying from breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that radiation and surgery are widely available treatments.", "answer": 2}, {"article": "He drank to forget.\n\u201cThe MDMA seems to act as a catalyst that allows the healing to happen.\u201d\n\nWhat do patients say about it?\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nThe current protocol calls for patients to take MDMA two or three times, each a month apart, interspersed with psychotherapy.\nI realized I had viewed myself as a monster, and I was able to start to have some compassion for myself.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that MDMA \u201cis about to enter larger Phase III trials,\u201d the FDA has granted pharmaceutical grade MDMA breakthrough therapy status, and that illegal sources exist but are potentially dangerous.\nIt\u2019s also mentioned that there have already been several other small-scale studies of the drug, and that if MDMA is eventually approved by the FDA it will only be administered by a licensed therapist.\nWe did have one quibble\u2013the story predicts that, if larger studies go well, the drug could be approved for this use \u201cby 2021.\u201d In reality, there\u2019s really no way of knowing what year a drug will get approved.", "answer": 1}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nThe new guidelines help clarify what used to be a gray area, Andrews explained.\nDoctors need to weigh the risks and benefits, Edge added.\nThe older woman, because her risk is lower, should have a discussion with her doctor to decide if the benefit outweighs the risk, Edge noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address availability. However, since it is referring to an existing form of therapy that is widely used, we\u2019ll rate this as not applicable.", "answer": 2}, {"article": "\u201cWe really don\u2019t have interventions for colds that work.\u201d\n\nThe review of 15 studies with 1,360 participants was published by the Cochrane group, an international collaboration of researchers that reviews evidence behind therapeutic interventions.\nFeb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not make it clear where zinc treatments are available. One could assume that most readers would know, but we think the Reuters Health story did a better job here by actually pointing out that zinc lozenges are sold in most drug stores and even adding the important detail that a specific zinc nasal spray, Zicam, was removed from the market.\u00a0To its credit however, the story does emphasize that additional research is needed to identify the right zinc preparation and dose.", "answer": 0}, {"article": "March 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\nResearchers say metabolic abnormalities that eventually lead to type 2 diabetes can be present years before diabetes is diagnosed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article says that further studies will be needed. It would have been useful to state that any clinically available screening test would be years off. The article doesn\u2019t give readers a sense of how far away this hypothetical test is from practice. Are the tools even being used in blood labs, or is this all being done purely in a research setting?", "answer": 1}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nNonetheless, the new study is \u201cvery credible,\u201d said Dr. Barnett Kramer, associate director for disease prevention at the .\n\u201cIt shows the relative impacts of screening versus therapy in an era in which therapy has been improving.\u201d\n\nDr. Otis Brawley of the said in a statement that the investigators used \u201ccareful methodology.\u201d The society, Dr. Brawley said, \u201cbelieves that the total body of the science supports the fact that regular mammography is an important part of a woman\u2019s .\u201d\n\nDr. Carol Lee, a radiologist at and chairwoman of the breast imaging commission of the American College of Radiology, said the new study affirmed that mammography saves lives.\n\u201cWe were surprised,\u201d said Dr. Mette Kalager, the lead author of the paper who is a breast surgeon at University and a visiting scientist at the Harvard School of Public Health.\n\u201cMortality from breast cancer is decreasing, and I have to believe that screening mammography has played a part,\u201d Dr. Lee said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe availability of mammography screening is not at issue. This story does point out that the women who were screened in Norway had access to special treatment teams. And it noted that these treatments are available at \u201cmany major medical centers in the United States.\u201d", "answer": 1}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe findings were published online March 7 in Acupuncture in Medicine.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThe U.S. National Women's Health Information Center has more about treating menopause symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a story about a Turkish study (not explained in the story) on Chinese acupuncture.\u00a0 If a woman doesn\u2019t know anything about acupuncture, this story told her nothing about its availability in the U.S.", "answer": 0}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\n\u201cThis new approach is a more reliable imaging technique for localizing tumors.\nThe technique is also valuable in surgical planning and image staging, said David S. Karow, MD, PhD, assistant professor of radiology at UC San Diego and the study\u2019s corresponding author.\nWhen compared to surrounding healthy tissues, it\u2019s hoped that contrast enhanced MRIs will reveal the shape and nature of any tumors present.\n\u201cProstate cancer can often be an indolent disease, where a patient may only require surveillance rather than aggressive surgery,\u201d noted co-author Christopher J. Kane, MD, professor of urology at UC San Diego.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release when or whether this technology might become available, if it\u2019s not available already.", "answer": 0}, {"article": "The Department of Nutrition, Exercise and Sports conducts research, education, innovation, and dissemination of information in nutrition, human physiology and sports at the highest international level, and incorporates the humanities as well as health and social sciences.\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nWhile we are looking into other biomarkers, it is quite amazing how much more we can do for our patients just by using those two simple biomarkers.\nThese diets could also be effective independent of caloric restriction.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The two biomarkers are said to be a simple alternative to other means of customizing dietary plans for persons with pre-diabetes or type 2 diabetes.\nHow do you know what kind of diet you\u2019re supposed to eat based on your biomarker profile? Presumably you\u2019re prescribed a diet and told what to eat. But if you\u2019re a consumer, how do you know what that diet is? In other words, how do you benefit from this? Is someone selling personalized nutrition recommendations based on these biomarkers? ", "answer": 0}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\nIn the trial, severe side-effects caused by the combination were rare.\nIt causes less severe side-effects than traditional chemotherapy.\nThe combination allowed many women with metastatic hormone-receptor-positive, HER2-negative cancer to delay the start of chemotherapy, which is the traditional treatment option in these patients once hormone drugs have stopped working.\nThe combination - of a first-in-class targeted drug called palbociclib, and the hormone drug fulvestrant - slowed cancer growth in around two thirds of women with advanced forms of the most common type of breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t say whether fulvestrant and palbociclib are available or FDA approved.", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nOf that group, 85 percent had small tumors that had not spread.\nUltimately, 535 were biopsied to see if they were lung cancer -- and 484 were.\nBut while the research clearly shows that the interval between diagnosis and death was longer in screened patients, it does not definitively show they lived longer -- a subtle difference with significant public health consequences.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not discuss if the lung cancer screenings are available, or how widely available the screening scanners may be. The story should have mentioned that the tests are being advertised by private\u00a0screening centers and some hospitals, but are not generally covered by insurance.", "answer": 0}, {"article": "In the current review, researchers found several trials that compared different doses of radiation and different types of radiation therapy, including external beam radiation therapy, in which a radiation is delivered through a beam through the skin, or brachytherapy, in which radioactive isotopes are delivered via injection into the prostate.\n\"Some of the distinctions being made are not really supported by the evidence.\"\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nIn part, that's because researchers found no randomized controlled trials -- considered the gold standard of research -- that compared radiation therapy with watching waiting, Ip said.\nFinally, patients and their doctors should weight the potential debilitating side effects of the treatments, such as incontinence and erectile dysfunction, against how comfortable the man is with holding off on treatment, experts say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The story didn\u2019t explicitly address the availability of radiation facilities, but that wasn\u2019t necessary.", "answer": 2}, {"article": "\"It affects your whole life.\"\nThe new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nFor Linda O'Brien, a grandmother and scratch golfer, chronic knee pain was making life unbearable.\nHelp for O'Brien finally arrived in a new kind of knee surgery, developed and perfected at Chicago's Rush University Medical Center by Dr. Richard Berger.\nTraditional knee surgery cuts through muscles and tendons.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story did not include discussion about availability of this treatment or whether it was an FDA approved medical device. According to the company website, in 2004 there were more than 500 orthopedic surgeons trained in the use of this device. So it\u2019s availability is limited. There was no mention that this particular type of knee replacement was not an option for all patients who were candidates for standard total knee replacement. Factors that may rule out some patients include variation in knee structure, prior surgery on the same knee, obesity, a recent history of deep vein thrombosis (DVT), and other unstable medical conditions. ", "answer": 0}, {"article": "\"To create the jet, you have to instantaneously create 100 times more pressure than you've got in the tire of a car,\" he says.\nAnquetil notes that the older devices sometimes made patients feel as if they had been punched.\nGomaa's hope is that vaccine patches will cost less than vaccinations do now.\nBeyond The Nasty Needle: Trying To Make Vaccines More Comfy And Convenient\n\nNews this summer of a flu vaccine patch sparked a lot of chatter.\n\"It feels like somebody snapped me with a rubber band,\" he says, adding that the injection happens too fast for some patients to register any sensation at all.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Overall, this story adequately addresses availability. It\u00a0explains that flu patches aren\u2019t yet available on the market; it may be some time until readers can walk down to the corner pharmacy and buy their own flu patch over the counter. The jet injection and nasal spray are described as already widely available.", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes a link to the Spire web site. It\u2019s clear that the device can be purchased.", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u201ds clear that \u201cThe Baseball Diet\u201d materials are for sale now. A link to the product web site is included.", "answer": 1}, {"article": "Since IVM results in lower fertilization rates, protocols that use IVM are more likely to also use intracytoplasmic sperm injection (ICSI), in which one sperm is injected into one egg.\nWhat are the limitations of IVM?\nAlthough ICSI is safe and effective, the bigger concern is if a patient going through IVM doesn\u2019t use ICSI, Shastri said.\n\u201cUltimately, you want to do the best for the patient so my preference would not be IVM.\u201d\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article really could have used some information about how widely available assisted reproductive medical expertise is in the U.S. and the fact that academic medical center, and major public hospitals and health systems, also offer the treatments along with free standing fertility clinics.", "answer": 0}, {"article": "HIV, which stands for human immunodeficiency virus, infects and can destroy or change the functions of immune cells that defend the body.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\n\u201cThe patients who didn\u2019t smoke marijuana had a very high level of inflammatory cells compared to those who did use,\u201d Kaminski said.\nHis lab was the first to identify the proteins that can bind marijuana compounds on the surface of immune cells.\nNewswise \u2014 EAST LANSING, Mich. \u2014 A chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Given that marijuana is still illegal in most states and considered illegal by the federal government, it would be worth mentioning that patients hoping to receive a marijuana treatment would have to live in a state where it is legal for medicinal purposes.", "answer": 0}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The column says that one of the products mentioned is available at many drugstores.\u00a0 There isn\u2019t any comment on availability of the other product mentioned.\u00a0 We\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "For example, before adjusting for these kinds of differences between the groups, the researchers found that light drinking was connected with 33% lower rates of overall behavior problems in boys \u2014 after the adjustment, that effect fell to 23%.\nEven More Evidence for the Health Benefits of Drinking\n\nPhotos: What Booze Looks like Under a Microscope\n(More on Time.com: 5 Pregnancy Taboos Explained (or Debunked))\n\nBut this does *not* mean that light drinking in pregnancy is good for your baby.\nWhatever the case, American health authorities remain united in their advice that no amount of alcohol is safe for the fetus during pregnancy \u2014 and anyone who is familiar with fetal alcohol syndrome knows why.\nThe research included 11,513 children participating in a large U.K. study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This does not seem to apply here.", "answer": 2}, {"article": "Their results are published in Annals of Internal Medicine.\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\n\u201cIn a population like the U.S. where selenium levels are adequate, there\u2019s no reason to take extra selenium in supplements.\u201d\n\nThe question of the link between selenium and health outcomes, Guallar said, \u201cis a very interesting story that\u2019s still developing.\u201d\nResearchers measured participants\u2019 cholesterol levels at the beginning of the study and after six months on the selenium supplements or placebo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses food sources of selenium and notes that the mineral is sold\u00a0as a supplement, so availability is not an issue.The story could have mentioned that selenium is pretty uniformly a component of multivitamin formulations. Individuals adding a selenium-specific supplement to a multivitamin could easily exceed the levels used in this study.", "answer": 1}, {"article": "DURHAM, N.C. - Most high-risk lung cancer patients might not need annual low-dose computed tomography (LDCT) screenings if they are cleared of disease in their initial test, according to a study led by a Duke Cancer Institute researcher.\nHe added that improving the accuracy of LDCT screening for lung cancer would also significantly reduce the number of annual screens.\n\"This has significant public policy implications,\" said Edward F. Patz, Jr., M.D., the James and Alice Chen Professor of Radiology at Duke and lead author of a study published online March 21, 2016 in The Lancet Oncology journal.\n\"Our analysis suggests that annual screens may not be warranted for patients who have had an initial negative scan, and future risk prediction and cost-effectiveness models could incorporate these data to improve screening guidelines,\" Patz said.\nAn additional 75 patients (0.4 percent of the initial negative group) were diagnosed with lung cancer between the first and second annual screening.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t specify where low-dose CT is used and if most readers can access it. We do know that the screen has been approved for use in the United States and is being adopted by some health centers.", "answer": 0}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that BRCA testing is available to women who want it.", "answer": 1}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nSo they're doing a lot of the work of managing their conditions.\nFor many of these people, says Brooks, animals can break through the isolation.\nThey give affection without needing to understand the disorder.\nTwenty-five of them considered their pets to be a part of their social network.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re going to act under the assumption that readers are familiar with the idea of pet ownership.", "answer": 2}, {"article": "Fewer than 1 percent of people have cluster headaches and most have a form called episodic cluster headaches, which come and go, as the name suggests, in clusters.\n\u201cIt is a way for patients to treat their symptoms as often as they need to use the device.\n\u201cGammaCore transmits a mild electrical stimulation to the vagus nerve through the skin, resulting in a reduction of pain,\u201d the company said in a statement.\nThe device is a vagus nerve stimulator and it\u2019s not entirely clear how it works.\nRelated: New Migraine Drugs Would Treat Pain Before it Starts\n\nSilberstein helped test the device, which users press against the neck.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that the product is available in the EU and that the company will begin selling it in the U.S. later in 2017.", "answer": 1}, {"article": "Recipients were at most seven years older or younger than the donors.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nIn an average follow-up of five years, they found that the rate of unusable donor kidneys and the long-term outcomes of recipients varied little among the first three age groups \u2014 around 18 percent of the organs had to be discarded, and the five-year survival was about 88 percent\nOld age is not necessarily a barrier to kidney donation.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Given that this study ran in a U.S. publication, we wanted to know what the guiding rules are on age of donors, in case they differ from what is standard in Italy. If older donors can donate in the U.S. already, then this study isn\u2019t very newsworthy, for example.", "answer": 0}, {"article": "Gestational diabetes increases the mother\u2019s chances for high blood pressure disorders of pregnancy and the need for cesarean delivery, and the risk for cardiovascular disease and type 2 diabetes later in life.\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nThe authors noted that further studies are needed to confirm whether measuring HbA1c levels in early pregnancy could determine a woman\u2019s later risk for gestational diabetes.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this test is far from ready for use in clinical screening. It states:\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.", "answer": 1}, {"article": "Vegetables particularly high in alpha-carotene include yellow-orange vegetables, such as carrots, sweet potatoes, pumpkin, and winter squash, and dark green vegetables, such as broccoli, green beans, green peas, spinach, turnip greens, collards, and lettuce.\nThe study shows that eating foods rich in antioxidants, like vegetables and fruits, fights disease and may prolong life.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\nNov. 22, 2010 -- Eat your veggies and you may live longer, a study suggests.\n\"These findings support increasing fruit and vegetable consumption as a means of preventing premature death,\" write researcher Chaoyang Li, MD, PhD, of the CDC and colleagues in the Archives of Internal Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story lists a number of common foods that contain relatively high levels of alpha-carotene.", "answer": 1}, {"article": "Some parents and even pediatricians believe elderberry extract or syrup can help kids stay healthy and lessen the symptoms when they do get sick.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\nBefore you start popping elderberries, beware: eating them raw can make you sick.\nBut Kevin Brennan says, for his family, the natural alternative seems to be working.\nAn ancient herbal remedy is getting fresh attention this cold and flu season.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It seems clear from the story that elderberry extract is readily available.", "answer": 1}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says \u201cMerck is expecting the FDA to approve Januvia by mid-October. The company has also submitted an application for a single tablet combination of Januvia and metformin, known as MK-0431a. The FDA is expected to make a decision on that drug by the end of March 2007.\u201d On the first statement, the story should not simply take the word of Merck on the date of \u2013 or the certainty of \u2013 expected FDA approval. And on the second statement, the story doesn\u2019t say who expects the FDA approval of the second drug. Who said that? Who\u2019s the source? ", "answer": 0}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.\nWe think it could be used to make clinical decisions about whether a PARP-inhibitor is working within as little as four to eight weeks of starting therapy.\nHe said: \u201cBlood tests for cancer promise to be truly revolutionary.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not help readers understand whether this blood test is available now\u2013or if not, when it might become available for wider, non-research use.\n\u00a0", "answer": 0}, {"article": "As with each of our next generation OTC drug products, we intend to license HSRx 2121 to a leading marketing entity that has the resources and expertise to maximize sales, here and abroad,\" Parise said.\nInformation is available at \u200eHSRxGroup.com.\nThe HSRx product demonstrated superior treatment performance throughout the entire clinical study.\nEach product is subjected to independently conducted clinical trials against a current market-leading product to demonstrate its ability to deliver superior treatment outcomes with reduced side effects.\nHSRx out-licenses or joint-ventures its products with select marketing brands.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t state if the product is available now or when it might become available.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss if women can get this test \u2014 a vital piece of information for those with a high risk of endometrial or ovarian cancers. While individual parts of the PapSeek test are FDA-approved, e.g. Pap smears and Tao brushes, the PapSeek genetic analysis does not yet appear to be approved (though approval criteria for medical devices are not as strict as they are for medications).\nAlso, there\u2019s been a reduction in frequency of Pap testing in recent years. It\u2019d be good to have a discussion of how implementing a new screening test in this environment muddies a message that\u2019s already been disseminating about how frequently women should be getting pelvic exams and Pap smears (i.e., less often, with some stopping altogether after a certain age). How would a test like this have to work upstream to be reincorporated into gynecological screening?", "answer": 0}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nAnd even then, success rates aren't high; they're effective only 20 to 30 percent of the time.\nThat meant Sheiner stopped breathing for at least 10 seconds about two times every minute.\nSheiner is one of only about a half-dozen patients to have this robotic surgery for apnea.\nNoninvasive measures are always the first lines of defense, she says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not totally clear on this point.\u00a0 The story states this one doctor has done the robotic surgery on only six patients. But it\u2019s not clear if she\u2019s the only one who\u2019s done this surgery.\u00a0 And if not, where else and how often?", "answer": 0}, {"article": "After five years, 74 percent of the angioplasty group and 72 percent of the medication group were free of chest pain \u2014 \"no significant difference,\" Boden said.\nHe led the study and gave results Monday at a meeting of the American College of Cardiology.\nNeither treatment proved better for any subgroups like smokers, diabetics, or older or sicker people.\nIt involved 2,287 patients throughout the U.S. and Canada who had substantial blockages, typically in two arteries, but were medically stable.\nAn even bigger surprise: Angioplasty gave only slight and temporary relief from chest pain, the main reason it is done.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a comparison of treatments for coronary artery disease that are used widely and described them as such.", "answer": 1}, {"article": "Whole plasma must be matched to blood type.\nThe study is a very long way from showing that.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nThe work made headlines and launched a company, Alkahest, that\u2019s working to develop young human plasma into treatments for aging-related diseases.\nAnd they got a tiny hint that they just may help.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that the small \u201cproof of concept trial\u201d is just the beginning, and that the company \u201cplans to move forward with formal clinical trials in 40 volunteers next year.\u201d That presumably would be just a phase one trial to show safety so readers should know that any working product would be years away, at the least (and if ever).", "answer": 1}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nUntil now, there has been little research into its activity.\nThe researchers tested the therapy in a small group of patients with Addison's disease.\nThe therapy could help people with conditions such as Addison's disease and congenital adrenal hyperplasia, who need steroid treatment to avoid the risk of potentially fatal illness during physical stress.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The research article is clear that corticosterone is available only for research purposes at this time, but the release is not specific about that, instead employing phrases such as \u201cAn improved therapy\u2026is a step closer\u201d) that suggest unavailability but also encourage the reader to conclude that the treatment is just around the corner.", "answer": 0}, {"article": "\"We're basically waiting until their red light goes on.\nWomen are typically tested some time in their teens for anemia -- the severe form of iron deficiency -- using a quick and affordable hemoglobin test.\nAs part of the survey, female participants had blood testing for iron deficiency as well as hemoglobin testing to identify anemia.\nTaken together, the studies suggest that risk factors and assessments should not be used to determine which young women should receive testing for iron deficiency.\nThis test should be given with hemoglobin testing to catch all young women on the spectrum of iron deficiency, Sekhar said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that low-cost hemoglobin tests are affordable and given to most young women, but that more sensitive tests that screen for iron deficiency are more costly and thus \u201cdifficult to obtain in the doctor\u2019s office.\u201d", "answer": 1}, {"article": "Gluck et al.\nMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nThe findings suggest a possible intervention for obesity, when combined with healthy eating and exercise.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "A brief comment that this is not expected to be available anytime soon would have been helpful to readers. However, the release does say that \u201cMore study is needed to confirm the safety and effectiveness of tDCS for weight loss.\u201d While it\u2019s a close call, we think most readers can gather from this that the technique isn\u2019t likely to be available soon.", "answer": 1}, {"article": "The two-year survival rate of patients treated with both drugs in combination is 69 percent.\n\"The response rate is better than we've seen for other potential second-line treatments and nivolumab is really well-tolerated, which is important because bladder cancer patients are a fragile group after frontline treatment with platinum chemotherapy,\" said Padmanee Sharma, M.D., Ph.D., professor of Genitourinary Medical Oncology at MD Anderson.\n\"We can get good results without choosing to treat patients based on PD-L1 status,\" said Sharma, who also is scientific director of MD Anderson's immunotherapy platform and an investigator with the Parker Institute for Cancer Immunotherapy at MD Anderson.\nThe study found no significant difference in response rates between those with little to no PD-L1 on their tumors (26 percent) and those with greater PD-L1 expression (24 percent).\nUntil May 18, there were no drugs approved for second-line treatment of metastatic bladder cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The main reason that this is not satisfactory is that it is pretty confusing for non-expert readers. Nivolumab has not been approved by the FDA for use in treating metastatic bladder cancer. However, the release tells readers that nivolumab has been approved by the FDA for use in treating a variety of other cancers \u2014 and goes on to discuss survival rates for patients who take the drug (alone or in combination with ipilimumab). What does the FDA approval for treating other cancers have to do with the likelihood of nivolumab\u2019s future availability for treating bladder cancer? That\u2019s not clear, because the release doesn\u2019t tell us.", "answer": 0}, {"article": "And Americans repeatedly have demonstrated a willingness to shell out money for aesthetic treatments intended to improve their appearance, if not their overall health.\nThat said, the agency warned Wednesday that the new drug can cause serious side effects, including trouble swallowing or nerve damage to the jaw that can result in an uneven smile or muscle weakness in the face.\nPatients can receive as many as 50 injections of the drug in a single treatment, the agency said, with up to six treatments administered no less than a month apart.\nA Kythera representative said Wednesday that the new treatment likely won't be available until June, as it must train doctors to administer Kybella, and that the company would not have more details about the potential cost of the drug until after its launch.\nKeith Leonard, chief executive of Kythera, the California-based firm that developed Kybella, said at a conference last month that he believes the new treatment \"can drive a very large market and leave very satisfied patients.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the drug will probably not be available before June.", "answer": 1}, {"article": "Medtronic Inc. and Eli Lilly & Co. agreed to collaborate on an early stage research project for a potential Parkinson's-disease treatment that involves delivering medication directly to the brain\u2014a goal that has long eluded drug makers.\n\nThe pact, announced Tuesday, adds to Medtronic's roster of projects aimed at using implantable drug pumps and catheters to circumvent the blood-brain barrier. The tightly packed network of cells in brain capillaries only lets certain substances through, such as key nutrients, making brain-based...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the effort \u201cis still many years from yielding a marketable treatment or even starting human testing\u2026The drug may not enter human clinical trials for up to five years.\u201d", "answer": 1}, {"article": "\u201cRemember this day.\nU.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24.\nAn editorial in the New England Journal of Medicine, where the Merck monotherapy results were published, said Keytruda could become \u201ca new standard of care\u201d.\nLead researcher Martin Reck of Germany\u2019s Lung Clinic Grosshansdorf predicted that testing for the PD-L1 biomarker would now become standard \u201cfrom today\u201d.\nRoger Perlmutter, Merck\u2019s head of research, said both trials suggested Keytruda could offer a broad array of patients meaningful improvement over standard platinum-based chemotherapy, which is now more than two decades old.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says:\n\u201cU.S. regulators are expected to decide whether to approve Keytruda for first-line non-small cell lung cancer, the most common type, by Dec. 24.\u201d\nBut it doesn\u2019t explain how that\u2019s different from it\u2019s already approved use for advanced non-small cell lung cancer.", "answer": 0}, {"article": "Absorb also will compete with Medtronic Plc\u2019s traditional drug-coated Resolute stent and Boston Scientific Corp\u2019s Synergy and Promus stents.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\nAbsorb will be priced at a \u201cmodest\u201d premium to Xience, he said.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\nAbsorb\u2019s appeal is that it allows the blood vessel to return to a natural state, free from a permanent metal implant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Abbott Labs plans to make the stent available to some 100 hospitals in the near future, in order to train surgeons in its use, before \u201cramping up sales.\u201d This was information that we wished had been in the Associated Press story on the topic, which we also reviewed.", "answer": 1}, {"article": "In skin testing, a practitioner makes rows of pricks on a patient\u2019s back or forearm so allergen-containing extracts can seep into the skin.\nDr. Mitchell, the Manhattan allergist, called that approach promising.\n\u201cAbsolutely.\u201d\n\nSome allergists have made the switch to blood testing \u2014 especially in the area of food allergies, where blood testing is replacing the so-called food challenge test, a two- to six-hour procedure in which patients are given increasing amounts of suspect foods like egg or milk to determine whether they will have an allergic reaction.\nThe quick turnaround allows doctors to offer a diagnosis and immediate advice.\nFor that reason, he and other experts say, most sufferers never even see an allergist.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does say that the test is available and comments that its use is limited in the U.S.", "answer": 1}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nAnd experts aren\u2019t even entirely sure why it works for Parkinson\u2019s in the first place.\nIf all goes as planned, Machado will insert the electrodes in the brain of someone severely disabled by stroke who has exhausted all other options without improvement.\nDBS has been used to treat tremors associated with Parkinson\u2019s disease, but Machado said the new approach, if successful, will achieve something novel.\nSince the procedure is experimental, there may be some unknown risks as well.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story is pretty clear that actual clinical application of DBS for stroke patients is a long way off, given that the first patient on which this will be tried hasn\u2019t been identified yet.\u00a0 So we\u2019ll rate this a marginally Satisfactory, with the caveat that stories like this which raise patient hopes prematurely can do real harm to people and their families. We would have liked it better if the story had spelled out how many steps it will take before this becomes an actual treatment (if ever).", "answer": 1}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nAll volunteers were encouraged \u2014 but not required \u2014 to stop drinking.\nIt's unclear whether the findings will make a dent in an addiction that affects millions of Americans.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\nThe drug costs at least $350 a month, plus the price of doctor's visits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made clear that the drug Topamax is not FDA approved for the treatment of alcoholism but that physicians are free to prescribe it for such use.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses Medicare and private insurance coverage for the procedure, and that description gives readers some insight as to availability. \u201cAs of now, Medicare covers eBx in 21 Western and Midwestern states. It covers the treatment on a case-by-case basis in Texas and the South and doesn\u2019t cover it in Florida or New England, where it is more difficult to find. Private insurance coverage also varies.\u201d", "answer": 1}, {"article": "Their median age was 63.\nStill there may be reasons to remove the cancer in the breast.\nA large, randomized, prospective study currently being conducted by the Eastern Clinical Oncology Group should produce the most reliable data on the subject to date, he said.\nBut with better therapies to control the cancer systemically and improved imaging that finds ever-smaller deposits of cancer in other parts of the body, it may be time to see whether surgery also can help increase the length of survival times, they said.\nNewman was not involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of risk-reducing\u00a0 breast surgery is not in question, since it is not a new intervention.", "answer": 2}, {"article": "Studies in mice, dogs, pigs, and monkeys have shown that so-called focused ultrasound waves can be used to heat tiny bubbles that then mechanically push open gaps in blood vessels, allowing drugs to leak out into the brain.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\n\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\nSucceeding in getting drugs across the barrier is \u201ca huge achievement\u201d said Dr. Nathan McDannold, a radiologist at Boston\u2019s Brigham and Women\u2019s Hospital, who has been working to open the barrier with ultrasound since he first accomplished the feat 15 years ago in animals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes this is a very new, very experimental technology, and several other patients are lined up for testing. Even after that testing, further testing will be necessary to establish appropriate doses etc, so we think it\u2019s pretty clear that this won\u2019t be available any time soon.", "answer": 1}, {"article": ", or find Mount Sinai on Facebook, Twitter and YouTube.\nFurther research is needed to investigate the impact of lung ultrasound on antibiotic use and stewardship.\nTo watch study author discuss this research, click this link: https:/\n\nPneumonia is the leading cause of death in children worldwide, according to the World Health Organization (WHO).\nFurthermore, the reduction in chest X-rays in the investigational arm resulted in an overall cost savings of $9,200, and length of stay in the Emergency Department was decreased by 26 minutes.\n\"In the era of precision medicine, lung ultrasound may also be an ideal imaging option in children who are at higher risk for radiation-induced cancers or have received multiple radiographic or CT imaging studies,\" says Dr. Tsung.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does make a point that ultrasound technology is widely available in health care facilities around the world.\u00a0 We would have liked for the release to include the fact that in perhaps three-quarters of the world, there is a lack of facilities that can provide even diagnostic X-rays. This fact, attributed to the WHO in the journal article, is absent in the news release. High resolution ultrasound machines would be even further out of reach in these countries.", "answer": 1}, {"article": "RotaTeq \"generally appears to have a better safety profile than the earlier vaccine,\" said Umesh D. Parashar, a medical epidemiologist at the CDC.\nBut it is also drawing new manufacturers into the vaccine market, which many drug companies had abandoned in the 1980s and 1990s, citing too little profit.\nFifty to 60 of them die, but it is a different story overseas, where babies often do not receive good medical care and hundreds of thousands die every year.\nVirtually every child in the world contracts the virus repeatedly by age 5, gradually building immunity.\nVaccine-safety advocates are urging parents to be wary of the new vaccine because of that history.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nNivolumab will still have to go through approval by the European Medicines Agency and NICE before it is available for head and neck cancer patients on the NHS.\nThis phase III clinical trial expands the repertoire of nivolumab even further, showing that it is the first treatment to have significant benefits in relapsed head and neck cancer.\nMedian survival for patients on nivolumab was 7.5 months, compared with 5.1 months for chemotherapy.\nNivolumab became the first treatment to extend survival in a phase III clinical trial for patients with head and neck cancer in whom chemotherapy had failed - and it did so with fewer side-effects than existing therapeutic options.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that nivolumab is not yet approved for use in head and neck cancer patients in Europe (including the U.K.).", "answer": 1}, {"article": "The closed loop insulin delivery system, for example, computes insulin doses and administers them according to glucose levels detected by a sensor.\nAlthough an accompanying journal editorial noted that the artificial pancreas is still \"in its infancy,\" some experts were cheered by the findings.\nWithout replacement insulin, people with type 1 diabetes couldn't survive.\nBut, replacing insulin isn't easy.\nThe current study included 24 people with type 1 diabetes and challenged an artificial pancreas prototype in two different real-life scenarios.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Statins are such a widely prescribed class of drug that we feel most readers will understand their availability. The story does hint at this by noting that one-third of the patients who had surgery in this study were taking statins.", "answer": 1}, {"article": "\"What it tells us is that statins might not be effective in slowing the progression of disease, but they might ... prevent disease,\" said Mary Haan of the University of Michigan.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\n\"But statins as prevention for Alzheimers is not indicated at this time.\"\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of statins is not in question. ", "answer": 2}, {"article": "Media campaigns, increased tobacco and tightening of smoking laws have all had an effect as well.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\nThe study did not follow people over time.\nThe products have been controversial since at least 2002, when researchers at the , reported from a large survey that they appeared to offer no benefit.\n\u201cPatient compliance is a very big issue,\u201d said Dr. Richard Hurt, director of the Nicotine Dependence Center at the , who was not involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story talks about the sales figures for nicotine products as one indication of widespread availability and use.", "answer": 1}, {"article": "\"Those who eat baked or broiled fish had larger brains,\" noted study author Dr. Cyrus Raji, a resident in the department of medicine at the University of Pittsburgh Medical Center, Mercy Hospital.\nBut fish and chips lovers, take note: No cranial benefit was evident with respect to consumption of fried fish.\nResearch presented at scientific meetings should be considered preliminary until published in a peer-reviewed medical journal.\nThe team cautioned that while eating baked and broiled fish appears to exert some cognitive benefit, other lifestyle and socioeconomic factors may play a role.\nRaji and his colleagues are slated to discuss their findings Wednesday at the annual meeting of the Radiological Society of North America, in Chicago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish is not in question.\n ", "answer": 2}, {"article": "Stress tests measure the heart's response to exertion, letting doctors see or hear any disease.\nEven more surprising, the rate of bad outcomes among the heart patients studied were extremely low.\n(He did not want his last name published).\nAnd while there's often no wrong choice between CTAs and stress tests, the new findings underscore a vital nuance, she added.\nBut \u2014 partly because his mother had died of coronary artery disease at age 49 \u2014 David remained unconvinced by those results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story does not make information about availability explicit, it is reasonably clear from the story that both types of diagnostic tests are currently available.", "answer": 1}, {"article": "\"Diet can have a remarkable effect on you,\" says Valter Longo, Professor of Gerontology at USC Davis, who has been long been researching the mechanisms behind human aging and has recently turned his attention to fasting.\nThe food items used, however, were specific to the trial and if translated to the public would involve designing meals made up of the right combination of nutrients.\n(CNN) How much -- or how little -- you eat could influence how long you live.\n\"Cells have a list of things to do every day,...like getting rid of toxins\" says Toribio-Mateas.\nThis activation, or reduction, of pathways is why the components of the diet, such a proteins, must also be controlled.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that fasting participants were given a specific type of meal that isn\u2019t available to the general public.", "answer": 1}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\nYet only 50 percent of those people have been diagnosed with a mental illness.\nWhile safety planning has begun to be used across the country, it ought to be adopted universally, says Goldstein Grumet.\nBut few of those suicide survivors get the follow-up care they need at a time when they are especially likely to attempt suicide again.\nThe findings offer a way for hospitals and clinics to help reduce the rising numbers of death by suicide across the country.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told that the SPI approach is becoming increasingly more available in hospitals across the country.", "answer": 1}, {"article": "Inflammation is a sign of damage from cholesterol.\nBy then, results will also be in on a large study of a similar drug, dalcetrapib, made by Merck\u2019s competitor, Roche.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nLee Davies, a Merck spokesman, said the company is not likely to seek FDA approval until those results are in, most likely in 2015.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nWe\u2019ll let this story pass on this criterion because it mentions that the next phase of clinical trials will take at least four years to complete and because it notes that success is not a sure thing. \nHowever, the lead sentence about people having a new cholesterol treatment option \u201csoon\u201d gives us pause. Also, the prediction in the story attributed to a drug company spokesman that application for approval could come in 2015 seems questionable, since the next study is not scheduled to begin recruiting participants until April 2011, and then there will be four years of observation, followed by data analysis. The trial just presented began in April 2008 and the participants were followed for an average of 14 to 16 months, yet it took more than a year after that for these results to be announced. The next trial may include 20 times as many patients.", "answer": 1}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nBut there's more hope than that from the study of some 1,200 men with late-stage cancer at 147 medical centers in 13 nations.\nThe treatment gave patients with metastatic, castration-resistant prostate cancer only an extra four months of life.\nAnd while the average patient survived only four months longer than those on standard chemotherapy -- 14.8 months vs. 10.9 months -- some patients did much better.\nDe Bono reported the study findings in at this week's meeting of the European Society for Medical Oncology in Milan, Italy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reader is given no information about whether this drug is available now, or, if not, what stage of research it is in.\u00a0 There\u2019s a hint \u2013 in the line that Johnson & Johnson is \"developing\"\u00a0the drug but news organizations shouldn\u2019t play guessing games with readers on the topic of the availability of prostate cancer drugs \u2013 or any topic. \nThe competing Wall Street Journal story, by contrast, reported:\u00a0\"Johnson & Johnson plans to file for new-drug approval in the U.S. and Europe by year-end, raising prospects that the drug could be on the market next year.\"\u00a0 There\u2019s no doubt about availability when you read that. (Although one could doubt the prediction of when it could be on the market.)\u00a0", "answer": 0}, {"article": "Decipher is a Medicare-covered genomic test capable of predicting tumor aggressiveness in men following prostate surgery.\nDecipher was developed in partnership with the Mayo Clinic.\nThe test provided a more accurate and precise estimate of a patient's risk of recurrence.\n\"Conflicting treatment recommendations by different specialists looking at the same disease can be highly confusing for patients and is a problem for the health care system in general,\" said Paul Nguyen, M.D., of Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School.\nIn partnership with leading medical centers, the company has assembled the largest genomic catalogue of prostate cancer tumors in the world, representing billions of data points and more than 20 years of prostate cancer research expertise.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told Decipher is commercially available and that Medicare can pay for the test.", "answer": 1}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\nMany desperate patients have spent their life savings flying overseas to have the procedure, only to have it fail a few months later.\n\"That's absolutely one of the potential problems in the previous studies: Are the techs who got negative results, did they just not know how to do the ultrasound in the way that Dr. Zamboni described doing the ultrasound?\nWhat is going on is still a bit of a mystery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article implies that there aren\u2019t yet a lot of doctors performing this\u00a0procedure, but it isn\u2019t clear.\u00a0Early in the story we learn of\u00a0a patient\u00a0who recently had the procedure performed in New York, but later on\u00a0the story\u00a0says that Canadians and\u00a0Americans\u00a0are going to Europe\u00a0to have\u00a0the surgery.\u00a0Are there not enough doctors\u00a0in North America who are trained to perform this procedure? Or are there regulatory, legal, or financial\u00a0issues that are preventing patients in North\u00a0America from getting\u00a0it done here? \u00a0The story should have told us.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article mentioned hyperbaric chambers are located in about 1,400 hospitals across the US. Given that Medicare also reimburses for hyperbaric therapy, access is probably relatively easy.", "answer": 1}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\nMichael Sand, director of clinical research at Boehringer, said the company intends to pursue regulatory approval based on the late-stage study findings.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\nFlibanserin could be the first success after a series of failures from drugmakers including Pfizer and Procter & Gamble.\nThe condition affects about 10 percent of all pre-menopausal women, according to experts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article accurately states that flibanserin is an experimental drug and is not FDA approved or commercially available.", "answer": 1}, {"article": "Behavior and quality of life also improved.\n\u201cWhat the study clearly shows is surgery for children produces seizure freedom compared to children not operated on for similar conditions,\u201d senior author Dr. Manjari Tripathi, a professor of neurology and epilepsy at the All India Institute of Medical Sciences in New Delhi, told Reuters Health in a telephone interview.\nThe researchers said that was to be expected and, without surgery, patients probably would have experienced similar problems as a result of their continuing seizures.\nRather than pay $35,000 to $50,000 on surgery that might cure the problem and prevent further damage to the child, insurance companies prefer to demand that more drugs be tried, even if the odds of them working in drug-resistant cases is small, he said.\nNot only \u201cdoes it reassure us that several surgical procedures are effective,\u201d she said, it demonstrates that surgery \u201cshould be done as early as possible\u201d once it becomes clear that a child is not responding to two anti-seizure medications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beyond noting that costs are a frequent barrier in India to getting the surgery, the article does not say anything about general availability of the operations, or define categories of candidates.", "answer": 0}, {"article": "\u201cIt\u2019s a combination,\u201d Hagan said.\nOptimistic people are likely to have better diets, they\u2019re exercising more, and they\u2019re getting better sleep.\u201d\n\nHowever, even after the researchers accounted for these factors, the results still suggest that optimism itself is linked to a longer life.\nHowever, they note, \u201cthere is no clear basis for believing that the effects of optimism on health differ by sex or race.\u201d\n\nFinally, the researchers emphasize that while some people may think they\u2019re just not optimistic, it is something that is modifiable.\n\u201cIf you\u2019re more optimistic, you tend to have healthier behaviors.\nHaving an optimistic outlook on life may do more than just boost your mood.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Optimism\u00a0may not be FDA-approved, but we\u2019ll optimistically assume all readers know that it\u2019s widely available. There could have been more included on how optimism can be a learned skill, for those who would like to become more optimistic.", "answer": 2}, {"article": "Unlike CT scans or MRIs, PET scans can show a tumor's internal activity, not just its size.\nGraham said there are maybe a dozen published human studies so far, most involving too few patients to draw a firm conclusion.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\nResearch into FLT PET is still in the early stages.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment is experimental and not currently available. Yet it is not until late in the story that we learn the research is very preliminary. The caveats appear eventually but should have framed the story from the outset.\u00a0 \nThe story allows advocates to offer unsupported speculation that the government may agree to pay for the procedure in \"two or three years\" and new PET technologies will transform cancer treatment within 10 years.\u00a0 \nThe use of the anecdote in the lede implies availability.\u00a0 ", "answer": 0}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nIn the randomized study, 151 patients were implanted with the device.\nThe study was funded by Respicardia.\nPositive airway pressure devices have been used, but many patients don't tolerate them well and a recent study showed them to be harmful.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The implant was made available to patient volunteers through a clinical trial, and that\u2019s an implication to savvy readers that the device isn\u2019t available to the general public. But there\u2019s no clear indication of whether the device is on the market or not. The news release should have stated that it is not generally available and it is unknown if major payers will cover it if it ever comes into wider use.", "answer": 0}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\nThe Dana-Farber scientists say current [EGFR] inhibitors Iressa and Tarceva prevent EGFR from sending signals that are essential to keep tumor cells growing, the researchers say.\nIt's early to discuss the use of such compounds in patients, the scientists say, but one of the researchers, Michael J. Eck, MD, PhD, also of Dana-Farber, says he's optimistic their approach \"will lead to an effective treatment for the thousands of non-small cell lung cancer patients worldwide who develop resistance to Iressa and Tarceva every year.\"\nThe scientists say in the news release that not only did they find that a compound called WZ4002 can slow tumor growth, but that it is possible to \"selectively target the drug-resistant mutant EGFR in tumors, with relatively less effect on the normal EGFR in health tissues.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not until the very end of the article do we learn that the dramatic results against NSCLC tumors occurred in mice, not human beings. In fact, it never states the setting for any results \u2014 an important point because the article fails to reveal that some results, such as the compound\u2019s apparent ability to spare normal tissues, were achieved in cell lines, not even in mice, according to the\u00a0press release\u00a0and\u00a0article\u00a0published in Nature.\u00a0Therefore, most of the article is misleading .\nRead the pivotal sentence below. Without any mention of animals preceding it, how could we\u00a0not\u00a0assume that the lungs, cancers, and powerful treatment effects were in humans?\nThis sentence, if not the article\u2019s title, should have been qualified with the word \"animal,\" \"mouse,\" or even \"murine.\" \nThe article provides almost no caveats about the preliminary nature of these results, nor the limitations of extrapolating to humans any data obtained from cell lines and animals.\u00a0While the article does contain two statements, essentially quoting the\u00a0press release, about what lies ahead following these early data, both sentences contain a \"but\" followed by the investigators\u2019 optimism.", "answer": 0}, {"article": "Brain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\nThere\u2019s no such thing as a blood test, cheek swab or other accepted biological marker so specialists must depend on parent and teacher reports, observations and play assessments.\nFiguring out a child's trajectory once he or she is diagnosed is just as challenging.\nNow scientists believe that they have a way to distinguish between those paths, at least in terms of language ability, in the toddler years using brain imaging.\nAutism has always been a tricky disorder to diagnose.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t state when or if clinicians will adopt the testing protocol for newly diagnosed autism patients. Because the research was only recently published in a journal, one must assume clinicians will not be implementing the protocol anytime soon. But the story doesn\u2019t make this clear or provide any sort of time frame for readers.", "answer": 0}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nThe association has strict policies to prevent these relationships from influencing the science content.\n\"To best evaluate this issue, we decided to compare a lacto-ovo-vegetarian diet with a Mediterranean diet in the same group of people,\" said Francesco Sofi, M.D., Ph.D, lead study author and professor of clinical nutrition at the University of Florence and Careggi University Hospital in Italy.\nAuthors said they did find two differences between the diets that may be noteworthy.\nAnderson, who was not involved in the study, added that promoting both diets by healthcare professionals \"offer a possible solution to the ongoing challenges to prevent and manage obesity and cardiovascular diseases.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release didn\u2019t specifically address availability.\u00a0 We do acknowledge that while different fruits and vegetables are limited in different parts of the world, it is feasible to adopt a Mediterranean style or vegetarian style diet almost anywhere by substituting some vegetables and protein sources for others.", "answer": 2}, {"article": "Warning signs include transient ischemic attacks (TIAS), or mini-strokes, which cause no permanent damage but are often followed by a stroke within a few days.\nThe patients who are at high risk are candidates for surgery, he said.\nThose who would benefit from the ultrasound test are people with known carotid stenosis who are fit for surgery, Topakian said.\nThe problem is identifying the patients at the highest risk for stroke, he said.\nMarquardt noted that the risks associated with the surgery are a lot higher than leaving the stenosis as it is and starting aggressive medical treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is based on what was found with \u201ctwo ultrasound methods.\u201d\u00a0 But it never clarified whether there was something extraordinary about these methods and, if so, how well known are they?\u00a0 How widespread?\u00a0 How available?", "answer": 0}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nFor now, ketamine has not received approval from the U.S. Food and Drug Administration for treating depression, though doctors can use it for that purpose.\nClinics have opened around the United States promising instant relief with their \u201cunique\u201d doses of ketamine in IVs, sprays or pills.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\n(AP Photo/Teresa Crawford)\n\nCHICAGO (AP) \u2014 It was launched decades ago as an anesthetic for animals and people, became a potent battlefield pain reliever in Vietnam and morphed into the trippy club drug Special K.\n\nNow the chameleon drug ketamine is finding new life as an unapproved treatment for depression and suicidal behavior.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that ketamine is widely available for treating depression \u2014 at \u201cabout 150 US. ketamine clinics,\u201d although it has not been approved by the FDA for that purpose.", "answer": 1}, {"article": "The FDA is not required to follow the advice of its expert panels, but the agency typically does.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\nThe review came in briefing documents that were filed Monday in advance of an FDA advisory panel meeting Wednesday, at which the panel is to vote on whether to recommend approval of Xarelto for treating people with acute coronary syndrome (a group of conditions brought on by sudden reduced blood flow to the heart).\nXarelto (rivaroxaban) is one of a new class of blood thinners that have been developed to overcome some of the problems that exist with the standard treatment, warfarin (Coumadin), which requires constant dose monitoring.\nIn the FDA briefing documents, an agency reviewer recommended approving the drug for treatment of acute coronary syndrome, mostly because trial data showed there was a reduction in cardiovascular death, even though there was also an increased risk of potentially fatal bleeding.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug is already used for atrial fibrillation and in people having hip or knee replacement surgery.\nAnd with that general availability comes the ability of people to ask for Xarelto and for their physicians to prescribe it without the benefit of seeing the final recommendation from the scientific advisory board or final FDA approval for this new indication.", "answer": 1}, {"article": "\u2022 Paulsen AJ, Cruickshanks KJ, Fischer ME, et al.\n\"As a clinician who specializes in diagnosing and treating dry eye, this novel formulation of cyclosporine A would be a unique and welcome addition to our armamentarium to treat these patients\".\nThese results are highly encouraging for millions of Dry Eye patients[4]-[6] across the globe that have yet to find relief for their condition.\n[1] Additionally, several key secondary endpoints showed statistically significant improvements compared to vehicle with some showing an even earlier onset of action.\n[1]-[3] As Sun continues to analyze the data, additional significant findings will be shared at upcoming medical conferences.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was another close call. We\u2019ll rate this category satisfactory since the release reports on a phase 3 trial, which means the product is not yet available to the public, and a Sun Pharma executive is quoted as saying, \u201cWe look forward to discussing these results with US FDA and agree on next steps for the program.\u201d\u00a0 FDA approval is prerequisite on a product\u2019s availability to the public.", "answer": 1}, {"article": "AMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe disorder is estimated to affect about one in 500 people and causes extremely high cholesterol.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story points out that the drug is still experimental.", "answer": 1}, {"article": "Lack of F.D.A.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nThe fact that it\u2019s not licensed for this has definitely kept doctors away.\u201d\n\nFor example, on Solvay Pharmaceutical\u2019s Web site for Omacor, www.solvay-omacor.com, the first question a user sees is, \u201cAre you a U.S. citizen?\u201d\n\nIf the answer is yes, the user is sent to a page where heart attacks are not mentioned.\nSo community doctors do not learn how to use the drug.\nThe fact that heart patients receive such different treatments in sophisticated hospitals around the world highlights the central role that drug companies play in disseminating medical information, experts said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explicitly states that prescribed fish oil is not approved by the FDA for use in heart patients as a treatment. This is not an accurate statement. The FDA announced approval of a qualified health claim of reduced risk of coronary heart disease for omega-3 fatty acids in 2004. And while not FDA approved for use for all coronary disease, there is currently an omega-3 fatty acid product on the market that has been approved for the treatment of very high triglycerides. Fish oil is widely available over the counter, which is the most important piece of information for readers. This story focuses too much on the availability of one prescription fish oil brand.", "answer": 0}, {"article": "\"Given significant concerns regarding overuse of antibiotics and increased antibiotic resistance, we conducted this trial to see if reducing the duration of antibiotic treatment would be equally effective along with decreased antibiotic resistance and fewer adverse reactions,\" Dr. Alejandro Hoberman said in a university news release.\nThese infections are the most common reason why children are given antibiotics, the University of Pittsburgh researchers noted.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\n\"Though we should be rightly concerned about the emergence of resistance overall for this condition, the benefits of the 10-day regimen greatly outweigh the risks,\" he added.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story just generally refers to the drugs used as \u201cantibiotics\u201d making it unclear what specific drug was studied. Without that information, availability is impossible to even infer.", "answer": 0}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\nThe examination relies on gadolinium-based contrast agents that need to be injected intravenously.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This report is based on a retrospective study early in the process of testing the new imaging procedure. It is too early to comment on availability. Also, it appears this study was conducted in Europe so it\u2019s unclear if the algorithm would become available to use in US clinics.", "answer": 2}, {"article": "It's crazy enough to laugh off.\nBut rather than stocking up on the sugar-rich chocolate bars at the checkout line, researchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\nWhile there has been a lot of research on similar compounds over the past decade, no one has been able to pinpoint which ones are the most beneficial or how exactly they bring about any benefit -- until now.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Readers of the entire release are told that this work is an early step toward developing compounds for testing. However, the headline, lead paragraphs and images (featuring Hershey\u2019s bars) all conspire to imply that the researchers looked at chocolate found on candy shelves.\nCocoa is widely available, the compound being investigated in this study is not, and the\u00a0researchers\u00a0don\u2019t give any idea about how hard it is to extract it.", "answer": 0}, {"article": "Drs.\nSo for up to two years the new study followed more than 5,000 Group Health patients who started taking an antidepressant.\nBupropion should be considered the first-line drug of choice for people who are overweight or obese, Dr. Simon said.\nGrant R01 MH083671 from the National Institute of Mental Health funded this research.\nBut patients should consult their doctor about which medication is right for them, before making any changes, including starting, switching, or stopping medication.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that all of the antidepressants are available and approved.", "answer": 1}, {"article": "Craft said.\nBut, she added, if her study goes forward, many will be able to participate in it.\nIn the meantime, she cautions Alzheimer\u2019s patients not to rush out and try to take insulin.\nBut Dr. Martha Daviglus of Northwestern University, who led a panel last year that assessed published papers on preventing and treating Alzheimer\u2019s, urged caution.\nCraft reasoned, perhaps if more insulin could be put into the brains of people with the degenerative brain disease, their memories and ability to function might improve.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that this treatment is experimental and\u00a0that the\u00a0device used to administer insulin deep inside the nose is not on the market. It urges readers not to rush out and take\u00a0insulin for the\u00a0treatment of Alzheimer\u2019s\u00a0disease.\u00a0The story closes with\u00a0the implied promise of a larger study in which \u201cmany\u201d people might have access to the intranasal insulin therapy, which sets an overly optimistic tone. Only a small\u00a0fraction of people who might benefit from this therapy will be eligible to participate in any future studies.\u00a0On the whole, though,\u00a0the story\u2019s message on availability is correct and\u00a0merits a satisfactory.", "answer": 1}, {"article": "Gout occurs when uric acid builds up in the body and forms crystals in the joints or in soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\nThe drug is associated with some serious side effects.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about new FDA approval of the drug.\u00a0 It notes that the manufacturer expects it to be available by prescription later this year. ", "answer": 1}, {"article": "Parkinson's disease is a neurological disorder that can cause tremors, stiffness, slowness of movement, trouble balancing, problems walking and difficulty coordinating movement.\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\nHowever, the test cannot distinguish between the different atypical disorders, which doctors must rely on symptoms to diagnose.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Via the lead researcher\u2019s discussion of what the test may do in the future, the article implies that the blood test is not yet available.\nIdeally that hint should have been more explicit and perhaps accompanied by some details on what\u2019s left before this test becomes available.", "answer": 1}, {"article": "\"In our analysis, daily aspirin use was associated with about a 16% lower risk of dying from cancer overall,\" Jacobs says.\nMany other strategies will also reduce the risk of cancer, he says.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nThe new analysis is published in the Journal of the National Cancer Institute.\nHe describes that reduction as modest.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of aspirin is not in question.", "answer": 2}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nEveryone from plastic surgeons to your friendly snake oil salesman have been promising a ticket to eternal youth for some time, so the prospect of a prescription pill based on red wine that could trigger a longevity gene sounds too good to be true.\nAnd yet scientists have actually known for years of one surefire of doing that: stay hungry.\n\"If the promise holds true, I think this has the chance to change healthcare,\" Dr. Christoph Westphal tells\n\nDr. Westphal says we all may soon be taking a drug that just might beat the clock, a simple pill that could delay the inevitable.\nIt's normally inactive, but when it is active, Sinclair believes it triggers a survival mechanism that extends life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Here\u2019s an excerpt of the story taken from the CBS website: \nBut the question that most of us want answered is: when do we get this pill? \n\"I would say five years to be conservative that this\u2019ll happen within our lifetimes. I\u2019m fairly certain about that,\" Sinclair says.\u00a0 \n\u00a0Sinclair is one of the co-founders of the company working on the drug.\u00a0 His 5-year estimate should have been checked with at least one independent source for comment.\u00a0 Also, note how that comment \u2013 as transcribed by CBS \u2013 makes no sense.\u00a0 ", "answer": 0}, {"article": "At the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nThe study is published Feb. 9 in the New England Journal of Medicine.\n\"Our preliminary results provide evidence supporting a possible mechanism for enhancing memory, particularly as people age or suffer from early dementia.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this research is in its early stages, though devices are available that provide similar deep brain stimulation to patients with other disorders.", "answer": 1}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nOn the need for more scientific research, all these experts agree.\nShe added that the new study is \"critically important\" for the epilepsy community, which believes a CBD-based medical product would be a first-in-class therapeutic option.\nHe noted that generating more evidence of effective use is \"a good thing.\"\n\"Hopefully, the FDA will see this as a sign it should be moved off of Schedule I.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is a significant section on availability of marijuana and marijuana-derived drugs. A reader can fairly easily infer that this intervention is not yet available.\nBut, as we noted in our news release review, \u201cThe FDA does, however, consider cannabidiol an investigational product for treating children with epilepsy and has \u201cexpanded access provisions\u201d that allow its use.\u201d\nThis would have been useful information to include in the story.", "answer": 1}, {"article": "A moderate dose of MDMA was found to significantly increase feelings of loving, friendliness and playfulness, the researchers said, whereas the low dose of MDMA boosted feelings of loneliness.\nAll said they had taken MDMA for recreational purposes at least twice in their lives.\nEach session lasted at least 4.5 hours, or until all effects of the drug had worn off.\nBut if used in the right setting wisely, many things can also be helpful.\nThis effect, the Bedi and his team suggested, could help people improve their social skills by shielding them from the negative emotions of others.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that \u201cMDMA is part of a family of so-called \u201cclub drugs,\u201d which are popular with some teens and young at all night dances or \u201craves.\u201d\nBut it doesn\u2019t tell readers anything about whether this is MDMA\u2019s only use, and how it might be made available/distributed.", "answer": 0}, {"article": "People getting the combination of immunotherapy and chemotherapy were 51% less likely to die after 10.5 months than people receiving chemotherapy alone.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\nAnd when the scientists studied the blood of the people receiving the immunotherapy, they discovered a close match between the types of immune cells in the blood and certain targets on the tumor cells, suggesting that nivolumab had released the immune system to pump out the appropriate cells it needed to tackle the cancer.\nPutting together everything that doctors currently know about lung tumors, \u201cmore than half of people with lung cancer can avoid chemotherapy and get more precision-based treatments,\u201d says Dr. Matthew Hellmann of the Memorial Sloan Kettering Cancer Center (MSKCC), lead author of the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says Keytruda is \u201calready approved for treating about 25% to 30% of people with advanced (non-small cell lung cancer) who have a certain genetic profile that makes their cancer vulnerable to the drug.\u201d\nMore generally it says that \u201ca series of checkpoint inhibitor drugs was first approved in 2011 initially for treating melanoma.\u201d\nThe story could have clarified whether additional FDA approvals are needed to expand uses of these drugs.", "answer": 1}, {"article": "Because about one-half of the deaths in people with type 2 diabetes are caused by cardiovascular disease, reducing cardiovascular risk is considered essential to diabetes care.\nHe has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\nBut they did not unveil detailed data until Thursday at the medical meeting.\n\u201cThe big news here is that the drug reduced cardiovascular stuff.\nLilly shares jumped as much as 9 percent after data from the trial was released Thursday at a medical meeting in Stockholm.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Jardiance was approved for use in the United States last fall, so it\u2019s clear that the drug is available.", "answer": 1}, {"article": "Zied is also the author, with Ruth Winter, of a book titled \"So What Can I Eat?\"\nFor more information about the businesses featured in the series, click on:\n\nThe Consumer Product Safety Commission wishes to remind you that using camp stoves, portable camping heaters, or lanterns or charcoal grills inside your home produces dangerous levels of carbon monoxide, as does using a portable generator inside your home.\nElisa Zied, a registered dietitian and a spokesperson for the American Dietetic Association, talked about how to properly interpret information on food labels.\nEarly Show national correspondent Hattie Kauffman did a two part series, \"Up and Running,\" in which she spoke to moms with home businesses, doing what they love.\nOn The Early Show Friday, Family Circle magazine Editor in Chief Linda Fears discussed everyday lessons that can make a big difference.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story discussed folic acid supplements,\u00a0but would have been better if it had explicitly mentioned that these are available over the counter.\u00a0 The story mentioned multivitamins, but would have been better had it included the caveat that consumers need to check the label to determine whether the product contained 400 mcg.\u00a0 The story also discussed food sources (leafy green vegetables, liver, dried beans, citrus fuits, whole grain bread and cereals); however this\u00a0was somewhat incomplete because\u00a0without mention of the amounts of folic acid or the % of the recommended 400 mcg they might get in a single serving a person does not know how to use these foods to insure\u00a0sufficient folic acid\u00a0intake.\nIncluding guidance, such as reading labels, would have made this story more useful for the viewer interested in meeting the recommended intake.", "answer": 1}, {"article": "Toshiaki Higashihara, President & COO of Hitachi, Ltd. stated that, \u201cWe are greatly honored that Johns Hopkins selected Hitachi as their proton partner.\nIn fiscal year 2015 (ending March 2016), one of Hitachi's new PBT site is planning to start treatment of patients.\nThe next-generation system \u201cPROBEAT\u201d, which comes with IMPT (Intensity Modulated Proton Therapy) and cone-beam CT, will have improved spot scanning capability in all 3 gantry-type treatment rooms, along with a fixed irradiation room dedicated to cancer research.\nHitachi will continue to globally expand the healthcare business where proton therapy is its flagship solution, and contribute to cancer treatment around the world.\nThis will be Hitachi\u2019s fifth PBT system in North America.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Several PBT systems are under construction in Washington, DC, proper and within the region. The release did not establish when the newly announced facility is expected to be ready or when those other facilities will be ready. The availability of proton therapy outside the DC area is not discussed.", "answer": 0}, {"article": "Montreal, October 7, 2015 -- Millions of people suffer from asthma.\nCould a prescription for exercise be the result of this study Bacon is hopeful.\nForty per cent of people don't exercise at all, he says.\nThis news release is available in French.\nFortunately, new research shows there is a simple antidote: 30 minutes of exercise a day, year-round.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of exercise is not in question.", "answer": 2}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\nThe researchers cautioned that the drug was given in tightly controlled conditions in the presence of two clinically trained monitors and said they do not recommend use of the compound outside of such a research or patient care setting.\nIn general, the commentaries were supportive of the research and of using these drugs in a clinical setting as tools for psychiatry.\nBoth studies are published in the Journal of Psychopharmacology on Dec. 1.\nNewswise \u2014 Note: A media teleconference with researchers and patients from Johns Hopkins and New York University will be held on Wednesday, Nov. 30, from 11 a.m. to 12:30 p.m.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear from the release whether psilocybin treatment is currently available, or what the short- or long-term prospects are for psilocybin treatment availability.\nPsylocybin is categorized as a Schedule 1 drug by the Drug Enforcement Administration and its availability is tightly controlled. There is a precautionary note in the release,\u201d\u2026they do not recommend use of the compound outside of such a research or patient care setting.\u201d \u00a0But given the availability of \u201cmagic mushrooms\u201d and the availability of DIY instructions on identifying and growing same, we think that some additional comments would have been worthwhile.", "answer": 0}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the test is available and most insurers will pay for it.", "answer": 1}, {"article": "The findings, reported in the journal Diabetes Care, do not suggest that yoga should replace other forms of exercise for people with type 2 diabetes \u2014 a disease commonly associated with obesity.\nMeanwhile, their average blood sugar levels held steady \u2014 in contrast to the non-yoga-practicing \u201ccontrol\u201d group, whose blood sugar levels rose.\nThey found that, on average, the yoga group\u2019s levels of the chemicals dipped by 20 percent.\nFurther, long-term studies are needed to see whether that is the case, the researchers say.\nThe yoga used in this study was a gentle form, Hegde said, and parts of the practice were adapted for people who had additional health problems; certain poses were avoided in people who had heart disease, for example.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that gentle yoga classes might be found in hospitals and local community settings.", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nThe study did not look at possible side effects of kampo herbs.\nThere's much room for improvement, Shimoide says.\nHe says it was accidentally discovered that kampo herbs could wipe out symptoms in many people while testing the ancient remedy against an allergic skin disorder known as atopic dermatitis.\nYoshiteru Shimoide, MD, head of the Yoshiteru Shimoide Clinic of Internal Medicine in Kagoshima City, Japan, presented the results here at the annual meeting of the American Academy of Allergy, Asthma, & Immunology (AAAAI).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t discuss the availability or use of the kampo herbs in the US.", "answer": 0}, {"article": "\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\n\"This drug is relatively new and available only in China and Japan.\nThe findings have been published in Scientific Reports.\n\"While it could possibly have that effect, it might be able to help reboot the brain and reverse the deficits the alcohol abuse causes - both the inhibition to the brain's ability to regenerate, and the behavioural consequences that come from what alcohol is doing to the brain, like increases in anxiety and depression.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release clarifies that \u201cThis drug is relatively new and available only in China and Japan.\u201d", "answer": 1}, {"article": "The amygdala processes incoming emotionally salient stimuli, whereas the prefrontal cortex, as the executive center of the brain, decides whether the incoming stimuli are noteworthy.\nThe initial results demonstrate that the efficacy of this digital therapeutic is comparable to drug therapy, with a highly favorable safety profile.\n\"The aim is to target the thinking abnormality we see in patients with MDD - that of perseverating, ruminating, obsessing, dwelling on the negative - by activating these two nodes (emotion processing and cognitive control) simultaneously.\nThis treatment was developed at the Icahn School of Medicine at Mount Sinai by Brian Iacoviello, PhD, an Assistant Professor of Psychiatry who is Director of Scientific Affairs for Click Therapeutics, and Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean and Professor of Psychiatry, Neuroscience, and Pharmacological Sciences.\nThis aims to balance brain activity in these regions to work in concert with each other.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Because the release is about a new therapy, we assume it is not available outside of a clinical study yet.", "answer": 2}, {"article": "Condoms, the most common non-hormonal method of contraception, have an efficacy rate of 82 percent.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\nThe company\u2019s shares were up 22.6 percent at $4.28 in mid-morning trade after touching a high of $4.90.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this a product under development, not yet approved or marketed.", "answer": 1}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nOne of the components in the venom of the scorpion called Buthus tamulus specifically blocks the potassium channel of FLS and not the channels in other cells such as those of the nervous system,\" said first author Dr. Mark Tanner, a graduate student in the Beeton lab during the development of this project.\nDecades ago, scientists discovered this and realized that, if handled correctly, venoms also might have medicinal applications.\n\"We think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\"\nA treatment that improves the lives of nearly 1.3 million people with rheumatoid arthritis might one day originate from scorpion venom.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes it clear that scorpion venom isn\u2019t available yet as a treatment with this researcher\u2019s quote: \u201cWe think that this venom component, iberiotoxin, can become the basis for developing a new treatment for rheumatoid arthritis in the future.\u201d But since the drug is available through Peptide International it is possible that some people may try to get it from the company and try it.", "answer": 1}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nSome laboratory studies and a number of observational studies suggest that metformin may prevent cancer, but the data from human studies, however, are conflicting, explained Sakoda.\nThis study was funded by the National Institutes of Health.\nAssiamira Ferrara, Charles Quesenberry Jr., and Laurel Habel, coauthors on this study, have received research funding from Takeda to Kaiser Foundation Research Institute for a study of pioglitazone and cancer and from Sanofi through a subcontract from University of North Carolina to Kaiser Foundation Research Institute for a study of insulin glargine and cancer.\nAdditional large, well-conducted studies are needed to clarify whether metformin may be used to prevent lung or other cancers, particularly in specific subpopulations, such as nonsmokers.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not directly address the availability of metformin. However, it\u2019s apparent that the drug is available, since thousands of people in the study have been taking it for years.", "answer": 1}, {"article": "The women were asked to keep diaries for six months.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\nExercises to strengthen the pelvic floor muscles can help, as can \u201cbladder training\u201d to accustom the body to urinating at regular times.\nOn average, both treatments cut the number of \u201caccidents\u201d \u2013 Botox by almost four times a day and the nerve stimulator by about three times a day.\nDoctors usually try to start people off with lifestyle treatment, such as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both of these treatments are widely available. But,\u00a0a description of the procedures themselves would have been helpful (they are both quite invasive and require seeing providers with special training). While \u2018regular\u2019 Botox cosmetic treatments can be easily given by various medical professionals, without specialized training, in the office, this may not be the case for Botox injections into the bladder.", "answer": 1}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\nThere are many other causes of bedwetting, Lakshmanan said.\nExactly how sleep apnea results in bedwetting is not fully understood, but hormonal changes may play a role.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\nThe findings were to be presented Monday at the annual meeting of the American Urological Association (AUA), in Washington, D.C. Research presented at medical meetings should be viewed as preliminary until it has been published in a peer-reviewed medical journal.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The story does not explicitly state how common tonsillectomies are, but the surgery is so routine at this point, we do not feel there is a need for further explanation.", "answer": 2}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article is clear that these tests aren\u2019t available in your local hospital, and that the FDA hasn\u2019t approved a blood test. But the overall tone is so unchecked that it seems like a foregone conclusion that it will be available \"soon.\"\nIf researchers are close, why does the article lead with the evidence from rats? Again, the article is clear that the technique is not available, but we think it needed context about how preliminary this research is. Many readers would be shocked to learn how many techniques with promising\u00a0preliminary results in the lab fail when tested in clinical trials.\nThe story is also unclear about the pivotal DOD\u00a0trial. Will it specifically study UCH-L1, the biomarker investigated by Banyan Labs, or is it about a panel of biomarkers? Are they all Banyan biomarkers? Is UCH-L1 even in there? We don\u2019t know how much of the research discussed in this article will even be investigated in the future study and, thus, potentially available.", "answer": 0}, {"article": "For more about cryoablation, visit the U.S. National Cancer Institute.\nAt least in the short-run -- meaning three months after the procedure -- the intervention known as \"cryoablation\" appeared to kill all targeted tumors that had spread to the lung from elsewhere, preliminary results suggest.\nBut they acknowledged that more research needs to be done to track the treatment's impact over the long haul.\n\"And I would say that there are multiple different technologies for doing this kind of very localized approach,\" he added.\nSUNDAY, April 14, 2013 (HealthDay News) -- A method designed to target, freeze and destroy a tumor's cellular function seems effective in combating lung tumors, a small ongoing study finds.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story at least noted that cryoablation \u201chas been around for years.\u201d\u00a0 But to what degree?\u00a0 Around for years in how many places?\u00a0 What level of proliferation/penetration?\u00a0 How likely is a lung cancer patient in Arkansas or Alabama or Albuquerque to find the approach in use nearby?", "answer": 0}, {"article": "And finally, this is a very real world study.\u201d\n\nThe study was received well by the audience.\n\u201cSecondly, we only look at the trade-off between efficacy and safety, but your study is looking more at efficacy and effectiveness and practicality, issues that are also very important.\nEngaging patients in such a way could be a very powerful tool in promoting behavioral change, Nolan said.\nParticipants were also largely white and well-educated, with most having a postsecondary education, so the results of the study might not be generalize well to other groups.\nOnline lifestyle counseling works well, too, according to research presented Saturday at the American College of Cardiology\u2019s 66th Annual Scientific Session and Expo in Washington.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t address the availability of the web-based program.\u00a0Because high blood pressure\u00a0is so common, we think it would have been useful for the story to address when or if this technology will become widely available.", "answer": 0}, {"article": "Older people tend to get less slow-wave sleep and are at greater risk for memory impairment.\nA small new study published in suggests that one easy way for older adults to get deeper sleep and stronger memories is to listen to a certain soothing sound called \u201cpink noise\u201d\u2014a mix of high and low frequencies that sounds more balanced and natural than its better-known cousin, \u201cwhite noise.\u201d\n\nIt may sound strange, but previous studies have found that playing so-called pink noise during sleep improves the memory of younger adults.\nZee says that the effectiveness of pink noise is all in the timing.\nMusic, nature sounds and white (or pink) noise apps may still help improve sleep, she says\u2014which, in itself, is good for the body and for the brain.\nNorthwestern has a patent pending on the new technology, and one of the study authors has cofounded a company that plans to market it commercially.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that a pink noise generator timed to slow wave sleep is not yet available. The article does mention (parenthetically) that pink noise apps exist.", "answer": 1}, {"article": "\"Our research and clinical teams are immensely proud of these breakthrough findings, which are so profound they will likely result in a paradigm shift that will not be seen again for many years in the field of stroke therapeutics,\" says Michael Frankel, MD, professor of neurology, Emory University School of Medicine, chief of neurology and director of the Marcus Stroke and Neuroscience Center for the Grady Health System.\n\"However, this does not diminish urgency with which patients must be rushed to the ER in the event of a stroke.\nThere was no difference in mortality or other safety end-points between the two groups.\nThe researchers planned to enroll a maximum of 500 patients over the course of the study period.\nThe DAWN trial results were presented at the European Stroke Organization Conference in May.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "In this case, availability has to do with whether hospitals offer this procedure. Since the procedure is already part of standard practice we\u2019ll rate this Satisfactory, even though it\u2019s not explicitly stated.", "answer": 1}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that \u201cthe first patients were treated in Australia by the end of 2005. Initial clearance from the U.S. Food and Drug Administration did not come until 2013, but now more than half of the 30,000 patients treated to date are in this country,\u201d according to the manufacturer\u2019s chief executive officer Dave Amerson.\nThe story would have been stronger if it had discussed how many\u00a0urologists can do the procedure.", "answer": 1}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\nA recent review by Canadian researchers, focusing specifically on mindfulness meditation, concluded that it did \u201cnot have a reliable effect on depression and anxiety.\u201d\n\nTherapists who incorporate mindfulness practices do not agree when the meditation is most useful, either.\nSince mindfulness meditation may have different effects on different mental struggles, the challenge for its proponents will be to specify where it is most effective \u2014 and soon, given how popular the practice is becoming.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that mindfulness training in psychotherapy and for the management of chronic conditions is not standardized; thus, practicioners may have different interpretations of the practice in the clinical setting.\u00a0 The story notes that practitioners who use elements of mindfulness meditation and related therapies may do so with different types of patients and for different conditions; there is not yet agreement or clear evidence for which patients are most helped by mindfulness mediation.\u00a0 The article does a good job of explaining elements of the practice and listing resources (in the form of books, experts, clinical training centers and accessible home-based practices). Readers could practice or learn more about mindfulness mediation on their own based on information presented in the article. ", "answer": 1}, {"article": "While other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThe new Swedish study echoes previous research in men and women.\nLarsson isn't sure why.\n\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of chocolate bars is not in question. But it is important to note that the chocolate sold in Sweden typically has a higher concentration of cocoa solids \u2014 the likely source of any protective effect \u2014 than chocolate sold in the U.S. The story makes this clear.", "answer": 1}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\n\"Our research could help develop policies that make the service more accessible to low-income women,\" added senior author Nazeem Muhajarine, a professor in community health and epidemiology at the University of Saskatchewan and McRae's supervisor while she conducted the research.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\n\"Our findings show that women who are more vulnerable benefit from the care of a midwife, likely because they receive more time, counselling and education on how to care for themselves,\" said the study's lead author Daphne McRae, a post-doctoral research fellow at the UBC school of population and public health who conducted the study while she was a PhD student at the University of Saskatchewan.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a strong point. The news release noted that midwifery is \u201cnot available in all parts of the country.\u201d\nIt added:\n\u201cWaitlists for midwives can be quite long, so women who are educated and health-conscious typically access midwives early on in their pregnancies,\u201d said [lead author Daphne] McRae. \u201cBut more vulnerable women might not be as aware of the services available to them, so expanding midwifery to make it available for all women is important.\u201d", "answer": 1}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nAnd here's a biggie: There wasn't much information about adverse effects on women and babies, something everyone would certainly want to know.\nAnd there wasn't much hard data on psychological, social or economic outcomes, according to the report.\nThe studies in the review comprised more than 4,000 women who were up to 20 weeks pregnant.\nIn the late '50s the drug was billed as a way to ameliorate morning sickness.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The whole point of the story was to discuss the most commonly used treatments for morning sickness: acupuncture, acupressure, ginger, vitamin B-6 and conventional anti-vomiting drugs. \u00a0", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that boceprevir is an experimental drug currently in development. ", "answer": 1}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nThere was also no difference in the quality of life or mood scores that participants reported when they were on any of the four treatments.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n\u201cA lot of the treatments that are used for neuropathic pain ...might also be associated with disruptions in sleep,\u201d Dr. Andrea Hohmann, who studies marijuana and pain at the University of Georgia and was not involved with the current study, told Reuters Health.\nIn the second, third and fourth rounds of treatment, most - but not all - patients were able to tell when they had been on either the highest THC dose or the placebo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Strangely, neither story we reviewed pointed out that marijuana is illegal in most states and in Canada, where the study took place. The story could have, at a minimum, mentioned which states have medical marijuana laws or talked about whether any other countries currently allow cannabis to be sold in pill form the way it was used in this study.", "answer": 0}, {"article": "Susan Pisano, a spokeswoman for the Association of Health Insurance Plans, the largest trade group, said insurers would wait for guidance from the FDA, but adds, \"If the FDA pulls back its approval for this particular indication, it would trigger a review of plan policies.\nBecause Avastin is approved to treat other cancers, losing the breast cancer indication would not, technically, remove it from a doctor's toolkit.\nIn 2008, the FDA granted Avastin what's known as accelerated approval as a therapy for metastatic breast cancer.\nMarcia Gilbert has had no significant side effects since starting on Avastin.\nSince then, it has also been approved as a treatment for certain types of lung, kidney and brain cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Avastin received preliminary approval for treating metastatic\u00a0breast cancer in 2008 and formal FDA approval is currently pending. ", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that although this is a new technology, it is not available everywhere.", "answer": 1}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that \"the new cream may not be widely available for 10 years,\" but that didn\u2019t stop them from writing about it or touting its \"promise.\" ", "answer": 1}, {"article": "A three-year-old Silicon Valley start-up, Counsyl Inc., won the Bronze Innovation Award for its simple, low-cost genetic test that can alert prospective parents who might be carrying genes that could cause hereditary diseases in their children.\n\nCounsyl's technology promises a \"high quality-of-life impact for families at risk for conceiving children with familial diseases,\" says Larry Bock, an Innovation Awards judge and special limited partner at venture firm Lux Capital. \"This technology bundles previously...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story says that after a period during which the test was available only at certain clinics, it now is available nationally. That sounds like good news, but I was left wondering if \"nationally\" meant the same as \"everywhere.\" Are we just as likely to see this test in Casper, Wyoming, as we are in Manhattan?", "answer": 1}, {"article": "New York Eye and Ear Infirmary of Mount Sinai is ranked No.\nThis is the first study to demonstrate that among advanced cancer patients admitted to an inpatient oncology service, standardized use of triggers for palliative care consultation is associated with substantial improvement on multiple quality measures.\nPublished today in the Journal of Oncology Practice, the study also determined that a systemized process of referrals resulted in significant improvements in 30-day readmission rates, hospice referral, and receipt of chemotherapy after discharge in patients with advanced cancers.\n\u201cPalliative care involvement helps patients understand their prognosis, establish goals of care, and formulate discharge plans in line with those goals, and this study is the first to confirm the impact of using standardized criteria and automatic palliative care consultation on quality of cancer care.\u201d\n\nCo-authors of the study include Kerin Adelson, MD, Division of Hematology/Oncology at Yale University School of Medicine.\nPatients were eligible for this prospective cohort study if they met one or more eligibility criteria: advanced solid tumor cancer, prior hospitalization within 30 days, hospitalization for more than 7 days, or active symptoms.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although this piece makes it plain that palliative care has positive implications for cancer care, it doesn\u2019t tell readers what is currently happening at hospitals around the country. It assumes readers are already aware of palliative care availability but that may not always be the case.", "answer": 0}, {"article": "Researchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story points out that most clinicians are not able to provide this sort of test and that at least one expert says that specialized testing centers would need to be developed.", "answer": 1}, {"article": "About 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\nMillions of people take a low-dose aspirin daily in hopes of reducing their chances of having a heart attack.\nHowever, aspirin can increase the risk for internal bleeding, so women should talk with their doctors before starting a low-dose aspirin regimen, for any reason.\nAbout 1 of every 8 women in the United States will develop breast cancer at some point.\nThose who take a daily low-dose aspirin, also called a baby aspirin, usually do so to prevent cardiovascular disease, the leading cause of death for women older than 25.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Low-dose aspirin is already widely available and is used by many women to reduce their risk of cardiovascular disease.", "answer": 2}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the robotic apparatus needed for the procedure reported on is not available in all facilities though it was becoming more common.", "answer": 1}, {"article": "They found participants had lower body temperatures after spending a sleep-deprived night in the lab, as well as longer reaction times and increased sleepiness.\nBut light was associated with better driving.\nBut there are still things drivers can do now to stay safer on the road.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nMore research is needed on the potential of bright light therapy to make exhausted drivers safer, said Dr. Donald Redelmeier, a researcher at the University of Toronto who wasn\u2019t involved in the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Light sources are readily available.", "answer": 2}, {"article": "\"It's kind of amazing that something so simple could be an answer,\" Paul said.\nHoney also beat out no treatment at all.\nOne local pediatrician said she wouldn't discourage parents from trying honey with their children, but more studies are needed to draw solid conclusions.\nThe study comes at a time when parents are on the lookout for new ways to give sick children relief.\n\"Consider using this as a treatment before going to the pharmacy to pick up an over-the-counter cough and cold medicine.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly honey and over-the-counter cough medicine are available.", "answer": 1}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that hormone therapy has been around for a long time and is very common.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that there are a wide range of counseling activities that are available. The story also covers medications for weight loss and the fact that they are under-prescribed given the obesity\u00a0epidemic.", "answer": 1}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is made clear that the blood test is not currently available, and the article gives a prospective date for\u00a0when the test will be launched.", "answer": 1}, {"article": "In deep brain stimulation, surgeons insert wires into the brain that allows a specific region to be continuously hit with an electronic pulse.\nDeep brain stimulation has been around for more than 20 years, Mayberg said, and is commonly used to treat Parkinson's disease.\nPrevious research by Mayberg and others suggested that deep brain stimulation had potential as a treatment for depression.\nDr. Samuel James Collier, an assistant professor of psychiatry at the University of Texas Southwestern Medical Center at Austin, predicted that even if deep brain stimulation turns out to be an effective treatment for depression, it'll be far from the first line of defense.\nMost of the patients continued to receive the treatment over two years, although researchers temporarily turned it off in three of them as part of the study before realizing that doing so caused their depression to return.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is widely available, saying, \u201cDeep brain stimulation has been around for more than 20 years\u2026and is commonly used to treat Parkinson\u2019s disease.\u201d", "answer": 1}, {"article": "Consultant hematologist John Snowden said: \u201cThe immune system is being reset or rebooted back to a time point before it caused MS ...\nI\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\nThis is not a technology you can patent and we have achieved this without industry backing.\u201d\n\nEmma Gray, the head of clinical trials at the MS Society, said: \u201cOngoing research suggests stem cell treatments such as HSCT could offer hope, and it\u2019s clear that in the cases highlighted by Panorama, they\u2019ve had a life-changing impact.\nPaul Kirkham, another patient who has undergone the treatment at a cost of about \u00a330,000, said: \u201cIt does knock you out.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reader must infer that, because the information comes from an ongoing clinical trial, the treatment is not yet available. And the story implies that it may be available outside of a research study: \u201cIt needs to be carried out at an accredited centre or as part of a clinical trial\u201d. Does this mean that if I have 30,000 pounds, I can have this done to me in the UK?", "answer": 0}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As other stories covering the study pointed out,\u00a0access to palliative care is limited by complicated reimbursement and\u00a0lack of\u00a0skilled providers in some areas. The\u00a0WSJ didn\u2019t mention\u00a0these\u00a0barriers. \u00a0", "answer": 0}, {"article": "They have.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\n\"It's pretty much while they're in training or while they're on the field performing, because that's when the adrenalin is flowing,\" and that's when they're calling on the heart for peak performance.\nAccording to Zipes, \"The adrenalin that is released when you're participating [in sports] can stimulate this abnormally thick heart muscle and cause a fatal heart rhythm problem, that is a very rapid heartbeat with no effective contraction, no blood being ejected to the brain and other organs.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n\nThe story states that electrocardiograms are not provided to all student athletes prior to participation in sports. Although it satisfies the minimum standard for a satisfactory rating on this criterion, the story could have done a better job in explaining that heart screening for student athletes (including EKG) is routinely available and relatively easy to obtain. A brief description of the way in which an EKG is obtained would have provided some context for the reader. \n", "answer": 1}, {"article": "Ultrasound waves applied to the whole brain improve cognitive dysfunction in mice with conditions simulating vascular dementia and Alzheimer's disease.\nThe first clinical trials to evaluate the effectiveness and safety of the LIPUS treatment are already underway.\n\"The LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly,\" says Shimokawa.\nThe research, conducted by scientists at Tohoku University in Japan, suggests that this type of therapy may also benefit humans.\nThis limits the types of drugs and cell therapies that could be made available to treat dementia.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that clinical trials are underway, which tells us (not quite clearly) that the LIPUS treatment isn\u2019t yet available to the public.", "answer": 1}, {"article": "In a study published last month in Nature, 80 percent of infants diagnosed with autism as toddlers had an increased rate of growth in the surface area of their brains in their first year, compared to toddlers who were not diagnosed with autism.\nAdditional studies are needed to confirm the finding, he said.\nExcess brain fluid may be more than an early marker for autism, Di Martino said.\nCompletely different mechanisms may be at work for kids without an older sibling with autism, said Shen and Dimartino.\nHe and his colleagues are working on improving accuracy by combining their brain fluid findings with other recent research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No explicit discussion is provided about the availability of MRIs for this sort of detection procedure (and if any special, different tools or procedures are needed), but the story does make it clear that this idea is still under research, so it\u2019s experimental for now.", "answer": 1}, {"article": "\u201cBut there were other components to it -- there was oppositional defiant disorder, there were some [autism] spectrum-like behaviors, and difficulty later on socializing with other children.\u201d\n\nOppositional defiant disorder is one of the most common conditions linked to ADHD in children and is characterized by anger, tantrums, opposition to authority and, sometimes, aggressive behavior.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\n\u201cIf you get a child who has really strong left brain and delayed right brain, those are kids that may be labeled with attentional problems or behavioral problems or social issues,\u201d Melillo said.\n\u201cWhat thinking really is is really coordinating different networks in the brain so that we can bring all of those networks together at one time,\u201d Melillo told FoxNews.com.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are dozens of\u00a0Brain Balance centers in the United States. The story does not directly address availability and could lead readers to think the New Jersey facility was one of a kind. But maybe the news organization felt it covered the issue when it\u00a0generously offered a free link to the centers at the end of the piece.", "answer": 0}, {"article": "\"Those stem cells are given back to the patient where they can go back to the bone marrow and make the blood cells for the rest of the patient's life,\" Kohn said.\nDr. Kohn said of an experimental treatment for SCID, \"It's gone from a 'one day, maybe' to a real clinical reality.\"\nThat means an actual cure for the disease, said Kohn, who is also director of the Human Gene Medicine Program at UCLA.\nDr. Kohn is currently working with the FDA to make his treatment available nationwide.\nIt's a genetic disorder that leaves the body with a weakened immune system, making infants extremely vulnerable to illness.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes, \u201cDr. Kohn is currently working with the FDA to make his treatment available nationwide. He\u2019s also testing the same method as a cure for sickle cell disease. Clinical trials for that treatment are now underway.\u201d This gives the impression that although the approach is still experimental, its availability nationally is a forgone conclusion.\u00a0In fact, many treatments get to this stage and do not pan out.", "answer": 0}, {"article": "In addition to He and Dibaba, other contributors included Pengcheng Xun, a faculty member in IU's Department of Epidemiology and Biostatistics; Kuninobu Yokota of The Jikei University School of Medicine in Tokyo, Japan; and Emily White of the University of Washington in Seattle.\nIndiana University researchers have found that magnesium intake may be beneficial in preventing pancreatic cancer.\n\"While more study is needed, the general population should strive to get the daily recommendations of magnesium through diet, such as dark, leafy greens or nuts, to prevent any risk of pancreatic cancer.\"\nPrevious studies have found that magnesium is inversely associated with the risk of diabetes, which is a risk factor of pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release briefly mentions dietary magnesium can be found in \u201cdark, leafy greens or nuts\u201d but a longer list of dietary sources might have been helpful. It\u2019s generally understood that magnesium supplements are widely available on any grocery or drug store shelf.", "answer": 1}, {"article": "Shares in Angle, which has a market cap of about 50 million pounds, rose 2.2 percent to 68 pence.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\nHeadline results from a study of 400 patients in Europe and the United States showed the test to detect cancerous cells in the bloodstream correctly identified cancer in up to 95 percent of cases, the company said.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicates that further studies are needed to fulfill European and US regulatory requirements, implying that the test is not yet available. But the comments of the company spokesperson make the likelihood of approval seem like a foregone conclusion.", "answer": 1}, {"article": "Radiologists and urologists have been frustrated for decades by the inability of conventional imaging tests, such as CT and MRI, to distinguish benign from malignant kidney tumors.\nAt Johns Hopkins, use of this test has already spared a number of our patients from unnecessary surgery and unnecessary removal of a kidney that would require them to be on dialysis.\nFOR IMMEDIATE RELEASE\n\n\n\nNewswise \u2014 The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT to CT or MRI increases the accuracy of kidney tumor classification.\nOn this measure, a value of 0.50 indicates that a diagnostic test is no better than chance.\nThe research team reports that the potential improvement in diagnostic accuracy will spare thousands of patients each year in the United States alone from having to undergo unnecessary surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes in several places, including in the first sentence, that the technique is \u201cwidely available.\u201d We know that to be true.", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that these drugs have been and continue to be readily available to patients.\u00a0", "answer": 1}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\nA California company, Genomic Health Inc., has sold a test called Oncotype DX since 2004 to help gauge this risk.\nOthers besides Oncotype DX also are on the market, and Hudis said he hopes the new study will encourage more, to compete on price and accuracy.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\nMary Lou Smith, a breast cancer survivor and advocate who helped design the trial for ECOG, the Eastern Cooperative Oncology Group, which ran it, said she thought women \u2018\u2018would be thrilled\u2019\u2019 to skip chemo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Associated Press report talks about costs of the Oncotype DX gene test by California company Genomic Health and adds that other tests are also on the market.", "answer": 1}, {"article": "During a treatment, a patient sits in a chair like one in a dentist\u2019s office while an electromagnetic coil is placed against her head.\nThe fee is generally about $10,000, but officials say they work with patients who can't afford that.\n\u201cThe initial treatment with rTMS is $12,000: That\u2019s a lot of generic Prozac or Effexor,\u201d which are cost-effective antidepressants with long track records, said Joel Rubinstein, associate medical director of Harvard Pilgrim HealthCare, an insurer that does not cover rTMS.\nThat 19-member panel voted 10 to 5 last year that studies of the treatment showed it to be as good as or better than usual care for depression.\nThe treatment, which has been approved by the Food and Drug Administration, is covered by Medicare in five states, but few private insurers pay for it routinely.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that an rTMS device has been approved by the FDA and that availability of treatment is growing. It also explains that treatment usually is not covered by insurance, so patients are on the hook for the $6,000 to $12,000 cost of treatment.\nStill, availability is very limited in most parts of the country", "answer": 1}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nThe time from gene discovery to successful drug may be shortening, but there are only a handful of successful drugs so far, and for a while at least, the appearance of new ones will be slow.\nBut the success of Kalydeco has been more than two decades in the making.\nBut for people who do have that mutation, the drug works remarkably well.\nThat's the day scientists from the U.S. and Canada announced the discovery of the gene associated with the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers can infer that this drug is available from the final sentence that establishes cost. It would have been easy for the story to specify clearly that the drug is now available by prescription, with some estimate of how widespread is the use.\u00a0 Nonetheless, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "RA Nash et al.\nThe treatment carries some risks, and many participants experienced the expected side effects of HDIT/HCT, such as infections.\n\u201cAlthough further evaluation of the benefits and risks of HDIT/HCT is needed, these five-year results suggest the promise of this treatment for inducing long-term, sustained remissions of poor-prognosis relapsing-remitting MS,\u201d said Richard Nash, M.D., of Colorado Blood Cancer Institute and Presbyterian-St. Luke\u2019s Hospital.\n\u201cIf these findings are confirmed in larger studies, HDIT/HCT may become a potential therapeutic option for patients with active relapsing-remitting MS, particularly those who do not respond to existing therapies,\u201d said Daniel Rotrosen, M.D., director of NIAID\u2019s Division of Allergy, Immunology and Transplantation.\nOther studies have indicated that currently available MS drugs have lower success rates.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no mention of whether this therapy is currently available, where it\u2019s performed, or whether regulatory approval is required. Also, there\u2019s no discussion of whether it is likely to be covered by most insurance plans. It appears that this is still purely a research therapy and would not be\u00a0available outside of research settings. \u00a0However, there are many physician\u00a0practices that do research, usually for industry, which don\u2019t\u00a0have the same safety features as this\u00a0research lab had.", "answer": 0}, {"article": "One therapy at M.D.\nDespite the endorsements, not everyone is ready to proclaim immunotherapy the future of cancer treatment.\nBecause it doesn't inflict the damage to healthy tissue caused by chemotherapy and radiation, immunotherapy's great appeal is its nontoxicity.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\n\"So many claims have been made about immunotherapy that have not borne out,\" says Dr. Steven Rosenberg, an NCI scientist who conducted the melanoma study but also published a review about the lack of randomized trials in support of the therapy.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story claims that many immunotherapies are almost ready to go up for FDA approval. This is not sufficient information on availability. The story should have made it clear that these therapies are currently only available through clinical trials. Furthermore, the story should have cautioned the reader that these therapies would only be appropriate after first-line treatments have failed (except in certain rare cases).", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that American surgeons perform about half a million total knee replacements annually, suggesting that the operation is widely available.", "answer": 1}, {"article": "WASHINGTON\u2014People with mild Alzheimer\u2019s disease who started taking an experimental Eli Lilly & Co. drug earlier in the course of their disease fared better than patients who started later in a clinical trial.\n\nThe outcome may bolster the company\u2019s case that the drug, solanezumab, can slow the decline of memory and function in mild Alzheimer\u2019s patients, despite prior studies with negative results. But the new data aren\u2019t final proof of the drug\u2019s benefit\u2014a separate, continuing study due to end in late 2016 is designed to...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes that solanezumab is the subject of a more definitive trial that won\u2019t end until at least 2016, and that aducanumab is still in early-stage clinical trials. That\u2019s sufficient for a Satisfactory rating. However, we wish that the story had explained that it will be years \u2014 at least \u2014 before either drug is on the market. And it\u2019s entirely possible that neither will come to market. On a health issue like this one, when people are often willing to grasp at straws to help a loved one, it\u2019s important to be as clear as possible when it comes to availability.", "answer": 1}, {"article": "The study, published in the December 26 issue of the Journal of Clinical Oncology, showed that patients treated with reduced radiation had less difficulty swallowing solids (40 percent versus 89 percent of patients treated with standard doses of radiation) or impaired nutrition (10 percent versus 44 percent of patients treated with regular doses of radiation).\nOther authors on the paper include: Shanthi Marur (Johns Hopkins Medicine) and Anthony Cmelak (Vanderbilt University).\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The issue of availability of\u00a0reduced dosages doesn\u2019t apply here.", "answer": 2}, {"article": "For more details and to read the full study, please visit the For The Media website.\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\nTo place an electronic embedded link to this article in your story Link will be live at the embargo time: http://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2017.2388\n\nPatients reported improvement in symptoms of eye floaters after treatment with a laser, according to a study published by JAMA Ophthalmology.\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nEMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JULY 20, 2017\n\nThe commentary, \u201cYAG Laser Vitreolysis\u2014Is It as Clear as It Seems?,\u201d by Jennifer I. Lim, M.D., of the University of Illinois at Chicago; and Editor, JAMA Ophthalmology, also is available at the For The Media website.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although wording of the release makes it clear that laser treatments are an option for eye floaters, the release does not provide information about availability.\nHowever, there is\u00a0enough information in the published study for any\u00a0ophthalmologist who is skilled\u00a0in the use of the YAG laser to be able to use the\u00a0treatment.", "answer": 0}, {"article": "LDL was 8.3 points lower on the moderate-fat diet without the avocado and 7.4 points less on the lower-fat diet.\nSo that was the only difference between the two diets, which then tells us that it's the avocado that has additional benefits which are beyond the unsaturated fat.\u201d\n\nThe findings are similar to a batch of studies that showed people who were given olive oil and nuts and told to add them to their diets ended up healthier.\n\u201cAnd certainly there's an emerging research base showing that some of these bioactive components may affect another lipoprotein particle favorably, like high-density lipoprotein.\nAnd it\u2019s one more piece of evidence in favor of adding good fats to the diet.\n\u201cI love guacamole and with my recipe, I'll use avocados, cilantro, lime juice and garlic... and then sometimes I'll put salsa in, or red pepper flakes.\u201d\n\nBut like anything, too much of a good thing can be harmful.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story gives the impression (largely correct) that avocados are widely available. As with the competing stories, we would have liked to have seen some acknowledgment that there are areas where avocados may be more difficult to find.", "answer": 1}, {"article": "CT scanning uses X-rays and computers to produce a clearer image than traditional X-ray techniques, but CT also uses higher radiation doses to generate those images.\nResearchers led by Dr. Ryoichi Kondo of Shinshu University Hospital in Matsumoto looked back at outcomes for close to 500 non-smoking lung cancer patients whose cancer was caught by CT scan screening, or by standard X-ray screening \u2014 another strategy for catching cancer early \u2014 or when patients came into the doctor with lung symptoms.\nEast Asian countries are more likely to regularly screen non-smokers for lung cancer because biological differences seem to put Asians at a higher risk than other non-smokers, researchers explained.\nThat\u2019s consistent with the findings of the National Lung Screening Trial in the U.S., which in November released data \u2014 published online in the New England Journal of Medicine last week \u2014 showing that 20 percent fewer middle-aged heavy smokers died of lung cancer when they were screened annually with a CT scan compared to a standard, less detailed chest X-ray.\nBut experts say the findings likely don\u2019t apply in non-Asian countries, where the majority of all lung cancers are found in people who smoke \u2014 and where using computed tomography (CT) scans to screen for lung cancer in smokers has recently been a controversial topic.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story differentiates between this study\u2019s screening in people who\u2019ve never smoked and the practice in non-Asian countries where most lung cancers are found in people who\u2019ve smoked. It stated:\n\u201cEast Asian countries are more likely to regularly screen non-smokers for lung cancer because biological differences seem to put Asians at a higher risk than other non-smokers, researchers explained.\nNon-smokers without symptoms generally are not screened for lung cancer in the U.S.\u201d", "answer": 1}, {"article": "Almost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or loss of balance, or symptoms reported by the child, like blurred vision or headaches.\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nWhen cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\nThis suggests that the blood test could be used by clinicians for up to a week after injury to detect brain injury.\nThe blood test also indicated which patients were in need of life-saving neurosurgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that the test is only part of a clinical trial and not available.", "answer": 1}, {"article": "[3] Yokell et al.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\n\"By empowering more patients to have access to this potentially life-saving medicine, we believe that EVZIO will help reduce the burden of opioid overdose in the United States.\n\"People at an overdose scene may be very emotional, so it really helps that EVZIO has audio instructions on how to administer this potentially life-saving medication,\" said Laurie Fugitt, RN, BSN, co-founder of Georgia Overdose Prevention.\nOur mission is to provide innovative solutions that empower patients to confidently take control of their medical conditions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the product is FDA approved and quotes numerous public officials discussing its use in their communities, so one can infer that it is on the market. However, since the release suggests that everyone should have the product in their medicine cabinets, it\u2019s really important to know whether and how members of the general public could purchase this product. It\u2019s not made clear that naloxone is something that must be prescribed. So we\u2019re rating this Not Satisfactory on that basis.", "answer": 0}, {"article": "NEW YORK -- Three years ago, Tomas Sandoval was looking forward to the birth of his second child when he was diagnosed with a rare form of a blood cancer called lymphoma.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nThe FDA will review these results and could make a decision on approval by the end of the year.\n\u201cEverything is at stake.\nDespite chemotherapy and a stem cell transplant, the cancer returned before his daughter\u2019s first birthday.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that this treatment is being reviewed by the FDA. It says that a decision \u201ccould\u201d come by the end of the year, which provides wiggle room.", "answer": 1}, {"article": "Added Dr. John C. LaRosa, president of the State University of New York (SUNY) Downstate Medical Center in New York City: \"It's very preliminary but it's important because the last drug out of the barrel of this type was not a success.\nA big study to confirm the results would take four to five years to complete so the drug is still years away from market, said Cannon, who is a cardiologist with Brigham and Women's Hospital in Boston.\nA large trial on torcetrapib was killed after investigators found an increased risk of death and other cardiovascular outcomes.\nOther experts are intrigued by the findings, but note that the research is still in very early stages.\n\"We saw very encouraging reductions in clinical events,\" said Dr. Christopher Cannon, lead author of the study, which also appears in the Nov. 18 issue of the New England Journal of Medicine.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story points out that anacetrapib still must be tested in a large clinical trial and is years away from being considered for approval.", "answer": 1}, {"article": "A serious mood disorder that affects as many as 1 in 7 women after childbirth, postpartum depression can lead to panic attacks, inconsolable sadness, and deep feelings of inadequacy.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nIt\u2019s also working on an oral form of the drug.\nThe company is also testing SAGE-547 as a treatment for a rare form of epilepsy.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this drug is still being tested and that the company has not applied for FDA approval.", "answer": 1}, {"article": "Images on paint can display on the left, a cancer free mouse; image on right illustrates how the tumor paint shows cancerous cells even after the cancerous organ has been removed.\n\nWhen treating cancer with surgery, there's nothing as important as making sure that every last bit of the disease has been removed. That's not always possible, since tumors have nasty habits of embedding themselves within healthy tissue and of breaking away and spreading malignancies to other parts of the body. But Researchers at Seattle's Fred Hutchinson Cancer Research Center have come up with an innovative way of giving surgeons the upper hand against these wily tumors. They have created a molecular \"paint\" that coats cancer cells so doctors can see the wayward cells that they may otherwise miss.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that testing of the \"paint\" described in the research would be expected to begin next year.\u00a0 Presumably these would be tests to determine effectiveness; before that there would need to be tests conducted to determine whether it is safe for use in humans.\nIt is not clear that the equipment (Xenogen IVIS-100 system) needed to visualize the \"paint\" in patients is available.\nIn general, the leap that is required from animal research to possible human application is not well explained. \u00a0", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nThe authors note that further research is needed to identify precisely how sleep deprivation causes rapid and significant reductions in depression severity.\nAlso, future studies are needed to include a more comprehensive assessment of potential predictors of treatment outcome to identify those patients most likely to benefit from sleep deprivation.\nPrevious studies have shown rapid antidepressant effects from sleep deprivation for roughly 40-60 percent of individuals, yet this response rate has not been analyzed to obtain a more precise percentage since 1990 despite more than 75 studies since then on the subject.\nSuch drugs typically take weeks or longer to experience results, yet 16.7 percent of 242 million U.S. adults filled one or more prescriptions for psychiatric drugs in 2013.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not say whether sleep-deprivation therapy is available as an alternative for most patients. In fact, sleep deprivation is not used as a treatment \u2014 only in research studies \u2014 and has been for decades.", "answer": 0}, {"article": "\"People are different.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\n\"This is a good foundation to design a trial where you would look at Spiriva plus steroids versus doubling the dose of steroids in a large number of asthmatics who are poorly controlled and then you follow them long-term,\" Shafazand said, but right now there is no data on long-term efficacy and safety.\nHowever, at this stage there is no definitive answer whether Spiriva should or shouldn't be used in asthma, she said.\nThese drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The headline and early sentences establish that Spiriva is available for COPD. It\u2018s not clear about the availability of Severent, one of the comparator regimens used in the study.", "answer": 1}, {"article": "The Centers for Disease Control and Prevention estimates 1 in 110 children in the United States have an autism spectrum disorder and boys are far more likely to have this neurological disorder that affects language and social behavior \u2013 that number is about 1 in 70.\nThis method, this test, needs to be tried [and confirmed] with many more subjects outside our laboratory,\" he says.\nLange is quick to caution that this type of test is not yet ready for prime time.\nStill he believes this is new study can help pinpoint the earliest markers of concern in developing brains.\n\"What this paper seems to be doing is taking the first steps towards parlaying what we are able to glean from brain imaging into potential diagnostic tools.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a better job than the Reuters story of showing that these scans will not be rolling into your local mall anytime soon. \u201cLange is quick to caution that this type of test is not yet ready for prime time. \u201cWe do not want to give anyone false hopes that this is ready for the clinic yet. This method, this test, needs to be tried [and confirmed] with many more subjects outside our laboratory,\u201d he says.\u201d", "answer": 1}, {"article": "In postpartum depression, the GABA pathway may play a key role in regulating hormones that researchers believe can lead to PPD.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials.\nThe FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018.\nA New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation.\nBrexanolone injection works differently than existing anti-depressant medications, and if approved by the U.S. Food and Drug Administration (FDA) later this year, will be the first new class of anti-depressants in decades, and the first drug specifically indicated for PPD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug is currently under FDA review, with a decision on its approval expected by the end of the year.", "answer": 1}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\nCurrently, stent retriever therapy is offered in just a few hundred hospitals across the country, including more than 100 Comprehensive Stroke Centers accredited by the American Heart Association and The Joint Commission.\nWhen it comes to a stroke, time is of the essence and according to the National Stroke Association using the FAST approach can help one determine the warning signs.\nThe American Heart Association has a select list of some of the comprehensive stroke centers in the U.S.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this procedure is not going to be widely available in the U.S. It says, \u201cCenters accredited by the American Heart Association.currently, stent retriever therapy is offered in just a few hundred hospitals across the country, including all 96 Comprehensive Stroke Centers.\u201d It also provides a map showing how few centers there are in the West.", "answer": 1}, {"article": "of fat lost over 30 days.\n\"Capsimax is supported by multiple studies with findings showing safety, increased lipolysis and satiety and improved healthy body composition.\nThe company develops IP-protected, science-backed branded ingredients from natural sources using cutting edge technologies.\nMorristown, N.J., Aug. 7, 2017 - As we age, managing healthy weight may become more difficult due to a slowing metabolism, however, help may come from a fiery source -- the capsicum pepper.\nThe company's centers of excellence are located in North America and India, whereas its cGMP and HACCP system-compliant manufacturing operations are located at multiple FDA inspected sites in India.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t offer any advice to readers about where to acquire Capsimax \u2014 just that it\u2019s available in \u201chundreds\u201d of products. An online search for \u201cCapsimax\u201d turns up numerous products containing the extract but\u00a0 can people shopping for supplements online be assured of purity of ingredients and accuracy of dosing? The release could have done a lot better job by directly people to reputable sources of the supplement.", "answer": 0}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\nTUESDAY, Nov. 23, 2010 (HealthDay News) -- Implantable devices designed to control heart rhythm and efficiency while preventing sudden death among heart failure patients are as effective at ensuring patient survival in real-world situations as they are in controlled study environments, new research suggests.\nRemote monitoring via telephone lines and online physician access is available for all ICD and CRT-D devices, the authors noted, and enrollment in such programs is typically free with a cardiologist's recommendation.\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says, \u201cThe finding is based on an analysis of nearly 186,000 patients outfitted with either an implantable cardioverter defibrillator (ICD), a cardiac resynchronization therapy device (CRT), or a defibrillator combined with a CRT device (a CRT-D).\u201d The size of the study might make one think that these devices are widely available, but because we are talking about three different devices, some nod should have been made to how widespread they are.\u00a0The story does make it clear that the remote monitoring system used is available to patients.\u00a0We give this a barely satisfactory as a result.\n", "answer": 1}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0This story mentioned that the company producing the labeling compound would be applying for FDA approval this year.\u00a0 ", "answer": 1}, {"article": "Cao's team found that men and women who took a regular dose of aspirin (325 milligrams) two times a week or more had a lower risk of cancer overall than people who did not regularly take aspirin.\nThe benefit was no longer seen within four years of stopping it, the researchers found.\nSo the more aspirin taken, the more the risk was reduced.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\nAmounts ranged from less than one aspirin a week to 15 or more, the researchers said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No explicit mention is made of aspirin\u2019s availability, but the drug is widely known to be commonly available, and the story certainly conveys that impression.", "answer": 1}, {"article": "Sabourin Lussier, born with spina bifida, faced the possibility of kidney failure when she was just 19 years old. Her bladder, damaged by the devastating birth disorder, leaked uncontrollably and often backed urine up into her kidneys.\n\nA conventional surgery to reconstruct her bladder with intestinal tissue threatened further health complications. So in May 2000, Ms. Lussier and her mother, Gail Johnston, agreed to an experiment under which she and eight other patients with spina bifida would receive partial, laboratory-built...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that this transplantation has only been done in a very small number of people and it is still very experimental. FDA approval has not given because tissue-based products need to be manufactured to standards similar to those for drugs or medical devices. ", "answer": 1}, {"article": "Regular aspirin use may lower the risk of Alzheimer\u2019s.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\nOne of the most prominent followed more than 6,000 older women for nearly a decade and found that those who regularly took 100 milligrams of aspirin did no better on cognitive tests, over time, than those who were given a placebo.\nDoctors have long said that an aspirin a day can help ward off heart attacks.\nBut more recent, randomized studies have called those findings into question.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story did not explicitly state that low-dose aspirin is a readily available, over-the-counter product, this information is common knowledge.", "answer": 2}, {"article": "By 2013, 56 percent of the Danes had a BMI of 25 or higher.\nThey looked at age, sex, smoking, cancer and heart disease.\nA body mass index under 25 is deemed normal and healthy, and a higher BMI that's \"overweight\" or \"obese\" is not.\nThe most relevant was the decline in smoking since the 1970s.\nMore than 100,000 people were involved.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "Psilocybin acts on the serotonin system, suggesting it could be developed for treating depression.\nThat kind of approach could be risky.\u201d\n\nNutt said the results showed that psilocybin \u201cis safe and fast acting, so may - if administered carefully - have value for these patients.\u201d\nA small-scale pilot study of psilocybin\u2019s use in cases of treatment-resistant depression showed it was safe and effective, the British researchers said.\nRobin Carhart-Harris, who led the study at Imperial College London\u2019s department of medicine, said the results, published in the Lancet Psychiatry journal, were striking.\nMany patients described a profound experience, he said, and appeared to undergo a shift in the way they perceived the world.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There are some small hints (it was called a \u201cpilot study\u201d), and one of the researchers warns readers\u00a0to avoid \u201cpicking their own magic mushrooms,\u201d but the story offers no other availability information. This sort of treatment under the supervision of a physician would not occur until after FDA approval for this specific indication, which would take many years.", "answer": 0}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\n\"Often, a diagnosis is made and then people are sent home with no information, no follow-up appointments and no clue about what is going to happen next.\"\nAnd the scans would be \"well set up for routine testing,\" according to Chiesa.\n\"It's very easy to do, and it's very quick to do.\"\nHow you live your life... has a real impact on how quickly your condition can decline.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that more work needs to be done before this becomes anything approaching a standard of care.", "answer": 1}, {"article": "Paul Delios of Saugus, Mass.\nHutcher says it's now about one in 1,000, which makes it less deadly than most major surgeries.\nIt's safer because of new surgical techniques which have also made it more effective.\nIt used to be that roughly one in 100 people died from this operation.\nA big reason the operation works is because it seems to suppress appetite.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that the gastric bypass operation is widely available and done as many as 200,000 times per year. ", "answer": 1}, {"article": "Obesity puts children at greater risk of developing preventable conditions like heart disease and diabetes at a younger age, and suffering poor health later in life.\nTaking vitamin D could help overweight and obese children lose weight, scientists believe.\nIt's encouraging that a simple intervention could have these effects and this certainly merits further investigation to consider its potential impacts on vitamin D supplementation for children with obesity.\"\n\"Future studies should explore what the underlying mechanisms are that explain this specific relationship between vitamin D and visceral adipose tissue.\"\nThe researchers randomly assigned 117 children with supplements containing 50,000 IU vitamin D for six weeks, while the others acted as the control group.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Vitamin D is easy to find and used pervasively, so we\u2019ll mark this N/A.", "answer": 2}, {"article": "They focused on genes known to play a role in folate metabolism.\nExactly why the prenatal vitamins may protect against autism is not clear, she says.\nOverall, Hertz-Picciotto says, \"For the women who didn't take prenatal vitamins, there was about a 60% higher risk of having a child with autism.\"\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers will know that the vitamins discussed in the story are widely available either by prescription or as over the counter (OTC)\u00a0supplements, so we\u2019ll\u00a0award a satisfactory here.\u00a0However, the story could have been more precise about what exactly these women were taking. Were they using formulations specifically designed for women of childbearing age or\u00a0simply taking a standard multivitamin supplement\u00a0during the prenatal period?\u00a0Did the benefits extend to women who only took folic acid, which\u00a0is widely regarded as the most important vitamin\u00a0to supplement during the prenatal period? In addition, the story\u00a0might have\u00a0noted that there\u00a0are different formulations of prenatal vitamins with varying doses of\u00a0key nutrients. It would have been helpful to include some discussion of\u00a0the nutrients women\u00a0should look for and why.", "answer": 1}, {"article": "Those are things that have low sodium, high potassium and high magnesium,\u201d said Larry Goldstein, director of the stroke center at the Duke University Medical Center in Durham, North Carolina.\n\"It's again the diet per se, not any one individual component of the diet.\"\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\n\u201cDietary magnesium intake is inversely associated with risk of stroke, specifically ischemic stroke,\u201d wrote lead author Susanna Larsson, a professor at the Karolinska Institute in Stockholm, Sweden.\nOther experts said the results were consistent with dietary recommendations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of this kind of diet is not in question.", "answer": 2}, {"article": "\u201cDr.\n\u201cOver the past decade there have been dramatic improvements in breast reconstruction that utilize various types of surgical innovations, implants, and biologic tissue,\u201d notes Dr. Small.\nI want to also commend the pathologists at Valley, who were exceptional in their diagnostic results.\u201d Dr. Wilson and Laura Klein, M.D., Medical Director of the Breast Center, have extensive experience in performing nipple-sparing mastectomy, a technically demanding surgery that is performed within aesthetically appealing minimally invasive incisions.\nI am also grateful for Dr. Small\u2019s willingness to \u2018look outside the box\u2019 and for his determination to perform my reconstruction in a way that would give me the best results with the least amount of recovery time.\n\u201cThis variation of a standard technique used during breast reconstruction will revolutionize the post-operative recovery in patients who meet certain criteria for the procedure,\u201d notes Dr. Small.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told\u00a0The Valley Hospital performed this surgery, and \u2014 by implication of going through the effort of issuing a news release \u2014 we have to assume the hospital plans to perform\u00a0this surgery again for patients who qualify. However, that isn\u2019t made clear.", "answer": 0}, {"article": ".\nMONDAY, Nov. 7, 2011 (HealthDay News) -- An investigational drug called pridopidine seems an effective and safe treatment for people with the progressive movement disorder Huntington's disease, researchers report.\nStill, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\n\"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that study results are from a phase III clinical trial, but it does not clearly comment on the availability of pridopidine, or the class of dopidine drugs in general. The story could have simply said that this drug is investigational and is not available yet.", "answer": 0}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is about a trial of a drug called candesartan, which is currently approved for treating hypertension. Researchers studied it for managing a condition that is now called pre-hypertension. But the story didn\u2019t make clear where the drug stood with the FDA for approval for the use described in the article.", "answer": 0}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nThe study is by Peter Rothwell, MD, PhD, FRCP, of John Radcliffe Hospital in Oxford, England, and colleagues, and has been published online by the journal the Lancet.\nThe latest study confirms the earlier results and concludes that similar effects can be shown for other types of cancers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that aspirin has been widely recommended for cardiovascular benefits.", "answer": 1}, {"article": "Only 1.8 percent of men with PSA scores below 1.0 were diagnosed with prostate cancer, with only 0.04 percent dying of the disease.\nOne caution, though, is that the study only looked at three surgeons performing RALP.\nA final study of almost 4,000 patients found that surgeons needed to perform 1,600 procedures known as robotic-assisted laparoscopic radical prostatectomies (RALP) to become adept at the procedure.\n\"This gives us some confidence that annual PSA screening is going to soon become a thing of the past,\" said Dr. Nicholas J. Vogelzang, chair of the Developmental Therapeutics Committee of US Oncology, who moderated the teleconference.\n\"We recommend that this operation should not be done by all urologists in small community hospitals but should be focused and concentrated on high volume centers of excellence... in order to achieve best possible results for patients,\" said study author Dr. Prasanna Sooriakumaran, a visiting fellow in urology at the Weill Cornell Medical College in New York.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported on three different aspects of prostate cancer testing and treatment \u2013 PSA testing, medical therapy as an adjunct to active surveillance, and data about the learning curve in the use of robots in the surgical treatment of prostate cancer.\nIf one reads between the lines, one can infer the widespread availability of all three approaches from the story.", "answer": 1}, {"article": "Reductions were seen of 35 percent at 10 weeks, and just over 22 percent at one year, for those given real acupuncture, compared with 24.5 percent and 5 percent, respectively, for those given sham acupuncture, the researchers said.\nFibromyalgia treatment usually starts with medications such as the nerve pain medication Lyrica (pregabalin), and if that fails or is only partly effective, doctors might add acupuncture to the mix, Rances said.\nMONDAY, Feb. 15, 2016 (HealthDay News) -- Acupuncture may help ease pain and improve quality of life for people with fibromyalgia, a new study suggests.\nHowever, although taking less pain medication, acupuncture patients were using higher levels of antidepressants after one year, which may have artificially boosted the positive results, he said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Acupuncture is now considered a fairly common alternative therapy for a number of conditions and is usually available in most locales. The story hints as much when it says that 9 out of 10 patients with fibromyalgia report using some form of alternative therapy, including acupuncture.", "answer": 1}, {"article": "More recently, inflammation has been implicated in development of the insulin resistance that leads to elevated blood sugar levels associated with type 2 diabetes.\nDue to the small size of the study and short follow-up time, researchers say it's too soon to recommend use of salsalate for the treatment of type 2 diabetes.\nLike aspirin, salsalate is an anti-inflammatory drug derived from salicylate and is often used to treat arthritis.\nHowever, it also has been shown to increase protein in the urine and its long-term safety will need further investigation.\nThat prompted researchers to take another look at salsalate in reducing blood sugar levels.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that salsalate is commonly used in arthritis but it\u2019s not recommended yet for the treatment of diabetes.", "answer": 1}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nHe's said it's unclear if the results will be mirrored in older cataract patients, the same concern expressed by others in the field.\nBhat was not involved in the new research, but said it's \"extremely exciting\" because it offers an alternative to \"an extraordinarily invasive\" procedure.\nShe said, even without answers to the question of whether it will work in aging eyes, it creates hope for children with congenital issues.\nHe hopes the surgery will be available to the general population within four to five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story includes several statements by the researchers saying that larger studies are needed as well as a longer follow-up period in patients before the success with this research is confirmed, which should give the average reader and understanding that this approach is not available at this time. A quote from one of the researchers also lets us know they hope to bring this surgery to the public within four to five years.", "answer": 1}, {"article": "Berzofsky declares no conflicts of interest.\nAccording to Berzofsky, the main scientific limitation of the study is that it is a relatively small, phase I clinical trial with no placebo control.\nIn the dose escalation portion of the phase I clinical trial, patients were injected with the vaccine on weeks 0, 4, 8, 16, and 24 after enrollment in the study.\nAmong the six patients who received the lowest dose of the vaccine, 5 million dendritic cells per injection, no clinical benefit was seen.\n\"Based on the current safety and clinical benefit data, the dose of the vaccine was increased to 40 million dendritic cells per injection and the trial opened to patients who have previously been treated with a HER2-targeted therapeutic, including patients with breast cancer,\" said Berzofsky.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There was no discussion of the availability, although with it being a phase 1 clinical trial, you can assume that it is not available yet. There was no mention about scaling this work since the vaccine was produced using each individual\u2019s immune cells to create the vaccine. It\u2019s unclear if the trial moves forward and enrolls more subjects, how difficult (or costly) it would be to bring this method of treatment to a wider audience.", "answer": 0}, {"article": "But in the study group overall, more-inflammatory diets were not linked to fracture and - in fact - the researchers found a modestly lower risk of lower-arm and total fracture in women with the highest dietary inflammation scores.\n\"I think this gives us yet another reason to support the recommendations for a healthy diet in the Dietary Guidelines for Americans.\"\nThe study, led by Tonya Orchard, an assistant professor of human nutrition at The Ohio State University, appears in the Journal of Bone and Mineral Research.\nThis was despite the fact that they started off with lower bone density overall.\nThe findings suggest that women's bone health could benefit when they choose a diet higher in beneficial fats, plants and whole grains, said Orchard, who is part of Ohio State's Food Innovation Center.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We are giving this a pass here because the release makes mention of \u201ca diet higher in beneficial fats, plants and whole grains,\u201d which includes foods that are widely available.", "answer": 1}, {"article": "Other medications, including raloxifene and a class of drugs called aromatese inhibitors, do much the same thing, though the Food and Drug Administration has not yet approved aromatese inhibitors for this use.\nEach one very likely came as a devastating blow, both to the patient and to her family.\nWhat if there was a medication that could at least reduce a woman\u2019s risk of developing breast cancer?\nBoth the ASCO and the task force guidelines recommend such a conversation.\nA 2010 study found \u201cexceptionally low\u201d rates of usage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discusses the availability of these drug therapies.", "answer": 1}, {"article": "\"The potential is huge.\"\nAtherectomy is only used in about 15 to 20 percent of PAD cases, but Dr. Lawrence Garcia, a principal investigator in the study, said he expects that to change with these results.\nAlso of note, Garcia said, is that the procedure proved as effective at improving blood flow for patients with diabetes as those without diabetes.\nThe company says this is a major step forward in treating PAD because, unlike stents, atherectomy \"leaves no metal behind.\"\nThomas Gunderson, a senior analyst for Piper Jaffray & Co., said the Covidien study could lead to greater use of atherectomy and a bigger market.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story never established if the device is approved by the FDA, and, if so, how widely it is used and available. There\u2019s a quote from the principal investigator that atherectomy is \u201conly used in about 15-20% of PAD cases\u201d but that he expects that to change with these results.\u00a0 But not all atherectomy is done with these tools.\u00a0 We actually aren\u2019t told how many are done with these tools.", "answer": 0}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\nBut because fennel extract, certain herbal teas and sugar water are generally safe, and because the research does suggest babies may benefit, pediatricians said they would feel comfortable recommending them to parents.\n(If parents want to try it, they could deliver sugar water in a dropper, or put a small amount in a bottle, Adesman said.)\nThis may help if the underlying cause of colic is cramping or discomfort due to an immature digestive tract, although that is just a theory, Brown added.\nBecause pediatricians can't offer parents much help with it -- for the most part, babies grow out of colic in time -- desperate parents often turn to alternative or complementary treatments, according to the study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "All of the alternative therapies discussed are widely available, but we think the story could have made this more explicit. For example, if you are a mom in rural Montana, are you expected to know how widespread is the availability (and where) of fennel extract, probiotics, etc.?\u00a0 Even the line about \u201csimethicone is considered the best available\u201d doesn\u2019t tell you what that means. She may have no idea whether you can find these things in the drug store, in the grocery store, in a health food store or all of the above.", "answer": 0}, {"article": "But in the U.S., most prostate cancers are identified by PSA screening, and less than half have palpable tumors.\nSecond, the Swedish study compared radical prostatectomy to watchful waiting.\nThe study found 38 percent fewer prostate cancer deaths among men randomly assigned to the surgery group versus those in what the Swedes called the watchful-waiting group.\nSo there's reason to think men followed with active surveillance and treated when necessary would fare better than the \"watchful waiting\" group in the newly published study.\nAlmost 90 percent had tumors their doctors could feel on digital rectal exams.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discussed the treatments in the study, radical prostatectomy and watchful waiting, and explained how watchful waiting differed from the active surveillance approach used in this country.", "answer": 1}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes it clear that the device is being developed and that human trials are needed to test its accuracy.", "answer": 1}, {"article": "Ann Thorac Surg 2015;100:785-93. doi:10.1016/j.athoracsur.2015.05.021\n\nFull text of the article is available to credentialed journalists upon request; contact Cassie McNulty cmcnulty@sts.org at +1 312 202 5865\n\nAbout The Annals of Thoracic Surgery\n\nThe Annals of Thoracic Surgery is the official journal of STS and the Southern Thoracic Surgical Association.\nWhile the current study did not evaluate other alternative options for TAVR, these techniques may include transaortic, transcaval, transcarotid, or trans-subclavian.\nOur study shows that age alone should not preclude referral for TAVR in patients age 90 years and older.\"\nHowever, with the advent of TAVR technology, we can now offer these extreme elderly patients a treatment option that otherwise would have been high-risk or prohibitive.\"\nAs part of the PARTNER-I trial, Vinod H. Thourani, MD, from Emory University in Atlanta, and colleagues from 12 other institutions in the United States found that transcatheter aortic valve replacement (TAVR) is a safe and effective way to treat aortic stenosis in nonagenarians who qualify for the surgical technique.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Based on the language in the release, it is not possible to tell whether TF-TAVR and/or TA-TAVR are widely available, if they are available only at specialized medical centers, or if these treatment options are still undergoing review for use outside of clinical trials. It is implied that this is an available procedure, but it could have been stated more clearly.", "answer": 0}, {"article": "One week after surgery I was off the crutches, walking on my own,\" Wallace said.\nSubchondroplasty has shown solid potential, but orthopedic surgeon Dr. Matthew Hepinstall is concerned that it might be \"oversold\" to desperate patients who want to avoid joint replacement surgery.\nHowever, subchondroplasty is only feasible in a narrow range of patients.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nIt is much less invasive than a knee or hip replacement, and typically is performed on an outpatient basis, Vasileff said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Bone cement procedures seem to be widely available for vertebral compression fractures, but it is not clear from this story or an internet search whether access to a bone cement procedure for knee and/or hip pain is still very limited or relatively accessible.", "answer": 0}, {"article": ".\nThey then followed nearly 90,000 people who had filled prescriptions for the anticoagulants warfarin, which has been used as a medication since 1954, and dabigatran, which was approved by the U.S. Food and Drug Administration in 2010.\nFurthermore, restarting therapy with the new oral anticoagulant dabigatran was associated with a lower risk of recurrent hemorrhage in these cases than the old standby drug warfarin.\n\"If a patient who is on an anticoagulant to avoid a stroke has a major bleeding event, doctors are faced with a catch-22: Discontinue the anticoagulant to avoid future bleeding, but again place their patient at increased risk of stroke; or resume the anticoagulant to continue avoiding a stroke, but then have to worry about another bleeding event,\" said lead author Inmaculada Hernandez, Pharm.D., Ph.D., an assistant professor in Pitt's School of Pharmacy, who completed this work as a doctoral student at Pitt's Graduate School of Public Health.\nMore than 1,500 of those people suffered a major bleeding event while using one of the drugs.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states that warfarin has been used as a medication since 1954 and dabigatran was approved by the U.S. Food and Drug Administration in 2010. It could have added that both are usually covered in drug plans, although the co-pay for dabigatran may make it less feasible for some patients.", "answer": 1}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "From the story\u2019s discussion, it is clear that all of the options being discussed in the story are available.", "answer": 1}, {"article": "About the University of Pittsburgh School of Medicine\n\nAs one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition.\nThe METREO results narrowly missed statistical significance.\nPatients included in the trials were still having flare-ups despite a year of a standard treatment known as \"triple inhaled therapy\" that includes bronchodilators and glucocorticoids.\nThe safety profile of mepolizumab did not differ from placebo in either trial.\nThe 300-milligram dose did not provide an advantage over the lower dose.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gets a satisfactory in this category since it mentions that the drug maker intends to seek FDA approval for its use in this type of patient, a fact that suggests to readers that it isn\u2019t currently available to patients.", "answer": 1}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the article that estrogen is readily available.", "answer": 1}, {"article": "Common symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nAn approval for Crohn\u2019s would give the drug entry into an estimated $1.3 billion U.S. market and $2.7 billion market worldwide.\nThe intravenous biotech drug met the primary goal of the study as almost 40 percent of patients who received the 6 milligrams per kilogram of weight dose of Stelara achieved a clinical response \u2014 defined as a 100-point reduction in the Crohn\u2019s Disease Activity Index (CDAI) \u2014 after six weeks of treatment.\n\u201cTo see these kind of outcomes, where you have high response rates in the short term and then good remission rates out toward five or six months of therapy, it shows unequivocally that the drug is effective for treating Crohn\u2019s disease,\u201d said Dr. William Sandborn, the study\u2019s lead investigator, who presented the data at the Digestive Disease Week meeting in Chicago on Sunday.\n\u201cIt\u2019s effective in the patient population that has the greatest unmet need at this point in time,\u201d Sandborn said of patients who do not respond to anti-TNF drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was borderline on this criterion. On the plus, the current indication is mentioned, as well as trials into other conditions. But on the minus,\u00a0our standard requires that articles provide readers with information about what phase of research the drug is in. It\u2019s not clear what phase the study is at and how close the drug is to the market in even the best-case scenario.\nThe article calls the trial \u201cmid-stage.\u201d According to the press release, that means phase 2b. Many readers won\u2019t know the significance of mid-stage, or that it\u2019s only at the \u201clate-stage\u201d (phase 3) that trials are designed to meet FDA requirements.\u00a0If it\u2019s phase 2b, mid-stage, generally we\u2019d expect another 2-4 years before piggy gets to market.\u00a0That\u2019s why we like to see a statement about exactly when patients could expect to see this medicine available to them. (Off-label use could occur before FDA approval, but given the expected price, it\u2019s unlikely to be covered off-label.) It tempers the hope of a breakthrough with the reality that, even if it aces its upcoming exams, the drug probably won\u2019t be readily available to patients until 2013-2015.", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nBenefits from the treatment lasted as long as people stayed on the treatment.\nWhen treatment was stopped, the benefits gradually tapered off, Baker said.\nWhen GHRH goes down with aging, it's a physiological adaptation.\nThe study medications were supplied by the manufacturer of the growth hormone-releasing hormone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There could have been a line or two about how GHRH is used now in medicine and whether there is much off-label use of the injections.", "answer": 0}, {"article": "\"D.C.I.S.\nAnother issue is that the message from the cancer institute seemed to play down a shortcoming of raloxifene that cancer doctors consider important.\nShe compared the drugs to statins and blood pressure drugs, which people take even though they feel well, to lower their risks of heart attacks and strokes.\nBut Dr. Ford of the cancer institute said raloxifene's ability to prevent invasive cancers was more important.\nThe institute emphasized that raloxifene lowered the risk of \"invasive\" breast cancer, tumors that have penetrated surrounding tissue and that have the potential to spread and turn deadly.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that Raloxifene is already marketed as Evista, a drug used to prevent osteoporosis after menopause, but that Eli Lilly has petitioned the FDA to approve it to prevent breast cancer.", "answer": 1}, {"article": "In a hip replacement, an artificial joint comprising a ball and socket is implanted to replace the natural ball and socket in the pelvis, enabling movement that is typical of the hip joint.\nThis research presented at the conference has not yet been published in a peer-reviewed journal and is currently in submission.\nThis exhibit in greater details demonstrates the treatment algorithm, patient cases, and the success with use of the standardized stepwise risk assessment and treatment algorithm to address dislocation risk in patients with spinal deformity.\nSE01 The Spinopelvic Relationship: A Stepwise Approach to Ensuring Stability in High-Risk Dislocation Patients Undergoing Total Hip Arthroplasty Nima Eftekhary MD, Ameer Elbuluk BA, Edward Delsole MD, Vinay Aggarwal MD, Richard Iorio MD, Aaron Buckland FRACS, Ran Schwarzkopf MD, Jonathan Vigdorchik MD./p>\nThis poster, \"A New Risk-Assessment Score and Treatment Algorithm for Patients at High Risk of Dislocation following Total Hip Arthroplasty,\" was selected by the AAOS Central Program Committee as the Best Poster in the Adult Reconstruction Hip classification at the 2018 AAOS Annual Meeting.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that patients who undergo hip replacement at NYU Langone Orthopedic Hospital have access to the risk assessment screening and treatment algorithm prior to surgery. But what about patients who can\u2019t travel to New York? Is anything similar in use at other institutions? The release is silent on this point.", "answer": 0}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBut this specific benefit data is being released on Saturday at the European Society for Medical Oncology\u2019s annual conference in Munich.\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\nNovartis plans to file with regulators for approval of the drug this year, Hirawat said, adding he also has strategies to broaden the indication, including tough-to-treat triple-negative breast cancer.\nOther drugmakers including Roche have seen similar investigational medicines stumble, making Novartis\u2019s progress here hopeful news, doctors involved in the trial said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that Novartis plans to file for approval for the drug this year.", "answer": 1}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nThere were no improvements seen in test scores of those who got the other treatment.\nThis is often not enough to make a meaningful improvement.\nAnd according to the new study, it helps.\nDec. 14, 2011 -- It can be an all too common scenario for certain stroke survivors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study is described as \u201cpreliminary\u201d and the treatment is called \u201cnot ready for prime time.\u201d We think readers get the idea that this treatment is not available for stroke rehabilitation outside of a research setting.", "answer": 1}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that there are current products for sale in grocery stores that contain probiotic bacteria and that in addition, there are new products being developed. \u00a0However \u2013 the story should have mentioned that there is no evaluation process to ascertain that the products sold as probiotics actually contain the organisms in the doses advertised. So true \"availability\" is difficult to ascertain.\u00a0 Consumers should know this. \nIt should be noted that the table that is a part of this story provides an inadequate listing of sources of probiotic containing foods.\u00a0", "answer": 0}, {"article": "U.S. alone, seventy-five percent of teens and adults are vitamin D deficient.\n\"This study will lead to a new generation of technology that can be labeled as photopharmacology in which the use of LEDs with targeted wavelengths can cause specific biologic effects in human skin to help treat and prevent chronic illnesses.\"\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nThanks to the work of the research team and the pioneering work of the Boston University Photonics Center on UV LEDs, we may soon see innovative treatment options like simple integration with a wearable device could aid millions of people.\"\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "RayVio already has other UV LEDs out on the market for health and hygiene purposes, but these don\u2019t include the 293nm UV LED \u2014 the prototype tested in this study. The news release makes clear that this technology is still being developed, hinting that a \u201cwearable device\u201d could be available to consumers in the future.\nWe wish the news release had given more information on the types of UV light therapies accessible now for patients, as well as what a treatment session currently looks like.\nSince the news release makes clear that the 293nm UV LED technology isn\u2019t widely available, we rate this one Satisfactory.", "answer": 1}, {"article": "\u201cIt was a little humiliating, to be honest,\u201d she said of the testing.\nThe new study is the latest chapter in an extraordinary, decades-long collaboration among cognitive scientists, brain surgeons and people with severe epilepsy being evaluated for an operation.\nThis study used data from 150 patients, and had 20 collaborators from institutions around the country, including Emory University, the University of Washington, the Mayo Clinic and the University of California, San Francisco.\n\u201cThe average enhancement effect was about 12 to 13 percent,\u201d Dr. Kahana said.\nAll the while, the scientists monitored a handful of \u201chot spots\u201d in the brain which, previous work had shown, were strongly related to memory encoding.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s made clear that this study focused on epilepsy patients whose doctors deemed they needed brain-stimulating implants, and that the research may not apply to broader populations.", "answer": 1}, {"article": "The rates are highest among Hispanics: Latina women are roughly 20 percent more likely to have a baby with a neural tube defect compared to non-Latina white women.\nIt all has to do with nixtamalization, the process by which tough corn kernels are softened by soaking in an alkaline solution, usually of slaked lime.\nSo a coalition of groups including the March of Dimes Foundation and the National Council of La Raza has petitioned the FDA to change its stance and allow corn masa flour to be fortified with folic acid.\nMichael Dunn, the Brigham Young University food scientist who led the study, cannot comment on the test results while they're under FDA review, but he has previously called them encouraging.\nBut the FDA worries that this alkaline treatment could also \"affect the stability of added folic acid,\" the agency told The Salt in a statement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that extra folic acid is already widely available in other flours. It notes that there is debate about adding it to corn flour.\u00a0Concerns about the technical difficulty of\u00a0adding folic acid that remains in usable effective form is a central point.", "answer": 1}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states\u00a0that the drug companies involved plan to ask FDA for approval later this year. This is a clear enough signal that the drugs aren\u2019t available yet.\nHowever, by speculating on how these drugs will be used by doctors, some of the statements imply that the drugs will definitely be approved, e.g.: \u201cMany doctors say they expect the drug to benefit patients whose diseases go undertreated because their fears about steroids cause them to use the drugs less frequently than prescribed.\u201d\nMany FDA applications for approval can be derailed by unforeseen safety concerns or other issues, and so the passage above could have been toned down to indicate this still all hinges on events that haven\u2019t happened yet.", "answer": 1}, {"article": "But the F.D.A.\nSo injecting it is an off-label use.\nThat said, polidocanol was the \u201csecond most commonly used sclerosing agent\u201d because, he said, \u201cmost physicians want to give their patients the best available treatment.\u201d\n\nF.D.A.\nShe said veins as large as a Sharpie marker can be tackled with foam sclerotherapy.\nA series of sessions is usually required for a large area.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story provides very specific information as to the availability of\u00a0different treatments for varicose veins in the U.S.", "answer": 1}, {"article": "Diabetes patients' blood sugar levels become abnormally high, causing a host of serious complications including nerve damage, the need for amputations, blindness, and increased risk of heart attacks and strokes.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\nOfficials defended the study, saying previous research had suggested that intensive blood sugar lowering would be beneficial.\nAlthough the reason for the increased risk remains a mystery, Nabel and other experts stressed that the benefits of blood sugar control have been well established for diabetics and said patients should not make any changes in their care without consulting their doctors.\nThe researchers stressed that the findings would not alter current guidelines or treatment for most diabetics, many of whom can control their blood sugar without drugs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that the medications used in this study where those that are commonly used for lowering blood sugar.\u00a0 ", "answer": 1}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This article clearly\u00a0indicates\u00a0that the two studies studies are preliminary and\u00a0that this treatment is in the experimental stages.\u00a0 It is implicit that the treatment is not clinically available but\u00a0available only to patients participating in clinical trials.\u00a0 ", "answer": 1}, {"article": "Last year, 2.3 million young Europeans (aged 15 to 34) used cocaine, and the US National Institute on Drug Abuse estimates that 1.4 million Americans suffer from cocaine addiction1.\nAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\nIt is also important to emphasize that, in this study patients were seeking treatment for their cocaine addiction in a hospital setting: the group studied, albeit small, was a \"real world\" sample.\nIt is important that this is taken forward to a larger trial.\nAs author, Dr Antonello Bonci (Scientific Director, National Institute on Drug Abuse, and Adjunct Professor, John Hopkins University, Baltimore) said:\n\n\"Despite the fact that more than 20 million people worldwide suffer from cocaine use disorders2, there are no effective neurobiological treatments for patients with this devastating condition\".\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While the release does state that this particular form of brain stimulation is being used to treat some other conditions, there is no suggestion that the treatment is readily available in most hospital or out-patient facilities, information which would help readers gauge the practicality of seeking such treatments.", "answer": 0}, {"article": "\"I say, 'Go for it!'\n\"But probably in over 90 percent of the cases, it does significantly improve a patient's quality of life.\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\nShe'd consider a second operation, but Metson says usually that's advised only for patients with nasal polyps that regrow -- not a problem she has.\nForeman writes a health column for The Boston Globe and other newspapers, so she's an unusually well-informed patient.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that about\u00a0300,000 people a year\u00a0undergo sinus surgery, making it one of the most commonly performed\u00a0procedures in the U.S.\u00a0 However, it does not provide statistics on the number or percentage of those procedures that are performed endoscopically and the type of hospital setting in which they are done. Enodoscopic surgery with CT guidance as described in the story may be out of the reach of smaller community based practitioners.\u00a0We\u2019ll call this satisfactory, but some additional detail\u00a0would have been appropriate.\u00a0", "answer": 1}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nCooling treatment also reduces the number and severity of cerebral palsy and increases the number of patients who survive normally.\"\nCooling babies deprived of oxygen at birth (perinatal asphyxia) can reduce the number of children who develop epilepsy later in childhood, according to a new study published in the journal Epilepsia.\nIt is known that newborn babies who suffer perinatal asphyxia may develop permanent brain injury resulting in cerebral palsy or other conditions, like epilepsy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Someone reading the release could easily think that therapeutic hypothermia is a treatment currently available only from the researchers who worked on this study. That\u2019s not the case. It\u2019s not something available at every hospital, but it is available at many hospitals. A 2014 report from the American Academy of Pediatrics addressed related limitations and challenges regarding the use of hypothermia to treat neonatal encephalopathy. This quote from that report would seem to apply here as well: \u201cInfants selected for cooling must meet the criteria outlined in published clinical trials. The implementation of cooling needs to be performed at centers that have the capability to manage medically complex infants. Because the majority of infants who have neonatal encephalopathy are born at community hospitals, centers that perform cooling should work with their referring hospitals to implement education programs focused on increasing the awareness and identification of infants at risk for encephalopathy, and the initial clinical management of affected infants.\u201d", "answer": 0}, {"article": "Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\nThe uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\n\"While some of the effects of this guideline may be beneficial in terms of reducing harms of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern for delayed diagnoses of important cancers associated with inferior cancer outcomes,\" noted Dr. Barocas.\n\"Future research should focus on prostate cancer screening paradigms that both minimize harms and maximize the potential benefits of screening, as well as accounting for individual patient risk factors and preferences.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is pretty clear from the release that PSA testing and related treatment are widely available.", "answer": 1}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The report makes clear what\u2019s FDA approved and what\u2019s not; and where to get the latest immunotherapies, and where people cannot get them. Good job on this.", "answer": 1}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\n\"The UroLift System has an excellent safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery.\nImportantly, the UroLift System provides fast and meaningful relief from BPH symptoms, improving overall quality of life for our patients.\"\nRead more about urology care at Northwestern Memorial Hospital.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The FDA \u201ccleared\u201d this surgical implant system in 2013 and it is available at Northwestern University, but there are no details about its general availability in other regions or health systems. We are left wondering.", "answer": 0}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Again, the story could\u00a0have benefited from some cost information about the tests and whether they are covered by most insurance plans. It also would have benefited from a sentence about how women can best arrange for such testing, and how widely available they are at prenatal clinics and private practices. But it does give information about the total number of tests done in the U.S. and about their growing popularity.", "answer": 1}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nThe new study was funded by Picato manufacturer LEO Pharma.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\nThis has long been used as a folk remedy for skin lesions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story repeatedly refers to the drug as a \u201cnew gel\u201d but never explains if it is available.\u00a0 It was recently approved by the FDA.", "answer": 0}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nScott Shikora of Tufts Medical Center in Boston says that until recently he hadn't performed a second obesity operation on anybody but is already up to about a half-dozen patients.\nAnother difference between the band and the bypass that proves both a plus and a minus is that the band doesn't cause the dumping syndrome.\nThayer says his banding operation, which would typically take about an hour, kept him under general anesthesia for 3 1/2 hours because his surgeon \"ran into a lot of adhesions.\"\nWhen the 6-foot Thayer edged up to 310 earlier this year at age 45, he decided to go for a second operation: adjustable banding, more commonly known as lap-band surgery, which allows for repeated stomach-tightening and thereby offers a new opportunity for reining in appetite.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not give any indication as to whether all bariatric surgeons perform gastric banding after gastric bypass surgery or if it was a select subset.", "answer": 0}, {"article": "For dementia, which people with Type 2 diabetes have double the risk of developing compared with non-diabetics, metformin has been found in a number of studies to cut that risk substantially.\nFor Price, there was yet another possible benefit \u2014 as a treatment for polycystic ovary syndrome, an endocrine disorder that doctors thought might explain the difficulty she and her husband had had conceiving.\nThe study does not explain why that might be.\nBut Price, a science and medical reporter in Oakland, Calif., doesn\u2019t have Type 2 diabetes.\n\u201cThere are legitimate reasons to put patients on one drug rather than another.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly notes that metformin is an existing prescription drug marketed under a number of unpronounceable names.", "answer": 1}, {"article": "Then they would have gotten even better yet.\nMORE: 7 Amazing Things That Happen to Your Body When You Give Up Soda\n\nBecause some of the children lost weight, to convince themselves that the effects weren\u2019t due to the small amount of weight that some of the children lost, Lustig and his team compared those who lost weight to those who didn\u2019t during the study, and found similar improvements in both groups.\nShe also points out that the children self-reported their initial diet, which can often be inaccurate.\n\u201cSo there was no change in [the children\u2019s] weight and no change in calories.\u201d\n\nAfter nine days of having their total dietary sugar reduced to 10% of their daily calories, however, they showed improvements in all of these measures.\nThe only difference in the nine-day diet was that most of the sugar the children ate was replaced by starch \u2014 the overall number of calories remained the same.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the dietary changes they made in the study could be made by anyone. The story says:\n\u201cWe took chicken teriyaki out, and put turkey hot dogs in. We took sweetened yogurt out, and put baked potato chips in. We took pastries out and put bagels in,\u201d says Lustig. \u201cSo there was no change in [the children\u2019s] weight and no change in calories.\u201d", "answer": 1}, {"article": ".\nForward looking statements with respect to predicted improved survival described in the poster presentation and video, are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MR-guided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer.\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\n\"The data presented at the 2017 ASTRO Annual Meeting suggests that higher radiation doses with adaptive MR guided radiation therapy may improve survival in pancreatic cancer while maintaining a very favorable toxicity profile.\nThe early results highlighted above, along with other data obtained using MRIdian will be tested in a multi-center, prospective, single-arm clinical trial for inoperable, locally advanced or borderline resectable pancreatic cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release notes that the next step is a prospective clinical trial and that tells savvy readers that this treatment strategy has a long road of testing ahead. Still, we think the release could have done a better job clarifying that this therapy is not yet ready for patients, outside of the clinical trial.\nA study that suggests a doubling of median survival is sure to capture the attention of patients newly diagnosed with pancreatic cancer. These patients and their families are closely aware of the glum statistics for the disease. This is a practical concern that the release should have touched on.", "answer": 1}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the two blood tests have been available since 2009.", "answer": 1}, {"article": "Other studies have linked this genetic factor, specifically for the \u03b15 nicotinic acetylcholine receptor, to increased risk of lung cancer and obstructive lung disease.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\nSmoking was defined as having had one or more cigarettes in the last week.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\nThe Society\u2019s more than 16,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability but it can be safely presumed that readers know vitamin C supplements are widely available.", "answer": 2}, {"article": "Stem cells are immature cells that differentiate into adult cells such as intestinal cells.\n'However, our work is the first to identify AIM2's role in controlling proliferation of intestinal stem cells.\nHowever, AIM2's established function in the cell was not in the machinery of cancer, said one of the paper's first authors Si Ming Man, Ph.D., a postdoctoral fellow in Kanneganti's laboratory.\nRather, he said, AIM2 was known to work in the immune system to detect invading bacteria and viruses and help 'alert' the immune system to battle them.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes one story author on this point: \u201c\u2018We have only scratched the surface of the role of AIM2 in controlling stem cell proliferation and the maintenance of a healthy gut microbiota,\u2019 Kanneganti said. \u2018How exactly AIM2 does both of these functions is an exciting research area to pursue.'\u201d Unfortunately, that\u2019s the last paragraph of the release. And the first seven paragraphs talk about research as if it were done in a human model. It\u2019s not until the eighth paragraph that we learn the study was done using mice. In short, this work is far, far removed from any potential clinical intervention for cancer patients. That should be said explicitly somewhere in the text, and the fact that the work was done in an animal model should have been made clear at the very top.", "answer": 0}, {"article": "Microcapsules loaded with stem cell-derived insulin-producing cells retrieved after they had been transplanted into a mouse.\nScientists on Monday showed they had overcome some of the major hurdles standing in the way of a long-sought therapeutic fix for patients with type 1 diabetes, outlining an approach that the body\u2019s immune system could tolerate and providing a possible pathway toward clinical trials in the next few years.\nMost of these other companies are taking a different approach from the work done in the studies published Monday.\n\u201cThe main issue with type 1 diabetes is a loss of beta cells,\u201d said ViaCyte CEO Paul Laikind, \u201cbut there\u2019s also good data out there to suggest dysfunction in other regulatory cell types.\u201d\n\nThe team behind the studies published Monday, meanwhile, is working on tests now in monkey models.\nBut experts say the findings provide hope for future treatments for people.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story at the top makes it clear that the treatment is not available, saying, \u201cScientists on Monday showed they had overcome some of the major hurdles standing in the way of a long-sought\u00a0therapeutic fix for patients with type 1 diabetes, outlining an approach that the body\u2019s immune system could tolerate and providing a possible pathway toward clinical trials in the next few years.\u201d Not the qualifier of \u201cpossible\u201d in that sentence.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The \u201cgrowing number of doctors\u201d offering this procedure, the lack of insurance coverage, the FDA OK for one device and off-label use of others all address general availability issues.", "answer": 1}, {"article": "Tau has been tied to neurofibrillary tangles in the brain; researchers find that an increase in tau in cerebrospinal fluid is associated with Alzheimer's also.\n\"The way we diagnose Alzheimer\u2019s disease is by evaluating the behavior and the risk factor medical profile, not by looking at biological markers at this point.\"\nThe current thinking is that interventions will be most effective when given to a patient as early as possible, Brickman said.\nDown the road, the \"fantasy\" is that asymptomatic people will be able to get a biomarker test to determine whether they'll one day get Alzheimer's, but that's not possible right now, he adds.\nBut it's too early to use this as a diagnostic tool in clinical settings, says Brickman.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Again, the independent expert\u2019s perspective was important:\n\u201cWhen these sorts of studies get published, Brickman and other doctors get phone calls from aging adults wondering whether they should be getting spinal taps to assess their risk.\u00a0 But it\u2019s too early to use this as a diagnostic tool in clinical settings, says Brickman. Down the road, the \u201cfantasy\u201d is that asymptomatic people will be able to get a biomarker test to determine whether they\u2019ll one day get Alzheimer\u2019s, but that\u2019s not possible right now, he adds.\u201d", "answer": 1}, {"article": "\u201cPatients readmitted after surgery almost always have a postoperative complication, either medical or surgical,\u201d Drs.\nDoctors who did not perform the surgery won\u2019t have that context, which may explain part of the survival benefit of returning to the original hospital, he said.\nIt might be harder for patients to get appropriate care at the other hospitals, where they don\u2019t have a pre-existing relationship with a surgeon, and so treatment might be delayed, Dimick and Miller wrote.\nAmbulance drivers and emergency department doctors should make every effort to get a patient who has had major surgery back to their original hospital, he said.\nJustin B. Dimick and David C. Miller, both of the University of Michigan, wrote in an editorial.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, seeking to ensure that patients who have undergone major surgery would be readmitted to the hospital where the initial surgery was performed would appear to be logistically difficult, at best. The story did not address that concern.", "answer": 0}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\nThe drug combination is now being tested in a larger phase 3 study, which is required for U.S. Food and Drug Administration approval.\nBy targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.\nSATURDAY, Sept. 29, 2012 (HealthDay News) -- Researchers say they've discovered a two-drug combination that delays treatment resistance in patients with advanced melanoma.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says that the drug combination is\u00a0being tested in a larger phase 3 study, which is required for FDA\u00a0approval. While this is true, it could also have noted that the drugs individually have already been submitted for approval as monotherapies. If they are approved, oncologists could presumably use the drugs in an off-label\u00a0combination treatment similar to the one studied here.", "answer": 1}, {"article": "\"What we are developing, and a lot of other companies too, are small molecule antiviral agents that specifically target the virus.\"\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\nTwo of these drugs, Vertex Pharmaceutical's telaprevir and Merck's boceprevir, are in the final stages of study and may make it to the market as early as next year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story called the research on BMS-790052 \"preliminary\" and made it clear that\u00a0the drug\u00a0was not close to approval. It also was more cautious than the competing HealthDay piece in its description of two other antiviral drugs that are nearing FDA approval.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states the robotic tool is available at selected hospitals throughout the country and that availability is expected to increase. ", "answer": 1}, {"article": "\u201cMuch higher than red wine, for instance.\u201d\n\nThe researchers figured an antioxidant-rich diet might help patients with kidney failure, because the level of free radicals in their blood increases as the blood circulates through the dialysis device.\nDoes this make pomegranates better than any other fruit?\nA 16-oz bottle of POM Wonderful sells for about $4.\nThey also made fewer trips to the hospital.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of pomegranate juice is not in question.", "answer": 2}, {"article": "\"I could ride a bike!\nThe organization creates and shares bionic arm designs for free download at EnablingTheFuture.org that can be assembled for as little as $20 to $50.\nMiddle and high school student groups and Girl and Boy Scout troops are among those donating their time and materials to assemble limbs for kids and give them to recipients for free.\n\"It's really just a step-by-step process of solving problems.\nThe students use the printer in the school's manufacturing lab and cover the cost of materials -- about $350 -- through donations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story includes links to the groups developing these prosthetics, there is really no exploration of how easy it is to get one. Apparently the process involves finding a group of local volunteers, such as middle school students and Boy Scouts, who can assist with printing and assembling the limbs. Are these volunteers widely distributed throughout the country? Do they have the capacity to meet demand? We\u2019ll give the benefit of the doubt, but relying on such volunteer groups sounds like it could lead to disappointment, especially if the publicity from stories like this one leads to a surge in demand.", "answer": 1}, {"article": "Platelets, the blood cells that promote clotting, contain hundreds of proteins, called growth factors, that are important in repairing injuries.\nThose who seek this treatment must look for a clinician with considerable PRP experience \u2014 someone who does the procedure several times a day, not once or twice a month \u2014 and who has a good success rate, Ferrell says.\nIts practitioners believe it will transform orthopedics.\nBefore undergoing PRP treatment, I read quite a bit about it, learning that it holds promise for healing soft-tissue injuries such as tearing of the rotator cuff (the group of tendons and muscles that provide stability to the shoulder), tennis elbow, plantar fasciitis, Achilles tendinitis, patella tendinitis and hamstring tears; it may even provide relief for mild to moderate osteoarthritis.\nFerrell told me not to use nonsteroidal anti-inflammatories, such as ibuprofen, for a week after the injection because the goal is to encourage, not stifle, inflammation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that platelets are removed from a patient\u2019s blood using a centrifuge, equipment readily available in most practices.\u00a0 It makes the point of advising readers to seek out practitioners who do the procedure frequently.\u00a0 The story suggests that the PRP procedure is becoming more available.", "answer": 1}, {"article": "\"Therefore,\" he said, \"we need to be extremely aggressive in treating atrial fibrillation patients with anticoagulants [blood thinners] when indicated.\nBut a new study suggests these drugs may also help keep dementia at bay.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\nA score of zero to one usually means blood thinners aren't needed because the risk for stroke is low.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Warfarin is a common drug, as are a number of other blood thinners.", "answer": 1}, {"article": "The researchers compared breast cancer deaths in women who had a breast cancer diagnosis in counties that had screening with deaths in counties that did not.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe availability of mammography was not explicitly addressed, but we can\u2019t criticize the story for that.\u00a0 Instead, we give a Not Applicable score for this criterion. ", "answer": 2}, {"article": "\u201cIt\u2019s an important part of this challenge,\u201d Frank said.\nBut as Stanford pain specialist Sean Mackey emphasized to me, opioids should not be a first-line treatment due to the risks, and alternatives should be tried first.\nSeveral of the studies were done in pain centers where they have expert programs, and those just are not widespread.\u201d\n\nIn fact, the lack of access to non-opioid strategies may be one big reason that doctors resorted to opioids in the first place.\nFor one, the reviewed studies generally looked at the results of tapering, when patients are slowly weaned off opioid painkillers \u2014 a process that, Stanford psychiatrist Anna Lembke told me, can take months or even years.\nBased on his reading of the data, \u201cit\u2019s John with PTSD on the 10 milligrams.\u201d\n\nBut as is true for addiction and pain treatments, adequate mental health care is also out of reach for many patients \u2014 showing just another way that the US health care system isn\u2019t built to adequately address the full needs of patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story delivers: It states that tapering is available, yet that it\u2019s to be attempted with caution. Non-opioid pain-relief treatments, which are also noted by the story, are also said to be available, though out of reach for many.", "answer": 1}, {"article": "Up to 89 percent of the men who received the combination formulas saw their sperm concentrations plunge to less than 1 million sperm per milliliter, versus just 23 percent of those receiving only testosterone.\n\"I think [men] would use it more than is realized,\" said Alukal, who was not involved in the new research.\nPrevious research involved administering the combination by injection or via a patch, said study senior author Dr. Christina Wang, a professor of medicine at Los Angeles Biomedical Research Institute.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nThe combination contraceptive needs to undergo further testing before it is commercially available.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201cThe combination contraceptive needs to undergo further testing before it is commercially available.\u201d", "answer": 1}, {"article": "Dr Sheraz Markar, an NIHR Clinical Trials Fellow from Imperial College London, under the supervision of Professor George Hanna, told the Congress: \"At present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy.\nThe results showed that the test was 85% accurate overall, with a sensitivity of 80% and a specificity of 81%.\nThe new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the breath test is not available. The release did not make any predictions about when such a test might make its way through the full course of experimental trials.", "answer": 1}, {"article": "\"And that there's bound to be a 5 percent extraction rate of these bands per year that they're in.\nAlmost 50 percent had to have the bands entirely removed, while 60 percent needed to undergo subsequent surgery.\n\"[I] therefore think patients will continue to ask for the procedure.\"\nBut he cautioned that patients undergoing band surgery should do so knowing that they need to commit themselves to rigorous long-term follow-up.\nWith gastric bypass that's not as much of an issue.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The gastric banding procedure was appropriately described as an available treatment.", "answer": 1}, {"article": "In fiscal year 2017, Penn Medicine provided more than $500 million to benefit our community.\nSpironolactone is not approved for the treatment of acne by the U.S. Food and Drug Administration despite expert opinion supporting its use, and Barbieri says the findings of this study should be confirmed by a randomized controlled trial that directly compares the two treatment options.\nThe study, published this month in the Journal of Drugs and Dermatology, found patients who were originally prescribed spironolactone changed to a different drug within one year at almost the same rate as those who were prescribed antibiotics.\n\"It's clear that a safe alternative to oral antibiotics could have a huge benefit, and our data show spironolactone may be that alternative,\" said the study's lead author John S. Barbieri, MD, MBA, Dermatology chief resident at Penn.\nIn addition to the benefits for antibiotic stewardship, Barbieri pointed to several studies showing long-term oral antibiotic use may be associated with antibiotic resistance, lupus, inflammatory bowel disease, and even colon and breast cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release explains that both methods are currently available and in use. It states that while some dermatologists already prescribe\u00a0spironolactone for acne, the FDA has not approved it for that use. Without FDA approval, most insurers will not cover the cost of treatment.", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nAt the heart of the paramount discovery is the dietary supplement vitamin B3, also known as niacin.\nThis discovery is akin to the revolutionary breakthrough made last century that confirmed folic acid supplementation can prevent spina bifida and other neural tube defects in babies.\nThe landmark study found that a deficiency in a vital molecule, known as NAD, can prevent a baby\u2019s organs from developing correctly in the womb.\nWorld first research at the Victor Chang Institute has found that this deficiency can be particularly harmful during a pregnancy as it can cripple an embryo when it is forming.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release noted that niacin is available as a dietary supplement. ", "answer": 1}, {"article": "If you do that, 2 out of 3 parents don't fill out the prescription.\"\nThe Finnish noted that limiting use of antibiotics may reduce the development of drug-resistant bacteria and increase the chance the future use of antibiotic will be effective.\nRosenfeld says it's never wrong to prescribe an antibiotic for a well-diagnosed ear infection.\nAccording to one of the studies, ear infection, or acute otitis media, is the most frequently diagnosed illness in children in the United States, and most children with these ear infections are routinely given antibiotics.\nGiving babies and toddlers antibiotics when doctors are certain they have ear infections can help speed up their recovery, supporting current treatment guidelines for children between the ages of 6 months and 23 months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of antibiotics to treat ear infections is not in question.", "answer": 2}, {"article": "Dr. Kenneth Liao used the da Vinci surgical robot Thursday to restore lost blood flow to the heart of 58-year-old John Carter Holmes.\nThose limitations haven\u2019t deterred hospital executives, though, who see the robotic systems as crucial for attracting and retaining surgeons and patients.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nThe number of da Vinci robots has doubled in Minnesota in less than two years, with two at the university and four at the Mayo Clinic in Rochester.\nThe learning curve for cardiac surgeons was too steep, though, and the system\u2019s tools weren\u2019t as useful for heart surgeries as they were for other procedures, said Dr. Goya Raikar, a cardiothoracic surgeon at Regions Hospital in St. Paul.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does a good job of specifying how many daVinci surgery robots are available in Minnesota\u2013and which facilities have them. ", "answer": 1}, {"article": "Nearly all patients diagnosed with early-stage melanoma can be treated and cured, but 85 percent of patients with late-stage melanoma die from it within five years.\nThe company plans to bring them next year to just 200 dermatologists on the East coast, all of whom must undergo company training before they can begin using the device.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\n\"Every day patients come in with 20 moles on their back and the dilemma is, which ones are suspicious and need to be biopsied?\"\nMela Sciences does not plan to ask insurers to cover the device until several years from now, after it is more widely used.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says clearly that the devices are not currently available in most areas. \u201cBut don\u2019t expect to see a MelaFind machine at your next doctor\u2019s appointment. The company plans a limited rollout next year of just 200 dermatologists on the East coast, all of whom must undergo company training before they can begin using the device.\u201d", "answer": 1}, {"article": "\u201cBut this is a small study, a proof of concept.\n\u201cWe can\u2019t yet say that this study means that DHEA is a viable alternative to HRT, but ... we should be looking to do larger studies to confirm these initial results.\u201d\n\nDHEA, or dehydroepiandrosterone, is a natural steroid hormone mostly made in the adrenal glands and has a variety of therapeutic uses.\nItalian researchers writing in the journal of the International Menopause Society, Climacteric, said they had found the first robust evidence that low doses of DHEA can help sexual function and menopausal symptoms, suggesting it may one day become an alternative to hormone replacement therapy (HRT).\nGenazzani said the results showed DHEA has potential, especially for those women who may have problems in taking more conventional HRT.\nHRT, which is a combination of the hormones oestrogen and progesterone, is an approved treatment for women going through the menopause, who often experience unpleasant symptoms such as hot flushes, night sweats, loss of sex drive and mood swings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability is implied, but the story could have been more explicit about how readers might purchase the specific drugs that were studied or whether they were in specific trial stages for this type of treatment. In fact, tibolone is not available in the U.S. though it is available in Europe.\u00a0 DHEA is sold as a supplement over the counter.\n\u00a0", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n(Agatston does not make any money from the coronary calcium scan.)\nA calcium score would answer that question, she says.\nThere's a third test Agatston likes: a $65 blood test that looks at a patient's LDL, or bad cholesterol.\nThese new tests give patients a chance to make major changes in their diet and lifestyle, and give doctors an opportunity to treat them with medication.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story makes it clear that the three tests discussed are available at most hospitals.", "answer": 1}, {"article": "Vemurafenib, approved in 2011, can cause non-lethal skin cancers.\nA few years ago, that would have been a very short list.\nAnd none are risk-free.\nFor the first time, however, patients such as Herry have options.\n\"Well, 'manageable' can mean something different to patients.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The varying stages of availability of the various drugs was made clear in the story.", "answer": 1}, {"article": "Dec. 2, 2011 (Chicago) -- An experimental approach in which penile nerve tissue is frozen to knock out overactive nerves helped men with premature ejaculation last three times longer.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\nIts supporters say the technique, or a similar one involving heat therapy, could someday become a standard treatment for the condition.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this procedure is not currently available to the typical patient.", "answer": 1}, {"article": "Due to diffuse symptoms, pancreatic cancer is usually diagnosed very late in the disease progression.\n\"Our test can detect pancreatic cancer with 96% accuracy at stage I and II, while there is still the possibility of successful surgical intervention.\nThe next step has already been initiated, which is a large US prospective study for high risk individuals.\nSince the immune system is the first to respond to threats like complex diseases, such as cancer, autoimmune diseases and infections, the microarray was designed to mirror this early response.\nThere is currently no cure and few treatment options for advanced pancreatic cancer, which is the late stage when pancreatic cancer is usually diagnosed\", explains Carl Borrebaeck, professor at the department of Immunotechnology at Lund University.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "At the very end of the news release we read:\n\u201cIn the future, the screening method could be used to screen people who are at high risk of developing pancreatic cancer, such as those with a hereditary risk, newly onset diabetes patients, and patients with chronic inflammation of the pancreas. The next step has already been initiated, which is a large US prospective study for high risk individuals.\u201d\nThis is an important inclusion but it would have helped to put this higher up in the news release because it provides an opportunity to emphasize that the blood test is unproven as a screening tool.\nMore importantly, it\u2019s currently not commercially available and the news release should have made this clear.", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a wonderful job highlighting concerns about the availability of the treatment offered in these studies. \u00a0We are told that only specialized centers have the expertise and technology available to perform the procedures, \u00a0and that insurance coverage has been spotty. The story also mentions the three clot retrieval devices that are approved for use in the United States.", "answer": 1}, {"article": "Those whose tumors expressed PD-L1, but not at high levels, did not show such a statistically significant benefit in progression-free survival.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nThe approval was contingent on the company providing more detailed data in the future on Keytruda\u2019s safety and effectiveness.\nKeytruda and a similar treatment from Bristol-Myers Squibb Co called Opdivo are antibodies designed to block the interaction between PD-L1 and another protein, PD-1, whose natural function is to put checks on the immune system.\nMore detailed data from the study will be provided soon, Merck said, adding that it will ask the U.S. Food and Drug Administration later this year to add the new data to the drug\u2019s package insert label.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that Keytruda has been approved for use in treating lung cancer.", "answer": 1}, {"article": "Arthritis pain is caused by bones rubbing together after protective cartilage is damaged or worn away.\nAfter years of cortisone treatments and therapy, wrist replacement became a last resort.\nAfter replacement surgery and months of physical therapy, patients can lift no more than 15 or 20 pounds, he said.\nShe still can't lift more than 11 pounds, but the pain has greatly subsided.\nMore than a dozen bones lie beneath the skin and muscles of the hand and wrist, compared with two or three for those larger joints.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article explains that wrist replacement has been available for decades. But why is the procedure \u201cseldom used\u201d? Is the device FDA-approved? Is the operation widely available in the U.S., offered in the local community hospital, or mostly consigned to large or academic medical centers? The article does not say.", "answer": 0}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nAnd dietitians say too much chocolate can be harmful.\nFor now, said registered dietitian Katie Clark, \"caution should be taken not to promote chocolate as a health food,\" even though it's fine in moderation.\nSo, should you and your sweetheart add dark chocolate to your diet?\nThe health benefit may come from antioxidants called flavonoids that are present in chocolate, Saposnik said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of chocolate is not in question. ", "answer": 2}, {"article": "\"In that population, there is a benefit,\" Coleman said.\nSaid Coleman: \"Zoledronic acid cannot be routinely recommended for prevention of cancer returning, but it remains a very good drug for patients where the cancer has already spread to the bone.\"\nIn one previous study, the use of the drug was linked with a 32 percent improvement in survival and lowered recurrence in younger women with breast cancer.\nBisphosphonates have been used to treat osteoporosis as well as bone complications of breast cancer treatment, she said.\n\"The role of bisphosphonates in preventing cancer recurrence has been less clear,\" she said, noting that multiple studies have had conflicting findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article did not make it clear that the FDA has not yet approved zoledronic acid as adjunctive treatment for women with early breast cancer.\n\u00a0", "answer": 0}, {"article": "In the study, patients who received monthly gantenerumab injections showed reductions in such brain plaques.\nThe study is published in the online edition of Archives of Neurology.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story ends with an appropriate send-off:\u00a0 \u201cWe need more studies to know if it is safe or effective.\u201d\u00a0 The early, experimental nature of the research is clear.", "answer": 1}, {"article": "she asked.\nFor one, this study was done in school-aged children, many of whom were actually teenagers, so it is impossible to know if these differences in neuroimaging would also be found in younger patients, Adesman pointed out.\n\"Although this technique holds promise for identifying infants at risk for autism, it still needs to be determined whether the atypical patterns of brain activation are specific to autism,\" said Geraldine Dawson, chief science officer for Autism Speaks.\n\"There is a serious unmet need in the autism world, where diagnosis is currently done by subjective reports, and after the child has missed many developmental milestones,\" said lead researcher Joy Hirsch, a professor of functional neuroradiology, neuroscience and psychology, and director of the Functional MRI Laboratory at Columbia University Medical Center in New York City.\n\"The other major limitation of this study is that the investigators did not look at whether these brain differences are specific to children with autism, or if they would also be seen, for example, in children with language delays who are not autistic,\" Adesman said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that using MRIs to diagnose autism is an uNPRoven approach. The author of the study says, \u201cThis is not the diagnostic that you can package and send to all community health centers in the United States. This is an announcement that this can be done,\u201d she said. The story could have pointed out that the validity of the testing would be dependent on the expertise of the radiologist, as reading functinal MRI is different from traditional MRI.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "\"This can potentially decrease having to go back to the operating room and with no real effect on your [cosmetic] outcome,\" said study leader Dr. Susan Boolbol, chief of breast surgery at Beth Israel Medical Center, in New York City.\nHowever, she thinks more research is needed.\nIn June, the radiation-free device won the blessing of a U.S. Food and Drug Administration advisory panel.\nThe expected cost of the MarginProbe in the United States, if approved, is not yet known, said Michael Graffeo, a spokesman for its maker, Dune Medical Devices.\nThe device is also being studied for use with prostate cancer, the company said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are told that an FDA advisory panel recommended that the FDA approve the device, which has been used for several years in Europe.", "answer": 1}, {"article": "CNN Films Presents:\" Glen Campbell ...\n(The current study was a phase 2 trial, typically meant to evaluate safety and get an early look at efficacy of a new drug.)\nThe main goal of the current study, which included 119 patients, was to find out whether high doses of resveratrol could be safe.\nThere is probably little benefit in taking currently available resveratrol supplements, even if they claim to contain levels similar to the ones used in this study.\nThe current study used high doses of resveratrol to increase the chances that enough of the compound got into the brain to have an effect.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study addresses this specifically: \u201cEven if concentrated forms of resveratrol pills like the kind used in this study were available, it\u2019s too soon to recommend going out and getting some just yet.\u201d", "answer": 1}, {"article": "The Site is down for maintenance.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The experimental nature of the drug was clear in the story.", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most readers will know that ibuprofen is a widely available, over-the-counter drug.\nHowever, it\u2019s not made clear how available (or accurate) the saliva test for Abeta42 is.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This\nrating does not apply, as the story focuses on watchful waiting and active surveillance in lieu of preventative surgery for\nhernias. Hernia operations are a common procedure and available in most hospitals; the new treatment (no intervention, save\nfor monitoring general health or symptoms typical of a hernia) is also now an evidence-based option for treatment.", "answer": 2}, {"article": "\u201cYou could not have convinced me that I would ever have done this or continued with this,\u201d she said.\nBut not all of these reports have been conclusive, and tai chi is hard to study because there are many styles and approaches.\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\n\u201cFibromyalgia is so common, and we have such a difficult time treating it effectively.\n\u201cIt\u2019s hard for some patients\u2019 families and their doctors to get their head around what it is and whether it\u2019s real.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story makes it clear that there are multiple versions of tai chi. It could have been more clear about how widely available it might be, especially in sparsely populated areas.", "answer": 0}, {"article": "\"Whereas the typical developing kid will have an explosion of their language ability starting at about 12 months in both comprehension and production, kids in autism delay don't start comprehending or producing until later, and they don't ever have that kind of explosion.\nAnd when it is ready for prime time, it probably won't be applicable to all children with autism.\nBut another expert pointed out that the study is still extremely preliminary.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\n\"It's a very early study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear several ways that this is early research and would require further development before a detection protocol was available.", "answer": 1}, {"article": "High blood pressure, or hypertension, is a major risk factor for cardiovascular diseases \u2014 the leading causes of death worldwide.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\nElaine Rush, a professor of nutrition at Auckland University of Technology in Australia, said that putting a spotlight on single trials and generalizing dietary advice for a single nutrient such as salt was \u201cnot helpful.\u201d\n\n\u201cWhat is helpful is for the food industry to reformulate products to reduce sodium and increase the nutrient quality of foods by using real ingredients,\u201d she said in an emailed comment.\nIn Britain, the National Institute of Health and Clinical Guidance (NICE) has called for an acceleration of the reduction in salt in the general population from a maximum intake of 6 grams(g) a day for adults by 2015 to 3 g by 2025.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of salt is not in question.", "answer": 2}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nHe added that although the study proved the treatment's effectiveness and safety only in children, adults would probably benefit in the same way.\nThere are more than a few caveats when it comes to the treatment regimen.\nThough the immunotherapy treatment is simply a matter of gradually increasing your tolerance to peanuts, you could have a severe reaction at home.\nEllis is one of the majority of children for whom the treatment works.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the treatment is not yet FDA-approved, and is not currently commercially available.", "answer": 1}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\nThe device is being developed by Cameron Health, a small company in San Clemente, Calif., that was co-founded by Dr. Bardy.\nBefore the device can be sold here, Cameron Health will have to submit more extensive human trial data to the F.D.A.. Dr. Bardy said a larger study of the device has just begun in this country and overseas and that it will most likely take a year or more to assemble data from it for the agency\u2019s review.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\nThe story points out that the new type of implantable defibrillator is available in some countries in Europe, but that further trials are needed to produce evidence that could be used to apply for FDA approval in the United States.", "answer": 1}, {"article": "-- Icing the bottom of the foot, sometimes using ice to massage the heel area\n\n-- Using cups made of gel in shoes to cushion the heel (and many orthopedic surgeons say expensive custom-made orthotics are not necessary)\n\n-- Wearing a night splint, a simple brace that holds the foot in a flexed position to keep the plantar fascia stretched during sleep\n\n-- Physical therapy, though some studies indicate that some PT practices such as ultrasound and whirlpool are not helpful\n\n-- Use of NSAID (non-steroidal anti-inflammatory) drugs such as ibuprofen and naproxen\n\n-- Corticosteroid injections into the heel, though this is controversial and should not be used repeatedly\n\n-- Backing off activities like running until the pain goes away, and then reinitiating them gradually\n\nAbout 90 percent of sufferers will get better with time.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\nMeanwhile, foot specialists and their patients are left with a smattering of low-tech treatments that they say all plantar fasciitis patients should try, whether or not they eventually go on to shock-wave therapy.\nDuggal says foot specialists don't really know what causes the pain of plantar fasciitis.\nBut while inflammation can be involved in plantar fasciitis, it doesn't seem to be the cause, Duggal says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0says that shockwave therapy is \"beginning to catch on around the U.S.\" While this\u00a0gives readers the accurate impression that the treatment is approved for use and available in some places, it doesn\u2019t really give readers a sense as to how\u00a0likely they are to find it at their local doctor\u2019s\u00a0or orthopedist\u2019s office. Although it earns a satisfactory, the story could have provided a bit more detail on the history of these devices in the U.S. (they were first approved for use in 2000) and how widespread they have become.", "answer": 1}, {"article": "Side effects of male hormone therapy can include erectile dysfunction (impotence), loss of sex drive, hot flashes, growth of breast tissue, loss of muscle and bone mass, weight gain, nausea, liver problems, fatigue, memory problems and mood swings.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nThe hormone therapy started two months before radiation.\nSo, that brings into question how much, if any, hormone therapy is needed, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained about the treatment used in the study reported on as well as how radiation therapy has changed since the men in the study were treated.", "answer": 1}, {"article": "This compared with 1.9 percent using mitoxantrone.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\nThe French drugmaker said on Thursday that the combination of the treatments led to an improved median overall survival of 15.1 months against 12.7 months in patients who took a chemotherapy of mitoxantrone with prednisone/prednisolone.\nCabazitaxel won priority review from the U.S. Food and Drug Administration (FDA), meaning the health regulator will take about six months instead of the usual 10 months to assess if a drug is efficient and safe to be marketed.\n\u201cThe development of cabazitaxel is one of many investigational compounds we hope to present to the cancer community in the months and years to come,\u201d Debasish Roychowdhury, Sanofi\u2019s oncology senior vice president, said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story indicated that the drug reported on was not yet approved for use in the EU; it also mentioned that drug is currently scheduled for an expedited review by the US FDA.\u00a0 ", "answer": 1}, {"article": "The drugs are benzodiazepines, which are widely known by their brand names Xanax and Valium and commonly prescribed to help treat anxiety.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\nFor one, emergency room visits and inpatient admissions for opioid overdoses likely aren\u2019t a perfect one-to-one proxy for overdoses that didn\u2019t involve a trip to a doctor.\nAnd since the research relied on patients who were continuously insured throughout the study period, it\u2019s possible the findings don\u2019t exactly apply to people with spottier coverage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "On balance the story could have done a better job of exploring what it would take to halt these dangerous drug interactions. The headline describes their elimination as a \u201csimple way to help combat the opioid epidemic,\u201d but the story acknowledges otherwise:\nFor some patients, eliminating these co-prescriptions could involve some tough trade-offs. If someone genuinely suffers from pain and anxiety, doctors and patients will need to work out which condition is more important to treat and which one can be treated with alternatives \u2014 to avoid a potentially deadly overdose.\nThe story also could have addressed the difficulty in changing physicians\u2019 prescribing patterns. If indeed, as the story contends, \u201cit\u2019s well established that benzodiazepine and opioids compound each other\u2019s overdose risk,\u201d why have so many dual prescriptions been written?\u00a0 Are there readily available and affordable alternatives to these two classes of drugs? The story doesn\u2019t say.", "answer": 0}, {"article": "A study shows that not all good fats are the same when it comes to protecting your health\n\nA study shows that not all good fats are the same when it comes to protecting your health.\nThe study is actually a reanalysis of data that had not been included in the original publication of results from the Sydney Diet Heart Study, a trial that was conducted from 1966 to 1973.\nRamsden says the findings provide some refined understanding of unsaturated fats, which come in different chemical forms that may have varying benefits or risks.\n\u201cWhat happened is that in the 1960s all polyunsaturated fats were considered the same.\nFor more than three years, researchers at the time followed 458 men aged 30 to 59 years old who had a history of heart disease; about half were told to replace the saturated fats they consumed from animal and dairy sources with omega-6 linoleic acid, which is commonly found in safflower oil or margarines made from it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As with the competing HealthDay story, there really wasn\u2019t enough information about the fatty acid composition of different vegetable oils, including\u00a0which ones are rich sources of linoleic acid (e.g. safflower oil and corn oil) and which ones\u00a0have a balance of omega-3 and omega-6 fats (e.g. canola, soy). There\u2019s still good evidence that the latter group are healthier than saturated fats. As with the previous criterion comment, it would have not taken much space to explain this to readers.", "answer": 0}, {"article": "There's no definitive answer to that just yet, Wang said.\nMost patients, according to background information in the article, remain in pain years after the diagnosis, are aerobically unfit, have poor muscle strength and flexibility, and need medications to control symptoms.\nDoctors will often suggest exercise, sleep hygiene techniques and medications to treat the condition, but often with limited success, said Dr. Gloria Yeh, an assistant professor of medicine at Harvard Medical School, who wrote an accompanying editorial in the journal.\nWhile larger studies are needed to confirm the findings, tai chi looks promising as an alternative treatment, Yeh said.\n\"Also, since tai chi has a meditative component, it may also help to address the stress and anxiety that may be associated with the condition.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are left to make their own assumptions about the availability of tai chi classes in their communities. More problematic is that the story does not provide any detail about the style or rigor of the tai chi classes (aside from the fact that the classes last an hour), making it difficult for a patient, or health care advisor, to make an informed decision as to how to proceed.", "answer": 0}, {"article": "And when you have an episode, it is one of the most life-changing and life-re-evaluating events,\" Babin says.\nThe studies for these drugs, which are not yet on the market, were funded by the drug manufacturers.\nIn light of that experience, federal regulators may go slowly with the two new drugs, called fingolimod and cladribine.\nThe new pills also appear to be more effective than most current drugs.\nDr. John Richert, executive vice president of research and clinical programs at the National MS Society, says the introduction of these pills will mark a major improvement in the lives of MS patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story was clear that the drugs in question are not yet on the market and that \"federal regulators may go slowly with the two new drugs.\"", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a common dietary component and its association with bone mineral density.", "answer": 1}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The purpose of the story was to announce FDA approval of the new device, so it\u2019s clear that it\u2019s not widely available yet.", "answer": 1}, {"article": "These plaques, which are caused by blood cholesterol, build up over time and cause arteries to narrow, leading to heart disease as the heart works harder to pump blood through the body.\nThey generally cost less than $100, she said.\n\"The best use is in patients who have no symptoms, but the value of the test is not well known.\"\nThe findings appear in the July 7 issue of Annals of Internal Medicine.\nThis study confirms their usefulness in that regard, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that CAC testing is widely available.", "answer": 1}, {"article": "When his heart disease was first diagnosed four and a half years ago, Mr. Del Sontro, now 50, told his cardiologist he wanted to run one more Bay to Breakers race, a century-old 12-kilometer race in San Francisco.\nThat strategy alone, Dr. Biesecker said, has eliminated the vast majority of candidate genes.\nResearchers\u2019 ignorance of these control regions and what many of them do might doom the effort.\nThe researchers are now searching for culprits among genes that remain \u2014 a search that could take years.\nDr. Biesecker acknowledged that there was no guarantee of success.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. Any\u00a0tests or treatments based on this research are many years away.", "answer": 2}, {"article": "\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\nSome might not have a large enough sample to find a small but statistically significant effect.\nThe authors acknowledged certain weaknesses in their study.\nThere are more than 200 species of virus that cause colds, Dr. Coleman said, and a study could test one species against which echinacea proves ineffective, while leaving open the question of whether it works for others.\n\u201cBut if adults believe in echinacea, they\u2019re going to get benefits \u2014 maybe from placebo \u2014 but they\u2019ll get benefits.\u201d\n\nDr. Coleman, who described himself as \u201cnot much of a pill taker,\u201d hedged a bit when asked if he planned to use echinacea himself.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article fails to say\u00a0how widely the herb is used and where it\u2019s available. But it\u2019s probably safe to assume that most Americans know how to find it.\u00a0 ", "answer": 2}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the first sentence that the device is not yet available and that the FDA just approved the device for marketing to breast cancer patients.\nDigniCap wrote on its website: \u201cWe will be finalizing agreements with major cancer centers and community oncology groups across the country so that they will be able to offer DigniCap\u00ae treatments to patients as soon as possible.\u201d", "answer": 1}, {"article": "\"We have no right as parents or as physicians or adults to strap them down and chop off a normal part of their body.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\nChapin and other critics argue that the scientific evidence is questionable.\nAs Shots reported last week, a lot of state Medicaid programs have stopped covering circumcision.\nFor its part, the pediatricians group hopes the new recommendations will encourage more parents to circumcise their sons \u2014 and more insurance plans to pay for it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability is clear in the story, as is the decline in use\u2026and the fact that many state Medicaid programs have stopped covering it.", "answer": 1}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nHowever, it isn\u2019t clear whether such a reclassification would involve CBD products in general, the CBD formulation used specifically in Epidiolex or something else.\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\n\u201cWe are just scratching the surface of what could be a range of cannabis-based medications.\u201d\n\nThe medication, which will continue to be manufactured in Britain, will be marketed by Greenwich Biosciences, the U.S. subsidiary of GW Pharmaceuticals.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article does not state exactly when the drug will be on the U.S. market, but generally, FDA approval coincides with market availability.", "answer": 1}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nTUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\nPeople interested in trying it should reach out to one of the big clinical trials; Johns Hopkins is one of the centers testing Marinol.\n\"It's a milder form of TCH\" compared to whole-leaf marijuana, Lanctot said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that a form of synthetic THC (dronabinol; trade name \u2018Marinol\u2019) also is available in the U.S. (The story makes it sound like Nabilone is only available in Canada, but it does appear to be FDA approved in the US for cancer treatment as side effects, known as Cesamet.)\nGiven the fact that this a Canadian study (where medical marijuana has been legal since 2001), and that the legality of medical marijuana in the US varies by state, it might have helped readers to clarify if a synthetic like nabilone is considered legal, experimental, and/or requires a prescription.", "answer": 1}, {"article": "Every year, 1.3 million men in the U.S. undergo a prostate biopsy.i Although a biopsy is the only way to diagnose prostate cancer, the procedure is invasive and results in complications in 18 percent of patients, with 3 percent hospitalized for infection within 30 days.ii,iii,iv Common complications from a prostate biopsy may include bleeding, infection, sepsis/bacteremia, urinary symptoms/retention, and sexual dysfunction.\nThe full paper is accessible via the online edition of The Journal of Urology.\nAll other trademarks and service marks are the property of their respective owners.\n2011.\nThe test has been included in the 2018 European Association of Urology (EAU) clinical guidelines.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that the test is already in use.", "answer": 1}, {"article": "People feel less stimulation at lower pulse widths.\n\u201cAll stimulation treatments given so far have been in the head,\u201d said lead study author Dr. David Yarnitsky, an advisory board member for Theranica, the company developing the device.\nIt\u2019s designed to stimulate nerves under the skin in the arm and block pain signals from reaching the brain.\nEven though the study\u2019s participants were not told whether they were assigned active or placebo treatment, one limitation of the experiment is that participants often stopped placebo treatments before the recommended 20-minute course of stimulation was done, the authors note in Neurology.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes that TENS was already available for use on the head, but uses a researcher\u2019s words to carefully note that\u00a0it remains to be seen if TENS on the arm is a reliable stand-alone treatment that doesn\u2019t need to be paired with drugs. It also makes it clear that the technology is still being tested.", "answer": 1}, {"article": "The researchers wanted to evaluate whether in a group of women suffering from severe menstrual pain, aged between 18 and 34, self-acupressure would be more effective at achieving a sustained reduction in menstrual pain than usual care alone (e.g.\nThe app Luna has recently been updated and optimized for use with iOS.\nAdditionally, the app was used to collect all study-related data.\nIt can also send regular reminders.\nThe app helped participants to apply simple self-acupressure techniques to three different acupressure points.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release links to a website where the app is available in German and where it can be downloaded for free.", "answer": 1}, {"article": "Prostate cancer cells express up to 100 times more PCA3 RNA than do normal cells.\nThe PCA3 test can do things the PSA test can't, says Jack Groskopf, PhD, of Gen-Probe Inc., which manufactures the test and funded the new research.\nThe test, which is approved in some European countries but not in the U.S., detects genetic material -- RNA -- from prostate cancer gene 3 or PCA3.\n\"More often than not, the damage is due to benign (noncancerous) conditions such as enlarged prostate\" -- a condition called benign prostatic hyperplasia or BPH, Groskopf tells WebMD.\nThe PCA3 test isn\u2019t a replacement for PSA testing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story does mention that this test is not approved for use in the US but that is approved for use in several European countries. \u00a0It closes by indicating that the company that makes the test is hoping to file for approval later this year.", "answer": 1}, {"article": "They rated themselves as healthier and were less likely to report problems with mobility, pain, daily activities, social interactions and feelings of depression and anxiety, among other factors that can compromise well-being.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\nAnd the reason is not a lack of willpower.\n\u201cBariatric surgery is probably the most effective intervention we have in health care,\u201d says Laurie K. Twells, a clinical epidemiologist at Memorial University of Newfoundland.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the story that bariatric surgeries are common and widely available\u2013if not necessarily covered by one\u2019s insurance plan.", "answer": 1}, {"article": "N-acetylcysteine reduced PTSD symptoms, cravings, and depression in veterans with PTSD and substance use disorder in a randomized controlled pilot trial conducted at the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center\n\nN-acetylcysteine, when combined with group cognitive behavioral therapy (CBT), reduced symptoms of posttraumatic stress disorder (PTSD), cravings, and depression significantly more than CBT alone in veterans with co-occurring PTSD and substance use disorder, a particularly difficult-to-treat population, according to the findings of a randomized controlled pilot trial conducted by researchers at the Medical University of South Carolina (MUSC) and the Ralph H. Johnson VA Medical Center.\nThis is not an easy-to-turn-around population.\"\n\"This is a tough patient population with SUD to work with.\"\n\"We would not advocate using it instead of therapy,\" said Back.\n\"But this could be something to help prevent relapse when used alongside a behavioral treatment.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn it is sold over-the-counter and available everywhere.", "answer": 1}, {"article": "In May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\nStatins are not risk-free.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted,\u201d Samadder added in a statement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that statin medications are a popular medication for managing cholesterol levels and so it was clear that they are currently in use.\nIt would have been useful to indicate that these are prescription medications available in both brand name and generic versions.", "answer": 1}, {"article": "On day one, subjects reported to a laboratory after a 10-hour fast, completed a health status report, and had either a high- or low-nitrate breakfast.\nBeet roots contain high concentrations of nitrates, which are converted into nitrites by bacteria in the mouth .\nPrevious studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\n\u201cThere have been several very high-profile studies showing that drinking beet juice can lower blood pressure, but we wanted to show that drinking beet juice also increases perfusion, or blood flow, to the brain,\u201d Daniel Kim-Shapiro, PhD, director of the Translational Science Center at Wake Forest University, says in a news release.\nNov. 3, 2010 -- Drinking beet juice increases blood flow to the brain in older people, a finding that suggests the dark red vegetable may fight the progression of dementia , a new study shows.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that nitrites are found in high concentrations in beets, celery, cabbage and other leafy green vegetables like spinach.", "answer": 1}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nGilbert cautioned that the study results are preliminary.\nThe time of survival was also up significantly from the previous average of 14 months, said Sampson, who declined to reveal the exact number until he presents the data June 2 at the American Society of Clinical Oncology meeting in Chicago.\nIn all, the study enrolled 23 patients between 2005 and 2007.\nAlmost all the patients mounted an immune response.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explained that the treatment described was available only as part of a clinical trial.\nWhile this was accurately reported, the story should have mentioned whether or not patient recruitment for the trial was ongoing and if so, it could have included a link to \u00a0http://clinicaltrials.gov/.", "answer": 1}, {"article": "The average age of people in both groups was 73.\nOther assessments, such as PET scans for plaques of Alzheimer's proteins in the brain, are good at detecting early signs of Alzheimer's disease, but available to few patients.\nPET scans cost thousands of dollars and require radioactive materials not found in a typical hospital.\nIn a small study, MRI brain scans predicted with 89 percent accuracy who would go on to develop dementia within three years, according to research at Washington University School of Medicine in St. Louis and the University of California San Francisco.\nOne day, MRI brain scans may help predict whether older people will develop dementia, new research suggests.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "MRI scans are described as \u201cwidely available.\u201d", "answer": 1}, {"article": "Other times doctors may not realize how many tests involving radiation patients have already undergone -- information that could influence a doctor's decision -- or may order a CT scan when other tests that do not involve radiation, such as a blood test, an MRI or an ultrasound, would suffice.\nThese are X-rays from a CT scan.\n(See graphic.)\nYou can't get that kind of information any other way.\nThe upsurge in CT use has fueled a big jump in the annual amount of radiation that each American is receiving from medical procedures of all kinds.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available.", "answer": 1}, {"article": "A 2007 study of Chinese women in Shanghai found that middle-aged women who ate large amounts of white rice and other refined carbohydrates were also at increased risk for diabetes compared to their peers who ate less.\nCorrection: An earlier version of this story misidentified the amount of cooked rice in a serving.\nBut, Dr. Sun said, there were many possible explanations for why brown rice eaters are at lower risk for Type 2 diabetes.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nThe study, which was published in The Archives of Internal Medicine and used data from two Harvard nurses\u2019 health studies and a separate study of health professionals, isn\u2019t the first to point a finger at foods like white rice as a culprit in Type 2 diabetes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Both white rice and brown rice are widely available. \u00a0That said \u2013 there are food oases where comprehensive grocery stores are not accessible and where brown rice would be more difficult, though not impossible to come by. \u00a0There was no discussion of this in the story.", "answer": 1}, {"article": "People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions).\nThe drug was also granted a priority review.\nThe effectiveness of Nuplazid was shown in a six-week clinical trial of 199 participants.\nNo drug in this class is approved to treat patients with dementia-related psychosis.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release is reporting FDA\u2019s recent approval of Nuplazid so it\u2019s understood the drug isn\u2019t available now. Ideally, for patients\u2019 sake, the news release would have mentioned the company\u2019s announced roll-out plans.\nAccording to a company news release, the firm intends to launch the drug in June 2016.", "answer": 1}, {"article": "Everyone loses some bone with aging - women abruptly at menopause when estrogen levels decline, men more slowly as male hormones decline over time.\nBut remember: Not exercising also puts you at risk.\nIf a person simply stands, the muscles accommodate and do most of the work, he said - with no benefit to the bone.\nAnother 34 million are at risk because they have low bone density.\nAnd walking, though not as good for bones as jogging or jumping, is far better than just standing, he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "not applicable in this case", "answer": 2}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that Botox is available and FDA-approved for several other indications.", "answer": 1}, {"article": "\u201cDuchenne muscular dystrophy (DMD) is a progressive and fatal genetic disorder of muscle degeneration.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\nPatients with DMD lack expression of the protein dystrophin as a result of mutations in the X-linked dystrophin gene,\u201d the researchers wrote.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that sildenafil is the drug in Viagra, used to treat erectile dysfunction, and also Revatio, which is used to treat pulmonary hypertension. The story would have been better if it referred to the active ingredient in Viagra, rather than Viagra itself, and had pointed out that to treat heart problems, the drug would be given continually (as it is for pulmonary hypertension) and not just occasionally as it is when used to treat erectile dysfunction.", "answer": 1}, {"article": "SSRIs include drugs like sertraline (Zoloft), paroxetine\n\nBecause of the potential for harm from medications, many pregnant women with depression may prefer psychotherapy or other non-drug options.\n\u201cHowever,\u201d she added, \u201cunlike a pill, which always has the same ingredients, acupuncture, like psychotherapy, varies from one provider to the other.\u201d\n\nSo while the specific regimen used in this study appeared effective, Manber said, \u201cI do not think we can say that our study proves that acupuncture is effective for depression during pregnancy.\u201d\n\nIt\u2019s estimated that 3 to 5 percent of pregnant women are diagnosed with depression, Manber and her colleagues note in their report.\nIt is unclear, Manber said, why acupuncture might help lessen the severity of depression.\nOverall, Manber\u2019s team notes, the response to acupuncture in this study was comparable to what has been seen in studies of psychotherapy for depression during pregnancy.\nThe study, which followed 150 pregnant women with major depression, tested \u201cdepression-specific\u201d acupuncture against massage and acupuncture sessions that, according to traditional Chinese medicine, does not specifically target depression.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story didn\u2019t address whether any acupuncture therapists are trained in the \"depression-specific\" acunpuncture methods that were used in one arm of this study.\u00a0 ", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThe story notes that the FDA approved this asthma treatment earlier this year and that it is available at about 30 medical centers in the U.S.", "answer": 1}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that Rez\u016bm is clinically available.", "answer": 1}, {"article": "There was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nSpellberg also said people who used the drug this way would be exposing the bacteria they have in their gastro-intestinal tracts \u2014 their own gut flora \u2014 to regular doses of doxycycline.\nLike Molina and his co-authors, they said STI preventive use at this point is premature.\nThe results can\u2019t be taken in isolation, others experts warned.\nMolina noted that antibiotic resistance to doxycycline has not been seen in chlamydia or syphilis, despite the fact that the drug has been used to treat these infections for decades.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that doxycycline is widely available and that it is used to treat other diseases, including acne.", "answer": 1}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\nOverall, these results indicate that changes in intestinal inflammation can alter the trajectory of psychiatric mood disorders and that modulating the intestinal microbiota may be a new avenue of treatment for patients suffering from these diseases.\nThe beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation at the beginning of the study.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The dosage and composition of the probiotic mixture used in this study are not clarified. Therefore, readers have no idea if just any probiotic will do. This is worrisome since some readers \u2014 particularly those with bipolar illness \u2014 may extrapolate from the news release headline and start self-medicating based on these preliminary findings that don\u2019t prove probiotics help bipolar illness.", "answer": 0}, {"article": "WhoCosette Wheeler, PhD is a UNM Regents Professor in the Departments of Pathology and Obstetrics and Gynecology at the University of New Mexico Health Sciences Center.\nThe earlier the vaccine is given, the more efficacious it can be.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\nThe international study found that it protects against HPV infection in women older than 26 years.\nHPV vaccines are expected to prevent most of these cancer cases.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Most readers are probably aware of HPV vaccinations and that the vaccine is widely available. However, the vaccine isn\u2019t affordable to all.", "answer": 2}, {"article": "Sept. 8, 2010 -- People who take cholesterol -lowering statin drugs to reduce heart disease risk may also be cutting their risk for developing the painful inflammatory joint disease rheumatoid arthritis .\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\nThe study appears in the September issue of the journal PLoS Medicine.\n\"It would certainly be premature to suggest taking statins to prevent rheumatoid arthritis ,\" he tells WebMD.\n\"But one important message is that people who have been prescribed them should adhere to treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story notes that statins are the most commonly prescribed class of drugs in the world, which is an even better description than the one used in the HealthDay story.", "answer": 1}, {"article": "The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nA neurosurgical procedure in which an implanted neurostimulator delivers electrical signals to specific areas of the brain to help regulate abnormal signals, DBS is currently only approved in the U.S. for the treatment of Parkinson's disease and essential tremor.\nDuring the trial, 42 patients with mild Alzheimer's disease underwent the surgical procedure and were closely monitored for adverse effects.\nHowever, its use is being researched for a number of conditions, including epilepsy, depression and bipolar disorder.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the device is only approved for use in patients with Parkinson\u2019s disease and essential tremor. It\u2019s available to those patients, and only for research in other conditions.", "answer": 1}, {"article": "Others had them two to three times a week.\nThose with the new form of vertigo were also more likely to have severe motion sickness than those with other forms of the condition, the study showed.\nThis new form of the condition is called recurrent spontaneous vertigo with head-shaking nystagmus.\nTHURSDAY, May 24, 2018 (HealthDay News) -- Because vertigo can have many causes, treating it can be difficult, but researchers have identified a new type that may be effectively treated with medication.\nThe researchers noticed that uncontrolled eye movements, called nystagmus, lasted longer in people with this new form of vertigo.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The mechanism for diagnosis of this supposed new form of vertigo is explained by both the news story and the original paper.\u00a0 It requires some sort of audio-visual equipment to record eye movements, and there was discussion of a non-named medication providing relief. There is not enough information to fully inform the reader about the availability of getting screened for this type of vertigo, nor how to treat it.", "answer": 0}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nThe EAGeR trial focused on women with a history of one or two prior pregnancy losses.\nResults of a recent study to better understand modifiable factors such as physical activity that may affect a woman's ability to conceive a child suggest that walking may help women to improve their chances of becoming pregnant.\nWhitcomb says another way in which this study is distinct from other work in this area has to do with who was included in the study.\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "As noted above, the release mentions walking as both easily accessible and a potentially modifiable factor for those trying to get pregnant.", "answer": 1}, {"article": "In addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique.\nThe study is published in Annals of Internal Medicine.\nTo speak with the lead author, Dr. Hugh MacPherson, please contact David Garner at david.garner@york.ac.uk or +44 (0) 1904 322153.\nNote: For an embargoed PDF, please contact Cara Graeff.\nOver time, both interventions resulted in a greater increase in self-efficacy than did usual care, and these improvements were associated with better NPQ outcomes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that both of these therapies are widely available.", "answer": 1}, {"article": "\"Just telling people to do things doesn't work,\" says Sean Duffy, CEO of Omada Health.\nThere is some evidence that these kinds of programs are working.\nAnd he says the convenience of having the program delivered on a smartphone was key, too.\nAnd he says he's pleased with the results of the pilot study of Omada's program.\nNot every Omada Health participant makes the progress they're aiming for.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear the Omada program is available and in use around the country and even links to the company website.", "answer": 1}, {"article": "Even as a pigtailed child, Ashley Gallagher was self-conscious about a certain fullness in her face.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\n\u201cIt was receding.\u201d\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the treatment will be available in late summer after doctors are trained to give the injections.", "answer": 1}, {"article": "A short bike ride put him on a long road to recovery\nOften, Efrati and others say, injured brain cells don't die, but may persist for years or decades, alive but hobbled.\nOverall, there is relatively little research on hyperbaric treatment for brain injury, in part because pressurized oxygen can't be patented, which limits its potential profitability.\nOf course, such anecdotes are not the same as rigorous scientific research.\nEfrati agreed that hyperbaric treatment requires more research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of hyperbaric chambers, or rooms, is not discussed.\nAccording to the Undersea & Hyperbaric Medicine Society, there are over 200 accredited facilities in the United States.\nOne thing we wanted to note: The statement from a researcher that there\u2019s no way to patent (and thus, make money from) hyperbaric oxygen therapy as an explanation for why the evidence base is so fragmentary seemed to ring false in the setting of these private clinics that can create frequent return visits for long periods of time.", "answer": 0}, {"article": "In the other study, by Ugur Sahin and colleagues, tested a personalized vaccine based on RNA (an essential link in the production of proteins encoded by DNA).\nThese vaccines are not necessarily the future of personalized cancer treatment.\n\u201cIt is still unknown whether these vaccines will extend the survival of cancer patients, or whether they are more effective than other recently developed immunotherapies.\nBut working out the unique mutations of each person\u2019s cancer, a time-consuming and complicated process, must first be identified before a vaccine can be developed for them.\nHe added, however, that the studies confirm the potential of cancer vaccines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although not explicitly stated, most readers will understand that the vaccines are not currently available and have to undergo a lot more testing before they are available \u2014 if ever.", "answer": 1}, {"article": "[1] Quotes direct from authors and cannot be found in text of Article.\nSurprisingly, the findings also revealed that the standard altona RT-PCR test, under the conditions deployed in the field, was itself an imperfect reference standard.\n\"Laboratory results can sometimes take days to return.\nAlthough the RDT requires refrigeration, this is already available in many health centres in endemic areas, particularly those that store vaccines and other medical products.\"\n[1]\n\nIn this study, the researchers compared the diagnostic accuracy of the new RDT against the benchmark RT-PCR test (altona Diagnostics) being used for clinical diagnosis in the field reference laboratory run by Public Health England at Port Loko in Sierra Leone.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re\u00a0told the following, via a quote from a researcher: \u201cAlthough the RDT requires refrigeration, this is already available in many health centres in endemic areas, particularly those that store vaccines and other medical products.\u201d Although we\u2019d like to know more about the regulatory approval status of the test, we\u2019ll award a Satisfactory here.", "answer": 1}, {"article": "Learn more about Mayo Clinic.\nHowever, it was unclear whether these drugs could be used safely in cancer patients until now.\nHe says these qualities make this class of drug much easier to use than the traditional blood thinners.\nDr. McBane noted that cancer and cancer treatment can be associated with kidney injury, which can limit the drug's use further.\nSAN DIEGO -- Mayo Clinic researchers have found that an oral drug, apixaban, used to treat blood clots in patients undergoing cancer therapy, is safe and effective.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that apixaban, a member of a new class of \u201cblood thinners called \u2018direct oral anticoagulants\u2019 have become available.\u201d Both oral and injectable anti-coagulant medications are now widely available at hospitals and clinics where they are administered to patients.", "answer": 1}, {"article": "As the researchers had hypothesized, the participants' Fitbits captured a portion of this fertile window by showing that their resting heart rates rose one or two days before ovulation, as well as during ovulation itself.\nBut as Clue\u2019s and Ava\u2019s fertility research indicates, increasingly sophisticated sensors and algorithms could significantly open up wearables\u2019 capabilities \u2014 and make them that much more able to tackle bigger, complicated health issues.\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\nFitbits aren't the only wearables that can track fertility-related biometrics in the background.\nDepending on the device, it could even help you go one step further and actually conceive.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Fitbits are widely available, though the story seems to take it for granted that readers will know this. Similarly, the story refers to the relevant app, called \u201cClue,\u201d as a \u201cwomen\u2019s health data startup.\u201d It\u2019s not clear from that description whether the relevant app is already available. (It is.) The story does note the availability of other, related technologies.", "answer": 0}, {"article": "\"These days it's possible for a food company to pay just about anybody to conduct a study,\" says Silverglade.\nProbably not,\" says Dr. Lenard Lesser, M.D., one of the co-authors of that study and a researcher at UCLA.\nMost health beverage drinkers aren't as enthusiastic as the realtor from Alaska who posted the above testimonial.\nBut that doesn't mean the claims are invented -- most are based in research.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We know that one company racked up $91 m in sales in one recent year, giving some indication of how widespread is the use of some of these products.", "answer": 1}, {"article": "As they age, people with elevated diastolic blood pressure are at a higher-than-average risk of developing elevated systolic blood pressure.\n\"Heart disease and strokes are a leading cause of death in the United States.\nThe diets were exactly the same, except for their content of whole grains or refined grains.\nVisit us at http://www.\nThese evidence-based data demonstrate the effect of diet on cardiovascular disease outcomes, particularly diastolic blood pressure.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Whole grain foods are readily available at grocery stores and markets, so availability is not an issue here.", "answer": 2}, {"article": "Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure.\nKnowing the genotype helps inform treatment recommendations and the duration of treatment.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\n\u201cThis approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,\u201d said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA\u2019s Center for Drug Evaluation and Research.\nEpclusa is a fixed-dose combination tablet containing sofosbuvir, a drug approved in 2013, and velpatasvir, a new drug, and is the first to treat all six major forms of HCV.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is announcing the approval of the drug which usually means it will be available in the near future.", "answer": 1}, {"article": "\u2022 Using other options to collect urine, such as bedpans.\nNow, researchers report that a new program shows it might be possible to reduce both catheter use and its associated infections.\nFor the study, Saint and his colleagues tried the new program in 600 hospitals.\nRoughly 250,000 such infections occur in hospitals each year in the United States, costing about $250 million, the researchers pointed out.\nBut there was no drop in infections or catheter use in intensive care units (ICUs), the study findings showed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019re told the procedure is in use at 600 hospitals, though it would have helped to note they\u2019re spread across 32 states, plus Washington D.C. and Puerto Rico. It could have been made clearer that any hospital can use this safety bundle now that the methods are published widely.", "answer": 1}, {"article": "\"It's just like physical exercise -- when we are approaching the new year we will buy a pass for the gym and go fervently in January and then slack off,\" Willis said.\nSherry L. Willis, the lead author of the study and a Pennsylvania State University professor of human development, said those who had the training also reported greater confidence in their ability to solve everyday problems, and this was especially true of the group that got the reasoning training.\nThe researchers also showed that the benefits of the brain exercises extended well beyond the specific skills the volunteers learned.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story did contain advice (from the lead author of the study) about working on puzzles that are more difficult, something new, and stretch the mind \u2013 the nature of the three distinct interventions used with the ACTIVE study participants was not clear, nor was the\u00a0difficulty of\u00a0finding people to work with on these specific sorts of mental training activities mentioned.\u00a0 How one might access the interventions used in the study was not clarified for the reader.\u00a0 It is also not clear how the study interventions actually relate to the kinds of examples given in the story such as doing puzzles.", "answer": 0}, {"article": "My spine isn\u2019t cured, and I still hurt all the time.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nIt can interfere with work and home life and leave patients debilitated, disabled and depressed.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\nThat aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these devices are available and in some cases covered by insurance. Though it may have been helpful to note that these devices are usually performed by specialists and particularly in rural areas, access to them may be harder to get.", "answer": 1}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is something that the story really should have done high up. Why has it become standard practice to do a CT\u00a0scan and not an MRI? One of the authors says that 40% of his time is spent giving MRIs and 40% doing CT scans. Is that typical? Nonethless, we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nTreatment requires a coordinated effort by dermatologists and rheumatologists to help manage symptoms such as swelling, inflammation and skin changes.\nPatients who saw the most improvements had more severe disease at the time of surgery and were of an older age at diagnosis.\nPsoriasis is a condition that affects 7.5 million Americans, according to the National Psoriasis Foundation.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Bariatric surgery is widely available and most people with internet access (or any access to medical care) can figure that out fairly quickly in their area.", "answer": 1}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that Abraxane is already used to treat advanced breast cancer and non-small-cell lung cancer.", "answer": 1}, {"article": "So does cardiologist Roger Blumenthal, who heads the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins.\nIt's important to note that statin drugs are generally safe, and harms are uncommon.\nThey worry that it will trigger overtreatment of conditions that the scan will pick up, but which don't require urgent attention.\nAnd it is only useful as a screening test for people who haven't had heart disease.\nYet that kind of dialog is increasingly the expectation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that statins are widely prescribed.", "answer": 1}, {"article": "\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\nIf so, this could change the nature of medicine.\nThe finding, just in time for Valentine's Day, is the clearest evidence yet that literally broken hearts can heal.\nAll that's needed is a little help from one's own heart stem cells.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is still in the experimental stage.\n\u00a0", "answer": 1}, {"article": "People with Type 2 diabetes get an earful of grim lectures about their health prospects and endure much hardship to manage their condition well. But new research offers those who do so a rare reward. A glass of wine every day not only won't hurt, says a new study: It can actually improve cardiac health, help manage cholesterol and foster better sleep.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is obvious that red and white wine are readily available to most readers.", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story did not explicitly state that this drug is not yet available, the first sentence makes it quite clear this drug is still in development and in the process of undergoing clincial trials.", "answer": 1}, {"article": "She said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nThe study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.\nAfter 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said.\nOther diabetes experts had mixed views on the new findings.\nHowever, like Wissner-Greene, Sood said that \"further investigation is warranted, especially including [heart disease] patients.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Right in the headline, the story shows that the drug is not widely available, calling it \u201cexperimental.\u201d Also, the lead of the story says that the findings are \u201caccording to the results of a phase 2 clinical trial.\u201d However, the story did not specifically clarify that this drug has years to go before it ever reaches the market.", "answer": 1}, {"article": "\"Many patients who have a heart attack will go on to suffer heart failure,\" he said.\n(CNN) -- If you've just had your first heart attack, doctors may one day be able to reverse the damage done with stem cell therapy.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nMore broadly, besides bone marrow transplantations, there have not been any major successes in the stem cell field in terms of helping large numbers of patients, Karp said.\nFirst, they are adult stem cells, so there are no ethical issues that surround research on embryonic stem cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Most of the story makes it clear that the technique is in early trials and not in clinical use. Only the opening line is troubling \u2013 \"If you\u2019ve just had your first heart attack, doctors may one day be able to reverse the damage done with stem cell therapy.\" Due to clumsy wording,\u00a0 this suggests that if you had your first\u00a0 heart attack in late 2009, doctors may someday be able to reverse today\u2019s damage from it \u2013 which is not\u00a0 at all the case. \nBut this misstep is remedied by a later statement that it would take a best-case scenario to have such an approach approved even in five years. \n", "answer": 1}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nShe said this is a model easily adaptable to other medical centers, whether through providing participants with a phone, having a rotating supply of phones at the hospitals for patients to borrow, or relying on a patient's personal device.\nAlthough capturing specific numbers related to cost-savings was not part of this study, Dr. Gunter said it is an important area of focus for future studies.\nSSIs are the most common hospital-acquired infection and the leading cause of hospital readmission following an operation.1,2,3 Due to the prevalence off SSIs, the WiSOR research team decided to see if postoperative wound monitoring could be effectively achieved by having patients upload photos through the WoundCare app and answer a few brief questions to gather information not easily captured through images.\nThe app was developed by researches from the Wisconsin Institute of Surgical Outcomes Research (WiSOR), Department of Surgery, University of Wisconsin, Madison, with the goal of earlier detection of surgical site infections (SSIs) and prevention of hospital readmissions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no discussion of how many hospitals are using this app.\nThe release did discuss some of the practical aspects of implementation but nothing about whether such an app is available or if insurance will pay for any of the costs involved.", "answer": 0}, {"article": "Scientists hypothesize that the electrical currents may disrupt bacteria in two ways: by interrupting the production of chemical messages that instruct bacteria to develop biofilms and by weakening the molecular structure of existing biofilms, potentially making them more susceptible to antibiotics or the body\u2019s natural immune response.\n\u201cThis technology has a long shelf life and is compact enough to be put into any field medical kit.\nGood news for the millions of people who suffer from skin wounds that won\u2019t heal.\nIt could be applied immediately to wounds help keep bacteria from mobilizing and start promoting healing until the soldier could be transported to a facility for more intensive medical care.\u201d\n\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\nLike present WEDs, the new prototype is flexible, portable and self-contained.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that this research of an \u201cadvanced\u201d WED is experimental and the technology has not yet been tested in humans. There\u2019s a strong implication that the bandages won\u2019t be available anytime soon.", "answer": 1}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nSo far, the four drugs have performed similarly in clinical trials, and analysts expect the contenders will have to compete on price to grab market share.\nThe first therapy could hit the market in 2018, and, if everything works out, all four could available by the end of the decade.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nYet scientific progress has been slow, in part because migraine was long considered a psychosomatic condition not worthy of serious research funding, Bates said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Yes, and the news is not good: The drugs are moving through the clinical trial process\u00a0and have not yet received FDA approval. The story speculates that \u201cthe first therapy could hit the market in 2018,\u201d a prediction that presumes no glitches will slow the process.", "answer": 1}, {"article": "PepsiCo's product portfolio includes a wide range of enjoyable foods and beverages, including 22 brands that generate more than $1 billion each in estimated annual retail sales.\nNewly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\nThe Quaker Oats Center of Excellence is focused on elevating the relevance and benefits of oats through science, agriculture and innovation.\nFor more information, visit the Quaker Oats Center of Excellence at www.QuakerOats.com.\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release, by naming the brand of oatmeal studied, makes it clear that it is available. Few people will not have heard of Quaker instant oatmeal.", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of colonoscopies is not in question.", "answer": 2}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the article stated the device had been available in the U.S. since February, it was unclear if this was only for people in clinical trials, or if hospitals and cancer centers across the country were currently using it. Nonetheless, we\u2019ll give the story the benefit of the doubt on this one.", "answer": 1}, {"article": "J Transl Med.\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\nActual results may differ materially from those currently anticipated in such statements.\n2013 Jun 9;11:139. https://www.ncbi.nlm.nih.gov/pubmed/23758954\n\nOTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release appears to be overly optimistic in stating when this therapy may be available to patients. Moreover, other than the study site that performed this small trial, there is no mention of where this procedure may be had.\nThe news release did say that they expect \u201cthat the procedure will be available to patients that meet the eligibility criteria within the next 60 days.\u201d Yet this statement raises some red flags. First of all, it does not say what the eligibility criteria are, which may give ineligible patients false hope. Secondly, the 60-day time frame is incredibly quick. Even after promising safety studies, most medications and procedures undergo a third study that looks solely at efficacy (the primary outcome of this study was listed as safety and tolerability).\u00a0 ", "answer": 0}, {"article": "must sanction a medical device for a specific use before a company can market that use.\nDr. Bass was not a clinical investigator for Zeltiq, but he said, \u201cI\u2019m convinced both on the science and clinical experience, it\u2019s able to eliminate fat noninvasively.\u201d\n\nNadine Tosk, a publicist for Zeltiq, explained that the rollout of the device was \u201cvery limited right now.\u201d Dr. Jeffrey Dover, a dermatologist in Chestnut Hill, Mass., who advises Zeltiq and participated in its clinical trial, said a few board-certified plastic surgeons and dermatologists were \u201chandpicked\u201d because \u201cwe know they do good work.\u201d Restraint is key, he said, because a doctor could apply Zeltiq to \u201cthe same spot\u201d in the same day, which isn\u2019t how it\u2019s meant to be used.\nHourlong treatments are best spaced out by two months, said Dr. Dover, who charges $700 per spot.\nIn general, Karen Riley, a spokeswoman for the F.D.A., said \u201cit is considered off-label promotion if you are marketing to the public a use that has not been cleared.\u201d Steven Shanks, the president of Erchonia Medical, said, \u201cSince we use the exact same power for liposuction and breast augmentation, we self-certified the device.\u201d He said that in January 2009, the company had applied for a 510K clearance \u2014 which is based on the notion that an older device is substantially equivalent to a new one \u2014 and had yet to receive it.\nMore than five dozen \u201cZeltiq specialists\u201d can be found by ZIP code at body-contouring.com, which is a patient guide not sponsored by manufacturers of body-slimming devices.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that Zerona is available nationwide through medical spas, chiropractors, dermatologists and plastic surgeons. Zeltiq, the story says, is available at over five dozen clinics identified on a website. ", "answer": 1}, {"article": "About 8% and 18% of Serada users reported daytime sleepiness and dizziness, respectively, compared to about 3% and 8% of women who took a placebo.\nNAMS founder and former executive director Wulf Utian, MD, says Serada does not appear to be as effective as hormonal therapy, but it may be a useful alternative treatment for women who can\u2019t take hormones or don\u2019t want to.\nMichael Sweeney, MD, who is vice president of research and development for Serada manufacturer Depomed Inc., says the company\u2019s slow-release gabapentin formulation avoids many of these side effects.\n\u201cEstrogen and estrogen-progestin drugs are about 95% effective for treating hot flashes,\u201d he tells WebMD.\nThe study was presented in Chicago at the annual meeting of the North American Menopause Society (NAMS).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The oblique reference to this drug perhaps being \"one step closer to becoming the first approved nonhormonal treatment for menopause-related hot flashes\" is likely to leave many readers unsure about whether this drug is not yet available or whether it is just not approved specifically for treatment of hot flashes.\nThe standard formul gabapentin, which is approved for treatment of seizures and pain,\u00a0can be prescribed off label for treatment of hot flashes even though it isn\u2019t FDA approved for this use. (In fact, Pfizer has recently been slapped with large fines for promoting unapproved off-label uses of the drug.) However, the slow-release form of the drug discussed here is not available commercially. Although it calls the new drug \"experimental,\"\u00a0the story\u00a0doesn\u2019t\u00a0explicitly address\u00a0the\u00a0availability of the immediate-release vs. slow-release forms of the drug.\u00a0The article should have been clearer that the FDA has not approved this new slow release form, and that it is not available.\u00a0\u00a0", "answer": 0}, {"article": ".\nThe authors said now that this has been shown to be effective in a non-academic clinical setting, there also is potential for insurance companies to reimburse CAMBRA and other preventive therapies for adults, thereby lowering patient costs while increasing profits for dental practices.\nThe findings, which support earlier research demonstrating positive results of the assessment and treatment method in a university setting, have the potential to transform dental care for high-risk patients at a lower cost to both patients and dental clinics and practices.\nThe researchers said the risk reduction among the control group may have been caused by the fluoride toothpaste enhancing tooth repair, as well as the mouth rinse enhancing saliva flow and having bactericidal effects.\nThe treatment plan typically incorporates remineralization through the use of fluoride and/or antibacterial therapies such as chlorhexidine and xylitol, minimally invasive restorative procedures to conserve tooth structure, and regular patient follow up.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This CAMBRA method is available at about half of US schools and colleges of dentistry according to the release. However, the prescription fluoride toothpaste is available from most pharmacies.", "answer": 1}, {"article": "Nerve cells in the brain die, and in a few short years, children lose the ability to walk or talk.\nOne of medicine\u2019s greatest villains: HIV.\nFor the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible.\nThe patients were children who had inherited a mutated gene causing a rare disorder, adrenoleukodystrophy, or ALD.\nThey usually die within five years of diagnosis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t make clear that this treatment is, at the very least, years away from clinical use. The story notes only that Bluebird Bio is \u201cin hopes of marketing gene therapy for ALD.\u201d This line, found more than halfway through a 1,300 word story, isn\u2019t sufficient. This is an area where the Associated Press story fared better, noting that the FDA \u201crequires gene therapy participants to be monitored for 15 years, so these patients will continue to be studied.\u201d The AP story also notes that Bluebird Bio \u201cplans to seek approval of the therapy in the U.S. and Europe.\u201d The AP was stronger on this criterion.", "answer": 0}, {"article": "Complications can include fluid buildup around the heart, called cardiac tamponade, which makes it difficult for the heart to pump blood.\nCatheter ablation is covered by most insurance, including Medicare, the researchers said.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nAbout 11 percent suffered complications during the year after the ablation, she said.\nAblation was successful in 74 percent of patients, Arbelo said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Catheter ablation is available in most medical centers offering broad cardiac services, but the story didn\u2019t explain that.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "The study found that 78 percent of patients reported being pain-free or having adequate relief within 15 minutes of receiving high-flow oxygen, compared with 20 percent of patients after they received high-flow air.\nTUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\nThe National Pain Foundation has more about cluster headache.\nHigh-flow oxygen also provided better pain relief at 30 and 60 minutes.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says high-flow oxygen is in \"limited use\" to treat cluster headaches. But it fails to say where or how it is available \u2013 or even what \"limited\" really means.\u00a0 Two places in the US?\u00a0 Twenty?\u00a0 ", "answer": 0}, {"article": "It has been 51 years since the first birth-control pill became available in the U.S., bringing dozens of contraceptive options for women in its wake. There are currently two options on the market for men\u2014vasectomy or a condom.\n\nThe research pipeline is full of possibilities, though. Scientists at Columbia University Medical Center have halted sperm production and started it again in mice with no apparent side effects, using a drug that blocks receptors for vitamin A. An injectable synthetic substance, in Phase 3 clinical trials...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We like the left column sidebar that lists 3 \u201cpromising\u201d methods and specifies status and availability.\u00a0 Nice touch.", "answer": 1}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nThe first new drug, Pradaxa, from the German drug maker Boehringer Ingelheim, was introduced in the United States last fall.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story opened by indicating that Eliquis (apixabane) was experimental and closed by indicating the expectation of submission to the FDA for approval.", "answer": 1}, {"article": "\u2022 LPCN 1021 was well tolerated and had a favorable safety profile in the long-term management of hypogonadal patients\n\u2022 No hepatic, cardiac or drug-related serious adverse events were reported\n\u2022 The most common drug-related adverse events for LPCN 1021 and T gel 1.62 percent were acne (2.9 percent vs. 2.9 percent, respectively), headache (0.5 percent vs. 3.8 percent, respectively), weight increase (2.4 percent vs. 0 percent, respectively), hematocrit increase (1.9 percent vs. 0 percent, respectively), liver enzyme level increase (1.4 percent vs. 0 percent, respectively), fatigue (0.5 percent vs. 1.9 percent, respectively), and hypertension (0.5 percent vs. 1.9 percent, respectively)\n\u2022 Lipid parameters (i.e., cholesterol, LDL, HDL, and TG) were comparable between treatment groups at Week 52\n\u2022 Androgenic parameters including hematocrit, hemoglobin, platelet, prothrombin, and prostate-specific antigen (PSA) showed no significant differences in change from baseline to end of study between treatments\n\n\"Based on the results of this study, we might be closer than ever to having an oral form of therapy to treat the millions of men with hypogonadism,\" said Dr. K\u00f6hler.\nFollowing a 13-week efficacy phase, men continued to receive their assigned treatment for up to 52 weeks.\nThe research will be highlighted by study authors during a special press conference to be moderated by Tobias S. K\u00f6hler, MD, MPH, FACS, AUA spokesperson and associate professor of Surgery at Southern Illinois University on May 8, 2016 at 7:30 a.m. PT in the San Diego Convention Center.\nIt is often administered as a gel, patch, injection or implant (pellet).\n\"Making sure an oral treatment is safe and effective for men and for the children and partners at risk for inadvertent testosterone transference is the top priority, and what we've found so far has shown we're on the right track.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states \u201cThere is currently no oral form of testosterone therapy approved for use in the United States by the Federal Drug Agency\u201d and then talks about this new product under development. Readers can assume the product is not yet available.", "answer": 1}, {"article": "But they are most often used in patients who have a blocked artery and chest pain that occurs, for example, walking up a hill or going up stairs.\nMore than 500,000 heart patients worldwide have stents inserted each year to relieve chest pain, according to the researchers.\nA procedure used to relieve chest pain in hundreds of thousands of heart patients each year is useless for many of them, researchers reported on Wednesday.\nSometimes patients get stents when they have no pain at all, just blockages.\nOther estimates are far higher.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Stenting procedures are clearly widely available in the U.S. and across the world. What\u2019s less clear, the story says, is whether guidelines or practice for stenting will change in the U.S.: \u201cThe idea that stenting relieves chest pain is so ingrained that some experts said they expect most doctors will continue with stenting, reasoning that the new research is just one study.\u201d We thought this was an interesting point and are glad it was included.", "answer": 1}, {"article": "In 2015, he was ranked the No.\nAlthough a number of randomized trials demonstrate the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over the age of 74, especially minorities.\nAmong elder women, the American Cancer Society and the United States Preventive Services Task Force recommend regular mammography for ages 65 to 74.\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\nIn 2010, 41 percent of breast cancer deaths occurred in the more than 19 million women who are between the ages of 65 to 84 years.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that mammograms are widely available. However, most current guidelines cap recommended annual or biannual mammograms at age 74. These recommendations have a direct effect on Medicare and private insurance coverage.", "answer": 1}, {"article": "During a salvage radical prostatectomy, the prostate gland and surrounding tissue are surgically removed to keep the cancer from spreading.\n\"However, this study shows that it is a viable treatment option.\n\"Prostate cancer, unfortunately, is a common cancer, and more than 27,000 men are estimated to have died from the disease in 2015,\" said Naveen Pokala, M.D., an assistant professor in the Division of Urology at the MU School of Medicine and lead author of the study.\n\"By studying a national database of prostate cancer cases, we found that a procedure known as salvage radical prostatectomy can greatly increase a man's chance of survival when traditional radiation therapy has failed to eradicate the cancer.\"\n\"Because radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\" Pokala said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Data analyzed in the release relates to surgeries performed between 1988 and 2010 at many different institutions so we assume it is widely available.", "answer": 2}, {"article": "And people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\nRaji presented the findings here at the annual meeting of the Radiological Society of North America.\nSeveral studies have linked a diet rich in certain fish to a reduced risk of Alzheimer's disease.\n\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\nThis benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish is not in question.\n ", "answer": 2}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nBut ketamine's story took a surprising turn in 2006, when researchers at the National Institutes of Health showed that an intravenous dose could relieve severe depression in a matter of hours.\nIt typically appears in childhood and often doesn't respond to traditional psychiatric drugs.\nAnd almost from the time it reached the market it has also been used as a mind-bending party drug.\nKetamine \"helped me get my life back,\" says James, who asked that we not use his last name to protect his career.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story highlights a patient using a ketamine nasal spray without making it clear that this form of the drug has not been approved by the FDA.", "answer": 0}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was made clear that both bilateral and staged knee replacement surgeries are fairly common and widely available. Similarly, it was made clear that some surgeons refuse to perform bilateral surgeries, or will only perform them for patients that meet fairly stringent criteria.", "answer": 1}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nOne challenge: People who have healthy diets often have other healthy habits, too \u2014 such as getting regular exercise.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nSo, think of it this way: You can start consuming more of the foods that are protective.\nIf you love foods that are associated with cardiovascular risks, you don't have to give them up entirely.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of the foods discussed in the story is not an issue, which is why we\u2019ll rate this Not Applicable. However, the fact that so many \u201cbad for you\u201d foods are so much more readily available today than they used to be is something the story could have touched on. In addition, such foods are often cheaper\u00a0than more healthy alternatives in many communities.", "answer": 2}, {"article": "But plasma insulin response was sharply lower in fructose drinkers, which may affect what we eat, according to the senior author, Dr. Kathleen A.\nPage said.\n\u201cNo,\u201d Dr.\n\u201cDon\u2019t stop eating fruit.\nPage, an assistant professor of clinical medicine at the Keck School of Medicine of the University of Southern California.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not relevant to this story.", "answer": 2}, {"article": "Happiness won\u2019t help you live longer (but unhappiness won\u2019t kill you either)\n\nGuinea is finally declared Ebola-free, but that does not mean the crisis is over\n\nMost popular Washington Post health stories of 2015: A mother tells her story of how she lost her darling daughter a few weeks short of her 29th birthday when she stepped in front of a train in Baltimore.\nBut some doctors and researchers were puzzled by the fact that in head-to-head comparisons between the two classes of drugs they appeared to equally safe and effective.\nThe other piece of good news regarding the medications is that ACE inhibitors, as well as many ARBs, are now generic -- meaning that the cost difference is minimal.\nNow a large new analysis involving 250,000 patients shows that these medications may be as effective and safe as their older cousins, the angiotensin converting enzyme, or ACE inhibitors.\nIf there really was such a big difference between the medications, why didn't it show up in these types of studies?\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does point out that ACE inhibitor drugs have been available for decades and that ARBs have been available since the year 2000.", "answer": 1}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nPut another way, 21 percent of stented patients had died after four years compared with 16 percent of surgery patients.\nThe National Heart, Lung and Blood Institute, which funded the study with new \"stimulus\" money from the American Recovery and Reinvestment Act, is more bullish on the implications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Unlike the Wall Street Journal story and the Associated Press story we reviewed, this story at least mentioned the fact that more people have been opting for stents instead of bypass surgery.", "answer": 1}, {"article": "Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nThis is relatively new thinking.\nThat warning was especially strong for those with a family history of allergies.\nExactly why is a question researchers are still exploring.\nThe authors of the just-published study reviewed all of the available evidence on the topic and included 146 studies in their final analysis.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The food items are widely available.", "answer": 2}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does make it clear that this is an experimental approach and that the surgeon in question may be one of the few practicing this technique \u2013 although he claims to have trained 250 surgeons around the world. .", "answer": 1}, {"article": "Hernias occur when part of an internal organ, such as the intestines, bulges out through muscle.\nIt was developed in the 1990s, Brunt said.\nWhy use the traditional approach if the laparoscopic technique is better in some ways?\nThe study authors didn't examine a third approach, known as \"patch and plug,\" he said.\n\"One repair isn't appropriate for all circumstances.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both approaches seem to be widely available, so the fact that the story didn\u2019t discuss this shouldn\u2019t be held against it. We\u2019ll rule it not applicable.", "answer": 2}, {"article": "\"When people have serious injuries, whether from accidents or violence, and when they have severe hemorrhage they can bleed to death.\nThe drug, tranexamic acid (TXA) is cheap, widely available around the world and easily administered, experts said.\nIn fact, a trial to see whether TXA can reduce postpartum bleeding has started, the team noted.\nThe report, which was primarily funded by philanthropic groups and the British government, is published in the June 15 online edition of The Lancet.\nThe drug could also be used to reduce postpartum bleeding, which the researchers say causes some 100,000 deaths a year worldwide.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that TXA is widely available around the world and easily administered.", "answer": 1}, {"article": "Radiation oncologist Dr. Richard Stock, of Mt.\nThe technology is two decades old, but Mass.\nIt's the most expensive device in medicine today.\nBut proton beam therapy is at the heart of the debate over rising health-care costs.\nJust weeks later, Rianta was getting the therapy and the tumor was shrinking.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story describes the limited availability of proton beam therapy.", "answer": 1}, {"article": "The drugs, which include Depakote, Lamictal, Topamax, Keppra, Lyrica and Neurontin, are sometimes prescribed for chronic pain and headaches, as well.\nThe increased risks, while double in relative terms, are small.\nDrugs for epilepsy, bipolar illness and mood problems double the risks of suicidal thoughts and behavior, and patients taking them should be watched for sudden behavioral changes, drug regulators have said.\nDoctors said Thursday that the increased risk did not outweigh the benefits of the drugs.\nThese medications are primarily used to help epileptics control seizures and to calm the surges in energy and mood that, along with bouts of depression, characterize bipolar disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes some pharmacological treatments available for epilepsy.\u00a0 The story notes these same medications may also be used to treat chronic pain, mood disorders and headaches. The risks of suicidality are not as great in non-epileptics. ", "answer": 1}, {"article": "This signal is passed to a computer that decodes it, and the resulting instruction is then sent to a sleeve he wears on his forearm that stimulates the muscles that move his wrist and fingers.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\nThat's why the device requires training every time Burkhart uses it.\nOur understanding of how brain signals change will also be crucial to making this technology usable on a large scale.\nDetails of the system that allows him to do this, developed by scientists at Ohio State University and Battelle Memorial Institute, are published in the journal Nature today.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that this device is in laboratory testing. The comments from independent sources at the very end of the story help describe the long and uncertain road ahead for researchers.", "answer": 1}, {"article": "Seventeen percent were having moderate to severe vasomotor symptoms, and 18 percent reported moderate to severe sexual symptoms.\nThere is also, she said, a complete lack of understanding that for most women, these symptoms are not fleeting.\n\u201cWomen and doctors simply are not aware that symptoms can last this long.\u201d\n\nFinally, many women don\u2019t realize that non hormonal options can be safe and effective, she added.\nBut most were not receiving any kind of treatment.\nDr. Wulf H. Utian, medical director of the North American Menopause Society, agrees that many reasons may underlie the lack of treatment.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes that all of the treatments discussed \u2014 hormone pills, estrogen creams, and non-hormonal treatments \u2014 are available.", "answer": 1}, {"article": "FcMBL binds to pathogens and pathogen-released fragments, known as Pathogen-Associated Molecular Patterns (PAMPs) by recognizing carbohydrate molecules on their surface.\n\"This assay could become a real game changer in this clinical area, and it also should lead to more judicious use of antibiotics, helping to decrease the worrisome rise we are seeing in antibiotic-resistant organisms.\"\nNow, a Wyss Institute team led by Donald Ingber reports in eBioMedicine that it has filled this void with a rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.\nWe are currently working to ready it for high-throughput use in clinical and point of care situations and to accelerate it even further,\" said Mark Cartwright, Ph.D., a Staff Scientist at the Wyss Institute and a lead-author on the study.\nAs a prerequisite to their clinical study, the Wyss Institute's team had successfully tested the assay in rat and pig models of infection with pathogenic E. coli bacteria.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release gets a pass here but just barely. Unless you\u2019re reading carefully you might think the test is already ready for prime-time. Instead, a researcher notes that \u201cWe are currently working to ready it for for high-throughput use in clinical and point of care situations and to accelerate it even further.\u201d", "answer": 1}, {"article": "\u201cIt\u2019s quite amazing,\u201d she said.\nWomen may be particularly receptive to these approaches when they\u2019re coping with a cancer diagnosis, said Laura S. Porter, an associate professor at Duke University Medical Center.\nAnd researchers want to know whether relaxation actually reduces the recurrence of breast cancer.\nSo Stagl, now a clinical fellow at Massachusetts General Hospital, helped study a University of Miami program that taught 240 breast-cancer patients relaxation techniques and coping strategies.\nThe women who took the 10-week stress-management class shortly after surgery reported feeling better and having fewer depressive symptoms such as anxiety than those who took a one-day, breast-cancer education session.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Many breast cancer treatment providers can offer patients information about programs to help patients deal with stress, anxiety, and other depressive symptoms associated with a cancer diagnosis. However, the story does not make clear how widely available such programs are, and how much existing programs resemble the study intervention.", "answer": 0}, {"article": "Ductal breast cancer is the most common type of breast cancer and forms in the milk ducts.\nMany people currently take fish oil supplements to decrease their risk for heart disease.\nThe use of fish oil was linked to lower risk of invasive ductal breast cancer.\nResearchers did not have information on the doses of fish oil that were taken by women in the study.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish oil supplements is not in question.", "answer": 2}, {"article": "\"If the question were just, 'Does egg freezing and thawing work to achieve a pregnancy?'\nAnd yet, even Widra agrees that egg freezing has appeal if it can help avoid the anguish of infertility.\nStill, he says, freezing eggs offers many women the biggest game changer since the birth control pill 50 years ago.\nDr. Alan Copperman of Reproductive Medicine Associates of New York wastes no time laying out this harsh reality: By the time a woman hits her 40s, 90 percent of her eggs are abnormal.\nAnd the uterus doesn't decline like eggs do; in some cases, it can actually be coaxed back into working order.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story barely meets this requirement. It describes the procedure as something gaining acceptance, but still \u201cexperimental.\u201d What isn\u2019t emphasized is that this is not offered by many centers that can freeze ooccytes and far from all infertility programs have successful protocols in place.", "answer": 1}, {"article": "But \"that trial is never getting done, nor should it be done,\" Golden said.\nThe findings come as the American Academy of Pediatrics debates updating its recommendations regarding circumcision among newborns.\nAnd there's more to consider, Perera said.\nThe American Academy of Pediatrics has more on circumcision.\nThe academy now takes a neutral stance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 2}, {"article": "(image: transmission electron micrograph of Zika virus, NIAID)\n\n\"If we could find a way to specifically target those GSCs that are the source of recurrence, then that might provide an option to prevent recurrence or even a cure,\" says Qin.\nIt enhances laboratory capacity around the globe through training and resources.\nIn addition, the Zika virus was much less efficient at attacking the differentiated, healthy brain cells.\nNext, the team will work with clinicians to develop safety tests of the ZIKV-LAV in glioblastoma patients.\nIn a study published this week in mBio\u00ae, an open-access journal of the American Society for Microbiology, the team shows that a live, attenuated version of the Zika virus could form the basis of a new treatment option for this fatal brain cancer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear this treatment isn\u2019t yet available for use in humans. The release could have put the findings into clearer perspective if it noted that availability for human use is years in the future, if ever.", "answer": 2}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\nIn their study published in Computers in Biology and Medicine, researchers detected breast cancer with more than 95 percent average accuracy using an inexpensive commercial electronic nose (e-nose) that identifies unique breath patterns in women with breast cancer.\nThe study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world.\n\"We've now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages,\" says Prof. Zeiri.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes the lead author claiming: \u201cWe\u2019ve now shown that inexpensive, commercial electronic noses are sufficient for classifying cancer patients at early stages.\u201d This implies that such \u201cnoses\u201d are already commercially available for breast cancer detection but we\u2019re not told where they are available and how frequently they\u2019re used.", "answer": 0}, {"article": "And exercise does seem to be protective -- even if you don't lose all the weight, it absolutely has beneficial effects,\" she said.\nA total of 68 participants underwent the procedure; two opted out of the surgery, and another died of a heart condition prior to surgery.\nThe study speaks both to the benefits of bariatric surgery and to the tremendous toll obesity takes on health.\nThe study looked at the effects of bariatric surgery in a relatively short timeframe, one to three years after surgery.\nModesitt, of the UVA's Division of Gynecologic Oncology in the Department of Obstetrics and Gynecology, was most surprised by the dramatic changes seen in the patients' metabolic profiles derived from the gut microbiome, the population of microorganisms living inside us.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the participants underwent a standard bariatric surgery and that these procedures are available. The release could have specified the criteria used to determine who is eligible for such procedures and whether insurance will cover it.", "answer": 1}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes clear that the drug is currently on the market and approved for other uses. But it did not state whether Rituxan is, or may become, used off-label for relapsing-remitting MS. And, as noted in our summary comment below, there are issues surrounding off-label use that could have been addressed.", "answer": 0}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nWhether the advice would benefit women with normal urine output, however, is unclear, Wessells noted.\nWomen are more prone to UTIs than men, partly due to their anatomy.\nTheir total daily fluid intake, including water and other beverages, averaged nearly 12 cups.\nThey drank roughly four cups of fluid per day, including just 2 cups of water a day.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "For most people in the U.S, water is easily available.", "answer": 2}, {"article": "METs, or metabolic equivalents, are a measure of physiological measure expressing the energy cost of physical activities.\nwhich we ask you to fill in / sign off / scan Please also ensure you create/update your MY ESC profile to enable us to create your registration record https:/ We will check your documents, and if these match our criteria we will liaise with our registration department to ensure you are issued a registration number/confirmation enabling you to attend the congress as a media representative.\n\"This could include brisk walking, cycling, swimming or gymnastics,\" he suggested, \"all possibly associated with leisure time physical activity or daily life activities.\"\nThese differences in risk were statistically significant.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It isn\u2019t a big deal that the news release didn\u2019t discuss the availability of exercise methods, since the elderly can pursue any physical activity for at least 15 minutes a day, five days a week. But we\u2019d note that access to some of the activities mentioned (cycling, swimming, gymnastics) might be limited, and the release could have noted that as well.", "answer": 2}, {"article": "\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\nThey also aim to gain a better understanding of exactly how bile acids can prevent cardiac fibrosis from occurring.\nThe study discovered the specific triggers activating the development of fibrosis which accelerates heart failure.\nBlocking the triggers through the use of a specific kind of bile acid prevented cardiac fibrosis from occurring.\nThe team is now pushing forward with additional studies to see if the same therapeutic effect can be achieved in humans.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release is silent on the availability of\u00a0TUDCA, the bile salt used in the study. As noted above, it is available commercially as a supplement. However, due to the pre-clinical nature of the research it is premature and ill-advised to rely on TUDCA for cardiac fibrosis prevention.", "answer": 0}, {"article": "Reavill says he may be proudest of his intention to hire disabled veterans in southern Illinois, a hard-hit region economically.\nIt remains to be seen whether that saved time will result in saved lives.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nIt can be inserted in a nonsterile environment such as an emergency room.\nHe recently procured a bank loan agreement and is hoping the award recognition and hospitals' willingness to try the catheter will attract a venture capitalist.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not clearly explained.\u00a0 Is anyone using this catheter clinically right now?", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Because this is an announcement from the FDA about approval, the drug will now be marketed for treatment, and the story clearly indicates that the drug combination is distributed by Genentech.\nWe\u2019ll rule this Satisfactory, but we\u2019d caution that\u00a0FDA approval does not necessarily equal availability. The key factor here is the cost and who will pay for it, or not. The story doesn\u2019t address this.", "answer": 1}, {"article": "\u201cIt\u2019s a promising result from an interesting data set,\u201d he said.\nThe program is now incorporated in Posit Science\u2019s BrainHQ.com brain training program.\nThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science.\nThe letter was in response to heavy marketing by companies touting the benefits of their programs based on scant scientific data.\nEdwards said she was frustrated with the scientific debate, which is one reason she agreed to present her findings before they were published.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "According to the article, there already exist companies such as Posit Science who offer these so-called brain games.", "answer": 1}, {"article": "\"They have a lot of promise and are potentially very important,\" said Katherine Hamilton, a headache specialist at Penn Medicine. The drugs, which are injected under the skin, offer hope for patients who have not responded to other treatments, but Hamilton said that what is \"potentially even more clinically relevant is they have a lower side-effect profile\" than other medications commonly used for migraine. She added, though, that it remains to be seen how patients who take them for long periods will fare. As new drugs, their long-term impact is not yet known.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported that all three drugs have been approved for sale by the FDA and a fourth \u2014 which isn\u2019t named \u2014 is in development.", "answer": 1}, {"article": "Guadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\n\"We did see that giving a higher dose of the drug seemed to produce a better methylation response among patients,\" says Valerie Lee, M.D., a fellow at the Johns Hopkins Kimmel Cancer Center.\nAlthough the study's main purpose was to test the safety rather than the effectiveness of guadecitabine doses, \"we were very happy to see some patients who benefited from the combination of the therapies for many months to more than a year,\" says Nilofer Azad, M.D., professor of oncology at the Johns Hopkins University School of Medicine.\nThe drug combination is being tested in an ongoing phase II clinical trial (NCT01896856) in a larger group of metastatic colorectal cancer patients at multiple institutions to determine the effectiveness of the dual therapy compared with chemotherapy regimens that do not include guadecitabine, says Azad.\nThe current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes clear that this was a preliminary trial and that a phase II trial is ongoing. That\u2019s good. In addition, the release states: \u201cGuadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\u201d That\u2019s great. We wish all releases were this straight-forward about drug/treatment availability.", "answer": 1}, {"article": "This, too, is suggested by sense and common experience, as it is affirmed by the science reported here,\" Katz said.\nThose in the second phase of the trial continued their diet and exercise program.\nFor more information on obesity, visit the U.S. National Library of Medicine.\nThese factors may also have a biological impact, he added.\nThe report, funded by the U.S. National Institutes of Health, is published in the March 29 online edition of the International Journal of Obesity.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.", "answer": 2}, {"article": "In a transvaginal ultrasound (TVU), sound waves emitted from a probe placed in vagina help a physician check if Essure has been placed properly.\nSome of the complaints related to the placement of the device.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nThe training will start in September, the same month the FDA will hold a public panel meeting to discuss the safety and effectiveness of Essure.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "TVU is an established imaging technique and procedure, carried out by both ob-gyns and by radiologists (and in some cases ultrasound technicians). The requirement for additional training and certification is a bit curious. But since one can gather from the story that the procedure is widely available, we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "A normal level is below 6.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\n\u201cThe clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system,\u201d said Dr. Mihai Netea of Radboud University Medical Center in the Netherlands, who was not involved in the study.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\nThe experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not explicitly address the issue of when, if ever, patients might have access to the BCG vaccine as a treatment for Type 1 diabetes. However, it does state that the treatment is being tested in a Phase 2 clinical trial involving 150 patients with Type 1 diabetes. The story also notes that one barrier to further development of BCG as a diabetes treatment is that it would appear to have little commercial value, meaning that drug manufacturers aren\u2019t interested in it.", "answer": 1}, {"article": "\u201cThe feeling that I\u2019m never going to see my kids or husband again and that asthma is finally going to get me.\u201d\n\nTwo years ago, Ms. DiGiusto\u2019s doctor told her about a new procedure called bronchial thermoplasty, the first non-drug therapy approved by the Food and Drug Administration for patients with severe asthma.\nThe one-time cost of $20,000, they say, is dwarfed by the tens of thousands of dollars in hospital bills and medication costs that a severe asthmatic can easily accumulate in a single year.\nAs a result, many people who need it, doctors say, are forced to go without it.\nEvery year, about 3,400 die because of it.\nBut the procedure is expensive, costing around $20,000, and insurers have been reluctant to cover it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the story states that about 650 people have been treated, and although it discusses lack of insurance coverage, it never explicitly explains how widespread is its availability.\u00a0 Do only high-tech teaching hospitals provide it?", "answer": 0}, {"article": "But this study doesn't tell us about long-term outcomes or what transpired over a long period of time,\" he said.\nClearly, the earlier a breast cancer is diagnosed, the less treatment that will be required.\n\"There are multiple benefits of mammography in terms of early detection.\nStill, \"the observations are consistent with what we have seen with the value of early detection.\nAnd the women who were screened earlier had smaller tumors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We believe that mammograms are well-known to be widely available. And the earlier and more frequent screening described here is not earlier or more frequent than what many guidelines recommend, so would not be expected to be denied by health insurers.", "answer": 1}, {"article": "\"We were very intrigued by the higher lean mass, the possibility that vitamin D can help infants to not only grow healthy skeletons but also healthy amounts of muscle and less fat,\" said Hope Weiler, one of the study's authors and Director of the Mary Emily Clinical Nutrition Research Unit at McGill University.\nThis amount is in line with current Canadian health guidelines.\nVitamin D supplementation is routinely recommended for babies until they can get an adequate amount through their diet.\nThe new study confirmed the importance for the development of strong bones of a vitamin D supplement of 400 IU/day during a baby's first year.\nThe researchers achieved this by following up on a 2013 study in which 132 infants in Montr\u00e9al, Qu\u00e9bec, were given a vitamin D3 supplement at one of four different dosages between the ages of 1 month and 12 months.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that vitamin D supplementation is already widely recommended for infants.", "answer": 1}, {"article": "\n\u2022 Read this story at www.uab.edu/news\n\u2022 The UAB News Studio is available for live or taped interviews with UAB experts.\nNewswise \u2014 BIRMINGHAM, Ala. \u2013 The Food and Drug Administration recently approved lifitegrast, a new eye drop for treating signs and symptoms of dry eye in adult patients.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\nKelly Nichols, O.D., Ph.D., a dry eye expert and dean of the University of Alabama at Birmingham School of Optometry, conducted research studies for the parent drug company to explore the efficacy and safety of lifitegrast in treating this eye condition that affects more than 16 million adults in the United States.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Though the news release does not say anything about availability, it does note that the FDA has approved the product.\u00a0 The drug was approved July\u00a012, 2016.", "answer": 1}, {"article": "Multiple neurological disorders, including Parkinson\u2019s disease and dementia with Lewy bodies, involve the abnormal clumping of a protein called alpha-synuclein into brain deposits called Lewy bodies.\nImportantly, test results were available within two days, compared to related assays that require up to 13 days.\nByron Caughey, Ph.D., a senior investigator in NIAID\u2019s Laboratory of Persistent Viral Diseases, is available to comment on this study.\nThe NIAID group continues to adapt the RT-QuIC assay to detect additional types of neurological diseases with greater accuracy using the least invasive patient sample possible \u2014 whether that is blood, skin, nasal brushings, or other samples.\nThis research was supported in part by NIH funding awards ZIA AI001086-08, AGO5131, and PHS P30-AG010133.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The tentative wording of the lead \u2014 that the test could \u201coffer the possibility of improving early diagnosis\u201d \u2014 raises the question of what needs to happen for this test to become widely available. The release doesn\u2019t answer that question.\nNor does the study discuss improved diagnosis since that\u2019s not the intent of the test\u2019s development \u2014 it\u2019s research to determine who to include in trials and follow their disease progression.", "answer": 0}, {"article": "The average age of children in the study was 7.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nThey also want to find out how early in life such a test might be used.\nIt wasn't clear if this impairment would show up in a test of the sniff response, however.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release not only makes clear that a sniff test is \u201cin no way ready\u201d for clinical use, but lays out several questions for relevant future research that needs to be done before such a clinical tool can be developed.", "answer": 1}, {"article": "In the September issue of Cancer Prevention Research, researchers report that metformin was associated with a substantial reduction (up to 73 percent) in the number of tumors mice developed when they were given a common carcinogen found in tobacco.\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\nThis adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.\nThe reduction is real and ranges from 30 to 70 percent.\"\nAt this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The current widespread use and availability of metformin is clear from the story", "answer": 1}, {"article": "However, gluconate binds the zinc ion more tightly than acetate does.\nAccording to Dr. Hemil\u00e4, there is no justification for the popular phrase that \"there is no cure for the common cold\" because of the strong evidence that zinc lozenges can shorten common cold duration by over 30%.\nThe optimum frequency of their administration also warrants further investigation.\nThus, zinc doses of over 100 mg per day do not seem to provide any more benefit.\nHowever, in future studies the optimal composition of zinc lozenges should be investigated.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t talk about the availability of zinc lozenges, but given that a search on Amazon turns up hundreds of sources, and most grocery and drug stores stock zinc, that\u2019s not a significant omission.", "answer": 2}, {"article": "Chan School of Public Health, and Brigham and Women's Hospital.\n\"It takes co-operation and effort from multiple areas, like insurance companies, employers, policy makers and city planners, to figure out how to creatively support and encourage more exercise into most busy adults' working day.\n\"This study underscores the ongoing need for more effective prevention measures and policies to increase exercise, improve diet quality and reduce tobacco use in our population,\" said senior author June M. Chan, ScD, from the departments of Urology, and Epidemiology and Biostatistics at UCSF.\n\"It's interesting that vigorous activity had the highest potential impact on prevention of lethal prostate cancer.\nTo gage the effects of lifestyle habits, the researchers developed a score based on the results of the health professionals survey, then applied it to the physicians' study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The study was limited to a relatively high level income group and the interventions may not be attainable for all men, in all socioeconomic groups. Does partaking of vigorous physical exercise on a regular basis require access to a gym or just a high degree of motivation? Are tomatoes and fish attainable year round for all socioeconomic groups? The study addresses this to some extent when it says, \u201cIt takes co-operation and effort from multiple areas, like insurance companies, employers, policy makers and city planners, to figure out how to creatively support and encourage more exercise into most busy adults\u2019 working day.\u201d We\u2019ll award a Satisfactory here.", "answer": 1}, {"article": "Recently a large, government-funded study found that longtime smokers at high risk for lung cancer who received annual rapid computed tomography (CT) scans of their lungs cut their risk of dying of the disease by 20%.\nHe was not involved in the research.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nAug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that this very preliminary research procedure with dogs is not available yet.", "answer": 1}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nBut even with those risks, it\u2019s worthwhile, Gaziano\u2019s team found.\nThere\u2019s an online tool that people or their doctors can use to calculate their risk of heart disease, which is based on age, sex, blood pressure and cholesterol levels.\nIt would be, they report in the Journal of the American Medical Association.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story made it clear that statins are widely available. They are also paid for by insurance plans.", "answer": 1}, {"article": "The volumetric impedance phase shift spectroscopy (VIPS) device (Cerebrotech VisorTM, Cerebrotech Medical Systems, Pleasanton, CA) works by sending low-energy radio waves through the brain that change frequency when passing through fluids.\n\"If we can give the information to emergency personnel out in the field that this is a large-vessel occlusion, that should change their thought process in triage as to which hospital they go to.\"\nIn their next steps, the researchers are undertaking the VITAL 2.0 study to determine if the VIPS device can use complex machine learning algorithms to teach itself how to discriminate between minor and severe stroke without the help of neurologists.\nThe researchers hope that the device will save valuable time -- especially important in stroke where time is brain -- when it is deployed with emergency medical personnel in the field.\nThis study was funded by Cerebrotech Medical Systems.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We learn that this is very preliminary research and that the researchers will do another study to \u201cdetermine if the VIPS device can use complex machine learning algorithms to teach itself how to discriminate between minor and severe stroke without the help of neurologists.\u201d", "answer": 1}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\n\"We still have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\"\nThe new results were part of a multi-center randomized, placebo-controlled phase 3 clinical trial for TX004HR, an investigational bio-identical 17\u03b2-estradiol applicator free vaginal softgel capsule.\nPrevious survey research completed by Dr. Kingsberg and others has shown that while 32 million women may be experiencing symptomatic VVA and suffering from related impacts on sexual function, interpersonal relationships, self-esteem and overall quality of life, only 7 percent are currently using a prescription therapy to alleviate symptoms.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says nothing about when these softgels might be available.", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of tomatoes is not in question.", "answer": 2}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nThe resource has been open to bona fide health researchers for 18 months.\n[2] For preview login details for the Ubble website, please email daisy.barton@lancet.com.\nThis study was funded by Knut and Alice Wallenberg Foundation and the Swedish Research Council.\nWhether this will help individuals improve self-awareness of their health status, however, or only lead to so-called cyberchondria, is a moot point.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Notes at the end of the news release speak to the availability of the interactive \u201cUbble\u201d website once the research article is published. We could not access the calculator, perhaps due to high traffic levels accompanying the rollout.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly, oophorectomy, surgical removal of the ovaries, is available.", "answer": 1}, {"article": "BRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\nThey also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\nIt is unclear how common the mutations are in other racial and ethnic groups.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The comments of Drs. Domchek, Offit, and Bakkum-Gamez make it clear that the surgical procedure is widely available.", "answer": 1}, {"article": "Vaginal and vulvar cancers are usually caused by the human papillomavirus, which also causes cervical cancer.\nRaloxifene, sold by Eli Lilly & Company under the name Evista, is now approved only to prevent bone-thinning.\nBut raloxifene's edge in blood-clot and uterine-cancer avoidance was not statistically significant, and tamoxifen proved better at reducing the rate of noninvasive breast cancer.\nThe new data are not likely to settle the debate about which drug is better.\nThe breast cancer trial, the Study of Tamoxifen and Raloxifene, or STAR, has been a focus of intense debate.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that both tamoxifen and raloxifene are currently available, and notes the conditions for which they are approved.", "answer": 1}, {"article": "Melanie Ashton continued, \"We found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI, showed better response to add-on nutraceutical treatment than did those who reported a low-quality diet, or a diet including foods that promote inflammation, or who were overweight.\nWhile current medications are useful, they are better at targeting mania symptoms (the 'up' phase), leaving a lack of effective treatment for people experiencing depressive episodes.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\nThese are early results, but if replicated may mean that treatment of some mental health problems could benefit from the inclusion of dietary advice.\nThe fact that there are two opposite sets of symptoms means that finding an effective treatment is difficult.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests \u201cnutraceuticals,\u201d including the\u00a0anti-inflammatory amino acid n-acetylcysteine (NAC) are potentially helpful. NAC is widely available in both prescription and over-the-counter formulations.", "answer": 1}, {"article": "\"It's about prevention.\"\nBredesen said that his team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\nJames E. Galvin, M.D., M.P.H., a professor of clinical biomedical science at FAU's Charles E. Schmidt College of Medicine and a professor in the Christine E. Lynn College of Nursing, who was not involved in the study, agreed that personalized approaches such as the MEND protocol are the types of approaches needed for this disease going forward.\nA Buck Institute press release on the study stated: \"None of the patients were able to stick to the entire protocol.\nOne expert, Dr. Dale Bredesen, a professor at the Buck Institute for Research on Aging and a professor at the Easton Laboratories for Neurodegenerative Disease Research at UCLA, thinks he might have found a way to reverse memory loss, a hallmark of the disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes Bredesen saying \u201chis team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\u201d\nBut the story could have served readers better if it had pressed Bredesen for specifics about when these trials might occur. The complexity of the protocol, the expense and time involved and questions about insurance coverage all make availability\u00a0a very key question.", "answer": 0}, {"article": "Many pregnant women who have symptoms of depression worry that taking antidepressants might harm their unborn babies -- so they stop taking their medications, say researchers at the Stanford University School of Medicine.\nSome received depression-specific acupuncture treatments, others had needles inserted in acupuncture points not known to relieve depression, and a third group received massage therapy.\n\"I hope that people will respect the rigorous methodology used in this blinded, randomized, controlled trial and accept the result,\" study researcher Deirdre Lyell, MD, assistant professor of obstetrics and gynecology at Stanford University School of Medicine, says in a news release.\nThe study is published in the March issue of Obstetrics & Gynecology.\nThe study included 150 pregnant women diagnosed with major depressive disorder.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The acupuncture treatment appears to have been customized for depression. Depression-specific acupuncture is not likely to be available everywhere. The story didn\u2019t tell us. ", "answer": 0}, {"article": "To find out more about the activities of EULAR, visit: http://www.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\nFor those patients who either fail to respond, or who develop an inadequate response to these drugs over time, a biologic DMARD is an effective add-on treatment option.2 The first choice of biologic therapy is usually a TNFi2 and currently identical dosing regimens of TNFi are used both to induce and then maintain a clinical response.1\n\nOver the first six months of the study, flares (exacerbations of symptoms and signs) occurred in 14% of patients who stayed on the same TNFi dose, compared to a similar figure of 13% in those patients for whom the dose was reduced by one-third.\nThe OPTTIRA study is a 12-month multicentre, randomised controlled trial designed to evaluate if reducing TNFi doses (of either etanercept or adalimumab) caused a loss of response in RA patients who were also receiving a synthetic DMARD.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although availability is not explicitly addressed, the release does note that\u00a0biologic drugs are used as an add-on treatment option to methotrexate, which suggests that they are approved and available. This is true in the U.S., and also seems to be true in the UK, where the study originated.", "answer": 1}, {"article": "How (Study Design): This was a randomized clinical trial (RCT).\nAuthors: Andrew K. Chang, M.D., M.S., of Albany Medical College, Albany, New York, and coauthors\n\nResults: After 2 hours pain was less in all participants, without any important difference in effect between the four groups.\nThe following related elements also are available on the For The Media website:\n\nThe editorial, \"Opioid vs Nonopioid Acute Pain Management in the Emergency Department,\" by Demetrios N. Kyriacou, M.D., Ph.D., Senior Editor, JAMA, Chicago; Northwestern University Feinberg School of Medicine, Chicago.\nStudy Limitations: The results apply only to pain after two hours.\nAbout 1 in 5 patients required additional medication to control their pain.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release does not address this explicitly, but it is fairly clear from the context that all of these painkillers are already clinically available.", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nThe research team is now looking to fund a full clinical trial.\nAfter further sample testing the next step is to take this technology and put it into a user friendly format.\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe research team used a gas chromatography sensor system called Odoreader that was developed by a team led by Professor Probert and Professor Norman Ratcliffe at UWE Bristol.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that this screening tool is still in development and that the developers are seeking funders to expand the testing.", "answer": 1}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nShockney asks.\nYet Shockney says her husband of nearly 35 years would have wanted her to do everything possible to survive.\n\"It's very exciting.\"\n\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is well-established in the story.", "answer": 1}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\n\"These findings will help us to better understand how anal cancer patients should be treated, ultimately improving survival rates and quality of life.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release states that the study is likely to have an impact on treatment plans of future patients, but we never learn what that impact might precisely be, and what next steps might be taken by the oncology treatment community to use the findings and correct misleading statistics on diagnosis and treatment.", "answer": 0}, {"article": "About the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\nThe full text of \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\" can be accessed at http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142766.\nFor more information, please visit www.alzheimersprevention.org.\nKhalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\nThe print edition is scheduled to be published in August.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release establishes that the Kirtan Kriya meditation technique is currently in use. Instructions can be found on the Alzheimer\u2019s Research and Prevention Foundation\u2019s website.", "answer": 1}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nBut the regulators weren't buying the evidence put forward by the company to prove the medicine's benefits in treating travelers' \"excessive sleepiness\" outweighed its risks.\nThe regulators just gave a second thumbs down to drugmaker Cephalon's application to sell Nuvigil as a remedy for jet lag.\nSo who wouldn't want a pill to fight the doldrums caused by skipping too many time zones too fast?\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that Nuvigil is already approved for some uses but not for jet lag.", "answer": 1}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\n\"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,\" said Professor Sudipta Seal, who directs of UCF's NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study.\n\"Unique approaches to target tumor cells with nanoparticle delivery systems hold promise for treatment of resistant tumors, such as the high risk neuroblastoma.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The beginning of the news release makes it sound like this technology is available at your local hospital. Later in the report, however, the news release makes it clear that this study was conducted in cell lines in a laboratory. Researchers hope to expand this research to animal models and direct the curcumin nanoparticles to tumor sites, the news release adds.\nWe feel this is enough for a Satisfactory rating.", "answer": 1}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of cherries is not in question.", "answer": 2}, {"article": "Dying tumor cells release cell-free DNA (cfDNA) into the blood, where cancer-specific methylation changes can be detected at any disease stage.\nI am therefore very encouraged with the results of this study, showing that EpiCheck has the ability to identify both non-small-cell and small-cell lung cancer at early stages, with a high level of sensitivity and specificity.\n\"Clearly, we must establish screening programs for lung cancer worldwide.\n\"Furthermore, these results were validated prospectively in an independent cohort.\nSuch promising results combined with the simplicity of the test, could allow us to detect lung cancer at the early stages and hence improve 5-year survival from about 15% to about 50-70%.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll give this a marginal satisfactory for giving readers a hint that the test is not yet available when it says the company is \u201clooking forward to begin extensive clinical trials in the US,\u00a0Europe\u00a0and\u00a0China\u00a0next year, in order to get the test to the market as soon as possible at an affordable price.\u201d That tells us that the test is likely years away from being commercialized \u2014 if ever.", "answer": 1}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\nThe researchers say the trials also have shed light on new ways to grow the MILs.\nNoonan says the research team has used these data to guide two other ongoing MILs clinical trials.\nBorrello notes that several U.S. cancer centers have conducted similar experimental treatments, known as adoptive T cell therapy, but says the Johns Hopkins team is believed to be the only one to use MILs.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release points out that \u201cseveral U.S. cancer centers have conducted similar experimental treatments\u201d but adds that Johns Hopkins is the only one using the MIL cells. It also points to several other ongoing clinical trials at Hopkins that build on the findings of this small study. Using the terms \u201cpilot\u201d and \u201cexperimental,\u201d the release signals that availability is very limited.", "answer": 1}, {"article": "That's been the brass ring.\"\n\"We need to be mindful of the fact that the majority of human studies of oxytocin have been conducted using adults, including this study, and only one paper has included individuals between the ages of 12 and 18.\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nBecause oxytocin does not last long in the body and produces its effects for a relatively brief period, some experts said the findings were more likely to encourage drug companies to develop alternative substances that had the same benefits.\nWhile cautioning that more research is needed on children and additional patients to make sure oxytocin is safe and effective, advocates for families with children with autism welcomed the findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment, oxytocin nasal spray, is not commercially available as such and is not approved for this indication. These facts are not explicitly noted in the story. However, the story does note the apparent use of the drug for this purpose by some, without noting the lack of FDA approval of the product. Although this could have been much more clear, the story does make it clear that some people are getting the stuff somehow.\u00a0 It would have been relatively easy to explain how. \n", "answer": 1}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\nLooking to the future\n\n\"Evidence at this point suggests that cytokine antagonists -- which are much more specific in their anti-inflammatory effects than drugs like aspirin -- show modest antidepressant effects in individuals with depression and increased inflammation,\" said Raison, who did not participate in in Khandaker's research.\nTheir potential side effects also must be investigated, Khandaker said, adding that \"we and other research groups from both sides of the Atlantic are currently planning and conducting such randomized control trials.\"\nKhandaker said that five of the 20 studies focused on one specific cytokine.\nThe immune system acts like a thermostat, turned down low most of the time but cranked up when we have an infection, according to Khandaker.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that more research needs to be done before the new anti-inflammatories could be prescribed as a direct therapy for depression, and\u00a0one of the researchers notes that it\u2019s too early to prescribe them for depression.\u00a0We\u00a0also liked that the story mentioned other diseases that are treated by anti-inflammatories.", "answer": 1}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nAnd despite going to some of the best hospitals in the country, four years would pass before Andy\u2019s condition was properly diagnosed.\nRemarkably, their efforts seem to be paying off and may finally offer hope not only to those who with fragile X but to carriers like Andy\u2019s sister, Laura.\nSure enough, mice, fish and fruit flies that through genetic engineering were made to have fragile X seemed to become normal when given Dr. Bear\u2019s compound.\nThe discovery was front-page news around the world, and experts predicted that widespread fetal testing and therapies were in the offing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no question that the\u00a0drug discussed in the story is years away from being available and may never get approved by the FDA.\u00a0\u00a0", "answer": 1}, {"article": "An electromagnetic wave then agitates water molecules in the surrounding tumor tissue, producing friction and heat that eventually destroy the tumor.\nU.S. researchers say the technique certainly shows promise.\nBut more patients have to be followed for far longer to see if they stay in remission, they say.\nThe procedure, which costs about $2,000, takes about an hour, and the patient is typically kept overnight in the hospital for observation.\nIn a preliminary study, the technique, called microwave ablation, eliminated lung tumors in 19 of 28 patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers are really only told that this was a study in Italy and that \u201cUS researchers say the technique certainly shows promise.\u201d The story does not make it clear whether a patient could expect to have this technique performed in a typical hospital or how many clinical trials are currently ongoing involving microwave ablation.", "answer": 0}, {"article": "\u201cIt\u2019s a bit like with mobile phones.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nI see the same thing with this system.\u201d\n\nThe Juvenile Diabetes Research Foundation said last month it was teaming up with U.S. drugmaker Johnson & Johnson\u2019s unit Animas, which makes insulin pumps, and DexCom Inc, which makes continuous glucose monitoring devices, to develop and test an artificial pancreas system.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests that it will be several more years before the \"new device\" supposedly tested in this study will be available on the commercial market. But as the competing story in the New York Times makes clear,\u00a0the\u00a0researchers in this study did not test a \"device\"\u00a0per se\u00a0but rather an algorithm that could hypothetically be used to link up a glucose monitor and an insulin pump to create\u00a0a new device for automatically managing blood glucose.\u00a0The\u00a0suggestion that there is a device\u00a0already in testing\u00a0exaggerates the level of progress that\u00a0has been made and will give readers a false sense\u00a0as to\u00a0how close\u00a0this product is to\u00a0becoming a reality.\u00a0 ", "answer": 0}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nAnd the exercise needs to be performed four to five times a week.\nThe new study appears in Circulation, a journal of the American Heart Association.\n\u2022 One or two weekly strength training sessions using weights or exercise machines were included on a separate day, or after an endurance session.\nTwo to three times a week was not enough, the researchers found in an earlier study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The intervention in question here is aerobic exercise. Widely available.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\nIn light of these positive results, \u201cit is more important than ever for patients with diabetes to be evaluated on a regular basis for eye disease and receive treatment promptly once indicated as we now have excellent success in treating patients with DME,\u201d says Dr. Aiello.\nWith the rate of diabetes increasing dramatically worldwide, many individuals will be at risk for vision loss from diabetic eye complications and DME is a major global health concern,\u201d says Jennifer K. Sun, M.D., M.P.H., a member of the study research team and writing committee, and an Investigator in the Section on Vascular Biology, an ophthalmologist in Beetham Eye Institute at Joslin and an Assistant Professor at Harvard Medical School.\nPhysicians now have robust data to help them counsel patients and make informed decisions regarding treatment options,\u201d says study co-author Lloyd P. Aiello, M.D., Ph.D., Professor of Ophthalmology at Harvard Medical School, Director of Joslin\u2019s Beetham Eye Institute, co-head of Joslin's Section of Vascular Cell Biology, and founding chair of the DRCR Network.\n\u201cThe results clearly remove any doubts about anti-VEGF drugs\u2019 efficacy in treating DME.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Two of these drugs are available specifically for macular edema and the third, although used off label, is also available in proper form and dosage. The story makes this clear. Since\u00a0availability also relates to cost and who will pay for it \u2014 especially this era of high deductible health plans \u2014 some comment about the increased availability of the lower-cost option would not have been inappropriate.", "answer": 1}, {"article": "In addition to Chang, other authors on the all-MD Anderson study include: Stephen Hahn, M.D., Ritsuko Komaki, M.D., Pamela K. Allen, Ph.D., Zhongxing Liao, M.D., Steven H. Lin, M.D., Ph.D., Daniel Gomez, M.D., James Welsh, M.D., Melenda Jeter M.D., James Cox, M.D., Michael O'Reilly, M.D., Ming Li, M.D.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\nIn contrast, the historical OS rate with standard of care concurrent chemotherapy and traditional radiation was 16 months at the time when the study was designed.\nOf note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\nVivek Verma, M.D., now at the University of Nebraska Medical Center, also contributed to the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "How widespread the treatment options are is not clear. The release does clearly state that this was done at a single site. However, it would have been relatively easy to state that there are only a small number of facilities that can deliver proton beam therapy.", "answer": 0}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cThere has been no way of killing viruses in the air in public spaces, and this is an approach that may solve that problem.\u201d\n\u201cSo up until now, they\u2019re only really practical when people aren\u2019t around,\u201d say Brenner.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a just passing satisfactory\u2013it\u2019s implied that the product is not available yet, because the story mentioned the lead author \u201cis working with a company to develop a commercially available version of the lamp.\u201d", "answer": 1}, {"article": "\"So I don't need any chemotherapy, I don't need any radiation.\nA chest X-ray showed nothing suspicious.\nIt turned out to be cancer.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if lung cancer screening is widely available.", "answer": 0}, {"article": "An analysis of 106 randomized trials involving more than 250,000 patients examined the effects of newer angiotensin receptor blockers (ARBs) and older angiotensin-converting enzyme (ACE) inhibitors.\n\"This is the first time that we have a clear and consistent message from the three buckets of trials of ACE inhibitors and ARBs, all of which show that there is no outcome difference between the two agents, except for better tolerability of ARBs,\" Bangalore said.\nMONDAY, Jan. 4, 2016 (HealthDay News) -- Newer blood pressure drugs are as safe and effective as older medications, new research suggests.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that both ACE inhibitors and ARBs have been around for years, the latter since the year 2000 and the former for at least a decade earlier, so readers can easily understand this story is about currently available drugs", "answer": 1}, {"article": "MORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThat doesn\u2019t mean you should extend your own use of the contraceptives without talking to your doctor.\nThe study is still continuing, and it could be quite a long time before any changes to clinical recommendations are considered.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\nTwo highly effective contraceptives\u2014the intrauterine device (IUD) and the implant\u2014actually last much longer than they are currently recommended, according to new research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that these birth control choices are widely available in the United States. The story could have noted that access to LARCs in developing countries may be limited, and that using these devices longer might help with that problem.", "answer": 1}, {"article": "The found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\nThe study is unique because it used objective measures to show that poor sleep habits make people more vulnerable to a cold virus, says Badr, who was not involved in the research.\nHe calls the study's results \"powerful.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Of course, not everyone can find six or more hours in a day to sleep. But the study did not address this.", "answer": 0}, {"article": "A systematic review of C.B.T.\nImprovements like mine and those reported in the study bring sleep statistics for those with insomnia quite close to those without it.\nMy experience is consistent with these averages.\nAnd as studies show, it works better than drugs.\nThis further emphasizes the point that many insomniacs aren\u2019t that different from normal sleepers.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We are not given a lot of detail, but consider both CBT and medications to be widely available.\u00a0This is particularly true because the writer makes it clear that an online program was helpful (rather than requiring a specialized clinic or provider).", "answer": 1}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\nIt also suggests the potential to improve postoperative survival among the frail through systematic administrative screening, review, and optimization of perioperative plans.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\n\u201cThe ultimate cause of the survival benefit is likely multifactorial, including changes in preoperative decision making, intraoperative management, and postoperative rescue,\u201d the authors write.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is not clear if the screening index and action plans for surgery among frail patients are readily available for other institutions to use.", "answer": 0}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nThere aren't strong guidelines regarding the use of tonsillectomy to treat sleep disorders, so the doctors reviewed the evidence to see whether the surgery outperformed so-called watchful waiting -- monitoring the situation.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nStill, Chinnadurai and Hackett warned against automatically choosing the surgery for every sore throat.\nAlso, there was limited research on long-term results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that \u201cTonsillectomy is the third most common surgery performed on U.S. children.\u201d\u00a0 We know tonsillectomies are readily available through the health care system, if needed.", "answer": 1}, {"article": "I was absolutely terrified because I saw my mom go through it, and I saw how much pain she was in,\" Barletta says.\nThat's still the standard procedure for the 50,000 Americans who are operated on each year for this problem.\nLaPook notes that it will be a few more years before this procedure is widely available.\nHe says it's in the final stages of testing at about 30 hospitals around the country.\nInstead of 10 days in the hospital, there long months of recovery and a lasting scar like her mother \u2014 one that she had to have plastic surgery to repair \u2014 Barletta was out of the hospital in two days.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This piece did include a disclaimer at the end that this procedure is done only in a limited number of centers and is investigational at this time.\n\u00a0", "answer": 1}, {"article": "On average, using probiotics reduced a bout of diarrhea by more than a day, and reduced the risk of a prolonged diarrhea episode -- four days or more -- by 59 percent.\nStephen Allen, a pediatrician at Swansea University in the United Kingdom who lead the review, tells Shots that probiotics were effective in almost all the studies, which had more than 8,000 participants total, his team evaluated.\nAmong the different bacteria tested were L. acidophilus, S. boulardii, and L. casei, which occur naturally or are added to products like supplements, yogurt, miso, soy milk and some juices.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story listed several different types of products containing \u2018probiotics\u2019, indicating that they may normally be found in some products while others represent supplemented products.", "answer": 1}, {"article": "The average daily dose of insulin dropped almost 39 percent after 12 weeks for the group with some beta cell function and 25 percent in those with no beta cell function, suggesting that the group with no beta cell function now produced insulin.\nBoth experts said the treatment appears safe, with no risk of rejection.\nThis was an initial clinical trial designed to test for safety.\nThis treatment could potentially be useful in other autoimmune diseases, such as lupus and rheumatoid arthritis.\nBut, even if that's not possible, the recovery of some beta cell function would be welcome news.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that this type of treatment is not yet available and no claims were made about a timetable for reaching the market.", "answer": 1}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on obesity.\nThe balloon treatment will be available starting in January, but the cost hasn't been announced, Pryor said.\nThe device, called the Obalon Balloon System, was approved in September by the U.S. Food and Drug Administration.\nThe results were also presented at a medical meeting in May.\nSix months after the balloons were removed, nearly 90 percent maintained the weight loss they achieved during treatment, Pryor said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reports that the Obalon balloon was approved by the FDA in September and will be available in January 2017.", "answer": 1}, {"article": "Not everyone agreed with that notion, however.\nWEDNESDAY, Nov. 10, 2010 (HealthDay News) -- Offering your baby a special formula when weaning off breastfeeding may offer some protection against the development of the antibodies associated with type 1 diabetes, if you have a family history of the disease, new research suggests.\n\"We observed that early dietary intervention [with extensively hydrolyzed formula] decreased the frequency of diabetes-associated autoantibodies, which are markers of an ongoing disease process, by about 50 percent by the age of 10 years,\" said the study's lead author, Dr. Michael Knip, a professor of pediatrics at the Hospital for Children and Adolescents in Helsinki, Finland.\n\"The data in this study is not sufficiently strong to support recommending any changes for parents,\" said the author of an accompanying editorial, Dr. David Harlan, co-director of the Diabetes Center of Excellence at the University of Massachusetts Memorial Medical Center in Worcester.\nHow the highly hydrolyzed formula might reduce the risk of developing diabetes-predictive antibodies is unknown, but the researchers speculated that it might contribute to reduced gut permeability or changes in gut microflora, among other things.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Various infant formulas are available when weaning infants from breast milk, or when breastfeeding is not an option.\u00a0 The story discusses research that compared regular infant formula with a type of extensively hydrolyzed formula that helps break down proteins during digestion.\nThis formula may not be available to some parents due to greater expense.", "answer": 0}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nNotable requirements of the Siliq REMS Program include the following:\n\u2022 Prescribers must be certified with the program and counsel patients about this risk.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since Siliq is a new psoriasis drug that just received FDA approval, it is clear that it is now coming onto the market. The news release states the drug will only be available through a restricted program called the Siliq Risk Evaluation and Mitigation Strategy. The release then lists the requirements of the program, which include patient counseling, signing of a patient-prescriber agreement form and pharmacy certification.\nWe feel this is good enough for a Satisfactory rating here.", "answer": 1}, {"article": "A new study offers a fresh strategy for treating patients suffering from both coronary artery disease and heart failure, afflictions linked to poor quality of life and high risk of death that affect as many as two million Americans.\n\nThe 1,212-patient study calls into question the need for immediate bypass surgery in these patients\u2014an approach commonly recommended by doctors. The study, called Stich, found benefits in treating people with medication only, and in treating people with a combination of bypass surgery and medication....", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the range of treatments studied by the authors are widely available.", "answer": 1}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\n\"With these new blood tests, many patients will now be able to proceed right to therapy for their condition.\"\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release clearly states that the tests are already on the market.", "answer": 1}, {"article": "\u00b7\nAnother 7,000 people -- aided by a network of nurses hired by Cyberonics, the Houston-based manufacturer of the device -- are seeking approval from their insurance companies for the $25,000 operation.\nThe pocket-watch-sized device is billed as \"a pacemaker for the brain,\" the newest cutting-edge treatment for as many as 4 million adults whose severe depression is not relieved by psychotherapy, drugs or even shock treatments.\nThe device has also attracted attention on Capitol Hill, where the Senate Finance Committee has spent two years looking into decision-making at the FDA.\nThe company's Web site says that \"preliminary imaging studies suggest that VNS Therapy affects many areas of the brain implicated in mood regulation.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains how many Americans have had the device implanted (more than 550 since FDA approval), how many are waiting insurance company approval (7,000), and how many Washington, DC-area physicians have been trained in the use of the device (more than 3,700). ", "answer": 1}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story discussed several approaches to treatment. \u00a0It focused on liver transplantation and indicated that livers were in short supply. \u00a0It indicated that weight loss was a means to stop progression of the condition and may be an adequate approach. \u00a0It also mentioned that there are a number of clinical trials being conducted for treatment of cirrhosis.", "answer": 1}, {"article": "Individuals with panic chronically hyperventilate, even when not experiencing a panic attack.\nFreespira is both easy to use and effective.\nTheir first product, Freespira, is an FDA-cleared treatment for individuals suffering from panic disorder, panic attacks and other symptoms of panic.\nAbout Freespira\n\nFreespira is an FDA-cleared, drug-free, four-week at-home treatment for panic attacks and other panic symptoms.\nFreespira is commercially available throughout the U.S. To learn more, visit http://www.freespira.com or contact info@pahealthsciences.com.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The device has apparently been commercially available for many years but this is not specifically addressed in the release.", "answer": 0}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\nThe current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years.\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\nFurther research is needed to establish whether efforts to improve muscle strength are likely to reduce an individual's risk of death and cardiovascular disease.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release implies that the type of dynamometer used to assess grip strength in this study is widely available, but a clearer statement about availability, especially in low-income countries, would have made the release better.", "answer": 1}, {"article": "Baltimore, Md.\nOptions for these patients are few, and they come with substantial adverse effects.\nThis new radionuclide drug shows strong binding to the protein PSMA and is readily and safely taken up by malignant PSMA-positive tumors.\nResults of the human study showed that imaging was effective for the evaluation of metastatic prostate cancer, and subsequent therapy resulted in a drop in prostate-specific antigen levels from 38.0 to 4.6 nanograms per milliliter.\nTo be clear, other PSMA-based theranostics have reached the research bench, but previous contenders had too many limitations in terms of instability in live subjects, a lack of imaging contrast between targeted tissue and background signal and increased PSMA-associated binding to normal organs such as the kidneys.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This release does eventually make it clear that only one patient has been tested, that this is very preliminary work and that the drug is not available.", "answer": 1}, {"article": "The single-color digital PCR test offers several advantages over other methods of circulating tumor DNA analysis, compared to next-generation targeted sequencing and fluorescent probe-based digital PCR assays.\nThe main advantage is that the new technique does not rely on pre-amplification, which can introduce errors and biases.\n\"This test is simple enough to set up and analyze without extensive training, and therefore, it can be implemented by anyone, making it highly accessible to any laboratory.\nAccording to the report in The Journal of Molecular Diagnostics, this highly sensitive test has the potential to be personalized to recognize mutations unique to any individual cancer.\nThe report describes the use of the test to analyze samples from six patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear from the release that the test is not widely available and is only just now being developed.", "answer": 1}, {"article": "Tendon stem/progenitor cells regulate inflammation in tendon healing via JNK and STAT3 signaling.\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\nSubmit to The FASEB Journal by visiting http://fasebj.\n\"Our findings represent an important foundation for the development of a new treatment that would regulate overwhelmed inflammation for tendon ruptures and tears, tendonitis, tendinopathy, and other tendon injuries and diseases.\"\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t provide any indication when a therapy might be available \u2014 if ever. This very preliminary basic research has\u00a0a long research path ahead.", "answer": 0}, {"article": "Since 2013, the American Academy of Pediatrics endorses a wait-and-see approach, seeking to let more earaches heal on their own without antibiotics.\nMoms have flooded https://www.facebook.com/ClearPop with glowing testimonials for this simple drug-free solution that:\n\n-can be given along with analgesics or antibiotics.\nFounder and Chairman: Dr. Scott Morehouse, scott@clearpop.com\nWALNUT CREEK, Calif., Jan. 15, 2016 /PRNewswire/ -- Child screams from the pain of earache; exhausted parent ventures to drugstore in wee hours to find\u2026nothing.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release\u00a0states clearly where the product is available.", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the vaccination is already in use for people over age 65.\u00a0 ", "answer": 1}, {"article": "6 Kowdley KV, et al.\nThis ongoing, open-label study enrolled 90 children aged between six and 11 years with chronic HCV, mostly genotype 1 (n=86).\nNo children discontinued the study due to side effects or had a severe or life-threatening adverse event related to the study drug.\n\"These data establish the use of the oral direct-acting antivirals as an important treatment option in HCV-infected children aged six to 11 years old.\"\nThe study, presented at The International Liver Congress\u2122 2017 in Amsterdam, The Netherlands, also showed that the fixed-dose combination of LDV/SOF was well-tolerated, and no patients experienced a serious adverse event considered related to the study drug.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t explain what hurdles, such as FDA approval, are required to make this therapy available to children.", "answer": 0}, {"article": "The monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\nThe improvements were more robust in those who were adherent to PAP therapy.\n\"Our study also serves as a basis for targeted efforts to optimize quality of life in younger adults and lower socioeconomic subgroups,\" said Walia.\nResults also show that older patients and those in a higher socioeconomic subgroup had better quality of life measures after PAP therapy.\nResults show that there were significant and clinically meaningful improvements in general quality of life and sleep-related quality of life measures after the initiation of PAP therapy for sleep apnea.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release made no mention of the availability of CPAP machines, even though they are easy to find. As mentioned above, however, their cost can often be prohibitive. It would have been helpful if the news release discussed low-cost options, especially since they mentioned that the intervention seemed to have less effect for lower socio-economic subgroups.", "answer": 0}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nTurner says the findings don\u2019t suggest that red wine is a cure for Alzheimer\u2019s.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nWe need more studies to see if it really does have benefit and then it could be turned into more effective drugs that can better target Alzheimer\u2019s.\u201d\n\nCorrection: The original version of this story misstated that all the participants were men.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does make clear that this study does not mean people should begin drinking red wine or taking resveratrol supplements to combat Alzheimer\u2019s disease, and notes that more studies are needed to determine benefit or to create drugs for clinical use.", "answer": 1}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nPeople who were taking medication for OCD continued to do so for the trial.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Readers will understand that the TMS device is now commercially available for OCD, although the article does not offer any information about facilities that offer the treatment.", "answer": 1}, {"article": "In clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.\nTheir labeling does not contain language about suicide.\nThe agency recently began notifying the public earlier about possible safety issues.\nMerck says the information is on the company's Web site, though one must go to the fourth page of a product labeling file to find it.\nFDA said it asked the company to dig deeper into its data on Singulair for evidence of possible links to suicide.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The segment makes clear that Singulair is widely used. ", "answer": 1}, {"article": "Send your questions to Julia via the submission form or @juliaoftoronto on Twitter.\nAcetaminophen, after all, is the most popular over-the-counter painkiller worldwide.\nBetween 1998 and 2003, acetaminophen was the leading cause of acute liver failure in the US.\nThis is why aspirin has its place as a protective agent against strokes and heart attacks for people at a higher risk.\nNow, Moore was referring here to acute pain that strikes after a specific event, like a surgery, a cut, or a burn, but his message was simple: Ibuprofen seems to work best, followed by acetaminophen, and then aspirin.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s obvious from the story that all of the medications profiled have been widely available without a prescription for many decades. Aspirin, a modified version of salicyclic acid, was created by a Bayer chemist in 1897; acetaminophen followed in 1956; and ibuprofen in 1962.", "answer": 1}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the FDA just approved the drug for patients with inherited BRCA gene mutations who have undergone chemotherapy, and that it\u2019s been on the market since 2014 for ovarian cancer. Presumably, that means it\u2019s widely available.\nBut, it then mentions that a \u201ccompanion\u201d blood test was also just approved to look for these genes. It\u2019s not clear if this test specifically will be required before women receive the new drug, and if that test will be available right away.", "answer": 0}, {"article": "\u201cWe still found the same thing,\u201d Brandt said.\nBy 2018, those fats will be nearly eliminated from American diets, they add.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nStill, the study can\u2019t say the trans fat restrictions caused fewer admissions in those counties.\nPrevious research found that death from cardiovascular disease declined 4.5 percent within a year after counties enacted trans fat restrictions, the researchers write in JAMA Cardiology.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes where trans fats are now restricted (New York City) and explains that restrictions will become nationwide in 2018.\nBy 2018, those fats will be nearly eliminated from American diets, they add.", "answer": 1}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\nWhile pembrolizumab has been a significant advancement for treating people with a variety of advanced or metastatic cancers, a majority of metastatic melanoma tumors are still resistant to the drug.\nThe results of the study suggest that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\nThe study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment.\nIn UCLA-led study, new treatment is more effective in people receiving immunotherapy for the first time\n\nA UCLA-led study has found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma, an aggressive form of skin cancer, live longer.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release makes clear that this is an experimental therapy that is not yet available. The release could have been improved by noting that Keytruda was approved by the FDA for use in metastatic melanoma in 2015.", "answer": 1}, {"article": "A new study shows women who drank the equivalent of a beer or small glass of wine each day were less likely to develop chronic diseases like heart disease, cancer, and diabetes as they got older compared to nondrinkers or those who drink four or more drinks at one time.\nSept. 6, 2011 -- \"A drink a day keeps disease away\" may be the new motto for middle-age women hoping to age gracefully.\nResearchers then analyzed health status information collected after the women turned 70.\nThe women filled out questionnaires about what they ate and drank at midlife, about age 58.\nIn the study, researchers looked at the effects of drinking alcohol at midlife on the risk of diseases commonly associated with aging in a group of 13,894 women enrolled in the Nurses' Health Study.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of alcoholic drinks is not in question.", "answer": 2}, {"article": "Bipolar disorder carries one of the highest rates of suicide of any mental illness, alongside schizophrenia and alcohol and drug addiction.\nPeople rightly have suspicions about it.\nThis may be medication, talking therapies, or a mixture of both.\u201d\nThe researchers\u2019 analysis bore out one of the two main criticisms of lithium, but found the other to be baseless.\n\u201cDifferent people will find that different treatments help with managing their mental health problems.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the four drugs studied are indeed available.", "answer": 1}, {"article": "In other words, they are the precursors to muscle, fat, bone, and tendon tissue.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nFurthermore, there were no life-threatening effects linked to the procedure used to administer them.\nIn addition to setting the stage for an expanded trial of the procedure, the promising results also change \u201cour notion of what happens after a stroke,\u201d Steinberg explained.\nAnd in a clinical trial testing the technique, researchers found injections can safely improve patients' motor function.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that the investigators are planning a larger trial of the procedure.", "answer": 1}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that bone density screenings are common and done in a variety of ways.", "answer": 1}, {"article": "Migraines are characterised by an intense, throbbing headache, sensitivity to light and noise, nausea, vomiting, low energy, and visual disturbances.\n\u201cThis is probably the first example of a migraine preventing drug that was rationally designed, rather than serendipitously found,\u201d he added.\nA new migraine drug that can halve the length of attacks has been hailed as \u201cthe start of real change\u201d in how the condition is treated.\nAttacks can last anything from four to 72 hours.\nPhase three trial data on nearly 1,000 patients showed that it typically cut between three and four \u201cmigraine days\u201d per month.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of\u00a0erenumab was never clear established. Yes, one could deduce that a Phase III trial was just reported, so it probably isn\u2019t on the market yet. But the story never said that. In addition, there can still be a troubled road between completion of a Phase III trial and approval. For a story that trumpeted \u201cincredibly important step forward\u2026.start of a real change (in treatment)\u2026first drug in 20 years proven to prevent migraine attacks\u201d and other superlatives, the story could have helped readers see through one trial\u2019s optimism to explain what pitfalls might lie ahead.", "answer": 0}, {"article": "After adjusting for non-modifiable stroke risk factors (such as age and family history), researchers found stroke risk among women who breastfed their babies was on average:\n\u2022 19 percent lower in women who had breastfed for up to six months.\nThe Association has strict policies to prevent these relationships from influencing the science content.\nHowever, because the Women's Health Initiative is large, researchers were able to adjust for many characteristics, and the effects of breastfeeding remained strong, Jacobson said.\nThe WHI was supported by the National Health, Lung, and Blood Institute.\nThe Dallas-based association is the nation's oldest and largest voluntary organization dedicated to fighting heart disease and stroke.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release requests that pregnant women make breastfeeding part of their \u201cbirthing plan\u201d and to breastfeed for at least six months to receive the most benefits. It\u2019s assumed readers know that breastfeeding is an available option unless there are medical or lifestyle barriers.", "answer": 1}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n\nThe story mentions that chronic fatigue syndrome has \u201cno effective treatment.\" It also states that \"some doctors are already prescribing drugs approved for HIV\u00a0for fatigue patients.\" We\u2019ll give the story a satisfactory score on this criterion, although we have mixed feelings about the message it left with readers. \n", "answer": 1}, {"article": "Amy Berrington de Gonzalez of the National Cancer Institute and colleagues developed a computer model to estimate the impact of so many scans.\nThat is a lot of excess deaths.\u201d\n\nCT scans give doctors a view inside the body, often eliminating the need for exploratory surgery.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nBut CT scans involve much higher radiation dose than conventional X-rays.\n\u201cWhat we learned is there is a significant amount of radiation with these CT scans, more than what we thought, and there is a significant number of cancers,\u201d said Dr. Rita Redberg, editor of the Archives of Internal Medicine, where the studies were published.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly CT scans are available. The story does a good job of describing the\u00a0dramatic increase in the use of CT scanning in the past 20 years.", "answer": 1}, {"article": "BLOOMINGTON, Ind.\n\"While concerns about prescribing medications to treat ADHD that have the potential for abuse are understandable, this study provides further evidence that the use of these medications is not associated with increased risk of substance use problems in adolescence or adulthood,\" Quinn said.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\nThis research was supported in part by the National Institutes of Health's National Institute of Mental Health and National Institute on Drug Abuse.\n\"The results also highlight the importance of careful diagnosis and compliance with treatment.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release did not discuss the availability of ADHD medications. However, these are commonly prescribed medications that are widely available in the US and Europe.", "answer": 2}, {"article": "ZURICH (Reuters) - Roche\u2019s Tecentriq immunotherapy combined with other drugs boosted lung cancer patients\u2019 survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nAnalysts from Baader Helvea said its announcement completes an \u201calready robust\u201d set of data for regulators who now must sign off on Tecentriq\u2019s use as an initial treatment of lung cancer.\n\u201cFacing biosimilar competition... we see Tecentriq sales coming timely to support Roche\u2019s profitability going forward.\u201d\nThe Basel-based company, which had previously announced Tecentriq, Avastin and chemotherapy had reduced the risk of disease progression or death, said on Monday it hopes for a quick approval from authorities for the cocktail.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "For better or worse, the story makes clear that Roche intends to submit the new data to regulators right away.", "answer": 1}, {"article": "More than 1 in 20 American, ages 12 and older, are struggling with depression, according to the Centers for Disease Control and Prevention.\n\"We look at it as a tool to help the physician.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nFinally, her psychiatrist, suspicious that her body might process medication differently than most, recommended a genetic test to see why Ellis wasn\u2019t responding to the prescriptions.\nThe test offered by Avera is $179 and is often covered by insurance.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It says Avera is \u201coffering\u201d the test and that there are others used in hospitals. It\u2019s pretty clear that they are available, at least to some people. This is sufficient for a Satisfactory rating, though the story would have been stronger if it had explained this more thoroughly.", "answer": 1}, {"article": "About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI, a part of the National Institutes of Health (NIH), plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nWHAT: NIH-supported researchers are reporting additional details about a widely-publicized study that linked a systolic blood pressure target under 120 mm Hg (millimeters of mercury) with reduced cardiovascular disease and a lower risk of death.\nWHO: Lawrence Fine, M.D., chief of the Clinical Applications and Prevention Branch at NHLBI and a co-author of the study, is available to comment on the findings and implications of this research.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Without naming the drugs used in the study, the release leaves us to assume the ready availability of any of the medications. It would have been easy for the news release to indicate that the study did not use any investigational agents \u2014 just widely available blood pressure medicines. Unfortunately, the release doesn\u2019t explain that, thus netting an unsatisfactory rating.", "answer": 0}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear how widely available this fast-track surgery option is in general, but this is\u00a0something you\u2019d want to know if you were a patient/caregiver trying to find some place that offers this.", "answer": 0}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says \u201ca small but growing number of hospitals offer microsurgical attempts at relief from lymphedema.\u201d It also mentions that it\u2019s sometimes covered by insurance.", "answer": 1}, {"article": "The Ohio State University, Northern Arizona University and Arizona State University researchers found a parallel between behavioral symptoms of autism and gastrointestinal distress, and improvements to both after fecal transplant.\nChildren without autism were used as a control for the study, the news release reported.\nOne of the study\u2019s limitations is its small size, and researchers cautioned that families should not try to replicate the treatment at home.\n\u201cWe have to be mindful of the placebo effect, and we have to take [the findings] with a grain of salt,\u201d Matthew Sullivan, an associate professor of microbiology at The Ohio State University, said in the release.\nResearchers also asked the children\u2019s doctors to perform pre- and post-diagnostic evaluations, which suggested lasting benefits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about how this treatment is nowhere ready for widespread use, but it did indicate the study was small, and it included the warning that \u201cresearchers cautioned that families should not try to replicate the treatment at home.\u201d", "answer": 1}, {"article": "ET, or more than twice their 25-day average trading volume.\nIts success is a key step toward proving that embryonic stem cell research could cure diseases such as cancer, Parkinson\u2019s and serious health conditions such immune deficiencies, stroke and spinal injuries.\nAsterias is looking to show recovery of mobility in four out of every 10 patients treated with OPC-1, compared with two out of 10 achieving the same level of improvement without any treatment, Chief Executive Pedro Lichtinger told Reuters in early August.\n(Reuters) - Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The Reuters story makes it fairly clear that this therapy is in its early phases. The article describes how Asterias acquired the therapy from another research company in 2013 and how this announcement has been the first about the research in more than two years.", "answer": 1}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article provides no information\u00a0about the availability of the new tests, either temporally or geographically.", "answer": 0}, {"article": "5 Million Have Heart Failure in U.S.\n\nMore than 5 million Americans have heart failure, which occurs when the heart muscle loses its ability to pump enough blood throughout the body.\nThe device has gas sensors that detect various odorous molecules in sweat.\nThe new device was about that accurate at differentiating between severe and less severe heart failure patients.\nThe goal of the project is to develop a simple, accurate, noninvasive, and reproducible method for early identification of chronic heart failure, he tells WebMD.\n\"Still, much more work is needed before we will know if the electronic nose will make it to the clinic,\" says Ruschitzka, who moderated a news briefing to discuss the findings.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this device is still in the early phases of testing.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story reported on a new method for detecting clots that can cause cardioembolic strokes and a new method for treating massive deep vein thrombosis in the leg.\u00a0 The story could have emphasized that neither of these is routinely used.\u00a0 Although the story did say that they are new, readers could easily be confused about this application of MRI because they may be familiar with the use of MRI for other diagnostic procedures.\nThe story also included no information about the availability of the Angiojet, the medical device discussed.\u00a0 While the story made it sound like this was something new, this device has had FDA approval since 1999.\u00a0 http://www.fda.gov/cdrh/pdf/P980037b.pdf", "answer": 0}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\nNone of the operations was converted to open surgery and all but two patients were ambulatory on the day of or day after surgery.\n\"This is a complex condition and the complication rate with open surgery is 12% to 47%, depending on the thrombus level, with a mortality rate of 5% to 10%,\" explained lead investigator Ronney Abaza, MD, Robotic Surgery Director at OhioHealth Dublin Methodist Hospital.\nExperts from nine leading U.S. medical centers report here on their combined experience of 32 cases since 2008.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that robot assisted minimally invasive surgery is available in many institutions and has become the mainstay for prostatic surgery. The news release does point out that the surgeons who participated in the story were experienced with the technique. While implied in some parts of the release and downplayed in others, this is not a surgical procedure that should be undertaken lightly.", "answer": 1}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There isn\u2019t any question about the availability of statins.\u00a0", "answer": 1}, {"article": "The researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\n\u201cThis is more evidence to suggest that omega-3s are beneficial and may have anti-inflammatory action helpful in reducing cancer risk,\u201d said the lead author, Dr. Harvey J. Murff, an associate professor of medicine at Vanderbilt.\nAll patients were interviewed about diet, health habits and medical history.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of fish is not currently in question, although its future availability has been questioned considering the rate we are overharvesting wild stocks. Stories that don\u2019t critically evaluate these kinds of studies might conceivably contribute to the problem.", "answer": 2}, {"article": "Those who consumed above the median amount of caffeine for this group (with an average intake of 261 mg per day) were diagnosed at a lower rate than those who fell below the median (with an average intake of 64 mg per day).\nThe findings come from participants in the Women's Health Initiative Memory Study, which is funded by the National Heart, Lung, and Blood Institute.\nThis level is equivalent to two to three 8-oz cups of coffee per day, five to six 8-oz cups of black tea, or seven to eight 12-ounce cans of cola.\nThe paper \"Relationships Between Caffeine Intake and Risk for Probable Dementia or Global Cognitive Impairment: The Women's Health Initiative Memory Study\" is available at: http://biomedgerontology.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release quotes the principal investigator saying, essentially, that caffeine is an easy thing to add to the diet and is widely available.\u00a0True enough.", "answer": 1}, {"article": "Jet lag occurs when sleeping and waking patterns are not synchronized to circadian rhythms.\nZeitzer's latest study, published Monday in the Journal of Clinical Investigation , could make treatment easier by providing light exposure during sleep, before the trip, without changing or interrupting your routine.\nThere's still more testing to be done before the technique is available to the public.\nThey put them on a routine sleep-wake cycle, going to bed and waking up at the same time every day for about two weeks.\nThis time around, researchers tried to further optimize the process.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that the light therapy wasn\u2019t ready for prime time yet.", "answer": 1}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\nValeant Pharmaceuticals, Siliq\u2019s manufacturer, says that pricing information is not available at this time, and expects to begin sales and marketing in the second half of 2017.\nThe drug also comes with a more serious warning, as well.\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story deals with the availability issue by saying it \u201cexpects to begin sales and marketing in the second half of 2017.\u201d", "answer": 1}, {"article": "Personal sound amplification products (PSAPs) are less-expensive, over-the-counter devices not specifically labeled for hearing loss treatment, but some are technologically comparable with hearing aids and may be appropriate for mild to moderate hearing loss.\nAccording to nationally representative estimates, less than 20 percent of adults with hearing loss report hearing aid use.\nA limitation of the study was the modest number of participants.\nNicholas S. Reed, Au.D., of the Johns Hopkins School of Medicine, Baltimore, and colleagues compared five of these devices (costs, approximately $350 to $30) with a conventional hearing aid (cost, $1,910) among 42 adults (average age, 72 years) with mild to moderate hearing loss.\nThe researchers found that the change in accuracy in speech understanding from unaided to aided varied by device.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Availability of both hearing aids (\u201cthrough a licensed professional\u201d) and PSAPs (\u201cover-the-counter\u201d) is clearly established.", "answer": 1}, {"article": "\"Historically, patients with chronic systolic heart failure were considered too frail to exercise and, through the late 1980s, avoidance of physical activity was a standard recommendation,\" the study's authors write.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\nThe movement is tai chi, an ancient martial art turned exercise, and a study out this week in Archives of Internal Medicine says it may help people suffering from heart failure feel better about life.\nHeart failure is a tough disease to live with; the shortness of breath and low energy that can come because the heart can't pump enough blood make physical activity unappealing.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests that tai chi is widely practiced in China,\u00a0but\u00a0it didn\u2019t discuss the\u00a0availability of classes in the United States. While it isn\u2019t hard to find trained instructors in\u00a0a city such as Boston, where the study being\u00a0covered was conducted, readers from rural areas might find it difficult to locate classes led by someone experienced in this form of therapy.\u00a0\u00a0Someone with\u00a0heart failure may also have trouble finding transportation to a class. The story should have mentioned these issues.", "answer": 0}, {"article": "Physical symptoms can include bloating, abdominal cramps, constipation, lower back pain, acne, breast swelling, muscle pain and others.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\n\"Realizing the significance of this discovery, it encouraged us to further explore a product line for women's health utilizing Lipogen's proprietary phospholipid ingredients.\"\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nOur patented solution is made of natural ingredients, is GMO-free, and can save significant health costs over medication alternatives, all with no reported side-effects.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention when or in which formulation the supplement might be available in the U.S. market, even though the release is introducing the supplement to a U.S. audience.", "answer": 0}, {"article": "\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\nand a scientific founder of Living Proof, started searching for something that would work.\nThe skin still has to be able to breathe through this stuff.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes\u00a0these as preliminary studies, adding that they haven\u2019t obtained enough data yet to submit the product for FDA approval.", "answer": 1}, {"article": "What does that mean for men today?\nWASHINGTON \u2014 Prostate cancer is more likely to be life-threatening if the man's PSA level rose rapidly during the years before he was diagnosed, says a new study that may help change how PSA tests are used.\nBut Carter contends the findings suggest that men should consider getting a baseline PSA test around age 40, instead of the more usual 50, to use as a comparison for future changes.\nPerhaps more important, it suggests a more in-depth evaluation of the common blood tests could better predict who needs aggressive treatment and who has a slower-growing tumor that may be OK to monitor instead.\nA study with just 20 deaths is far too small to prove the value of PSA velocity, cautioned Dr. Durado Brooks, a prostate specialist with the American Cancer Society.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states this latest study could help change how PSA (or prostate specific antigen) tests are currently used, implying that PSA testing is available.\u00a0 The article also states that many doctors already use PSA velocity to help determine which men need biopsies, also implying that the use of PSA velocity, a particular way to use PSA testing, is available\u00a0although not necessarily used by all at this time.\u00a0 ", "answer": 1}, {"article": "A similar decrease in brain volume was found with some anti-amyloid immunotherapy trials,\" Turner adds.\nIt is not available commercially in this form.\nTurner, who treats patients at MedStar Georgetown University Hospital, cautions that the findings cannot be used to recommend resveratrol.\nResveratrol and similar compounds are being tested in many age-related disorders including cancer, diabetes and neurodegenerative disorders.\nTurner says the study also found that resveratrol was safe and well tolerated.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release states resveratrol is not available commercially in the 1-gram oral form.", "answer": 1}, {"article": "It\u2019s quite unusual,\u201d she added.\nI think the prognosis is going to be good now.\u201d\n\nThe most frequent mutation across all cancers occurs in a gene called p53, which contributes to cells becoming oncogenic when they produce a mutant form of the p53 protein (p53 gene mutations are present in about 50% of malignancies).\nBut we\u2019ve got to get these patients in.\u201d\n\nFollowing the success in Young, the formula has recently been given to two other triple negative breast cancer patients at City of Hope.\nIt was of tremendous magnitude in the last [blood] draw.\u201d\n\nThe next step will be to take bone and CT scans to see if the cancer is disappearing internally as well as externally, which Young will receive in a couple of weeks.\n\u201cEven the marks where it was climbing up my neck are all gone.\u201dFurther study needed\n\nWhat Diamond is hoping for now is funding for a full clinical trial so that he can test the combination in advanced triple-negative breast cancer patients who test positive for p53.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "While part of the drug combination (pembrolizumab) mentioned in the release is available, the experimental p53 vaccine appears to only be available through a City of Hope researcher. There was mention of a desire to create clinical trials open to \u201cto women from all over the country\u201d but that\u2019s far from certain.\nIt\u2019s clear from the release that City of Hope is trying to recruit new patients and generate pharmaceutical sponsors. Many patients with this type of breast\u00a0 cancer may get the impression from the release that they, too, can receive this \u201cremarkable\u201d treatment if they make their way to the hospital. But how practical is their open invitation?\u00a0Experimental therapies like the vaccine are not covered by health insurance.", "answer": 0}, {"article": "You've probably heard about it \u2014 maybe you even remember seeing it once \u2014 but you're not really sure what it is or even where to find it.\n\nThe female condom (FC2), or internal condom, is a non-hormonal barrier method of birth control. But instead of going on a penis, it goes in a vagina, which is why it's also sometimes referred to as an internal condom. For more information, BuzzFeed Health spoke with two experts who could demystify this lesser-known contraceptive:\n\n* Dr. Harry Fisch, clinical professor of urology and reproductive medicine at Weill Cornell Medical College, and chief corporate officer of Veru Healthcare, which distributes FC2\n\n* Dr. Lauren Streicher, associate clinical professor of obstetrics and gynecology at Northwestern University\u2019s Feinberg School of Medicine", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job of handling the nuances of availability.", "answer": 1}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story makes it clear that statins are widely available. ", "answer": 1}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story says the company that makes the Oncotype DX test, Genomic Health, plans to start selling the test early next year. \nBut the reader has no idea how realistic this prediction is. Given the economic self-interest of the source, the story should have indicated what regulatory or commercial barriers the company faces before it can bring the test to market.\u00a0 ", "answer": 0}, {"article": "Researchers then narrowed their analysis to see how the urine test scores matched the men\u2019s Gleason score, which helps doctors gauge how aggressive a cancer may be.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nSensitive means it\u2019s unlikely that the test would miss a case of cancer.\nThe two tests together appeared to generate both sensitive and specific results.\n\u201cThe real key is using this or any test to help drive decisions,\u201d says Jones, who was not involved in the research, \u201cIf it helps me to know who to biopsy or not biopsy, that\u2019s massively valuable information.\u201d\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story indicated that the test was in development.", "answer": 1}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\nThat's why he said it was important for MUSC to be involved in the study, which was funded by a grant from the commercial weight loss program, Weight Watchers.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that because Weight Watchers \u201chas centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\u201d We\u2019ll give this a marginal satisfactory because while there are, indeed, many Weight Watchers centers, the program will be too costly for many.", "answer": 1}, {"article": "But not a whole lot.\nIn 2009, the U.S. Food and Drug Administration warned Matrixx Initiatives to stop selling its widely used supplement Zicam after more than 130 users reportedly lost their sense of smell.\nThe review, published by the Cochrane Collaboration, an international organization that evaluates medical research, also shows that people taking the supplements tended to have milder symptoms.\nSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea.\nAn earlier Cochrane review from 1999 didn\u2019t find any signs that zinc supplements would work.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story, unlike the WebMD story, made it clear exactly what the review looked at and where those supplements could be found. \u201cSingh said the side effects of zinc lozenges, which can be bought for a few dollars in any drug store in the U.S., come down to bad taste and some cases of nausea. The researchers did not study nasal zinc remedies, however.In 2009, the U.S. Food and Drug Administration warned Matrixx Initiatives to stop selling its widely used supplement Zicam after more than 130 users reportedly lost their sense of smell.\u201d", "answer": 1}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\nIn this report, use of curcumin after burns and scalds were found to reduce the severity of the injury, lessen pain and inflammation, and improve healing with less than expected scarring, or even no scarring, of the affected skin.\nDr. Heng reports her experience using curcumin gel on such injuries using three examples of patients treated after burns and scalds, and provides a detailed explanation why topical curcumin may work on such injuries.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release discusses the uses of curcumin for gastronomical and cosmetic purposes \u2014 many of which go back centuries. It adds that medicinal aspects of curcumin have been studied intensely for various human ailments in recent years.\nIt\u2019s also clear from the news release that patients have the option of taking curcumin tablets orally for \u201cother conditions.\u201d A quick Google search shows that curcumin tablets are available for purchase at health food stores.\nFor these reasons, we give the news release a Satisfactory rating.", "answer": 1}]